An Open-Label Randomized, Phase 2A, Dose-Ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Phase: PHASE2
Conditions: Anemia, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small-Cell Lung, Bladder Cancer, Cancer of Head and Neck, Uterine Cervical Cancer
Sponsor: Merck Sharp & Dohme LLC

Official Protocol Title: 
NCT number:
NCT01284348
Document Date:            02-May-2012    
A Single-Blind, Randomized, Phase 2A, Dose Ranging Study 
(Part 1) of ACE-011 Therapy Followed by a Phase 2B/3, Double-
Blind, Randomized, Placebo-Controlled Study (Part 2) of ACE-011 
for Chemotherapy Induced Anemia (CIA) in Subjects With 
Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated With 
First-Line Platinum-Based Chemotherapeutic Regimens

088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
2
ACE-011-NSCL-001 FINAL: 17 SEP 2010
EMERGENCY CONTACT INFORMATION
Contact Information:
Note:  The back-up 24 hour global emergency contact call center should only be used if you 
are not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls  
Back-up 24 Hour Global Emergency Contact Call Center: 
Page 2 of 791
PPD
PPD
088VGY

088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
4
ACE-011-NSCL-001 FINAL: 17 SEP 2010
SITE PRINCIPAL INVESTIGATOR SIGNATURE PAGE
Signature of Site Principal Investigator
dd mmm yyyy
Printed Name of Site Principal Investigator and Title
Site Number:________
Institution Name:_______________________________________
By my signature, I agree to personally supervise the conduct of this study at my study 
site and to ensure its conduct is in compliance with the protocol, informed consent, 
Institutional Review Board (IRB)/Ethics Committee (EC) procedures, instructions from 
Celgene representatives, the Declaration of Helsinki, ICH Good Clinical Practices 
Guidelines, and local regulations governing the conduct of clinical studies.
Page 4 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
5
ACE-011-NSCL-001 FINAL: 17 SEP 2010
COORDINATING PRINCIPAL INVESTIGATOR SIGNATURE PAGE
Signature of Coordinating Principal Investigator
dd mmm yyyy
Printed Name of Coordinating Principal Investigator and Title
Site Number:________
Institution Name:_______________________________________
By my signature, I agree the protocol has been written to comply with ICH Good 
Clinical Practices guidelines and agree to offer guidance throughout the study as 
needed.
Page 5 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
6
ACE-011-NSCL-001 FINAL: 17 SEP 2010
PROTOCOL SUMMARY
Study Title
A single-blind, randomized, phase 2a, dose ranging study (Part 1) of ACE-011 therapy followed 
by a phase 2b/3, double-blind, randomized, placebo-controlled study (Part 2) of ACE-011 for 
chemotherapy induced anemia (CIA) in subjects with metastatic non-small cell lung cancer
(NSCLC) treated with first-line platinum-based chemotherapeutic regimens.  
Indication
Chemotherapy Induced Anemia in Subjects with Metastatic NSCLC.  
Objectives
The primary objectives are:

Part 1:  To determine an effective dose of ACE-011 showing a hematopoietic
response in the treatment of CIA in metastatic NSCLC subjects.

Part 2:  To assess transfusion rate within 4 months following initiation
ACE-011/placebo treatment.
The secondary objectives are:
Part 1 and Part 2:

To estimate the effect of ACE-011 treatment on objective response rate (ORR), time
to progression (TTP), progression free survival (PFS) and overall survival (OS) in
advanced NSCLC subjects with CIA.

To evaluate the safety and tolerability of ACE-011 treatment for advanced NSCLC
subjects with CIA.

To determine the pharmacokinetics (PK) of ACE-011 in subjects with advanced
NSCLC receiving platinum-based chemotherapy.

To estimate the duration of hematopoietic response associated with ACE-011.

To evaluate the effect of ACE-011 treatment on the quality of life (QoL) of NSCLC
subjects with CIA.
Part 2:

To evaluate hematopoietic response
The exploratory objectives are:
Part 1 and Part 2:

To estimate the effect of each ACE-011 treatment on bone metabolism in NSCLC
subjects with CIA.

To explore the relationship between ACE-011 exposure and response (hematology,
biomarkers, and other clinical outcomes as appropriate).
Page 6 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
7
ACE-011-NSCL-001 FINAL: 17 SEP 2010

To evaluate the expression/overexpression of Activin A and other 
proteins/biomarkers related to ACE-011 mechanism of action in blood and tumor 
tissue in the NSCLC population.  

Circulating tumor cell enumeration and molecular studies.  

To assess renal function biomarkers.  
Study Design
This is a single-blind, randomized, phase 2a, dose ranging study (Part 1) of ACE-011 therapy 
followed by a phase 2b/3, double-blind, randomized, placebo-controlled study (Part 2) of ACE-
011 for CIA subjects with metastatic non-small cell lung cancer treated with first-line platinum-
based chemotherapeutic regimens.  
The study will consist of two parts:
Part 1 is a dose finding segment in which up to approximately 90 subjects will be randomized to 
one of three ACE-011 dose treatment arms.  The primary objective is to determine an effective 
dose of ACE-011 showing a hematopoietic response in the treatment of CIA in advanced 
NSCLC subjects.  The sample size is for the purpose of hypothesis generation; however, it would 
allow approximately 80% power to detect an effect size of 0.33 using a 2 degrees of freedom 
Chi-Square Test with a significance level (alpha) of 0.05.  A Data Monitoring Committee
(DMC), composed of both internal Celgene and external independent reviewers, will conduct 
periodic data reviews during the review of Part 1 data, to define the recommended ACE-011 
dose to be used in Part 2 of the study.  
Part 2 is the Phase 2b/3 double-blind, randomized, placebo-controlled segment of the study and 
will be performed in two stages.  In the first stage, approximately 180 subjects will be 
randomized to receive ACE-011, at the dose determined from Part 1, or placebo at a ratio of 1:1.  
An interim futility assessment based on transfusion rate at 4 months will be performed as 
described in Section 10.8.  It is expected that accrual will continue during the interim assessment 
period, with up to an additional 570 subjects randomized to achieve full study accrual.  
During Part 2 (first and second stage) overall survival will assessed.  The total sample size of 
750 subjects will allow observation of at least 536 deaths and thus, at least 80% power to exclude 
more than 15% hazard increase in the ACE-011 arm compared with the placebo arm at one-sided 
significance level of 0.025, i.e., rejecting hazard ratio (Placebo:ACE-011) of 0.87, assuming the 
ACE-011 arm actually reduces at least 10% hazard, i.e., true hazard ratio (Placebo:ACE-011) of 
1.11.  
Study Population
Subjects must be receiving their first regimen of first-line platinum-containing chemotherapy, 
given every three weeks, for the treatment of metastatic NSCLC at the time of randomization.  
Subjects must be randomized prior to receiving Cycle 4 of this current first-line platinum-based 
chemotherapy regimen.  Subjects are expected to be eligible to receive 2 platinum-based 
chemotherapy cycles or maintenance therapy with a pemetrexed-based regimen following 
randomization.  
Subjects must not have received any other regimens of chemotherapy for the first-line platinum 
containing treatment of metastatic NSCLC prior to the regimen at the time of randomization.  
Page 7 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
8
ACE-011-NSCL-001 FINAL: 17 SEP 2010
Length of Study and Study Treatments
This study will consist of the following consecutive periods:  Screening, Treatment Period, Post 
Treatment Follow-Up Period, and Survival Follow-Up Period.  Study treatment is defined as 
ACE-011 in Part 1 and ACE-011/placebo in Part 2.  
Screening Period (28 days):
Potential study subjects will sign an informed consent form prior to undergoing any study-related 
procedures.  Subjects will undergo screening for protocol eligibility within 28 days of 
randomization, as outlined in the Table of Events, Section 5.  Historical tumor assessment data 
from six weeks prior to initiation of platinum-based chemotherapy through randomization 
to the study will be collected.  
Prior erythropoietic stimulating agent (ESA) treatment history starting from initial diagnosis of 
NSCLC and red blood cell (RBC) transfusion history starting from diagnosis of metastatic 
NSCLC at a minimum of up two months prior to randomization will be collected.  
All females of childbearing potential (FCBP) participating in the study are to use highly effective 
methods of birth control during the screening period, for at least 28 days before starting the 
study.  Some highly effective methods of birth control include:

Oral contraceptives, intrauterine device, tubal ligation or a partner with a vasectomy
OR

Two forms of barrier method birth control, e.g. a latex condom PLUS a diaphragm 
with spermicide OR a latex condom PLUS a contraceptive sponge with spermicide.  
If a non-latex condom is used, it cannot be made out of natural (animal) membrane.  
Subjects will also be provided the opportunity to participate in an optional full PK assessment.  
Treatment Period (up to 6-9 months):  
The treatment period is approximately six months (four doses of study treatment given on Day 1,
every 42 days), two additional ACE-011/placebo doses may be given only in Part 2, at the 
discretion of the Investigator.  
In Part 1 (the dose ranging portion of the study), subjects who meet all eligibility criteria will be 
randomized to receive one of the following ACE-011 dose levels, with 10-30 subjects per arm:

ACE-011 15.0 mg SC

ACE-011 30.0 mg SC
Following analysis of at least 10 subjects at each dose level (10 subjects at the 15.0 mg dose 
level and 10 subjects at the 30.0 mg dose level), a third dose level will be added to the 
randomization schema:

ACE-011 45.0 mg SC
Each dose level will be administered every 42 days for up to four doses.  
Page 8 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
9
ACE-011-NSCL-001 FINAL: 17 SEP 2010
The effective dose of ACE-011 is defined as follows:
An increase in hemoglobin (Hgb) of ≥ 1.0 g/dL above the study baseline value for 4 
consecutive weeks during the first two doses of ACE-011 (Dose 1/Day 1 through and 
including Dose 2/Day 43 [prior to Dose 3]), in approximately 70% of subjects, in at least one 
or more treatment arms (in the absence of RBC transfusions and/or ESAs.  
Evaluation of response decision status will be completed after dosing arms have separately 
enrolled up to 30 subjects, as needed, to determine the optimal dose for Part 2.  
In addition to the hematopoietic response, the safety profile, dose modifications and extent of 
exposure in each dosing level will be taken into account to determine the study dose to be used in 
Part 2. 
In Part 2, a total of 750 subjects will be randomized to receive either ACE-011 or placebo, at a
ratio of 1:1:

375 subjects will receive ACE-011 (at the dose determined in Part 1)

375 subjects will receive placebo
Each dose of ACE-011 or placebo will be administered every 42 days for four doses.  Up to two 
additional doses may be given at the discretion of the Investigator.  
Part 2 will be performed in two stages.  In the first stage, approximately 180 subjects will be 
randomized to receive ACE-011 (at the dose determined from Part 1) or placebo at a ratio of 1:1.  
An interim futility assessment based on transfusion rate at 4 months will be performed as 
described in Section 10.8. It is expected that accrual will continue during the interim assessment 
period, with up to an additional 570 subjects randomized to achieve full study accrual. 
During the Treatment Period, subjects will be assessed for hematopoietic response, transfusion 
need, safety and tumor response.  The severity of AEs will be graded according to the currently 
active minor version of the National Cancer Institute Common Terminology Criteria for Adverse 
Events (NCI CTCAE) version 4.0.  
Concurrent treatment for CIA with blood transfusions is recommended when Hgb value is 
< 8 g/dL or at the discretion of the Investigator if the Hgb value is > 8 g/dL and associated with 
anemia symptoms such as hemodynamic or pulmonary compromise requiring treatment.  If an 
RBC transfusion is given to a subject during the Treatment Period, ACE-011 should be 
administered ≥ 7 days from the date of the RBC transfusion.  
In Part 1, full PK blood samples will be collected to evaluate the full PK profile of ACE-011 
from approximately 30 subjects at select centers in approximately 10 subjects for each ACE-011 
dose group.  In subjects participating in the full PK assessment, RBC, Hgb, and reticulocyte 
counts will be collected at each PK time point (excluding the 4-hour time point on Day 1) from 
Day 1 to Day 43 after the first dose.  
In Part 2, sparse PK blood samples will be collected.  
Page 9 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
10
ACE-011-NSCL-001 FINAL: 17 SEP 2010
The following events are considered sufficient reasons for discontinuing a subject from the 
Treatment Period:

AE(s)

Medically significant hypertension which cannot be adequately controlled with 
antihypertensive therapy

Any AE > Grade 2 assessed to be related to ACE-011 therapy

Any persistent AE > Grade 1 considered to be related to ACE-011 treatment and 
causing a subject to miss three months ACE-011 therapy

Any thromboembolic event > Grade 2 

Elevated Hgb > 15.0 g/dL (sustained for a 7 day period, confirmed by laboratory 
assessment)

Creatinine clearance < 40 ml/min

Urine protein / creatinine ratio > 1.0 or > 2.0 (if bevacizumab [Avastin®] is 
concomitantly administered)

Persistent hematuria

Lack of ACE-011 therapeutic effect, defined as < 1.0 g/dL increase in Hgb following 
two doses of ACE-011 or ACE-011/placebo.  

Concomitant use of ESAs – In Part 1 if administered at any time and in Part 2 if 
administered < 4 months from first dose of study treatment. 

ACE-011 or ACE-011/placebo Dose Modifications

In Part 1 and Part 2:  A second Hgb increase of ≥3.0 g/dL following a two level 
dose reduction due to a Hgb increase ≥3.0 g/dL 

In Part 2:  > 3 dose reductions and/or delays

Disease progression of NSCLC

Withdrawal of consent

Death

Lost to follow-up

Protocol violation
The reason for treatment discontinuation should be recorded in the eCRF and in the source 
documents.  
Post Treatment Follow-Up Period (monthly for up to 6 months)
Subjects who enter the Post Treatment Follow-Up Period will be followed monthly for up to 6 
months from their last dose of ACE-011 or ACE-011/placebo.  All subjects will continue to be 
followed for TTP and PFS up to one year from their first dose of ACE-011 or ACE-011/placebo
or until progression of their NSCLC, whichever comes first.  
Page 10 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
11
ACE-011-NSCL-001 FINAL: 17 SEP 2010
The following events are considered sufficient reasons for discontinuing a subject from the 
study:

Completed study, per protocol (subject has completed six to nine month Treatment 
Period plus up to six month Post Treatment Follow-Up Period including one year 
tumor assessment to determine TTP and PFS).  Note: Survival data will continue to 
be collected for up to 24 months from first dose of study treatment.  

AE(s)

Disease Progression of NSCLC

Withdrawal of consent

Death

Lost to follow-up

Protocol violation
Survival Follow-up Period (monthly for up to 24 months after first dose of ACE-011 or 
ACE-011/placebo)
In both Part 1 and Part 2, survival data will be collected monthly via telephone contact for up to 
24 months following the subject’s first dose of ACE-011 (Part 1) or ACE-011/placebo (Part 2).  
Collection of survival data will begin following Study Discontinuation Visit.  

Overall survival

Post-Treatment Anti-Neoplastic Therapy
Overview of Efficacy Assessments

Serum hematology, absolute reticulocyte counts

Serum iron, total iron binding capacity (TIBC), transferrin and serum ferritin

Serum erythropoietin

Tumor Assessments

Documentation of concomitant RBC transfusions
Overview of Safety Assessments

Informed consent

Assessment of inclusion / exclusion criteria

Complete medical history including history of cardiac and thromboembolic events

Vital signs including height, weight, heart rate, seated systolic and diastolic blood 
pressure, and temperature.  

AE(s)

12-lead electrocardiogram (ECG)  

Medically supervised pregnancy testing
Page 11 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
12
ACE-011-NSCL-001 FINAL: 17 SEP 2010

Clinical laboratory evaluations (serum chemistry, hematology, absolute reticulocyte 
count, creatinine clearance, serum iron, total iron binding capacity, transferrin and 
serum ferritin, serum erythropoietin, Vitamin B12, serum folate levels, urinalysis, 
FSH, LH, dihyroepiandosterone, estrogen, estradiol, testosterone and serum thyroid-
stimulating hormone).  

QoL Assessment (FACIT Fatigue Scale [Version 4]) and Lung Cancer Symptom 
Scale (LCSS) questionnaire.  

Documentation of concomitant medications / procedures.  
Overview of Exploratory Assessments

Bone or other protein/biomarkers 

Circulating tumor cell enumeration and molecular studies

DXA scan

Renal function biomarkers 
Page 12 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
13
TABLE OF CONTENTS
TITLE PAGE..............................................................................................................................1
PROTOCOL SUMMARY ..........................................................................................................6
1.
INTRODUCTION..................................................................................................18
2.
STUDY OBJECTIVES...........................................................................................34
2.1.
Primary Objective...................................................................................................34
2.2.
Secondary Objectives .............................................................................................34
2.3.
Exploratory Objectives ...........................................................................................34
3.
STUDY ENDPOINTS............................................................................................35
3.1.
Primary Endpoint(s) ...............................................................................................35
3.2.
Secondary Endpoint(s)............................................................................................35
3.3.
Exploratory Endpoint(s)..........................................................................................36
4.
OVERALL STUDY DESIGN ................................................................................37
4.1.
Study Design ..........................................................................................................37
4.1.1.
ACE-011 Dose Modification, Reduction and Escalation Rules ...............................40
4.2.
Study Design Rationale ..........................................................................................42
4.2.1.
Fixed Dose .............................................................................................................43
4.2.2.
Dosing Schedule.....................................................................................................43
4.2.3.
Starting Dose Levels in Part 1.................................................................................43
4.2.4.
Evaluation of Dosing Schema via Modeling/Simulation .........................................44
4.3.
Study Duration .......................................................................................................45
5.
TABLE OF EVENTS.............................................................................................46
6.
PROCEDURES......................................................................................................53
7.
STUDY POPULATION.........................................................................................61
7.1.
Number of Subjects ................................................................................................61
7.2.
Inclusion Criteria....................................................................................................62
7.3.
Exclusion Criteria...................................................................................................63
8.
DESCRIPTION OF STUDY TREATMENTS........................................................65
8.1.
Description of Investigational Product(s)................................................................65
8.2.
Treatment Administration and Schedule .................................................................65
8.2.1.
Selection of Dose for the Study...............................................................................66
8.2.2.
Selection and Timing of Dosing for Each Subject ...................................................66
Page 13 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
14
8.2.3.
Discontinuation ......................................................................................................67
8.3.
Method of Treatment Assignment...........................................................................69
8.4.
Packaging and Labeling..........................................................................................69
8.5.
Investigational Product Accountability And Disposal .............................................69
8.6.
Investigational Product Compliance........................................................................69
9.
CONCOMITANT MEDICATIONS AND PROCEDURES....................................70
9.1.
Permitted Concomitant Medications and Procedures...............................................70
9.2.
Prohibited Concomitant Medications and Procedures..............................................71
9.3.
Required Concomitant Medications and Procedures................................................71
10.
STATISTICAL ANALYSES..................................................................................72
10.1.
Overview................................................................................................................72
10.2.
Study Population Definitions ..................................................................................72
10.3.
Sample Size and Power Considerations...................................................................72
10.4.
Background and Demographic Characteristics........................................................73
10.5.
Subject Disposition.................................................................................................73
10.6.
Efficacy Analysis....................................................................................................73
10.7.
Safety Analysis.......................................................................................................74
10.8.
Interim Analysis .....................................................................................................74
10.9.
Other Topics...........................................................................................................75
10.10.
Data Monitoring Committee (DMC).......................................................................75
11.
ADVERSE EVENTS..............................................................................................76
11.1.
Monitoring, Recording and Reporting of Adverse Events .......................................76
11.2.
Evaluation of Adverse Events.................................................................................76
11.2.1.
Seriousness.............................................................................................................76
11.2.2.
Severity ..................................................................................................................77
11.2.3.
Causality ................................................................................................................78
11.2.4.
Duration .................................................................................................................78
11.2.5.
Action Taken..........................................................................................................79
11.2.6.
Outcome.................................................................................................................79
11.3.
Abnormal Laboratory Values..................................................................................79
11.4.
Pregnancy...............................................................................................................79
11.4.1.
Females of Childbearing Potential: .........................................................................79
11.4.2.
Male Subjects .........................................................................................................80
Page 14 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
15
11.5.
Immediate Reporting of Serious Adverse Events ....................................................80
11.5.1.
Safety Queries ........................................................................................................80
11.6.
Expedited Reporting of Adverse Events..................................................................80
12.
DISCONTINUATIONS .........................................................................................82
13.
EMERGENCY PROCEDURES.............................................................................83
13.1.
Emergency Contact.................................................................................................83
13.2.
Emergency Identification of Investigational Products .............................................83
14.
REGULATORY CONSIDERATIONS...................................................................84
14.1.
Good Clinical Practice............................................................................................84
14.2.
Investigator Responsibilities ...................................................................................84
14.3.
Subject Information and Informed Consent.............................................................84
14.4.
Confidentiality........................................................................................................85
14.5.
Protocol Amendments.............................................................................................85
14.6.
Institutional Review Board/Independent Ethics Committee Review and 
Approval ................................................................................................................85
14.7.
Ongoing Information for Institutional Review Board / Ethics Committee................86
14.8.
Closure of the Study ...............................................................................................86
15.
DATA HANDLING AND RECORDKEEPING.....................................................87
15.1.
Data/Documents .....................................................................................................87
15.2.
Data Management...................................................................................................87
15.3.
Record Retention....................................................................................................87
16.
QUALITY CONTROL AND QUALITY ASSURANCE........................................89
16.1.
Study Monitoring and Source Data Verification......................................................89
16.2.
Audits and Inspections............................................................................................89
17.
PUBLICATIONS ...................................................................................................90
18.
REFERENCES.......................................................................................................91
19.
APPENDICES........................................................................................................94
Appendix A:  Response Evaluation Criteria in Solid Tumors.....................................................94
Appendix B:  ECOG Performance Status Scale .........................................................................96
Appendix C:  National Cancer Institute (NCI) Common Terminology Criteria for 
Adverse Events (CTCAE) Version 4.0....................................................................97
Appendix D:  New York Heart Association - Classification of Heart Failure.............................98
Page 15 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
16
LIST OF TABLES
Table 1:
A011-02:  A Phase 1b Study in Healthy Postmenopausal Women, 
Hemoglobin Evaluation ..........................................................................................26
Table 2:
Summary of Adverse Events Reported in Greater Than or Equal To 5 
Percent of Patients Overall......................................................................................29
Table 3:
Summary of SAEs Reported...................................................................................30
Table 4:
Number of Subjects with an Increase in Hgb from Baseline at Any Time and 
Sustained for Greater Than or Equal To 28 Days ....................................................30
Table 5:
ACE-011 and ACE-011/Placebo Dose Reduction Levels........................................41
Table 6:
ACE-011 Dose Escalation Levels (Part 1 Only)......................................................42
Table 7:
ACE-011 NSCLC Schedule of Assessments...........................................................46
Table 8:
Schedule of Pharmacokinetic Assessments .............................................................52
Table 9:
ECOG Performance Status Scale ............................................................................96
Table 10:
Classification of Heart Failure ................................................................................98
Page 16 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
17
LIST OF FIGURES
Figure 1:
Study Design ..........................................................................................................39
Figure 2:
 Simulated Hemoglobin Response in the Hypothetical Anemic Population .............45
Page 17 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
18
ACE-011-NSCL-001 FINAL: 17 SEP 2010
1.
INTRODUCTION
This is a single-blind, randomized, phase 2a, dose ranging study of ACE-011 therapy followed 
by a phase 2b/3, double-blind, randomized, placebo-controlled study of ACE-011 for 
chemotherapy induced anemia (CIA) in subjects with metastatic non-small cell lung cancer 
(NSCLC) treated with platinum-based chemotherapeutic regimens.  The study will consist of two 
parts.  Part 1 is a dose finding segment in which up to 90 subjects will be randomized to one of 
three ACE-011 dose treatment arms.  A Data Monitoring Committee (DMC), composed of both 
internal Celgene and external independent reviewers, will review data from Part 1 to define the 
recommended ACE-011 dose to be used in Part 2 which is the phase 2b/3, randomized, double-
blind, placebo-controlled segment of the study.  Part 2 will be performed in two stages.  In the 
first stage approximately 180 subjects will be randomized to receive ACE-011, at the dose 
determined from Part 1, or placebo at a ratio of 1:1.  An interim futility assessment based on 
transfusion rate at 4 months will be performed as described in Section 10.8.  It is expected that 
accrual will continue during the interim assessment period, with up to an additional 570 subjects 
randomized to achieve full study accrual.
ACE-011 (ActRIIA-IgG1Fc) is a human fusion protein consisting of the extracellular domain 
(ECD) of activin receptor IIA (ActRIIA) linked to the human IgG1 Fc domain, which includes 
the heavy chain hinge and constant domains, CH2 and CH3.  
The chemical structure of ACE-011 is composed of a disulfide-linked, glycosylated, dimeric 
protein.  ACE-011 competes with the activin receptor IIA that binds a number of TGF-β 
superfamily ligands including activin, GDF-11, BMP-10, GDF-3 and myostatin (growth 
differentiation factor [GDF]-8).  
In both a single and a multiple dose phase 1 study of ACE-011 in healthy volunteer, 
postmenopausal women, a dose and time dependent increase in hemoglobin (Hgb) and 
hematocrit (HCT), and red blood cell (RBC) levels were observed following ACE-011 treatment 
and remained elevated over the course of study.  
While the mechanism(s) underlying the stimulation effect of ACE-011 on erythropoiesis are not 
yet fully understood, it is hypothesized that a blockade of ActRIIA receptor signaling impedes 
the terminal differentiation step in erythropoiesis to allow additional rounds of erythroid cell 
replication before cells enter the terminal differentiation phase.  The result is a substantial 
increase in mature erythrocytes released into circulation.  Since this proposed mechanism is 
different to that of known agents, ACE-011 may provide a different clinical profile in the 
treatment of CIA.  
This study will provide information on the pharmacodynamic properties regarding the ability of 
ACE-011 to increase Hgb in subjects with CIA.  
Non-Small Cell Lung Cancer Current Therapy Status
Lung cancer is the leading cause of cancer death in the world, accounting for 32% of cancer 
deaths in males and 25% in females, affecting approximately 171,000 people annually in the US 
(Parker, 1997; Sandler, 2006) and more than 200,000 people in Europe (Rossi, 2006).  Of these 
patients, approximately 85% have NSCLC, including squamous carcinoma, adenocarcinoma and 
Page 18 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
19
ACE-011-NSCL-001 FINAL: 17 SEP 2010
large cell carcinoma (Rossi, 2006; Sandler, 2006).  These histologies are typically classified 
together because the approaches to diagnosis, staging and prognosis, and treatment are similar.  
Patients are often diagnosed with an advanced stage of disease.  Studies of advanced NSCLC 
patients treated with platinum-based chemotherapy report a one year survival rate that ranges 
from 30 to 43 percent and a median survival that ranges from seven to ten months (Dang, 2008).  
The 5-year survival rate of patients with NSCLC varies by stage, from 60 to 70% for patients 
with stage I disease to < 1% for patients with stage IV disease (Hong, 2008).  Patients having 
stage IIIb/IV NSCLC are not considered to be candidates for curative resection surgery or 
radiation, and radiation therapy is primarily used as palliative treatment in advanced stages of 
NSCLC.  
The role of chemotherapy is now well established as the recommended treatment of advanced 
NSCLC (Non-small Cell Lung Cancer Collaborative, Group 1995).  The current globally 
accepted standard of treatment for NSCLC is platinum-based combination therapy.  In advanced-
stage (stage IIB or IV) NSCLC, doublet combinations of platinum compounds (cisplatin or 
carboplatin) with gemcitabine (Gemzar®), vinorelbine, taxanes (paclitaxel or docetaxel) or 
pemetrexed are reference regimens.  When compared head-to-head in phase III studies, these 
doublets have shown comparable efficacy, in regards to overall survival (Schiller, 2002) with 
differences in toxicity profiles (Schiller, 2002).  When administered in a 3-week schedule, 
cisplatin plus gemcitabine, or cisplatin plus pemetrexed are effective and are widely used 
regimens for first-line treatment of NSCLC.  A recent phase III study in NSCLC compared 
cisplatin plus gemcitabine with cisplatin plus pemetrexed (Scagliotti, 2008).  Both had similar 
efficacy, with cisplatin plus pemetrexed having better tolerability and more convenient 
administration than cisplatin/gemcitabine.  This study was also the first prospective phase III 
study in NSCLC to show a survival difference based on histologic type (non-squamous benefited 
from pemetrexed plus cisplatin).  Drug-related grade (G) 3 or 4 anemia was at the rate of 6% for 
cisplatin/pemetrexed versus 10% for cisplatin/gemcitabine.  The incidence of RBC transfusion 
was 16.1% versus 27.3% and administration of erythropoietic agents 10.4% versus 18.1% 
respectively.  There was no significant difference between treatment arms in the incidence of or 
reason for deaths (7%).  
Treatment of Chemotherapy-Induced Anemia
Chemotherapy-induced anemia is an area of unmet medical need.  Erythropoiesis-stimulating 
agents (ESAs) can successfully mitigate transfusion need in a proportion of these patients, but 
concerns have emerged regarding apparent negative effects on survival and/or tumor progression 
in certain patient populations.  
Patients with cancer receiving multi-cycle chemotherapy are frequently anemic.  The etiology of 
CIA is multifactorial, resulting from the myelosuppressive effects of chemotherapy and the 
decrease in the production of the bone-marrow-stimulating hormone erythropoietin due to 
repeated cycles of chemotherapy (Vansteenkiste, 2002).  
The current treatment options for CIA include blood transfusion and ESAs.  However, the blood 
transfusion involves the risk of complications (such as potential transmission of infectious 
disease, alloimmunization, allergic reactions, hemolytic reactions, iron and circulatory overload, 
and possible immunosuppression) for the patient, and donor blood is a limited resource.  The 
practice of offering blood transfusions to cancer patients in chemotherapy has therefore been 
Page 19 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
20
ACE-011-NSCL-001 FINAL: 17 SEP 2010
rather restricted, generally reserved for emergencies, and severely anemic patients with serious 
symptoms. 
Erythropoiesis-stimulating agents have been approved for treating CIA.  Clinical studies have 
demonstrated that ESAs can successfully mitigate transfusion need in a proportion of these 
patients; however, new concerns have emerged regarding apparent negative effects on survival 
and/or tumor progression in certain patient populations.  In the pivotal Aranesp study for CIA in 
NSCLC, 27 % of patients were transfused with Packed Red Blood Cells (PRBC’s) at 4 months 
vs. 52% in the placebo arm.  In a subsequent recent Phase III study of Alimta/CDDP vs.
Gemcitabine/CDDP where all first-line NSCLC patients with anemia or not were enrolled, 
16.1% vs 27.3% of patients respectively were transfused with PRBC’s during that study.  
(Scagliotti, 2008)
Chemotherapy-induced anemia is a significant problem for patients with cancer, causing fatigue 
and reducing quality-of-life (QoL).  Treatment with ACE-011 resulted in increased HCT, Hgb
and absolute red cell number in both nonclinical and clinical studies.  The rapid and sustained 
increases in Hgb and HCT levels were observed in two Phase 1 studies in healthy volunteers, as 
well as in a Phase 2a study for multiple myeloma (MM). 
The ability for ACE-011 to rapidly increase and sustain Hgb levels in anemic subjects, while 
showing a safety benefit as well as no decrement in Overall Survival (as part of this study design 
endpoints), suggests that ACE-011 may then serve as an alternative therapeutic agent for the 
treatment of CIA.  
Activin Biology
The activins (A-E) are a group of proteins that form dimers and heterodimers.  All are part of the 
TGF-β protein superfamily.  The first described activin, Activin A was initially identified as a 
gonadal differentiation factor involved in modulating follicle stimulating hormone (FSH) 
secretion from the pituitary (Ying, 1988).  Subsequently, the pleiotropic nature of Activin A has 
become more apparent (Woodruff, 1998).  There is a growing body of data suggesting a role for 
activins in bone remodeling, specifically as a negative regulator of bone growth (Perrien, 2007).  
Before the two molecules were shown to be identical (Rivier, 1985), Activin A was also initially 
described as erythroid differentiation factor (EDF), effecting the maturation and differentiation 
of RBC’s (Murata, 1988).  The mechanism(s) by which Activin A influences erythropoiesis 
remains under investigation and, in fact, there are data from in vitro and in vivo studies that 
support erythropoiesis-stimulatory (Shiozaki, 1992; 1989) and erythropoiesis-inhibitory effects 
(Nakao, 1991).  
At the cellular level, the activins bind initially to the high-affinity Type II receptor (ActRIIA).  
The ligand-bound ActRIIA then recruits the low-affinity Type I receptor (ActRIA or ALK-4).  
The receptor heterocomplex, through its cytoplasmic protein kinase activity, then activates the 
Smad signal cascade to eventually influence nuclear transcriptional factors (Chen, 2002; 
Mathews, 1994).  The competitive binding of activins in the blood by the ACE-011 soluble 
fusion protein can result in inhibition of the ActRIIA receptor signaling pathway by impeding 
biological processes attributed to these pleiotropic proteins.  
The activin signaling pathway has been shown to induce terminal erythroid differentiation in 
some preclinical models.  Inhibition of activin may lead to increases in proliferation of the 
erythroid lineage.  Based on its pharmacologic effects, ACE-011 is being developed for the 
Page 20 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
21
ACE-011-NSCL-001 FINAL: 17 SEP 2010
treatment of anemia associated with a variety of disorders, such as in chronic renal failure and 
CIA.  
In a retrospective study (Seder, 2009) activin immunoreactivity was found in 78% of lung 
adenocarcinomas surveyed (n=164).  Expression ranged from moderate in the majority of 
individuals to high in approximately 19.7% of samples evaluated.  Gene expression analysis was 
also used to measure activin mRNA in 86 lung adenocarcinomas and 10 normal lung samples.  
An average of three-fold more activin transcript was detected in diseased tissue relative to 
normal samples and particularly high levels of overexpression were associated with worse 
overall survival in stage I patients with NSCLC.  
Additionally, in the NIH “directors challenge” study for NSCLC adenocarcinoma (Shedden, 
2008), three of the 12 molecular subgroups, including the subgroup with the worst survival 
prognosis, demonstrated overexpression of Activin A.  Thus, overexpression of activin may play 
a role in NSCLC tumor progression.  
ACE-011
ACE-011 (ActRIIA-IgG1Fc) is a human fusion protein consisting of the extracellular domain 
(ECD) of activin receptor IIA (ActRIIA) linked to the human IgG1 Fc domain, which includes 
the heavy chain hinge and constant domains, CH2 and CH3.  The ECD sequence of ActRIIA is 
completely conserved among numerous species including mouse, rat, cynomolgus monkey and 
humans, thus mouse, rat and cynomolgus monkeys have been considered relevant species for 
nonclinical evaluation of ACE-011.  However, in order to reduce the potential immunogenicity 
of the human molecule, ACE-011, and to maximize the opportunity to maintain exposures in 
chronic models, a murine surrogate molecule was constructed by exchanging the human 
immunoglobulin Fc sequence portion of ACE-011 with its murine IgG2a homolog.  The resultant 
construct is referred to as RAP-011 (ActRIIA-mIgG2aFc), and is described in the pharmacology 
studies below.  
Pharmacology Studies
RAP-011 was evaluated in a broad range of animal pharmacology studies to assess the effects of 
inhibition of Activin A on the biological processes attributed to that regulatory protein.  RAP-
011 has been shown to have significant effects on the red cell compartment.  RAP-011 treatment 
of mice at 10, 30 and 50 mg/kg by intraperitoneal injection (IP) twice per week for 3 months 
resulted in a 16-26% increase in RBC counts compared to control animals.  Rats treated with 
ACE-011 at 0.3, 3 and 30 mg/kg once per week for 3 months showed RBC count increases of 6-
15% over control animals.  Finally, in cynomolgus monkeys treated with 10, 30 or 50 mg/kg of 
ACE-011 twice per month for 3 months, there was a 21-24% increase in RBC counts compared 
to control animals.  In this study, the RBC count increase was apparent as early as 2 weeks 
following the initial dose of ACE-011.  
RAP-011 administered at 10 mg/kg to mice three days prior to administration of paclitaxel at 30 
mg/kg was sufficient to prevent decreases in RBC parameters typically seen three days later.  
Mice receiving paclitaxel alone had decreased HCT levels from 43% to 38% three days 
following treatment.  RAP-011 administered three days prior to paclitaxel injection was 
sufficient to keep the HCT levels above 42% at three days and up to two weeks following 
paclitaxel administration.  Therefore, prophylactic treatment with RAP-011 was able to prevent 
paclitaxel-induced anemia in mice.  
Page 21 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
22
ACE-011-NSCL-001 FINAL: 17 SEP 2010
RAP-011 has also been shown to significantly increase bone mineral density (BMD) and 
strength in normal animals and in a variety of animal models of bone loss (Chantry, 2008; 
Lotinun, 2008; Pearsall, 2008).  In a murine ovariectomy (OVX)-induced model of osteopenia, 
RAP-011 (10 mg/kg intravenous [IV], twice per week x 12 weeks) increased trabecular BMD > 
25% in 6-12 weeks compared to the phosphate buffered saline (PBS)-treated controls (p<0.002).  
RAP-011 treatment was able to reverse the accelerated bone loss associated with ovariectomy.  
As expected sham-operated (SHAM) mice (i.e., intact ovaries) started the study with a greater 
trabecular BMD than OVX mice.  PBS-treated SHAM mice showed a 10% decrease in 
trabecular BMD after 12 weeks of treatment compared to baseline, while SHAM-RAP-011 mice 
had a 32% increase in trabecular BMD over the same period.  These data demonstrate that RAP-
011 is able to increase trabecular BMD in both the normal state and in a model of established 
bone loss.  The femurs of both the RAP-011 treated OVX and SHAM mice showed statistically 
significant increases in all measured parameters of bone strength (i.e., maximum load, stiffness, 
energy, ultimate strength, and elastic modulus).  In summary, treatment with RAP-011 produced 
bone of superior quality consistent with an anabolic agent.  
RAP-011 was evaluated in a mouse model of skeletal metastasis using luciferase-tagged, human 
MDA-MB-231 breast cancer cells (estrogen receptor negative).  Mice were pretreated for 2 
weeks with RAP-011 (10 mg/kg, biweekly, subcutaneous [SC]) prior to intracardiac injection of 
tumor cells.  Treatment with RAP-011 was continued for an additional 5 weeks following tumor 
implantation.  A parallel study was conducted to examine the effect of RAP-011 treatment, as 
described above, on survival of MDA-MB-231 bearing mice.  
The data demonstrate that RAP-011 treatment acts to inhibit MDA-MB-231 metastasis to bone 
and may also play a role in inhibiting tumor growth in soft tissue.  Furthermore, in the presence 
of tumor cells, RAP-011 is able to prevent lytic disease through an anabolic mechanism of bone 
formation.  Lastly, inhibition of tumor growth and metastasis with RAP-011 leads to a greater 
than 25% survival benefit in this model.  
RAP-011 was also evaluated in osteolytic bone disease of multiple myeloma.  Multiple myeloma 
is associated with the development of bone disease characterised by increased osteoclast activity 
and a suppression of osteoblastic bone formation.  
Results obtained in the 5T2MM murine model of myeloma in which the extra-cellular domain of 
the murine activin type II receptor, fused to a murine IgG-Fc fragment, (RAP-011) was shown to 
prevent the development of osteolytic bone disease in a preventative setting.  Additionally, RAP-
011, an antagonist of activin, was shown to reverse ovariectomy-induced bone loss in vivo.  
The effect of this antagonist on the inhibition of bone formation and osteoblast function in 
myeloma bone disease was investigated in isolated 5T2MM murine myeloma cells from the bone 
marrow of disease bearing animals.  
5T2MM cells promoted the development of osteolytic bone lesions (p<0.001), a reduction in 
trabecular volume (p<0.001) and cortical volume (p<0.005).  RAP-011 completely prevented 
5T2MM-induced decreases in trabecular volume and number in both tibia (p<0.001 and p<0.01), 
femur (p<0.001 and p<0.001) and vertebrae (p<0.01 and p<0.01) when compared to vehicle 
treated mice.  Bone volume was 19% higher in the tibia, 35% higher in the femur and 12% 
higher in vertebrae of RAP-011 treated mice than naïve non-tumour bearing mice.  
Page 22 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
23
ACE-011-NSCL-001 FINAL: 17 SEP 2010
This study showed that, in the preclinical murine model for myeloma, RAP-011 stimulates bone 
formation by increasing osteoblast perimeter and number, mineralisation and bone formation rate 
but had no effect on osteoclast activity.  RAP-011 also prevented the development of osteolytic 
bone disease.  
In addition, the RAP-011 was highly effective in restoring bone mineral density (BMD) when 
administered therapeutically in a murine model of postmenopausal osteoporosis.  RAP-011 has 
also been shown to increase trabecular bone density in normal mice.  
The efficacy of RAP-011 was also examined in two orthotopic metastatic models of breast 
cancer using luciferase-tagged human MCF-7 and MDA-MB-231 breast cancer cells (estrogen 
receptor positive and negative, respectively).  Mice were pretreated for 2 weeks with RAP-011 
(10 mg/kg, biweekly, SC) prior to the intra-cardiac implantation of tumor cells into female nude 
mice.  Treatment with RAP-011 was continued for an additional 7 weeks following tumor 
implantation at which time mice were sacrificed and assessed for tumor burden.  RAP-011 either 
modestly decreased the tumor burden (in the case of mice bearing MCF-7 tumors) or delayed 
tumor growth by approximately 3 weeks (MDA-MB-231 model) as measured by bio-
luminescence.  In addition, in the MCF-7 model, a 60% reduction in tumor weight was observed 
in the RAP-011 treated mice.  
The ability of RAP-011 to repair osteolytic lesions caused by metastatic disease was investigated 
in mice.  In this model, MDA-MB-231-Luc cells were intratibially implanted in athymic nude 
mice to mimic bone metastasis.  Mice were treated with a chemotherapy regimen of paclitaxel 
(20 mg/kg, IP, every three days) starting seven days after tumor injection and continuing for the 
duration of the study.  On study day 42, mice with detectable but minimal tumor burden, as 
measured by bioluminescent imaging, were divided into two groups and treated with either 
RAP-011 (10 mg/kg, SC, biweekly) or vehicle.  Prior to dosing, μCT scans of the tumor bearing 
tibia were conducted to identify osteolytic lesions.  RAP-011 treatment continued for four weeks 
(to study day 70) and a final μCT scan of the tibia was performed.  On study day 70 there was a 
trend toward decreased number and size of osteolytic lesions in RAP-011-treated mice compared 
to control animals.  While osteolytic disease (most likely related to tumor burden) did progress in 
some of the treated mice, the majority of mice treated receiving RAP-011 developed less severe 
or no bone lesions compared to the untreated group.  Finally, treated animals also demonstrated 
an increased HCT, confirming the ability of RAP-011 to prevent CIA.  To summarize, treatment 
with RAP-011 has the ability to inhibit osteolytic lesions caused by tumors and to build new 
bone after cytotoxic chemotherapy with paclitaxel.  
Toxicology
ACE-011 has been evaluated for toxicological effects in two species, Sprague-Dawley rats and 
cynomolgus monkeys.  The dose levels ranged from 0.3 to 30 mg/kg in rats and from 1 to 50 
mg/kg in monkeys.  These dose ranges were designed to support phase 1a single-dose levels of 
0.01 to 3.0 mg/kg IV and phase 1b multiple doses of 0.1 to 2 mg/kg (monthly, SC).  Weekly (rat 
and IV monkey studies) or every 2 week (SC monkey studies) dosing in animals was designed to 
provide continuous, but fluctuating serum concentrations of ACE-011, which would be 
mimicked by a one-month dosing interval in humans.  
Test article related hematological (increase in RBC parameters) and reproductive (epididymal 
granulomas, testicular degeneration, decreased sperm counts and motility, and change in 
Page 23 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
24
ACE-011-NSCL-001 FINAL: 17 SEP 2010
ovarian/uterine weights) findings were expected pharmacodynamic effects of ActRIIA signal 
inhibition, likely mediated via modulation of erythropoiesis and FSH secretion, respectively.  
Unique to rats were adrenocortical and pancreatic findings.  Neither finding was associated with 
any clinical signs of adrenocortical (anorexia, weakness, gastrointestinal disturbances, serum 
electrolyte disturbances) or pancreatic (abnormal stool, weight loss) insufficiency.  Kidney 
findings include membranoproliferative glomerulonephritis and/or tubulointerstitial nephritis in 
rats and monkeys.  The glomerulonephritis was presumed to be due to anti-ACE-011 antibody 
deposition in the kidneys.  This presumption is supported by a robust anti-drug antibody 
response observed in rats.  However, high plasma concentrations of ACE-011 in monkeys likely 
interfered with the immunogenicity assay, so the true incidence of anti-drug antibodies is 
unknown in this species.  
The no-observed-adverse effects levels (NOAELs) from the 3 month SC studies were 3 and 30 
mg/kg in rats and monkeys, respectively.  Since the kidney findings were observed at all dose 
levels, the NOAEL from the 6 month monkey study is < 10 mg/kg.  A 9-month monkey study to 
evaluate the effects of lower concentrations of ACE-011 has been completed (refer to Potential 
Risks for Human Use).  
Summary of Clinical Experience
A011-01:  A Phase 1a Study in Healthy Postmenopausal Women (Single Dose)
ACE-011 was first studied in a randomized, phase 1a, single dose, dose escalation study in 
healthy, postmenopausal females (Ruckle, 2009).  ACE-011 was diluted in normal saline 
administered as an IV infusion (over approximately 1 hour) or as a SC injection on Day 1.  Dose 
levels were 0.01, 0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg IV and 0.03 and 0.1 mg/kg SC.  A total of 48 
subjects were enrolled; 5 active and 1 placebo at each of the IV and SC dose levels.  All subjects 
were followed for 4 months following a single dose administration.  
The pharmacokinetics (PK) of ACE-011 was linear.  The overall mean exposure (AUC) was 
proportional to doses (0.01-3 mg/kg IV, 0.03-0.1 mg/kg SC).  Across IV doses ranging from 0.1 
through 3.0 mg/kg, the mean clearance (CL) ranged from 0.092 to 0.128 mL/h/kg, the volume of 
distribution ranged from 73.7 to 110 mL/kg, and the mean terminal half life in serum (t1/2, z) 
ranged from 23.7 to 31.8 days, with no apparent dependence on dose.  After SC administration of 
0.03 and 0.1 mg/kg, ACE-011 was completely absorbed, and the mean t1/2, z was approximately 
30 days, with no apparent dependence on dose.  
The most commonly occurring treatment-emergent adverse events (AEs; i.e., those occurring in 
more than 1 subject in any treatment group) were headache, infusion site reaction, injection site 
hemorrhage, and toothache.  The majority of the injection site reactions and injection site 
hemorrhages were in the first IV cohort and were related to infiltration of the IV site.  The 
majorities of treatment-emergent AEs was mild in severity and were judged to be unrelated to 
ACE-011.  No deaths, serious AEs (SAEs), or AEs leading to discontinuation were reported.  
Changes in RBCs, Hgb, reticulocytes, liver function tests, glucose, uric acid, amylase and lipase 
occurred in some subjects.  Mild, transient elevations in pancreas enzymes, liver enzymes, or 
glucose were reported as AEs in five subjects.  
There were no clinically significant changes from baseline in vital signs, physical examination, 
endocrine function, or electrocardiogram (ECG) data.  Preservation of adrenal cortical function 
Page 24 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
25
ACE-011-NSCL-001 FINAL: 17 SEP 2010
was monitored through evaluation of serum electrolytes (sodium and potassium levels) and 
through cortisol response to adrenocorticotropic hormone (ACTH) stimulation.  
No clinically significant findings were observed at doses up to 3.0 mg/kg IV, and ACE-011 was 
well tolerated in healthy, postmenopausal female volunteers in single dose levels up to 0.1 mg/kg 
SC and 3.0 mg/kg IV, the highest dose levels tested in this study.  
A011-02:  A Phase 1b Study in Healthy Postmenopausal Women (Multiple Dose)
ACE-011 was studied in a phase 1b, single-center, randomized, double-blind, placebo-
controlled, multi-dose, dose-escalating study to evaluate the safety, tolerability and 
pharmacodynamics of ACE-011 in healthy postmenopausal women.  Four cohorts of 10 subjects 
each were planned at the following dose levels:  0.1, 0.3, 1.0, and 2.0 mg/kg administered SC.  
Within each cohort, subjects were to be randomized to either active or placebo treatment in an 
8:2 ratio.  Subjects were to receive one SC injection of ACE-011 or placebo every 28 days for a 
total of 4 doses.  All subjects were to be followed for 12 weeks after the last dose.  
The treatment phase of the study was terminated early after a dose-limiting pharmacodynamic 
effect was observed.  While on study, one subject in the 1.0 mg/kg cohort experienced an SAE of 
progressive and persistent hypertension that was attributed to a rapid and significant rise in Hgb
levels, up to 20 g/dL and HCT levels, up to 57.3%.  Due to symptoms of headaches, nausea, eye 
pain, dizziness and vomiting approximately one week following the second dose, the subject was 
hospitalized for monitoring and evaluation of her hypertension.  The head MRI, fundoscopy, and 
ECG performed were reported as normal and headache symptoms resolved following corrective 
treatment by phlebotomy.  The SAE resolved and the subject was discharged from the hospital 
the following day.  The hypertension was monitored closely and managed initially with 
antihypertensive medication.  The hypertension resolved by the end of the study without need of 
any antihypertensive medication.  The subject received aspirin prophylactically until the end of 
the study and continued taking ibuprofen as needed for headaches.  Further details can be found 
in the Investigator’s Brochure.  
Based on the magnitude of the hematopoietic response, the Sponsor suspended dose escalation to 
the 2.0 mg/kg dose level and further dosing in all cohorts as a result of this dose-limiting 
pharmacodynamic effect at the 1.0 mg/kg dose level.  In total, 31 subjects were enrolled and 
treated.  Dose levels of ACE-011 administered included 0.1, 0.3, and 1.0 mg/kg (Cohorts 1, 2, 
and 3 respectively).  All subjects randomized to active treatment in Cohort 1 received all 4 
planned doses of ACE-011.  Due to early discontinuation of study drug, subjects randomized to 
active treatment in Cohort 2 received 3 doses of ACE-011, and subjects randomized to active 
treatment in Cohort 3 received 2 doses of ACE-011.  Subjects randomized to placebo treatment 
received between 1 and 4 doses of study treatment.  
Page 25 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
26
ACE-011-NSCL-001 FINAL: 17 SEP 2010
In the analysis of the data, after the administration of the first dose, a dose and time dependent 
increase in Hgb, HCT, and RBC values were observed (see Table 1 below for changes in Hgb 
levels):
Table 1:
A011-02:  A Phase 1b Study in Healthy Postmenopausal Women, 
Hemoglobin Evaluation
Mean Change from Baseline (g/dL)
Evaluation Time Point
Placebo
N=7a
ACE-011
0.1 mg/kg
N=8
ACE-011
0.3 mg/kg
N=8
ACE-011
1.0 mg/kg
N=8
Baseline Mean, pre-Dose 1
13.20
13.11
13.30
12.71
Day 8
0.17
0.68
0.85
1.21
Day 15
-0.27
0.43
0.44
1.75
Day 29
0.27
0.61
1.21
2.68b
Day 36
0.56
0.64
1.89
2.96
Day 43
-0.02
0.89
1.21
2.85
Day 57
0.27
1.28
1.64b
2.09
Day 64
0.53
1.11
2.49
2.21
Day 71
-0.10
1.34
2.09
1.66
Day 85
0.38
1.18b
2.55
1.86
Day 92
0.00c
1.04
1.60c
3.80c
Day 99
-0.20
1.21
3.20c
1.28c
Day 113
-0.02
1.30
1.29
1.04
Day 141
0.30
0.95
0.34
2.30
Day 169
0.20c
0.06
-
2.00c
aThe number of placebo subjects with data decreases over time as a result of the early discontinuation of the study
(i.e., there were placebo subjects in each dosing cohort).  There were seven placebo subjects with data at baseline, 
Days 8, 15, and 36; six subjects with data at Days 29, 43, 57, and 85; five subjects with data on Days 71 and 113; 
four subjects with data on Day 64; three subjects with data on Day 141; two subjects with data on Day 99; and one 
subject with data on Days 92 and 169.  
bNumber of doses administered per treatment group:  0.1 mg/kg 4 doses; 0.3 mg/kg 3 doses; 1.0 mg/kg 2 doses.
Data beyond this study day are considered follow-up results.  
cn=1
Other than the serious case of Hgb increase, no life-threatening events were reported.  The most 
notable AEs were those related to increases in hematologic laboratory measures in the 1.0 mg/kg 
dose group:  HCT, Hgb, and RBC count.  The AEs of increased Hgb and/or HCT were reported 
for seven of the eight subjects in this dose group.  These events were reported as mild or 
moderate elevations; all were considered probably related to study drug treatment.  Three of the 
subjects in the 1.0 mg/kg group with elevated Hgb levels underwent phlebotomies and all Hgb 
Page 26 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
27
ACE-011-NSCL-001 FINAL: 17 SEP 2010
elevations were resolved by the end of the follow-up period.  No erythroid lineage AEs were 
reported in the 0.1 or 0.3 mg/kg treatment groups.  
Paresthesia and dizziness were reported more frequently in the ACE-011 groups, though the 
events were < G 2 and generally not considered drug related.  Other frequently reported events 
(e.g. fatigue, upper respiratory infection) did not appear to increase with dose and were generally 
mild.  
Hemoglobin levels for all subjects with elevations had returned to within normal limits by the 
end of the study.  
Adrenal cortical function was monitored through evaluation of serum electrolytes (sodium and 
potassium levels) and through cortisol response to adrenocorticotropic hormone (ACTH) 
stimulation.  All ACTH simulation test results were normal.  
The PK of ACE-011 were linear after SC administration.  Both AUC28d and Cmax were 
proportional to dose from 0.1 to 1 mg/kg following the first SC administration.  The t1/2, z of 
ACE-011 following the last dose in all three dose groups was identical, with mean t1/2, z being 
approximately 23 days.  Based on the one-compartmental modeling, the mean CL/F ranged from 
3.05 to 3.90 mL/d/kg, the mean Vz/F ((apparent) volume of distribution) ranged from 97.47 to 
103.03 mL/kg, with no apparent dependence on dose.  
Bone mineral density was assessed by dual-energy X-ray absorptiometry (DXA).  A dose-
dependent increase in the BMD of the total hip from baseline to end of study was observed, with 
a significant and rapid increase of 2.4% in the 1.0 mg/kg dose group, compared to a 0.7% 
decrease in the placebo group.  BMD results for lumbar spine showed slight increases of 0.4% to 
1.0% from baseline to study end in all active treatment groups, compared with a 0.5% decrease 
in the placebo group.  
A011-04:  A Phase 2a Study in Patients with Osteolytic Lesions of Multiple Myeloma / 
Preliminary Results
Study A011-04 is a phase 2a, multi-center, randomized, multiple-dose study to evaluate the 
safety, tolerability and efficacy of ACE-011 in subjects with osteolytic lesions of multiple 
myeloma (MM).  
In this study, subjects were randomized in a 4:1 ratio to one of three dose levels of ACE-011 
(0.1, 0.3 and 0.5 mg/kg) or placebo, administered to subjects every 28 days by SC injection, for 
up to four doses over a 3-month period.  ACE-011 was evaluated in combination with the anti-
myeloma therapy of melphalan (4 mg/m2 on days 1-7), prednisolone (40 mg/m2 on days 1-7) and 
thalidomide (100 mg per day) (MPT).  The sites, Sponsor and Sponsor representatives were 
blinded to treatment assignment.  
Thirty subjects were randomized and received at least one dose of study medication:  6 subjects
received placebo, 8 subjects received 0.1 mg/kg ACE-011, 8 subjects received 0.3 mg/kg ACE-
011, and 8 subjects received 0.5 mg/kg ACE-011.  Twenty six (86.7%) subjects completed the 
study.  One subject in the 0.1 mg/kg dose group and one subject in the 0.5 mg/kg dose group 
discontinued due to AEs.  One subject in the 0.1 mg/kg dose group withdrew consent and was 
discontinued, and one subject in the 0.3 mg/kg dose group was discontinued at the request of the 
investigator.  
In this study, 50.0% of subjects were female and the mean (range) age was 60.9 (41 to 79) years.  
Page 27 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
28
ACE-011-NSCL-001 FINAL: 17 SEP 2010
The mean time since diagnosis of MM was 3.3 years, the majority of subjects had stage III 
disease at screening (83.3%) and had received prior chemotherapy (93.3%).  Approximately
43.3% of subjects were receiving bisphosphonates at screening, which continued during the 
study.  
Fourteen out of 24 subjects (58%) who received study treatment (ACE-011) did receive 3 doses
or more (4 out of 8 subjects in the 0.5 mg/kg dose level, 5 out of 8 subjects in the 0.3 mg/kg dose 
level and 5 out of 8 subjects in the 0.1 mg/kg dose level).  
Safety:  Overall, 22 (91.7%) subjects receiving ACE-011 and 4 (66.7%) subjects receiving
placebo reported at least one AE.  Among subjects receiving ACE-011, AEs were reported in 
87.5%, 87.5%, and 100% of subjects in the 0.1 mg/kg, 0.3 mg/kg, and 0.5 mg/kg dosing cohorts, 
respectively.  Treatment-related AEs (ie, those assessed by the Investigator as possibly, probably, 
or definitely related to treatment) were reported by 21 (87.5%) subjects receiving ACE-011 and 
4 (66.7%) receiving placebo.  Most subjects had AEs that were assessed as related to MPT:  21 
(87.5%) subjects receiving ACE-011 and 4 (66.7%) subjects receiving placebo.  No AEs were 
assessed by the Investigator as related to the study medication alone (ACE-011 or placebo).  Two 
subjects had AEs assessed as possibly or probably related to study drug and possibly or probably 
related to MPT, one subject in the 0.1 mg/kg ACE-011 dose group (increased blood pressure; 
sudden death) and one subject in the 0.5 mg/kg ACE-011 dose group (hypertension).  Four 
subjects had SAEs, 1 (12.5%) subject in the 0.1 mg/kg ACE-011 group and 3 (37.5%) subjects in 
the 0.5 mg/kg ACE-011 group.  Three subjects had SAEs that were assessed as treatment-related.  
Of the 3 treatment-related SAEs, 2 SAEs were assessed as possibly related to MPT and unrelated 
to ACE-011, and 1 SAE (sudden death) was assessed as probably related to MPT and possibly 
related to ACE-011.  One subject in the 0.5 mg/kg ACE-011 dose group discontinued study drug 
due to episodes of atrial fibrillation assessed as possibly related to MPT and unrelated to 
ACE-011.  
Table 2 summarizes the most frequent AEs ≥5% in all treatment groups and Table 3 is a 
summary of SAEs reported.  
Page 28 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
29
ACE-011-NSCL-001 FINAL: 17 SEP 2010
Table 2:
Summary of Adverse Events Reported in Greater Than or Equal To 5
Percent of Patients Overall
ACE-011 Treatment Group
Preferred 
Terma
Placebo
(N=6)
0.1 mg/kg
(N=8)
0.3 mg/kg
(N=8)
0.5 mg/kg
(N=8)
All ACE-011
(N=24)
Any 
Grade
Grade ≥3
Any 
Grade
Grade ≥3
Any 
Grade
Grade ≥3
Any 
Grade
Grade ≥3 Any Grade Grade ≥3
Neutropenia
4 (66.7%) 1 (16.7%) 4 (50.0%) 2 (25.0%) 6 (75.0%) 2 (25.0%) 6 (75.0%) 3 (37.5%) 16 (66.7%) 7 (29.2%)
Leukopenia
0
0
3 (37.5%) 1 (12.5%) 1 (12.5%) 0
1 (12.5%) 1 (12.5%) 5 (20.8%)
2 (8.3%)
Granulo-
cytopenia
0
0
2 (25.0%) 1 (12.5%) 1 (12.5%) 1 (12.5%) 1 (12.5%) 1 (12.5%) 4 (16.7%)
3 (12.5%)
Anaemia
0
0
1 (12.5%) 1 (12.5%) 1 (12.5%) 1 (12.5%) 2 (25.0%) 1 (12.5%) 4 (16.7%)
3 (12.5%)
Respiratory 
tract 
infection
0
0
1 (12.5%) 1 (12.5%) 1 (12.5%) 0
1 (12.5%) 0
3 (12.5%)
1 (4.2%)
Thrombo-
cytopenia
0
0
1 (12.5%) 0
0
0
2 (25.0%) 1 (12.5%) 3 (12.5%)
1 (4.2%)
Pyrexia
0
0
1 (12.5%) 0
1 (12.5%) 0
1 (12.5%) 0
3 (12.5%)
0
Blood 
pressure 
increased
0
0
1 (12.5%)*1 (12.5%)*0
0
1 (12.5%) 0
2 (8.3%)
1 (4.2%)
Bronchitis
1 (16.7%) 0
0
0
1 (12.5%) 0
1 (12.5%) 0
2 (8.3%)
0
Compression 
fracture
0
0
0
0
1 (12.5%) 0
1 (12.5%) 0
2 (8.3%)
0
Pathological 
fracture
0
0
1 (12.5%) 0
0
0
1 (12.5%) 1 (12.5%) 2 (8.3%)
1 (4.2%)
aAdverse events were those that were treatment-emergent, defined as newly acquired or worsened during or after 
administration of first dose of study medication.  A patient with multiple occurrences of an AE counted only once 
under each preferred term.  
*Indicates the adverse event was assessed by the investigator as related (possibly, probably, or definitely) to study 
drug (ACE-011 or placebo).  
Page 29 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
30
ACE-011-NSCL-001 FINAL: 17 SEP 2010
Table 3:
Summary of SAEs Reported
Study Treatment
Age (y) / 
Sex / Race
Preferred Term
(Verbatim Term)
[Severity / Gradea]
Study Dayb
at Onset
Outcome
(duration)
Relationship to Study 
Treatment
0.1 mg/kg 
ACE-011 and 
MPT
Sudden death
(sudden death)
103
Death
ACE-011:  possibly
MPT:  probably
0.5 mg/kg 
ACE-011 and 
MPT
Pain in extremity
(pain in leg)
[severe / G 3]
128
Ongoing at 
end of study
ACE-011:  not related
MPT:  not related
Pathological fracture
(pathological fracture of 
femur)
[severe / G 3]
130
Ongoing at 
end of study
ACE-011:  not related
MPT:  not related
0.5 mg/kg 
ACE-011 and 
MPT
Pneumonia
(pneumonia)
[moderate / G 2]
9
Resolved
(12 days)
ACE-011:  not related
MPT:  possibly
0.5 mg/kg 
ACE-011 and 
MPT
Atrial fibrillation
(atrial fibrillation)
[life-threatening / G 4]
6
Resolved
(1 day)
ACE-011:  not related
MPT:  possibly
F= female; M = male; MPT = melphalan, prednisolone, and thalidomide; NCI CTCAE, v3.0 = National Cancer 
Institute Common Terminology Criteria for Adverse Events, version 3.0; y = years
abased on NCI CTCAE, v3.0.  
bRelative to first dose of study drug.  
Following analysis of the central laboratory data, increases in Hgb values were observed within 
28 days after administration of the first dose of ACE-011/placebo and sustained for ≥ 28 days 
from baseline at any time as presented in Table 4.  
Table 4:
Number of Subjects with an Increase in Hgb from Baseline at Any Time and 
Sustained for Greater Than or Equal To 28 Days
Dose ACE-011/Placebo
Increase in Hgb
mg/kg
N=8
0.3 mg/kg
N=8
0.5 mg/kg
N=8
Placebo
N=6
Overall
N=30
≥ 1.0 g/dL
4
3
7
2
16
≥ 1.5 g/dL
2
3
3
1
9
≥ 2.0 g/dL
1
3
2
0
6
Taken together, these data, suggest a beneficial pharmacodynamic effect of ACE-011 on 
erythropoiesis in a patient population with cancer CIA.  
Potential Risks for Human Use
Nonclinical studies to determine the safety of ACE-011 have been conducted in cynomolgus 
monkeys and Sprague Dawley rats.  Many of the observed effects in these studies were as a 
result of the expected biologic activity of activin inhibition and can be summarized as a 
dose-dependent decrease in sperm count and motility secondary to FSH suppression as well as 
Page 30 of 791
PPD
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
31
ACE-011-NSCL-001 FINAL: 17 SEP 2010
reversible increases in RBC parameters due to the effects on erythroid differentiation factor 
(activin).  
The most significant toxicity findings are listed below:  

Hematological findings (increase in RBC parameters – RBCs, Hgb, HCT) were 
observed across all studies.  Associated with the increase in RBC parameters were 
increases in reticulocytes and decreases in mean corpuscular hemoglobin (MCH) and 
mean corpuscular hemoglobin concentration (MCHC).  The increase in RBC 
parameters is an anticipated effect of ACE-011 treatment and is being targeted as a 
therapeutic intervention for conditions associated with anemia.  

In the 6- and 9-month monkey studies, glomerulonephritis and/or tubulointerstitial 
nephritis were observed in monkeys administered ≥ 10 mg/kg administered 
subcutaneously (SC) every 2 or 4 weeks.  At 2.6 mg/kg administered SC every 4 
weeks for 9 months, kidney findings were limited to a single incidence of 
tubulointerstitial nephritis. The NOAEL in the 9-month study was considered to be 1 
mg/kg every 4 weeks.  Serum exposure in monkeys at the 1 mg/kg dose is estimated 
to be ~1.3-fold greater than the projected serum exposure in humans at the maximum 
proposed human dose of 61 mg every 6 weeks.  In the single- and multiple-dose 
studies in healthy postmenopausal women, there have been no changes in serum 
chemistry or urinalysis profiles suggestive of kidney injury. Subjects administered 
ACE-011 should continue to be closely monitored.  

In the 9-month monkey study, treatment-related findings in the choroid plexus 
included:  perivascular accumulations of foamy macrophages and intimal thickening 
of small arteries and arterioles primarily at 10 mg/kg administered every 2 weeks as 
well as an increased incidence of small, focal aggregates of mononuclear 
inflammatory cells at all dosages.  Findings at 1 mg/kg were limited to mononuclear 
cell infiltrates and were not adverse. 

Adrenal gland congestion or necrosis was observed in rats but not in monkeys.  The 
finding was more pronounced in female rats and appeared following either one month 
of IV dosing or 3 months of SC dosing.  Although the current data suggest adrenal 
toxicity may be specific to rats, the relevance of the adrenal findings to humans is 
uncertain.  

Elevations in liver enzymes (alanine aminotransferase [ALT], aspartate 
aminotransferase [AST], and/or alkaline phosphatase), as well as triglycerides, were 
observed sporadically in rats and monkeys treated with ACE-011.  There were no 
histological correlates in the liver, and often a dose-response relationship was not 
observed.  The relevance of these findings to ACE-011 treatment is uncertain; 
however, these endpoints will continue to be monitored in the clinic.  

Pregnancy and Lactation

Due to the potential for effects on hormones in the pituitary, including FSH, in 
addition to possible direct effects on fetus, there may be potential effects on the 
fetus.  Delays in fetal development (decreased fetal weights and delays in 
ossification) were observed at doses ≥15 mg/kg (15-fold greater on a mg/kg basis 
Page 31 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
32
ACE-011-NSCL-001 FINAL: 17 SEP 2010
than the maximum proposed human dose of 60 mg every 6 weeks assuming a 60 
kg person).  In addition, at 50 mg/kg (100-fold the maximum proposed human 
dose), there was an increase in late fetal death coupled with an overall increase in 
postimplantation loss and a reduction in live litter size, as well as an increase in 
the incidence of developmental variations of supernumerary ribs with 
corresponding increases and decreases in thoracic and lumber vertebrae, 
respectively.  No fetal malformations were observed in this study at dosages up to 
50 mg/kg. The NOAEL for embryofetal development effects was 5 mg/kg 
(~5-fold greater than the maximum proposed human dose of 60 mg every 6 weeks 
assuming a 60 kg person) based on reduced fetal weights and associated delays in 
ossification. Although the risks for embryofetal development effects are 
considered relatively low given the large safety margins, precautions should still 
be taken to protect females of childbearing potential.  Nonclinical studies on 
breast milk have not been done.  

If ACE-011 is taken during pregnancy, a teratogenic effect in humans cannot be 
ruled out.  Therefore, all ACE-011 protocols describe pregnancy prevention 
requiring females of child-bearing potential to use highly effective methods of 
birth control.  In addition, since it is unknown if ACE-011 is found in breast milk, 
breast feeding is prohibited in all protocols.  

Fertility

In male rats, sperm granulomas and testicular degeneration were observed 
histologically.  In addition, sperm analysis revealed a reduction in sperm counts 
and motility as well as sperm fragmentation in isolated animals (2/10 males) at 
doses of 30 mg/kg IV.  Sperm fragmentation was also noted in 2/5 males 
administered 10 mg/kg IV at the end of the recovery period.  Overall, there was 
some evidence of recovery (motility similar to controls) at the end of the 4-week 
recovery period.  There was no evidence of a treatment-related impact on 
reproductive organs (testes, ovary, uterus) of monkeys in the toxicity studies; 
however, the monkeys on these studies, were too immature to fully assess the 
potential impact on reproductive organs.  The NOAEL for reproductive effects 
(testicular or ovarian) was 1 mg/kg IV.  Serum exposure (AUC28d) in rats at the 
NOAEL was estimated to be ~ 8,000 µg·hr/mL based on the single-dose IV 
pharmacokinetic study in rats (Report TR148), ~ 2-fold greater than the serum 
exposure observed in humans at the maximum proposed dose of 60 mg every 6 
weeks (estimated AUC28d ~ 4548 μg·hr/mL). 

In summary, in view of the potential risks ACE-011 treatment has on fertility, 
ACE-011 is targeted toward patient groups for whom the potential benefits 
outweigh the perceived risks.  
Because of the potential risks ACE-011 treatment has on fertility, ACE-011 was first studied in 
healthy postmenopausal in two completed phase 1 clinical trials.  In addition, due to the potential 
for effects on hormones in the pituitary, levels of growth hormone, ACTH, and thyroid 
stimulating hormone (TSH) were monitored closely in the phase 1 studies.  
Page 32 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
33
ACE-011-NSCL-001 FINAL: 17 SEP 2010
Completed studies in humans carried out in postmenopausal females showed a dose-dependent 
decrease in circulating levels of FSH, with mean levels in the multidose study in the two higher 
dose groups remaining below baseline at study end.  FSH will continue to be evaluated in 
ongoing studies.  No abnormal effects of ACE-011 on growth hormone, ACTH, and TSH and 
kidney toxicities were observed.  
Based on the safety data from the two completed phase 1 studies, single doses of ACE-011 up to 
3.0 mg/kg IV and multiple doses of ACE-011 up to 0.3 mg SC were generally well-tolerated in 
healthy postmenopausal women.  Consistent with observations from nonclinical safety studies, 
many of the observed pharmacodynamic effects in the phase 1 clinical studies could be attributed 
to the expected biologic activity of activin inhibition, i.e., dose-dependent decrease in circulating 
levels of FSH, and transient, reversible effects on RBC parameters.  In Study A011-02 one 
subject experienced persistent, progressive hypertension and headaches approximately 1 week 
following her second dose of 1.0 mg/kg ACE-011 SC that were attributed to a rapid and 
significant rise in Hgb levels.  The hypertension was reported as an SAE.  
In regards to the above safety concerns, appropriate vitals, hematologic, clinical chemistry and 
endocrine testing will be closely monitored in this clinical study.  There may be an effect of 
delayed wound healing, thus subjects with major surgeries within 30 days prior to study 
initiation will be excluded.  As with all biologics there is the potential for anti-drug antibodies 
that can be associated with increased drug clearance and hypersensitivity reactions.  Although no 
current evidence of neutralizing anti-drug antibodies formation was seen in two completed phase 
1 clinical trials, anti-drug antibody formation will be monitored in this clinical study.  
Please refer to the Investigator Brochure for further detailed information on the available 
pharmacology, toxicology, drug metabolism, clinical studies and AE profile of ACE-011.  
Page 33 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
34
ACE-011-NSCL-001 FINAL: 17 SEP 2010
2.
STUDY OBJECTIVES
2.1.
Primary Objective

Part 1:  To determine an effective dose of ACE-011 showing a hematopoietic 
response in the treatment of CIA in advanced NSCLC subjects.  

Part 2:  To assess transfusion rate within 4 months following initiation ACE-011 
treatment.  
2.2.
Secondary Objectives
Part 1 and Part 2:

To estimate the effect of ACE-011 treatment on objective response rate (ORR), time 
to progression (TTP), progression free survival (PFS) and overall survival (OS) in 
advanced NSCLC subjects with CIA.  

To evaluate the safety and tolerability of ACE-011 treatment for advanced NSCLC 
subjects with CIA.  

To determine the PK of ACE-011 in subjects with advanced NSCLC receiving 
platinum-based chemotherapy.  

To estimate the duration of hematopoietic response associated with ACE-011.  

To evaluate the effect of ACE-011 treatment on the quality of life (QoL) of NSCLC 
subjects with CIA.  
Part 2:

To evaluate hematopoietic response
2.3.
Exploratory Objectives
Part 1 and Part 2:

To estimate the effect of each ACE-011 treatment on bone metabolism in NSCLC 
subjects with CIA.  

To explore the relationship between ACE-011 exposure and response (hematology, 
biomarkers, and other clinical outcomes as appropriate).  

To evaluate the expression/overexpression of Activin A and other 
proteins/biomarkers related to ACE-011 mechanism of action in blood and tumor 
tissue in the NSCLC population.  

To assess circulating tumor cells and molecular studies

To assess renal function biomarkers
Data from exploratory objectives may not be included in the Clinical Study Report.  
Page 34 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
35
ACE-011-NSCL-001 FINAL: 17 SEP 2010
3.
STUDY ENDPOINTS
3.1.
Primary Endpoint(s)
Part 1:  Dose Finding
The following are decision rules for dose determination in Part 1 in order to move forward to 
Part 2:

After completion of two doses of ACE-011, a hematopoietic response in 
approximately 70% of subjects, in at least one or more treatment arms.  

Hematopoietic response is defined as an increase in Hgb of ≥ 1.0 g/dL above the 
study baseline value for 4 consecutive weeks, in the absence of RBC transfusions 
and/or ESAs.  In order to determine the optimal dose of ACE-011 to be used in Part 
2, evaluation of hematopoietic response will be determined from ACE-011 Dose 1/
Day 1 through and including Dose 2/Day 43 (prior to Dose 3).  

In addition to the hematopoietic response, the safety profile, dose modifications and 
extent of exposure in each dosing level will be taken into account to determine the 
study dose to be used in Part 2.  
Hematopoietic response will be determined by laboratory analysis.  
Part 2:  Phase 2b/3 Double-Blind

Rate of RBC transfusion within four months following ACE-011/placebo treatment
3.2.
Secondary Endpoint(s)

Safety (type, frequency, and severity [National Cancer Institute (NCI) Common 
Terminology for Adverse Events (CTCAE) current active minor version 4.0] of 
adverse events

TTP 

PFS (including at 6 and 12 months)

OS (at 12 months and up to 24 months)

ORR

ACE-011 concentration in serum 

Non-compartmental PK parameters for ACE-011 (Part 1 only)

QoL assessment (FACIT Fatigue Scale (Version 4)) and LCSS questionnaire (Hollen, 
1995)
Page 35 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
36
ACE-011-NSCL-001 FINAL: 17 SEP 2010
3.3.
Exploratory Endpoint(s)

Change in serum and urine bone biomarkers, including osteocalcin (OC), serum bone 
specific alkaline phosphatase (BSAP), procollagen type 1 N-terminal propeptide 
(P1NP), C-terminal type 1 collagen telopeptide (CTX) and tartrate-resistant acid 
phosphatase isoform-5b (TRACP-5b), the urine bone biomarker (urine N-telopeptide 
[uNTX]) related to activin or ACE-011 mechanism of action  

Change in BMD (DXA scans of lumbar spine and hip)

Change in time to first symptomatic skeletal related event (SRE) defined as 
pathologic fracture, clinical need for radiation therapy, surgery to bone or spinal cord 
compression

A population PK model for ACE-011  

A population pharmacodynamic model describing Hgb response as a function of time, 
ACE-011 exposure, and subject characteristics 

Expression/overexpression of Activin A and other protein/biomarkers related to 
ACE-011 mechanism of action in blood and tissue in a NSCLC population 

Change in circulating tumor cells and molecular studies

Renal function biomarkers via urinalysis measuring urine albumin / creatinine ratio, 
urine protein / creatinine ratio and other serum biomarkers
Page 36 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
37
ACE-011-NSCL-001 FINAL: 17 SEP 2010
4.
OVERALL STUDY DESIGN
4.1.
Study Design 
This is a single-blind, randomized, phase 2a, dose ranging study of ACE-011 therapy followed 
by a phase 2b/3, double-blind, randomized, placebo-controlled study of ACE-011 for CIA in 
subjects with metastatic NSCLC treated with platinum-based chemotherapeutic regimens.  
The study will consist of two parts.  Part 1 is a dose finding segment in which subjects will be 
randomized to one of three ACE-011 dose treatment arms.  A DMC, will conduct periodic data 
reviews, including the review of Part 1 data, to define the recommended ACE-011 dose to be 
used in Part 2, the phase 2b/3, double-blind, randomized placebo-controlled segment of the 
study.  
Part 1 is planned to be conducted primarily at selected US sites.  The study will then be 
extended to additional global sites for the conduct of Part 2.  
Study treatment is defined as ACE-011 in Part 1 and ACE-011/placebo in Part 2.  
Three starting ACE-011 dose levels, 15.0, 30.0, and 45.0 mg, were selected for Part 1 of the 
study. Up to approximately 90 subjects will be randomized to one of the following ACE-011 
dose levels, with 10-30 subjects per arm:

ACE-011 15.0 mg SC

ACE-011 30.0 mg SC
Following DMC review, analysis of safety data and assessment of dose effects of Hgb levels, a 
decision will be made to start concurrent randomization to:  

ACE-011 45.0 mg SC
Each dose level will be administered every 42 days for four doses.  
The DMC will continue to monitor safety of the ACE-011 45.0 mg dose level.  
In Part 2, a total of 750 subjects will be randomized to receive either ACE-011 (at the dose 
determined in Part 1) or placebo, at a ratio of 1:1:

375 subjects will receive ACE-011 (at the dose determined in Part 1)

375 subjects will receive placebo
Each dose of ACE-011 or placebo will be administered every 42 days for four doses; two 
additional doses may be given at the discretion of the Investigator.  
Part 2 will be performed in two stages.  In the first stage, approximately 180 subjects will be 
randomized to receive ACE-011, at the dose determined from Part 1, or placebo at a ratio of 1:1.  
An interim futility assessment based on transfusion rate at 4 months will be performed as 
described in Section 10.8.  It is expected that accrual will continue during the interim assessment 
period, with up to an additional 570 subjects randomized to achieve full study accrual. 
The Treatment Period for Part 1 is up to approximately six months and for Part 2 up to nine
months.  Subjects who enter the Post Treatment Follow-Up Period will be followed for up to 6 
Page 37 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
38
ACE-011-NSCL-001 FINAL: 17 SEP 2010
months from their last dose of ACE-011 or ACE-011/placebo.  All subjects will continue to be 
followed for TTP and PFS up to 12 months from their first dose of ACE-011 or ACE-
011/placebo or until progression of their NSCLC, whichever comes first.  
Survival data will be collected monthly for up to 24 months following the subject’s first dose of 
ACE-011 in Part 1 or ACE-011/placebo in Part 2.  
At the time of randomization, all subjects must be receiving a first-line platinum-containing 
chemotherapy regimen, given every three weeks, for the treatment of metastatic NSCLC.  
Subjects may have already received up to 3 cycles of this first-line platinum-based regimen to be 
eligible for the study.  Subjects are expected to be eligible to receive 2 platinum-based 
chemotherapy cycles or maintenance therapy with a pemetrexed-based regimen following 
randomization.  
Maintenance chemotherapy with a pemetrexed-containing regimen will only be allowed 
following completion of the subject’s platinum-based chemotherapy, with a best response of at 
least stable disease.  
Stratification and randomization will be performed utilizing a validated interactive voice 
response system (IVRS).  

In Part 1, subjects will be randomized to one of three ACE-011 dose levels and will be 
stratified by:
1. Baseline Hgb level 

6.5 to < 9.0 g/dL

9.0 to < 11.0 g/dL
2. Type of platinum-based chemotherapy (cisplatin versus carboplatin)

In Part 2 subjects will be randomized to receive either ACE-011 or placebo and will be 
stratified by:
1. Baseline Hgb level 

6.5 to < 9.0 g/dL

9.0 to < 11.0 g/dL
2. Type of platinum-based chemotherapy (cisplatin versus carboplatin)
3. NSCLC histology (Squamous NSCLC vs. Non-Squamous NSCLC)
4. ECOG Performance Status 0-1 vs. 2
Page 38 of 791
088VGY

088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
40
ACE-011-NSCL-001 FINAL: 17 SEP 2010
4.1.1.
ACE-011 Dose Modification, Reduction and Escalation Rules
Subjects should have Hgb and blood pressure measured prior to each dose of study drug.  The 
Investigator must adhere to the following Hgb and blood pressure-based dose modification rules 
for ACE-011 or ACE-011/placebo for the subject’s second dose of study treatment and beyond.  
ACE-011 Dose Modification Rules:
Hemoglobin < 11g/dL
(per local lab value) 
Hemoglobin ≥ 11g/dL
(per local lab value) 
Hypertension > Grade 2
1Subjects who have received an RBC transfusion in the past 42 days should continue at the same ACE-011 dosing 
level if the transfusion was given greater than 7 days from the previous dose of ACE-011 (or ACE-011/placebo) 
AND the Hgb level is < 11 g/dL AND hypertension is ≤ Grade 2 on the day of dosing.  ACE-011 (or ACE-
011/placebo) should not be administered within 7 days post RBC transfusion.  
< 2.0 g/dL increase within a 
dosing period
≥ 2.0 g/dL increase sustained for a 
28 day period since last dosing day2
Note: ≥ 3.0 g/dL increase sustained 
for a 28 day period since last dosing 
day requires a two level dose 
reduction.  
< 2.0 g/dL increase within a 
dosing period
≥ 2.0g/dL increase sustained for a 
28 day period since last dosing 
day2
Note: ≥ 3.0g/dL increase sustained 
for a 28 day period since last 
dosing day requires a two level 
dose reduction.  If  Hgb is > 15.0 
g/dL, sustained for 7 days, subject 
is to be discontinued from 
treatment2. 
Dose Delay5
Continue 
Dosing1
(Part 1only-
Dose 
Escalation 
Table 6)
Dose 
Reduction
Table 5:
Dose Delay3
Dose Delay
then, Dose 
Reduction4
Page 40 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
41
ACE-011-NSCL-001 FINAL: 17 SEP 2010
For Part 1 only:  if the RBC transfusion was given > 7 days following the previous dose of ACE-011, the 
subsequent dose of ACE-011 will be increased one dose level (Refer to ACE-011 Dose Escalation Levels-
Table 6).  
2Hemoglobin increases of > 2 g/dL sustained for a 28 day period since last dosing day should be confirmed by the 
local lab for the dosing day, 7, 14 , 22 (after first dose of study treatment) and 28 days after dosing, and reviewed
in comparison to Hgb level on previous dosing day.  Any Hgb increase of ≥3.0 g/dL sustained for 28 days will 
require a subsequent ACE-011 or ACE-011/placebo dose reduction of two dose levels (Refer to ACE-011and 
ACE-011/Placebo Dose Reduction Levels (Table 5).  A second Hgb increase of ≥3.0 g/dL sustained for 28 days, 
following a two level dose reduction, will require the subject discontinue from study treatment.  If Hgb is > 15.0
g/dL (sustained for a 7 day period, confirmed by laboratory assessment) subject is to be discontinued from 
treatment.  (See Section 8.2.3 Discontinuation)  
3ACE-011 should be delayed until Hgb is < 11g/dL and hypertension ≤Grade 2.  The follow-up dosing can 
commence at 7 days or later after the originally planned ACE-011/placebo dose that was delayed.  Subsequent 
ACE-011/placebo doses will then begin 42 days following this revised treatment dose date.  
A delayed ACE-011/placebo dose is defined as a dose not administered > 4 days from the planned dosing date 
(due to Hgb ≥ 11.0 g/dL, hypertension > Grade 2, and/or ACE-011 related toxicity).  
4ACE-011 should be delayed as above in foot note (3), a reduced dose as above in foot note (2) of ACE-011 will be 
administered based on the evaluation of the Hgb and blood pressure at that time.  
5ACE-011 should be held until hypertension resolves to ≤ Grade 2 (current active minor version NCI CTCAE v4.0) 
and may then be resumed beginning seven days after the previous planned scheduled treatment visit as above in 
foot note (3).  
Table 5:
ACE-011 and ACE-011/Placebo Dose Reduction Levels
When required, per dose modification rules above, ACE-011 dose(s) in Part 1 and ACE-
011/placebo dose(s) in Part 2 should be reduced as follows:  
Dose Schedule
ACE-011 or
ACE-011/placebo
Dose Reduction*
 #1
Dose Reduction*
 #2
Dose Reduction*
 #3
Every 42 days-
45.0 mg
38.0 mg
33.0 mg
28.0 mg
Every 42 days-
30.0 mg
26.0 mg
22.0 mg
18.0 mg
Every 42 days-
15.0 mg
13.0 mg
11.0 mg
9.0 mg
*Note:  Any Hgb increase of ≥3.0 g/dL will require a subsequent ACE-011 or ACE-011/placebo 
dose reduction of two dose levels.  A second Hgb increase of ≥3.0 g/dL following a two level 
dose reduction will require the subject discontinue from study treatment.  
Dosing visits are on Day 1 and repeated every 42 days, for four doses.  An additional two doses 
(total of 6 doses) may be given only during Part 2 at the discretion of the Investigator.  
Blood pressure and Hgb values must be evaluated prior to dosing at each dosing day for
consideration in administration of ACE-011 and ACE-011/placebo.  
The dose level for the initial dose reduction will be maintained unless subsequent dose 
reductions need to be administered upon evaluation of the dose modification rules listed above.  
A dose level may not be increased following a dose reduction.  
Page 41 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
42
ACE-011-NSCL-001 FINAL: 17 SEP 2010
Dose reduction steps and the subsequent administration of the reduced dose(s) of ACE-011 or 
ACE-011/placebo will be conducted in a manner that will preserve the blinded status of the 
original treatment group of each subject.  In Part 2, subjects in the placebo group who are 
designated by their treating physician to undergo dose reduction will continue to receive placebo.  
Placebo will be administered at the same volume as the corresponding ACE-011 or ACE-
011/placebo dose reduction.  
ACE-011 Dose Escalation Levels:
The following dose escalation rules apply for ACE-011 dose(s) in Part 1 only.  Dose escalations 
are not allowed in Part 2:

Less than 1.0 g/dL increase in Hgb in response to prior ACE-011 dose

Hgb level must be < 11.0 g/dL and hypertension < Grade 2

Dose escalation to begin at next every 42 day scheduled dosing visit 

ACE-011 should not be administered ≤7 days from the date of RBC transfusion.  
Subjects who have received an RBC transfusion should receive a one level dose increase of 
ACE-011 at the subsequent visit per the escalation table below.  
Table 6:
ACE-011 Dose Escalation Levels (Part 1 Only) 
Dose Schedule
ACE-011
Dose Increase  #1
Dose Increase  #2
Dose Increase #3
Every 42 days-
45.0 mg
50.0 mg
55.0 mg
61.0 mg
Every 42 days-
30.0 mg
33.0 mg
36.0 mg
40.0 mg
Every 42 days-
15.0 mg
17.0 mg
20.0 mg
23.0 mg
Blood pressure and Hgb values must be evaluated prior to dosing at each dosing day for 
consideration in administration of ACE-011 and ACE-011/placebo.  
Dose increase steps and the subsequent administration of the increased dose(s) of ACE-011 will 
be conducted in a manner that will preserve the blinded status of the original treatment group of 
each subject.  
4.2.
Study Design Rationale
The A011-01, A011-02 and A011-04 studies have shown that dosing with ACE-011 resulted in a
significant increase in hematopoietic parameters, beginning rapidly and sooner than would be 
expected from a stimulation of the erythropoietic effect by an ESA.  This fact, as well as the 
fairly rapid and persistent elevation in the relative Hgb, HCT, and RBC counts of the majority of 
subjects from each dose of ACE-011, suggests an entirely novel mechanism of RBC production.  
Page 42 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
43
ACE-011-NSCL-001 FINAL: 17 SEP 2010
Treatment of subjects with metastatic lung cancer with myelosuppressive platinum-based 
chemotherapy is frequently associated with anemia.  Chemotherapy induced anemia is a 
significant problem for subjects with cancer, causing fatigue and reduced quality of life 
(Groopman, 1999).  Subjects with CIA are currently treated with blood transfusion and/or ESAs 
(NCCN Clinical Practice Guidelines in Oncology:  Cancer and Chemotherapy Induced Anemia, 
2009).  However, with these treatment options CIA is still an area of major medical morbidity.  
Erythropoiesis-stimulating agents can successfully mitigate transfusion need in a proportion of 
these subjects, but concerns have emerged regarding apparent negative effects on survival and/or 
tumor progression in certain patient populations.  
4.2.1.
Fixed Dose
ACE-011 dose will be fixed at the indicated levels regardless of the subject’s body weight.  The 
fixed dosing approach is supported by an exploratory analysis of the relationship between body 
weight and ACE-011 PK in the previous studies (A011-01, A011-02, and A011-04).  In healthy 
postmenopausal women (Studies A011-01 and A011-02), body weight was estimated to explain 
less than 2.5% of intersubject variability for the two PK parameters dictating ACE-011 exposure, 
clearance and central volume of distribution, compared to an overall intersubject variability of 
17.4-25.5% for the two parameters.  In MM subjects (Study A011-04), body weight had no 
apparent effect on ACE-011 exposure.  Because the Hgb response is dependent on ACE-011 
exposure and because body weight is not a major source for the intersubject variability of ACE-
011 exposure, a fixed dosing approach is considered to be appropriate for the current study.  
4.2.2.
Dosing Schedule
The dosing schedule of once every 42 days (6 weeks) is proposed for the current study.  This 
dosing schedule was chosen by taking into consideration the rapid and prolonged Hgb response 
to ACE-011 as well as the dosing schedule for the platinum-based chemotherapies.  The Hgb-
increasing effect of ACE-011 was usually evident approximately 1 week after a SC dose and 
remained detectable through 6-8 weeks.  In addition, as platinum-based chemotherapy is often 
administered once every 3 weeks, a once every 6 weeks dosing schedule allows administration of 
ACE-011 at the same visit for the chemotherapy, which is convenient to both subjects and study 
sites.  
4.2.3.
Starting Dose Levels in Part 1
Three starting dose levels, 15.0, 30.0, and 45.0 mg, were chosen for Part 1 of the study.  
Selection of these doses is primarily based on the safety and exposure-response data observed in 
MM subjects under the standard MPT chemotherapy, who received up to four doses of ACE-011 
at 0.1, 0.3, or 0.5 mg/kg (Study A011-04).  In these subjects, ACE-011 had an acceptable safety 
profile and caused exposure-dependent Hgb response.  Further, there was no relationship 
observed between an increase in blood pressure and the maximal ACE concentration or the 
maximal Hgb rise within 28 days of the first dose (Report A011-04-CP).  The three starting dose 
levels approximate the average doses received by a 70 kg subject over a 6-week interval (10.5 
mg, 31.5 mg, and 52.5 mg, respectively) in the A011-04 study.  
In Study A011-04, four MM subjects received at least three ACE-011 doses at 0.5 mg/kg every 4 
weeks without a dose interruption, and none of them was reported to have an AE related to ACE-
011.  In this study, the starting dose level of 45.0 mg (during the dose finding Part 1) will be 
Page 43 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
44
ACE-011-NSCL-001 FINAL: 17 SEP 2010
implemented only after at least 10 subjects at each lower dose level (10 subjects at the 15.0 mg 
dose level and 10 subjects at the 30.0 mg dose level) have been evaluated as well as following 
DMC review of safety data and assessment of dose effects on Hgb levels.  
In addition, in the current NSCLC study, during the first 6-week treatment period for a 70 kg 
subject receiving the starting dose at 45.0 mg, the ACE-011 exposure (Cmax, day 1-43 and AUC1-43) 
is projected to be approximately 10% lower than the exposure for the dose regimen of 0.5 mg/kg 
once every 4 weeks.  Afterwards, safety measures (Hgb and blood pressure) will be used to guide 
the adjustment of the second dose and beyond.  Thus, the use of the 45.0 mg starting dose in the 
current study is not anticipated to significantly compromise subject safety.  
In the current study, the 45.0 mg group will have the highest starting dose, and it may be titrated 
up to 61.0 mg for the last dose (Dose 4).  Assuming a 70 kg subject who receives the maximal 
amount of dose during the entire study (i.e., starting at 45.0 mg followed by dose escalation 
every 6 weeks to 50.0, 55.0, and 61.0 mg for Doses 2, 3, and 4, respectively), the projected 
cumulative AUC during the treatment period (168 days) would be approximately 60% of the 
steady state AUC cumulated during the same period at the NOAEL level of 1 mg/kg (given 
every 4 weeks for a total of 6 doses) as reported in the 9-month, repeat-dose toxicity study in 
monkeys.  The projected highest Cmax for the current study would be less than 50% of the steady 
state Cmax in the monkey study.  
4.2.4.
Evaluation of Dosing Schema via Modeling/Simulation
The performance of the proposed dosing schema (three fixed starting dose levels, 6-week dosing 
interval, and dose adjustment rules [see Section 4.1.1 for details]) for this study was evaluated 
via PK/pharmacodynamic modeling/simulation.  A tentative mechanistic PK/pharmacodynamic
model for Hgb was developed using PK and Hgb data from healthy postmenopausal women and 
the model was extended to include MM subjects as a sub-population.  The model was required to 
appropriately reproduce the observed PK and Hgb profiles in MM subjects.  Monte Carlo 
simulations of the Hgb response to ACE-011 in a hypothetical anemic population (6.5 ≤ baseline 
Hgb < 11 g/dL; body weight 47 – 108 kg) were performed using the model parameterized with 
preliminary PK and pharmacodynamic parameters from MM subjects.  In this simulation 
analysis, efficacy refers to an Hgb increase > 1 g/dL from the baseline for 28 consecutive days 
while safety refers to both the absolute Hgb levels and the rate of Hgb increase.  
The simulation predicts that the desired efficacy would be achieved 6 weeks after the second 
dose in approximately 70% subjects of the 45 mg group and 6 weeks after the last dose in >70% 
subjects of the 30 mg group.  Further, the simulation predicts the Hgb level would be maintained 
under 12 g/dL in 90% subjects and under 13 g/dL in 95% of subjects during the course of the 
study (Figure 2).  No subjects are predicted to have a Hgb level above the upper limit of the 
normal range for Hgb (16 g/dL).  Approximately 6% subjects are predicted to have an Hgb rise 
> 2 g/dL within 28 days of the first dose, mostly from the 45.0 mg group (4%); however, the 
fraction of subjects with an Hgb rise > 3 g/dL per 28 days is predicted to be similar between the 
three dose groups (approximately 2.5% for each group).  
Page 44 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
45
ACE-011-NSCL-001 FINAL: 17 SEP 2010
Figure 2:
 Simulated Hemoglobin Response in the Hypothetical Anemic Population
Time (days)
0
50
100
150
200
250
300
Hb (g/dL)
6
8
10
12
14
Time (days)
0
50
100
150
200
250
300
6
8
10
12
14
Time (days)
0
50
100
150
200
250
300
6
8
10
12
14
Starting dose = 15 mg
Starting dose = 30 mg
Starting dose = 45 mg
The middle solid lines represent the median Hgb level.  The top and bottom solid lines represent the Hgb level at 5% 
and 95% percentile, respectively.  The area between 5% and 95% percentiles represents 90% prediction interval.  
The straight dot lines represent the Hgb level of 12 g/dL.  The arrows indicate the dosing time of ACE-011.  The 
two level dose reductions upon ≥ 3 g/dL increase sustained for 28 days of a dose (Table 5) was not included in the 
simulation.  
4.3.
Study Duration
To evaluate sequence and study timelines, please see the Table of Events (see Section 5).  
Approximately 60-90 subjects in Part 1 and 750 subjects in Part 2 will be randomized prior to 
receiving the fourth cycle of platinum-based chemotherapy for metastatic NSCLC.  Each subject 
will be on the study for approximately 12 – 15 months (including the Screening Period, the 
Treatment Period, and the Post Treatment Follow-Up Period).  The Treatment Period is 
approximately 6 to 9 months (four to six doses every 42 days) with a Post Treatment Follow-Up 
Period of six months from the subjects’ last dose of ACE-011 or ACE-011/placebo.  Subjects 
who discontinue treatment early will still continue to the Post Treatment Follow-Up Period for 
six months from their last dose of ACE-011 or ACE-011/placebo.  
All subjects will continue to be followed for TTP and PFS up to 12 months from their first dose 
of ACE-011 or ACE-011/placebo or until progression of their NSCLC, whichever comes first.  
All subjects will continue to be followed for survival up to 24 months from their first dose of 
ACE-011 or ACE-011/placebo.
Page 45 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
46
ACE-011-NSCL-001 FINAL: 17 SEP 2010
5.
TABLE OF EVENTS 
Table 7:
ACE-011 NSCLC Schedule of Assessments
Treatment Period
Screening 
Period
ACE-011 Dose 1 Schedule
(± 3 days)
ACE-011 Subsequent
Doses 2  through 6 Schedule
(± 3 days)
Post Treatment Follow-Up Period
(± 1 week)
Survival
(±1wk)
Assessments
Day -28
to
Day -1
D1
D8
D15 D22 D29
D43/
D1
D8
D15 D29
D43 
Post Last 
Dose/End 
of Study
Txt
1
Month
2
Month
3
Month
4
Month
5
Month
6
Month/
Study
DCu
Survival
Informed Consent
X
Inclusion/Exclusion Criteria
X
Complete Medical History
X
Cancer History and Prior Therapiesa
X
Prior ESA and RBC transfusion historya
X
X
Clinical visits (*study treatment visit)
X
X*
X
X
X*
X
X
X
X
X
X
X
X
ECOG Performance Status
X
X
X
X
X
X
X
X
X
X
X
X
Vital Signs / Blood Pressureb
X
X
X
X
X
X
X
X
X
X
X
X
X
Height (at randomization only)/Weight
X
X
X
X
X
X
X
X
X
12-Lead Electrocardiogram (ECG) –
Part 1c
X
X
X
X
X
12-Lead Electrocardiogram (ECG) –
Part 2c
X
X
X
Pregnancy Testingd
X
X
X
X
X
X
X
Xd
Hematologye
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Absolute Reticulocyte Counte
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Page 46 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
47
ACE-011-NSCL-001 FINAL: 17 SEP 2010
Table 7:
ACE-011 NSCLC Schedule of Assessments (Continued)
Treatment Period
Screening 
Period
ACE-011 Dose 1 Schedule
(± 3 days)
ACE-011 Subsequent
Doses 2 through 6 Schedule
(± 3 days)
Post Treatment Follow-Up Period
(± 1 week)
Survival
(±1wk)
Assessments
Day -28
to
Day -1
D1
D8
D15 D22 D29
D43/
D1
D8
D15 D29
D43 
Post Last 
Dose/End 
of study 
Txt
1
Month
2
Month
3
Month
4
Month
5
Month
6
Month/
Study
DCu
Survival
Serum Chemistryf
X
X
X
X
X
X
X
X
Serum Creatinine and Creatinine 
Clearanceg
X
X
X
X
X
X
X
X
X
X
X
X
X
Serum Iron, TIBC, Transferrin and Serum 
Ferritin, Vitamin B12 and RBC Folate 
Levelsh
X
Xh
X
Serum Erythropoietin (**Full PK subjects 
post first dose only)i
X
X
X**
X
X** X**
X
Xi
X
X
Urinalysisj
X
X
X
X
X
X
X
X
X
X
X
X
FSH and LH – Males and Females
X
X
X
X
X
X
X
X
Dihyroepiandosterone and Testosterone 
(Free & Total) - Males Only 
X
X
X
X
X
X
X
X
Estrogen and Estradiol & Menstrual 
Status - Females Only
X
X
X
X
X
X
X
X
TSHk
X
X
X
X
ACE-011 drug antibody test
(pre-ACE-011 or ACE-011/placebo dose)
X
X
X
X
X
X
Bone and other Biomarkers (BSAP, OC, 
P1NP, CTX, TRACP-5b and uNTX)l
(**Full PK subjects post first dose only)
X
X** X**
X** X**
X
X
X
Page 47 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
48
ACE-011-NSCL-001 FINAL: 17 SEP 2010
Table 7:
ACE-011 NSCLC Schedule of Assessments (Continued)
Treatment Period
Screening 
Period
ACE-011 Dose 1 Schedule
(± 3 days)
ACE-011 Subsequent
Doses 2 through 6 Schedule
(± 3 days)
Post Treatment Follow-Up Period
(± 1 week)
Survival
(±1wk)
Assessments
Day -28
to
Day -1
D1
D8
D15 D22 D29
D43/
D1
D8
D15 D29
D43
Post Last 
Dose/End 
of study 
Txt
1
Month
2
Month
3
Month
4
Month
5
Month
6
Month/
Study
DCu
Survival
Bone Imaging (DXA)m (Optional in 
Selected Centers)
X
X
Activin A and other Proteins/Biomarkers 
in Blood and Tissue  (pre-dose study 
treatment in a subset of subjects)
X
X
X
Circulating Tumor Cells  (pre-dose study 
treatment in a subset of subjects) 
X
X
X
X
Pharmacokinetics–
Part 1 and Part 2)n
Refer to Table 8 – Schedule of Pharmacokinetic Assessments
Tumor Assessmentso
X
Every 9 weeks ± 1 week
QoL Assessment
(LCSS and FACIT Fatigue Scale)p
X
X
X
X
X
X
X
X
X
X
X
X
X
Adverse Events
X
All AEs regardless of causality up to 6 weeks (42 days) post last dose of study treatment, after day 43 of last dose 
only AEs assessed as related to study treatment are to be reported
Concomitant Medications
(including ESAs and transfusions)
X
X
X
X
X
X
X
X
X
Concomitant Procedures
X
X
X
X
X
X
X
X
X
Hospitalizations (Record)
X
X
X
X
X
X
X
X
X
Randomization
X
Page 48 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
49
ACE-011-NSCL-001 FINAL: 17 SEP 2010
Table 7:
ACE-011 NSCLC Schedule of Assessments (Continued)
Treatment Period
Screening 
Period
ACE-011 Dose 1 Schedule
(± 3 days)
ACE-011 Subsequent
Doses 2 through 6 Schedule
(± 3 days)
Post Treatment Follow-Up Period
(± 1 week)
Survival
(±1wk)
Assessments
Day -28
to
Day -1
D1
D8
D15 D22 D29
D43/
D1
D8
D15 D29
D43 
Post Last 
Dose/End 
of study 
Txt
1
Month
2
Month
3
Month
4
Month
5
Month
6
Month/
Study
DCu
Survival
Administer 
ACE-011/Perform Drug Accountabilityq
X
X
Platinum-based Chemotherapyr
X
Dosing of allowed regimen(s) per standard practice
Maintenance chemotherapys
Dosing of allowed regimen(s) per standard practice
Overall Survivalv
X
Post Treatment Anti-Neoplastic Therapy
X
X
X
X
X
X
X
X
aInclude NSCLC history, date of original diagnosis, clinical stage at Screening and date of metastases and metastatic site involvement.  Record prior ESA history,
starting at diagnosis of NSCLC.  Record RBC transfusion history, starting from diagnosis of metastatic NSCLC, at a minimum of two months prior to 
randomization.  
bVital signs (including heart rate, seated blood pressure, and temperature) will be measured at Screening and all subsequent clinical visits, at Treatment 
Discontinuation, and at Study Discontinuation.  Investigators are to report any clinically significant abnormal findings as adverse events.  
cECG to be performed as follows:  For Part 1:  At Screening, Day 1 pre and post ACE-011 or ACE-011/placebo dose,  Day 8 post dose 1, every 
ACE-011/ACE-011/placebo dosing Visit and at end of study treatment (day 43 post last dose).  
For Part 2:  At Screening, Day 1 pre and post ACE-011 or ACE-011/placebo dose and at end of study treatment (day 43 post last dose).  
dFemales of childbearing potential (FCBP) only:  A female of childbearing potential is a sexually mature woman who has not undergone a hysterectomy or who 
has not been postmenopausal for at least 24 consecutive months (i.e. who has had menses at some time in the preceding 24 months).  A medically supervised 
pregnancy test with a minimum sensitivity of 25mIU/ml must be performed within 3 days prior to the start of ACE-011 or ACE-011/placebo or administration 
(Day 1) once the subject has been on effective contraception for at least 28 days.  Subjects must agree to use highly effective birth control measures (eg, oral 
contraceptives or two forms of barrier method birth control) during study participation and for at least 112 days following the last dose of ACE-011 or ACE-
011/placebo.  Pregnancy test will be performed at Study Discontinuation if date is ≤ 112 days following the last dose of ACE-011 or ACE-011/placebo.  
Page 49 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
50
ACE-011-NSCL-001 FINAL: 17 SEP 2010
eHematology laboratory evaluations (RBC count, Hgb, HCT, WBC count and differential, ANC, platelet count and reticulocyte count).  Hemoglobin should be 
tested prior to dosing with ACE-011 or ACE-011/placebo to ensure levels are within normal limits and that ACE-011 dose modification rules are followed as 
outlined in Section 4.1.1.  Any laboratory evaluations may be repeated more frequently if clinically indicated.  In addition, RBC, Hgb, and reticulocyte counts 
will be included at each timepoint within the full PK assessment (Part 1).  
fSerum chemistry laboratory evaluations (sodium, potassium, chloride, CO2 (bicarbonate), calcium, magnesium, phosphorus, BUN, creatinine, glucose, amylase, 
albumin, total protein, alkaline phosphatase, bilirubin [total and direct], AST/SGOT, ALT/SGPT, LDH and uric acid) if clinically significant any or all 
laboratory evaluations may be reported as AE and repeated more frequently.  
gCreatinine clearance (per Cockcroft-Gault formula) every 2 weeks during the treatment period, every month (except month 1) during the post treatment follow-
up period and at study discontinuation .  
hSerum Iron, TIBC, Transferrin, Serum Ferritin, Vitamin B12 and RBC Folate to be performed at Screening, pre-last dose of ACE-011 or ACE-011/placebo and 
end of study treatment (day 43 post last dose).  
iErythropoietin – collected at day 15 following first 2 doses of ACE-011 or ACE-011/placebo. For full PK assessment, weekly after first dose of ACE-011.  
jUrine collection for:  Urine albumin, urine albumin creatinine ratio, urine protein creatinine ratio and other biomarkers of glomerular and/or tubular injury.  
kTSH – collected at screening, on Day 1 of the first and second dose of ACE-011 or ACE-011/placebo and at 2 month post-treatment follow-up visit. 
lBone Biomarkers- Collected for full PK subjects prior to dose 1, weekly following dose 1, prior to dose 2 ,  post last dose day 43 and month 3 post treatment 
follow-up visit.  For all other subjects collected prior to dose 1,  prior to dose 2 ,  post last dose day 43 and month 3 post treatment follow-up visit.  Biomarker 
serum samples should be consistently collected early morning. The urine sample should not be from the first morning void.  
mDual Energy X-ray Absorptiometry (DXA) scan to evaluate overall health on approximately 200 subjects at selected US site(s).  Performed at Screening, and 
Month 3 during the Post Treatment Follow-Up Period.  
nPharmacokinetics (Part 1):  Blood samples will be collected to evaluate the blood or serum concentrations of ACE-011.  Approximately 10 subjects at each 
ACE-011 dose level, 15.0, 30.0 and 45.0 mg, will have more full PK sampling.  In addition, RBC, Hgb, and reticulocyte counts will be collected at each time
point (excluding the 4-hour time point on Day 1) from Day 1 to Day 43 after the first dose within the full PK assessment.  
Pharmacokinetics (Part 2):  Blood samples will be collected to evaluate the blood or serum concentrations of ACE-011.  ACE-011 doses 5 and 6 will have pre-
dose Day 1 PK (if applicable).  
REFER TO Table 8, SCHEDULE OF PHARMACOKINETIC ASSESSMENTS.  
oTumor assessments:  Screening tumor assessments may be performed up to six weeks prior to randomization.  Historical tumor assessment data from prior to 
initiation of platinum-based chemotherapy through randomization to the study will also be collected.  Following randomization, tumor assessments will be 
performed every 9 weeks (± 7 days).  
pQoL assessments, FACIT Fatigue Scale (Version 4) and LCSS questionnaire, to be completed by the subject upon arrival at clinic and prior to any study 
procedures or testing at all visits, as indicated in the schedule, and at Study Discontinuation/One-Year Follow-Up Visit.  
Page 50 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
51
ACE-011-NSCL-001 FINAL: 17 SEP 2010
qACE-011 or ACE-011/placebo dosing repeats every 42 days and will begin after the subject begins an every 3 week platinum-based chemotherapy regimen.  
The first dose of ACE011 or ACE-011/placebo should be given within +/- 3 days of a chemotherapy cycle.  Subsequent cycles of the chemotherapy dosing 
schedule, included dose reductions and delays, should not affect the ACE-011 or ACE-011/placebo dosing schedule, unless determined to be necessary by the 
Investigator.  ACE-011 or ACE-011/placebo can be administered at any time point during the chemotherapy cycle.  If there is a chemotherapy dose delay, 
ACE-011 or ACE-011/placebo administration does not need to be delayed until start of next chemotherapy cycle.  
rEvery 3-week platinum-based chemotherapy is to be administered based on guidelines for administration according to manufacturer’s recommendations and 
standard clinical practice.  Type of chemotherapy and dosing will be recorded.  ACE-011 or ACE-011/placebo administration should be given prior to 
chemotherapy administration on ACE-011 or ACE-011/placebo administration days.  
sPemetrexed maintenance chemotherapy is to be administered based on guidelines for administration according to manufacturer’s recommendations and standard 
clinical practice. 
tDay 43 (6 weeks) post last dose corresponds to the end of Treatment Period.  Subjects who discontinue the ACE-011 or ACE-011/placebo Treatment Period 
early will continue to the Post Treatment Follow-Up Period and be followed for up to 6 months after their last dose of ACE-011/placebo.  
uStudy Discontinuation visit should occur 12 months after starting treatment with ACE-011 or ACE-011/placebo.
vSurvival data will be collected monthly, via telephone contact, following the Study Discontinuation visit for an additional 12 months (up to 24 months after first 
dose of ACE-011 or ACE-011/placebo).  
Page 51 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
52
ACE-011-NSCL-001 FINAL: 17 SEP 2010
Table 8:
Schedule of Pharmacokinetic Assessments
Part 1b
Part 2b
Scheduled Time
Time relative to 
ACE-011/placebo dosea
Full PKc
Sparse PKd
Sparse PKd
Collection 
Windowe
Dose 1, D1
pre-Dose 1
X
X
X
-2  to  0 hour
Dose 1, D1
4 hours after Dose 1
X
X
X
±1 hour
Dose 1, D5
4 days after Dose 1
X
-
-
± 1 day
Dose 1, D8
7 days after Dose 1
X
X
X
± 1 day
Dose 1, D11
10 days after Dose 1
X
-
-
± 1 day
Dose 1, D15
14 days after Dose 1
X
X
X
± 1 day
Dose 1, D22
21 days after Dose 1
X
-
-
± 1 day
Dose 1, D29
28 days after Dose 1
X
X
X
± 1 day
Dose 1, D36
35 days after Dose 1
X
-
-
± 1 day
Dose 1, D43 (Dose 2, D1)
pre-Dose 2
X
X
X
± 2 days
Dose 2, D8
7 days after Dose 2
X
-
-
± 2 days
Dose 2, D15
14 days after Dose 2
X
-
-
± 2 days
Dose 2, D43 (Dose 3, D1)
pre-Dose 3
X
X
X
± 2 days
Dose 3, D8
7 days after Dose 3
X
-
-
± 2 days
Dose 3, D15
14 days after Dose 3
X
-
-
± 2 days
Dose 3, D43 (Dose 4, D1)
pre-Dose 4
X
X
X
± 2 days
Dose 4, D8
7 days after Dose 4
X
-
-
± 2 days
Dose 4, D15
14 days after Dose 4
X
-
-
± 2 days
Dose 4, D29
28 days after Dose 4
X
-
-
± 3 days
Dose 4, D43 (Dose 5, D1)
42 days after Dose 4
(pre-Dose 5 in Part 2)
X
X
X
± 3 days
Dose 5, D43 (Dose 6, D1)
pre-Dose 6 in Part 2
-
-
X
± 3 days
Follow up, 1 month
72 days after final dose
X
-
-
± 1 week
PT Follow up, 2 month
102 days after final dose
X
-
-
± 1 week
PT Follow up, 3 month
132 days after final dose
X
X
X
± 1 week
PT Follow up, 4 month
162 days after final dose
X
-
-
± 1 week
PT Follow up, 5 month
192 days after final dose
X
X
X
± 1 week
a Notes about PK sampling times:

For subjects participating in full PK sampling, RBC, Hgb and reticulocyte counts will be collected at each 
time point (excluding the 4-hour time point on Day 1) from Day 1 to Day 43 post first ACE-011 dose.  
Erythropoietin and bone biomarkers will be collected at D1, D8, D15, D22, D29, and D43 post first ACE-
011 dose.  If the time points for RBC, Hgb, reticulocyte, erythropoietin and bone biomarkers overlap with 
the time points defined in Table 7, only one sample is required.  

For subjects who discontinue the treatment early, PK blood sample collection will be continued during the 
follow-up period.  
bAt each time point, collect approximately 2 mL of blood.  After collection, allow the blood to clot at room 
temperature for approximately 1 hour and then centrifuge the blood sample at room temperature for 10 min (1100-
1300 g) to obtain serum.  
cTo be collected for approximately 30 subjects (approximately 10 subjects in each dose group).  
dTo be collected in other subjects.  
eFor subjects who participate in full PK sampling only.  The collection window for sparse PK samples will be the 
same as the visit window defined in Table 7.  
Page 52 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
53
ACE-011-NSCL-001 FINAL: 17 SEP 2010
6.
PROCEDURES
Screening Period (Day -28 to Day -1)
Prior to screening, subjects must sign an informed consent.  Potentially protocol-eligible subjects 
will be evaluated for the inclusion and exclusion criteria for the Treatment Period of this study.  
All screening assessments must be completed within 28 days prior to randomization.  Historical 
tumor assessment data from six weeks prior to initiation of platinum-based chemotherapy 
through randomization to the study will be collected.  Hematology and chemistry laboratory 
assessments should be performed within 14 days of randomization.  
The assessments and procedures that will be performed during the Screening Period are outlined 
in the Table of Events (see Section 5) and include:

Informed consent

Assessment of inclusion / exclusion criteria

Complete medical history including history of cardiac, renal and thromboembolic 
events

NSCLC history, including date of original diagnosis, histopathology, clinical stage at 
screening, date of metastatic stage and site involvement

Prior ESA treatment history starting from initial diagnosis of NSCLC

RBC transfusion history starting from diagnosis of metastatic NSCLC at a minimum 
of up two months prior to randomization

ECOG performance status

Vital signs including height, weight, heart rate, seated systolic and diastolic blood 
pressure, and temperature.  

12-lead electrocardiogram (ECG)  

Medically supervised pregnancy test, with a minimum sensitivity of 25mIU/ml, for 
females of childbearing potential (FCBP) to be assessed within 3 days prior to 
ACE-011 or ACE-011/placebo administration

Serum chemistry, hematology, absolute reticulocyte count to be assessed within 14 
days of randomization

Creatinine clearance (per Cockroft-Gault formula) within 14 days prior to study 
treatment administration

Serum iron, total iron binding capacity (TIBC), transferrin and serum ferritin

Vitamin B12 and red blood cell folate levels

Serum erythropoietin

Urinalysis
Page 53 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
54
ACE-011-NSCL-001 FINAL: 17 SEP 2010

FSH (include current menstrual cycle status for pre-menopausal female subjects) and 
LH – both males and females 

Dihyroepiandosterone and Testosterone (free and total)– males only

Estrogen and estradiol – females only

TSH

Bone imaging – DXA scan

Tumor Assessment - Screening tumor assessments and tumor evaluation 
documentation, as per RECIST criteria, must be performed within 6 weeks prior to 
randomization to this study.  Also, historical tumor assessment data from prior to 
initiation of platinum based chemotherapy through randomization to the study will be 
collected.  

QoL Assessment (FACIT Fatigue Scale [Version 4]) and LCSS questionnaire  

Documentation of concomitant medications / procedures / hospitalizations

Documentation of concomitant platinum-based chemotherapy
Treatment Period (Day 1/Dose 1 of study treatment to Day 43 post last study treatment 
dose)
Results from screening evaluations must be reviewed prior to randomization to confirm subject 
eligibility.  
In Part 1 (the dose ranging portion of the study), subjects who meet all eligibility criteria will be 
randomized by a single-blind procedure utilizing IVRS to receive one of the following ACE-011 
dose levels, with 10-30 subjects per arm:

ACE-011 15.0 mg SC

ACE-011 30.0 mg SC
Following analysis of at least 10 subjects at each dose level (10 subjects at the 15.0 mg dose 
level and 10 subjects at the 30.0 mg dose level), a third dose level will be added to the 
randomization schema:

ACE-011 45.0 mg SC
In Part 2, subjects meeting all inclusion and exclusion criteria will enter into the Treatment 
Period and be randomized by a double-blind procedure utilizing IVRS to receive ACE-011 or 
placebo (1:1 ratio).  
A subject will be considered randomized once a unique multi-digit subject identification number 
has been assigned by IVRS.  
Following randomization, subjects will receive SC doses of ACE-011 or ACE-011/placebo every 
42 days during the Treatment Period, as specified in the Table of Events (see Section 5).  
In Part 1, the Treatment Period will last approximately 6 months, where subjects randomized to 
ACE-011 will receive treatment on Day 1 every 42 days for a planned 4 doses.  
Page 54 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
55
ACE-011-NSCL-001 FINAL: 17 SEP 2010
In Part 2, the Treatment Period will last approximately 6 to 9 months, where subjects 
randomized to ACE-011/Placebo will receive treatment on Day 1 every 42 days for a planned 4 
doses with and additional two doses of ACE-011/placebo allowable, at the discretion of the 
Investigator, for a total of up to 6 doses.  
The assessments and procedures that will be performed during the Treatment Period are outlined 
in the Table of Events (see Section 5).  

Updated prior ESA and RBC transfusion history which may have occurred between 
the screening visit and randomization

ECOG performance status

Vital signs including weight, heart rate, seated systolic and diastolic blood pressure, 
and temperature

ECG 

Medically supervised pregnancy test, with a minimum sensitivity of 25mIU/ml, for 
FCBP.  

Serum chemistry, hematology, absolute reticulocyte count.  

Hematology laboratory evaluations (RBC count, Hgb, HCT, WBC count and 
differential, absolute neutrophil count [ANC], platelet count and reticulocyte 
count) will be collected weekly after the first dose of ACE-011 or ACE-
011/placebo and at subsequent ACE-011 or ACE-011/placebo doses collected at 
7, 14 days and 28 days post-dose by local laboratory.  

Within full PK assessment, RBC, Hgb and reticulocyte counts are collected at 
each time point; erythropoietin and bone biomarkers at weekly intervals post first 
dose of study treatment.  

Creatinine clearance will be assessed every 14 days.  

Serum iron, total iron binding capacity (TIBC), transferrin and serum ferritin at last 
dose and 43 days after last dose of study treatment

Vitamin B12 and RBC folate levels at last dose and 43 days after last dose of study 
treatment

Serum erythropoietin

Urinalysis

FSH (include current menstrual cycle status for premenopausal female subjects) and 
LH – both males and females 

Dihyroepiandosterone and Testosterone (free and total)– males only 

Estrogen and estradiol – females only 

TSH  

Serum for ACE-011 drug antibody test (pre-dose on the day of ACE-011 or ACE-
011/placebo administration)
Page 55 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
56
ACE-011-NSCL-001 FINAL: 17 SEP 2010

Bone or other biomarkers 

Activin A and other ACE-011-related proteins/biomarkers in blood and tissue (pre-
dose on Day 1 and Day 8 after first dose of ACE-011 or ACE-011/placebo)

Circulating Tumor Cells (pre-dose ACE-011 or ACE-011/placebo)

Tumor Assessment and Response Evaluation, as per RECIST criteria, (every 9 weeks
± one week) following chemotherapy schedule

Pharmacokinetics

QoL Assessment (FACIT Fatigue Scale (Version 4)) and LCSS questionnaire

Evaluation and all AE/SAE reporting (regardless causality)

Documentation of concomitant medications / procedures (including use of ESAs and 
all transfusions) / hospitalizations

Documentation of concomitant platinum-based chemotherapy and/or maintenance 
chemotherapy

Administration of ACE-011 or ACE-011/placebo at:  Day 1 every 42 days 
Subjects who discontinue from the Treatment Period early will enter the Post Treatment Follow-
Up Period and be followed for 6 months after their last dose of ACE-011 or ACE-011/placebo.  
Upon completion of the Post Treatment Follow-Up Period, subjects will have a discontinuation 
visit and be followed for survival for up to 24 months from their first dose of ACE-011 or ACE-
011/placebo.  
Post Treatment Follow-Up Period (Day 43 post last dose of study treatment to six months 
post last dose of study treatment)
Following completion or early discontinuation from the Treatment Period, subjects will enter the 
Post Treatment Follow-Up Period and continue to be followed for 6 months after their last dose 
of ACE-011 or ACE-011/placebo. Visits will occur every month.  The assessments and 
procedures that will be performed during this period are outlined in the Table of Events (see
Section 5) and include:

ECOG performance status

Vital signs including weight, heart rate, seated systolic and diastolic blood pressure, 
and temperature. 

ECG – end of study treatment (day 43 post last dose)

Medically supervised pregnancy test, with a minimum sensitivity of 25mIU/ml, for 
FCBP

Serum chemistry, hematology, absolute reticulocyte count

Creatinine clearance 

Serum iron, total iron binding capacity (TIBC), transferrin and serum ferritin – end of 
study treatment (at day 43 post last dose)
Page 56 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
57
ACE-011-NSCL-001 FINAL: 17 SEP 2010

Vitamin B12 and red blood cell folate levels – end of study treatment (at day 43 post 
last dose)

Serum erythropoietin

Urinalysis

FSH (include current menstrual cycle status for pre-menopausal female subjects) and 
LH – both males and females 

Dihyroepiandosterone and Testosterone (free and total)– males only 

Estrogen and estradiol – females only

TSH (at 2 month end of treatment follow-up visit)

Serum for ACE-011 drug antibody test (pre-ACE-011 or ACE-011/placebo dose)

Bone or other biomarkers 

Bone imaging – DXA scan (at 3 month end of treatment follow-up visit)

Activin A and other ACE-011 related proteins/biomarkers in blood and tissue (pre-
dose ACE-011 or ACE-011/placebo at 1 month end of treatment follow-up visit)

Circulating Tumor Cells (pre-dose ACE-011 or ACE-011/placebo at day 43 post last 
dose and 1 month end of treatment follow-up visit)

Pharmacokinetics

Tumor Assessment and Response Evaluation, as per RECIST criteria, (every 9 weeks
± one week) following chemotherapy schedule

QoL Assessment (FACIT Fatigue Scale (Version 4)) and LCSS questionnaire

Evaluation and reporting of all AEs regardless of causality (up to 6 weeks after last 
dose of ACE-011 or ACE-011/placebo).  After 6 weeks post last dose of ACE-011 or 
ACE-011/placebo, only AEs assessed as related to ACE-011 or ACE-011/placebo or 
study related procedures are to be reported.  

Documentation of concomitant medications / procedures (including use of ESAs and 
all transfusions) / hospitalizations

Post-Treatment Anti-Neoplastic Therapy
Study Discontinuation 
Study Discontinuation is the final scheduled visit for this study and should be performed for all 
enrolled subjects. 
Subjects who discontinue from treatment early will enter the Post Treatment Follow-Up Period 
and be followed for 6 months from their last dose of ACE-011 or ACE-011/placebo.  Follow-up 
for twelve months for TTP and PFS will be performed from the subject’s first dose of ACE-011 
or ACE-011/Placebo.  Following the Study Discontinuation Visit, subjects will be contacted 
monthly and survival data collected for an additional 12 months (up to 24 months following the 
subject’s first dose of ACE-011 or ACE-011/placebo).  
Page 57 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
58
ACE-011-NSCL-001 FINAL: 17 SEP 2010
The assessments and procedures that will be performed during the Study Discontinuation Visit 
are outlined in the Table of Events (see Section 5) and include:

ECOG performance status

Vital signs including weight, heart rate, seated systolic and diastolic blood pressure, 
and temperature

Medically supervised pregnancy test, with a minimum sensitivity of 25 mIU/ml, for 
females of childbearing potential (FCBP) – if Study Discontinuation date is ≤ 112 
days following the last dose of ACE-011 or ACE-011/placebo.  

Serum chemistry, hematology, absolute reticulocyte count

Creatinine clearance 

Urinalysis 

FSH (include current menstrual cycle status for pre-menopausal female subjects) and 
LH – both males and females 

Estrogen and estradiol – females only

Dihyroepiandosterone and Testosterone (free and total) – males only

Tumor Assessment and Response Evaluation, as per RECIST criteria (PFS at 12 
months)

QoL Assessment (FACIT Fatigue Scale (Version 4)) and LCSS questionnaire 

Reporting of adverse events (only AE/SAE assessed related to study treatment are to 
be reported)

Documentation of concomitant medications / procedures (including use of ESAs and 
all transfusions) / hospitalizations

Post-Treatment Anti-Neoplastic Therapy
Survival Follow-Up Period:
Monthly collection of survival data will begin following the Study Discontinuation Visit and 
continue for an additional 12 months (up to 24 months after first dose of ACE-011 or 
ACE-011/placebo).  

Overall survival

Post-Treatment Anti-Neoplastic Therapy
Additional Procedure Descriptions:
Central ECG
Part 1 – ECGs will be performed and read per Central ECG vendor.  
Part 2 – ECGs will be performed locally and read per Central ECG vendor.  
Please refer to vendor manual for procedures.  
Page 58 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
59
ACE-011-NSCL-001 FINAL: 17 SEP 2010
Clinical Laboratory Evaluations
Clinical laboratory evaluations (serum chemistry, hematology, absolute reticulocyte count, 
creatinine clearance, serum iron, total iron binding capacity, transferrin and serum ferritin, serum 
erythropoietin, Vitamin B12, serum folate levels, urinalysis, FSH, LH, dihyroepiandosterone, 
estrogen, estradiol, testosterone and serum thyroid-stimulating hormone will be performed by a 
central laboratory.  
Please refer to vendor manual for procedures.  
Note:  Local laboratory assessments are allowed in cases when timely results are needed (e.g., 
randomization, study treatment and chemotherapy dosing decisions, hematology assessments 
between clinic visits).  Local laboratory data should be collected in the eCRF.  
Exploratory Biomarkers
Analyses will be undertaken to evaluate the expression/overexpression of Activin A and other 
proteins/biomarkers related to ACE-011 mechanism of action in blood and tumor tissue in the 
NSCLC population in a subset of subjects.  
Renal function biomarkers via urinalysis measuring urine albumin / creatinine ratio, urine protein
/ creatinine ratio, and other serum biomarkers will also be evaluated from all subjects.  
Circulating Tumor Cell Enumeration and Molecular Studies
Analysis will be performed in a subset of subjects.  
Pharmacokinetics

Part 1 - Full PK blood samples will be collected to evaluate the full PK profile of 
ACE-011 from approximately 30 subjects at select centers (approximately 10 subjects 
for each ACE-011 dose group).  For full PK sampling, subjects who miss more than 
two PK sampling time points from Days 1 through 43 will be replaced.  

Part 2- Sparse PK blood samples will be collected from all subjects.  
Detailed PK sampling schedule is presented in Table 8: Schedule of Pharmacokinetic 
Assessments.  

PK samples must be collected predose on the day of ACE-011 or ACE-011/placebo 
administration.  PK samples may be collected at any time on non-dosing days.  After 
collection, allow the blood to clot at room temperature for approximately one hour 
and then centrifuge the blood sample at room temperature for 10 minutes (1100-
1300g) to obtain serum.  At each time point, approximately 2 mL or less blood will be 
collected.  
Bone Biomarkers
Bone or other biomarkers will be evaluated in all subjects.  The serum and urine biomarkers will 
include BSAP, OC, P1NP, CTX, TRACP-5b and uNTX.  Both serum and urine samples will be 
collected.  
Biomarker serum samples should be consistently collected early morning.  The urine sample 
should not be from the first morning void.  
Page 59 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
60
ACE-011-NSCL-001 FINAL: 17 SEP 2010
Bone Imaging
DXA scan to evaluate overall bone health will be performed on approximately 200 subjects at 
select site(s) 
Quality of Life Assessments
QoL Assessment (FACIT Fatigue Scale [Version 4]) and LCSS questionnaire will be completed 
by the subject upon arrival at clinic and prior to any study procedures or testing.  
Independent External Radiology Review  
At least 3 independent external radiologists (2 reviewers and 1 adjudicator) will perform a 
blinded, independent assessment of response, including the development of progressive disease 
(PD).  
Independent Review Committee (IRC):  The IRC will review the tumor response data (to 
include results from the central radiologist and relevant clinical laboratory and physical 
examination findings) and the dates of disease progression for each patient.  These data reviewed 
by the IRC will be used in the primary analyses ORR, TTP and PFS for the Clinical Study 
Report.  
Page 60 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
61
ACE-011-NSCL-001 FINAL: 17 SEP 2010
7.
STUDY POPULATION
Subjects must be receiving their first regimen of first-line platinum-containing chemotherapy, 
given every three weeks, for the treatment of metastatic NSCLC at the time of randomization.  
Subjects must be randomized prior to receiving Cycle 4 of this current first-line platinum-based 
chemotherapy regimen.  Subjects are expected to be eligible to receive 2 platinum-based 
chemotherapy cycles or maintenance therapy with a pemetrexed-based regimen following 
randomization.  
Subjects must not have received any other regimens of chemotherapy for the first-line platinum 
containing treatment of metastatic NSCLC prior to the regimen at the time of randomization.  
7.1.
Number of Subjects
This NSCLC platinum-based CIA study will enroll approximately 840 subjects in Part 1 and 
Part 2.  
In Part 1, up to 90 subjects will be randomized to receive one of the following ACE-011 dose 
levels, with 10-30 subjects per arm:

ACE-011 15.0 mg SC

ACE-011 30.0 mg SC

ACE-011 45.0 mg SC
and will be stratified by:
1. Baseline Hgb level 

6.5 to < 9.0 g/dL

9.0 to < 11.0 g/dL
2. Type of platinum-based chemotherapy (cisplatin versus carboplatin)
In Part 2, an additional 750 subjects will be randomized to receive either ACE-011, at the dose 
determined in Part 1, or placebo at a ratio of 1:1.  Subjects will be randomized to receive either 
ACE-011 or placebo and will be stratified by:
1. Baseline Hgb level 

6.5 to < 9.0 g/dL

9.0 to < 11.0 g/dL
2. Type of platinum-based chemotherapy (cisplatin versus carboplatin)
3. NSCLC histology (Squamous NSCLC vs. Non-Squamous NSCLC)
4. ECOG Performance Status 0-1 vs. 2
Page 61 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
62
ACE-011-NSCL-001 FINAL: 17 SEP 2010
7.2.
Inclusion Criteria
Subjects must satisfy the following criteria to be enrolled in the study:
1. Men and women > 18 years of age at the time of signing the informed consent document
2. Histologically confirmed (cytology or biopsy) non-small cell carcinoma of the lung
3. Documented metastatic (Stage IV) disease, including pleural or pericardial effusion
involvement
4. Measurable or non-measurable disease evaluable by RECIST criteria (Appendix A)
5. All of the following laboratory values:

Hemoglobin ≥ 6.5 to < 11.0 g/dL (≥ 65 to < 110 g/L)

Absolute neutrophil count ≥ 500/mm3

Platelet count ≥ 25,000/mm3 (> 72 hours since prior platelet transfusion) 

Adequate renal function (creatinine < 1.5 x upper limit of normal [ULN] or  ≥ 50 
mL/min)

Hepatic function (bilirubin < 1.5 x ULN; AST and ALT < 3.0 x ULN and ≤5 ULN for 
subjects with liver metastases)

Corrected calcium within normal limits (WNL), previous hypercalcemia treatment is 
allowed
6. Subjects may have received up to 3 cycles of a current first line platinum-based 
chemotherapy treatment regimen for metastatic NSCLC.  Allowed regimens are:

gemcitabine plus cisplatin or carboplatin ± bevacizumab

pemetrexed plus cisplatin or carboplatin ± bevacizumab

paclitaxel plus carboplatin ± bevacizumab
Subjects are expected to be eligible to receive 2 platinum-based chemotherapy cycles or 
maintenance therapy with a pemetrexed-based regimen following randomization.  
7. ≥ 28 days must have elapsed since previous treatment with ESA
8. ≥ 14 days must have elapsed (prior to Day 1) since the last RBC transfusion and receipt 
of ≤ 2 units of blood in the past 56 days (prior to Day 1)
9. ECOG Performance status of 0 – 2 (Appendix B)  
10. If currently receiving bisphosphonate therapy, be on a stable dose for ≥ 2 months before 
Day 1 (ongoing bisphosphonate therapy is allowed during study provided it is kept at a 
stable level, bisphosphonate therapy may not be started on study, other than for the 
treatment of hypercalcemia).  Subjects not currently on bisphosphonates must not have 
received bisphosphonates within 2 months prior to Day 1.  
Page 62 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
63
ACE-011-NSCL-001 FINAL: 17 SEP 2010
11. Females of childbearing potential participating in the study are to use highly effective 
methods of birth control for at least 28 days before starting the study, during study 
participation and for at least 112 days following the last dose of ACE-011 or ACE-
011/placebo.  
Some highly effective methods of birth control include:

Oral contraceptives, intrauterine device, tubal ligation or a partner with a vasectomy
OR

Two forms of barrier method birth control, e.g. a latex condom PLUS a diaphragm 
with spermicide OR a latex condom PLUS a contraceptive sponge with spermicide.  
If a non-latex condom is used, it cannot be made out of natural (animal) membrane.  
Females of childbearing potential must have a negative pregnancy test, with a minimum 
sensitivity of 25 mIU/ml, within 3 days prior to ACE-011 or ACE-011/placebo 
administration (Day 1).  In addition, subjects must be educated concerning measures to 
be used to prevent pregnancy and potential toxicities.  (A female of childbearing potential 
is a sexually mature woman who has not undergone a hysterectomy or bilateral 
oophorectomy; or who has not been postmenopausal for at least 24 consecutive months 
i.e. who has had menses at some time in the preceding 24 months).  
12. Males must agree to use a latex condom or non-latex condom NOT made of natural 
(animal) membrane during any sexual contact with females of childbearing potential or a 
pregnant female while participating in the study and for at least 112 days following the 
last dose of ACE-011 or ACE-011/placebo, even if he has undergone a successful 
vasectomy.  
13. Life expectancy of ≥ 3 months
14. Is willing to adhere to the study visit schedule, understand and comply with all protocol 
requirements
15. Understand and voluntarily sign a written informed consent document prior to any study 
related assessments/procedures are conducted
7.3.
Exclusion Criteria
The presence of any of the following will exclude a subject from enrollment:
1. Subjects who have any Grade > 3 toxicity (according to the currently active minor 
version of the NCI National Cancer Institute Common Terminology for Adverse Events 
[CTCAE] version 4.0 [Appendix C] at the time of screening, except for the following 
disease related toxicities:  hematological events [e.g. anemia, thrombocytopenia or 
neutropenia] or non hematological events [e.g. nausea, vomiting, fatigue, or muscle or 
bone/joint pain]).  
2. Prior radiation therapy to > 20% of the whole skeleton.  Use of palliative radiation if the 
area being treated is < 15% of body surface area with no pelvic radiation or no more than 
10% of the bone marrow reserve is radiated is permitted during subject participation in 
the study, at the discretion of the Investigator.  
Page 63 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
64
ACE-011-NSCL-001 FINAL: 17 SEP 2010
3. History of prior regimen(s) of platinum-based chemotherapy for metastatic NSCLC.  
4. CNS metastases (exception:  CNS metastases treated with whole brain radiotherapy > 6 
months prior to randomization).  
5. Clinically significant pulmonary, endocrine, neurologic, gastrointestinal, hepatic or 
genitourinary disease unrelated to underlying NSCLC.  
6. Subjects with classification of 3 or higher heart failure as classified by the New York 
Heart Association (NYHA) (Appendix D).  
7. History of thrombosis, deep vein thrombosis (DVT), pulmonary emboli (PE), or embolic 
stroke if not stable on anticoagulants and/or one of these events occurring within the past 
6 months.  Local central line thrombosis is allowed.  
8. Diagnosis of a myeloid malignancy or known history of myelodysplasia.  
9. History of second malignancy within 3 years (except excised and cured basal cell 
carcinoma, squamous cell carcinoma of the skin or cervical carcinoma in situ).  
10. Subjects with a recent history (within 14 days of Day 1) of administration of IV 
antibiotics or oral antibiotics (due to post septic episode).  Subjects should be free of 
infection at least 14 days after the last dose of systemic antibiotic treatment (prior to Day 
1).  
11. Uncontrolled hypertension.  If hypertension is considered clinically stable, systolic blood 
pressure (BP) must be < 160 mmHg and diastolic BP must be < 100 mmHg.  
12. Known infection with human immunodeficiency virus (HIV).  
13. Known active hepatitis B or C antibody defined by positive serology.  
14. Deficiency in iron (transferrin saturation < 20%), vitamin B12, or folate.  Subjects may be 
re-screened following treatment with supplements and normalization of levels.  
15. History of anemia as a result of inherited hemoglobinopathy such as sickle cell anemia or 
thalassemia.  
16. History of anemia due to autoimmune or hereditary hemolysis or gastrointestinal 
bleeding.  
17. Urine protein / creatinine ratio < 1.0 
18. Received treatment with another investigational drug or device within 28 days prior to 
Day 1, or if the half life of the previous product is known, within 5 times the half life 
prior to dosing, whichever may be longer.  
19. Any prior use of ACE-011.  
20. Pregnant or lactating females or females planning to become pregnant.  
21. History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant 
proteins or excipients in the investigational product (Refer to the Investigator’s Brochure 
for further information).  
22. Major surgery within 30 days prior to Day 1 (subjects must have completely recovered 
from any previous surgery prior to Day 1).  
Page 64 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
65
ACE-011-NSCL-001 FINAL: 17 SEP 2010
8.
DESCRIPTION OF STUDY TREATMENTS
8.1.
Description of Investigational Product(s)
Process IIa Clinical Drug Product
ACE-011 will be provided as a 1 mL solution of 50 mg/mL in phosphate buffered saline (PBS), 
pH 7.5, in labeled 2 mL vials with rubber stoppers, providing 50 mg per vial.  ACE-011 is 
recommended to be stored at -65˚C (colder than -65˚C) until thawed for administration.  ACE-
011 should be used within 6 hours of thawing.  
In Part 2, the ACE-011 placebo to be used in the study will be sterile normal saline (0.9% 
sodium chloride for injection) administered as a SC injection.  Sterile, normal saline will be 
supplied by the investigational site’s pharmacy.  The manufacturer’s directions for placebo 
storage and handling are to be followed, as are standard clinical practices for ensuring sterility of 
the placebo.  
8.2.
Treatment Administration and Schedule
ACE-011 or placebo will be administered as a SC injection to subjects by the study staff at the 
clinical site and will be documented in the study source record.  Subcutaneous injections will be 
given in the upper arm, abdomen, or thigh.  Vials of ACE-011 must be completely thawed 
(approximately 30 minutes at room temperature) prior to preparation for dosing and must be used 
within six (6) hours of being thawed.  
At the time of randomization all subjects must be receiving their first-line regimen of platinum-
containing chemotherapy, given every three weeks, for the treatment of metastatic NSCLC.  
Subjects will be randomized to this study during the time period in which they are receiving 
Cycle 1 to Cycle 3 of their first regimen of first-line platinum-based chemotherapy.  Subjects 
must not have received any prior regimens of platinum-based chemotherapy for metastatic 
NSCLC.  
Allowed concomitant platinum-based chemotherapy regimens are:

gemcitabine plus cisplatin or carboplatin  ± bevacizumab

pemetrexed plus cisplatin or carboplatin ± bevacizumab

paclitaxel plus carboplatin ± bevacizumab
Investigative sites will utilize commercial supply of these medications.  
Subjects may receive 4-6 cycles of the allowed platinum-based regimen selected by the 
Investigator.  The addition of up to 2 cycles of platinum-based chemotherapy may be given 
following cancer response.  The platinum-based tumor therapy may be revised at the discretion 
of the Investigator for toxicity reasons only.  
Maintenance chemotherapy with a pemetrexed-containing regimen will only be allowed 
following completion of the subject’s platinum-based chemotherapy, with a best response of at 
least stable disease.  
Page 65 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
66
ACE-011-NSCL-001 FINAL: 17 SEP 2010
Subjects must be given ACE-011 or ACE-011/placebo prior to chemotherapy administration on 
the dose administration days.  
In Part 1 and Part 2, ACE-011 or ACE-011/placebo dosing may occur on different weeks of the 
chemotherapy cycle due to the subjects’ Hgb.  Dose delays of ACE-011 or ACE-011/placebo 
and/or dose delays of chemotherapy may occur.  
8.2.1.
Selection of Dose for the Study
In Part 1, subjects will be randomized to one of the following ACE-011 dose levels, with 10-30 
subjects per arm:

ACE-011 15.0 mg SC

ACE-011 30.0 mg SC
Following analysis of at least 10 subjects at each dose level (10 subjects at the 15 mg dose level 
and 10 subjects at the 30 mg dose level), a third dose level will be added to the randomization 
schema:

ACE-011 45.0 mg SC
The following are decision rules for dose determination in Part 1 in order to move forward to 
Part 2:

After completion of two doses of ACE-011, a hematopoietic response in 
approximately 70% of subjects, in at least one or more treatment arms.  

Hematopoietic response is defined as an increase in Hgb of ≥ 1.0 g/dL above the 
study baseline value for 4 consecutive weeks, in the absence of RBC transfusions 
and/or ESAs.  In order to determine the optimal dose of ACE-011 to be used in Part 
2, evaluation of hematopoietic response will be determined from ACE-011 dose 1/day 
1 through and including dose 2/day 43 (prior to dose 3).  

In addition to the hematopoietic response, safety profile, dose modifications and 
extent of exposure will be taken into account for dose level selection for Part 2.  
Hematopoietic response will be determined by laboratory analysis.  
In Part 2, subjects will be randomized to receive either ACE-011 (at the dose determined in Part 
1) or placebo.  
8.2.2.
Selection and Timing of Dosing for Each Subject
Subjects will be randomized to receive ACE-011 or ACE-011/placebo starting on Day 1 (one SC 
dose every 42 days) and continuing during the six month Treatment Period, as outlined in the 
Table of Events (see Section 5).  
In Part 1, subjects will be randomized to receive one of three doses of ACE-011, with 10-30 
subjects per arm.  In Part 2, 750 subjects will be randomized to receive ACE-011 or placebo at a 
ratio of 1:1.  
Each subject will return to the site on Day 1 of each scheduled visit.  During the Treatment 
Period, subjects will receive ACE-011 or ACE-011/placebo every 42 days as determined by Hgb 
Page 66 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
67
ACE-011-NSCL-001 FINAL: 17 SEP 2010
levels and randomization schedule.  Hemoglobin levels and reticulocyte counts will be repeated 
by local lab weekly after the first dose of ACE-011 or ACE-011/placebo then at 7, 14 and 28 
days after each subsequent dose of ACE-011 or ACE-011/placebo.  
The first dose of ACE-011 or ACE-011/placebo should be given within +/- 3 days of Day 1 of a 
platinum-based chemotherapy Cycle.  Subsequent cycles of the chemotherapy dosing schedule, 
included dose reductions and delays, should not affect the ACE-011 or ACE-011/placebo dosing 
schedule, unless determined to be necessary by the Investigator.  ACE-011 or ACE-011/placebo 
can be administered at any time point during the chemotherapy cycle.  If there is a chemotherapy 
dose delay, ACE-011 or ACE-011/placebo administration does not need to be delayed until the 
start of the next chemotherapy cycle.  ACE-011 or ACE-011/placebo should be given prior to 
chemotherapy administration.  
Following completion of the Treatment Period, subjects who enter the Post Treatment Follow-
Up Period will be followed for 6 months from their last dose of ACE-011 or ACE-011/placebo.  
Visits will occur every month.  All subjects will continue to be followed for PFS up to 12 
months from their first dose of ACE-011 or ACE-011/placebo, or until progression of their 
NSCLC, whichever comes first.  
Subjects will be discontinued from the study treatment for reasons listed in Section 8.2.3 of the 
protocol, for unacceptable toxicity, or for progression of NSCLC that requires the initiation of 
another treatment.  
Following the Study Discontinuation Visit, subjects will be contacted monthly and survival data 
collected for an additional 12 months (up to 24 months following the subject’s first dose of ACE-
011 or ACE-011/placebo).  
8.2.3.
Discontinuation
Treatment Discontinuation
The following events are considered sufficient reasons for discontinuing a subject from ACE-011 
treatment:

AE(s)

Medically significant hypertension which cannot be adequately controlled with 
antihypertensive therapy

Any AE > Grade 2 assessed to be related to ACE-011 therapy

Any persistent AE > Grade 1 considered to be related to ACE-011 treatment and 
causing a subject to miss three months ACE-011 therapy 

Any thromboembolic event > Grade 2 

Elevated Hgb > 15.0 g/dL (sustained for a 7 day period, confirmed by laboratory 
assessment)

Creatinine clearance < 40 ml/min

Urine protein / creatinine ratio > 1.0 or > 2.0 (if bevacizumab [Avastin®] is 
concomitantly administered)
Page 67 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
68
ACE-011-NSCL-001 FINAL: 17 SEP 2010

Persistent hematuria

Lack of ACE-011 therapeutic effect, defined as < 1.0 g/dL increase in Hgb following 
two doses of ACE-011 or ACE-011/placebo

Concomitant use of ESAs – In Part 1 if administered at any time and in Part 2 if 
administered < 4 months from first dose of study treatment.  

ACE-011 or ACE-011/placebo Dose Modifications

In Part 1 and Part 2:  A second Hgb increase of ≥3.0 g/dL following a two level 
dose reduction due to a Hgb increase ≥3.0 g/dL 

In Part 2:  > 3 dose reductions and/or delays

Disease Progression of NSCLC

Withdrawal of consent

Death

Lost to follow up

Protocol violation
The reason for treatment discontinuation should be recorded in the eCRF and in the source 
documents.  
Study Discontinuation:  
The following events are considered sufficient reasons for discontinuing a subject from the 
study:

Completed study, per protocol (subject has completed six to nine month Treatment 
Period plus up to six month Post Treatment Follow-Up Period including one year 
tumor assessment to determine TTP and PFS).  Note:  Survival data will continue to 
be collected for up to 24 months from first dose of study treatment.  

AE(s)

Disease progression of NSCLC

Withdrawal of consent

Death

Lost to follow up

Protocol violation
The reason for study discontinuation should be recorded in the eCRF and in the source 
documents.  The Investigator must notify the Medical Monitor immediately when a subject has 
been discontinued/ withdrawn due to an AE (any unacceptable toxicity).  All subjects who are 
withdrawn from the study should complete the tests and evaluations scheduled for Study 
Discontinuation at the time of withdrawal.  
Page 68 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
69
ACE-011-NSCL-001 FINAL: 17 SEP 2010
8.3.
Method of Treatment Assignment
All subjects who qualify for the study will be randomly enrolled into the study and receive up to 
4 doses of ACE-011 in Part 1.  In Part 2, subjects will be randomized at a ratio of 1:1 and receive 
up to 4 doses of study treatment with an additional 2 doses of ACE-011/placebo allowed, if 
clinically indicated, at the discretion of the Investigator.  A unique multi-digit subject 
identification number will be assigned by IVRS to each subject entering the Treatment Period.  
8.4.
Packaging and Labeling
The label(s) for investigational product (IP) will include Sponsor name, address and telephone 
number, the protocol number, IP name, dosage form and strength (where applicable), amount of 
IP per container, lot number, expiry date (where applicable), medication identification/kit 
number (if applicable), dosing instructions, storage conditions, and required caution statements 
and/or regulatory statements as applicable.  Additional information may be included on the label 
as applicable per local regulations.  
8.5.
Investigational Product Accountability And Disposal
Accountability for ACE-011 is the responsibility of the Investigator.  Investigational clinical 
supplies must be received by a designated person at the clinical site and kept in a secured 
location.  The investigational site must maintain accurate records demonstrating dates and 
amounts of ACE-011 received, to whom it was administered (subject-by-subject accounting), 
and accounts of any ACE-011 accidentally or deliberately destroyed or returned.  Unless 
otherwise notified, all vials of ACE-011, both used and unused, must be saved for drug 
accountability.  The used vials may be discarded, per the institution’s standard practice, after 
drug accountability has been completed by the monitor.  The Investigator must return all unused 
vials of ACE-011 to the Sponsor at the end of the study, or the ACE-011 may be destroyed at the 
clinical site with the permission of the Sponsor.  For either scenario, the outcome must be 
documented on the drug accountability log.  The Sponsor will provide direction for the outcome 
of all unused vials.  
Celgene will instruct the Investigator on the return, disposal and/or destruction of investigational 
medicinal product.  
8.6.
Investigational Product Compliance
Accurate recording of all IP administration will be made in the appropriate section of the 
subject’s eCRF and source documents.  
The Investigator or designee is responsible for accounting for all IP that is administered during 
the course of the study.  
Page 69 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
70
ACE-011-NSCL-001 FINAL: 17 SEP 2010
9.
CONCOMITANT MEDICATIONS AND PROCEDURES
9.1.
Permitted Concomitant Medications and Procedures
General concomitant medication usage
During screening, and during the study, subjects may take only stable doses of medications for 
chronic conditions that are not specifically excluded by the protocol (see Sections 7.2 and 7.3
Inclusion Criteria and Exclusion Criteria).  The Medical Monitor should be consulted by the 
Investigator if there are any concerns about what constitutes a stable dose or what is a chronic 
condition.  Concomitant medications will be recorded on the subject’s eCRF throughout the 
course of the study.  
Concomitant therapies considered as supportive care are acceptable while participating in this 
study including growth colony stimulating factors (G-CSF), anti-emetics to limit chemotherapy-
related nausea and vomiting and palliative radiation and bisphosphonates (Refer to Inclusion 
Criterion, Section 7.2) for bone metastases.  Additionally, the study site should use its standard 
of care regarding hydration and the minimization of nephrotoxicity prior to/following the 
administration of platinum-based regimens.  
Concomitant medication for anemia
Concurrent therapy with a new prescription medication related to treatment of anemia during the 
course of the study must first be discussed with the Medical Monitor prior to administration, 
unless appropriate medical care necessitates that medication should begin before the Medical 
Monitor can be consulted.  
Iron supplementation
Iron supplementation within 7 days of Day 1 (besides an oral general multivitamin with iron) 
will not be allowed.  If a subject becomes iron replete during study treatment (ferritin < 100 
ng/mL [< 224.7 pmol/L] or transferrin saturation < 20%), treatment with iron supplementation is 
at the discretion of the Investigator.  
Erythropoiesis-stimulating agents (ESAs)
The use of ESAs are not allowed in Part 1 of the study; however, ESAs are allowed in 
Part 2 only after a subject has received at least 4 months of study treatment.  The use of 
ESAs will need to result in immediate notification to the study sponsor and Medical Monitor, as
well as to the unblinded clinical site pharmacist, so that no further dosing with ACE-011 in 
that study subject will occur.  Subjects will not be unblinded.  If treatment with ESAs is 
required in the opinion of the Investigator, the ESA label instructions are to be strictly followed.  
In Part 1, all subjects who receive an ESA will be discontinued from the study treatment period 
and continue to the post treatment follow-up period. In Part 2, subjects who receive an ESA at < 
4 months from their first dose of ACE-011 or ACE-011/placebo will be discontinued from the 
study treatment period and continue to the post treatment follow-up period.  Subjects who 
receive an ESA at ≥ 4 months from their first dose of ACE-011/placebo will continue in the 
treatment period.  The unblinded pharmacist will ensure that subjects randomized to receive 
Page 70 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
71
ACE-011-NSCL-001 FINAL: 17 SEP 2010
treatment with ACE-011 are changed over to receive treatment with placebo.  Subjects 
randomized to treatment with placebo will continue to receive placebo.  
RBC transfusions
Concurrent treatment for CIA with blood transfusions is recommended when Hgb value is 
< 8 g/dL or at the discretion of the Investigator if the Hgb value is > 8 g/dL and associated with 
anemia symptoms such as hemodynamic or pulmonary compromise requiring treatment.  If an 
RBC transfusion is given to a subject during the Treatment Period, ACE-011 should be 
administered no sooner than 7 days from the date of the RBC transfusion.  
9.2.
Prohibited Concomitant Medications and Procedures
No concurrent treatments with any other investigational agent are allowed.  Bisphosphonate 
therapy (see Section 7.2), other than for the treatment of hypercalcemia, must not be started on 
study.  
9.3.
Required Concomitant Medications and Procedures
Not applicable.  
Page 71 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
72
ACE-011-NSCL-001 FINAL: 17 SEP 2010
10.
STATISTICAL ANALYSES
10.1.
Overview
This is a single-blind, randomized, phase 2a, dose ranging study of ACE-011 therapy followed 
by a phase 2b/3, double-blind, randomized, placebo-controlled study of ACE-011 for CIA in 
subjects with metastatic NSCLC treated with platinum-based chemotherapeutic regimens.  An 
IVRS will be utilized to ensure an equal weight central randomization based on a permuted-
block randomization method according to stratification factors defined in Section 4.1 Study 
Design.  In Part 1, subjects will be randomized to one of three doses of ACE-011 plus platinum-
based chemotherapy.  In Part 2, subjects will be randomized to placebo or the selected ACE-011 
dosing schedule from Part 1 plus platinum-based chemotherapy.  
A DMC will be used to monitor the study conduct.  
10.2.
Study Population Definitions
Three study populations will be used for analyses.  

The Intent-to-Treat (ITT) Population – All randomized subjects.  

Safety Population – All subjects who take at least one dose of study medication.  

Efficacy Evaluable (EE) Population – All ITT subjects who take at least one dose of 
study medication and have baseline and at least one post-baseline efficacy assessment 
without major protocol deviation.  
10.3.
Sample Size and Power Considerations
In Part 1, up to 90 subjects will be randomized among three dosing groups.  This sample size is 
for the purpose of hypothesis generation.  However, it would allow approximately 80% power to 
detect an effect size of 0.33 using a 2 degrees of freedom Chi-Square Test with a two-sided 
significance level (alpha) of 0.05.  
In Part 2, subjects will be enrolled in two stages.  In the first stage, approximately 180 subjects 
will be randomized in a 1:1 ratio to the selected ACE-011 dose group or placebo group.  An 
interim analysis of transfusion rate will be performed after these 180 subjects have received at 
least two doses of ACE-011/placebo, and have been followed for at least 4 months from 
randomization.  A Data Monitoring Committee will review the results and provide 
recommendations on continuing or stopping the study. Based on the results of the futility 
analysis, further enrollment in the second stage of Part 2 of the study could be continued.  
Upon recommendation to continue the study, an additional 570 subjects will be subsequently 
randomized in the second stage.  The total sample size of 750 subjects in Part 2 (first plus second 
stage) would allow observation of at least 536 deaths and thus at least 80% power to exclude 
more than 15% risk reduction in the ACE-011 arm compared with the placebo arm at one-sided 
significance level of 0.025, i.e., rejecting hazard ratio (Placebo:ACE-011) of 0.87,  assuming the 
ACE-011 arm actually reduces at least 10% hazard, i.e., true hazard ratio (Placebo:ACE-011) of 
1.11.  
Page 72 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
73
ACE-011-NSCL-001 FINAL: 17 SEP 2010
10.4.
Background and Demographic Characteristics
Subjects’ age, height, weight, and baseline characteristics will be summarized using descriptive 
statistics by treatment arm, while gender, race and other categorical variables will be provided 
using frequency tabulations.  Medical history data will be summarized using frequency 
tabulations by system organ class and preferred term. 
10.5.
Subject Disposition
Subject disposition (analysis population allocation, entered, discontinued, along with primary 
reason for discontinuation) will be summarized using frequency and percent by treatment arm.  
A summary of subjects enrolled by site will be provided.  Protocol deviations will be 
summarized using frequency tabulations.  
10.6.
Efficacy Analysis
In Part 1, the primary endpoint will be the hematopoietic response defined as an increase in Hgb
of ≥ 1.0 g/dL above the study baseline value for 28 consecutive days, in the absence of RBC 
transfusions and/or ESAs.  The analysis will be based on the EE population.  The proportion of 
subjects with hematopoietic response will be estimated and a Chi-square test will be performed 
to compare response rates across treatment groups.  
In Part 2, the primary endpoint will be rate of RBC transfusion within 4 months following the 
first ACE-011 treatment.  It will be estimated based on Kaplan-Meier estimates for time to the 
first RBC transfusion.  The analysis will be based on ITT population and will be conducted 
according to the approximate timeline as described in Section 10.8.  Subjects with a documented 
RBC transfusion will be considered having the event.  Subjects without documented RBC 
transfusion will be censored on the date of last contact or a month after the last dose of study 
treatment, or termination of the concomitant chemotherapy, whichever is earlier.  The
comparison on the distribution difference between the treatment groups will be based on the 
stratified log-rank test.  
As secondary endpoints for Part 2 of the study, time to progression, progression free survival and 
overall survival will be analyzed based on the ITT population.  
Time to progression (TTP) is defined as the time between the randomization date and date of 
disease progression. Disease progression is based on the IRC reviewed progression date.  If 
a subject dies due to reasons other than disease progression, the subject will be censored at the 
death date.  If a subject does not have disease progression, then the subject will be censored at 
the last tumor assessment (prior to or on the first day of the first subsequent antitumor therapy).  
Progression free survival (PFS) is defined as the time between the randomization and disease 
progression or death.  Disease progression is based on the IRC reviewed progression date.  
Subjects who progressed or died will be considered to have had an event, except if this event 
occurs after the start of subsequent antitumor therapy, in which case the subject is censored at the 
time of last tumor assessment prior to or on the first day of the first subsequent antitumor 
therapy.  The date of progression is taken as the earliest date of:  Date of PD as evaluation of 
response, date of new lesion on tumor measurements page, death date, if death is caused by PD, 
treatment termination date if reason is PD, progression date as documented on treatment 
termination page, progression date as documented on the follow-up visit page.  Subjects who did 
Page 73 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
74
ACE-011-NSCL-001 FINAL: 17 SEP 2010
not progress nor died (lost to follow-up or still being treated without documented disease 
progression or started subsequent antitumor therapy) will be censored at the date of the last 
tumor assessment prior to or on the first day of the first subsequent antitumor therapy.  PFS 
based on investigators’ assessment will also be analyzed.  
Overall survival (OS) is defined as the time between the randomization and death.  A subject
that dies, regardless of the cause of death, will be considered to have had an event.  All subjects 
who are lost to the follow-up prior to the end of the trial or who are withdrawn from the trial will 
be censored at the time of last contact.  Subjects who are still being treated will be censored at 
the last available date where the subject is known to be alive.  
For TTP, PFS and OS, Kaplan-Meier method will be used to estimate the distribution function, 
six-month and one-year survival rates, as well as the medians and 95% confidence intervals will 
be provided.  The stratified log rank test will be used to compare the distributions of TTP, PFS 
and OS respectively.  The stratification factors are described in Section 4.1 .  The associated 
hazard ratios and confidence intervals will be provided using stratified Cox proportional hazard 
model respectively for each endpoint.  
Sensitivity analyses will be performed on TTP, PFS, and efficacy analyses will also be 
performed using EE population.  Data listings will be provided for all relevant data collected 
during the studies.  Further details will be included in the Statistical Analysis Plan.  
10.7.
Safety Analysis
All safety subjects will be used for safety analyses.  ACE-011 exposure will be summarized.  
Adverse events, vital sign measurements, clinical laboratory information, ECG interpretations, 
and concomitant medications will be tabulated and summarized by study part and treatment arm.  
The incidence of AEs will be summarized by severity grade based on the NCI CTCAE version 
4.0 (current active minor version).  Serious adverse events (SAE), deaths and AEs leading to 
dose modifications and study treatment discontinuation will be summarized.  Safety information 
obtained during the Post Treatment Follow-Up Period during each segment will be incorporated 
into these analyses.  
10.8.
Interim Analysis
There are two interim analyses planned for this study.  At the first interim analysis, the 
transfusion rate result will be used for go/no go decision, and overall survival will also be 
analyzed.  At the second interim analysis, only the overall survival will be analyzed.  
The first interim analysis on transfusion rate will be conducted after the first 180 eligible subjects 
randomized in Part 2 of the study (stage 1) who have received at least two doses of 
ACE-011/placebo, have been followed for at least 4 months from randomization.  This sample 
size would allow at least 90% power to detect a 15% difference between two arms (ACE-011 
arm 15% vs. placebo 30%) in 4 month transfusion rates at two-sided 5% significance level based 
on the stratified log rank test and the assumption of exponential distribution for time to RBC 
transfusion.  If the p-value at the interim analysis does exceed significance level of 0.05, the 
result will be considered as lack of efficacy.  If the p-value is less than or equal to 0.05, 
additional subjects will be enrolled and the study will move on to the Part 2; however, the futility 
analysis result based on RBC transfusion rate may be up to DMC evaluation.  For superiority, 
Page 74 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
75
ACE-011-NSCL-001 FINAL: 17 SEP 2010
Type I error 0.0001 will be spent at this interim for transfusion rate, and the remaining 0.0499 
will be spent at the final analysis after 750 subjects being enrolled.  
Overall survival will also be analyzed at this interim, Type I error spending will be based on 
O’Brien and Fleming Boundary.  
The second interim analysis will be performed when approximately 265 deaths are observed in 
Part 2.  Type I error spending will be based on O’Brien and Fleming boundary.  
The final analysis will be performed when approximately 536 deaths are observed in Part 2.  
10.9.
Other Topics
Pharmacokinetic Analysis
Approximately 10 subjects will be enrolled for full PK sampling in each treatment cohort of Part 
1.  For this portion of the study, subjects who miss more than two PK sampling time points from 
Days 1 through 43 will be replaced.  
Noncompartmental PK parameters for ACE-011, such as tmax, Cmax, AUC42, CL/F, Vz/F, and 
t1/2,z, will be estimated for subjects providing full PK samples.  Dose proportionality will be 
assessed by regression analysis using the exposure data after the first dose.  Descriptive statistics 
will be provided for plasma concentrations and PK parameters.  
In exploratory population PK analysis, covariates to be tested may include type of chemotherapy, 
the presence of anti-ACE-011 antibodies, demographics (age, race, gender, and body weight), 
markers for hepatic and renal function, and other factors as deemed appropriate.  Both full and 
sparse PK data will be included for population PK analyses.  
The relationship between ACE-011 exposure and response (hematology, biomarkers, and other 
clinical outcomes as appropriate) will be explored.  
10.10.
Data Monitoring Committee (DMC)
A DMC will review safety and efficacy data to ensure the protection of study subjects.  The 
DMC will receive periodic updates of all serious treatment-related toxicities and SAEs leading to 
deaths from all causes.  The first planned review by the DMC will be conducted following the 
randomization and treatment of twenty subjects.  The DMC will continue to monitor safety on an 
ongoing basis including recommendation of ACE-011 dose selection for Part 2.  The first interim 
analysis will be conducted after the first 180 eligible subjects in Part 2 of the study (stage 1) have 
been followed for at least 4 months for RBC transfusion rate.  The second interim analysis will 
be performed when approximately 265 deaths are observed in Part 2.  The final analysis will be 
performed when approximately 536 deaths are observed in Part 2.  
Ad hoc meetings will be scheduled as needed.  
The DMC will have a consultative role with respect to the Sponsor.  The Sponsor will make the 
final decision regarding the recommendation proposed by the committee.  A separate DMC 
charter will detail the activities of this committee.  
Page 75 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
76
ACE-011-NSCL-001 FINAL: 17 SEP 2010
11.
ADVERSE EVENTS
11.1.
Monitoring, Recording and Reporting of Adverse Events
An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen 
in a subject during the course of a study.  It may be a new intercurrent illness, a worsening 
concomitant illness, an injury, or any concomitant impairment of the subject’s health, including 
laboratory test values (as specified by the criteria below), regardless of etiology.  Any worsening 
(i.e., any clinically significant adverse change in the frequency or intensity of a pre-existing 
condition) should be considered an AE.  A diagnosis or syndrome should be recorded on the AE 
page of the eCRF rather than the individual signs or symptoms of the diagnosis or syndrome.  
An overdose, accidental or intentional, whether or not it is associated with an AE, or abuse, 
withdrawal, sensitivity or toxicity to an investigational product should be reported as an AE.  If 
an overdose is associated with an AE, the overdose and AE should be reported as separate terms.  
All subjects will be monitored for AEs during the study.  Assessments may include monitoring 
of any or all of the following parameters:  the subject’s clinical symptoms, laboratory, 
pathological, radiological or surgical findings, physical examination findings, or other 
appropriate tests and procedures.  
All AEs will be recorded by the Investigator from the time the subject signs informed consent to 
at least 42 days after the last dose of IP.  The AEs and SAEs will be recorded on the AE page of 
the eCRF and in the subject’s source documents.  All SAEs must be reported to Celgene Drug 
Safety immediately (i.e., within 24 hours of the Investigator’s knowledge of the event) by 
facsimile, or other appropriate method, using the SAE Report Form, or approved equivalent 
form.  After 42 days post last dose, only AEs assessed as related to study treatment are to be 
reported.  
11.2.
Evaluation of Adverse Events
A qualified Investigator will evaluate all AEs as to: 
11.2.1.
Seriousness 
An SAE is any AE occurring at any dose that:

Results in death;

Is life-threatening (i.e., in the opinion of the Investigator, the subject is at immediate 
risk of death from the AE);

Requires inpatient hospitalization or prolongation of existing hospitalization 
(hospitalization is defined as an inpatient admission, regardless of length of stay);

Results in persistent or significant disability/incapacity (a substantial disruption of the 
subject’s ability to conduct normal life functions);

Is a congenital anomaly/birth defect;

Constitutes an important medical event.  
Page 76 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
77
ACE-011-NSCL-001 FINAL: 17 SEP 2010
Important medical events are defined as those occurrences that may not be immediately life 
threatening or result in death, hospitalization, or disability, but may jeopardize the subject or 
require medical or surgical intervention to prevent one of the other outcomes listed above.  
Medical and scientific judgment should be exercised in deciding whether such an AE should be 
considered serious.  
Events not considered to be SAEs are hospitalizations for:

A standard procedure for protocol therapy administration.  However, hospitalization 
or prolonged hospitalization for a complication of therapy administration will be 
reported as an SAE.  

Routine treatment or monitoring of the studied indication not associated with any 
deterioration in condition.  

The administration of blood or platelet transfusion as routine treatment of studied 
indication.  However, hospitalization or prolonged hospitalization for a complication 
of such transfusion remains a reportable SAE.  

A procedure for protocol/disease-related investigations (e.g., surgery, scans, 
endoscopy, sampling for laboratory tests, bone marrow sampling).  However, 
hospitalization or prolonged hospitalization for a complication of such procedures 
remains a reportable SAE.  

Hospitalization or prolongation of hospitalization for technical, practical, or social 
reasons, in absence of an AE.  

A procedure that is planned (i.e., planned prior to starting of treatment on study); 
must be documented in the source document and the eCRF.  Hospitalization or 
prolonged hospitalization for a complication remains a reportable SAE.  

An elective treatment of a pre-existing condition unrelated to the studied indication.  

Emergency outpatient treatment or observation that does not result in admission, 
unless fulfilling other seriousness criteria above.  
If an AE is considered serious, both the AE page/screen of the eCRF and the SAE Report Form 
must be completed.  
For each SAE, the Investigator will provide information on severity, start and stop dates, 
relationship to IP, action taken regarding IP, and outcome.  
11.2.2.
Severity
For both AEs and SAEs, the Investigator must assess the severity of the event.  
The severity of AEs will be graded based upon the subject’s symptoms according to the current 
active minor version of National Cancer Institute (NCI) Common Terminology Criteria for 
Adverse Events (CTCAE, Version 4.0); 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
Page 77 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
78
ACE-011-NSCL-001 FINAL: 17 SEP 2010
AEs that are not defined in the NCI CTCAE should be evaluated for severity according to the 
following scale:
Grade 1 = Mild – transient or mild discomfort; no limitation in activity; no medical 
intervention/therapy required
Grade 2 = Moderate – mild to moderate limitation in activity, some assistance may be needed; no 
or minimal medical intervention/therapy required
Grade 3 = Severe – marked limitation in activity, some assistance usually required; medical 
intervention/therapy required, hospitalization is possible
Grade 4 = Life threatening – extreme limitation in activity, significant assistance required; 
significant medical intervention/therapy required, hospitalization or hospice care probable
Grade 5 = Death – the event results in death
The term “severe” is often used to describe the intensity of a specific event (as in mild, moderate 
or severe myocardial infarction); the event itself, however, may be of relatively minor medical 
significance (such as severe headache).  This criterion is not the same as “serious” which is 
based on subject/event outcome or action criteria associated with events that pose a threat to a 
subject’s life or functioning.  
Seriousness, not severity, serves as a guide for defining regulatory obligations.  
11.2.3.
Causality 
The Investigator must determine the relationship between the administration of IP and the 
occurrence of an AE/SAE as Not Suspected or Suspected as defined below:
Not Suspected:
The temporal relationship of the adverse event to IP 
administration makes a causal relationship unlikely or 
remote, or other medications, therapeutic interventions, or 
underlying conditions provide a sufficient explanation for the 
observed event.
Suspected:
The temporal relationship of the adverse event to IP 
administration makes a causal relationship possible, and other 
medications, therapeutic interventions, or underlying conditions 
do not provide a sufficient explanation for the observed event.
If an event is assessed as suspected of being related to a comparator, ancillary or additional IP 
that has not been manufactured or provided by Celgene, please provide the name of the 
manufacturer when reporting the event.  
11.2.4.
Duration
The Investigator will provide a record of the start and stop dates of the AE/SAE.  
The duration of the AE and the SAE may vary within one event.  For example, a non-serious AE 
may begin on 01-Jan.  The event will become serious when it meets one of the criteria for 
seriousness (e.g., the subject is hospitalized on 05-Jan).  The SAE will continue until it no longer 
Page 78 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
79
ACE-011-NSCL-001 FINAL: 17 SEP 2010
meets the seriousness criteria (e.g., the subject is discharged on 07-Jan).  However, the AE 
continues until 10-Jan when the event resolves.  The AE dates may extend from before and 
beyond the SAE dates, but not the reverse.  
11.2.5.
Action Taken
The Investigator will report the discontinuation or reduction of IP following an AE and report if 
concomitant and/or additional treatments were given for the AE.  
11.2.6.
Outcome
All SAEs that have not resolved upon discontinuation of the subject’s participation in the study 
must be followed until recovered, recovered with sequelae, not recovered (death due to another 
cause) or death (due to the SAE).  
11.3.
Abnormal Laboratory Values
An abnormal laboratory value is considered to be an AE if the abnormality:

Results in discontinuation from the study;

Requires treatment, modification/ interruption (delay) of IP dose, or any other 
therapeutic intervention; or

Is judged to be of significant clinical importance.  
Regardless of severity grade, only laboratory abnormalities that fulfill a seriousness criterion 
need to be documented as an SAE.  
If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis 
or syndrome should be recorded on the AE page/screen of the eCRF.  If the abnormality was not 
a part of a diagnosis or syndrome, then the laboratory abnormality should be recorded as the AE.  
11.4.
Pregnancy
11.4.1.
Females of Childbearing Potential:
Pregnancies and suspected pregnancies (including a positive pregnancy test regardless of age or 
disease state) of a female subject occurring while the subject is on IP, or within 112 days of the 
subject’s last dose of IP, are considered immediately reportable events.  IP is to be discontinued 
immediately.  The pregnancy, suspected pregnancy, or positive pregnancy test must be reported 
to Celgene Drug Safety immediately by facsimile, or other appropriate method, using the Initial 
Pregnancy Report Form, or approved equivalent form.  
The female should be referred to an obstetrician-gynecologist.  
The Investigator will follow the female subject until completion of the pregnancy, and must 
notify Celgene Drug Safety immediately about the outcome of the pregnancy (either normal or 
abnormal outcome) using the Follow-up Pregnancy Report Form, or approved equivalent form.  
If the outcome of the pregnancy was abnormal (e.g., spontaneous or therapeutic abortion [any 
congenital anomaly detected in an aborted fetus must be documented], stillbirth, neonatal death, 
or congenital anomaly [including that in an aborted fetus]), the Investigator should report the 
Page 79 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
80
ACE-011-NSCL-001 FINAL: 17 SEP 2010
abnormal outcome as an AE.  If the abnormal outcome meets any of the serious criteria, it must 
be reported as an SAE to Celgene Drug Safety immediately by facsimile, or other appropriate 
method, within 24 hours of the Investigator’s knowledge of the event) using the SAE Report 
Form, or approved equivalent form.  
All neonatal deaths that occur within 28 days of birth should be reported, without regard to 
causality, as SAEs.  In addition, any infant death after 28 days that the Investigator suspects is 
related to the in utero exposure to the IP should also be reported to Celgene Drug Safety 
immediately by facsimile, or other appropriate method, within 24 hours of the Investigator’s 
knowledge of the event using the SAE Report Form, or approved equivalent form.  
11.4.2.
Male Subjects
Female partners of male subjects taking IP should be advised to call their healthcare provider 
immediately if they become pregnant, and male subjects should notify the Investigator.  
11.5.
Immediate Reporting of Serious Adverse Events
Any AE that meets any criterion for an SAE requires the completion of an SAE Report Form in 
addition to being recorded on the AE page/screen of the eCRF.  All SAEs must be reported to 
Celgene Drug Safety immediately (i.e., within 24 hours of the Investigator’s knowledge of the 
event) by facsimile, or other appropriate method, using the SAE Report Form, or approved 
equivalent form.  This instruction pertains to initial SAE reports as well as any follow-up reports.  
The Investigator is required to ensure that the data on these forms is accurate and consistent.  
This requirement applies to all SAEs (regardless of relationship to IP) that occur during the study 
from the time the subject signs informed consent up to 112 days after the last dose of IP, and 
those made known to the Investigator at anytime thereafter that are suspected of being related to 
IP.  SAEs occurring prior to treatment will be captured.  
The SAE report should provide a detailed description of the SAE and include copies of hospital 
records and other relevant documents.  If a subject died and an autopsy has been performed, 
copies of the autopsy report and death certificate are to be sent to Celgene Drug Safety as soon as 
these become available.  Any follow-up data will be detailed in a subsequent SAE Report Form, 
or approved equivalent form, and sent to Celgene Drug Safety.  
Where required by local legislation, the Investigator is responsible for informing the Institutional 
Review Board (IRB)/Ethics Committee (EC) of the SAE and providing them with all relevant 
initial and follow-up information about the event.  The Investigator must keep copies of all SAE 
information on file including correspondence with Celgene and the IRB/EC.  
11.5.1.
Safety Queries
Queries pertaining to SAEs will be communicated from Celgene Drug Safety to the site via 
facsimile or electronic mail.  The response time is expected to be no more than five (5) business 
days.  Urgent queries (e.g., missing causality assessment) may be handled by phone.  
11.6.
Expedited Reporting of Adverse Events
For the purpose of regulatory reporting, Celgene Drug Safety will determine the expectedness of 
events suspected of being related to ACE-011 based on the Investigator Brochure.  
Page 80 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
81
ACE-011-NSCL-001 FINAL: 17 SEP 2010
For countries within the European Economic Area (EEA), Celgene or its authorized 
representative will report in an expedited manner to Regulatory Authorities and Ethics 
Committees concerned, suspected unexpected serious adverse reactions (SUSARs) in accordance 
with Directive 2001/20/EC and the Detailed Guidance on collection, verification and 
presentation of adverse reaction reports arising from clinical trials on investigational products for 
human use (ENTR/CT3) and also in accordance with country-specific requirements.  
Celgene or its authorized representative shall notify the Investigator of the following 
information:

Any AE associated with the use of IP in this study or in other studies that is both 
serious and unexpected (i.e., SUSAR);

Any finding from tests in laboratory animals that suggests a significant risk for 
human subjects including reports of mutagenicity, teratogenicity, or carcinogenicity.  
Where required by local legislation, the Investigator shall notify his/her IRB/EC promptly of 
these new serious and unexpected AE(s) or significant risks to subjects.  
The Investigator must keep copies of all pertinent safety information on file including 
correspondence with Celgene and the IRB/EC.  (See Section 15.3 for record retention 
information).  
Celgene Drug Safety Contact Information:
For Local Drug Safety Affiliate Office contact information, please refer to the Serious Adverse 
Event Report Form Completion Guidelines or to the SAE Report Form.  
Page 81 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
82
ACE-011-NSCL-001 FINAL: 17 SEP 2010
12.
DISCONTINUATIONS
Please refer to Section 8.2.3.  
Stopping Rules
In addition to Celgene routine pharmacovigilance surveillance, a DMC will review unblinded 
data on a regular basis (mainly grade 3 or 4 toxicities, SAEs and subject deaths).  Any relevant 
imbalance in toxic deaths, related SAEs or detrimental survival would be considered for study 
discontinuation.  
Page 82 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
83
ACE-011-NSCL-001 FINAL: 17 SEP 2010
13.
EMERGENCY PROCEDURES
13.1.
Emergency Contact
In emergency situations, the Investigator should contact the responsible Clinical Research 
Physician/Medical Monitor or designee by telephone at the number(s) listed on the Emergency 
Contact Information page of the protocol (after title page).  
In the unlikely event that the Clinical Research Physician/Medical Monitor or designee cannot be 
reached, please contact the global Emergency Call Center by telephone at the number listed on 
the Emergency Contact Information page of the protocol (after title page).This global Emergency 
Call Center is available 24 hours a day and 7 days a week.  The representatives are responsible 
for obtaining your call-back information and contacting the on call Celgene/CRO Medical 
Monitor, who will then contact you promptly.  
Note:  The back-up 24 hour global emergency contact call center should only be used if you are 
not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls.  
13.2.
Emergency Identification of Investigational Products
In both Part 1 and Part 2 the blind must not be broken during the course of the study unless in the 
opinion of the Investigator, it is absolutely necessary to safely treat the subject.  If it is medically 
imperative to know what IP the subject is receiving, the Investigator or authorized person should 
call IVRS for unblinded dose information, etc.  However, every effort should be made to contact 
the Clinical Research Physician/Medical Monitor prior to breaking the blind.  Contact or 
attempted contact with the Clinical Research Physician/Medical Monitor as well as the reason 
for breaking the blind must be documented in the source documents.  
Page 83 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
84
ACE-011-NSCL-001 FINAL: 17 SEP 2010
14.
REGULATORY CONSIDERATIONS
14.1.
Good Clinical Practice
The procedures set out in this study protocol pertaining to the conduct, evaluation, and 
documentation of this study are designed to ensure that Celgene, its authorized representative, 
and Investigator abide by Good Clinical Practice (GCP), as described in International 
Conference on Harmonization (ICH) Guideline E6 and in accordance with the general ethical 
principles outlined in the Declaration of Helsinki.  The study will receive approval from an 
IRB/EC prior to commencement.  The Investigator will conduct all aspects of this study in 
accordance with applicable national, state, and local laws of the pertinent regulatory authorities.  
14.2.
Investigator Responsibilities
Investigator responsibilities are set out in the ICH Guideline for Good Clinical Practice and in 
the local regulations.  Celgene staff or an authorized representative will evaluate and approve all 
Investigators who in turn will select their staff.  
The Investigator should ensure that all persons assisting with the study are adequately informed 
about the protocol, amendments, study treatments, as well as study-related duties and functions.  
The Investigator should maintain a list of Sub-investigators and other appropriately qualified 
persons to whom he or she has delegated significant study-related duties.  
The Investigator is responsible for keeping a record of all subjects who sign an informed consent 
document and are screened for entry into the study.  Subjects who fail screening must have the 
reason(s) recorded in the subject’s source documents.  
The Investigator, or a designated member of the Investigator’s staff, must be available during 
monitoring visits to review data, resolve queries and allow direct access to subject records (e.g., 
medical records, office charts, hospital charts, and study-related charts) for source data 
verification.  The Investigator must ensure timely and accurate completion of eCRFs and queries.  
14.3.
Subject Information and Informed Consent
The Investigator must obtain informed consent of a legal representative prior to any study related 
procedures.  
Documentation that informed consent occurred prior to the study subject’s entry into the study 
and of the informed consent process should be recorded in the study subject’s source documents 
including the date.  The original informed consent document signed and dated by the study 
subject and by the person consenting the study subject prior to the study subject’s entry into the 
study, must be maintained in the Investigator’s study files and a copy given to the study subject.  
In addition, if a protocol is amended and it impacts on the content of the informed consent, the 
informed consent document must be revised.  Study subjects participating in the study when the 
amended protocol is implemented must be re-consented with the revised version of the informed 
consent document.  The revised informed consent document signed and dated by the study 
subject and by the person consenting the study subject must be maintained in the Investigator’s 
study files and a copy given to the study subject.  
Page 84 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
85
ACE-011-NSCL-001 FINAL: 17 SEP 2010
14.4.
Confidentiality
Celgene affirms the subject's right to protection against invasion of privacy and to be in 
compliance with ICH and other local regulations (whichever is most stringent).  Celgene requires 
the Investigator to permit Celgene's representatives and, when necessary, representatives from 
regulatory authorities, to review and/or copy any medical records relevant to the study in 
accordance with local laws.  
Should direct access to medical records require a waiver or authorization separate from the 
subject’s signed informed consent document, it is the responsibility of the Investigator to obtain 
such permission in writing from the appropriate individual.  
14.5.
Protocol Amendments
Any amendment to this protocol must be approved by the Celgene Clinical Research 
Physician/Medical Monitor.  Amendments will be submitted to the IRB/EC for written approval.  
Written approval must be obtained before implementation of the amended version occurs.  The 
written signed approval from the IRB/EC should specifically reference the Investigator name, 
protocol number, study title and amendment number(s) that is applicable.  Amendments that are 
administrative in nature do not require IRB/IEC approval but will be submitted to the IRB/IEC 
for information purposes.  
14.6.
Institutional Review Board/Independent Ethics Committee Review 
and Approval
Before the start of the study, the study protocol, informed consent document, and any other 
appropriate documents will be submitted to the IRB/EC with a cover letter or a form listing the 
documents submitted, their dates of issue, and the site (or region or area of jurisdiction, as 
applicable) for which approval is sought.  If applicable, the documents will also be submitted to 
the authorities in accordance with local legal requirements.  
IP can only be supplied to an Investigator by Celgene or its authorized representative after 
documentation on all ethical and legal requirements for starting the study has been received by 
Celgene or its authorized representative.  This documentation must also include a list of the 
members of the IRB/EC and their occupation and qualifications.  If the IRB/EC will not disclose 
the names, occupations and qualifications of the committee members, it should be asked to issue 
a statement confirming that the composition of the committee is in accordance with GCP.  For 
example, the IRB General Assurance Number may be accepted as a substitute for this list.  
Formal approval by the IRB/EC should mention the protocol title, number, amendment number 
(if applicable), study site (or region or area of jurisdiction, as applicable), and any other 
documents reviewed.  It must mention the date on which the decision was made and must be 
officially signed by a committee member.  Before the first subject is enrolled in the study, all 
ethical and legal requirements must be met.  
The IRB/EC and, if applicable, the authorities, must be informed of all subsequent protocol 
amendments in accordance with local legal requirements.  Amendments must be evaluated to 
determine whether formal approval must be sought and whether the informed consent document 
should also be revised.  
Page 85 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
86
ACE-011-NSCL-001 FINAL: 17 SEP 2010
The Investigator must keep a record of all communication with the IRB/EC and, if applicable, 
between a Coordinating Investigator and the IRB/EC.  This statement also applies to any 
communication between the Investigator (or Coordinating Investigator, if applicable) and 
regulatory authorities.  
Any advertisements used to recruit subjects for the study must be reviewed by Celgene and the 
IRB/EC prior to use.  
14.7.
Ongoing Information for Institutional Review Board / Ethics 
Committee
If required by legislation or the IRB/EC, the Investigator must submit to the IRB/EC:

Information on serious or unexpected adverse events as soon as possible; 

Periodic reports on the progress of the study;

Deviations from the protocol or anything that may involve added risk to subjects.  
14.8.
Closure of the Study
Celgene reserves the right to terminate this study at any time for reasonable medical or 
administrative reasons.  Any premature discontinuation will be appropriately documented 
according to local requirements (e.g., IRB/EC, regulatory authorities, etc...).  
In addition, the Investigator or Celgene has the right to discontinue a single site at any time 
during the study for medical or administrative reasons such as:

Unsatisfactory enrollment;

GCP noncompliance;

Inaccurate or incomplete data collection;

Falsification of records;

Failure to adhere to the study protocol.  
Page 86 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
87
ACE-011-NSCL-001 FINAL: 17 SEP 2010
15.
DATA HANDLING AND RECORDKEEPING 
15.1.
Data/Documents
The Investigator must ensure that the records and documents pertaining to the conduct of the 
study and the distribution of the investigational product are complete, accurate, filed and 
retained.  Examples of source documents include:  hospital records; clinic and office charts; 
laboratory notes; memoranda; subject’s diaries or evaluation checklists; dispensing records; 
recorded data from automated instruments; copies or transcriptions certified after verification as 
being accurate copies; microfiche; x-ray film and reports; and records kept at the pharmacy, and 
the laboratories, as well as copies of eCRFs or CD-ROM.  
15.2.
Data Management
Data will be collected via an electronic data capture (EDC) system rather than paper.  Data will 
be entered into the clinical database as per Celgene SOPs.  These data will be electronically 
verified through use of on-line checks during data entry, and through programmed edit checks 
specified by the clinical team.  The Clinical team and investigational site personnel will be 
alerted of discrepant data by the functionality of the system.  Resolutions to these issues will be 
reflected in the database.  An audit trail within the system will track all changes made to the data.  
15.3.
Record Retention
Essential documents must be retained by the Investigator for a minimum of 2 years after the last 
approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region, or at least 2 years have elapsed since the 
formal discontinuation of clinical development of the IP.  The Investigator must retain these 
documents for the time period described above or according to local laws or requirements, 
whichever is longer.  Essential documents include, but are not limited to, the following:

Signed informed consent documents for all subjects;

Subject identification code list, screening log (if applicable), and enrollment log;

Record of all communications between the Investigator and the IRB/EC;

Composition of the IRB/EC;

Record of all communications between the Investigator, Celgene, and their authorized 
representative(s);

List of Sub-investigators and other appropriately qualified persons to whom the 
Investigator has delegated significant study-related duties, together with their roles in 
the study, curriculum vitae, and their signatures;

Copies of CRFs (if paper) and of documentation of corrections for all subjects;

IP accountability records;

Record of any body fluids or tissue samples retained;
Page 87 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
88
ACE-011-NSCL-001 FINAL: 17 SEP 2010

All other source documents (subject records, hospital records, laboratory records, 
etc.); 

All other documents as listed in Section 8 of the ICH consolidated guideline on GCP 
(Essential Documents for the Conduct of a Clinical Trial).  
The Investigator must notify Celgene if he/she wishes to assign the essential documents to 
someone else, remove them to another location or is unable to retain them for a specified period.  
The Investigator must obtain approval in writing from Celgene prior to destruction of any 
records.  If the Investigator is unable to meet this obligation, the Investigator must ask Celgene 
for permission to make alternative arrangements.  Details of these arrangements should be 
documented.  
All study documents should be made available if required by relevant health authorities.  
Investigator/Institution should take measures to prevent accidental or premature destruction of 
these documents.  
Page 88 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
89
ACE-011-NSCL-001 FINAL: 17 SEP 2010
16.
QUALITY CONTROL AND QUALITY ASSURANCE
All aspects of the study will be carefully monitored by Celgene or its authorized representative 
for compliance with applicable government regulations with respect to current GCP and standard 
operating procedures.  
16.1.
Study Monitoring and Source Data Verification
Celgene ensures that appropriate monitoring procedures are performed before, during and after 
the study.  Before the study is initiated at a site visit or at an investigator meeting, all aspects of 
the study are reviewed with the Investigator and the staff.  Prior to enrolling subjects into the 
study, a Celgene representative will review the protocol, eCRFs, procedures for obtaining 
informed consent, record keeping, and reporting of AEs/SAEs with the Investigator.  Monitoring 
will include on-site visits with the Investigator and his/her staff as well as any appropriate 
communications by mail, email, fax, or telephone.  At each monitoring visit, the facilities, 
investigational product storage area, eCRFs, subject’s source documents, and all other study 
documentation will be inspected/reviewed by the Celgene representative for accuracy, adherence 
to the protocol and Good Clinical Practice.  
Accuracy will be checked by performing source data verification that is a direct comparison of 
the entries made onto the eCRFs against the appropriate source documentation.  Any resulting 
discrepancies will be reviewed with the Investigator and/or his/her staff.  Any necessary 
corrections will be made directly to the eCRFs or via queries by the Investigator and/or his/her 
staff.  Monitoring procedures require that informed consents, adherence to inclusion/exclusion 
criteria and documentation of SAEs and their proper recording be verified.  Additional 
monitoring activities may be outlined in a study-specific monitoring plan.  
16.2.
Audits and Inspections
In addition to the routine monitoring procedures, a Good Clinical Practice Quality Assurance 
unit exists within Celgene.  Representatives of this unit will conduct audits of clinical research 
activities in accordance with Celgene SOPs to evaluate compliance with Good Clinical Practice 
guidelines and regulations.  
The Investigator is required to permit direct access to the facilities where the study took place, 
source documents, eCRFs and applicable supporting records of study subject participation for 
audits and inspections by IRB/IECs, regulatory authorities (e.g. FDA, EMEA, Health Canada) 
and company authorized representatives.  The Investigator should make every effort to be 
available for the audits and/or inspections.  If the Investigator is contacted by any regulatory 
authority regarding an inspection, he/she should contact Celgene immediately.  
Page 89 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
90
ACE-011-NSCL-001 FINAL: 17 SEP 2010
17.
PUBLICATIONS
The results of this study may be published in a medical publication, journal, or may be used for 
teaching purposes.  Additionally, this study and its results may be submitted for inclusion in all 
appropriate health authority study registries, as well as publication on health authority study 
registry websites, as required by local health authority regulations.  
Page 90 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
91
ACE-011-NSCL-001 FINAL: 17 SEP 2010
18.
REFERENCES
Chantry A, Heath D, Mulivor A, Coulton L, Evans H, Abdul N, Werner ED, Bouxsein ML, 
Pearsall RS, Seehra J, Vanderkerken K, and Croucher PI.  Inhibiting activin-A signalling 
stimulates bone formation, prevents tumor-induced osteolytic bone destruction and blocks bone 
metastasis.  Submitted 2008.  
Chen Y-G, Lui HM, Lin S-L, Lee JM, and Ying S-Y.  Regulation of cell proliferation, apoptosis, 
and carcinogenesis by activin.  Exp Biol Med 2002; 227: 75-87.  
Dang TP, Carbone DP:  Cancer of the Lung, in DeVita, VT, Hellman S, Rosenberg SA (eds): 
Cancer: Principles & Practice of Oncology, 8th edition, Philadelphia, PA. Lippincott Williams & 
Wilkens, 2008, 887-971.  
Functional Assessment of Chronic Illness Therapy-Fatigue, FACIT-F Version 4. 
http://www.facit.org/qview/qlist.aspx, last accessed 21Jul2010.
Groopman JE, Itri LM.  Chemotherapy-Induced Anemia in Adults:  Incidence and Treatment.  
Journal of the National Cancer Institute 1999, 91, 1616-1634.  
Hollen PJ, Gralla RJ, Kris MG ‘Lung Cancer Symptom Scale (LCSS)’, Administration, Scoring 
and Procedures Manual, (1995) Ver.1.1.  
Hong WK, Tsao AS, in Lung Carcinoma: Tumors of the Lungs: Merck Manuals Online Medical 
Library for Healthcare Professionals, 2008. 
http://www.merck.com/mmpe/print/sec05/ch062/ch062b.html
Lotinun S, Fajardo RJ, Pearsall RS, Bouxsein ML, and Baron R.  A soluble activin receptor type
IIA fusion protein, ACE-011, increases bone mass by stimulating bone formation and inhibiting 
bone resorption in cynomolgus monkeys.  ASBMR 30th annual meeting, 2008.  
Mathews LS.  Activin receptors and cellular signaling by the receptor serine kinase family.  
Endocr Rev 1994; 15: 310-25.  
Murata M, Onomichi K, Eto Y, Shibai H, and Muramatsu M.  Expression of erythroid 
differentiation factor (EDF) in Chinese hamster ovary cells.  Biochem Biophys Res Commun
1988; 151: 230-5.  
Nakao K, Kosaka M and Saito S.  Effects of erythroid differentiation factor (EDF) on 
proliferation and differentiation of human hematopoietic progenitors.  Exp Hematol 1991; 19: 
1090-5.  
National Heart, Lung, and Blood Institute, National Institutes of Health.  New York Heart 
Association Classification. 2008.  
NCCN Clinical Practice Guidelines in Oncology:  Cancer and Chemotherapy Induced Anemia, 
V.2. 2010 http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf; 2009.  
Non-small Cell Lung cancer Collaborative Group ‘Chemotherapy in non-small cell lung cancer:  
a metaanalysis using updated data on individual patients from 52 randomized clinical trials’, 
British Medical Journal 1995 vol. 311, no.7010, 899-909.  
Page 91 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
92
ACE-011-NSCL-001 FINAL: 17 SEP 2010
Oken, MM., Creech, R.H., Tormey, D.C., et. al.  Toxicity And Response Criteria Of The Eastern 
Cooperative Oncology Group.  Am J Clin Onco 1982; 5:649-655.  
Parker SL, Tong T, Bolden S, et. al.  Cancer statistics, 1997.  CA Cancer J Clin, 1997, 47, no. 1, 
5-27.  
Pearsall RS, Canalis E, Cornwall-Brady M, Underwood KW, Haigis B, Ucran J, Kumar R, Pobre 
E, Grinberg A, Werner ED, Glatt V, Stadmeyer L, Smith D, Seehra J, and Bouxsein ML.  A 
soluble activin type IIA receptor induces bone formation and improves skeletal integrity.  Proc 
Natl Acad Sci USA 2008, 105: 7082-7.  
Perrien DS, Akel NS, Edwards PK, et. al.  Inhibin A is an endocrine stimulator of bone mass and 
strength.  Endocrinology 2007; 148: 1654-65.  
Rivier J, Spiess J, McClintock R, Vaughan J and Vale W.  Purification and partial 
characterization of inhibin from porcine follicular fluid.  Biochem Biophys Res Commun 1985; 
133: 120-7.  
Rossi A, Maione P, Gridelli C Cetuximab in advanced non-small cell lung cancer.  Critical 
Reviews in Oncology/Hematology, 2006 59, 139-149.  
Ruckle J, Jacobs M, Kramer W, et. al.  A single-dose, randomized, double-blind, placebo-
controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women.  J Bone Miner Res
2009; 24 (4): 744-52.  
Sandler A, Gray R, Perry M, et al Paclitaxel-Carboplatin alone or with Bevacizumab for Non 
Small Cell Lung Cancer, NEJM, 2006 vol.355, no.24, 2542-50.  
Scagliotti G, Parikh P, von Pawel J, et al Phase III Study Comparing Cisplatin Plus Gemcitabine 
With Cisplatin Plus Pemetrexed in Chemotherapy-Naïve patients With Advanced-Stage Non-
Small-Cell Lung Cancer, JCO, 2008, 26 (21): 3543-51.  
Schiller J, Harrington D, Belani C, et al Comparison of Four Chemotherapy Regimens for 
Advanced Non-Small-Cell Lung Cancer.  N Engl J Med 2002; 346:92-98.  
Seder C, Hartojo W, Lin L, et al Upregulated INHBA Expression May Promote Cell 
Proliferation and Is Associated with Poor Survival in Lung Adenocarcinoma, Neoplasia, 2009, 
11: 388-396.  
Shedden K, Taylor J, Enkemann S, et al Gene Expression-Based Survival prediction in Lung 
Adenocarcinoma: A Multi-Site, Blinded Validaion Study: Director’s Challenge Consortium for 
the Molecular Classification of Lung Adenocarcinoma, Nat Med, 2008, 14 (8): 822-827.  
Shiozaki M, Sakai R, Tabuchi M, et. al.  Evidence for the participation of endogenous activin 
A/erythroid differentiation factor in the regulation of erythropoiesis.  Proc Natl Acad Sci USA
1992; 89: 1553-6.  
Shiozaki M, Sakai R, Tabuchi M, et. al.  In vivo treatment with erythroid differentiation factor 
(EDF/activin A) increases erythroid precursors (CFU-E and BFU-E) in mice.  Biochem Biophys 
Res Commun 1989; 165: 1155-61.  
Vansteenkiste J, Pirker R, Massuti B, et.al.  Double-Blind, Placebo-Controlled, Randomized 
Phase III Trial of Darbepoetin Alfa in Lung Cancer Patients Receiving Chemotherapy.  Journal 
of the National Cancer Institute, 2002, 94: 16: 1211-1220.  
Page 92 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
93
ACE-011-NSCL-001 FINAL: 17 SEP 2010
Woodruff TK.  Regulation of cellular and system function by activin.  Biochem Pharmacol 1998; 
55: 953-63.  
Ying S-Y.  Inhibins, activins, and follistatins:  gonadal proteins modulating the secretion of 
follicle-stimulating hormone.  Endocrine Rev 1988; 9: 267-93.  
Page 93 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
94
ACE-011-NSCL-001 FINAL: 17 SEP 2010
19.
APPENDICES
Appendix A:  Response Evaluation Criteria in Solid Tumors
Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Terms
Definition
Measurable disease
The presence of at least one measurable lesion by CT or MRI.  If the measurable 
disease is restricted to a solitary lesion, its neoplastic nature should be confirmed by 
cytology/histology.  
All measurements should be taken and recorded in metric notation, using a ruler or 
calipers.  All baseline evaluations should be performed as closely as possible to the 
beginning of treatment and never more than 4 weeks before the beginning of the 
treatment. 
Measurable lesions
Lesions that can be accurately measured in least one dimension by CT scan with
longest diameter > 10 mm (CT scan thickness no greater than 5 mm).  
The same method of assessment and the same technique should be used to characterize 
each identified and reported lesion at baseline and during follow-up. 
Non-measurable lesion
All other lesions, including small lesions (longest diameter <10mm or pathological 
lymph nodes with P10 to <15mm short axis) as well as truly non-measurable lesions.  
Lesions considered truly non-measurable include:  leptomeningeal disease, ascites, 
pleural or pericardial effusion, inflammatory breast disease, lymphangitic involvement 
of skin or lung, abdominal masses/abdominal organomegaly identified by physical 
exam that is not measurable by reproducible imaging techniques.
RECIST Criteria-Response Evaluation
Evaluation of target lesions
Complete Response (CR)
Disappearance of all target lesions.  
Any pathological lymph nodes (whether target or non-target) must have 
reduction in short axis to <10 mm.
Partial Response (PR):
At least a 30% decrease in the sum of diameters of target lesions, taking as 
reference the baseline sum diameters.
Stable Disease (SD):
Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify 
for PD, taking as reference the smallest sum diameters while on study.
Progressive Disease (PD):
At least a 20% increase in the sum of diameters of target lesions, taking as 
reference the smallest sum on study (this includes the baseline sum if that is the 
smallest on study).  In addition to the relative increase of 20%, the sum must 
also demonstrate an absolute increase of at least 5 mm.  
(Note:  the appearance of one or more new lesions is also considered 
progression).
Page 94 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
95
ACE-011-NSCL-001 FINAL: 17 SEP 2010
RECIST Criteria-Response Evaluation (continued)
Evaluation of non-target 
lesions
Complete Response (CR):
Disappearance of all non-target lesions and normalisation of tumour marker 
level.  All lymph nodes must be non-pathological in size (<10mm short 
axis).
Non-CR/Non-PD
Persistence of one or more non-target lesion(s) and/or maintenance of 
tumour marker level above the normal limits.
Progressive Disease (PD): 
Unequivocal progression (see comments below) of existing non-target 
lesions.  
(Note:  the appearance of one or more new lesions is also considered 
progression).
Evaluation of best overall response
The best overall response is the best response recorded from the start of the 
treatment until disease progression/recurrence (taking as reference for PD 
the smallest measurements recorded since the treatment started).  In general, 
the patient's best response assignment will depend on the achievement of 
both measurement and confirmation criteria.  
Patients with a global deterioration of health status requiring discontinuation 
of treatment without objective evidence of disease progression at that time 
should be classified as having “symptomatic deterioration”.  Every effort 
should be made to document the objective progression even after 
discontinuation of treatment.  
In some circumstances it may be difficult to distinguish residual disease 
from normal tissue.  When the evaluation of complete response depends on 
this determination, it is recommended that the residual lesion be investigated 
(fine needle aspirate/biopsy) to confirm the complete response status.  
Source:  Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R,  Dancey J, Arbuck S, Gwyther S, 
Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R,  Lacombe D, Verweij J.  New response evaluation 
criteria in solid tumours:  Revised RECIST guideline (version 1.1)  (2009).  European Journal of Cancer 45, 228-
247.  
Page 95 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
96
ACE-011-NSCL-001 FINAL: 17 SEP 2010
Appendix B:  ECOG Performance Status Scale 
The ECOG scale (Oken, 1982) is used to assess a patient’s quality of life in an evaluation by a 
health professional of the daily activities and how the activities are affected by the disease of the 
patient.  
Table 9:
ECOG Performance Status Scale
Score
Description
0
Fully active, able to carry on all pre-disease performance without restriction
1
Restricted in physically strenuous activity but ambulatory and able to carry out work of 
a light or sedentary nature, e.g., light housework, office work.
2
Ambulatory and capable of all self-care but unable to carry out any work activities.  Up 
and about more than 50% of waking hours.
3
Capable of only limited self-care, confined to bed or chair more than 50% of waking 
hours.
4
Completely disabled.  Cannot carry on any self-care.  Totally confined to bed or chair
5
Dead
Page 96 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
97
ACE-011-NSCL-001 FINAL: 17 SEP 2010
Appendix C:  National Cancer Institute (NCI) Common Terminology Criteria 
for Adverse Events (CTCAE) Version 4.0
Currently active minor version of NCI CTCAE, Version 4.0:
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
Page 97 of 791
088VGY

ACE-011
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
98
ACE-011-NSCL-001 FINAL: 17 SEP 2010
Appendix D:  New York Heart Association - Classification of Heart Failure
Table 10:
Classification of Heart Failure
Class
Symptoms
Class 1
No limitation of activities.  No symptoms from ordinary activities
Class 2
Mild limitation of activity.  Comfortable with rest or mild exertion
Class 3
Marked limitation of activity and be comfortable only at rest
Class 4
Complete rest, confined to bed or chair; any physical activity brings on discomfort and 
symptoms occur at rest
Page 98 of 791
088VGY

088VGY

088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
3
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
1.
JUSTIFICATION FOR AMENDMENT
Significant changes included in this amendment are summarized below.  These changes were 
based on feedback obtained from the FDA, investigators/sites and internal discussions:
1. FDA approval of use of Sotatercept (ACE-011) Process III Clinical Drug Product –
Lyophilized Powder.  
2. USAN/INN approval of “sotatercept” as the generic name for ACE-011.
3. Objectives
a.
Clarification of Part 2 primary objective of transfusion rate.
b. Clarification of Parts 1 and 2 secondary objectives to evaluate the hematopoietic 
response and duration associated with ACE-011. 
c.
Clarification of exploratory objectives
i.
Defined Activin A and other proteins/biomarkers, including mysostatin 
and follistatin, assessed in blood.
ii. Defined Activin A and other proteins/biomarkers assessed in tumor tissue.
iii. Deleted circulating tumor cell assessment. 
4. Endpoints
a.
Clarification of Part 2 primary endpoint of transfusion rate.
b. Addition of secondary endpoint – Duration of hematopoietic response.
c.
Specification of renal biomarkers for renal function assessment.
5. Clarification of metastatic non small cell lung cancer patient population.
6. Clarification of hemoglobin level and RBC transfusion for chemotherapy-induced anemia 
and timeframe of RBC transfusion versus ACE-011 (sotatercept) administration.
7. Revision of Introduction Section to include updated nonclinical findings and deletion of 
comparator claims.
8. Modification to increase the allowed dosing time period of the first dose of sotatercept 
(ACE-011) or sotatercept (ACE-011)/placebo prior to and following a cycle of platinum-
based chemotherapy. 
9. Clarification of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dosing schedule 
versus platinum-based chemotherapy dosing schedule and order of dosing, if 
administered on the same day.
10. Clarification of randomization in Part 1 to describe the analysis of safety data following 
the treatment of at least 10 subjects at the 15.0 mg dose level and 10 subjects at the 30.0 
mg dose level, with each subject having received at least of one dose of sotatercept 
(ACE-011), plus a 12 week follow-up period from first dose and the subsequent decision 
to add a third dose level of 45.0 mg to the randomization schema. 
Page 101 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
4
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
11. Revision of Inclusion Criteria:
a.
Revised typographical error – Platelet count ≥75,000/mm3 instead of  
≥25,000/mm3
b. Defined adequate renal function as creatinine clearance > 40 mL/min or > 50 
mL/min if cisplatin concomitantly administered.
c.
Addition of concomitant platinum-based chemotherapy regimen docetaxel plus 
cisplatin + bevacizumab.
d. Clarification that subjects are expected to be eligible to receive at least two 
additional cycles of platinum-based chemotherapy at the time of randomization.
e.
Revision of timeframe of pre-dose Day 1 RBC transfusion > 14 days and receipt 
of < 2 units in past 30 days.
f.
Addition of denosumab (XGEVATM) as an acceptable concomitant therapy for the 
treatment of bone metastases.  
12. Revision of Exclusion Criteria:
a.
Clarification of exclusion of subjects with ≥ Grade 3 toxicities or major end-organ 
dysfunction, irrespective of whether they are considered disease related, except 
for hematotoxicity and non hematologic events occurring during the 
chemotherapy period and resolving. 
b. Modified to exclude CNS metastases that have not been treated and stable for at 
least 2 weeks prior to randomization.  
c.
Modified to exclude subjects with > 150mm Hg systolic or diastolic blood 
pressure > 100mm Hg.
d. Modified to exclude subjects with a history of gastrointestinal bleeding occurring 
with the past 6 months.
e.
Correction of typographical error to – urine protein / creatinine ratio > 1.0.
13. Revision of dose modification algorithm for hypertension and additional clarification of 
dose modification rules.  
14. Clarification of collection of historical tumor assessment data and acceptable screening 
tumor assessment timeframes. Modification of post - randomization tumor assessment 
timeframes. 
15. Addition of erlotinib (Tarceva®) - based regimens as allowed maintenance therapy. 
16. Clarification of Treatment Discontinuation Rules:
a.
Revised language to instruct investigators regarding criteria for study therapy
discontinuation.
b. Addition of specific blood pressure parameters.
c.
Addition of definition of persistent hematuria. 
Page 102 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
5
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
17. Clarification of Study Discontinuation Rules to define events that are considered reasons 
for study discontinuation versus events that may be considered reasons for discontinuing 
a subject from the study.
18. Revisions to Schedule of Assessments
a.
Addition of blood pressure measurement at Day 29 following dosing of 
sotatercept (ACE-011).
b. Clarification that blood pressure measurements should be confirmed by two 
measurements obtained five minutes apart.
c.
Addition of measurement of weight to correspond with creatinine clearance 
assessments.
d. Addition of serum chemistry assessments to correspond with creatinine clearance 
assessments.
e.
Clarification that renal biomarkers are assessed at the same visits as urinalysis.
f.
Clarification that tumor tissue is an archival sample and not required to be 
collected on study.
19. Clarification of Pharmacokinetic Assessments 
a.
Clarification that subjects not participating in the full pharmacokinetic assessment 
in Part 1 of the study will participate in the sparse pharmacokinetic assessment.  
b. Clarification that sparse pharmacokinetic samples will be collected from 
approximately 300 subjects in Part 2 of the study.
c.
Addition of a separate Schedule of Pharmacokinetic Assessments Table for Part 2 
of the study.
20. Revision of term in Iron Supplementation from ‘iron deficient’ to ‘iron replete’.
21. Revisions to Statistical Analyses
a.
Clarification that data from Parts 1 and 2 of the study will not be combined in 
safety and efficacy analyses. 
b. Correction of typographical error in Sample Size and Power Considerations from 
‘15% risk reduction’ to ‘15% hazard increase’.
c.
Clarification of Efficacy Analysis to better define the primary endpoint, 
transfusion rate, in Part 2 of the study.    
22. Data Monitoring Committee – clarification throughout the protocol on the role and 
responsibilities of the DMC.
23. Revision of serious adverse event reporting period from 112 to 42 days for events not 
suspected to be related to investigational product. 
Other administrative changes (e.g., protocol template section updates, correction of 
typographical errors, editorial changes, etc.) were also incorporated and are outlined in Section 2 
Itemized Changes.
Page 103 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
6
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
2.
ITEMIZED CHANGES
2.1.
Section:  Title Page, (page 1)
Original Text:
A SINGLE-BLIND, RANDOMIZED, PHASE 2A, DOSE 
RANGING STUDY (PART 1) OF ACE-011 THERAPY 
FOLLOWED BY A PHASE 2B/3, DOUBLE-BLIND, 
RANDOMIZED, PLACEBO-CONTROLLED STUDY 
(PART 2) OF ACE-011 FOR CHEMOTHERAPY
INDUCED ANEMIA IN SUBJECTS WITH METASTATIC 
NON-SMALL CELL LUNG CANCER TREATED WITH 
FIRST-LINE PLATINUM-BASED 
CHEMOTHERAPEUTIC REGIMENS
Revised Text:
A SINGLE-BLIND, RANDOMIZED, PHASE 2A, DOSE-
RANGING STUDY (PART 1) OF SOTATERCEPT 
(ACE-011) THERAPY FOLLOWED BY A PHASE 2B/3, 
DOUBLE-BLIND, RANDOMIZED, PLACEBO-
CONTROLLED STUDY (PART 2) OF SOTATERCEPT 
(ACE-011) FOR CHEMOTHERAPY- INDUCED ANEMIA 
IN SUBJECTS WITH METASTATIC NON-SMALL CELL 
LUNG CANCER TREATED WITH FIRST-LINE 
PLATINUM-BASED CHEMOTHERAPEUTIC 
REGIMENS
Rationale:
The USAN/INN approved the name sotatercept for ACE-011. The term “ACE-011” has been 
replaced with “sotatercept (ACE-011)” throughout the protocol. 
Page 104 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
7
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
2.2.
Section:  Title Page, (page 1)
Original Text:
INVESTIGATIONAL PRODUCT (IP):
ACE-011
PROTOCOL NUMBER:
ACE-011-NSCL-001
DATE FINAL:
17 SEPTEMBER 2010 
EudraCT NUMBER:
2010-022561-10
IND NUMBER:
103362
Revised Text:
INVESTIGATIONAL PRODUCT (IP):
Sotatercept (ACE-011)
PROTOCOL NUMBER:
ACE-011-NSCL-001
DATE FINAL:
17 SEPTEMBER 2010 
AMENDMENT 1.0 DRAFT:
15 MARCH 2011 (DRAFT)
EudraCT NUMBER:
2010-022561-10
IND NUMBER:
103362
Rationale:
Updated to include amendment version and date.
Page 105 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
8
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
2.3.
Section:  MEDICAL MONITOR / EMERGENCY CONTACT 
INFORMATION, (page 2)
Original Text:
Contact Information:
Revised Text:
Contact Information:
Rationale:
Addition of Medical Monitor to the header information to align with the current protocol 
template.  Also, updated information to include the new Clinical Research Physician. 
Page 106 of 791
PPD
PPD
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
9
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
2.4.
Section:  Protocol Summary, (page 6)
Original Text:
Study Title
A single-blind, randomized, phase 2a, dose ranging study (Part 1) of ACE-011 therapy followed 
by a phase 2b/3, double-blind, randomized, placebo-controlled study (Part 2) of ACE-011 for 
chemotherapy induced anemia (CIA) in subjects with metastatic non-small cell lung cancer 
(NSCLC) treated with first-line platinum-based chemotherapeutic regimens.  
Revised Text:
Study Title
A single-blind, randomized, phase 2a, dose-ranging study (Part 1) of sotatercept (ACE-011)
therapy followed by a phase 2b/3, double-blind, randomized, placebo-controlled study (Part 2) 
of sotatercept (ACE-011) for chemotherapy-induced anemia (CIA) in subjects with metastatic 
non-small cell lung cancer (NSCLC) treated with first-line platinum-based chemotherapeutic 
regimens.  
Rationale:
The USAN/INN approved the name sotatercept. The term ACE-011 has been replaced with 
sotatercept (ACE-011) throughout the protocol. 
Page 107 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
10
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
2.5.
Section:  Protocol Summary, (pages 6-7)
Original Text:
The primary objectives are:

Part 1:  To determine an effective dose of ACE-011 showing a hematopoietic 
response in the treatment of CIA in advanced NSCLC subjects.  

Part 2:  To assess transfusion rate within 4 months following initiation ACE-011 
treatment.  
The secondary objectives are:
Part 1 and Part 2:

To estimate the effect of ACE-011 treatment on objective response rate (ORR), time 
to progression (TTP), progression free survival (PFS) and overall survival (OS) in 
advanced NSCLC subjects with CIA.  

To evaluate the safety and tolerability of ACE-011 treatment for advanced NSCLC 
subjects with CIA.  

To determine the PK of ACE-011 in subjects with advanced NSCLC receiving 
platinum-based chemotherapy.  

To estimate the duration of hematopoietic response associated with ACE-011.  

To evaluate the effect of ACE-011 treatment on the quality of life (QoL) of NSCLC 
subjects with CIA.  
Part 2:

To evaluate hematopoietic response
Revised Text:
Objectives
The primary objectives are:
Part 1:  To determine an effective dose of sotatercept (ACE-011) showing a 
hematopoietic response in the treatment of CIA in metastatic NSCLC subjects.  
Part 2:  To assess transfusion rate within 4 months following initiation of sotatercept 
(ACE--011)/placebo treatment.  
The secondary objectives are:
Part 1 and Part 2:
To estimate the effect of sotatercept (ACE-011) treatment on objective response rate 
(ORR), time to progression (TTP), progression free survival (PFS) and overall 
survival (OS) in advancedmetastatic NSCLC subjects with CIA.  
Page 108 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
11
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
To evaluate the safety and tolerability of sotatercept (ACE-011) treatment for 
advancedin metastatic NSCLC subjects with CIA.  
To determine the pharmacokinetics (PK) of sotatercept (ACE-011) in subjects with 
advancedmetastatic NSCLC receiving platinum-based chemotherapy.  
To estimateevaluate the duration of hematopoietic response and its duration 
associated with sotatercept (ACE-011) treatment.  
To evaluate the effect of sotatercept (ACE-011) treatment on the quality of life (QoL) 
of NSCLC subjects with CIA.  
Part 2:
To evaluate hematopoietic response
Rationale:
Primary objectives – Revised to clarify patient population and primary objective.
Secondary objectives – Revised to clarify patient population and analysis of hematopoietic 
response and delete redundant wording.
                                                     
Original Text:
The exploratory objectives are:
Part 1 and Part 2:

To estimate the effect of each ACE-011 treatment on bone metabolism in NSCLC 
subjects with CIA.  

To explore the relationship between ACE-011 exposure and response (hematology, 
biomarkers, and other clinical outcomes as appropriate).  

To evaluate the expression/overexpression of Activin A and other 
proteins/biomarkers related to ACE-011 mechanism of action in blood and tumor 
tissue in the NSCLC population.  

To assess circulating tumor cells and molecular studies

To assess renal function biomarkers
Page 109 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
12
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Revised Text:
The exploratory objectives are:
Part 1 and Part 2:
To estimate the effect of each sotatercept (ACE-011) treatment on bone metabolism 
in NSCLC subjects with CIA.  
To explore the relationship between sotatercept (ACE-011) exposure and response 
(hematology, biomarkers, and other clinical outcomes as appropriate).  
To evaluate the expression/overexpression of Activin A and other 
proteins/biomarkers (including myostatin and follistatin) related to sotatercept (ACE-
011) mechanism of action in blood. 
To evaluate the expression of Activin A and other proteins/biomarkers in archival 
tumor tissue in the NSCLC population.  
Circulating tumor cell enumeration and molecular studies. .
To assess renal function biomarkers.  
Rationale:
Updated to provide clarification and specification of Parts 1 and 2 of exploratory objectives.  
Evaluating expression of Activin A, myostatin and follistatin as well as other additional 
biomarkers in both serum and in tumor tissue may help to better understand sotatercept (ACE-
011) mechanism of action. Assessment of circulating tumor cells was deleted because the 
expression is very low in patients undergoing treatment with chemotherapy and because, to date, 
there is little evidence that tumor cells circulate at quantifiable levels in NSCLC patients.  
Page 110 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
13
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
2.6.
Section:  Protocol Summary, (page 7)
Original Text:
Study Population
Subjects must be receiving their first regimen of first-line platinum-containing chemotherapy, 
given every three weeks, for the treatment of metastatic NSCLC at the time of randomization.  
Subjects must be randomized prior to receiving Cycle 4 of this current first-line platinum-based 
chemotherapy regimen.  Subjects are expected to be eligible to receive 2 platinum-based 
chemotherapy cycles or maintenance therapy with a pemetrexed-based regimen following 
randomization.  
Revised Text:
Study Population
At  the time of randomization, all subjects must be receiving their first regimen of  first-line 
platinum-containing chemotherapy, given every three weeks, for the treatment of metastatic 
NSCLC.  Subjects may have already received up to 3 cycles and must be randomized prior to 
receiving Cycle 4 of this current first-line platinum-based regimen to be eligible for the study.  It 
is  expected that subjects be eligible to continue to receive ≥ 2 additional platinum-based 
chemotherapy cycles while on study treatment.  
Rationale:
Modified to include additional erlotinib-based maintenance regimen per investigator 
recommendation. Also, per FDA’s recommendation clarification of study population description 
based on subjects being eligible to continue to receive platinum-based chemotherapy following 
randomization.   
Page 111 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
14
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
2.7.
Section:  Protocol Summary, (page 8)
Original Text:
Screening Period (28 days):
Potential study subjects will sign an informed consent form prior to undergoing any study-related 
procedures.  Subjects will undergo screening for protocol eligibility within 28 days of 
randomization, as outlined in the Table of Events, Section 5.  Historical tumor assessment data 
from six weeks prior to initiation of platinum-based chemotherapy through randomization 
to the study will be collected.  
Revised Text:
Screening Period (28 days):
Potential study subjects will sign an informed consent form prior to undergoing any study-related 
procedures.  Subjects will undergo screening for protocol eligibility within 28 days of 
randomization, as outlined in the Table of Events, Section 5.  Note: Screening period tumor 
assessments should be performed within six weeks prior to randomization.  Also, hHistorical 
tumor assessment data, from from six weeks prior to the initiation of platinum-based 
chemotherapy through the screening period, randomization to the study will be collected
and used for assessment of tumor response.  
Rationale:
Updated description of collection of tumor assessment data from prior to randomization. 
Clarification of  the screening period timeframe and of the additional collection of historical 
tumor assessment data, from prior to initiation of first line platinum-based chemotherapy, to be 
used as the baseline tumor assessment. 
Page 112 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
15
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
2.8.
Section:  Protocol Summary, (pages 8-10)
Original Text:
Treatment Period (up to 6-9 months):  
                                                     
Following analysis of at least 10 subjects at each dose level (10 subjects at the 15.0 mg dose 
level and 10 subjects at the 30.0 mg dose level), a third dose level will be added to the 
randomization schema:
ACE-011 45.0 mg SC
                                                     
Evaluation of response decision status will be completed after dosing arms have separately 
enrolled up to 30 subjects, as needed, to determine the optimal dose for Part 2.  
                                                     
Concurrent treatment for CIA with blood transfusions is recommended when Hgb value is 
< 8 g/dL or at the discretion of the Investigator if the Hgb value is > 8 g/dL and associated with 
anemia symptoms such as hemodynamic or pulmonary compromise requiring treatment.  If an 
RBC transfusion is given to a subject during the Treatment Period, ACE-011 should be 
administered ≥ 7 days from the date of the RBC transfusion.  
Revised Text:
Treatment Period (up to 6-9 months):  
Analysis of safety data will be performed following the treatment of at least 10 subjects at the 
15.0 mg dose level and 10 subjects at the 30.0 mg dose level, with each subject having received 
at least of one dose of sotatercept (ACE-011), plus a 12 week follow-up period from first dose.  
Following this analysis, the addition of a third dose level:
SFollowing analysis of at least 10 subjects at each dose level (10 subjects at the 15.0 mg dose 
level and 10 subjects at the 30.0 mg dose level), a third dose level will be added to the 
randomization schema:
ACE-011otatercept (ACE-011) 45.0 mg SC
to the randomization schema will be determined.
                                                     
Evaluation of hemoglobin response decision status will be completed after dosing arms have 
separately enrolled up to 30 subjects, as needed, to determine the optimal dose for Part 2.  
                                                     
Page 113 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
16
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Concurrent treatment for CIA with blood transfusions is recommended when Hgb value is 
< 8 g/dL or at the discretion of the Investigator if the Hgb value is >≥8 g/dL and associated with 
anemia symptoms such as hemodynamic or pulmonary compromise requiring treatment.  If an 
RBC transfusion is given to a subject during the Treatment Period, sotatercept (ACE-011) should 
be administered ≥> 7 days from the date of the RBC transfusion.  
Rationale:
Revised per FDA’s recommendation to clarify when safety analysis of the first 10 subjects 
treated with 15 and 30 mg dose levels of sotatercept (ACE-011) would occur. 
Addition of term ‘hemoglobin’ to clarify the type of response to be evaluated for the optimal 
dose decision for Part 2 of the study.   
Clarification of recommended RBC transfusion for the treatment of CIA per Hgb level and 
timeframe for RBC transfusion and sotatercept (ACE-011) administration. 
                                                     
Original Text:
In Part 1, full PK blood samples will be collected to evaluate the full PK profile of ACE-011 
from approximately 30 subjects at select centers in approximately 10 subjects for each ACE-011 
dose group.  In subjects participating in the full PK assessment, RBC, Hgb, and reticulocyte 
counts will be collected at each PK time point (excluding the 4-hour time point on Day 1) from 
Day 1 to Day 43 after the first dose.  
In Part 2, sparse PK blood samples will be collected.  
Revised Text:
In Part 1, full PK blood samples will be collected to evaluate the full PK profile of 
ACE-011sotatercept (ACE-011) from approximately 30 subjects at select centers, in 
approximately 10 subjects for each ACE-011sotatercept (ACE-011) dose group.  In subjects 
participating in the full PK assessment, RBC, Hgb, and reticulocyte counts will be collected at 
each PK time point (excluding the 4-hour time point on Day 1) from Day 1 to Day 43 after the 
first dose.  Subjects not participating in the optional full PK assessment will participate in the 
sparse PK assessment.  
In Part 2, the sparse PK assessment will be performed in approximately 300 (40%) of 750blood 
samples will be collected subjects (approximately 150 subjects in each arm).  
Rationale:
Section updated to provide clarification of PK requirements in Parts 1 and 2 of the study.  
                                                     
Page 114 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
17
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Original Text:
The following events are considered sufficient reasons for discontinuing a subject from the 
Treatment Period:
AE(s)
Medically significant hypertension which cannot be adequately controlled with 
antihypertensive therapy
                                                     
Creatinine clearance < 40 ml/min
                                                     
Persistent hematuria
Revised Text:
Subjects will be discontinued from Study Treatment due to the following:The following events 
are considered sufficient reasons for discontinuing a subject from the Treatment Period:

Adverse  events(s)

Hypertension ≥ Grade 3 – defined as Stage 2 hypertension (systolic blood 
pressure [SBP] ≥ 160 mm Hg or diastolic blood pressure [DBP] ≥ 100mm Hg), 
confirmed by two measurements obtained five minutes apart; medical 
intervention indicated; more than one drug or more intensive therapy than 
previously used indicated or medically significant hypertension which cannot be 
adequately controlled with antihypertensive therapy.
                                                     

Creatinine clearance < 40 ml/min
                                                     
Persistent hematuria  ≥Grade 2 - defined as symptomatic; urinary catheter or 
bladder irrigation indicated; limiting instrumental activities of daily living, and 
persisting for one week.
Rationale:
Updated to comply with FDA’s feedback to use command language to instruct investigators to 
discontinue study therapy, provide blood pressure parameters and define persistent hematuria. 
Discontinuation based on creatinine clearance was deleted based on updated toxicology study 
data and investigator recommendation.    
Page 115 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
18
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
2.9.
Section:  Protocol Summary, (pages 10-11)
Original Text:
Post Treatment Follow-Up Period (monthly for up to 6 months)
                                                     
The following events are considered sufficient reasons for discontinuing a subject from the 
study:
Completed study, per protocol (subject has completed six to nine month Treatment 
Period plus up to six month Post Treatment Follow-Up Period including one year 
tumor assessment to determine TTP and PFS).  Note:  Survival data will continue to 
be collected for up to 24 months from first dose of study treatment.  
AE(s)
Disease Progression of NSCLC
Withdrawal of consent
Death
Lost to follow-up
Protocol violation
Revised Text:
Post Treatment Follow-Up Period (monthly for up to 6 months)
                                                     
The following events are considered sufficient reasons for discontinuing a subject from the 
study:
Completed study, per protocol (subject has completed six- to nine- month Treatment 
Period plus up to six-month Post Treatment Follow-Up Period including one year 
tumor assessment to determine TTP and PFS).  Note:  Survival data will continue to 
be collected for up to 24 months from first dose of study treatment.  

AE(s)

Disease Progression of NSCLC
Withdrawal of consent
Death
Lost to follow-up

Protocol violation
Page 116 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
19
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
The following events may be considered sufficient reasons for discontinuing a subject from the 
study:
AE(s)
Disease progression of NSCLC
Protocol violation
Rationale:
Separated the reasons for study discontinuation into two types to better define the reasons that 
will necessitate study discontinuation and reasons that may lead to study discontinuation.
Page 117 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
20
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
2.10.
Section:  Protocol Summary, (page 12)
Original Text:
Overview of Exploratory Assessments
Bone or other protein/biomarkers 
Circulating tumor cell enumeration and molecular studies
Revised Text:
Overview of Exploratory Assessments
Bone or other potential mechanistic or disease-related proteins/biomarkers 

Circulating tumor cell enumeration and molecular studies
Rationale:
Updated to clarify exploratory assessments and delete circulating tumor cell assessment due to 
very low expression in patients undergoing treatment with chemotherapy and because, to date, 
there is little evidence that tumor cells circulate at quantifiable levels in NSCLC patients.  
Page 118 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
21
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
2.11.
Section 1:  Introduction, (page 18)
Original Text:
This is a single-blind, randomized, phase 2a, dose ranging study of ACE-011 therapy followed 
by a phase 2b/3, double-blind, randomized, placebo-controlled study of ACE-011 for 
chemotherapy induced anemia (CIA) in subjects with metastatic non-small cell lung cancer 
(NSCLC) treated with platinum-based chemotherapeutic regimens.  The study will consist of two 
parts.  Part 1 is a dose finding segment in which up to 90 subjects will be randomized to one of 
three ACE-011 dose treatment arms.  A Data Monitoring Committee (DMC), composed of both 
internal Celgene and external independent reviewers, will review data from Part 1 to define the 
recommended ACE-011 dose to be used in Part 2 which is the phase 2b/3, randomized, double-
blind, placebo-controlled segment of the study.  Part 2 will be performed in two stages. In the 
first stage approximately 180 subjects will be randomized to receive ACE-011, at the dose 
determined from Part 1, or placebo at a ratio of 1:1.  An interim futility assessment based on 
transfusion rate at 4 months will be performed as described in Section 10.8.  It is expected that 
accrual will continue during the interim assessment period, with up to an additional 570 subjects 
randomized to achieve full study accrual.
Revised Text:
This is a single-blind, randomized, phase 2a, dose-ranging study of sotatercept (ACE-011)
therapy followed by a phase 2b/3, double-blind, randomized, placebo-controlled study of 
sotatercept (ACE-011) for chemotherapy-induced anemia (CIA) in subjects with metastatic non-
small cell lung cancer (NSCLC) treated with platinum-based chemotherapeutic regimens.  The 
study will consist of two parts.  Part 1 is a dose finding segment in which up to 90 subjects will 
be randomized to one of three sotatercept (ACE-011) dose treatment arms.  A Data Monitoring 
Committee (DMC), composedContinuous monitoring of both internal Celgene and external 
independent reviewers, safety data will be conducted, including the review data from of Part 1 
data to define the recommended sotatercept (ACE-011) dose to be used in Part 2 which is, the 
phase 2b/3, randomized, double-blind, randomized placebo-controlled segment of the study.  
Part 2 will be performed in two stages. In the first stage approximately 180 subjects will be 
randomized to receive sotatercept (ACE-011), at the dose determined from Part 1, or placebo at a 
ratio of 1:1.  An interim futility assessment based on transfusion rate at 4 months will be 
performed as described in Section 10.8.  It is expected that accrual will continue during the 
interim assessment period, with up to an additional 570 subjects randomized to achieve full study 
accrual.
A Data Monitoring Committee (DMC) will monitor the conduct of the study.  
Rationale:
Updated to confirm continuous safety data monitoring and better clarify the role and composition 
of the DMC consistently throughout the protocol. 
                                                     
Page 119 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
22
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Original Text:
While the mechanism(s) underlying the stimulation effect of ACE-011 on erythropoiesis are not 
yet fully understood, it is hypothesized that a blockade of ActRIIA receptor signaling impedes 
the terminal differentiation step in erythropoiesis to allow additional rounds of erythroid cell 
replication before cells enter the terminal differentiation phase.  The result is a substantial 
increase in mature erythrocytes released into circulation.  Since this proposed mechanism is 
different to that of known agents, ACE-011 may provide a different clinical profile in the 
treatment of CIA.  
Revised Text:
Although the mechanism(s) underlying the stimulation effect of sotatercept (ACE-011) on 
erythropoiesis are not yet fully understood, the result of clinical experience showed a rapid and 
sustainable increase in mature erythrocytes released into circulation.  The sotatercept (ACE-011)
proposed mechanism of action may be different than that of known erythropoiesis-stimulating
agents (ESAs) and may provide a different clinical profile in the treatment of CIA.  
Rationale:
Updated to reflect clinical experience and nonclinical findings.
Page 120 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
23
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
2.12.
Section 1:  Introduction, (page 19-20)
Original Text:
Treatment of Chemotherapy-Induced Anemia
The ability for ACE-011 to rapidly increase and sustain Hgb levels in anemic subjects, while 
showing a safety benefit as well as no decrement in Overall Survival (as part of this study design 
endpoints), suggests that ACE-011 may then serve as an alternative therapeutic agent for the 
treatment of CIA.  
Revised Text:
Treatment of Chemotherapy-Induced Anemia
The ability for ACE-011sotatercept (ACE-011) to rapidly increase and sustain Hgb levels in 
anemic subjects supports the clinical development of, while showing a safety benefit as well as 
no decrement in Overall Survival (as part of this study design endpoints), suggests that ACE-
0011 may then serve as an alternative therapeutic agent for the treatment of CIA.  
Rationale:
Updated per FDA’s recommendation to avoid comparator claims.
Page 121 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
24
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
2.13.
Section 1:  Introduction, (pages 20-23)
Original Text:
Activin Biology
The activin signaling pathway has been shown to induce terminal erythroid differentiation in 
some preclinical models.  Inhibition of activin may lead to increases in proliferation of the 
erythroid lineage.  Based on its pharmacologic effects, ACE-011 is being developed for the 
treatment of anemia associated with a variety of disorders, such as in chronic renal failure and 
CIA.  
                                                     
Pharmacology Studies
The data demonstrate that RAP-011 treatment acts to inhibit MDA-MB-231 metastasis to bone 
and may also play a role in inhibiting tumor growth in soft tissue.  Furthermore, in the presence 
of tumor cells, RAP-011 is able to prevent lytic disease through an anabolic mechanism of bone 
formation.  Lastly, inhibition of tumor growth and metastasis with RAP-011 leads to a greater 
than 25% survival benefit in this model.  
RAP-011 was also evaluated in osteolytic bone disease of multiple myeloma.  Multiple myeloma 
is associated with the development of bone disease characterised by increased osteoclast activity 
and a suppression of osteoblastic bone formation.  
Results obtained in the 5T2MM murine model of myeloma in which the extra-cellular domain of 
the murine activin type II receptor, fused to a murine IgG-Fc fragment, (RAP-011) was shown to 
prevent the development of osteolytic bone disease in a preventative setting.  Additionally, RAP-
011, an antagonist of activin, was shown to reverse ovariectomy-induced bone loss in vivo.  
The effect of this antagonist on the inhibition of bone formation and osteoblast function in 
myeloma bone disease was investigated in isolated 5T2MM murine myeloma cells from the bone 
marrow of disease bearing animals.  
5T2MM cells promoted the development of osteolytic bone lesions (p<0.001), a reduction in 
trabecular volume (p<0.001) and cortical volume (p<0.005).  RAP-011 completely prevented 
5T2MM-induced decreases in trabecular volume and number in both tibia (p<0.001 and p<0.01), 
femur (p<0.001 and p<0.001) and vertebrae (p<0.01 and p<0.01) when compared to vehicle 
treated mice.  Bone volume was 19% higher in the tibia, 35% higher in the femur and 12% 
higher in vertebrae of RAP-011 treated mice than naïve non-tumour bearing mice.  
This study showed that, in the preclinical murine model for myeloma, RAP-011 stimulates bone 
formation by increasing osteoblast perimeter and number, mineralisation and bone formation rate 
but had no effect on osteoclast activity.  RAP-011 also prevented the development of osteolytic 
bone disease.  
Page 122 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
25
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Revised Text:
Activin Biology
The activin signaling pathway has been shown to induce terminal erythroid differentiation in 
some preclinical models.  Inhibition of activin may indirectly lead to increases in proliferation of 
the erythroid lineage.  Based on its pharmacologic effects, sotatercept (ACE-011) is being 
developed for the treatment of anemia associated with a variety of disorders, such as in chronic 
renal failure and CIA.  
                                                     
Pharmacology Studies
The data demonstrate that RAP-011 treatment acts to inhibit decrease the incidence of MDA-
MB-231 metastasis to bone and may also play a role in inhibiting tumor growth in soft tissuethe 
bone marrow environment.  Furthermore, in the presence of tumor cells, RAP-011 is able to 
prevent lytic disease through an anabolic mechanism of bone formation.  Lastly, inhibition of 
tumor growth and metastasis with RAP-011 leads to a greater than 25% survival benefit in this 
model.  
RAP-011 was also evaluated in osteolytic bone disease of multiple myeloma.  Multiple myeloma 
is associated with the development of bone disease characterised by increased osteoclast activity 
and a suppression of osteoblastic bone formation. 
Results obtained in the 5T2MM murine model of myeloma in which the extra-cellular domain of 
the murine activin type II receptor, fused to a murine IgG-Fc fragment, (demonstrated that RAP-
011) was shown to could prevent the development of osteolytic bone disease in a preventative 
setting.  Additionally, RAP-011, an antagonist of activin, was shown to reverse ovariectomy-
induced bone loss in vivo.  
The effect of this activin antagonist on the inhibition of bone formation and osteoblast function 
in myeloma bone disease was investigated in isolated 5T2MM murine myeloma cells isolated 
from the bone marrow of disease bearing animals.  
5T2MM cells promoted the development of osteolytic bone lesions (p<0.001), a reduction in 
trabecular volume (p<0.001) and cortical volume (p<0.005).  RAP-011 completely prevented 
5T2MM-induced decreases in trabecular volume and number in both tibia (p<0.001 and p<0.01), 
femur (p<0.001 and p<0.001) and vertebrae (p<0.01 and p<0.01) when compared to vehicle 
treated mice.  Bone volume was 19% higher in the tibia, 35% higher in the femur and 12% 
higher in vertebrae of RAP-011 treated mice than naïve non-tumour bearing mice.  
This study showed that, in the preclinical murine model for myeloma, RAP-011 stimulates bone 
formation by increasing osteoblast perimeter and number, mineralisation and bone formation rate 
but had no effect on osteoclast activity.  RAP-011 also prevented the developmentappeared to 
directly inhibit tumor growth as demonstrated by decreased serum M protein, indicative of 
osteolytic bone diseasedecreased tumor burden.  
Rationale:
Modified to update preclinical data.
Page 123 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
26
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
2.14.
Section 2.1:  Primary  Objectives, (page 34)
Original Text:
The primary objectives are:

Part 1:  To determine an effective dose of ACE-011 showing a hematopoietic 
response in the treatment of CIA in advanced NSCLC subjects.  

Part 2:  To assess transfusion rate within 4 months following initiation ACE-011 
treatment.  
2.15.
Section 2.2:  Secondary  Objectives, (page 34)
Original Text:
The secondary objectives are:
Part 1 and Part 2:

To estimate the effect of ACE-011 treatment on objective response rate (ORR), time 
to progression (TTP), progression free survival (PFS) and overall survival (OS) in 
advanced NSCLC subjects with CIA.  

To evaluate the safety and tolerability of ACE-011 treatment for advanced NSCLC 
subjects with CIA.  

To determine the PK of ACE-011 in subjects with advanced NSCLC receiving 
platinum-based chemotherapy.  

To estimate the duration of hematopoietic response associated with ACE-011.  

To evaluate the effect of ACE-011 treatment on the quality of life (QoL) of NSCLC 
subjects with CIA.  
Part 2:

To evaluate hematopoietic response
Revised Text:
The primary objectives are:
Part 1:  To determine an effective dose of sotatercept (ACE-011) showing a 
hematopoietic response in the treatment of CIA in advancedmetastatic NSCLC 
subjects.  
Part 2:  To assess transfusion rate within 4 months following initiation of sotatercept 
(ACE-011) treatment.  
Page 124 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
27
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
The secondary objectives are:
Part 1 and Part 2:
To estimate the effect of sotatercept (ACE-011) treatment on objective response rate 
(ORR), time to progression (TTP), progression free survival (PFS) and overall 
survival (OS) in advancedmetastatic NSCLC subjects with CIA.  
To evaluate the safety and tolerability of sotatercept (ACE-011) treatment for 
advancedin metastatic NSCLC subjects with CIA.  
To determine the PK of sotatercept (ACE-011) in subjects with advancedmetastatic
NSCLC receiving platinum-based chemotherapy.  
To estimateevaluate the duration of hematopoietic response and its duration 
associated with sotatercept (ACE-011) treatment.  

To evaluate the effect of sotatercept (ACE-011) treatment on the quality of life 
(QoL) of NSCLC subjects with CIA.  
Part 2:
To evaluate hematopoietic response
Rationale:
Primary objectives – Revised to clarify patient population and primary objective.
Secondary objectives – Revised to clarify patient population and analysis of hematopoietic 
response and delete redundant wording.
Page 125 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
28
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
2.16.
Section 2.3:  Exploratory Objectives, (page 34)
Original Text:
The exploratory objectives are:
Part 1 and Part 2:

To estimate the effect of each ACE-011 treatment on bone metabolism in NSCLC 
subjects with CIA.  

To explore the relationship between ACE-011 exposure and response (hematology, 
biomarkers, and other clinical outcomes as appropriate).  

To evaluate the expression/overexpression of Activin A and other 
proteins/biomarkers related to ACE-011 mechanism of action in blood and tumor 
tissue in the NSCLC population.  

To assess circulating tumor cells and molecular studies

To assess renal function biomarkers
Revised Text:
The exploratory objectives are:
Part 1 and Part 2:
To estimate the effect of each sotatercept (ACE-011) treatment on bone metabolism 
in NSCLC subjects with CIA.  
To explore the relationship between sotatercept (ACE-011) exposure and response 
(hematology, biomarkers, and other clinical outcomes as appropriate).  
To evaluate the expression/overexpression of Activin A and other 
proteins/biomarkers (including myostatin and follistatin) related to sotatercept (ACE-
011) mechanism of action in blood.
To evaluate the expression of Activin A and other proteins/biomarkers in archival 
tumor tissue in the NSCLC population. .
To assess circulating tumor cells and molecular studies
To assess renal function biomarkers
Rationale:
Updated to provide clarification and specification of  Parts 1 and 2 exploratory objectives.  
Evaluating expression of Activin A, myostatin, folistatin as well as other additional biomarkers 
in both serum and in tumor tissue may help to better understand sotatercept (ACE-011) 
mechanism of action. Assessment of circulating tumor cells was deleted because the expression 
is very low in patients undergoing treatment with chemotherapy and because, to date, there is 
little evidence that tumor cells circulate at quantifiable levels in NSCLC patients.  
Page 126 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
29
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
2.17.
Section 3.1:   Primary Endpoint(s),  (page 35)
Original Text:
Part 2:  Phase 2b/3 Double-Blind

Rate of RBC transfusion within four months following ACE-011/placebo treatment
Revised Text:
Part 2:  Phase 2b/3 Double-Blind

Rate of RBC transfusion within four months following the date of randomization to 
sotatercept (ACE-011)/placebo treatment
2.18.
Section 3.2:   Secondary Endpoint(s), (page 36)
Original Text:
(Text not previously present.)
Revised Text:
Duration of hematopoietic response
Rationale:
Primary Endpoint - Revised per FDA’s recommendation to provide a detailed definition of the 
primary endpoint, transfusion rate.  
Secondary Endpoint - Added to better clarify hematopoietic response endpoint.
Page 127 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
30
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
2.19.
Section 3.3:  Exploratory Endpoint(s), (page 36)
Original Text:

Change in time to first symptomatic skeletal related event (SRE) defined as 
pathologic fracture, clinical need for radiation therapy, surgery to bone or spinal cord 
compression
Revised Text:
Change in timeTime to first symptomatic skeletal related event (SRE) defined as 
pathologic fracture, clinical need for radiation therapy, surgery to bone or spinal cord 
compression
Rationale:
Revised to clarify SRE assessment. 
                                                     
Original Text:
Renal function biomarkers via urinalysis measuring urine albumin / creatinine ratio, 
urine protein / creatinine ratio and other serum biomarkers
Revised Text:
Change in rRenal function biomarkers via urinalysis measuring urine albumin / 
creatinine ratio, urine protein / creatinine ratio and other biomarkers of glomerular 
and/or tubular injury - urine kidney injury molecule-1 (KIM-1), urine trefoil factor 3 
(TTF3), urine cystatin C and + or – urine β2-microglobulin measuring urine albumin / 
creatinine ratio, urine protein / creatinine ratio and   other serum biomarkers
Rationale:
Revised to provide specification of  renal biomarkers for renal function assessment.
Page 128 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
31
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
2.20.
Section 4.1:  Study Design, (pages 37-38)
Original Text:
The study will consist of two parts.  Part 1 is a dose finding segment in which subjects will be 
randomized to one of three ACE-011 dose treatment arms.  A DMC, will conduct periodic data 
reviews, including the review of Part 1 data, to define the recommended ACE-011 dose to be 
used in Part 2, the phase 2b/3, double-blind, randomized placebo-controlled segment of the 
study.  
                                                     
Three starting ACE-011 dose levels, 15.0, 30.0, and 45.0 mg, were selected for Part 1 of the 
study. Up to approximately 90 subjects will be randomized to one of the following ACE-011 
dose levels, with 10-30 subjects per arm:
ACE-011 15.0 mg SC
ACE-011 30.0 mg SC
Following DMC review, analysis of safety data and assessment of dose effects of Hgb levels, a 
decision will be made to start concurrent randomization to:  
ACE-011 45.0 mg SC
Each dose level will be administered every 42 days for four doses.  
The DMC will continue to monitor safety of the ACE-011 45.0 mg dose level.  
                                                     
At the time of randomization, all subjects must be receiving a first-line platinum-containing 
chemotherapy regimen, given every three weeks, for the treatment of metastatic NSCLC.  
Subjects may have already received up to 3 cycles of this first-line platinum-based regimen to be 
eligible for the study.  Subjects are expected to be eligible to receive 2 platinum-based 
chemotherapy cycles or maintenance therapy with a pemetrexed-based regimen following 
randomization.  
Maintenance chemotherapy with a pemetrexed-containing regimen will only be allowed 
following completion of the subject’s platinum-based chemotherapy, with a best response of at 
least stable disease.  
Page 129 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
32
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Revised Text:
The study will consist of two parts.  Part 1 is a dose finding segment in which subjects will be 
randomized to one of three ACE-011sotatercept (ACE-011) dose treatment arms. Continuous 
monitoring of safety data will be conducted, includingA DMC, will conduct periodic data 
reviews, including the review of Part 1 data, to define the recommended ACE-011sotatercept 
(ACE-011) dose to be used in Part 2, the phase 2b/3, double-blind, randomized placebo-
controlled segment of the study.  
A DMC will monitor the conduct of the study. 
                                                     
Three starting ACE-011sotatercept (ACE-011) dose levels, 15.0, 30.0, and 45.0 mg, were 
selected for Part 1 of the study. Up to approximately 90 subjects will be randomized to one of 
the following ACE-011sotatercept (ACE-011) dose levels, with 10-30 subjects per arm:
SACE-011otatercept (ACE-011) 15.0 mg SC
SACE-011otatercept (ACE-011) 30.0 mg SC
Analysis of safety data will be performed following the treatment of at least 10 subjects at the 
15.0 mg dose level and 10 subjects at the 30.0 mg dose level, with each subject having received 
at least of one dose of sotatercept (ACE-011), plus a 12 week follow-up period from first dose.  
Following this analysis, the addition of a third dose level:Following DMC review, analysis of 
safety data and assessment of dose effects of Hgb levels, a decision will be made to start 
concurrent randomization to:  
SACE-011otatercept (ACE-011) 45.0 mg SC
to the randomization schema will be determined.
Each dose level will be administered every 42 days for four doses.  The DMC will continue to 
monitor safety of the ACE-011 45.0 mg dose level.  
                                                     
At the time of randomization, all subjects must be receiving atheir first regimen of first-line 
platinum-containing chemotherapy regimen, given every three weeks, for the treatment of 
metastatic NSCLC.  Subjects may have already received up to 3 cycles of this first-line platinum-
based regimen to be eligible for the study.  Subjects are expected to be eligible to continue to 
receive ≥ 2 additional platinum-based chemotherapy cycles orwhile on study treatment prior to 
initiating any maintenance therapy with a pemetrexed-based regimen following randomization.  
Maintenance chemotherapy with a pemetrexed-containing regimen will only be allowed 
following completion offor the subject’s platinum-based chemotherapy, with a best 
responsetreatment of at least stable disease. metastatic NSCLC.
Rationale:
Revised to clarify study design, confirm continuous safety monitoring, clarify the role and
composition of consistently throughout the protocol.
Page 130 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
33
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Modified to include clarification on when maintenance can be initiation and, per investigator 
recommendation, to add erlotinib-based maintenance regimen.
Revised per FDA’s recommendations, clarification of when safety analysis of the first 10 
subjects treated with 15 and 30 mg dose levels of sotatercept (ACE-011) would occur and 
clarification of study population description based on subjects being eligible to continue to 
receive platinum-based chemotherapy following randomization.  
Page 131 of 791
088VGY

088VGY

088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
36
ACE-011-NSCL-001 Amendment 1 Draft: 15 MAR 2011
Rationale:
Revised to clarify number of sotatercept (ACE-011) doses allowed in Part 1 and that randomization to Part 2 will be subsequent to 
Part 1 and not performed concurrently. 
Page 134 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
37
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Section 4.1.1:  ACE-011 Dose Modification, Reduction and Escalation Rules, 
(pages 40-41)
Original Text:
4.1.1.
ACE-011 Dose Modification, Reduction and Escalation Rules
                                                     
ACE-011 Dose Modification Rules:
Hemoglobin < 11g/dL
(per local lab value) 
Hemoglobin ≥ 11g/dL
(per local lab value) 
Hypertension > Grade 2
< 2.0 g/dL increase within a 
dosing period
≥ 2.0 g/dL increase sustained for a 
28 day period since last dosing day2
Note: ≥ 3.0 g/dL increase sustained 
for a 28 day period since last dosing 
day requires a two level dose 
reduction.  
< 2.0 g/dL increase within a 
dosing period
≥ 2.0g/dL increase sustained for a 
28 day period since last dosing 
day2
Note: ≥ 3.0g/dL increase sustained 
for a 28 day period since last 
dosing day requires a two level 
dose reduction.  If Hgb is > 15.0 
g/dL, sustained for 7 days, subject 
is to be discontinued from 
treatment2. 
Dose Delay5
Continue 
Dosing1
(Part 1only-
Dose 
Escalation 
Table 6)
Dose 
Reduction
Table 5:
Dose Delay3
Dose Delay
then, Dose 
Reduction4
Page 135 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
38
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
1Subjects who have received an RBC transfusion in the past 42 days should continue at the same ACE-011 dosing 
level if the transfusion was given greater than 7 days from the previous dose of ACE-011 (or ACE-011/placebo) 
AND the Hgb level is < 11 g/dL AND hypertension is ≤ Grade 2 on the day of dosing.  ACE-011 (or ACE-
011/placebo) should not be administered within 7 days post RBC transfusion.  
For Part 1 only:  if the RBC transfusion was given > 7 days following the previous dose of ACE-011, the 
subsequent dose of ACE-011 will be increased one dose level (Refer to ACE-011 Dose Escalation Levels-
Table 6).  
                                                     
3ACE-011 should be delayed until Hgb is < 11g/dL and hypertension ≤Grade 2.  The follow-up dosing can 
commence at 7 days or later after the originally planned ACE-011/placebo dose that was delayed.  Subsequent 
ACE-011/placebo doses will then begin 42 days following this revised treatment dose date.  
A delayed ACE-011/placebo dose is defined as a dose not administered > 4 days from the planned dosing date 
(due to Hgb ≥11.0 g/dL, hypertension > Grade 2, and/or ACE-011 related toxicity).  
                                                     
5ACE-011 should be held until hypertension resolves to ≤ Grade 2 (current active minor version NCI CTCAE v4.0) 
and may then be resumed beginning seven days after the previous planned scheduled treatment visit as above in 
foot note (3).  
Page 136 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
39
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Revised Text:
4.1.1:
ACE-011Sotatercept (ACE-011) Dose Modification, Reduction and Escalation 
Rules                                                     
Ace-011sotatercept (ace-011) Dose  Modification Rules:
Hemoglobin < 11g/dL
(per local* lab value)
Hemoglobin ≥ 11g/dL
(per local* lab value)
Hypertension > Grade 2
≥SBP 150 mm Hg and ≥ DBP 100 mm Hg
*Note:  Local laboratory assessments are allowed in cases when timely results are needed (e.g., randomization, 
study treatment and chemotherapy dosing decisions, hematology assessments between clinic visits).  Whenever 
possible a “split” sample should also be forwarded to the central laboratory for analysis. Local laboratory data 
should be collected in the eCRF.  
< 2.0 g/dL increase within a 
dosing period or  ≥ 2.0 g/dL 
increase not sustained for a 28 
day period since last dosing day 
≥ 2.0 g/dL increase sustained for a 
28 day period since last dosing day2
Note: ≥ 3.0 g/dL increase sustained 
for a 28 day period since last dosing 
day requires a two level dose 
reduction.  
< 2.0 g/dL increase within a 
dosing period or a  ≥ 2.0g/dL 
increase not sustained for a 28 
day period since last dosing day
≥ 2.0g/dL increase sustained for a 28 day 
period since last dosing day2
Note: ≥ 3.0g/dL increase sustained for a 28 
day period since last dosing day requires a 
two level dose reduction.  If Hgb is > 15.0 
g/dL, sustained for 7 days, subject is to be 
discontinued from treatment2. 
Dose Delay5
Continue 
Dosing1
(Part 1only-
Dose Escalation 
Table 6)
Continue Dosing 
with Dose 
RReduction 
Table 5:Sotatercept 
(ACE-011) and 
Sotatercept (ACE-
011)/Placebo Dose 
Reduction Levels
Dose Delay3
Dose Delay 
then, Dose 
Reduction4
Page 137 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
40
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
1If Hgb increase ≥ 1.0 but < 2.0 g/dL, dose remains the same.
For Part 1 only:  if the RBC transfusion was given > 7 days following the previous dose of sotatercept (ACE-011), 
the subsequent dose of sotatercept (ACE-011) will be increased one dose level (Refer to sotatercept (ACE-011) 
Dose Escalation Levels- Table 6).  Hemoglobin level must be < 11 g/dL AND hypertension  < SBP 150mm Hg 
and < DBP 100 mm Hg on the day of dosing.  Sotatercept (ACE-011) should not be administered within 7 days 
post RBC transfusion.  
For Part 2:  Subjects who have received an RBC transfusion in the past 42 days should continue at the 
sameACE-011 sotatercept (ACE-011)/placebo doseing level if the transfusion was given greater than 7 days from 
the previous dose of ACE-011 (orACE-011sotatercept (ACE-011)/placebo) AND the Hgb level is < 11 g/dL AND 
hypertension is < SBP 150mm Hg and < DBP 100 mm Hg≤ Grade 2 on the day of dosing.  ACE-011 (orACE-
011Sotatercept (ACE-011)/placebo) should not be administered within 7 days post RBC transfusion.  
                                                     
3ACE-011Sotatercept (ACE-011)or sotatercept (ACE-011)/placebo should be delayed until Hgb is < 11g/dL and 
hypertension < SBP 150mm Hg and < DBP 100 mm Hg.≤Grade 2.  The follow-up Ddosing can commence at ≥7 
days or laterafter the originally planned sotatercept (ACE-011) or ACE-011sotatercept (ACE-011)/placebo dose 
that was delayed.  Subsequent sotatercept (ACE-011) or ACE-011sotatercept (ACE-011)/placebo doses will then 
begin 42 days following this revised treatment dose date.  
A delayed sotatercept (ACE-011) or ACE-011sotatercept (ACE-011)/placebo dose is defined as a dose not 
administered > 4 days from the planned dosing date (due to Hgb ≥11.0 g/dL, hypertension > < SBP 150mm Hg 
and < DBP 100 mm Hg Grade 2,and/or ACE-011sotatercept (ACE-011) related toxicity).  
                                                     
5ACE-011Sotatercept (ACE-011)or sotatercept (ACE-011)/placebo should be held until hypertension resolves to < 
SBP 150mm Hg and < DBP 100 mm Hg ≤ Grade 2 (current active minor version NCI CTCAE v4.0) and may then 
be resumed beginning seven days after the previous planned scheduled treatment visit as above in foot note (3).  
Rationale:
Revised per FDA’s recommendation to modify dose modification algorithm for hypertension. 
Additional revisions to better clarify dosing based on hemoglobin level and duration sustained, 
RBC transfusion timepoints and use of local laboratory assessments.   
Page 138 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
41
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Section 4.1.1:  Sotatercept (ACE-011) Dose Modification, Reduction and 
Escalation Rules (pages 42)
Original Text:
ACE-011 Dose Escalation Levels:

Hgb level must be < 11.0 g/dL and hypertension < Grade 2

Dose escalation to begin at next every 42 day scheduled dosing visit. 
Revised Text:
Sotatercept (ACE-011) Dose Escalation Levels:
Hgb level must be < 11.0 g/dL and hypertension < Grade 2SBP 150mm Hg and < 
DBP 100 mm Hg
Dose escalation to begin at next every 42 day scheduled dosing treatment visit. 
Rationale:
Revised per FDA’s recommendation to revise dose modification algorithm for hypertension.
Clarification of wording to describe the visit at which when dose escalation would occur. 
Page 139 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
42
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
2.22.
Section 5:  Table Of Events, (pages 46-51)
Original Text:
Table 7:
ACE-011 NSCLC Schedule of Assessments
Treatment Period
Screening 
Period
ACE-011 Dose 1 Schedule
(± 3 days)
ACE-011 Subsequent
Doses 2  through 6 Schedule
(± 3 days)
Post Treatment Follow-Up Period
(± 1 week)
Survival
(±1wk)
Assessments
Day -28
to
Day -1
D1
D8
D15 D22 D29
D43/
D1
D8
D15 D29
D43 
Post Last 
Dose/End 
of Study 
Txt
1
Month
2
Month
3
Month
4
Month
5
Month
6
Month/
Study
DCu
Survival
                                                     
Vital Signs / Blood Pressureb
X
X
X
X
X
X
X
X
X
X
X
X
X
Height (at randomization only)/Weight
X
X
X
X
X
X
X
X
X
                                                     
Pregnancy Testingd
X
X
X
X
X
X
X
Xd
Hematologye
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Absolute Reticulocyte Counte
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Serum Chemistryf
X
X
X
X
X
X
X
X
                                                     
Urinalysisj
X
X
X
X
X
X
X
X
X
X
X
X
                                                     
TSHk
X
X
X
X
Page 140 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
43
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Table 7:
ACE-011 NSCLC Schedule of Assessments
Treatment Period
Screening 
Period
ACE-011 Dose 1 Schedule
(± 3 days)
ACE-011 Subsequent
Doses 2  through 6 Schedule
(± 3 days)
Post Treatment Follow-Up Period
(± 1 week)
Survival
(±1wk)
Assessments
Day -28
to
Day -1
D1
D8
D15 D22 D29
D43/
D1
D8
D15 D29
D43 
Post Last 
Dose/End 
of Study 
Txt
1
Month
2
Month
3
Month
4
Month
5
Month
6
Month/
Study
DCu
Survival
                                                     
Activin A and other Proteins/Biomarkers 
in Blood and Tissue  (pre-dose study 
treatment in a subset of subjects)
X
X
X
Circulating Tumor Cells  (pre-dose study 
treatment in a subset of subjects) 
X
X
X
X
Pharmacokinetics–
Part 1 and Part 2)n
Refer to Table 8 – Schedule of Pharmacokinetic Assessments
Tumor Assessmentso
X
Every 9 weeks ± 1 week
                                                     
Maintenance chemotherapys
Dosing of allowed regimen(s) per standard practice
                                                     
bVital signs (including heart rate, seated blood pressure, and temperature) will be measured at Screening and all subsequent clinical visits, at Treatment 
Discontinuation, and at Study Discontinuation. Investigators are to report any clinically significant abnormal findings as adverse events.  
                                                     
Page 141 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
44
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
dFemales of childbearing potential (FCBP) only:  A female of childbearing potential is a sexually mature woman who has not undergone a hysterectomy or who 
has not been postmenopausal for at least 24 consecutive months (i.e. who has had menses at some time in the preceding 24 months).  A medically supervised 
pregnancy test with a minimum sensitivity of 25mIU/ml must be performed within 3 days prior to the start of ACE-011 or ACE-011/placebo or administration 
(Day 1) once the subject has been on effective contraception for at least 28 days.  Subjects must agree to use highly effective birth control measures (eg, oral 
contraceptives or two forms of barrier method birth control) during study participation and for at least 112 days following the last dose of ACE-011 or ACE-
011/placebo.  Pregnancy test will be performed at Study Discontinuation if date is ≤112 days following the last dose of ACE-011 or ACE-011/placebo.  
eHematology laboratory evaluations (RBC count, Hgb, HCT, WBC count and differential, ANC, platelet count and reticulocyte count).  Hemoglobin should be 
tested prior to dosing with ACE-011 or ACE-011/placebo to ensure levels are within normal limits and that ACE-011 dose modification rules are followed as 
outlined in Section 4.1.1.  Any laboratory evaluations may be repeated more frequently if clinically indicated.  In addition, RBC, Hgb, and reticulocyte counts 
will be included at each timepoint within the full PK assessment (Part 1).  
fSerum chemistry laboratory evaluations (sodium, potassium, chloride, CO2 (bicarbonate), calcium, magnesium, phosphorus, BUN, creatinine, glucose, amylase, 
albumin, total protein, alkaline phosphatase, bilirubin [total and direct], AST/SGOT, ALT/SGPT, LDH and uric acid) if clinically significant any or all 
laboratory evaluations may be reported as AE and repeated more frequently.  
                                                     
jUrine collection for:  Urine albumin, urine albumin creatinine ratio, urine protein creatinine ratio and other biomarkers of glomerular and/or tubular injury.  
kTSH – collected at screening, on Day 1 of the first and second dose of ACE-011 or ACE-011/placebo and at 2 month post-treatment follow-up visit.  
                                                     
nPharmacokinetics (Part 1):  Blood samples will be collected to evaluate the blood or serum concentrations of ACE-011.  Approximately 10 subjects at each 
ACE-011 dose level, 15.0, 30.0 and 45.0 mg, will have more full PK sampling.  In addition, RBC, Hgb, and reticulocyte counts will be collected at each time 
point (excluding the 4-hour time point on Day 1) from Day 1 to Day 43 after the first dose within the full PK assessment.  
Pharmacokinetics (Part 2):  Blood samples will be collected to evaluate the blood or serum concentrations of ACE-011.  ACE-011 doses 5 and 6 will have pre-
dose Day 1 PK (if applicable).  
REFER TO Table 8, SCHEDULE OF PHARMACOKINETIC ASSESSMENTS.  
oTumor assessments:  Screening tumor assessments may be performed up to six weeks prior to randomization.  Historical tumor assessment data from prior to 
initiation of platinum-based chemotherapy through randomization to the study will also be collected.  Following randomization, tumor assessments will be 
performed every 9 weeks (± 7 days).  
                                                     
qACE-011 or ACE-011/placebo dosing repeats every 42 days and will begin after the subject begins an every 3 week platinum-based chemotherapy regimen.  
The first dose of ACE011 or ACE-011/placebo should be given within +/- 3 days of a chemotherapy cycle.  Subsequent cycles of the chemotherapy dosing 
schedule, included dose reductions and delays, should not affect the ACE-011 or ACE-011/placebo dosing schedule, unless determined to be necessary by the 
Investigator.  ACE-011 or ACE-011/placebo can be administered at any time point during the chemotherapy cycle.  If there is a chemotherapy dose delay, 
ACE-011 or ACE-011/placebo administration does not need to be delayed until start of next chemotherapy cycle.  
Page 142 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
45
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
rEvery 3-week platinum-based chemotherapy is to be administered based on guidelines for administration according to manufacturer’s recommendations and 
standard clinical practice.  Type of chemotherapy and dosing will be recorded.  ACE-011 or ACE-011/placebo administration should be given prior to 
chemotherapy administration on ACE-011 or ACE-011/placebo administration days.  
                                                     
sPemetrexed maintenance chemotherapy is to be administered based on guidelines for administration according to manufacturer’s recommendations and standard 
clinical practice.  
Page 143 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
46
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Revised Text:
Table 7:
ACE-011Sotatercept (ACE-011) NSCLC Schedule of Assessments
Treatment Period
Screening 
Period
ACE-011Sotatercept (ACE-
011)
Dose 1 Schedule
(± 3 days)
ACE-011Sotatercept (ACE-011)
Subsequent
Doses 2  through 6 Schedule
(± 3 days)
Post Treatment Follow-Up Period
(± 1 week)
Survival
(±1wk)
Assessments
Day -28
to
Day -1
D1
D8
D15 D22 D29
D43/
D1
D8
D15 D29
D43 
Post Last 
Dose/End 
of Study 
Txt
1
Month
2
Month
3
Month
4
Month
5
Month
6
Month/
Study
DCu
Survival
                                                     
Vital Signs / Blood Pressureb
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Height (at randomization only)/Weight
X
X
X
X
X
X
X
X
X
X
X
X
X
                                                     
Pregnancy Testingd
X
X
X
X
X
X
X
Xd
                                                     
Hematologye
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Absolute Reticulocyte Counte
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Serum Chemistryf
X
X
X
X
X
X
X
X
X
X
X
X
X
                                                     
Urinalysis and Renal Biomarkersj
X
X
X
X
X
X
X
X
X
X
X
X
                                                     
TSHk
X
X
Xk
X
Page 144 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
47
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Table 7:
ACE-011Sotatercept (ACE-011) NSCLC Schedule of Assessments
Treatment Period
Screening 
Period
ACE-011Sotatercept (ACE-
011)
Dose 1 Schedule
(± 3 days)
ACE-011Sotatercept (ACE-011)
Subsequent
Doses 2  through 6 Schedule
(± 3 days)
Post Treatment Follow-Up Period
(± 1 week)
Survival
(±1wk)
Assessments
Day -28
to
Day -1
D1
D8
D15 D22 D29
D43/
D1
D8
D15 D29
D43 
Post Last 
Dose/End 
of Study 
Txt
1
Month
2
Month
3
Month
4
Month
5
Month
6
Month/
Study
DCu
Survival
                                                     
Activin A and other Proteins/
Biomarkersproteins/biomarkers in Blood 
and Tissue  (pre-dose study treatment in a 
subset of subjects)
X
X
X
X
Circulating Tumor Cells  (pre-dose study 
treatment in a subset of subjects) Activin 
and other proteins/biomarkers in archival 
tumor tissue
X
X
X
X
X
Pharmacokinetics–
Part 1 and Part 2)n
Refer to Table 8 and Table 9 – Schedule of Pharmacokinetic Assessments
Tumor Assessmentso
X
< Every 9 weeks ± 1 week or per standard of care at study site
                                                     
Maintenance chemotherapysTherapys
Dosing of allowed regimen(s) per standard practice
                                                     
bVital signs (including heart rate, seated blood pressure, and temperature) will be measured at Screening and all subsequent clinical visits, on Day 29 post 
sotatercept (ACE-011) or sotatercept (ACE-011)/ placebo dose, at Treatment Discontinuation, and at Study Discontinuation. Blood pressure measurements 
should be confirmed by two measurements obtained five minutes apart. Investigators are to report any clinically significant abnormal findings as adverse 
events.  
Page 145 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
48
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
                                                     
dFemales of childbearing potential (FCBP) only:  A female of childbearing potential is a sexually mature woman who has not undergone a hysterectomy or who 
has not been postmenopausal for at least 24 consecutive months (i.e. who has had menses at some time in the preceding 24 months).  A medically supervised 
pregnancy test with a minimum sensitivity of 25mIU/ml must be performed within 3 days prior to the start of ACE-011sotatercept (ACE-011) or ACE-
011sotatercept (ACE-011)/placebo or administration (Day 1) once the subject has been on effective contraception for at least 28 days and be performed within 
3 days prior to dose administration of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo during the treatment period..  Subjects must agree to use highly 
effective birth control measures (eg, oral contraceptives or two forms of barrier method birth control) during study participation and for at least 112 days 
following the last dose of ACE-011sotatercept (ACE-011) or ACE-011sotatercept (ACE-011)/placebo.  Pregnancy test will be performed at Study 
Discontinuation if date is ≤112 days following the last dose of ACE-011sotatercept (ACE-011) or ACE-011sotatercept (ACE-011)/placebo.  
eHematology laboratory evaluations (RBC count, Hgb, HCT, WBC count and differential, ANC, MCV, platelet count and reticulocyte count).  Hemoglobin 
should be tested prior to dosing with ACE-011sotatercept (ACE-011) or ACE-011sotatercept (ACE-011)/placebo to ensure levels are within normal limits and 
that ACE-011sotatercept (ACE-011) dose modification rules are followed as outlined in Section 4.1.1.  Any laboratory evaluations may be repeated more 
frequently if clinically indicated.  In addition, RBC, Hgb, and reticulocyte counts will be included at each timepoint within the full PK assessment (Part 1).  
fSerum chemistry laboratory evaluations (sodium, potassium, chloride, CO2 (bicarbonate), calcium, magnesium, phosphorus, BUN, creatinine, glucose, amylase, 
lipase, albumin, total protein, alkaline phosphatase, bilirubin [total and direct], AST/SGOT, ALT/SGPT, LDH and uric acid) if clinically significant any or all 
laboratory evaluations may be reported as AE and repeated more frequently.  
                                                     
jUrine collection for:  Urine albumin, urine albumin creatinine ratio, urine protein creatinine ratio and other renal biomarkers of glomerular and/or tubular injury.  
kTSH – collected at screening, on Day 1 of only the first and second dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo and at 2 month post-
treatment follow-up visit.  
                                                     
nPharmacokinetics (Part 1):  Blood samples will be collected to evaluate the blood or serum concentrations of ACE-011sotatercept (ACE-011).  Approximately 
10 subjects at each ACE-011sotatercept (ACE-011) dose level, 15.0, 30.0 and 45.0 mg, will have morefull PK sampling.  In addition, RBC, Hgb, and 
reticulocyte counts will be collected at each time point (excluding the 4-hour time point on Day 1) from Day 1 to Day 43 after the first dose within the full PK 
assessment.  Subjects not participating in the optional full PK assessment will participate in the sparse PK assessment.  
Pharmacokinetics (Part 2):  Sparse PK blood samples will be collected to evaluate the blood or serum concentrations of sotatercept (ACE-011) in 
approximately 300 (40%) of 750 subjects. Sotatercept (ACE-011) doses 5 and 6 will have pre-dose Day 1 PK (if applicable).  
REFER TO Table 8 and Table 9, SCHEDULE OF PHARMACOKINETIC ASSESSMENTS.  
                                                     
Page 146 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
49
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
oTumor assessments:  Screening period tumor assessments may be performed up to six weeks prior to randomization.  Also, historical tumor assessment data, 
from prior to the initiation of platinum-based chemotherapy through the screening period, will be collected.  Following randomization, tumor assessments will 
be performed at a maximum of every 9 weeks (± 7 days) or per standard of care at the study site, starting from the date of the previous (screening period) tumor 
assessment and following the chemotherapy schedule.  
                                                     
qSotatercept (ACE-011) or sotatercept (ACE-011)/placebo dosing repeats every 42 days and will start after the subject begins an every 3 week platinum-based 
chemotherapy regimen.  The first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo should be given within 7 days prior to or within 7 days 
following Day 1 of a platinum-based chemotherapy cycle.  Subsequent doses of Sotatercept (ACE-011) or sotatercept (ACE-011)/placebo can be 
administered at any time point during the chemotherapy cycle. 
Administration of subsequent cycles of chemotherapy, including dose reductions and dose delays, should not affect the sotatercept (ACE-011) or sotatercept 
(ACE-011)/placebo dosing schedule, unless determined to be necessary by the Investigator.  If there is a chemotherapy dose delay, sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo administration does not need to be delayed until start of next chemotherapy cycle. 
If sotatercept (ACE-011) or sotatercept (ACE-011)/placebo is administered on the same day as chemotherapy, sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo should be given prior to chemotherapy administration.
rEvery 3-week platinum-based chemotherapy is to be administered based on guidelines for administration according to manufacturer’s recommendations and 
standard clinical practice.  Type of chemotherapy and dosing will be recorded.  If sotatercept (ACE-011) or sotatercept (ACE-011)/placebo is administered on 
the same day as chemotherapy, sotatercept (ACE-011) or sotatercept (ACE-011)/placebo should be given prior to chemotherapy administration.
                                                     
sPemetrexed or erlotinib maintenance chemotherapy is to be administered based on guidelines for administration according to manufacturer’s recommendations 
and standard clinical practice.  
                                                     
Page 147 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
50
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Rationale:
1. Addition of additional blood pressure measurement on Day 29 based on FDA’s recommendation of at least one additional 
blood pressure measurement between Day 15 and Day 43 post sotatercept (ACE-011) dosing. 
2. Clarification that blood pressure measurements should be confirmed by two measurements obtained five minutes apart.
3. Clarification that pregnancy testing is to be performed up to 3 days prior to sotatercept (ACE-011) dosing versus ± 3 days.
4. Addition of MCV to hematology assessments.
5. Addition of lipase to serum chemistry assessments.
6. Addition of measurement of weight to correspond with creatinine clearance calculations.
7. Addition of serum chemistry assessments to correspond with creatinine clearance assessments.
8. Clarification that renal biomarkers are assessed at the same visits as urinalysis.
9. Addition of superscript ‘k’ to further clarify TSH assessment only on Day 1 of first and second dose of sotatercept (ACE-011).  
10. Clarification of PK assessments in Part 1 and Part 2.
11. Clarification that tumor tissue is an archival sample and not required to be collected on study.  
12. Clarification of tumor assessment schedule and collection of historical tumor assessment data and modification of               
post- randomization tumor assessment timeframes. 
13. Modified to increase the allowed dosing time period of the first dose of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo prior to and following a cycle of platinum-based chemotherapy. 
14. Clarification of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dosing schedule versus platinum-based 
chemotherapy dosing schedule and order of dosing, if administered on the same day.
15. Addition of erlotinib as allowed maintenance therapy. 
Page 148 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
51
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
2.23.
Section 5:  Table Of Events, (page 52)
Original Text:
Table 8:
Schedule of Pharmacokinetic Assessments
Scheduled Time
Time relative to 
ACE-011/placebo dosea
Part 1b
Part 2b
Collection 
Windowe
Full PKc
Sparse PKd
Sparse PKd
Dose 1, D1
pre-Dose 1
X
X
X
-2  to  0 hour
Dose 1, D1
4 hours after Dose 1
X
X
X
±1 hour
Dose 1, D5
4 days after Dose 1
X
-
-
± 1 day
Dose 1, D8
7 days after Dose 1
X
X
X
± 1 day
Dose 1, D11
10 days after Dose 1
X
-
-
± 1 day
Dose 1, D15
14 days after Dose 1
X
X
X
± 1 day
Dose 1, D22
21 days after Dose 1
X
-
-
± 1 day
Dose 1, D29
28 days after Dose 1
X
X
X
± 1 day
Dose 1, D36
35 days after Dose 1
X
-
-
± 1 day
Dose 1, D43 (Dose 2, D1)
pre-Dose 2
X
X
X
± 2 days
Dose 2, D8
7 days after Dose 2
X
-
-
± 2 days
Dose 2, D15
14 days after Dose 2
X
-
-
± 2 days
Dose 2, D43 (Dose 3, D1)
pre-Dose 3
X
X
X
± 2 days
Dose 3, D8
7 days after Dose 3
X
-
-
± 2 days
Dose 3, D15
14 days after Dose 3
X
-
-
± 2 days
Dose 3, D43 (Dose 4, D1)
pre-Dose 4
X
X
X
± 2 days
Dose 4, D8
7 days after Dose 4
X
-
-
± 2 days
Dose 4, D15
14 days after Dose 4
X
-
-
± 2 days
Dose 4, D29
28 days after Dose 4
X
-
-
± 3 days
Dose 4, D43 (Dose 5, D1)
42 days after Dose 4 
(pre-Dose 5 in Part 2)
X
X
X
± 3 days
Dose 5, D43 (Dose 6, D1)
pre-Dose 6 in Part 2
-
-
X
± 3 days
Follow up, 1 month
72 days after final dose
X
-
-
± 1 week
PT Follow up, 2 month
102 days after final dose
X
-
-
± 1 week
PT Follow up, 3 month
132 days after final dose
X
X
X
± 1 week
PT Follow up, 4 month
162 days after final dose
X
-
-
± 1 week
PT Follow up, 5 month
192 days after final dose
X
X
X
± 1 week
Page 149 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
52
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Revised Text:
Table 8:
Schedule of Pharmacokinetic Assessments (Part 1)
Scheduled Time
Time relative to 
ACE-011/placebo dosea
Part 1b
Part 2b
Collection 
Windowe
Full PKc
Sparse PKd
Sparse PKd
Dose 1, D1
pre-Dose 1
X
X
X
-2  to  0 hour
Dose 1, D1
4 hours after Dose 1
X
X
X
±1 hour
Dose 1, D5
4 days after Dose 1
X
-
-
± 1 day
Dose 1, D8
7 days after Dose 1
X
X
X
± 1 day
Dose 1, D11
10 days after Dose 1
X
-
-
± 1 day
Dose 1, D15
14 days after Dose 1
X
X
X
± 1 day
Dose 1, D22
21 days after Dose 1
X
-
-
± 1 day
Dose 1, D29
28 days after Dose 1
X
X
X
± 1 day
Dose 1, D36
35 days after Dose 1
X
-
-
± 1 day
Dose 1, D43 (Dose 2, D1)
pre-Dose 2
X
X
X
± 2 days
Dose 2, D8
7 days after Dose 2
X
-
-
± 2 days
Dose 2, D15
14 days after Dose 2
X
-
-
± 2 days
Dose 2, D43 (Dose 3, D1)
pre-Dose 3
X
X
X
± 2 days
Dose 3, D8
7 days after Dose 3
X
-
-
± 2 days
Dose 3, D15
14 days after Dose 3
X
-
-
± 2 days
Dose 3, D43 (Dose 4, D1)
pre-Dose 4
X
X
X
± 2 days
Dose 4, D8
7 days after Dose 4
X
-
-
± 2 days
Dose 4, D15
14 days after Dose 4
X
-
-
± 2 days
Dose 4, D29
28 days after Dose 4
X
-
-
± 3 days
Dose 4, D43 (Dose 5, D1)
42 days after Dose 4 
(pre-Dose 5 in Part 2)
X
X
X
± 3 days
Dose 5, D43 (Dose 6, D1)
pre-Dose 6 in Part 2
-
-
X
± 3 days
Follow up, 1 month
72 days after final dose
X
-
-
± 1 week
PT Follow up, 2 month
102 days after final dose
X
-
-
± 1 week
PT Follow up, 3 month
132 days after final dose
X
X
X
± 1 week
PT Follow up, 4 month
162 days after final dose
X
-
-
± 1 week
PT Follow up, 5 month
192 days after final dose
X
X
X
± 1 week
Page 150 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
53
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Scheduled Time
Time relative to 
Sotatercept (ACE-011)
Part 1a,b
Collection 
Windowe
Full PKc
Sparse PKd
Dose 1, D1
pre-Dose 1
X
X
-2  to  0 hour
Dose 1, D1
4 hours after Dose 1
X
X
±1 hour
Dose 1, D5
4 days after Dose 1
X
-
± 1 day
Dose 1, D8
7 days after Dose 1
X
X
± 1 day
Dose 1, D11
10 days after Dose 1
X
-
± 1 day
Dose 1, D15
14 days after Dose 1
X
X
± 1 day
Dose 1, D22
21 days after Dose 1
X
-
± 1 day
Dose 1, D29
28 days after Dose 1
X
X
± 1 day
Dose 1, D36
35 days after Dose 1
X
-
± 1 day
Dose 1, D43 (Dose 2, D1)
pre-Dose 2
X
X
± 2 days
Dose 2, D8
7 days after Dose 2
X
-
± 2 days
Dose 2, D15
14 days after Dose 2
X
-
± 2 days
Dose 2, D43 (Dose 3, D1)
pre-Dose 3
X
X
± 2 days
Dose 3, D8
7 days after Dose 3
X
-
± 2 days
Dose 3, D15
14 days after Dose 3
X
-
± 2 days
Dose 3, D43 (Dose 4, D1)
pre-Dose 4
X
X
± 2 days
Dose 4, D8
7 days after Dose 4
X
-
± 2 days
Dose 4, D15
14 days after Dose 4
X
-
± 2 days
Dose 4, D29
28 days after Dose 4
X
-
± 3 days
Last Dose, D43 
42 days after final dose 
X
X
± 3 days
PTf Follow up, 1 month
72 days after final dose
X
-
± 1 week
PT Follow up, 2 month
102 days after final dose
X
-
± 1 week
PT Follow up, 3 month
132 days after final dose
X
X
± 1 week
PT Follow up, 4 month
162 days after final dose
X
-
± 1 week
PT Follow up, 5 month
192 days after final dose
X
X
± 1 week
Page 151 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
54
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Original Text:
(Text not previously present.)
Revised Text:
Table 9:
Schedule of Pharmacokinetic Assessments (Part 2)
Scheduled Time
Time relative to 
Sotatercept (ACE-
011)/placebo dose
Sparse PKa,b,c
Collection Windowd
Dose 1, D1
pre-Dose 1
X
-2  to  0 hour
Dose 1, D1
4 hours after Dose 1
X
±1 hour
Dose 1, D8
7 days after Dose 1
X
± 3 day
Dose 1, D15
14 days after Dose 1
X
± 3 day
Dose 1, D29
28 days after Dose 1
X
± 3 day
Dose 1, D43 (Dose 2, D1)
pre-Dose 2
X
± 3 days
Dose 2, D43 (Dose 3, D1)
pre-Dose 3
X
± 3 days
Dose 3, D43 (Dose 4, D1)
pre-Dose 4
X
± 3 days
Dose 4, D43 (Dose 5, D1)
pre-Dose 5 
X
± 3 days
Dose 5, D43 (Dose 6, D1)
pre-Dose 6 
X
± 3 days
PTe Follow up, 3 month
132 days after final dose
X
± 1 week
PT Follow up, 5 month
192 days after final dose
X
± 1 week
a For subjects who discontinue the treatment early, PK blood sample collection will be continued during the follow-
up period.  
bAt each time point, collect approximately 2 mL of blood.  After collection, allow the blood to clot at room 
temperature for approximately 1 hour and then centrifuge the blood sample at room temperature for 10 min (1100-
1300 g) to obtain serum.  
cTo be collected for approximately 300 (40%) of 750 subjects (approximately 150 subjects in each arm).
dExcept for Day 1 (Dose 1, D1), the collection window will be the same as the visit window defined in Table 7.  
ePT = Post Treatment
Rationale:
Table 8 and Table 9
Addition of a separate table - Table 9 - to display Part 2 pharmacokinetic assessments.  
Modification of Table 8 to now display only pharmacokinetic assessments in Part 1. 
Page 152 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
55
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
2.24.
Section 6:  Procedures, (pages 53-54)
Original Text:
Screening Period (Day -28 to Day -1)
Prior to screening, subjects must sign an informed consent.  Potentially protocol-eligible subjects 
will be evaluated for the inclusion and exclusion criteria for the Treatment Period of this study.  
All screening assessments must be completed within 28 days prior to randomization.  Historical 
tumor assessment data from six weeks prior to initiation of platinum-based chemotherapy 
through randomization to the study will be collected.  Hematology and chemistry laboratory 
assessments should be performed within 14 days of randomization.  
The assessments and procedures that will be performed during the Screening Period are outlined 
in the Table of Events (see Section 5) and include:
                                                     
Tumor Assessment - Screening tumor assessments and tumor evaluation 
documentation, as per RECIST criteria, must be performed within 6 weeks prior to 
randomization to this study.  Also, historical tumor assessment data from prior to 
initiation of platinum based chemotherapy through randomization to the study will be 
collected.  
Revised Text:
Screening Period (Day -28 to Day -1)
Prior to screening, subjects must sign an informed consent.  Potentially protocol-eligible subjects 
will be evaluated for the inclusion and exclusion criteria for the Treatment Period of this study.  
All screening assessments must be completed within 28 days prior to randomization.  Screening 
period tumor assessments and tumor evaluation documentation, as per RECIST criteria (Version 
1.1) (Appendix A), must be performed within 6 weeks prior to randomization.  Historical tumor 
assessment data, from six weeks prior to the initiation of platinum-based chemotherapy through 
the screening period,randomization to the study will be collected.  Hematology and chemistry 
laboratory assessments should be performed within 14 days of randomization.  
The assessments and procedures that will be performed during the Screening Period are outlined 
in the Table of Events (see Section 5) and include:
                                                     
Tumor Assessment - Screening period tumor assessments and tumor evaluation 
documentation, as per RECIST criteria (Version 1.1), must be performed within 6 
weeks prior to randomization to this study.  Also, historical tumor assessment data,
from prior to the initiation of platinum based chemotherapy through the screening 
period,randomization to the study will be collected. 
Page 153 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
56
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Rationale:
Updated description of collection of tumor assessment data from prior to randomization. 
Clarification of  the screening period timeframe and of the additional collection of historical 
tumor assessment data, from prior to initiation of first line platinum-based chemotherapy, to be 
used as the baseline tumor assessment. 
Page 154 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
57
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
2.25.
Section 6:  Procedures, (page 54-56)
Original Text:
Treatment Period (Day 1/Dose 1 of study treatment to Day 43 post last study treatment 
dose)
                                                     
In Part 1 (the dose ranging portion of the study), subjects who meet all eligibility criteria will be 
randomized by a single-blind procedure utilizing IVRS to receive one of the following ACE-011 
dose levels, with 10-30 subjects per arm:
ACE-011 15.0 mg SC
ACE-011 30.0 mg SC
Following analysis of at least 10 subjects at each dose level (10 subjects at the 15.0 mg dose 
level and 10 subjects at the 30.0 mg dose level), a third dose level will be added to the 
randomization schema:
ACE-011 45.0 mg SC
Revised Text:
Treatment Period (Day 1/Dose 1 of study treatment to Day 43 post last study treatment 
dose)
                                                     
In Part 1 (the dose-ranging portion of the study), subjects who meet all eligibility criteria will be 
randomized by a single-blind procedure utilizing IVRS to receive one of the following ACE-
011sotatercept (ACE-011) dose levels, with 10-30 subjects per arm:
ACE-011Sotatercept (ACE-011) 15.0 mg SC
ACE-011Sotatercept (ACE-011) 30.0 mg SC
Analysis of safety data will be performed following the treatment of at least 10 subjects at the 
15.0 mg dose level and 10 subjects at the 30.0 mg dose level, with each subject having received 
at least of one dose of sotatercept (ACE-011), plus a 12-week follow-up period from first dose.  
Following this analysis, the addition of a third dose level:
Following analysis of at least 10 subjects at each dose level (10 subjects at the 15.0 mg dose 
level and 10 subjects at the 30.0 mg dose level), a third dose level will be added to the 
randomization schema:
ACE-011Sotatercept (ACE-011) 45.0 mg SC
to the randomization schema will be determined.
Each dose level will be administered every 42 days for up to four doses.  
Page 155 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
58
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Rationale:
Revised per FDA’s recommendation to clarify when safety analysis of the first 10 subjects 
treated with 15 and 30 mg dose levels of sotatercept (ACE-011) would occur. 
                                                     
Original Text:
The assessments and procedures that will be performed during the Treatment Period are outlined 
in the Table of Events (see Section 5).  
Medically supervised pregnancy test, with a minimum sensitivity of 25mIU/ml, for 
FCBP.  
Revised Text:
The assessments and procedures that will be performed during the Treatment Period are outlined 
in the Table of Events (see Section 5).  

Medically supervised pregnancy test, with a minimum sensitivity of 25mIU/ml, for 
FCBP within 3 days prior to sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo administration.  
Rationale:
Clarified pregnancy testing is to be performed up to 3 days prior to sotatercept (ACE-011) 
dosing versus +/- 3 day procedure window as shown in Table 7 – Schedule of Assessments. 
                                                     
Page 156 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
59
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Original Text:
The assessments and procedures that will be performed during the Treatment Period are outlined 
in the Table of Events (see Section 5).  

Serum chemistry, hematology, absolute reticulocyte count.  

Hematology laboratory evaluations (RBC count, Hgb, HCT, WBC count and 
differential, absolute neutrophil count [ANC], platelet count and reticulocyte 
count) will be collected weekly after the first dose of ACE-011 or ACE-
011/placebo and at subsequent ACE-011 or ACE-011/placebo doses collected at 
7, 14 days and 28 days post-dose by local laboratory.  
Revised Text:
The assessments and procedures that will be performed during the Treatment Period are outlined 
in the Table of Events (see Section 5).  

Serum chemistry, hematology, absolute reticulocyte count.  
Hematology laboratory evaluations (RBC count, Hgb, HCT, WBC count and 
differential, mean corpuscular volume [MCV], absolute neutrophil count [ANC], 
platelet count and reticulocyte count) will be collected weekly after the first dose 
of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo and at subsequent 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo doses collected at 7, 14 
days and 28 days post-dose. by local laboratory.  
Rationale:
Revised to add MCV to hematology laboratory evaluation.
Clarification of use of local laboratory is now provided in Section 6 Procedures – Clinical 
Laboratory Assessments.  
                                                     
Original Text:
The assessments and procedures that will be performed during the Treatment Period are outlined 
in the Table of Events (see Section 5).  
Bone or other biomarkers 
Activin A and other ACE-011-related proteins/biomarkers in blood and tissue (pre-
dose on Day 1 and Day 8 after first dose of ACE-011 or ACE-011/placebo)
Circulating Tumor Cells (pre-dose ACE-011 or ACE-011/placebo) 
Page 157 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
60
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Revised Text:
The assessments and procedures that will be performed during the Treatment Period are outlined 
in the Table of Events (see Section 5).  
Bone or other potential mechanistic or disease-related proteins/biomarkers 

Bone or other biomarkers 
Activin A and other ACE-011sotatercept (ACE-011)-related proteins/biomarkers

in blood, including myostatin and follistatin:
o
and tissue (pre- dose on Day 1 and Day 8 after first dose of ACE-
011sotatercept (ACE-011) or ACE-011sotatercept (ACE-011)/placebo
o
pre-dose on Day 1 subsequent dosing visits
in) archival tumor tissue

Circulating Tumor Cells (pre-dose ACE-011 or ACE-011/placebo) 
Rationale:
Updated to clarify exploratory assessments and delete circulating tumor cell assessment due to 
very low expression in patients undergoing treatment with chemotherapy.  
                                                    
Original Text:
The assessments and procedures that will be performed during the Treatment Period are outlined 
in the Table of Events (see Section 5).  

Tumor Assessment and Response Evaluation, as per RECIST criteria, (every 9        
weeks ± one week) following chemotherapy schedule
Revised Text:
The assessments and procedures that will be performed during the Treatment Period are outlined 
in the Table of Events (see Section 5).  

Tumor Assessment and Response Evaluation, as per RECIST criteria (Version 1.1), 
(performed ≥every 9 weeks ± one week or per standard of care at the study site,
starting from the previous [screening] tumor assessment) and following the 
chemotherapy schedule
Rationale:
Revised to modify the allowed tumor assessment timeframe starting from the Screening Period.  
Page 158 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
61
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
2.26.
Section 6:  Procedures, (pages 56-57)
Original Text:
Post Treatment Follow-Up Period (Day 43 post last dose of study treatment to six months
post last dose of study treatment)
                                                     
The assessments and procedures that will be performed during this period are outlined in the 
Table of Events (see Section 5) and include:
                                                     
Bone or other biomarkers 
                                                     
Activin A and other ACE-011 related proteins/biomarkers in blood and tissue (pre-
dose ACE-011 or ACE-011/placebo at 1 month end of treatment follow-up visit)
Circulating Tumor Cells (pre-dose ACE-011 or ACE-011/placebo at day 43 post last 
dose and 1 month end of treatment follow-up visit)
Revised Text:
Post Treatment Follow-Up Period (Day 43 post last dose of study treatment to six months 
post last dose of study treatment)
                                                     
The assessments and procedures that will be performed during this period are outlined in the 
Table of Events (see Section 5) and include:
                                                     
Bone or other potential mechanistic or disease-related proteins/biomarkers 
                                                     
Activin A and other ACE-011sotatercept (ACE-011) related proteins/biomarkers, 
including myostatin and follistatin, in blood and tissue (pre-dose ACE-011 or ACE-
011/placebo at 1 month end of treatment follow-up visit))

Circulating Tumor Cells (pre-dose ACE-011 or ACE-011/placebo at day 43 post last 
dose and 1 month end of treatment follow-up visit)
Page 159 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
62
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Rationale:
Clarification to include bone and other potential biomarkers and defined in exploratory 
objectives that Activin A and other proteins/biomarkers, including mysostatin and follistatin, will 
be assessed in blood and Activin A and other proteins/biomarkers assessed in tumor tissue. 
Deletion of circulating tumor cell assessment due to very low expression in patients undergoing 
treatment with chemotherapy.  
                                                     
Original Text:
Post Treatment Follow-Up Period (Day 43 post last dose of study treatment to six months 
post last dose of study treatment)
                                                     
The assessments and procedures that will be performed during this period are outlined in the 
Table of Events (see Section 5) and include:
                                                     

Tumor Assessment and Response Evaluation, as per RECIST criteria, (every 9 weeks 
± one week) following chemotherapy schedule 
Revised Text:
Post Treatment Follow-Up Period (Day 43 post last dose of study treatment to six months 
post last dose of study treatment)
                                                     
The assessments and procedures that will be performed during this period are outlined in the 
Table of Events (see Section 5) and include:
                                                     

Tumor Assessment and Response Evaluation, as per RECIST criteria (Version 1.1), 
(performed ≥every 9 weeks ± one week or per standard of care at the study site), and
following the chemotherapy schedule
Rationale:
Revised to modify the allowed tumor assessment timeframe through the Post Treatment Follow-
Up Period.  
Page 160 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
63
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
3.
SECTION 6:  PROCEDURES, (PAGE 59)
Original Text:
Clinical Laboratory Evaluations
Clinical laboratory evaluations (serum chemistry, hematology, absolute reticulocyte count, 
creatinine clearance, serum iron, total iron binding capacity, transferrin and serum ferritin, serum 
erythropoietin, Vitamin B12, serum folate levels, urinalysis, FSH, LH, dihyroepiandosterone, 
estrogen, estradiol, testosterone and serum thyroid-stimulating hormone will be performed by a 
central laboratory.  
Please refer to vendor manual for procedures.  
Note:  Local laboratory assessments are allowed in cases when timely results are needed (e.g., 
randomization, study treatment and chemotherapy dosing decisions, hematology assessments 
between clinic visits).  Local laboratory data should be collected in the eCRF.  
Revised Text:
Clinical Laboratory Evaluations
Clinical laboratory evaluations (serum chemistry, hematology, absolute reticulocyte count, 
creatinine clearance, serum iron, total iron binding capacity, transferrin and serum ferritin, serum 
erythropoietin, vitamin B12, serum RBC folate levels, urinalysis, FSH, LH, 
dihyroepiandosterone, estrogen, estradiol, testosterone and serum thyroid-stimulating hormone)
will be performed by a central laboratory.  
Please refer to vendor manual for procedures.  
Note:  Local laboratory assessments are allowed in cases when timely results are needed (e.g., 
randomization, study treatment and chemotherapy dosing decisions, hematology assessments 
between clinic visits).  Whenever possible a “split” sample should also be forwarded to the 
central laboratory for analysis. Local laboratory data should be collected in the eCRF.  
Rationale:
Modified to clarify folate levels to be assessed and central laboratory requirements when a local 
laboratory is utilized.  
Page 161 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
64
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
3.1.
Section 6:  Procedures, (page 59)
Original Text:
Exploratory Biomarkers 
Analyses will be undertaken to evaluate the expression/overexpression of Activin A and other 
proteins/biomarkers related to ACE-011 mechanism of action in blood and tumor tissue in the 
NSCLC population in a subset of subjects.  
Renal function biomarkers via urinalysis measuring urine albumin / creatinine ratio, urine protein 
/ creatinine ratio, and other serum biomarkers will also be evaluated from all subjects.  
Circulating Tumor Cell Enumeration and Molecular Studies
Analysis will be performed in a subset of subjects.  
Revised Text:
Exploratory Biomarkers 
Analyses will be undertaken to evaluate the expression/overexpression of Activin A and other 
proteins/biomarkers related to ACE-011sotatercept (ACE-011) mechanism of action in blood 
(including myostatin and follistatin) and in archival tumor tissue in the NSCLC population in a 
subset of subjects.  
Renal function biomarkers via urinalysis measuring urine albumin / creatinine ratio, urine protein 
/ creatinine ratio and other biomarkers of glomerular and/or tubular injury - urine kidney injury 
molecule-1 (KIM-1), urine trefoil factor 3 (TTF3), urine cystatin C and + or – urine β2-
microglobulin measuring urine albumin / creatinine ratio, urine protein / creatinine ratio, and 
other serum biomarkers will alsobe evaluated infrom all subjects.  
Circulating Tumor Cell Enumeration and Molecular Studies
Analysis will be performed in a subset of subjects.  
Rationale:
Defined in exploratory objectives that Activin A and other proteins/biomarkers, including 
mysostatin and follistatin, will be assessed in blood and Activin A and other proteins/biomarkers 
assessed in tumor tissue. 
Clarification of renal biomarkers to be assessed for renal function.
Deletion of circulating tumor cell assessment due to very low expression in patients undergoing 
treatment with chemotherapy.  
Page 162 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
65
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
3.2.
Section 6:  Procedures, (page 59)
Original Text:
Pharmacokinetics
Part 1 - Full PK blood samples will be collected to evaluate the full PK profile of 
ACE-011 from approximately 30 subjects at select centers (approximately 10 subjects 
for each ACE-011 dose group).  For full PK sampling, subjects who miss more than 
two PK sampling time points from Days 1 through 43 will be replaced.  
Part 2- Sparse PK blood samples will be collected from all subjects.  
Revised Text:
Pharmacokinetics
Part 1 - Full PK blood samples will be collected to evaluate the full PK profile of 
ACE-011sotatercept (ACE-011) from approximately 30 subjects at select centers 
(approximately 10 subjects for each ACE-011sotatercept [ACE-011] dose group).  
For full PK sampling, subjects who miss more than two PK sampling time points 
from Days 1 through 43 will be replaced.  Subjects not participating in the optional 
full PK assessment will participate in the sparse PK assessment.  
Part 2- Sparse PK blood samples will be collected from approximately 300 (40%) of 
750 all subjects (approximately 150 subjects in each arm).  
Rationale:
Revised to clarify pharmacokinetic assessments required in Part 1 and 2 of the study and modify 
Part 2 sparse pharmacokinetic requirements.
Page 163 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
66
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
3.3.
Section 6:  Procedures, (page 59)
Original Text:
Bone Biomarkers
Bone or other biomarkers will be evaluated in all subjects.  The serum and urine biomarkers will 
include BSAP, OC, P1NP, CTX, TRACP-5b and uNTX.  Both serum and urine samples will be 
collected.  
Revised Text:
Bone Biomarkers
Bone or other biomarkers will be evaluated in all subjects.  The serum and urine bone
biomarkers will include BSAP, OC, P1NP, CTX, TRACP-5b and uNTX.  Both serum and urine 
samples will be collected.  
Rationale:
Revised to clarify bone biomarker in urine versus renal biomarkers also required in this study. 
Page 164 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
67
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
3.4.
Section 6:  Procedures, (page 60)
Original Text:
Quality of Life Assessments
QoL Assessment (FACIT Fatigue Scale [Version 4]) and LCSS questionnaire will be completed 
by the subject upon arrival at clinic and prior to any study procedures or testing.  
Independent External Radiology Review  
At least 3 independent external radiologists (2 reviewers and 1 adjudicator) will perform a 
blinded, independent assessment of response, including the development of progressive disease 
(PD).  
Independent Review Committee (IRC):  The IRC will review the tumor response data (to 
include results from the central radiologist and relevant clinical laboratory and physical 
examination findings) and the dates of disease progression for each patient.  These data reviewed 
by the IRC will be used in the primary analyses ORR, TTP and PFS for the Clinical Study 
Report.  
Revised Text:
Quality of Life Assessments
QoL Assessment (FACIT Fatigue Scale [Version 4]) and LCSS questionnaire will be completed 
by the subject upon arrival at clinic and prior to any study procedures or testing.  The LCSS 
consists of two scales: one for the patient (Patient Scale) and a counterpart for health 
professionals acting as observers (Observer Scale). 
Independent External Radiology Review (Part 2 Only)
At least 3 independent external radiologists (2 reviewers and 1 adjudicator) will perform a 
blinded, independent assessment of response, including the development of progressive disease 
(PD).  
Independent Review Committee (IRC): )  (Part 2 Only)
The IRC will review the tumor response data (to include results from the central radiologist and 
relevant clinical laboratory and physical examination findings) and the dates of disease 
progression for each patient.subject.  These data reviewed by the IRC will be used in the primary 
analyses ORR, TTP and PFS for the Clinical Study Report.  
Rationale:
Revised to clarify required scales within the LCSS.
Clarification that the required independent reviews to be performed in Part 2 only.  
Revised to correct typographical error ‘patient’ and replace with ‘subject’.
Page 165 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
68
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
3.5.
Section 7:  Study Population, (page 61)
Original Text:
Subjects must be receiving their first regimen of first-line platinum-containing chemotherapy, 
given every three weeks, for the treatment of metastatic NSCLC at the time of randomization.  
Subjects must be randomized prior to receiving Cycle 4 of this current first-line platinum-based 
chemotherapy regimen.  Subjects are expected to be eligible to receive 2 platinum-based 
chemotherapy cycles or maintenance therapy with a pemetrexed-based regimen following 
randomization.  
Subjects must not have received any other regimens of chemotherapy for the first-line platinum 
containing treatment of metastatic NSCLC prior to the regimen at the time of randomization.  
Revised Text:
Subjects must be receiving their first regimen of first-line platinum-containing chemotherapy, 
given every three weeks, for the treatment of metastatic NSCLC at the time of randomization.  
Subjects must be randomized prior to receiving Cycle 4 of this current first-line platinum-based 
chemotherapy regimen.  Subjects are expected to be eligible to continue to receive ≥ 2 
additional platinum-based chemotherapy cycles or maintenance therapy with a pemetrexed-based 
regimen following randomizationwhile on study treatment.  
Subjects must not have received any other regimens of chemotherapy for the first-line platinum 
containing treatment of metastatic NSCLC prior to the regimen at the time of randomization.  
Rationale:
Updated per FDA’s recommendation to clarify study population description based on subjects 
being eligible to continue to receive platinum-based chemotherapy following randomization.
Page 166 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
69
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
3.6.
Section 7.2:  Inclusion Criteria, (page 62-63)
Original Text:
Subjects must satisfy the following criteria to be enrolled in the study:
                                                     
5. All of the following laboratory values:

Platelet count ≥ 25,000/mm3 (> 72 hours since prior platelet transfusion) 
Revised Text:
Subjects must satisfy the following criteria to be enrolled in the study:
                                                     
5. All of the following laboratory values:
Platelet count ≥ 2575,000/mm3 (> 72 hours since prior platelet transfusion) 
Rationale:
Revised to correct typographical error. 
                                                     
Original Text:
Subjects must satisfy the following criteria to be enrolled in the study:
                                                     
5. All of the following laboratory values:

Adequate renal function (creatinine < 1.5 x upper limit of normal [ULN] or  ≥ 50 
mL/min)
Revised Text:
Subjects must satisfy the following criteria to be enrolled in the study:
                                                     
5. All of the following laboratory values:
Adequate renal function (creatinine < 1.5 x upper limit of normal [ULN] or  
creatinine clearance ≥ 40mL/min or ≥50 mL/min if cisplatin concomitantly 
administered)
Rationale:
Defined adequate renal function as creatinine clearance > 40 mL/min or > 50 mL/min if cisplatin 
concomitantly administered based on investigator and data monitoring committee feedback. 
Updated toxicology results showed renal findings were due to anti-drug antibody reaction rather 
than ACE-011 nephrotoxicity. 
                                                     
Page 167 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
70
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Original Text 
6. Subjects may have received up to 3 cycles of a current first line platinum-based 
chemotherapy treatment regimen for metastatic NSCLC.  Allowed regimens are:
gemcitabine plus cisplatin or carboplatin ± bevacizumab
pemetrexed plus cisplatin or carboplatin ± bevacizumab
paclitaxel plus carboplatin ± bevacizumab
Subjects are expected to be eligible to receive 2 platinum-based chemotherapy cycles or 
maintenance therapy with a pemetrexed-based regimen following randomization.  
Revised Text:
6. Subjects may have received up to 3 cycles of a currenttheir first regimen of first line 
platinum-based chemotherapy treatment regimen for metastatic NSCLC.  Allowed 
regimens are:
gemcitabine plus cisplatin or carboplatin ± bevacizumab
pemetrexed plus cisplatin or carboplatin ± bevacizumab
paclitaxel plus carboplatin ± bevacizumab
docetaxel plus cisplatin ± bevacizumab
At  randomization Ssubjects are expected to be eligible to continue to receive 2at least 
two additional platinum-based chemotherapy cycles or maintenance therapy with a 
pemetrexed-based regimen following randomization. while on study.
Rationale:
Modified  per FDA’s recommendation, to provide clarification of study population description 
based on subjects being eligible to continue to receive platinum-based chemotherapy following 
randomization.   
                                                     
Page 168 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
71
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Original Text
8. ≥ 14 days must have elapsed (prior to Day 1) since the last RBC transfusion and receipt 
of ≤ 2 units of blood in the past 56 days (prior to Day 1)
Revised Text:
8. ≥ 14 days must have elapsed (prior to Day 1) since the last RBC transfusion and receipt 
of ≤2 units of blood in the past 5630 days (prior to Day 1)
Rationale:
Updated to correct typographical error.
                                                     
Original Text
10. If currently receiving bisphosphonate therapy, be on a stable dose for ≥ 2 months before 
Day 1 (ongoing bisphosphonate therapy is allowed during study provided it is kept at a 
stable level, bisphosphonate therapy may not be started on study, other than for the 
treatment of hypercalcemia).  Subjects not currently on bisphosphonates must not have 
received bisphosphonates within 2 months prior to Day 1.  
Revised Text:
10. If currently receiving bisphosphonate or denosumab (XGEVA™) therapy for bone 
metastases, must be on a stable dose for ≥ 2 months before Day 1 (ongoing 
bisphosphonate or denosumab therapy is allowed during study provided it is kept at a 
stable level). Bisphosphonate or denosumab therapy may not be started on study.  
Bisphosphonate therapy may be started on study for the treatment of hypercalcemia.  
Subjects not currently on bisphosphonates or denosumab must not have received 
bisphosphonates or denosumab within 2 months prior to Day 1.  
Rationale:
Modified per investigator recommendation in alignment with standard of care. 
Page 169 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
72
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
3.7.
Section 7.3:  Exclusion Criteria, (pages 63-64)
Original Text:
The presence of any of the following will exclude a subject from enrollment:
1. Subjects who have any Grade > 3 toxicity (according to the currently active minor 
version of the NCI National Cancer Institute Common Terminology for Adverse Events 
[CTCAE] version 4.0 [Appendix C] at the time of screening, except for the following 
disease related toxicities:  hematological events [e.g. anemia, thrombocytopenia or 
neutropenia] or non hematological events [e.g. nausea, vomiting, fatigue, or muscle or 
bone/joint pain]).  
Revised Text:
The presence of any of the following will exclude a subject from enrollment:
1. Subjects who have any Grade > 3 toxicity (according to the currently active minor 
version of the NCI National Cancer Institute Common Terminology for Adverse Events 
[CTCAE] version 4.0 [Appendix C] at the time of screening, including except for    
Grade ≥ 3 residual adverse events related to either chemotherapy or underlying disease.  
Exception: Grade ≥ 3 hematotoxicity (e.g. asymptomatic anemia, neutropenia and 
thrombocytopenia) occurring during the chemotherapy nadir period and resolving or non 
hematological events (e.g. nausea, vomiting, fatigue, or muscle or bone/joint pain) 
occurring during the chemotherapy period and resolving.  the following disease related 
toxicities:  hematological events [e.g. anemia, thrombocytopenia or neutropenia] or non 
hematological events [e.g. nausea, vomiting, fatigue, or muscle or bone/joint pain]). 
Rationale:
Revised per FDA’s recommendation to exclude patients with Grade 4 toxicities or major 
end-organ dysfunction, irrespective of whether they are considered disease related. 
Clarification of exception for hematotoxicity and non hematologic events occurring during 
the chemotherapy period and resolving was added. 
                                                     
Page 170 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
73
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Original Text:
4. CNS metastases (exception:  CNS metastases treated with whole brain radiotherapy > 6 
months prior to randomization). 
Revised Text:
4. CNS metastases (exception: subjects with CNS metastases treated with whole brain 
radiotherapy, gamma knife radiosurgery and/or surgery and stable for at least  2 weeks > 
6 months prior to randomization)).  
Rationale:
Modified per investigator recommendation to allow for broader eligible patient population. 
                                                     
Original Text:
11. Uncontrolled hypertension.  If hypertension is considered clinically stable, systolic blood 
pressure (BP) must be < 160 mmHg and diastolic BP must be < 100 mmHg.  
Revised Text:
11. Uncontrolled hypertension.  If hypertension is considered clinically stable, systolic blood 
pressure (SBP) must be < 160150 mmHg andor diastolic BPblood pressure (DBP) must 
be < 100 mmHg.  
Rationale:
Modified per FDA’s recommendation. 
                                                     
Original Text:
14. Deficiency in iron (transferrin saturation < 20%), vitamin B12, or folate.  Subjects may be 
re-screened following treatment with supplements and normalization of levels.  
Revised Text:
14. Deficiency in iron (transferrin saturation < 20%), vitamin B12, or RBC folate.  Subjects 
may be re-screened following treatment with supplements and normalization of levels.  
Rationale:
Revised to clarify folate assessment.
                                                     
Page 171 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
74
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Original Text:
16. History of anemia due to autoimmune or hereditary hemolysis or gastrointestinal 
bleeding.
Revised Text:
16. History of anemia due to autoimmune or hereditary hemolysis; or gastrointestinal 
bleeding occurring within the past 6 months.  
Rationale:
Revised to allow inclusion of patients who may have had a history of bleeding (e.g. ulcers), that 
has now resolved.  
                                                     
Original Text:
17. Urine protein / creatinine ratio < 1.0 
Revised Text:
17. Urine protein / creatinine ratio >< 1.0 
Rationale:
Corrected typographical error.
Page 172 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
75
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
3.8.
Section 8.1:  Description of Investigational Product(s), (page 65)
Original Text:
Process IIa Clinical Drug Product
ACE-011 will be provided as a 1 mL solution of 50 mg/mL in phosphate buffered saline (PBS), 
pH 7.5, in labeled 2 mL vials with rubber stoppers, providing 50 mg per vial.  ACE-011 is 
recommended to be stored at -65˚C (colder than -65˚C) until thawed for administration.  ACE-
011 should be used within 6 hours of thawing.  
Revised Text:
Sotatercept (ACE-011) clinical drug product will be provided as a frozen liquid formulation, 
Process IIa, or as a lyophilized powder, Process III.  
Note: Subjects receiving Process IIa clinical drug product will begin to receive Process III 
clinical drug product as soon as it becomes available at the study site. 
Process IIa Clinical Drug Product – Frozen Liquid Formulation:
The clinical drug product consists of ACE-011sotatercept (ACE-011) will be provided as a 1 mL 
solution of 50 mg/mL in phosphate buffered saline (PBS), pH 7.5.  It is supplied as a 1 mL 
solution of 50 mg/mL sotatercept (ACE-011) , in labeled, rubber stoppered, 2 mL vials with 
rubber stoppers,providing 50 mg per vial.  The recommended storage temperature for ACE-
011sotatercept (ACE-011) is recommended to be stored at -65˚C (colder than -65˚C) until 
thawed for administration. Process IIa frozen liquid drug product is -65˚C (colder than -65˚C) 
until thawed for administration.  Vials of sotatercept (ACE-011) frozen liquid must be 
completely thawed (approximately 30 minutes at room temperature) prior to preparation for 
dosing and must be used within six (6) hours of being thawed.  
ACE-011 should be used within 6 hours of thawing.  Process III Clinical Drug Product-
Lyophilized Powder:
The clinical drug product consists of sotatercept (ACE-011) in 10 mM citrate buffer, pH 5.8, 8% 
sucrose, and 0.02% polysorbate 80.  It is supplied as a lyophilized powder in labeled, rubber 
stoppered, 3-mL glass vials.  The recommended storage temperature for sotatercept (ACE-011) 
lyophilized drug product is 2°C to 8°C.  Prior to administration, the lyophilized drug product is 
reconstituted with 1 mL water for injection (WFI).  The reconstituted drug product consists of a 
50 mg/mL solution of sotatercept (ACE-011).  The reconstituted sotatercept (ACE-011), in its 
original container closure system, may be held for up to 6 hours at 2°C to 8°C.
Rationale:
Investigational product information updated based on FDA’s approval of sotatercept (ACE-011) 
Process III lyophilized material.  Subjects receiving Process IIa clinical drug product will begin 
to receive Process III clinical drug product as soon as it becomes available at the study site.  
Page 173 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
76
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
3.9.
Section 8.2:  Treatment Administration and Schedule, (page 68)
Original Text:
ACE-011 or placebo will be administered as a SC injection to subjects by the study staff at the 
clinical site and will be documented in the study source record.  Subcutaneous injections will be 
given in the upper arm, abdomen, or thigh.  Vials of ACE-011 must be completely thawed 
(approximately 30 minutes at room temperature) prior to preparation for dosing and must be used 
within six (6) hours of being thawed.  
                                                     
Allowed concomitant platinum-based chemotherapy regimens are:
gemcitabine plus cisplatin or carboplatin  ± bevacizumab
pemetrexed plus cisplatin or carboplatin ± bevacizumab
paclitaxel plus carboplatin ± bevacizumab
Investigative sites will utilize commercial supply of these medications.  
Subjects may receive 4-6 cycles of the allowed platinum-based regimen selected by the 
Investigator.  The addition of up to 2 cycles of platinum-based chemotherapy may be given 
following cancer response.  The platinum-based tumor therapy may be revised at the discretion 
of the Investigator for toxicity reasons only.  
Maintenance chemotherapy with a pemetrexed-containing regimen will only be allowed 
following completion of the subject’s platinum-based chemotherapy, with a best response of at 
least stable disease.  
Revised Text:
Sotatercept (ACE-011) or placebo will be administered as a SC injection to subjects by the study 
staff at the clinical site and will be documented in the study source record.  Subcutaneous 
injections will be given in the upper arm, abdomen, or thigh.  Vials of ACE-011 must be 
completely thawed (approximately 30 minutes at room temperature) prior to preparation for 
dosing and must be used within six (6) hours of being thawed.  
                                                     
Allowed concomitant platinum-based chemotherapy regimens are:
gemcitabine plus cisplatin or carboplatin  ± bevacizumab
pemetrexed plus cisplatin or carboplatin ± bevacizumab
paclitaxel plus carboplatin ± bevacizumab
docetaxel plus cisplatin  ± bevacizumab
Investigative sites will utilize commercial supply of these medications.  
Page 174 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
77
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Subjects may receive 4-6 cycles of the allowed platinum-based regimen selected by the 
Investigator.  Up to The addition of up to 2 additional cycles (8 total cycles) of platinum-based 
chemotherapy may be given as determined by following cancer response.  The platinum-based 
tumor therapy may be revised at the discretion of the Investigator for toxicity reasons only.  
While on treatment subjects will be allowed to receive mMaintenance chemotherapy with a 
pemetrexed or erlotinib-containing regimen when indicated. will only be allowed following 
completion of the subject’s platinum-based chemotherapy, with a best response of at least stable 
disease.  
Rationale:
Revised to move Process IIa preparation instructions to Section 8.1 –Description of 
Investigational Products. 
Modified to include additional platinum-based chemotherapy regimen, clarify maximum number 
of cycles allowed and add erlotinib-based maintenance regimen per investigator 
recommendation. Also, per FDA’s recommendation, clarification of study population description 
based on subjects being eligible to continue to receive platinum-based chemotherapy following 
randomization.   
Page 175 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
78
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Section 8.2.1:  Selection of Dose for the Study, (page 66)
Original Text:
In Part 1, subjects will be randomized to one of the following ACE-011 dose levels, with 10-30 
subjects per arm:
ACE-011 15.0 mg SC
ACE-011 30.0 mg SC
Following analysis of at least 10 subjects at each dose level (10 subjects at the 15 mg dose level 
and 10 subjects at the 30 mg dose level), a third dose level will be added to the randomization 
schema:
ACE-011 45.0 mg SC
Revised Text:
In Part 1, subjects will be randomized to one of the following sotatercept (ACE-011) dose 
levels, with 10-30 subjects per arm:
Sotatercept (ACE-011) 15.0 mg SC
Sotatercept (ACE-011) 30.0 mg SC
Following analysisAnalysis of safety data will be performed following the treatment of at least 
10 subjects at each dose level (10 subjects at the 15.0 mg dose level and 10 subjects at the 30.0
mg dose level),, with at least of one dose of sotatercept (ACE-011), plus a 12-week follow-up 
period from first dose.  Following this analysis, the addition of a third dose level will be added :
Sotatercept (ACE-011) 45.0 mg SC
to the randomization schema: will be determined.
ACE-011 45.0 mg SC
Each dose level will be administered every 42 days for up to four doses.  
Rationale:
Revised per FDA’s recommendation to clarify when safety analysis of the first 10 subjects 
treated with 15 and 30 mg dose levels of sotatercept (ACE-011) would occur. 
Page 176 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
79
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Section 8.2.2:  Selection and Timing of Dosing for Each Subject (Page 66)
Original Text:
In Part 1, subjects will be randomized to receive one of three doses of ACE-011, with 10-30 
subjects per arm.  In Part 2, 750 subjects will be randomized to receive ACE-011 or placebo at a 
ratio of 1:1.  
Each subject will return to the site on Day 1 of each scheduled visit.  During the Treatment 
Period, subjects will receive ACE-011 or ACE-011/placebo every 42 days as determined by Hgb 
levels and randomization schedule.  Hemoglobin levels and reticulocyte counts will be repeated 
by local lab weekly after the first dose of ACE-011 or ACE-011/placebo then at 7, 14 and 28
days after each subsequent dose of ACE-011 or ACE-011/placebo.  
Revised Text:
In Part 1, subjects will be randomized to receive one of three doses dose levels of sotatercept 
(ACE-011), with 10-30 subjects per arm.  In Part 2, 750 subjects will be randomized to receive 
sotatercept (ACE-011) or placebo at a ratio of 1:1.  
Each subject will return to the site on Day 1 of each scheduled clinic visit.  During the Treatment 
Period, subjects will receive sotatercept (ACE-011) or sotatercept (ACE-011)/placebo every 42 
days as determined by Hgb levels and randomization schedule.  Hemoglobin levels and 
reticulocyte counts will be repeated by local lab weekly after the first dose of sotatercept (ACE-
011) or sotatercept (ACE-011)/placebo then at 7, 14 and 28 days after each subsequent dose of 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.  
Rationale:
Revised to clarify three dose levels of sotatercept (ACE-011) and that subjects are to return to the 
study site for each clinic visit. 
                                                     
Original Text:
The first dose of ACE-011 or ACE-011/placebo should be given within +/- 3 days of Day 1 of a 
platinum-based chemotherapy Cycle.  Subsequent cycles of the chemotherapy dosing schedule, 
included dose reductions and delays, should not affect the ACE-011 or ACE-011/placebo dosing 
schedule, unless determined to be necessary by the Investigator.  ACE-011 or ACE-011/placebo 
can be administered at any time point during the chemotherapy cycle.  If there is a chemotherapy 
dose delay, ACE-011 or ACE-011/placebo administration does not need to be delayed until the 
start of the next chemotherapy cycle.  ACE-011 or ACE-011/placebo should be given prior to 
chemotherapy administration.  
Page 177 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
80
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Revised Text:
The first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo should be given 
within 7 days prior to or within 7 days of administration of a platinum-based 
chemotherapy cycle.  Subsequent doses of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo can be administered at any time point during the chemotherapy cycle. 
Administration of subsequent cycles of chemotherapy, including dose reductions and dose 
delays, should not affect the sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dosing 
schedule, unless determined to be necessary by the Investigator.  If there is a chemotherapy dose 
delay, sotatercept (ACE-011) or sotatercept (ACE-011)/placebo administration does not need to 
be delayed until start of next chemotherapy cycle.  
If sotatercept (ACE-011) or sotatercept (ACE-011)/placebo is administered on the same day as 
chemotherapy, sotatercept (ACE-011) or sotatercept (ACE-011)/placebo should be given prior 
to chemotherapy administration.
Rationale:
Modified to increase the allowed dosing time period of the first dose of sotatercept (ACE-011) 
or sotatercept (ACE-011)/placebo prior to and following a cycle of platinum-based 
chemotherapy. 
Clarification of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dosing schedule versus 
platinum-based chemotherapy dosing schedule.
Clarification of the order of study treatment and platinum-based chemotherapy dosing, when 
administered on the same day.
Page 178 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
81
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Section 8.2.3:  Discontinuation, (pages 67-68)
Original Text:
Treatment Discontinuation
The following events are considered sufficient reasons for discontinuing a subject from ACE-011 
treatment:
AE(s)
Medically significant hypertension which cannot be adequately controlled with 
antihypertensive therapy
Any AE > Grade 2 assessed to be related to ACE-011 therapy
Any persistent AE > Grade 1 considered to be related to ACE-011 treatment and 
causing a subject to miss three months ACE-011 therapy 
Any thromboembolic event > Grade 2 
Elevated Hgb > 15.0 g/dL (sustained for a 7 day period, confirmed by laboratory 
assessment)
Creatinine clearance < 40 ml/min
Urine protein / creatinine ratio > 1.0 or > 2.0 (if bevacizumab [Avastin®] is 
concomitantly administered) 
Persistent hematuria
Revised Text:
Treatment Discontinuation
Subjects will be discontinued from Study Treatment due to the following:
The following events are considered sufficient reasons for discontinuing a subject from ACE-011 
treatment:

Adverse  events(s)

Hypertension ≥Grade 3 – defined as Stage 2 hypertension (SBP ≥160 mm 
Hg or DBP ≥100mm Hg), confirmed by two measurements obtained five minutes 
apart; medical intervention indicated; more than one drug or more intensive 
therapy than previously used indicated or medically significant hypertension 
which cannot be adequately controlled with antihypertensive therapy. Medically 
significant hypertension which cannot be adequately controlled with 
antihypertensive therapy
Any AE > Grade 2 assessed to be related to ACE-011sotatercept (ACE-011)
therapy
Page 179 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
82
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Any persistent AE > Grade 1 considered to be related to ACE-011sotatercept 
(ACE-011) treatment and causing a subject to miss three months 
ACE-011sotatercept (ACE-011) therapy 
Any thromboembolic event > Grade 2 
Elevated Hgb > 15.0 g/dL (sustained for a 7 day period, confirmed by laboratory 
assessment)

Creatinine clearance < 40 ml/min
Urine protein / creatinine ratio > 1.0 or > 2.0 (if bevacizumab [Avastin®] is 
concomitantly administered) 
Persistent hematuria ≥Grade 2 - defined as symptomatic; urinary catheter or 
bladder irrigation indicated; limiting instrumental activities of daily living and 
persisting for one week.
Rationale:
Updated to comply with FDA’s feedback to use command language to instruct investigators to 
discontinue study therapy, provide blood pressure parameters and define persistent hematuria. 
Discontinuation based on creatinine clearance was deleted based on updated toxicology study 
data and investigator recommendation.  
Page 180 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
83
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Section 8.2.3:  Discontinuation, (page 68)
Original Text:
Study Discontinuation:  
The following events are considered sufficient reasons for discontinuing a subject from the 
study:
Completed study, per protocol (subject has completed six to nine month Treatment 
Period plus up to six month Post Treatment Follow-Up Period including one year 
tumor assessment to determine TTP and PFS).  Note:  Survival data will continue to 
be collected for up to 24 months from first dose of study treatment.  
AE(s)
Disease progression of NSCLC
Withdrawal of consent
Death
Lost to follow up
Protocol violation
Revised Text:
Study Discontinuation:  
The following events are considered sufficient reasons for discontinuing a subject from the 
study:
Completed study, per protocol (subject has completed six- to nine-month Treatment 
Period plus up to six-month Post Treatment Follow-Up Period including one year 
tumor assessment to determine TTP and PFS).  Note:  Survival data will continue to 
be collected for up to 24 months from first dose of study treatment.  

AE(s)

Disease progression of NSCLC
WWithdrawal of consent
Death
Lost to follow-up

Protocol violation
The following events may be considered sufficient reasons for discontinuing a subject from the 
study:

Adverse  events(s)
Page 181 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
84
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Disease progression of NSCLC
Protocol violation
Rationale:
Separated the reasons for study discontinuation into two types to better define the reasons that 
will necessitate study discontinuation and reasons that may lead to study discontinuation. 
Page 182 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
85
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
3.10.
Section 9.1:  Permitted Concomitant Medications and Procedures, 
(page 70-71)
Original Text:
Iron supplementation
Iron supplementation within 7 days of Day 1 (besides an oral general multivitamin with iron) 
will not be allowed.  If a subject becomes iron replete during study treatment (ferritin < 100 
ng/mL [< 224.7 pmol/L] or transferrin saturation < 20%), treatment with iron supplementation is 
at the discretion of the Investigator.  
Revised Text:
Iron supplementation
Iron supplementation within 7 days of Day 1 (besides an oral general multivitamin with iron) 
will not be allowed.  If a subject becomes iron deficientreplete during study treatment (ferritin < 
100 ng/mL [< 224.7 pmol/L] or transferrin saturation < 20%), treatment with iron 
supplementation is at the discretion of the Investigator.  
Rationale:
Modified per FDA’s recommendation to replace term “replete” with “deficient”. 
                                                     
Original Text:
RBC transfusions
Concurrent treatment for CIA with blood transfusions is recommended when Hgb value is 
< 8 g/dL or at the discretion of the Investigator if the Hgb value is > 8 g/dL and associated with 
anemia symptoms such as hemodynamic or pulmonary compromise requiring treatment.  If an 
RBC transfusion is given to a subject during the Treatment Period, ACE-011 should be 
administered no sooner than 7 days from the date of the RBC transfusion.  
Revised Text:
RBC transfusions
Concurrent treatment for CIA with blood transfusions is recommended when Hgb value is 
< 8 g/dL or at the discretion of the Investigator if the Hgb value is >≥8 g/dL and associated with 
anemia symptoms such as hemodynamic or pulmonary compromise requiring treatment.  If an 
RBC transfusion is given to a subject during the Treatment Period, sotatercept (ACE-011) should 
be administered no sooner than 7 days from the date of the RBC transfusion.  
Rationale:
Clarification of recommended RBC transfusion for the treatment of CIA per Hgb level and 
timeframe for RBC transfusion and sotatercept (ACE-011) administration.  
Page 183 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
86
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
3.11.
Section 10.1:  Overview, (page 72)
Original Text:
(Text not previously present.)
Revised Text:
Data from Part 1 will not be combined with data from Part 2 in all safety and efficacy analyses. 
Rationale:
Revised to clarify Part 1 and Part 2 analyses. 
Page 184 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
87
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
3.12.
Section 10.3: Sample Size and Power Considerations (page 72)
Original Text:
Upon recommendation to continue the study, an additional 570 subjects will be subsequently 
randomized in the second stage.  The total sample size of 750 subjects in Part 2 (first plus second 
stage) would allow observation of at least 536 deaths and thus at least 80% power to exclude 
more than 15% risk reduction in the ACE-011 arm compared with the placebo arm at one-sided 
significance level of 0.025, i.e., rejecting hazard ratio (Placebo:ACE-011) of 0.87,  assuming the 
ACE-011 arm actually reduces at least 10% hazard, i.e., true hazard ratio (Placebo:ACE-011) of 
1.11.  
Revised Text:
Upon recommendation to continue the study, an additional 570 subjects will be subsequently 
randomized in the second stage.  The total sample size of 750 subjects in Part 2 (first plus second 
stage) would allow observation of at least 536 deaths and thus at least 80% power to exclude 
more than 15% risk reductionhazard increase in the sotatercept (ACE-011) arm compared with 
the placebo arm at one-sided significance level of 0.025, i.e., rejecting hazard ratio 
(Placebo:sotatercept [ACE-011]) of 0.87,  assuming the sotatercept (ACE-011) arm actually 
reduces at least 10% hazard, i.e., true hazard ratio (Placebo:sotatercept [ACE-011]) of 1.11.  
Rationale:
Revised to correct typographical error.
Page 185 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
88
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
3.13.
Section 10.6:  Efficacy Analysis, (page 73)
Original Text:
In Part 2, the primary endpoint will be rate of RBC transfusion within 4 months following the 
first ACE-011 treatment.  It will be estimated based on Kaplan-Meier estimates for time to the 
first RBC transfusion.  The analysis will be based on ITT population and will be conducted 
according to the approximate timeline as described in Section 10.8.  Subjects with a documented 
RBC transfusion will be considered having the event.  Subjects without documented RBC 
transfusion will be censored on the date of last contact or a month after the last dose of study 
treatment, or termination of the concomitant chemotherapy, whichever is earlier.  The 
comparison on the distribution difference between the treatment groups will be based on the 
stratified log-rank test.  
Overall survival (OS) is defined as the time between the randomization and death.  A subject 
that dies, regardless of the cause of death, will be considered to have had an event.  All subjects 
who are lost to the follow-up prior to the end of the trial or who are withdrawn from the trial will 
be censored at the time of last contact.  Subjects who are still being treated will be censored at 
the last available date where the subject is known to be alive.  
Revised Text:
In Part 1, the primary endpoint will be the hematopoietic response defined as an increase in Hgb 
of ≥ 1.0 g/dL above the study baseline value for 28 consecutive days, in the absence of RBC 
transfusions and/or ESAs.  The analysis will be based on the EE population.  The proportion of 
subjects with hematopoietic response will be estimated and a Chi-square test will be performed 
to compare response rates across treatment groups.  
In Part 2, the primary endpoint will be rate of RBC transfusion within 4 months following the 
first ACE-011 treatment.date of randomization.  It will be estimated based on Kaplan-Meier 
estimates method for time to the first RBC transfusion.  The analysis will be based on ITT 
population and will be conducted according to the approximate timeline as described in Section 
10.8.  Subjects with a who have documented RBC transfusion will be considered having the 
event.  Subjects without documented RBC transfusion will be censored on the date of last contact 
or a month after(s) from randomization until the last dose of study treatment, or termination of 
the concomitant platinum-based chemotherapy plus 30 days or from the initiation date of non-
platinum-based chemotherapy ,whichever is earlier , will be considered as having the event on 
the date of first RBC transfusion. Subjects who are discontinued from study treatment due to 
reasons other than disease progression or death will be considered as having the event on the date 
of study treatment discontinuation, or the last dose date of platinum-based chemotherapy plus 30 
days or the initiation date of non-platinum-based chemotherapy, whichever is earliest. Subjects 
who discontinue from study treatment due to disease progression or death will be censored on 
the date of study treatment discontinuation, or the last dose date of platinum-based chemotherapy 
plus 30 days or the initiation date of non-platinum-based chemotherapy, whichever is earliest. 
Otherwise subjects will be censored on the date of last contact, or on the date of last dose of 
concomitant platinum-based chemotherapy plus 30 days or on the initiation date of non-
platinum-based chemotherapy, whichever is earliest.  The comparison on the distribution 
Page 186 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
89
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
difference between the treatment groups will be based on the stratified log-rank test. , and the 
associated hazard ratio and 95% confidence interval will be provided using Cox proportional 
hazard model. The proportion of subjects receiving a transfusion based on Kaplan-Meier 
estimates at specific time points will also be provided by treatment arms.
Overall survival (OS) is defined as the time between the randomization and death.  A subject 
that who dies, regardless of the cause of death, will be considered to have had an event.  All 
subjects who are lost to the follow-up prior to the end of the trial or who are withdrawn from the 
trial will be censored at the time of last contact.  Subjects who are still being treated will be 
censored at the last available date where the subject is known to be alive.  
Rationale:
Modified per FDA’s recommendation to provide a detailed definition of the Part 2 primary
endpoint, transfusion rate.   
Revised typographical error.
Page 187 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
90
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
3.14.
Section 11.2:  Evaluation of Adverse Events (pages 78-79)
Section 11.2.4:  Duration, (pages 78-79)
Original Text:
The Investigator will provide a record of the start and stop dates of the AE/SAE.  
The duration of the AE and the SAE may vary within one event.  For example, a non-serious AE 
may begin on 01-Jan.  The event will become serious when it meets one of the criteria for 
seriousness (e.g., the subject is hospitalized on 05-Jan).  The SAE will continue until it no longer 
meets the seriousness criteria (e.g., the subject is discharged on 07-Jan).  However, the AE 
continues until 10-Jan when the event resolves.  The AE dates may extend from before and 
beyond the SAE dates, but not the reverse.  
Revised Text:
For both AEs and SAEs, the Investigator will provide a record of the start and stop dates of the 
event.
The Investigator will provide a record of the start and stop dates of the AE/SAE.  
The duration of the AE and the SAE may vary within one event.  For example, a non-serious AE 
may begin on 01-Jan.  The event will become serious when it meets one of the criteria for 
seriousness (e.g., the subject is hospitalized on 05-Jan).  The SAE will continue until it no longer 
meets the seriousness criteria (e.g., the subject is discharged on 07-Jan).  However, the AE 
continues until 10-Jan when the event resolves.  The AE dates may extend from before and 
beyond the SAE dates, but not the reverse.  
Rationale:
Updated in alignment with current protocol template.
Section 11.2.5:  Action Taken, (page 79)
Original Text:
The Investigator will report the discontinuation or reduction of IP following an AE and report if 
concomitant and/or additional treatments were given for the AE.  
Revised Text:
The Investigator will report the action taken with IP as a result of an AE or SAE, as applicable 
(e.g., discontinuation or reduction of IP, as appropriate) and report if concomitant and/or 
additional treatments were given for the event. The Investigator will report the discontinuation or 
reduction of IP following an AE and report if concomitant and/or additional treatments were 
given for the AE.  
Rationale:
Updated in alignment with current protocol template.
Page 188 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
91
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
3.15.
Section 11.4:  Pregnancy
Section 11.4.1:  Females of Childbearing Potential, (pages 79-80)
Original Text:
Pregnancies and suspected pregnancies (including a positive pregnancy test regardless of age or 
disease state) of a female subject occurring while the subject is on IP, or within 112 days of the 
subject’s last dose of IP, are considered immediately reportable events.  IP is to be discontinued 
immediately.  The pregnancy, suspected pregnancy, or positive pregnancy test must be reported 
to Celgene Drug Safety immediately by facsimile, or other appropriate method, using the Initial 
Pregnancy Report Form, or approved equivalent form.  
The female should be referred to an obstetrician-gynecologist.  
The Investigator will follow the female subject until completion of the pregnancy, and must 
notify Celgene Drug Safety immediately about the outcome of the pregnancy (either normal or 
abnormal outcome) using the Follow-up Pregnancy Report Form, or approved equivalent form.  
If the outcome of the pregnancy was abnormal (e.g., spontaneous or therapeutic abortion [any 
congenital anomaly detected in an aborted fetus must be documented], stillbirth, neonatal death, 
or congenital anomaly [including that in an aborted fetus]), the Investigator should report the 
abnormal outcome as an AE.  If the abnormal outcome meets any of the serious criteria, it must 
be reported as an SAE to Celgene Drug Safety immediately by facsimile, or other appropriate 
method, within 24 hours of the Investigator’s knowledge of the event) using the SAE Report 
Form, or approved equivalent form.  
The pregnancy, suspected pregnancy, or positive pregnancy test must be reported to Celgene 
Drug Safety immediately by facsimile, or other appropriate method, using the Initial Pregnancy 
Report Form, or approved equivalent form.  
Revised Text:
Pregnancies and suspected pregnancies (including a positive pregnancy test regardless of age or 
disease state) of a female subject occurring while the subject is on IP, or within 112 days of the 
subject’s last dose of IP, are considered immediately reportable events.  IP is to be discontinued 
immediately.  The pregnancy, suspected pregnancy, or positive pregnancy test must be reported 
to Celgene Drug Safety immediately by facsimile, or other appropriate method, using the Initial 
Pregnancy ReportInitial Repot Form, or approved equivalent form.  
The female subject should be referred to an obstetrician-gynecologist or another appropriate 
healthcare professional for further evaluation.  
The Investigator will follow the female subject until completion of the pregnancy, and must 
notify Celgene Drug Safety immediately about the outcome of the pregnancy (either normal or 
abnormal outcome) using the Pregnancy Follow-up Pregnancy Report Form, or approved 
equivalent form.  
Rationale:
Updated in alignment with current protocol template.
Page 189 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
92
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
Section 11.4.2:  Male Subjects, (page 80)
Original Text:
Female partners of male subjects taking IP should be advised to call their healthcare provider 
immediately if they become pregnant, and male subjects should notify the Investigator.  
Revised Text:
Female partnersIf a female partner of a male subjectssubject taking investigational product 
becomes pregnant, the male subject taking IP should notify the Investigator, and the pregnant 
female partner should be advised to call their healthcare provider immediately if they become 
pregnant, and male subjects should notify the Investigator.  
Rationale:
Updated in alignment with current protocol template.
Page 190 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
93
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
3.16.
Section 11.5:  Immediate Reporting of Serious Adverse Events, 
(page 80)
Original Text:
The Investigator is required to ensure that the data on these forms is accurate and consistent.  
This requirement applies to all SAEs (regardless of relationship to IP) that occur during the study
from the time the subject signs informed consent up to 112 days after the last dose of IP, and 
those made known to the Investigator at anytime thereafter that are suspected of being related to 
IP.  SAEs occurring prior to treatment will be captured.  
The SAE report should provide a detailed description of the SAE and include copies of hospital 
records and other relevant documents.  
Revised Text:
The Investigator is required to ensure that the data on these forms is accurate and consistent.  
This requirement applies to all SAEs (regardless of relationship to IP) that occur during the study 
from the time the subject signs informed consent up to 42112 days after the last dose of IP, and 
those made known to the Investigator at anytime thereafter that are suspected of being related to 
IP.  SAEs occurring prior to treatment will be captured.  
The SAE report should provide a detailed description of the SAE and include summariescopies
of hospital records and other relevant documents.  
Rationale:
Modified serious adverse event reporting period from 112 to 42 days for events not suspected to 
be related to investigational product to be in alignment with AE reporting and current protocol 
template.
Page 191 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
94
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
3.17.
Section 11.6:  Expedited Reporting of Adverse Events, (page 80-81)
Original Text:
Celgene or its authorized representative shall notify the Investigator of the following 
information:
Any AE associated with the use of IP in this study or in other studies that is both 
serious and unexpected (i.e., SUSAR);
                                                     
Celgene Drug Safety Contact Information:
For Local Drug Safety Affiliate Office contact information, please refer to the Serious Adverse 
Event Report Form Completion Guidelines or to the SAE Report Form.  
Revised Text:
Celgene or its authorized representative shall notify the Investigator of the following 
information:
Any AE suspected of being related assoctoiated with the use of IP in this study or in 
other studies that is both serious and unexpected (i.e., SUSAR);
                                                     
Celgene Drug Safety Contact Information:
For Local Drug Safety Affiliate Office contact information, please refer to the Serious Adverse 
Event Report Form / Completion Guidelines or to the PregnancySAE Report Form / Completion 
Guidelines.  
Rationale:
Updated in alignment with current protocol template.
Page 192 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
95
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
3.18.
Section 14.6:  Institutional Review Board/Independent Ethics 
Committee Review and Approval, (page 86)
Original Text:
IP can only be supplied to an Investigator by Celgene or its authorized representative after 
documentation on all ethical and legal requirements for starting the study has been received by 
Celgene or its authorized representative.  
Revised Text:
Investigational Product can only be supplied to an Investigator by Celgene or its authorized 
representative after documentation on all ethical and legal requirements for starting the study has 
been received by Celgene or its authorized representative.  
Rationale:
Updated in alignment with current protocol template.
Page 193 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
96
ACE-011-NSCL-001 AMENDMENT 1 FINAL: 22 MAR 2011
3.19.
Section 17:  Publications, (page 90)
Original Text:
(Text not previously present.)
Revised Text:
Selection of first authorship will be based on several considerations, including, but not limited to 
study participation, contribution to the protocol development, and analysis and input into the 
manuscript, related abstracts, and presentations in a study.
Rationale:
Updated in alignment with current protocol template.
Page 194 of 791
088VGY

088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
2
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
MEDICAL MONITOR / EMERGENCY CONTACT INFORMATION
Contact Information:
Note:  The back-up 24 hour global emergency contact call center should only be used if you 
are not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls  
Back-up 24 Hour Global Emergency Contact Call Center: 
Page 196 of 791
PPD
PPD
088VGY

088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
4
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
SITE PRINCIPAL INVESTIGATOR SIGNATURE PAGE
Signature of Site Principal Investigator
dd mmm yyyy
Printed Name of Site Principal Investigator 
Institution Name:_______________________________________
By my signature, I agree to personally supervise the conduct of this study at my study 
site and to ensure its conduct is in compliance with the protocol, informed consent, 
Institutional Review Board (IRB)/Ethics Committee (EC) procedures, instructions from 
Celgene representatives, the Declaration of Helsinki, ICH Good Clinical Practices 
Guidelines, and local regulations governing the conduct of clinical studies.
Page 198 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
5
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
COORDINATING PRINCIPAL INVESTIGATOR SIGNATURE PAGE
Signature of Coordinating Principal Investigator
dd mmm yyyy
Printed Name of Coordinating Principal Investigator 
Institution Name:_______________________________________
By my signature, I agree the protocol has been written to comply with ICH Good 
Clinical Practices guidelines and agree to offer guidance throughout the study as 
needed.
Page 199 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
6
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
PROTOCOL SUMMARY
Study Title
A single-blind, randomized, phase 2a, dose-ranging study (Part 1) of sotatercept (ACE-011)
therapy followed by a phase 2b/3, double-blind, randomized, placebo-controlled study (Part 2) 
of sotatercept (ACE-011) for chemotherapy-induced anemia in subjects with metastatic non-
small cell lung cancer treated with first-line platinum-based chemotherapeutic regimens.  
Indication
Chemotherapy Induced Anemia (CIA) in Subjects with Metastatic Non-Small Cell Lung Cancer 
(NSCLC).  
Objectives
The primary objectives are:

Part 1:  To determine an effective dose of sotatercept (ACE-011) showing a 
hematopoietic response in the treatment of CIA in metastatic NSCLC subjects.  

Part 2:  To assess transfusion rate following initiation of sotatercept (ACE-
011)/placebo treatment.  
The secondary objectives are:

Part 1 and Part 2:

To estimate the effect of sotatercept (ACE-011) treatment on objective response rate 
(ORR), time to progression (TTP), progression free survival (PFS) and overall 
survival (OS) in metastatic NSCLC subjects with CIA.  

To evaluate the safety and tolerability of sotatercept (ACE-011) treatment in
metastatic NSCLC subjects with CIA.  

To determine the pharmacokinetics (PK) of sotatercept (ACE-011) in subjects with 
metastatic NSCLC receiving platinum-based chemotherapy.  

To evaluate the hematopoietic response and its duration associated with sotatercept 
(ACE-011) treatment.  

To evaluate the effect of sotatercept (ACE-011) treatment on the quality of life (QoL)
of NSCLC subjects with CIA.  
The exploratory objectives are:
Part 1 and Part 2:

To estimate the effect of sotatercept (ACE-011) treatment on bone metabolism in 
NSCLC subjects with CIA.  

To explore the relationship between sotatercept (ACE-011) exposure and response 
(hematology, biomarkers, and other clinical outcomes as appropriate).  
Page 200 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
7
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011

To evaluate the expression of Activin A and other proteins/biomarkers (including 
myostatin and follistatin) related to sotatercept (ACE-011) mechanism of action in 
blood.

To evaluate the expression of Activin A and other proteins/biomarkers in archival 
tumor tissue.

To assess renal function biomarkers.  
Study Design
This is a single-blind, randomized, phase 2a, dose-ranging study (Part 1) of sotatercept (ACE-
011) therapy followed by a phase 2b/3, double-blind, randomized, placebo-controlled study 
(Part 2) of sotatercept (ACE-011) for CIA subjects with metastatic non-small cell lung cancer 
treated with first-line platinum-based chemotherapeutic regimens.  
The study will consist of two parts:
Part 1 is a dose-finding segment in which up to approximately 90 subjects will be randomized to 
one of three sotatercept (ACE-011) dose treatment arms.  The primary objective is to determine 
an effective dose of sotatercept (ACE-011) showing a hematopoietic response in the treatment of 
CIA in metastatic NSCLC subjects.  The sample size is for the purpose of hypothesis generation; 
however, it would allow approximately 80% power to detect an effect size of 0.33 using a 2 
degrees of freedom Chi-Square Test with a significance level (alpha) of 0.05.  
Part 2 is the phase 2b/3 double-blind, randomized, placebo-controlled segment of the study and 
will be performed in two stages. In the first stage, approximately 180 subjects will be 
randomized to receive sotatercept (ACE-011), at the dose determined from Part 1, or placebo at a 
ratio of 1:1.  An interim futility assessment based on transfusion rate at 4 months will be 
performed as described in Section 10.8. It is expected that accrual will continue during the 
interim assessment period, with up to an additional 570 subjects randomized to achieve full study 
accrual.  
During Part 2 (first and second stage) overall survival will be assessed.  The total sample size of 
750 subjects will allow observation of at least 536 deaths and thus, at least 80% power to exclude
more than 15% hazard increase in the sotatercept (ACE-011) arm compared with the placebo 
arm at one-sided significance level of 0.025, i.e., rejecting hazard ratio (Placebo:sotatercept 
[ACE-011]) of 0.87, assuming the sotatercept (ACE-011) arm actually reduces at least 10% 
hazard, i.e., true hazard ratio (Placebo:sotatercept [ACE-011]) of 1.11.  
A Data Monitoring Committee (DMC) will monitor the conduct of the study.  
Study Population
At the time of randomization, all subjects must be receiving their first regimen of first-line 
platinum-containing chemotherapy, given every three weeks, for the treatment of metastatic 
NSCLC.  Subjects may have already received up to 3 cycles and must be randomized prior to 
receiving Cycle 4 of this current first-line platinum-based regimen to be eligible for the study.  It 
is expected that subjects be eligible to continue to receive ≥ 2 additional platinum-based 
chemotherapy cycles while on study treatment.  
Subjects must not have received any other regimens of chemotherapy for the first-line platinum 
containing treatment of metastatic NSCLC prior to the regimen at the time of randomization.  
Page 201 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
8
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
Length of Study and Study Treatments
This study will consist of the following consecutive periods:  Screening, Treatment Period, Post 
Treatment Follow-Up Period, and Survival Follow-Up Period.  Study treatment is defined as 
sotatercept (ACE-011) in Part 1 and sotatercept (ACE-011)/placebo in Part 2.  
Screening Period (28 days):
Potential study subjects will sign an informed consent form prior to undergoing any study-related 
procedures.  Subjects will undergo screening for protocol eligibility within 28 days of 
randomization, as outlined in the Table of Events, Section 5.  Note: Screening period tumor 
assessments should be performed within six weeks prior to randomization.  Also, historical 
tumor assessment data, from prior to the initiation of platinum-based chemotherapy 
through the screening period, will be collected and used for assessment of tumor response.  
Prior erythropoietic stimulating agent (ESA) treatment history starting from initial diagnosis of 
NSCLC and red blood cell (RBC) transfusion history starting from diagnosis of metastatic 
NSCLC at a minimum of up to two months prior to randomization will be collected.  
All females of childbearing potential (FCBP) participating in the study are to use highly effective 
methods of birth control during the screening period, for at least 28 days before starting the 
study.  Some highly effective methods of birth control include:

Oral contraceptives, intrauterine device, tubal ligation or a partner with a vasectomy
OR

Two forms of barrier method birth control, e.g., a latex condom PLUS a diaphragm 
with spermicide OR a latex condom PLUS a contraceptive sponge with spermicide.  
If a non-latex condom is used, it cannot be made out of natural (animal) membrane.  
Treatment Period (up to 6-9 months):  
The treatment period is approximately six months (four doses of study treatment given on Day 1,
every 42 days), two additional sotatercept (ACE-011)/placebo doses may be given only in Part 
2, at the discretion of the Investigator.  
In Part 1 (the dose-ranging portion of the study), subjects who meet all eligibility criteria will be 
randomized to receive one of the following sotatercept (ACE-011) dose levels, with 10-30 
subjects per arm:

Sotatercept (ACE-011) 15.0 mg SC

Sotatercept (ACE-011) 30.0 mg SC
Analysis of safety data will be performed following the treatment of at least 10 subjects at the 
15.0 mg dose level and 10 subjects at the 30.0 mg dose level, with each subject having received 
at least of one dose of sotatercept (ACE-011), plus a 12-week follow-up period from first dose.  
Following this analysis, the addition of a third dose level:

Sotatercept (ACE-011) 45.0 mg SC
to the randomization schema will be determined.
Each dose level will be administered every 42 days for up to four doses.  
Page 202 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
9
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
The effective dose of sotatercept (ACE-011) is defined as follows:
An increase in hemoglobin (Hgb) of ≥ 1.0 g/dL above the study baseline value for 4 
consecutive weeks during the first two doses of sotatercept (ACE-011) (Dose 1/Day 1 
through and including Dose 2/Day 43 [prior to Dose 3]), in approximately 70% of subjects, 
in at least one or more treatment arms (in the absence of RBC transfusions and/or ESAs).  
Evaluation of hemoglobin response decision status will be completed after dosing arms have 
separately enrolled up to 30 subjects, as needed, to determine the optimal dose for Part 2.  
In addition to the hematopoietic response, the safety profile, dose modifications and extent of 
exposure in each dosing level will be taken into account to determine the study dose to be used in 
Part 2. 
In Part 2, a total of 750 subjects will be randomized to receive either sotatercept (ACE-011) or 
placebo, at a ratio of 1:1:

375 subjects will receive sotatercept (ACE-011) (at the dose determined in Part 1)

375 subjects will receive placebo
Each dose of sotatercept (ACE-011) or placebo will be administered every 42 days for four
doses.  Up to two additional doses may be given at the discretion of the Investigator.  
Part 2 will be performed in two stages. In the first stage, approximately 180 subjects will be 
randomized to receive sotatercept (ACE-011) (at the dose determined from Part 1) or placebo at 
a ratio of 1:1.  An interim futility assessment based on transfusion rate at 4 months will be 
performed as described in Section 10.8. It is expected that accrual will continue during the 
interim assessment period, with up to an additional 570 subjects randomized to achieve full study 
accrual. 
During the Treatment Period, subjects will be assessed for hematopoietic response, transfusion 
need, safety and tumor response.  The severity of AEs will be graded according to the currently 
active minor version of the National Cancer Institute Common Terminology Criteria for Adverse 
Events (NCI CTCAE) version 4.0.  
Concurrent treatment for CIA with blood transfusions is recommended when Hgb value is 
< 8 g/dL or at the discretion of the Investigator if the Hgb value is ≥8 g/dL and associated with 
anemia symptoms such as hemodynamic or pulmonary compromise requiring treatment.  If an 
RBC transfusion is given to a subject during the Treatment Period, sotatercept (ACE-011) should 
be administered > 7 days from the date of the RBC transfusion.  
In Part 1, full PK blood samples will be collected to evaluate the full PK profile of sotatercept 
(ACE-011) from approximately 30 subjects at select centers, in approximately 10 subjects for 
each sotatercept (ACE-011) dose group.  In subjects participating in the full PK assessment,
RBC, Hgb, and reticulocyte counts will be collected at each PK time point (excluding the 4-hour
time point on Day 1) from Day 1 to Day 43 after the first dose.  Subjects not participating in the 
optional full PK assessment will participate in the sparse PK assessment. 
In Part 2, the sparse PK assessment will be performed in approximately 300 (40%) of 750
subjects (approximately 150 subjects in each arm).  
Page 203 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
10
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
Subjects will be discontinued from Study Treatment due to the following:

Adverse  events(s)

Hypertension ≥Grade 3 – defined as Stage 2 hypertension (systolic blood 
pressure [SBP] ≥160 mm Hg or diastolic blood pressure [DBP] ≥100mm Hg), 
confirmed by two measurements obtained five minutes apart; medical 
intervention indicated; more than one drug or more intensive therapy than 
previously used indicated or medically significant hypertension which cannot be 
adequately controlled with antihypertensive therapy. Any AE > Grade 2 assessed 
to be related to sotatercept (ACE-011) therapy

Any persistent AE > Grade 1 considered to be related to sotatercept (ACE-011)
treatment and causing a subject to miss three months of sotatercept (ACE-011)
therapy

Any thromboembolic event > Grade 2 

Elevated Hgb > 15.0 g/dL (sustained for a 7 day period, confirmed by laboratory 
assessment)

Urine protein / creatinine ratio > 1.0 or > 2.0 (if bevacizumab [Avastin®] is 
concomitantly administered)

Persistent hematuria ≥Grade 2 - defined as symptomatic; urinary catheter or 
bladder irrigation indicated; limiting instrumental activities of daily living, and 
persisting for one week. 

Lack of sotatercept (ACE-011) therapeutic effect, defined as < 1.0 g/dL increase in 
Hgb following two doses of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo.  

Concomitant use of ESAs – In Part 1 if administered at any time and in Part 2 if 
administered < 4 months from first dose of study treatment. 

Sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dose modifications

In Part 1 and Part 2:  A second Hgb increase of ≥3.0 g/dL following a two-level 
dose reduction due to a Hgb increase ≥3.0 g/dL 

In Part 2:  > 3 dose reductions and/or delays

Disease progression of NSCLC

Withdrawal of consent

Death

Lost to follow-up

Protocol violation
The reason for treatment discontinuation should be recorded in the eCRF and in the source 
documents.  
Page 204 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
11
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
Post Treatment Follow-Up Period (monthly visits for up to 6 months)
Subjects who enter the Post Treatment Follow-Up Period will be followed monthly for up to 6 
months from their last dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.  All 
subjects will continue to be followed for TTP and PFS up to one year from their first dose of 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo or until progression of their NSCLC, 
whichever comes first.  
The following events are considered sufficient reasons for discontinuing a subject from the 
study:

Completed study, per protocol (subject has completed six- to nine- month Treatment 
Period plus up to six-month Post Treatment Follow-Up Period including one year 
tumor assessment to determine TTP and PFS).  Note: Survival data will continue to 
be collected for up to 24 months from first dose of study treatment.  

Withdrawal of consent

Death

Lost to follow-up
The following events may be considered sufficient reasons for discontinuing a subject from the 
study:

Adverse  event(s)

Disease progression of NSCLC

Protocol violation
Survival Follow-up Period (monthly for up to 24 months after first dose of sotatercept 
(ACE-011) or sotatercept (ACE-011)/placebo)
In both Part 1 and Part 2, survival data will be collected monthly via telephone contact for up to 
24 months following the subject’s first dose of sotatercept (ACE-011) (Part 1) or sotatercept 
(ACE-011)/placebo (Part 2).  Collection of survival data will begin following Study 
Discontinuation Visit.  

Overall survival

Post-Treatment Anti-Neoplastic Therapy
Overview of Efficacy Assessments

Serum hematology, absolute reticulocyte counts

Serum iron, total iron binding capacity (TIBC), transferrin and serum ferritin

Serum erythropoietin

Tumor Assessments

Documentation of concomitant RBC transfusions
Page 205 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
12
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
Overview of Safety Assessments

Informed consent

Assessment of inclusion / exclusion criteria

Complete medical history including history of cardiac and thromboembolic events

Vital signs including height, weight, heart rate, seated systolic and diastolic blood 
pressure, and temperature.  

AE(s)

12-lead electrocardiogram (ECG)  

Medically supervised pregnancy testing

Clinical laboratory evaluations (serum chemistry, hematology, absolute reticulocyte 
count, creatinine clearance, serum iron, total iron binding capacity, transferrin and 
serum ferritin, serum erythropoietin, Vitamin B12, serum RBC folate levels, 
urinalysis, FSH, LH, dihyroepiandosterone, estrogen, estradiol, testosterone and
serum thyroid-stimulating hormone).  

QoL Assessment (FACIT Fatigue Scale [Version 4]) and Lung Cancer Symptom 
Scale (LCSS) questionnaire.  

Documentation of concomitant medications / procedures. 
Overview of Exploratory Assessments

Bone or other potential mechanistic or disease-related proteins/biomarkers 

DXA scan

Renal function biomarkers 
Page 206 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
13
TABLE OF CONTENTS
TITLE PAGE..............................................................................................................................1
PROTOCOL SUMMARY ..........................................................................................................6
1.
INTRODUCTION..................................................................................................18
2.
STUDY OBJECTIVES...........................................................................................34
2.1.
Primary Objective...................................................................................................34
2.2.
Secondary Objectives .............................................................................................34
2.3.
Exploratory Objectives ...........................................................................................34
3.
STUDY ENDPOINTS............................................................................................35
3.1.
Primary Endpoint(s) ...............................................................................................35
3.2.
Secondary Endpoint(s)............................................................................................35
3.3.
Exploratory Endpoint(s)..........................................................................................36
4.
OVERALL STUDY DESIGN ................................................................................37
4.1.
Study Design ..........................................................................................................37
4.1.1.
Sotatercept (ACE-011) Dose Modification, Reduction and Escalation Rules...........40
4.2.
Study Design Rationale ..........................................................................................43
4.2.1.
Fixed Dose .............................................................................................................44
4.2.2.
Dosing Schedule.....................................................................................................44
4.2.3.
Starting Dose Levels in Part 1.................................................................................44
4.2.4.
Evaluation of Dosing Schema via Modeling/Simulation .........................................45
4.3.
Study Duration .......................................................................................................46
5.
TABLE OF EVENTS.............................................................................................47
6.
PROCEDURES......................................................................................................55
7.
STUDY POPULATION.........................................................................................63
7.1.
Number of Subjects ................................................................................................63
7.2.
Inclusion Criteria....................................................................................................64
7.3.
Exclusion Criteria...................................................................................................65
8.
DESCRIPTION OF STUDY TREATMENTS........................................................68
8.1.
Description of Investigational Product(s)................................................................68
8.2.
Treatment Administration and Schedule .................................................................68
8.2.1.
Selection of Dose for the Study...............................................................................69
8.2.2.
Selection and Timing of Dosing for Each Subject ...................................................70
Page 207 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
14
8.2.3.
Discontinuation ......................................................................................................71
8.3.
Method of Treatment Assignment...........................................................................72
8.4.
Packaging and Labeling..........................................................................................72
8.5.
Investigational Product Accountability And Disposal .............................................73
8.6.
Investigational Product Compliance........................................................................73
9.
CONCOMITANT MEDICATIONS AND PROCEDURES....................................74
9.1.
Permitted Concomitant Medications and Procedures...............................................74
9.2.
Prohibited Concomitant Medications and Procedures..............................................75
9.3.
Required Concomitant Medications and Procedures................................................75
10.
STATISTICAL ANALYSES..................................................................................76
10.1.
Overview................................................................................................................76
10.2.
Study Population Definitions ..................................................................................76
10.3.
Sample Size and Power Considerations...................................................................76
10.4.
Background and Demographic Characteristics........................................................77
10.5.
Subject Disposition.................................................................................................77
10.6.
Efficacy Analysis....................................................................................................77
10.7.
Safety Analysis.......................................................................................................78
10.8.
Interim Analysis .....................................................................................................79
10.9.
Other Topics...........................................................................................................79
10.10.
Data Monitoring Committee (DMC).......................................................................80
11.
ADVERSE EVENTS..............................................................................................81
11.1.
Monitoring, Recording and Reporting of Adverse Events .......................................81
11.2.
Evaluation of Adverse Events.................................................................................81
11.2.1.
Seriousness.............................................................................................................81
11.2.2.
Severity / Intensity..................................................................................................82
11.2.3.
Causality ................................................................................................................83
11.2.4.
Duration .................................................................................................................83
11.2.5.
Action Taken..........................................................................................................84
11.2.6.
Outcome.................................................................................................................84
11.3.
Abnormal Laboratory Values..................................................................................84
11.4.
Pregnancy...............................................................................................................84
11.4.1.
Females of Childbearing Potential: .........................................................................84
11.4.2.
Male Subjects.........................................................................................................85
Page 208 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
15
11.5.
Immediate Reporting of Serious Adverse Events ....................................................85
11.5.1.
Safety Queries ........................................................................................................85
11.6.
Expedited Reporting of Adverse Events..................................................................85
12.
DISCONTINUATIONS .........................................................................................87
13.
EMERGENCY PROCEDURES.............................................................................88
13.1.
Emergency Contact.................................................................................................88
13.2.
Emergency Identification of Investigational Products .............................................88
14.
REGULATORY CONSIDERATIONS...................................................................89
14.1.
Good Clinical Practice............................................................................................89
14.2.
Investigator Responsibilities ...................................................................................89
14.3.
Subject Information and Informed Consent.............................................................89
14.4.
Confidentiality........................................................................................................90
14.5.
Protocol Amendments.............................................................................................90
14.6.
Institutional Review Board/Independent Ethics Committee Review and 
Approval ................................................................................................................90
14.7.
Ongoing Information for Institutional Review Board / Ethics Committee................91
14.8.
Closure of the Study ...............................................................................................91
15.
DATA HANDLING AND RECORDKEEPING.....................................................92
15.1.
Data/Documents .....................................................................................................92
15.2.
Data Management...................................................................................................92
15.3.
Record Retention....................................................................................................92
16.
QUALITY CONTROL AND QUALITY ASSURANCE........................................94
16.1.
Study Monitoring and Source Data Verification......................................................94
16.2.
Audits and Inspections............................................................................................94
17.
PUBLICATIONS ...................................................................................................95
18.
REFERENCES.......................................................................................................96
19.
APPENDICES........................................................................................................99
Appendix A:  Response Evaluation Criteria in Solid Tumors.....................................................99
Appendix B:  ECOG Performance Status Scale .......................................................................101
Appendix C:  National Cancer Institute (NCI) Common Terminology Criteria for 
Adverse Events (CTCAE) Version 4.0..................................................................102
Appendix D:  New York Heart Association - Classification of Heart Failure...........................103
Page 209 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
16
LIST OF TABLES
Table 1:
A011-02:  A Phase 1b Study in Healthy Postmenopausal Women, 
Hemoglobin Evaluation ..........................................................................................26
Table 2:
Summary of Adverse Events Reported in Greater Than or Equal To 5 
Percent of Patients Overall......................................................................................29
Table 3:
Summary of SAEs Reported...................................................................................30
Table 4:
Number of Subjects with an Increase in Hgb from Baseline at Any Time and 
Sustained for Greater Than or Equal To 28 Days ....................................................30
Table 5:
Sotatercept (ACE-011) and Sotatercept (ACE-011)/Placebo Dose Reduction 
Levels.....................................................................................................................42
Table 6:
Sotatercept (ACE-011) Dose Escalation Levels (Part 1 Only) .................................43
Table 7:
Sotatercept (ACE-011) NSCLC Schedule of Assessments ......................................47
Table 8:
Schedule of Pharmacokinetic Assessments (Part 1).................................................53
Table 9:
Schedule of Pharmacokinetic Assessments (Part 2).................................................54
Table 10:
ECOG Performance Status Scale ..........................................................................101
Table 11:
Classification of Heart Failure ..............................................................................103
Page 210 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
17
LIST OF FIGURES
Figure 1:
Study Design ..........................................................................................................39
Figure 2:
Simulated Hemoglobin Response in the Hypothetical Anemic Population .............46
Page 211 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
18
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
1.
INTRODUCTION
This is a single-blind, randomized, phase 2a, dose-ranging study of sotatercept (ACE-011)
therapy followed by a phase 2b/3, double-blind, randomized, placebo-controlled study of 
sotatercept (ACE-011) for chemotherapy-induced anemia (CIA) in subjects with metastatic non-
small cell lung cancer (NSCLC) treated with platinum-based chemotherapeutic regimens.  The 
study will consist of two parts.  Part 1 is a dose finding segment in which up to 90 subjects will 
be randomized to one of three sotatercept (ACE-011) dose treatment arms.  Continuous 
monitoring of safety data will be conducted, including the review of Part 1 data to define the 
recommended sotatercept (ACE-011) dose to be used in Part 2, the phase 2b/3, double-blind, 
randomized placebo-controlled segment of the study.  
  Part 2 will be performed in two stages. In the first stage approximately 180 subjects will be 
randomized to receive sotatercept (ACE-011), at the dose determined from Part 1, or placebo at a 
ratio of 1:1.  An interim futility assessment based on transfusion rate at 4 months will be 
performed as described in Section 10.8.  It is expected that accrual will continue during the 
interim assessment period, with up to an additional 570 subjects randomized to achieve full study 
accrual.
A Data Monitoring Committee (DMC) will monitor the conduct of the study. 
Sotatercept (ACE-011) (ActRIIA-IgG1Fc) is a human fusion protein consisting of the 
extracellular domain (ECD) of activin receptor IIA (ActRIIA) linked to the human IgG1 Fc 
domain, which includes the heavy chain hinge and constant domains, CH2 and CH3.  
The chemical structure of sotatercept (ACE-011) is composed of a disulfide-linked, glycosylated, 
dimeric protein.  Sotatercept (ACE-011) competes with the activin receptor IIA and binds a 
number of TGF-β superfamily ligands including activin, GDF-11, BMP-10, GDF-3 and 
myostatin (growth differentiation factor [GDF]-8).  
In both a single and a multiple dose phase 1 study of sotatercept (ACE-011) in healthy volunteer, 
postmenopausal women, a dose and time dependent increase in hemoglobin (Hgb) and 
hematocrit (HCT), and red blood cell (RBC) levels were observed following sotatercept (ACE-
011) treatment and remained elevated over the course of study.  
Although the mechanism(s) underlying the stimulation effect of sotatercept (ACE-011) on 
erythropoiesis are not yet fully understood, the result of clinical experience showed a rapid and 
sustainable increase in mature erythrocytes released into circulation.  The sotatercept (ACE-011) 
proposed mechanism of action may be different than that of known erythropoiesis-stimulating 
agents (ESAs) and may provide a different clinical profile in the treatment of CIA.  
This study will provide information on the pharmacodynamic properties regarding the ability of 
sotatercept (ACE-011) to increase Hgb in subjects with CIA.  
Non-Small Cell Lung Cancer Current Therapy Status
Lung cancer is the leading cause of cancer death in the world, accounting for 32% of cancer 
deaths in males and 25% in females, affecting approximately 171,000 people annually in the US 
(Parker, 1997; Sandler, 2006) and more than 200,000 people in Europe (Rossi, 2006).  Of these 
patients, approximately 85% have NSCLC, including squamous carcinoma, adenocarcinoma and 
Page 212 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
19
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
large cell carcinoma (Rossi, 2006; Sandler, 2006).  These histologies are typically classified 
together because the approaches to diagnosis, staging and prognosis, and treatment are similar.  
Patients are often diagnosed with an advanced stage of disease.  Studies of advanced NSCLC 
patients treated with platinum-based chemotherapy report a one year survival rate that ranges 
from 30 to 43 percent and a median survival that ranges from seven to ten months (Dang, 2008).  
The 5-year survival rate of patients with NSCLC varies by stage, from 60 to 70% for patients 
with stage I disease to < 1% for patients with stage IV disease (Hong, 2008).  Patients having 
stage IIIb/IV NSCLC are not considered to be candidates for curative resection surgery or 
radiation, and radiation therapy is primarily used as palliative treatment in advanced stages of 
NSCLC.  
The role of chemotherapy is now well established as the recommended treatment of advanced 
NSCLC (Non-small Cell Lung Cancer Collaborative, Group 1995).  The current globally 
accepted standard of treatment for NSCLC is platinum-based combination therapy.  In advanced-
stage (stage IIB or IV) NSCLC, doublet combinations of platinum compounds (cisplatin or 
carboplatin) with gemcitabine (Gemzar®), vinorelbine, taxanes (paclitaxel or docetaxel) or 
pemetrexed are reference regimens.  When compared head-to-head in phase III studies, these 
doublets have shown comparable efficacy, in regards to overall survival (Schiller, 2002) with 
differences in toxicity profiles (Schiller, 2002).  When administered in a 3-week schedule, 
cisplatin plus gemcitabine, or cisplatin plus pemetrexed are effective and are widely used 
regimens for first-line treatment of NSCLC.  A recent phase III study in NSCLC compared 
cisplatin plus gemcitabine with cisplatin plus pemetrexed (Scagliotti, 2008).  Both had similar 
efficacy, with cisplatin plus pemetrexed having better tolerability and more convenient 
administration than cisplatin/gemcitabine.  This study was also the first prospective phase III 
study in NSCLC to show a survival difference based on histologic type (non-squamous benefited 
from pemetrexed plus cisplatin).  Drug-related grade (G) 3 or 4 anemia was at the rate of 6% for 
cisplatin/pemetrexed versus 10% for cisplatin/gemcitabine.  The incidence of RBC transfusion 
was 16.1% versus 27.3% and administration of erythropoietic agents 10.4% versus 18.1% 
respectively.  There was no significant difference between treatment arms in the incidence of or 
reason for deaths (7%).  
Treatment of Chemotherapy-Induced Anemia
Chemotherapy-induced anemia is an area of unmet medical need.  Erythropoiesis-stimulating 
agents can successfully mitigate transfusion need in a proportion of these patients, but concerns 
have emerged regarding apparent negative effects on survival and/or tumor progression in certain 
patient populations.  
Patients with cancer receiving multi-cycle chemotherapy are frequently anemic.  The etiology of 
CIA is multifactorial, resulting from the myelosuppressive effects of chemotherapy and the 
decrease in the production of the bone-marrow-stimulating hormone erythropoietin due to 
repeated cycles of chemotherapy (Vansteenkiste, 2002).  
The current treatment options for CIA include blood transfusion and ESAs.  However, the blood 
transfusion involves the risk of complications (such as potential transmission of infectious 
disease, alloimmunization, allergic reactions, hemolytic reactions, iron and circulatory overload, 
and possible immunosuppression) for the patient, and donor blood is a limited resource.  The 
practice of offering blood transfusions to cancer patients in chemotherapy has therefore been 
Page 213 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
20
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
rather restricted, generally reserved for emergencies, and severely anemic patients with serious 
symptoms.  
Erythropoiesis-stimulating agents have been approved for treating CIA.  Clinical studies have 
demonstrated that ESAs can successfully mitigate transfusion need in a proportion of these 
patients; however, new concerns have emerged regarding apparent negative effects on survival 
and/or tumor progression in certain patient populations.  In the pivotal Aranesp study for CIA in 
NSCLC, 27 % of patients were transfused with Packed Red Blood Cells (PRBC’s) at 4 months 
vs. 52% in the placebo arm.  In a subsequent recent Phase III study of pemetrexed (Alimta®) plus 
cisplatin vs. gemcitabine plus cisplatin where all first-line NSCLC patients with anemia or not 
were enrolled, 16.1% vs 27.3% of patients respectively were transfused with PRBC’s during that 
study (Scagliotti, 2008).
Chemotherapy-induced anemia is a significant problem for patients with cancer, causing fatigue 
and reducing quality-of-life (QoL).  Treatment with sotatercept (ACE-011) resulted in increased 
HCT, Hgb and absolute red cell number in both nonclinical and clinical studies.  The rapid and 
sustained increases in Hgb and HCT levels were observed in two Phase 1 studies in healthy 
volunteers, as well as in a Phase 2a study for multiple myeloma (MM). The ability for sotatercept 
(ACE-011) to rapidly increase and sustain Hgb levels in anemic subjects supports the clinical 
development of ACE-011 for the treatment of CIA.  
Activin Biology
The activins (A-E) are a group of proteins that form dimers and heterodimers.  All are part of the 
TGF-β protein superfamily.  The first described activin, Activin A was initially identified as a 
gonadal differentiation factor involved in modulating follicle stimulating hormone (FSH) 
secretion from the pituitary (Ying, 1988).  Subsequently, the pleiotropic nature of Activin A has 
become more apparent (Woodruff, 1998).  There is a growing body of data suggesting a role for 
activins in bone remodeling, specifically as a negative regulator of bone growth (Perrien, 2007).  
Before the two molecules were shown to be identical (Rivier, 1985), Activin A was also initially 
described as erythroid differentiation factor (EDF), effecting the maturation and differentiation 
of RBC’s (Murata, 1988).  The mechanism(s) by which Activin A influences erythropoiesis 
remains under investigation and, in fact, there are data from in vitro and in vivo studies that 
support erythropoiesis-stimulatory (Shiozaki, 1992; 1989) and erythropoiesis-inhibitory effects 
(Nakao, 1991).  
At the cellular level, the activins bind initially to the high-affinity Type II receptor (ActRIIA).  
The ligand-bound ActRIIA then recruits the low-affinity Type I receptor (ActRIA or ALK-4).  
The receptor heterocomplex, through its cytoplasmic protein kinase activity, then activates the 
Smad signal cascade to eventually influence nuclear transcriptional factors (Chen, 2002; 
Mathews, 1994).  The competitive binding of activins in the blood by the sotatercept (ACE-011)
soluble fusion protein can result in inhibition of the ActRIIA receptor signaling pathway by 
impeding biological processes attributed to these pleiotropic proteins.  
The activin signaling pathway has been shown to induce terminal erythroid differentiation in 
some preclinical models.  Inhibition of activin may indirectly lead to increases in proliferation of 
the erythroid lineage.  Based on its pharmacologic effects, sotatercept (ACE-011) is being 
developed for the treatment of anemia associated with a variety of disorders, such as in chronic 
renal failure and CIA.  
Page 214 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
21
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
In a retrospective study (Seder, 2009) activin immunoreactivity was found in 78% of lung 
adenocarcinomas surveyed (n=164).  Expression ranged from moderate in the majority of 
individuals to high in approximately 19.7% of samples evaluated.  Gene expression analysis was 
also used to measure activin mRNA in 86 lung adenocarcinomas and 10 normal lung samples.  
An average of three-fold more activin transcript was detected in diseased tissue relative to 
normal samples and particularly high levels of overexpression were associated with worse 
overall survival in stage I patients with NSCLC.  
Additionally, in the NIH “directors challenge” study for NSCLC adenocarcinoma (Shedden, 
2008), three of the 12 molecular subgroups, including the subgroup with the worst survival 
prognosis, demonstrated overexpression of Activin A.  Thus, overexpression of activin may play 
a role in NSCLC tumor progression.  
Sotatercept (ACE-011)
Sotatercept (ACE-011) (ActRIIA-IgG1Fc) is a human fusion protein consisting of the 
extracellular domain (ECD) of activin receptor IIA (ActRIIA) linked to the human IgG1 Fc 
domain, which includes the heavy chain hinge and constant domains, CH2 and CH3.  The ECD
sequence of ActRIIA is completely conserved among numerous species including mouse, rat, 
cynomolgus monkey and humans, thus mouse, rat and cynomolgus monkeys have been 
considered relevant species for nonclinical evaluation of sotatercept (ACE-011).  However, in 
order to reduce the potential immunogenicity of the human molecule, sotatercept (ACE-011), 
and to maximize the opportunity to maintain exposures in chronic models, a murine surrogate 
molecule was constructed by exchanging the human immunoglobulin Fc sequence portion of 
sotatercept (ACE-011) with its murine IgG2a homolog.  The resultant construct is referred to as 
RAP-011 (ActRIIA-mIgG2aFc), and is described in the pharmacology studies below.  
Pharmacology Studies
RAP-011 was evaluated in a broad range of animal pharmacology studies to assess the effects of 
inhibition of Activin A on the biological processes attributed to that regulatory protein.  RAP-
011 has been shown to have significant effects on the red cell compartment.  RAP-011 treatment 
of mice at 10, 30 and 50 mg/kg by intraperitoneal injection (IP) twice per week for 3 months 
resulted in a 16-26% increase in RBC counts compared to control animals.  Rats treated with 
sotatercept (ACE-011) at 0.3, 3 and 30 mg/kg once per week for 3 months showed RBC count 
increases of 6-15% over control animals.  Finally, in cynomolgus monkeys treated with 10, 30 or 
50 mg/kg of sotatercept (ACE-011) twice per month for 3 months, there was a 21-24% increase 
in RBC counts compared to control animals.  In this study, the RBC count increase was apparent 
as early as 2 weeks following the initial dose of sotatercept (ACE-011).  
RAP-011 administered at 10 mg/kg to mice three days prior to administration of paclitaxel at 30 
mg/kg was sufficient to prevent decreases in RBC parameters typically seen three days later.  
Mice receiving paclitaxel alone had decreased HCT levels from 43% to 38% three days 
following treatment.  RAP-011 administered three days prior to paclitaxel injection was 
sufficient to keep the HCT levels above 42% at three days and up to two weeks following 
paclitaxel administration.  Therefore, prophylactic treatment with RAP-011 was able to prevent 
paclitaxel-induced anemia in mice.  
RAP-011 has also been shown to significantly increase bone mineral density (BMD) and 
strength in normal animals and in a variety of animal models of bone loss (Chantry, 2008; 
Page 215 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
22
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
Lotinun, 2008; Pearsall, 2008).  In a murine ovariectomy (OVX)-induced model of osteopenia, 
RAP-011 (10 mg/kg intravenous [IV], twice per week x 12 weeks) increased trabecular BMD > 
25% in 6-12 weeks compared to the phosphate buffered saline (PBS)-treated controls (p<0.002).  
RAP-011 treatment was able to reverse the accelerated bone loss associated with ovariectomy.  
As expected, sham-operated (SHAM) mice (i.e., intact ovaries) started the study with a greater 
trabecular BMD than OVX mice.  PBS-treated SHAM mice showed a 10% decrease in 
trabecular BMD after 12 weeks of treatment compared to baseline, while SHAM-RAP-011 mice 
had a 32% increase in trabecular BMD over the same period.  These data demonstrate that RAP-
011 is able to increase trabecular BMD in both the normal state and in a model of established 
bone loss.  The femurs of both the RAP-011 treated OVX and SHAM mice showed statistically 
significant increases in all measured parameters of bone strength (i.e., maximum load, stiffness, 
energy, ultimate strength, and elastic modulus).  In summary, treatment with RAP-011 produced 
bone of superior quality consistent with an anabolic agent.  
RAP-011 was evaluated in a mouse model of skeletal metastasis using luciferase-tagged, human 
MDA-MB-231 breast cancer cells (estrogen receptor negative).  Mice were pretreated for 2 
weeks with RAP-011 (10 mg/kg, biweekly, subcutaneous [SC]) prior to intracardiac injection of 
tumor cells.  Treatment with RAP-011 was continued for an additional 5 weeks following tumor 
implantation.  A parallel study was conducted to examine the effect of RAP-011 treatment, as 
described above, on survival of MDA-MB-231 bearing mice.  
The data demonstrate that RAP-011 treatment acts to decrease the incidence of MDA-MB-231 
metastasis to bone and may also play a role in inhibiting tumor growth in the bone marrow 
environment.  Furthermore, in the presence of tumor cells, RAP-011 is able to prevent lytic 
disease through an anabolic mechanism of bone formation.  Lastly, inhibition of tumor growth 
and metastasis with RAP-011 leads to a greater than 25% survival benefit in this model.  
RAP-011 was also evaluated in osteolytic bone disease of multiple myeloma.  Multiple myeloma 
is associated with the development of bone disease characterised by increased osteoclast activity 
and a suppression of osteoblastic bone formation.  
Results obtained in the 5T2MM murine model demonstrated that RAP-011 could prevent the 
development of osteolytic bone disease in a preventative setting.  
The effect of this activin antagonist on the inhibition of bone formation and osteoblast function 
in myeloma bone disease was investigated in 5T2MM murine myeloma cells isolated from the 
bone marrow of disease bearing animals.  
5T2MM cells promoted the development of osteolytic bone lesions (p<0.001), a reduction in 
trabecular volume (p<0.001) and cortical volume (p<0.005).  RAP-011 completely prevented 
5T2MM-induced decreases in trabecular volume and number in both tibia (p<0.001 and p<0.01), 
femur (p<0.001 and p<0.001) and vertebrae (p<0.01 and p<0.01) when compared to vehicle 
treated mice.  Bone volume was 19% higher in the tibia, 35% higher in the femur and 12% 
higher in vertebrae of RAP-011 treated mice than naïve non-tumour bearing mice.  
This study showed that, in the preclinical murine model for myeloma, RAP-011 stimulates bone 
formation by increasing osteoblast perimeter and number, mineralisation and bone formation rate 
but had no effect on osteoclast activity.  RAP-011 also appeared to directly inhibit tumor growth 
as demonstrated by decreased serum M protein, indicative of decreased tumor burden.  
Page 216 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
23
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
In addition, the RAP-011 was highly effective in restoring bone mineral density (BMD) when 
administered therapeutically in a murine model of postmenopausal osteoporosis.  RAP-011 has 
also been shown to increase trabecular bone density in normal mice.  
The efficacy of RAP-011 was also examined in two orthotopic metastatic models of breast 
cancer using luciferase-tagged human MCF-7 and MDA-MB-231 breast cancer cells (estrogen 
receptor positive and negative, respectively).  Mice were pretreated for 2 weeks with RAP-011 
(10 mg/kg, biweekly, SC) prior to the intra-cardiac implantation of tumor cells into female nude 
mice.  Treatment with RAP-011 was continued for an additional 7 weeks following tumor 
implantation at which time mice were sacrificed and assessed for tumor burden.  RAP-011 either 
modestly decreased the tumor burden (in the case of mice bearing MCF-7 tumors) or delayed 
tumor growth by approximately 3 weeks (MDA-MB-231 model) as measured by bio-
luminescence.  In addition, in the MCF-7 model, a 60% reduction in tumor weight was observed 
in the RAP-011 treated mice.  
The ability of RAP-011 to repair osteolytic lesions caused by metastatic disease was investigated 
in mice.  In this model, MDA-MB-231-Luc cells were intratibially implanted in athymic nude 
mice to mimic bone metastasis.  Mice were treated with a chemotherapy regimen of paclitaxel 
(20 mg/kg, IP, every three days) starting seven days after tumor injection and continuing for the 
duration of the study.  On study day 42, mice with detectable but minimal tumor burden, as 
measured by bioluminescent imaging, were divided into two groups and treated with either 
RAP-011 (10 mg/kg, SC, biweekly) or vehicle.  Prior to dosing, μCT scans of the tumor bearing 
tibia were conducted to identify osteolytic lesions.  RAP-011 treatment continued for four weeks 
(to study day 70) and a final μCT scan of the tibia was performed. On study day 70 there was a 
trend toward decreased number and size of osteolytic lesions in RAP-011-treated mice compared 
to control animals.  While osteolytic disease (most likely related to tumor burden) did progress in 
some of the treated mice, the majority of mice treated receiving RAP-011 developed less severe 
or no bone lesions compared to the untreated group.  Finally, treated animals also demonstrated 
an increased HCT, confirming the ability of RAP-011 to prevent CIA.  To summarize, treatment 
with RAP-011 has the ability to inhibit osteolytic lesions caused by tumors and to build new 
bone after cytotoxic chemotherapy with paclitaxel.  
Toxicology
Sotatercept (ACE-011) has been evaluated for toxicological effects in two species, Sprague-
Dawley rats and cynomolgus monkeys.  The dose levels ranged from 0.3 to 30 mg/kg in rats and 
from 1 to 50 mg/kg in monkeys.  These dose ranges were designed to support phase 1a single-
dose levels of 0.01 to 3.0 mg/kg IV and phase 1b multiple doses of 0.1 to 2 mg/kg (monthly, 
SC).  Weekly (rat and IV monkey studies) or every 2 week (SC monkey studies) dosing in 
animals was designed to provide continuous, but fluctuating serum concentrations of sotatercept 
(ACE-011), which would be mimicked by a one-month dosing interval in humans.  
Test article related hematological (increase in RBC parameters) and reproductive (epididymal 
granulomas, testicular degeneration, decreased sperm counts and motility, and change in 
ovarian/uterine weights) findings were expected pharmacodynamic effects of ActRIIA signal 
inhibition, likely mediated via modulation of erythropoiesis and FSH secretion, respectively.  
Unique to rats were adrenocortical and pancreatic findings.  Neither finding was associated with 
any clinical signs of adrenocortical (anorexia, weakness, gastrointestinal disturbances, serum 
electrolyte disturbances) or pancreatic (abnormal stool, weight loss) insufficiency.  Kidney 
Page 217 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
24
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
findings include membranoproliferative glomerulonephritis and/or tubulointerstitial nephritis in 
rats and monkeys.  The glomerulonephritis was presumed to be due to anti-sotatercept (ACE-
011) antibody deposition in the kidneys.  This presumption is supported by a robust anti-drug 
antibody response observed in rats.  However, high plasma concentrations of sotatercept (ACE-
011) in monkeys likely interfered with the immunogenicity assay, so the true incidence of anti-
drug antibodies is unknown in this species.  
The no-observed-adverse effects levels (NOAELs) from the 3 month SC studies were 3 and 30 
mg/kg in rats and monkeys, respectively.  Since the kidney findings were observed at all dose 
levels, the NOAEL from the 6 month monkey study is < 10 mg/kg.  A 9-month monkey study to 
evaluate the effects of lower concentrations of sotatercept (ACE-011) has been completed (refer 
to Potential Risks for Human Use).  
Summary of Clinical Experience
A011-01:  A Phase 1a Study in Healthy Postmenopausal Women (Single Dose)
Sotatercept (ACE-011) was first studied in a randomized, phase 1a, single dose, dose escalation 
study in healthy, postmenopausal females (Ruckle, 2009).  Sotatercept (ACE-011) was diluted in 
normal saline administered as an IV infusion (over approximately 1 hour) or as a SC injection on 
Day 1.  Dose levels were 0.01, 0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg IV and 0.03 and 0.1 mg/kg SC.  
A total of 48 subjects were enrolled; 5 active and 1 placebo at each of the IV and SC dose levels.  
All subjects were followed for 4 months following a single dose administration.  
The pharmacokinetics (PK) of sotatercept (ACE-011) was linear.  The overall mean exposure 
(AUC) was proportional to doses (0.01-3 mg/kg IV, 0.03-0.1 mg/kg SC).  Across IV doses 
ranging from 0.1 through 3.0 mg/kg, the mean clearance (CL) ranged from 0.092 to 0.128 
mL/h/kg, the volume of distribution ranged from 73.7 to 110 mL/kg, and the mean terminal half 
life in serum (t1/2, z) ranged from 23.7 to 31.8 days, with no apparent dependence on dose.  After 
SC administration of 0.03 and 0.1 mg/kg, sotatercept (ACE-011) was completely absorbed, and 
the mean t1/2, z was approximately 30 days, with no apparent dependence on dose.  
The most commonly occurring treatment-emergent adverse events (AEs; i.e., those occurring in 
more than 1 subject in any treatment group) were headache, infusion site reaction, injection site 
hemorrhage, and toothache.  The majority of the injection site reactions and injection site 
hemorrhages were in the first IV cohort and were related to infiltration of the IV site.  The 
majorities of treatment-emergent AEs was mild in severity and were judged to be unrelated to 
sotatercept (ACE-011).  No deaths, serious AEs (SAEs), or AEs leading to discontinuation were 
reported.  Changes in RBCs, Hgb, reticulocytes, liver function tests, glucose, uric acid, amylase 
and lipase occurred in some subjects.  Mild, transient elevations in pancreas enzymes, liver 
enzymes, or glucose were reported as AEs in five subjects.  
There were no clinically significant changes from baseline in vital signs, physical examination, 
endocrine function, or electrocardiogram (ECG) data.  Preservation of adrenal cortical function 
was monitored through evaluation of serum electrolytes (sodium and potassium levels) and 
through cortisol response to adrenocorticotropic hormone (ACTH) stimulation.  
No clinically significant findings were observed at doses up to 3.0 mg/kg IV, and sotatercept 
(ACE-011) was well tolerated in healthy, postmenopausal female volunteers in single dose levels 
up to 0.1 mg/kg SC and 3.0 mg/kg IV, the highest dose levels tested in this study.  
Page 218 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
25
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
A011-02:  A Phase 1b Study in Healthy Postmenopausal Women (Multiple Dose)
Sotatercept (ACE-011) was studied in a phase 1b, single-center, randomized, double-blind, 
placebo-controlled, multi-dose, dose-escalating study to evaluate the safety, tolerability and 
pharmacodynamics of sotatercept (ACE-011) in healthy postmenopausal women.  Four cohorts 
of 10 subjects each were planned at the following dose levels:  0.1, 0.3, 1.0, and 2.0 mg/kg 
administered SC.  Within each cohort, subjects were to be randomized to either active or placebo 
treatment in an 8:2 ratio.  Subjects were to receive one SC injection of sotatercept (ACE-011) or 
placebo every 28 days for a total of 4 doses.  All subjects were to be followed for 12 weeks after 
the last dose.  
The treatment phase of the study was terminated early after a dose-limiting pharmacodynamic 
effect was observed.  While on study, one subject in the 1.0 mg/kg cohort experienced an SAE of 
progressive and persistent hypertension that was attributed to a rapid and significant rise in Hgb
levels, up to 20 g/dL and HCT levels, up to 57.3%.  Due to symptoms of headaches, nausea, eye 
pain, dizziness and vomiting approximately one week following the second dose, the subject was 
hospitalized for monitoring and evaluation of her hypertension.  The head MRI, fundoscopy, and 
ECG performed were reported as normal and headache symptoms resolved following corrective 
treatment by phlebotomy.  The SAE resolved and the subject was discharged from the hospital 
the following day.  The hypertension was monitored closely and managed initially with 
antihypertensive medication.  The hypertension resolved by the end of the study without need of 
any antihypertensive medication.  The subject received aspirin prophylactically until the end of 
the study and continued taking ibuprofen as needed for headaches.  Further details can be found 
in the Investigator’s Brochure.  
Based on the magnitude of the hematopoietic response, the Sponsor suspended dose escalation to 
the 2.0 mg/kg dose level and further dosing in all cohorts as a result of this dose-limiting 
pharmacodynamic effect at the 1.0 mg/kg dose level.  In total, 31 subjects were enrolled and 
treated.  Dose levels of sotatercept (ACE-011) administered included 0.1, 0.3, and 1.0 mg/kg 
(Cohorts 1, 2, and 3 respectively).  All subjects randomized to active treatment in Cohort 1 
received all 4 planned doses of sotatercept (ACE-011).  Due to early discontinuation of study 
drug, subjects randomized to active treatment in Cohort 2 received 3 doses of sotatercept (ACE-
011), and subjects randomized to active treatment in Cohort 3 received 2 doses of sotatercept 
(ACE-011).  Subjects randomized to placebo treatment received between 1 and 4 doses of study 
treatment.  
Page 219 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
26
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
In the analysis of the data, after the administration of the first dose, a dose and time dependent 
increase in Hgb, HCT, and RBC values were observed (see Table 1 below for changes in Hgb 
levels):
Table 1:
A011-02:  A Phase 1b Study in Healthy Postmenopausal Women, 
Hemoglobin Evaluation
Evaluation Time Point
Mean Change from Baseline (g/dL)
Placebo
N=7a
Sotatercept 
(ACE-011)
0.1 mg/kg
N=8
Sotatercept 
(ACE-011)
0.3 mg/kg
N=8
Sotatercept 
(ACE-011)
1.0 mg/kg
N=8
Baseline Mean, pre-Dose 1
13.20
13.11
13.30
12.71
Day 8
0.17
0.68
0.85
1.21
Day 15
-0.27
0.43
0.44
1.75
Day 29
0.27
0.61
1.21
2.68b
Day 36
0.56
0.64
1.89
2.96
Day 43
-0.02
0.89
1.21
2.85
Day 57
0.27
1.28
1.64b
2.09
Day 64
0.53
1.11
2.49
2.21
Day 71
-0.10
1.34
2.09
1.66
Day 85
0.38
1.18b
2.55
1.86
Day 92
0.00c
1.04
1.60c
3.80c
Day 99
-0.20
1.21
3.20c
1.28c
Day 113
-0.02
1.30
1.29
1.04
Day 141
0.30
0.95
0.34
2.30
Day 169
0.20c
0.06
-
2.00c
aThe number of placebo subjects with data decreases over time as a result of the early discontinuation of the study 
(i.e., there were placebo subjects in each dosing cohort).  There were seven placebo subjects with data at baseline, 
Days 8, 15, and 36; six subjects with data at Days 29, 43, 57, and 85; five subjects with data on Days 71 and 113; 
four subjects with data on Day 64; three subjects with data on Day 141; two subjects with data on Day 99; and one 
subject with data on Days 92 and 169.  
bNumber of doses administered per treatment group: 0.1 mg/kg 4 doses; 0.3 mg/kg 3 doses; 1.0 mg/kg 2 doses.  
Data beyond this study day are considered follow-up results.  
cn=1
Other than the serious case of Hgb increase, no life-threatening events were reported.  The most 
notable AEs were those related to increases in hematologic laboratory measures in the 1.0 mg/kg 
dose group:  HCT, Hgb, and RBC count.  The AEs of increased Hgb and/or HCT were reported 
for seven of the eight subjects in this dose group.  These events were reported as mild or 
moderate elevations; all were considered probably related to study drug treatment.  Three of the 
Page 220 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
27
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
subjects in the 1.0 mg/kg group with elevated Hgb levels underwent phlebotomies and all Hgb 
elevations were resolved by the end of the follow-up period.  No erythroid lineage AEs were 
reported in the 0.1 or 0.3 mg/kg treatment groups.  
Paresthesia and dizziness were reported more frequently in the sotatercept (ACE-011) groups, 
though the events were < G 2 and generally not considered drug related.  Other frequently 
reported events (e.g.. fatigue, upper respiratory infection) did not appear to increase with dose 
and were generally mild.  
Hemoglobin levels for all subjects with elevations had returned to within normal limits by the 
end of the study.  
Adrenal cortical function was monitored through evaluation of serum electrolytes (sodium and 
potassium levels) and through cortisol response to adrenocorticotropic hormone (ACTH) 
stimulation.  All ACTH simulation test results were normal.  
The PK of sotatercept (ACE-011) were linear after SC administration.  Both AUC28d and Cmax 
were proportional to dose from 0.1 to 1 mg/kg following the first SC administration.  The t1/2, z 
of sotatercept (ACE-011) following the last dose in all three dose groups was identical, with 
mean t1/2, z being approximately 23 days.  Based on the one-compartmental modeling, the mean 
CL/F ranged from 3.05 to 3.90 mL/d/kg, the mean Vz/F ((apparent) volume of distribution) 
ranged from 97.47 to 103.03 mL/kg, with no apparent dependence on dose.  
Bone mineral density was assessed by dual-energy X-ray absorptiometry (DXA).  A dose-
dependent increase in the BMD of the total hip from baseline to end of study was observed, with 
a significant and rapid increase of 2.4% in the 1.0 mg/kg dose group, compared to a 0.7% 
decrease in the placebo group.  BMD results for lumbar spine showed slight increases of 0.4% to 
1.0% from baseline to study end in all active treatment groups, compared with a 0.5% decrease 
in the placebo group.  
A011-04:  A Phase 2a Study in Patients with Osteolytic Lesions of Multiple Myeloma / 
Preliminary Results
Study A011-04 is a phase 2a, multi-center, randomized, multiple-dose study to evaluate the 
safety, tolerability and efficacy of sotatercept (ACE-011) in subjects with osteolytic lesions of 
multiple myeloma (MM).  
In this study, subjects were randomized in a 4:1 ratio to one of three dose levels of sotatercept 
(ACE-011) (0.1, 0.3 and 0.5 mg/kg) or placebo, administered to subjects every 28 days by SC 
injection, for up to four doses over a 3-month period. Sotatercept (ACE-011) was evaluated in 
combination with the anti-myeloma therapy of melphalan (4 mg/m2 on days 1-7), prednisolone 
(40 mg/m2 on days 1-7) and thalidomide (100 mg per day) (MPT). The sites, Sponsor and 
Sponsor representatives were blinded to treatment assignment.  
Thirty subjects were randomized and received at least one dose of study medication:  6 subjects
received placebo, 8 subjects received 0.1 mg/kg sotatercept (ACE-011), 8 subjects received 0.3 
mg/kg sotatercept (ACE-011), and 8 subjects received 0.5 mg/kg sotatercept (ACE-011).  
Twenty six (86.7%) subjects completed the study.  One subject in the 0.1 mg/kg dose group and 
one subject in the 0.5 mg/kg dose group discontinued due to AEs.  One subject in the 0.1 mg/kg 
dose group withdrew consent and was discontinued, and one subject in the 0.3 mg/kg dose group 
was discontinued at the request of the investigator.  
Page 221 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
28
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
In this study, 50.0% of subjects were female and the mean (range) age was 60.9 (41 to 79) years.  
The mean time since diagnosis of MM was 3.3 years, the majority of subjects had stage III 
disease at screening (83.3%) and had received prior chemotherapy (93.3%).  Approximately
43.3% of subjects were receiving bisphosphonates at screening, which continued during the 
study.  
Fourteen out of 24 subjects (58%) who received study treatment (sotatercept [ACE-011]) did 
receive 3 doses or more (4 out of 8 subjects in the 0.5 mg/kg dose level, 5 out of 8 subjects in the 
0.3 mg/kg dose level and 5 out of 8 subjects in the 0.1 mg/kg dose level).  
Safety:  Overall, 22 (91.7%) subjects receiving sotatercept (ACE-011) and 4 (66.7%) subjects
receiving placebo reported at least one AE.  Among subjects receiving sotatercept (ACE-011), 
AEs were reported in 87.5%, 87.5%, and 100% of subjects in the 0.1 mg/kg, 0.3 mg/kg, and 0.5 
mg/kg dosing cohorts, respectively.  Treatment-related AEs (ie, those assessed by the 
Investigator as possibly, probably, or definitely related to treatment) were reported by 21 
(87.5%) subjects receiving sotatercept (ACE-011) and 4 (66.7%) receiving placebo.  Most 
subjects had AEs that were assessed as related to MPT:  21 (87.5%) subjects receiving 
sotatercept (ACE-011) and 4 (66.7%) subjects receiving placebo.  No AEs were assessed by the 
Investigator as related to the study medication alone (sotatercept (ACE-011) or placebo).  Two 
subjects had AEs assessed as possibly or probably related to study drug and possibly or probably 
related to MPT, one subject in the 0.1 mg/kg sotatercept (ACE-011) dose group (increased blood 
pressure; sudden death) and one subject in the 0.5 mg/kg sotatercept (ACE-011) dose group 
(hypertension).  Four subjects had SAEs, 1 (12.5%) subject in the 0.1 mg/kg sotatercept (ACE-
011) group and 3 (37.5%) subjects in the 0.5 mg/kg sotatercept (ACE-011) group.  Three 
subjects had SAEs that were assessed as treatment-related.  Of the 3 treatment-related SAEs, 2 
SAEs were assessed as possibly related to MPT and unrelated to sotatercept (ACE-011), and 1 
SAE (sudden death) was assessed as probably related to MPT and possibly related to sotatercept 
(ACE-011).  One subject in the 0.5 mg/kg sotatercept (ACE-011) dose group discontinued study 
drug due to episodes of atrial fibrillation assessed as possibly related to MPT and unrelated to 
sotatercept (ACE-011).  
Table 2 summarizes the most frequent AEs ≥5% in all treatment groups and Table 3 is a 
summary of SAEs reported.  
Page 222 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
29
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
Table 2:
Summary of Adverse Events Reported in Greater Than or Equal To 5
Percent of Patients Overall
Sotatercept (ACE-011) Treatment Group
Preferred 
Terma
Placebo
(N=6)
0.1 mg/kg
(N=8)
0.3 mg/kg
(N=8)
0.5 mg/kg
(N=8)
All Sotatercept
(ACE-011)
(N=24)
Any 
Grade
Grade ≥3
Any 
Grade
Grade ≥3
Any 
Grade
Grade ≥3
Any 
Grade
Grade ≥3 Any Grade Grade ≥3
Neutropenia
4 (66.7%) 1 (16.7%) 4 (50.0%) 2 (25.0%) 6 (75.0%) 2 (25.0%) 6 (75.0%) 3 (37.5%) 16 (66.7%) 7 (29.2%)
Leukopenia
0
0
3 (37.5%) 1 (12.5%) 1 (12.5%) 0
1 (12.5%) 1 (12.5%) 5 (20.8%)
2 (8.3%)
Granulo-
cytopenia
0
0
2 (25.0%) 1 (12.5%) 1 (12.5%) 1 (12.5%) 1 (12.5%) 1 (12.5%) 4 (16.7%)
3 (12.5%)
Anaemia
0
0
1 (12.5%) 1 (12.5%) 1 (12.5%) 1 (12.5%) 2 (25.0%) 1 (12.5%) 4 (16.7%)
3 (12.5%)
Respiratory 
tract 
infection
0
0
1 (12.5%) 1 (12.5%) 1 (12.5%) 0
1 (12.5%) 0
3 (12.5%)
1 (4.2%)
Thrombo-
cytopenia
0
0
1 (12.5%) 0
0
0
2 (25.0%) 1 (12.5%) 3 (12.5%)
1 (4.2%)
Pyrexia
0
0
1 (12.5%) 0
1 (12.5%) 0
1 (12.5%) 0
3 (12.5%)
0
Blood 
pressure 
increased
0
0
1 (12.5%)*1 (12.5%)*0
0
1 (12.5%) 0
2 (8.3%)
1 (4.2%)
Bronchitis
1 (16.7%) 0
0
0
1 (12.5%) 0
1 (12.5%) 0
2 (8.3%)
0
Compression 
fracture
0
0
0
0
1 (12.5%) 0
1 (12.5%) 0
2 (8.3%)
0
Pathological 
fracture
0
0
1 (12.5%) 0
0
0
1 (12.5%) 1 (12.5%) 2 (8.3%)
1 (4.2%)
aAdverse events were those that were treatment-emergent, defined as newly acquired or worsened during or after 
administration of first dose of study medication. A patient with multiple occurrences of an AE counted only once 
under each preferred term.  
*Indicates the adverse event was assessed by the investigator as related (possibly, probably, or definitely) to study 
drug (sotatercept (ACE-011) or placebo).  
Page 223 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
30
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
Table 3:
Summary of SAEs Reported
Study Treatment
Age (y) / 
Sex / Race
Preferred Term
(Verbatim Term)
[Severity / Gradea]
Study Dayb
at Onset
Outcome
(duration)
Relationship to Study 
Treatment
0.1 mg/kg 
Sotatercept 
(ACE-011) and 
MPT
Sudden death
(sudden death)
103
Death
Sotatercept (ACE-011):  
possibly
MPT:  probably
0.5 mg/kg 
Sotatercept 
(ACE-011) and 
MPT
Pain in extremity
(pain in leg)
[severe / G 3]
128
Ongoing at 
end of study
Sotatercept (ACE-011):  not 
related
MPT:  not related
Pathological fracture
(pathological fracture of 
femur)
[severe / G 3]
130
Ongoing at 
end of study
Sotatercept (ACE-011):  not 
related
MPT:  not related
0.5 mg/kg 
Sotatercept 
(ACE-011) and 
MPT
Pneumonia
(pneumonia)
[moderate / G 2]
9
Resolved
(12 days)
Sotatercept (ACE-011):  not 
related
MPT:  possibly
0.5 mg/kg 
Sotatercept 
(ACE-011) and 
MPT
Atrial fibrillation
(atrial fibrillation)
[life-threatening / G 4]
6
Resolved
(1 day)
Sotatercept (ACE-011):  not 
related
MPT:  possibly
F= female; M = male; MPT = melphalan, prednisolone, and thalidomide; NCI CTCAE, v3.0 = National Cancer 
Institute Common Terminology Criteria for Adverse Events, version 3.0; y = years
abased on NCI CTCAE, v3.0.  
bRelative to first dose of study drug.  
Following analysis of the central laboratory data, increases in Hgb values were observed within 
28 days after administration of the first dose of sotatercept (ACE-011)/placebo and sustained for 
≥ 28 days from baseline at any time as presented in Table 4.  
Table 4:
Number of Subjects with an Increase in Hgb from Baseline at Any Time and 
Sustained for Greater Than or Equal To 28 Days
Increase in Hgb
Dose Sotatercept (ACE-011)/Placebo
mg/kg
N=8
0.3 mg/kg
N=8
0.5 mg/kg
N=8
Placebo
N=6
Overall
N=30
≥ 1.0 g/dL
4
3
7
2
16
≥ 1.5 g/dL
2
3
3
1
9
≥ 2.0 g/dL
1
3
2
0
6
Taken together, these data, suggest a beneficial pharmacodynamic effect of sotatercept (ACE-
011) on erythropoiesis in a patient population with cancer CIA.  
Potential Risks for Human Use
Nonclinical studies to determine the safety of sotatercept (ACE-011) have been conducted in 
cynomolgus monkeys and Sprague-Dawley rats.  Many of the observed effects in these studies 
Page 224 of 791
PPD
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
31
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
were as a result of the expected biologic activity of activin inhibition and can be summarized as a 
dose-dependent decrease in sperm count and motility secondary to FSH suppression as well as 
reversible increases in RBC parameters due to the effects on erythroid differentiation factor 
(activin).  
The most significant toxicity findings are listed below:  

Hematological findings (increase in RBC parameters – RBCs, Hgb, HCT) were 
observed across all studies.  Associated with the increase in RBC parameters were 
increases in reticulocytes and decreases in mean corpuscular hemoglobin (MCH) and 
mean corpuscular hemoglobin concentration (MCHC).  The increase in RBC 
parameters is an anticipated effect of sotatercept (ACE-011) treatment and is being 
targeted as a therapeutic intervention for conditions associated with anemia.  

In the 6- and 9-month monkey studies, glomerulonephritis and/or tubulointerstitial 
nephritis were observed in monkeys administered ≥ 10 mg/kg administered 
subcutaneously (SC) every 2 or 4 weeks. At 2.6 mg/kg administered SC every 4 
weeks for 9 months, kidney findings were limited to a single incidence of 
tubulointerstitial nephritis. The NOAEL in the 9-month study was considered to be 1 
mg/kg every 4 weeks. Serum exposure in monkeys at the 1 mg/kg dose is estimated 
to be ~1.3-fold greater than the projected serum exposure in humans at the maximum 
proposed human dose of 61 mg every 6 weeks.  In the single- and multiple-dose 
studies in healthy postmenopausal women, there have been no changes in serum 
chemistry or urinalysis profiles suggestive of kidney injury. Subjects administered 
sotatercept (ACE-011) should continue to be closely monitored.  

In the 9-month monkey study, treatment-related findings in the choroid plexus 
included:  perivascular accumulations of foamy macrophages and intimal thickening 
of small arteries and arterioles primarily at 10 mg/kg administered every 2 weeks as 
well as an increased incidence of small, focal aggregates of mononuclear 
inflammatory cells at all dosages. Findings at 1 mg/kg were limited to mononuclear 
cell infiltrates and were not adverse. 

Adrenal gland congestion or necrosis was observed in rats but not in monkeys.  The 
finding was more pronounced in female rats and appeared following either one month 
of IV dosing or 3 months of SC dosing.  Although the current data suggest adrenal 
toxicity may be specific to rats, the relevance of the adrenal findings to humans is 
uncertain.  

Elevations in liver enzymes (alanine aminotransferase [ALT], aspartate 
aminotransferase [AST], and/or alkaline phosphatase), as well as triglycerides, were 
observed sporadically in rats and monkeys treated with sotatercept (ACE-011).  There 
were no histological correlates in the liver, and often a dose-response relationship was 
not observed.  The relevance of these findings to sotatercept (ACE-011) treatment is 
uncertain; however, these endpoints will continue to be monitored in the clinic.  

Pregnancy and Lactation

Due to the potential for effects on hormones in the pituitary, including FSH, in 
addition to possible direct effects on fetus, there may be potential effects on the 
Page 225 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
32
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
fetus. Delays in fetal development (decreased fetal weights and delays in 
ossification) were observed at doses ≥15 mg/kg (15-fold greater on a mg/kg basis 
than the maximum proposed human dose of 60 mg every 6 weeks assuming a 60 
kg person). In addition, at 50 mg/kg (100-fold the maximum proposed human 
dose), there was an increase in late fetal death coupled with an overall increase in 
post implantation loss and a reduction in live litter size, as well as an increase in 
the incidence of developmental variations of supernumerary ribs with 
corresponding increases and decreases in thoracic and lumbar vertebrae, 
respectively. No fetal malformations were observed in this study at dosages up to 
50 mg/kg. The NOAEL for embryofetal development effects was 5 mg/kg 
(~5-fold greater than the maximum proposed human dose of 60 mg every 6 weeks 
assuming a 60 kg person) based on reduced fetal weights and associated delays in 
ossification. Although the risks for embryofetal development effects are 
considered relatively low given the large safety margins, precautions should still 
be taken to protect females of childbearing potential. Nonclinical studies on 
breast milk have not been done.  

If sotatercept (ACE-011) is taken during pregnancy, a teratogenic effect in 
humans cannot be ruled out.  Therefore, all sotatercept (ACE-011) protocols 
describe pregnancy prevention requiring females of child-bearing potential to use 
highly effective methods of birth control.  In addition, since it is unknown if 
sotatercept (ACE-011) is found in breast milk, breast feeding is prohibited in all 
protocols.  

Fertility

In male rats, sperm granulomas and testicular degeneration were observed 
histologically.  In addition, sperm analysis revealed a reduction in sperm counts 
and motility as well as sperm fragmentation in isolated animals (2/10 males) at 
doses of 30 mg/kg IV.  Sperm fragmentation was also noted in 2/5 males 
administered 10 mg/kg IV at the end of the recovery period.  Overall, there was 
some evidence of recovery (motility similar to controls) at the end of the 4-week 
recovery period.  There was no evidence of a treatment-related impact on 
reproductive organs (testes, ovary, uterus) of monkeys in the toxicity studies; 
however, the monkeys on these studies, were too immature to fully assess the 
potential impact on reproductive organs.  The NOAEL for reproductive effects 
(testicular or ovarian) was 1 mg/kg IV.  Serum exposure (AUC28d) in rats at the 
NOAEL was estimated to be ~ 8,000 µg·hr/mL based on the single-dose IV 
pharmacokinetic study in rats (Report TR148), ~ 2-fold greater than the serum 
exposure observed in humans at the maximum proposed dose of 60 mg every 6 
weeks (estimated AUC28d ~ 4548 μg·hr/mL). 

In summary, in view of the potential risks sotatercept (ACE-011) treatment has on 
fertility, sotatercept (ACE-011) is targeted toward patient groups for whom the 
potential benefits outweigh the perceived risks.  
Because of the potential risks sotatercept (ACE-011) treatment has on fertility, sotatercept (ACE-
011) was first studied in healthy postmenopausal in two completed phase 1 clinical trials.  In 
Page 226 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
33
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
addition, due to the potential for effects on hormones in the pituitary, levels of growth hormone, 
ACTH, and thyroid stimulating hormone (TSH) were monitored closely in the phase 1 studies.  
Completed studies in humans carried out in postmenopausal females showed a dose-dependent 
decrease in circulating levels of FSH, with mean levels in the multi-dose study in the two higher 
dose groups remaining below baseline at study end.  FSH will continue to be evaluated in 
ongoing studies.  No abnormal effects of sotatercept (ACE-011) on growth hormone, ACTH, and 
TSH and kidney toxicities were observed.  
Based on the safety data from the two completed phase 1 studies, single doses of sotatercept 
(ACE-011) up to 3.0 mg/kg IV and multiple doses of sotatercept (ACE-011) up to 0.3 mg SC 
were generally well-tolerated in healthy postmenopausal women.  Consistent with observations 
from nonclinical safety studies, many of the observed pharmacodynamic effects in the phase 1 
clinical studies could be attributed to the expected biologic activity of activin inhibition, i.e., 
dose-dependent decrease in circulating levels of FSH, and transient, reversible effects on RBC 
parameters.  In Study A011-02 one subject experienced persistent, progressive hypertension and 
headaches approximately 1 week following her second dose of 1.0 mg/kg sotatercept (ACE-011)
SC that were attributed to a rapid and significant rise in Hgb levels.  The hypertension was 
reported as an SAE.  
In regards to the above safety concerns, appropriate vitals, hematologic, clinical chemistry and 
endocrine testing will be closely monitored in this clinical study.  There may be an effect of 
delayed wound healing, thus subjects with major surgeries within 30 days prior to study 
initiation will be excluded.  As with all biologics there is the potential for anti-drug antibodies 
that can be associated with increased drug clearance and hypersensitivity reactions.  Although no 
current evidence of neutralizing anti-drug antibodies formation was seen in two completed phase 
1 clinical trials, anti-drug antibody formation will be monitored in this clinical study.  
Please refer to the Investigator Brochure for further detailed information on the available 
pharmacology, toxicology, drug metabolism, clinical studies and AE profile of sotatercept 
(ACE-011).  
Page 227 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
34
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
2.
STUDY OBJECTIVES
2.1.
Primary Objective

Part 1:  To determine an effective dose of sotatercept (ACE-011) showing a 
hematopoietic response in the treatment of CIA in metastatic NSCLC subjects.  

Part 2:  To assess transfusion rate following initiation of sotatercept (ACE-011)
treatment.  
2.2.
Secondary Objectives
Part 1 and Part 2:

To estimate the effect of sotatercept (ACE-011) treatment on objective response rate 
(ORR), time to progression (TTP), progression free survival (PFS) and overall 
survival (OS) in metastatic NSCLC subjects with CIA.  

To evaluate the safety and tolerability of sotatercept (ACE-011) treatment in
metastatic NSCLC subjects with CIA.  

To determine the PK of sotatercept (ACE-011) in subjects with metastatic NSCLC 
receiving platinum-based chemotherapy.  

To evaluate the hematopoietic response and its duration associated with sotatercept 
(ACE-011) treatment.  

To evaluate the effect of sotatercept (ACE-011) treatment on the quality of life 
(QoL) of NSCLC subjects with CIA.  
2.3.
Exploratory Objectives
Part 1 and Part 2:

To estimate the effect of sotatercept (ACE-011) treatment on bone metabolism in 
NSCLC subjects with CIA.  

To explore the relationship between sotatercept (ACE-011) exposure and response 
(hematology, biomarkers, and other clinical outcomes as appropriate).  

To evaluate the expression of Activin A and other proteins/biomarkers (including 
myostatin and follistatin) related to sotatercept (ACE-011) mechanism of action in 
blood.

To evaluate the expression of Activin A and other proteins/biomarkers in archival 
tumor tissue.

To assess renal function biomarkers
Data from exploratory objectives may not be included in the Clinical Study Report.  
Page 228 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
35
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
3.
STUDY ENDPOINTS
3.1.
Primary Endpoint(s)
Part 1: Dose Finding
The following are decision rules for dose determination in Part 1 in order to move forward to 
Part 2:

After completion of two doses of sotatercept (ACE-011), a hematopoietic response in 
approximately 70% of subjects, in at least one or more treatment arms.  

Hematopoietic response is defined as an increase in Hgb of ≥ 1.0 g/dL above the 
study baseline value for 28 consecutive days, in the absence of RBC transfusions 
and/or ESAs.  In order to determine the optimal dose of sotatercept (ACE-011) to be 
used in Part 2, evaluation of hematopoietic response will be determined from 
sotatercept (ACE-011) Dose 1/ Day 1 through and including Dose 2/Day 43 (prior to 
Dose 3).  

In addition to the hematopoietic response, the safety profile, dose modifications and 
extent of exposure in each dosing level will be taken into account to determine the 
study dose to be used in Part 2.  
Hematopoietic response will be determined by laboratory analysis.  
Part 2:  Phase 2b/3 Double-Blind

Rate of RBC transfusion within four months following the date of randomization to 
sotatercept (ACE-011)/placebo treatment
3.2.
Secondary Endpoint(s)

Safety (type, frequency, and severity [National Cancer Institute (NCI) Common 
Terminology for Adverse Events (CTCAE) current active minor version 4.0] of 
adverse events

TTP 

PFS (including at 6 and 12 months)

OS (at 12 months and up to 24 months)

ORR

Duration of hematopoietic response

Sotatercept (ACE-011) concentration in serum 

Non-compartmental PK parameters for sotatercept (ACE-011) (Part 1 only)

QoL assessment (FACIT Fatigue Scale [Version 4]) and LCSS questionnaire (Hollen, 
1995)
Page 229 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
36
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
3.3.
Exploratory Endpoint(s)

Change in serum and urine bone biomarkers, including osteocalcin (OC), serum bone 
specific alkaline phosphatase (BSAP), procollagen type 1 N-terminal propeptide 
(P1NP), C-terminal type 1 collagen telopeptide (CTX) and tartrate-resistant acid 
phosphatase isoform-5b (TRACP-5b), the urine bone biomarker (urine N-telopeptide 
[uNTX]) related to activin or sotatercept (ACE-011) mechanism of action  

Change in BMD (DXA scans of lumbar spine and hip)

Time to first symptomatic skeletal related event (SRE) defined as pathologic fracture, 
clinical need for radiation therapy, surgery to bone or spinal cord compression

A population PK model for sotatercept (ACE-011)  

A population pharmacodynamic model describing Hgb response as a function of time, 
sotatercept (ACE-011) exposure, and subject characteristics 

Expression of Activin A and other protein/biomarkers related to sotatercept (ACE-
011) mechanism of action in blood (including myostatin and follistatin) and in 
archival tumor tissue in the NSCLC population 

Change in renal function biomarkers via urinalysis measuring urine albumin / 
creatinine ratio, urine protein / creatinine ratio and other biomarkers of glomerular 
and/or tubular injury - urine kidney injury molecule-1 (KIM-1), urine trefoil factor 3 
(TTF3), urine cystatin C and + or – urine β2-microglobulin
Page 230 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
37
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
4.
OVERALL STUDY DESIGN
4.1.
Study Design 
This is a single-blind, randomized, phase 2a, dose-ranging study of sotatercept (ACE-011)
therapy followed by a phase 2b/3, double-blind, randomized, placebo-controlled study of 
sotatercept (ACE-011) for CIA in subjects with metastatic NSCLC treated with platinum-based 
chemotherapeutic regimens.  
The study will consist of two parts.  Part 1 is a dose finding segment in which subjects will be 
randomized to one of three sotatercept (ACE-011) dose treatment arms.  Continuous monitoring 
of safety data will be conducted, including the review of Part 1 data to define the recommended 
sotatercept (ACE-011) dose to be used in Part 2, the phase 2b/3, double-blind, randomized 
placebo-controlled segment of the study.  
A DMC will monitor the conduct of the study.
Part 1 is planned to be conducted at selected US sites.  The study will be extended to additional 
global sites for the conduct of Part 2.  
Study treatment is defined as sotatercept (ACE-011) in Part 1 and sotatercept (ACE-011)/placebo 
in Part 2.  
Three starting sotatercept (ACE-011) dose levels, 15.0, 30.0, and 45.0 mg, were selected for Part 
1 of the study. Up to approximately 90 subjects will be randomized to one of the following 
sotatercept (ACE-011) dose levels, with 10-30 subjects per arm:

Sotatercept (ACE-011) 15.0 mg SC

Sotatercept (ACE-011) 30.0 mg SC
Analysis of safety data will be performed following the treatment of at least 10 subjects at the 
15.0 mg dose level and 10 subjects at the 30.0 mg dose level, with each subject having received 
at least of one dose of sotatercept (ACE-011), plus a 12-week follow-up period from first dose.  
Following this analysis, the addition of a third dose level:

Sotatercept (ACE-011) 45.0 mg SC
to the randomization schema will be determined.
Each dose level will be administered every 42 days for four doses.  
In Part 2, a total of 750 subjects will be randomized to receive either sotatercept (ACE-011) (at 
the dose determined in Part 1) or placebo, at a ratio of 1:1:

375 subjects will receive sotatercept (ACE-011) (at the dose determined in Part 1)

375 subjects will receive placebo
Each dose of sotatercept (ACE-011) or placebo will be administered every 42 days for four
doses; two additional doses may be given at the discretion of the Investigator.  
Page 231 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
38
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
Part 2 will be performed in two stages. In the first stage, approximately 180 subjects will be 
randomized to receive sotatercept (ACE-011), at the dose determined from Part 1, or placebo at a 
ratio of 1:1.  An interim futility assessment based on transfusion rate at 4 months will be 
performed as described in Section 10.8.  It is expected that accrual will continue during the 
interim assessment period, with up to an additional 570 subjects randomized to achieve full study 
accrual. 
The Treatment Period for Part 1 is up to approximately six months and for Part 2 up to nine
months.  Subjects who enter the Post Treatment Follow-Up Period will be followed for up to 6 
months from their last dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.  All 
subjects will continue to be followed for TTP and PFS up to 12 months from their first dose of 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo or until progression of their NSCLC, 
whichever comes first.  
Survival data will be collected monthly for up to 24 months following the subject’s first dose of 
sotatercept (ACE-011) in Part 1 or sotatercept (ACE-011)/placebo in Part 2.  
At the time of randomization all subjects must be receiving their first regimen of first-line 
platinum-containing chemotherapy, given every three weeks, for the treatment of metastatic 
NSCLC.  Subjects may have already received up to 3 cycles of this first-line platinum-based 
regimen to be eligible for the study.  Subjects are expected to be eligible to continue to receive ≥ 
2 additional platinum-based chemotherapy cycles while on study treatment prior to initiating any 
maintenance chemotherapy for the treatment of metastatic NSCLC. 
Stratification and randomization will be performed utilizing a validated interactive voice 
response system (IVRS).  

In Part 1, subjects will be randomized to one of three sotatercept (ACE-011) dose levels 
and will be stratified by:
1. Baseline Hgb level 

6.5 to < 9.0 g/dL

9.0 to < 11.0 g/dL
2. Type of platinum-based chemotherapy (cisplatin versus carboplatin)

In Part 2 subjects will be randomized to receive either sotatercept (ACE-011) or placebo 
and will be stratified by:
1. Baseline Hgb level 

6.5 to < 9.0 g/dL

9.0 to < 11.0 g/dL
2. Type of platinum-based chemotherapy (cisplatin versus carboplatin)
3. NSCLC histology (Squamous NSCLC vs. Non-Squamous NSCLC)
4. ECOG Performance Status 0-1 vs. 2
Page 232 of 791
088VGY

088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
40
ACE-011-NSCL-001 1.0 FINAL: 22MAR2011
4.1.1.
Sotatercept (ACE-011) Dose Modification, Reduction and Escalation Rules
Subjects should have Hgb and blood pressure measured (confirmed by two measurements 
obtained five minutes apart) prior to each dose of study drug.  The Investigator must adhere to 
the following Hgb and blood pressure-based dose modification rules for sotatercept (ACE-011)
or sotatercept (ACE-011)/placebo for the subject’s second dose of study treatment and beyond.  
Sotatercept (ACE-011) Dose Modification Rules:
Hemoglobin < 11g/dL
(per local* lab value) 
Hemoglobin ≥11g/dL
(per local* lab value) 
Hypertension ≥SBP 150 mm Hg and ≥DBP 100 mmHg
*Note:  Local laboratory assessments are allowed in cases when timely results are needed (e.g., randomization, 
study treatment and chemotherapy dosing decisions, hematology assessments between clinic visits).  Whenever 
possible a “split” sample should also be forwarded to the central laboratory for analysis. Local laboratory data 
should be collected in the eCRF.  
< 2.0 g/dL increase within a 
dosing period or a ≥ 2.0 g/dL 
increase not sustained for a 28 
day period since last dosing day 
≥ 2.0 g/dL increase sustained for a 
28 day period since last dosing day2
Note: ≥ 3.0 g/dL increase sustained 
for a 28 day period since last dosing 
day requires a two level dose 
reduction.  
< 2.0 g/dL increase within a 
dosing period or a   ≥ 2.0g/dL 
increase not sustained for a 28 
day period since last dosing day
≥ 2.0g/dL increase sustained for a 28 day 
period since last dosing day2
Note: ≥ 3.0g/dL increase sustained for a 28 
day period since last dosing day requires a 
two level dose reduction.  If Hgb is > 15.0 
g/dL, sustained for 7 days, subject is to be 
discontinued from treatment2. 
Dose Delay5
Continue
Dosing1
(Part 1 only-
Dose Escalation 
Table 6)
Continue Dosing 
with Dose 
Reduction 
Table 5:
Sotatercept 
(ACE-011) and 
Sotatercept (ACE-
011)/Placebo Dose 
Reduction Levels
Dose Delay3
Dose Delay 
then, Dose 
Reduction4
Page 234 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
41
ACE-011-NSCL-001 1.0 FINAL: 22MAR2011
1If Hgb increase ≥ 1.0 but < 2.0 g/dL, dose remains the same.
For Part 1 only:  if the RBC transfusion was given > 7 days following the previous dose of sotatercept (ACE-011), 
the subsequent dose of sotatercept (ACE-011) will be increased one dose level (Refer to sotatercept (ACE-011)
Dose Escalation Levels- Table 6).  Hemoglobin level must be < 11 g/dL AND hypertension  < SBP 150mm Hg 
and < DBP 100 mm Hg on the day of dosing.  Sotatercept (ACE-011) should not be administered within 7 days 
post RBC transfusion.  
For Part 2:  Subjects who have received an RBC transfusion in the past 42 days should continue at the same
sotatercept (ACE-011)/placebo dose if the transfusion was given greater than 7 days from the previous dose of 
sotatercept (ACE-011)/placebo AND the Hgb level is < 11 g/dL AND hypertension is < SBP 150mm Hg and < 
DBP 100 mm Hg on the day of dosing.  Sotatercept (ACE-011)/placebo should not be administered within 7 days 
post RBC transfusion.  
2Hemoglobin increases of > 2 g/dL sustained for a 28 day period since last dosing day should be confirmed on the 
dosing day, 7, 14 , 22 (after first dose of study treatment) and 28 days after dosing, and reviewed in comparison to 
Hgb level on previous dosing day.  Any Hgb increase of ≥3.0 g/dL sustained for 28 days will require a subsequent 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dose reduction of two dose levels (Refer to sotatercept 
(ACE-011) and sotatercept (ACE-011)/Placebo Dose Reduction Levels (Table 5).  A second Hgb increase of ≥3.0 
g/dL sustained for 28 days, following a two level dose reduction, will require the subject discontinue from study 
treatment.  If Hgb is > 15.0 g/dL (sustained for a 7 day period, confirmed by laboratory assessment) subject is to 
be discontinued from treatment.  (See Section 8.2.3 Discontinuation)  
3Sotatercept (ACE-011)or sotatercept (ACE-011)/placebo should be delayed until Hgb is < 11g/dL and 
hypertension < SBP 150mm Hg and < DBP 100 mm Hg.. Dosing can commence at ≥7 days after the originally 
planned sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dose that was delayed.  Subsequent sotatercept 
(ACE-011) or sotatercept (ACE-011)/placebo doses will then begin 42 days following this revised treatment dose
date.
A delayed sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dose is defined as a dose not administered > 4 
days from the planned dosing date (due to Hgb ≥11.0 g/dL, hypertension  < SBP 150mm Hg and < DBP 100 mm 
Hg and/or sotatercept (ACE-011) related toxicity).  
4Sotatercept (ACE-011)or sotatercept (ACE-011)/placebo should be delayed as above in foot note (3), a reduced 
dose as above in foot note (2) of sotatercept (ACE-011) will be administered based on the evaluation of the Hgb
and blood pressure at that time.  
5Sotatercept (ACE-011)or sotatercept (ACE-011)/placebo should be held until hypertension resolves to < SBP 
150mm Hg and < DBP 100 mm Hg and may then be resumed beginning seven days after the previous planned
scheduled treatment visit as above in foot note (3).  
Page 235 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
42
ACE-011-NSCL-001 1.0 FINAL: 22MAR2011
Table 5:
Sotatercept (ACE-011) and Sotatercept (ACE-011)/Placebo Dose Reduction 
Levels
When required, per dose modification rules above, sotatercept (ACE-011) dose(s) in Part 1 and 
sotatercept (ACE-011)/placebo dose(s) in Part 2 should be reduced as follows:  
Dose Schedule
Sotatercept (ACE-011) or
Sotatercept (ACE-011)/placebo
Dose Reduction*
#1
Dose Reduction*
#2
Dose Reduction*
#3
Every 42 days-
45.0 mg
38.0 mg
33.0 mg
28.0 mg
Every 42 days-
30.0 mg
26.0 mg
22.0 mg
18.0 mg
Every 42 days-
15.0 mg
13.0 mg
11.0 mg
9.0 mg
*Note:  Any Hgb increase of ≥3.0 g/dL will require a subsequent sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo dose reduction of two dose levels.  A second Hgb increase of ≥3.0 g/dL, sustained for 28 days,
following a two-level dose reduction will require the subject discontinue from study treatment.  
Dosing visits are on Day 1 and repeated every 42 days, for four doses.  An additional two doses 
(total of 6 doses) may be given only during Part 2 at the discretion of the Investigator.  
Blood pressure (confirmed by two measurements obtained five minutes apart) and Hgb values 
must be evaluated prior to dosing at each dosing day for consideration in administration of 
sotatercept (ACE-011) and sotatercept (ACE-011)/placebo.  
The dose level for the initial dose reduction will be maintained unless subsequent dose 
reductions need to be administered upon evaluation of the dose modification rules listed above.  
A dose level may not be increased following a dose reduction.  
Dose reduction steps and the subsequent administration of the reduced dose(s) of sotatercept 
(ACE-011) or sotatercept (ACE-011)/placebo will be conducted in a manner that will preserve 
the blinded status of the original treatment group of each subject.  In Part 2, subjects in the 
placebo group who are designated by their treating physician to undergo dose reduction will 
continue to receive placebo.  
Placebo will be administered at the same volume as the corresponding sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo dose reduction.  
Sotatercept (ACE-011) Dose Escalation Levels:
The following dose escalation rules apply for sotatercept (ACE-011) dose(s) in Part 1 only.  
Dose escalations are not allowed in Part 2:

Less than 1.0 g/dL increase in Hgb in response to prior sotatercept (ACE-011) dose

Hgb level must be < 11.0 g/dL and hypertension < SBP 150mm Hg and 
      < DBP 100 mm Hg

Dose escalation to begin at next treatment visit 
Page 236 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
43
ACE-011-NSCL-001 1.0 FINAL: 22MAR2011

Sotatercept (ACE-011) should not be administered ≤7 days from the date of RBC 
transfusion.  
Subjects who have received an RBC transfusion should receive a one level dose increase of 
Sotatercept (ACE-011) at the subsequent visit per the escalation table below.  
Table 6:
Sotatercept (ACE-011) Dose Escalation Levels (Part 1 Only) 
Dose Schedule
Sotatercept (ACE-
011)
Dose Increase  #1
Dose Increase  #2
Dose Increase #3
Every 42 days-
45.0 mg
50.0 mg
55.0 mg
61.0 mg
Every 42 days-
30.0 mg
33.0 mg
36.0 mg
40.0 mg
Every 42 days-
15.0 mg
17.0 mg
20.0 mg
23.0 mg
Blood pressure (confirmed by two measurements obtained five minutes apart ) and Hgb values 
must be evaluated prior to dosing at each dosing day for consideration in administration of 
sotatercept (ACE-011) and sotatercept (ACE-011)/placebo.  
Dose increase steps and the subsequent administration of the increased dose(s) of sotatercept 
(ACE-011) will be conducted in a manner that will preserve the blinded status of the original 
treatment group of each subject.  
4.2.
Study Design Rationale
The A011-01, A011-02 and A011-04 studies have shown that dosing with sotatercept (ACE-011)
resulted in a significant increase in hematopoietic parameters, beginning rapidly and sooner than 
would be expected from a stimulation of the erythropoietic effect by an ESA.  This fact, as well 
as the fairly rapid and persistent elevation in the relative Hgb, HCT, and RBC counts of the 
majority of subjects from each dose of sotatercept (ACE-011), suggests an entirely novel 
mechanism of RBC production.  
Treatment of subjects with metastatic lung cancer with myelosuppressive platinum-based 
chemotherapy is frequently associated with anemia.  Chemotherapy induced anemia is a 
significant problem for subjects with cancer, causing fatigue and reduced quality of life 
(Groopman, 1999).  Subjects with CIA are currently treated with blood transfusion and/or ESAs 
(NCCN Guidelines, 2009).  However, with these treatment options CIA is still an area of major 
medical morbidity.  Erythropoiesis-stimulating agents can successfully mitigate transfusion need 
in a proportion of these subjects, but concerns have emerged regarding apparent negative effects 
on survival and/or tumor progression in certain patient populations.  
Page 237 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
44
ACE-011-NSCL-001 1.0 FINAL: 22MAR2011
4.2.1.
Fixed Dose
Sotatercept (ACE-011) dose will be fixed at the indicated levels regardless of the subject’s body 
weight.  The fixed dosing approach is supported by an exploratory analysis of the relationship 
between body weight and sotatercept (ACE-011) PK in the previous studies (A011-01, A011-02, 
and A011-04).  In healthy postmenopausal women (Studies A011-01 and A011-02), body weight 
was estimated to explain less than 2.5% of intersubject variability for the two PK parameters 
dictating sotatercept (ACE-011) exposure, clearance and central volume of distribution, 
compared to an overall intersubject variability of 17.4% -25.5% for the two parameters.  In MM 
subjects (Study A011-04), body weight had no apparent effect on sotatercept (ACE-011)
exposure.  Because the Hgb response is dependent on sotatercept (ACE-011) exposure and 
because body weight is not a major source for the intersubject variability of sotatercept (ACE-
011) exposure, a fixed dosing approach is considered to be appropriate for the current study.  
4.2.2.
Dosing Schedule
The dosing schedule of once every 42 days (6 weeks) is proposed for the current study.  This 
dosing schedule was chosen by taking into consideration the rapid and prolonged Hgb response
to sotatercept (ACE-011) as well as the dosing schedule for the platinum-based chemotherapies.  
The Hgb-increasing effect of sotatercept (ACE-011) was usually evident approximately 1 week 
after a SC dose and remained detectable through 6-8 weeks.  In addition, as platinum-based 
chemotherapy is often administered once every 3 weeks, a once every 6 weeks dosing schedule 
allows administration of sotatercept (ACE-011) at the same visit for the chemotherapy, which is 
convenient to both subjects and study sites.  
4.2.3.
Starting Dose Levels in Part 1
Three starting dose levels, 15.0, 30.0, and 45.0 mg, were chosen for Part 1 of the study.  
Selection of these doses is primarily based on the safety and exposure-response data observed in 
MM subjects under the standard MPT chemotherapy, who received up to four doses of 
sotatercept (ACE-011) at 0.1, 0.3, or 0.5 mg/kg (Study A011-04).  In these subjects, sotatercept 
(ACE-011) had an acceptable safety profile and caused exposure-dependent Hgb response.  
Further, there was no relationship observed between an increase in blood pressure and the 
maximal sotatercept (ACE-011) concentration or the maximal Hgb rise within 28 days of the 
first dose (Report A011-04-CP).  The three starting dose levels approximate the average doses 
received by a 70 kg subject over a 6-week interval (10.5 mg, 31.5 mg, and 52.5 mg, respectively) 
in the A011-04 study.  
In Study A011-04, four MM subjects received at least three sotatercept (ACE-011) doses at 0.5 
mg/kg every 4 weeks without a dose interruption, and none of them was reported to have an AE 
related to sotatercept (ACE-011).  In this study, the starting dose level of 45.0 mg (during the 
dose finding Part 1) will be implemented only after at least 10 subjects at each lower dose level
(10 subjects at the 15.0 mg dose level and 10 subjects at the 30.0 mg dose level) have been 
evaluated as well as following DMC review of safety data and assessment of dose effects on Hgb 
levels.  
In addition, in the current NSCLC study, during the first 6-week treatment period for a 70 kg 
subject receiving the starting dose at 45.0 mg, the sotatercept (ACE-011) exposure (Cmax, day 1-43
and AUC1-43) is projected to be approximately 10% lower than the exposure for the dose regimen 
Page 238 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
45
ACE-011-NSCL-001 1.0 FINAL: 22MAR2011
of 0.5 mg/kg once every 4 weeks.  Afterwards, safety measures (Hgb and blood pressure) will be 
used to guide the adjustment of the second dose and beyond.  Thus, the use of the 45.0 mg 
starting dose in the current study is not anticipated to significantly compromise subject safety.  
In the current study, the 45.0 mg group will have the highest starting dose, and it may be titrated 
up to 61.0 mg for the last dose (Dose 4).  Assuming a 70 kg subject who receives the maximal 
amount of dose during the entire study (i.e., starting at 45.0 mg followed by dose escalation 
every 6 weeks to 50.0, 55.0, and 61.0 mg for Doses 2, 3, and 4, respectively), the projected 
cumulative AUC during the treatment period (168 days) would be approximately 60% of the 
steady state AUC cumulated during the same period at the NOAEL level of 1 mg/kg (given 
every 4 weeks for a total of 6 doses) as reported in the 9-month, repeat-dose toxicity study in 
monkeys.  The projected highest Cmax for the current study would be less than 50% of the steady 
state Cmax in the monkey study.  
4.2.4.
Evaluation of Dosing Schema via Modeling/Simulation
The performance of the proposed dosing schema (three fixed starting dose levels, 6-week dosing 
interval, and dose adjustment rules [see Section 4.1.1 for details]) for this study was evaluated 
via PK/pharmacodynamic modeling/simulation.  A tentative mechanistic PK/pharmacodynamic
model for Hgb was developed using PK and Hgb data from healthy postmenopausal women and 
the model was extended to include MM subjects as a sub-population.  The model was required to 
appropriately reproduce the observed PK and Hgb profiles in MM subjects.  Monte Carlo 
simulations of the Hgb response to sotatercept (ACE-011) in a hypothetical anemic population 
(6.5 ≤ baseline Hgb < 11 g/dL; body weight 47 – 108 kg) were performed using the model 
parameterized with preliminary PK and pharmacodynamic parameters from MM subjects.  In 
this simulation analysis, efficacy refers to an Hgb increase > 1 g/dL from the baseline for 28 
consecutive days while safety refers to both the absolute Hgb levels and the rate of Hgb increase.  
The simulation predicts that the desired efficacy would be achieved 6 weeks after the second 
dose in approximately 70% subjects of the 45 mg group and 6 weeks after the last dose in >70% 
subjects of the 30 mg group.  Further, the simulation predicts the Hgb level would be maintained 
under 12 g/dL in 90% subjects and under 13 g/dL in 95% of subjects during the course of the 
study (Figure 2).  No subjects are predicted to have a Hgb level above the upper limit of the 
normal range for Hgb (16 g/dL).  Approximately 6% subjects are predicted to have an Hgb rise 
> 2 g/dL within 28 days of the first dose, mostly from the 45.0 mg group (4%); however, the 
fraction of subjects with an Hgb rise > 3 g/dL per 28 days is predicted to be similar between the 
three dose groups (approximately 2.5% for each group).  
Page 239 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
46
ACE-011-NSCL-001 1.0 FINAL: 22MAR2011
Figure 2:
Simulated Hemoglobin Response in the Hypothetical Anemic Population
Time (days)
0
50
100
150
200
250
300
Hb (g/dL)
6
8
10
12
14
Time (days)
0
50
100
150
200
250
300
6
8
10
12
14
Time (days)
0
50
100
150
200
250
300
6
8
10
12
14
Starting dose = 15 mg
Starting dose = 30 mg
Starting dose = 45 mg
The middle solid lines represent the median Hgb level.  The top and bottom solid lines represent the Hgb level at 5% 
and 95% percentile, respectively.  The area between 5% and 95% percentiles represents 90% prediction interval.  
The straight dot lines represent the Hgb level of 12 g/dL.  The arrows indicate the dosing time of sotatercept (ACE-
011).  The two level dose reductions upon ≥ 3 g/dL increase sustained for 28 days of a dose (Table 5) was not 
included in the simulation.  
4.3.
Study Duration
To evaluate sequence and study timelines, please see the Table of Events (see Section 5).  
Approximately 60-90 subjects in Part 1 and 750 subjects in Part 2 will be randomized prior to 
receiving the fourth cycle of platinum-based chemotherapy for metastatic NSCLC.  Each subject 
will be on the study for approximately 12 – 15 months (including the Screening Period, the 
Treatment Period, and the Post Treatment Follow-Up Period).  The Treatment Period is 
approximately 6 to 9 months (four to six doses every 42 days) with a Post Treatment Follow-Up 
Period of six months from the subjects’ last dose of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo.  Subjects who discontinue treatment early will still continue to the Post Treatment 
Follow-Up Period for six months from their last dose of sotatercept (ACE-011) or sotatercept 
(ACE-011)/placebo.  
All subjects will continue to be followed for TTP and PFS up to 12 months from their first dose 
of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo or until progression of their NSCLC, 
whichever comes first.  All subjects will continue to be followed for survival up to 24 months 
from their first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.
Page 240 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
47
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
5.
TABLE OF EVENTS
Table 7:
Sotatercept (ACE-011) NSCLC Schedule of Assessments
Treatment Period
Screening 
Period
Sotatercept (ACE-011)
Dose 1 Schedule
(± 3 days)
Sotatercept (ACE-011)
Subsequent
Doses 2  through 6 Schedule
(± 3 days)
Post Treatment Follow-Up Period
(± 1 week)
Survival
(±1wk)
Assessments
Day -28
to
Day -1
D1
D8
D15 D22 D29
D43/
D1
D8
D15 D29
D43 
Post Last 
Dose/End 
of Study
Txt
1
Month
2
Month
3
Month
4
Month
5
Month
6
Month/
Study
DCu
Survival
Informed Consent
X
Inclusion/Exclusion Criteria
X
Complete Medical History
X
Cancer History and Prior Therapiesa
X
Prior ESA and RBC transfusion historya
X
X
Clinical visits (*study treatment visit)
X
X*
X
X
X*
X
X
X
X
X
X
X
X
ECOG Performance Status
X
X
X
X
X
X
X
X
X
X
X
X
Vital Signs / Blood Pressureb
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Height (at randomization only)/Weight
X
X
X
X
X
X
X
X
X
X
X
X
X
12-Lead Electrocardiogram (ECG) –
Part 1c
X
X
X
X
X
12-Lead Electrocardiogram (ECG) –
Part 2c
X
X
X
Pregnancy Testingd
X
X
X
X
X
X
X
Xd
Page 241 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
48
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
Table 7:
Sotatercept (ACE-011) NSCLC Schedule of Assessments (Continued)
Treatment Period
Screening 
Period
Sotatercept (ACE-011)
Dose 1 Schedule
(± 3 days)
Sotatercept (ACE-011)
Subsequent
Doses 2  through 6 Schedule
(± 3 days)
Post Treatment Follow-Up Period
(± 1 week)
Survival
(±1wk)
Assessments
Day -28
to
Day -1
D1
D8
D15 D22 D29
D43/
D1
D8
D15 D29
D43 
Post Last 
Dose/End 
of Study
Txt
1
Month
2
Month
3
Month
4
Month
5
Month
6
Month/
Study
DCu
Survival
Hematologye
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Absolute Reticulocyte Counte
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Serum Chemistryf
X
X
X
X
X
X
X
X
X
X
X
X
X
Serum Creatinine and Creatinine 
Clearanceg
X
X
X
X
X
X
X
X
X
X
X
X
X
Serum Iron, TIBC, Transferrin and Serum 
Ferritin, Vitamin B12 and RBC Folate 
Levelsh
X
Xh
X
Serum Erythropoietin (**Full PK subjects 
post first dose only)i
X
X
X**
X
X** X**
X
Xi
X
X
Urinalysis and Renal Biomarkersj
X
X
X
X
X
X
X
X
X
X
X
X
FSH and LH – Males and Females
X
X
X
X
X
X
X
X
Dihyroepiandosterone and Testosterone 
(Free & Total) - Males Only 
X
X
X
X
X
X
X
X
Estrogen and Estradiol & Menstrual 
Status - Females Only
X
X
X
X
X
X
X
X
TSHk
X
X
Xk
X
Page 242 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
49
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
Table 7:
Sotatercept (ACE-011) NSCLC Schedule of Assessments (Continued)
Treatment Period
Screening 
Period
Sotatercept (ACE-011)
Dose 1 Schedule
(± 3 days)
Sotatercept (ACE-011)
Subsequent
Doses 2  through 6 Schedule
(± 3 days)
Post Treatment Follow-Up Period
(± 1 week)
Survival
(±1wk)
Assessments
Day -28
to
Day -1
D1
D8
D15 D22 D29
D43/
D1
D8
D15 D29
D43 
Post Last 
Dose/End 
of Study
Txt
1
Month
2
Month
3
Month
4
Month
5
Month
6
Month/
Study
DCu
Survival
Sotatercept (ACE-011) drug antibody test
(pre-dose)
X
X
X
X
X
X
Bone  Biomarkers (BSAP, OC, P1NP, 
CTX, TRACP-5b and uNTX)l
(**Full PK subjects post first dose only)
X
X** X**
X** X**
X
X
X
Bone Imaging (DXA)m (Optional in 
Selected Centers)
X
X
Activin A and other proteins/biomarkers 
in Blood (pre-dose study treatment in a 
subset of subjects)
X
X
X
X
Activin and other proteins/biomarkers in 
archival tumor tissue
X
Pharmacokinetics–
Part 1 and Part 2)n
Refer to Table 8 and Table 9 – Schedule of Pharmacokinetic Assessments
Tumor Assessmentso
X
< Every 9 weeks ± 1 week or per standard of care at study site
QoL Assessment
(LCSS and FACIT Fatigue Scale)p
X
X
X
X
X
X
X
X
X
X
X
X
X
Adverse Events
X
All AEs regardless of causality up to 6 weeks (42 days) post last dose of study treatment, after day 43 of last dose 
only AEs assessed as related to study treatment are to be reported
Concomitant Medications
(including ESAs and transfusions)
X
X
X
X
X
X
X
X
X
Page 243 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
50
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
Table 7:
Sotatercept (ACE-011) NSCLC Schedule of Assessments (Continued)
Treatment Period
Screening 
Period
Sotatercept (ACE-011)
Dose 1 Schedule
(± 3 days)
Sotatercept (ACE-011)
Subsequent
Doses 2  through 6 Schedule
(± 3 days)
Post Treatment Follow-Up Period
(± 1 week)
Survival
(±1wk)
Assessments
Day -28
to
Day -1
D1
D8
D15 D22 D29
D43/
D1
D8
D15 D29
D43 
Post Last 
Dose/End 
of Study
Txt
1
Month
2
Month
3
Month
4
Month
5
Month
6
Month/
Study
DCu
Survival
Concomitant Procedures
X
X
X
X
X
X
X
X
X
Hospitalizations (Record)
X
X
X
X
X
X
X
X
X
Randomization
X
Administer 
Sotatercept (ACE-011)/Perform Drug 
Accountabilityq
X
X
Platinum-based Chemotherapyr
X
Dosing of allowed regimen(s) per standard practice
Maintenance Therapys
Dosing of allowed regimen(s) per standard practice
Overall Survivalv
X
Post Treatment Anti-Neoplastic Therapy
X
X
X
X
X
X
X
X
aInclude NSCLC history, date of original diagnosis, clinical stage at Screening and date of metastases and metastatic site involvement.  Record prior ESA history,
starting at diagnosis of NSCLC.  Record RBC transfusion history, starting from diagnosis of metastatic NSCLC, at a minimum of two months prior to 
randomization.  
bVital signs (including heart rate, seated blood pressure, and temperature) will be measured at Screening and all subsequent clinical visits, on Day 29 post 
sotatercept (ACE-011) or sotatercept (ACE-011)/ placebo dose, at Treatment Discontinuation, and at Study Discontinuation.  Blood pressure should be 
confirmed by two measurements obtained five minutes apart Investigators are to report any clinically significant abnormal findings as adverse events.  
Page 244 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
51
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
cECG to be performed as follows:  For Part 1:  At Screening,   Day 1 Dose 1 pre and post sotatercept (ACE-011) dose,  Day 8 post dose 1, every sotatercept 
(ACE-011) dosing Visit (post-dose) and at end of study treatment (day 43 post last dose).  
For Part 2:  At Screening, Day 1 Dose 1 pre and post sotatercept (ACE-011)/placebo dose and at end of study treatment (day 43 post last dose).  
dFemales of childbearing potential (FCBP) only:  A female of childbearing potential is a sexually mature woman who has not undergone a hysterectomy or who 
has not been postmenopausal for at least 24 consecutive months (i.e. who has had menses at some time in the preceding 24 months).  A medically supervised 
pregnancy test with a minimum sensitivity of 25mIU/ml must be performed within 3 days prior to the start of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo administration (Day 1) once the subject has been on effective contraception for at least 28 days and be performed within 3 days prior to dose 
administration of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo during the treatment period.  Subjects must agree to use highly effective birth 
control measures (e.g., oral contraceptives or two forms of barrier method birth control) during study participation and for at least 112 days following the last 
dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.  Pregnancy test will be performed at Study Discontinuation if date is ≤112 days following 
the last dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.  
eHematology laboratory evaluations (RBC count, Hgb, HCT, WBC count and differential, ANC, MCV, platelet count and reticulocyte count).  Hemoglobin 
should be tested prior to dosing with sotatercept (ACE-011) or sotatercept (ACE-011)/placebo to ensure levels are within normal limits and that sotatercept 
(ACE-011) dose modification rules are followed as outlined in Section 4.1.1.  Any laboratory evaluations may be repeated more frequently if clinically 
indicated.  In addition, RBC, Hgb, and reticulocyte counts will be included at each timepoint within the full PK assessment (Part 1).  
fSerum chemistry laboratory evaluations (sodium, potassium, chloride, CO2 (bicarbonate), calcium, magnesium, phosphorus, BUN, creatinine, glucose, amylase, 
lipase, albumin, total protein, alkaline phosphatase, bilirubin [total and direct], AST/SGOT, ALT/SGPT, LDH and uric acid) if clinically significant any or all 
laboratory evaluations may be reported as AE and repeated more frequently.  
gCreatinine clearance (per Cockcroft-Gault formula) every 2 weeks during the treatment period, every month (except month 1) during the post treatment follow-
up period and at study discontinuation .  
hSerum Iron, TIBC, Transferrin, Serum Ferritin, Vitamin B12 and RBC Folate to be performed at Screening, pre-last dose of sotatercept (ACE-011) or
sotatercept (ACE-011)/placebo and end of study treatment (day 43 post last dose).  
iErythropoietin – collected at day 15 following first 2 doses of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.  For full PK assessment, weekly after 
first dose of sotatercept (ACE-011).  
jUrine collection for:  Urine albumin, urine albumin creatinine ratio, urine protein creatinine ratio and other renal biomarkers of glomerular and/or tubular injury.  
kTSH – collected at screening, on Day 1 of only the first and second dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo and at 2 month post-
treatment follow-up visit. 
lBone Biomarkers- Collected for full PK subjects prior to dose 1, weekly following dose 1, prior to dose 2 ,  post last dose day 43 and month 3 post treatment 
follow-up visit.  For all other subjects collected prior to dose 1,  prior to dose 2 ,  post last dose day 43 and month 3 post treatment follow-up visit.  Biomarker 
serum samples should be consistently collected early morning. The urine sample should not be from the first morning void.  
mDual Energy X-ray Absorptiometry (DXA) scan to evaluate overall health on approximately 200 subjects at selected US site(s).  Performed at Screening, and 
Month 3 during the Post Treatment Follow-Up Period.  
Page 245 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
52
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
nPharmacokinetics (Part 1):  Blood samples will be collected to evaluate the blood or serum concentrations of sotatercept (ACE-011).  Approximately 10 
subjects at each sotatercept (ACE-011) dose level, 15.0, 30.0 and 45.0 mg, will have full PK sampling.  In addition, RBC, Hgb, and reticulocyte counts will be 
collected at each time point (excluding the 4-hour time point on Day 1) from Day 1 to Day 43 after the first dose within the full PK assessment.  Subjects not 
participating in the optional full PK assessment will participate in the sparse PK assessment. 
Pharmacokinetics (Part 2):  Sparse PK blood samples will be collected to evaluate the blood or serum concentrations of sotatercept (ACE-011) in 
approximately 300 (40%) of 750 subjects.  Sotatercept (ACE-011) doses 5 and 6 will have pre-dose Day 1 PK (if applicable).  
REFER TO Table 8 and Table 9, SCHEDULE OF PHARMACOKINETIC ASSESSMENTS.  
oTumor assessments:  Screening period tumor assessments may be performed up to six weeks prior to randomization.  Also, historical tumor assessment data,
from prior to the initiation of platinum-based chemotherapy through the screening period, will be collected.  Following randomization, tumor assessments will 
be performed at a maximum of every 9 weeks (± 7 days) or per standard of care at the study site, starting from the date of the previous (screening period) tumor 
assessment and following the chemotherapy schedule.  
pQoL assessments, FACIT Fatigue Scale (Version 4) and LCSS questionnaire, to be completed by the subject upon arrival at clinic and prior to any study 
procedures or testing at all visits, as indicated in the schedule, and at Study Discontinuation/One-Year Follow-Up Visit.  
qSotatercept (ACE-011) or sotatercept (ACE-011)/placebo dosing repeats every 42 days and will start after the subject begins an every 3 week platinum-based 
chemotherapy regimen.  The first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo should be given within 7 days prior to or within 7 days 
following Day 1 of a platinum-based chemotherapy cycle.  Subsequent doses of Sotatercept (ACE-011) or sotatercept (ACE-011)/placebo can be 
administered at any time point during the chemotherapy cycle. 
Administration of subsequent cycles of chemotherapy, including dose reductions and dose delays, should not affect the sotatercept (ACE-011) or sotatercept 
(ACE-011)/placebo dosing schedule, unless determined to be necessary by the Investigator.  If there is a chemotherapy dose delay, sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo administration does not need to be delayed until start of next chemotherapy cycle. 
If sotatercept (ACE-011) or sotatercept (ACE-011)/placebo is administered on the same day as chemotherapy, sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo should be given prior to chemotherapy administration.
rEvery 3-week platinum-based chemotherapy is to be administered based on guidelines for administration according to manufacturer’s recommendations and 
standard clinical practice.  Type of chemotherapy and dosing will be recorded.  If sotatercept (ACE-011) or sotatercept (ACE-011)/placebo is administered on 
the same day as chemotherapy, sotatercept (ACE-011) or sotatercept (ACE-011)/placebo should be given prior to chemotherapy administration.
sPemetrexed or erlotinib maintenance therapy is to be administered based on guidelines for administration according to manufacturer’s recommendations and 
standard clinical practice. 
tDay 43 (6 weeks) post last dose corresponds to the end of Treatment Period.  Subjects who discontinue the sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo Treatment Period early will continue to the Post Treatment Follow-Up Period and be followed for up to 6 months after their last dose of 
sotatercept (ACE-011)/placebo.  
uStudy Discontinuation visit should occur 12 months after starting treatment with sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.
vSurvival data will be collected monthly, via telephone contact, following the Study Discontinuation visit for an additional 12 months (up to 24 months after first 
dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo).  
Page 246 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
53
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
Table 8:
Schedule of Pharmacokinetic Assessments (Part 1)
Scheduled Time
Time relative to 
Sotatercept (ACE-011)
Part 1a,b
Collection 
Windowe
Full PKc
Sparse PKd
Dose 1, D1
pre-Dose 1
X
X
-2  to  0 hour
Dose 1, D1
4 hours after Dose 1
X
X
±1 hour
Dose 1, D5
4 days after Dose 1
X
-
± 1 day
Dose 1, D8
7 days after Dose 1
X
X
± 1 day
Dose 1, D11
10 days after Dose 1
X
-
± 1 day
Dose 1, D15
14 days after Dose 1
X
X
± 1 day
Dose 1, D22
21 days after Dose 1
X
-
± 1 day
Dose 1, D29
28 days after Dose 1
X
X
± 1 day
Dose 1, D36
35 days after Dose 1
X
-
± 1 day
Dose 1, D43 (Dose 2, D1)
pre-Dose 2
X
X
± 2 days
Dose 2, D8
7 days after Dose 2
X
-
± 2 days
Dose 2, D15
14 days after Dose 2
X
-
± 2 days
Dose 2, D43 (Dose 3, D1)
pre-Dose 3
X
X
± 2 days
Dose 3, D8
7 days after Dose 3
X
-
± 2 days
Dose 3, D15
14 days after Dose 3
X
-
± 2 days
Dose 3, D43 (Dose 4, D1)
pre-Dose 4
X
X
± 2 days
Dose 4, D8
7 days after Dose 4
X
-
± 2 days
Dose 4, D15
14 days after Dose 4
X
-
± 2 days
Dose 4, D29
28 days after Dose 4
X
-
± 3 days
Last Dose, D43 
42 days after final dose 
X
X
± 3 days
PTf Follow up, 1 month
72 days after final dose
X
-
± 1 week
PT Follow up, 2 month
102 days after final dose
X
-
± 1 week
PT Follow up, 3 month
132 days after final dose
X
X
± 1 week
PT Follow up, 4 month
162 days after final dose
X
-
± 1 week
PT Follow up, 5 month
192 days after final dose
X
X
± 1 week
a Notes about PK sampling times:

For subjects participating in full PK sampling, RBC, Hgb and reticulocyte counts will be collected at each 
time point (excluding the 4-hour time point on Day 1) from Day 1 to Day 43 post first sotatercept (ACE-
011) dose.  Erythropoietin and bone biomarkers will be collected at D1, D8, D15, D22, D29, and D43 post 
first sotatercept (ACE-011) dose.  If the time points for RBC, Hgb, reticulocyte, erythropoietin and bone 
biomarkers overlap with the time points defined in Table 7, only one sample is required.  

For subjects who discontinue the treatment early, PK blood sample collection will be continued during the 
follow-up period.  
bAt each time point, collect approximately 2 mL of blood.  After collection, allow the blood to clot at room 
temperature for approximately 1 hour and then centrifuge the blood sample at room temperature for 10 min (1100-
1300 g) to obtain serum.  
cTo be collected for approximately 30 subjects (approximately 10 subjects in each dose group).  
dTo be collected in other subjects.  
eFor subjects who participate in full PK sampling only.  The collection window for sparse PK samples will be the 
same as the visit window defined in Table 7.  
fPT = Post Treatment
Page 247 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
54
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
Table 9:
Schedule of Pharmacokinetic Assessments (Part 2)
Scheduled Time
Time relative to 
Sotatercept (ACE-
011)/placebo dose
Sparse PKa,b,c
Collection Windowd
Dose 1, D1
pre-Dose 1
X
-2  to  0 hour
Dose 1, D1
4 hours after Dose 1
X
±1 hour
Dose 1, D8
7 days after Dose 1
X
± 3 day
Dose 1, D15
14 days after Dose 1
X
± 3 day
Dose 1, D29
28 days after Dose 1
X
± 3 day
Dose 1, D43 (Dose 2, D1)
pre-Dose 2
X
± 3 days
Dose 2, D43 (Dose 3, D1)
pre-Dose 3
X
± 3 days
Dose 3, D43 (Dose 4, D1)
pre-Dose 4
X
± 3 days
Dose 4, D43 (Dose 5, D1)
pre-Dose 5 
X
± 3 days
Dose 5, D43 (Dose 6, D1)
pre-Dose 6 
X
± 3 days
PTe Follow up, 3 month
132 days after final dose
X
± 1 week
PT Follow up, 5 month
192 days after final dose
X
± 1 week
a For subjects who discontinue the treatment early, PK blood sample collection will be continued during the follow-
up period.  
bAt each time point, collect approximately 2 mL of blood.  After collection, allow the blood to clot at room 
temperature for approximately 1 hour and then centrifuge the blood sample at room temperature for 10 min (1100-
1300 g) to obtain serum.  
cTo be collected for approximately 300 (40%) of 750 subjects (approximately 150 subjects in each arm).
dExcept for Day 1 (Dose 1, D1), the collection window will be the same as the visit window defined in Table 7.  
ePT = Post Treatment
Page 248 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
55
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
6.
PROCEDURES
Screening Period (Day -28 to Day -1)
Prior to screening, subjects must sign an informed consent.  Potentially protocol-eligible subjects 
will be evaluated for the inclusion and exclusion criteria for the Treatment Period of this study.  
All screening assessments must be completed within 28 days prior to randomization.  Screening 
period tumor assessments and tumor evaluation documentation, as per RECIST criteria (Version 
1.1) (Appendix A), must be performed within 6 weeks prior to randomization.  Historical tumor 
assessment data, from prior to the initiation of platinum-based chemotherapy through the 
screening period, will be collected.  Hematology and chemistry laboratory assessments should be 
performed within 14 days of randomization.  
The assessments and procedures that will be performed during the Screening Period are outlined 
in the Table of Events (see Section 5) and include:

Informed consent

Assessment of inclusion / exclusion criteria

Complete medical history including history of cardiac, renal and thromboembolic 
events

NSCLC history, including date of original diagnosis, histopathology, clinical stage at 
screening, date of metastatic stage and site involvement

Prior ESA treatment history starting from initial diagnosis of NSCLC

RBC transfusion history starting from diagnosis of metastatic NSCLC at a minimum 
of up two months prior to randomization

ECOG performance status

Vital signs including height, weight, heart rate, seated systolic and diastolic blood 
pressure, and temperature.  

12-lead electrocardiogram (ECG)  

Medically supervised pregnancy test, with a minimum sensitivity of 25 mIU/ml, for 
females of childbearing potential (FCBP) to be assessed within 3 days prior to 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo administration

Serum chemistry, hematology, absolute reticulocyte count to be assessed within 14 
days of randomization

Creatinine clearance (per Cockroft-Gault formula) within 14 days prior to study 
treatment administration

Serum iron, total iron binding capacity (TIBC), transferrin and serum ferritin

Vitamin B12 and RBC folate levels

Serum erythropoietin
Page 249 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
56
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011

Urinalysis

FSH (include current menstrual cycle status for pre-menopausal female subjects) and 
LH – both males and females 

Dihyroepiandosterone and Testosterone (free and total) – males only

Estrogen and estradiol – females only

TSH

Bone imaging – DXA scan

Tumor Assessment - Screening period tumor assessments and tumor evaluation 
documentation, as per RECIST criteria (Version 1.1), must be performed within 6 
weeks prior to randomization to this study.  Also, historical tumor assessment data,
from prior to the initiation of platinum based chemotherapy through the screening 
period, will be collected.  

QoL Assessment (FACIT Fatigue Scale [Version 4]) and LCSS questionnaire  

Documentation of concomitant medications / procedures / hospitalizations

Documentation of concomitant platinum-based chemotherapy
Treatment Period (Day 1/Dose 1 of study treatment to Day 43 post last study treatment 
dose)
Results from screening evaluations must be reviewed prior to randomization to confirm subject 
eligibility.  
In Part 1 (the dose-ranging portion of the study), subjects who meet all eligibility criteria will be 
randomized by a single-blind procedure utilizing IVRS to receive one of the following 
sotatercept (ACE-011) dose levels, with 10-30 subjects per arm:

Sotatercept (ACE-011) 15.0 mg SC

Sotatercept (ACE-011) 30.0 mg SC
Analysis of safety data will be performed following the treatment of at least 10 subjects at the 
15.0 mg dose level and 10 subjects at the 30.0 mg dose level, with each subject having received 
at least of one dose of sotatercept (ACE-011), plus a 12-week follow-up period from first dose.  
Following this analysis, the addition of a third dose level:

Sotatercept (ACE-011) 45.0 mg SC
to the randomization schema will be determined.
Each dose level will be administered every 42 days for up to four doses.  

In Part 2, subjects meeting all inclusion and exclusion criteria will enter into the 
Treatment Period and be randomized by a double-blind procedure utilizing IVRS to 
receive sotatercept (ACE-011) or placebo (1:1 ratio).  

A subject will be considered randomized once a unique multi-digit subject 
identification number has been assigned by IVRS.  
Page 250 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
57
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
Following randomization, subjects will receive SC doses of sotatercept (ACE-011) or sotatercept 
(ACE-011)/placebo every 42 days during the Treatment Period, as specified in the Table of 
Events (see Section 5).  
In Part 1, the Treatment Period will last approximately 6 months, where subjects randomized to 
sotatercept (ACE-011) will receive treatment on Day 1 every 42 days for a planned 4 doses.  
In Part 2, the Treatment Period will last approximately 6 to 9 months, where subjects 
randomized to sotatercept (ACE-011)/Placebo will receive treatment on Day 1 every 42 days for 
a planned 4 doses with an additional two doses of sotatercept (ACE-011)/placebo allowable, at 
the discretion of the Investigator, for a total of up to 6 doses.  
The assessments and procedures that will be performed during the Treatment Period are outlined 
in the Table of Events (see Section 5).  

Updated prior ESA and RBC transfusion history which may have occurred between 
the screening visit and randomization

ECOG performance status

Vital signs including weight, heart rate, seated systolic and diastolic blood pressure, 
and temperature

ECG 

Medically supervised pregnancy test, with a minimum sensitivity of 25 mIU/ml, for 
FCBP within 3 days prior to sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo administration.  

Serum chemistry, hematology, absolute reticulocyte count.  

Hematology laboratory evaluations (RBC count, Hgb, HCT, WBC count and 
differential, mean corpuscular volume [MCV], absolute neutrophil count [ANC], 
platelet count and reticulocyte count) will be collected weekly after the first dose 
of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo and at subsequent 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo doses collected at 7, 14
days and 28 days post-dose.   

Within full PK assessment, RBC, Hgb and reticulocyte counts are collected at 
each time point; erythropoietin and bone biomarkers at weekly intervals post first 
dose of study treatment.  

Creatinine clearance will be assessed every 14 days.  

Serum iron, total iron binding capacity (TIBC), transferrin and serum ferritin at last 
dose and 43 days after last dose of study treatment

Vitamin B12 and RBC folate levels at last dose and 43 days after last dose of study 
treatment

Serum erythropoietin

Urinalysis
Page 251 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
58
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011

FSH (include current menstrual cycle status for premenopausal female subjects) and 
LH – both males and females 

Dihyroepiandosterone and Testosterone (free and total)– males only 

Estrogen and estradiol – females only 

TSH  

Serum for sotatercept (ACE-011) drug antibody test (pre-dose on the day of 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo administration)

Bone or other potential mechanistic or disease-related proteins/biomarkers 

Activin A and other sotatercept (ACE-011)-related proteins/biomarkers

in blood, including myostatin and follistatin:
o
pre- dose on Day 1 and Day 8 after first dose of sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo
o
pre-dose on Day 1 subsequent dosing visits

in archival tumor tissue

Tumor Assessment and Response Evaluation, as per RECIST criteria (Version 1.1), 
(performed ≥ every 9 weeks ± one week or per standard of care at the study site,
starting from the previous [screening] tumor assessment) and following the 
chemotherapy schedule

Pharmacokinetics

QoL Assessment (FACIT Fatigue Scale (Version 4)) and LCSS questionnaire

Evaluation and all AE/SAE reporting (regardless causality)

Documentation of concomitant medications / procedures (including use of ESAs and 
all transfusions) / hospitalizations

Documentation of concomitant platinum-based chemotherapy and/or maintenance 
therapy

Administration of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo at:  Day 1 
every 42 days 
Subjects who discontinue from the Treatment Period early will enter the Post Treatment Follow-
Up Period and be followed for 6 months after their last dose of sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo.  Upon completion of the Post Treatment Follow-Up Period, 
subjects will have a discontinuation visit and be followed for survival for up to 24 months from 
their first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.  
Post Treatment Follow-Up Period (Day 43 post last dose of study treatment to six months 
post last dose of study treatment)
Following completion or early discontinuation from the Treatment Period, subjects will enter the 
Post Treatment Follow-Up Period and continue to be followed for 6 months after their last dose 
Page 252 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
59
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo. Visits will occur every month.  The 
assessments and procedures that will be performed during this period are outlined in the Table of 
Events (see Section 5) and include:

ECOG performance status

Vital signs including weight, heart rate, seated systolic and diastolic blood pressure, 
and temperature.  

ECG – end of study treatment (day 43 post last dose)

Medically supervised pregnancy test, with a minimum sensitivity of 25mIU/ml, for 
FCBP

Serum chemistry, hematology, absolute reticulocyte count

Creatinine clearance 

Serum iron, total iron binding capacity (TIBC), transferrin and serum ferritin – end of 
study treatment (at day 43 post last dose)

Vitamin B12 and RBC folate levels – end of study treatment (at day 43 post last dose)

Serum erythropoietin

Urinalysis

FSH (include current menstrual cycle status for pre-menopausal female subjects) and 
LH – both males and females 

Dihyroepiandosterone and Testosterone (free and total)– males only 

Estrogen and estradiol – females only

TSH (at 2 month end of treatment follow-up visit)

Serum for sotatercept (ACE-011) drug antibody test (pre-sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo dose)

Bone or other potential mechanistic or disease-related proteins/biomarkers 

Bone imaging – DXA scan (at 3 month end of treatment follow-up visit)

Activin A and other sotatercept (ACE-011) related proteins/biomarkers, including 
myostatin and follistatin, in blood at 1 month end of treatment follow-up visit)

Pharmacokinetics

Tumor Assessment and Response Evaluation, as per RECIST criteria (Version 1.1), 
(performed ≥ every 9 weeks ± one week or per standard of care at the study site, and 
following the chemotherapy schedule

QoL Assessment (FACIT Fatigue Scale (Version 4)) and LCSS questionnaire

Evaluation and reporting of all AEs regardless of causality (up to 6 weeks after last 
dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo).  After 6 weeks 
post last dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo, only AEs 
Page 253 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
60
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
assessed as related to sotatercept (ACE-011) or sotatercept (ACE-011)/placebo or 
study related procedures are to be reported.  

Documentation of concomitant medications / procedures (including use of ESAs and 
all transfusions) / hospitalizations

Post-Treatment Anti-Neoplastic Therapy
Study Discontinuation 
Study Discontinuation is the final scheduled visit for this study and should be performed for all 
enrolled subjects.  
Subjects who discontinue from treatment early will enter the Post Treatment Follow-Up Period 
and be followed for 6 months from their last dose of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo.  Follow-up for twelve months for TTP and PFS will be performed from the 
subject’s first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/Placebo.  Following the 
Study Discontinuation Visit, subjects will be contacted monthly and survival data collected for 
an additional 12 months (up to 24 months following the subject’s first dose of sotatercept (ACE-
011) or sotatercept (ACE-011)/placebo).  
The assessments and procedures that will be performed during the Study Discontinuation Visit 
are outlined in the Table of Events (see Section 5) and include:

ECOG performance status

Vital signs including weight, heart rate, seated systolic and diastolic blood pressure, 
and temperature

Medically supervised pregnancy test, with a minimum sensitivity of 25 mIU/ml, for 
females of childbearing potential (FCBP) – if Study Discontinuation date is ≤ 112 
days following the last dose of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo.  

Serum chemistry, hematology, absolute reticulocyte count

Creatinine clearance 

Urinalysis 

FSH (include current menstrual cycle status for pre-menopausal female subjects) and 
LH – both males and females 

Estrogen and estradiol – females only

Dihyroepiandosterone and Testosterone (free and total) – males only

Tumor Assessment and Response Evaluation, as per RECIST criteria (Version 1.1)
(PFS at 12 months)

QoL Assessment (FACIT Fatigue Scale (Version 4)) and LCSS questionnaire 

Reporting of adverse events (only AE/SAE assessed related to study treatment are to 
be reported)
Page 254 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
61
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011

Documentation of concomitant medications / procedures (including use of ESAs and 
all transfusions) / hospitalizations

Post-Treatment Anti-Neoplastic Therapy
Survival Follow-Up Period:
Monthly collection of survival data will begin following the Study Discontinuation Visit and 
continue for an additional 12 months (up to 24 months after first dose of sotatercept (ACE-011)
or sotatercept (ACE-011)/placebo).  

Overall survival

Post-Treatment Anti-Neoplastic Therapy
Additional Procedure Descriptions:
Central ECG
Part 1 – ECGs will be performed and read per Central ECG vendor.  
Part 2 – ECGs will be performed locally and read per Central ECG vendor.  
Please refer to vendor manual for procedures.  
Clinical Laboratory Evaluations
Clinical laboratory evaluations (serum chemistry, hematology, absolute reticulocyte count, 
creatinine clearance, serum iron, total iron binding capacity, transferrin and serum ferritin, serum 
erythropoietin, vitamin B12, serum RBC folate levels, urinalysis, FSH, LH, 
dihyroepiandosterone, estrogen, estradiol, testosterone and serum thyroid-stimulating hormone)
will be performed by a central laboratory.  
Please refer to vendor manual for procedures.  
Note:  Local laboratory assessments are allowed in cases when timely results are needed (e.g.,
randomization, study treatment and chemotherapy dosing decisions, hematology assessments 
between clinic visits).  Whenever possible a “split” sample should also be forwarded to the 
central laboratory for analysis. Local laboratory data should be collected in the eCRF.  
Exploratory Biomarkers
Analyses will be undertaken to evaluate the expression of Activin A and other 
proteins/biomarkers related to sotatercept (ACE-011) mechanism of action in blood (including 
myostatin and follistatin) and in archival tumor tissue in the NSCLC population in a subset of 
subjects.  
Renal function biomarkers via urinalysis measuring urine albumin / creatinine ratio, urine protein 
/ creatinine ratio and other biomarkers of glomerular and/or tubular injury - urine kidney injury 
molecule-1 (KIM-1), urine trefoil factor 3 (TTF3), urine cystatin C and + or – urine β2-
microglobulin will be evaluated in all subjects.  
Pharmacokinetics

Part 1 - Full PK blood samples will be collected to evaluate the full PK profile of 
sotatercept (ACE-011) from approximately 30 subjects at select centers 
Page 255 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
62
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
(approximately 10 subjects for each sotatercept [ACE-011] dose group).  For full PK 
sampling, subjects who miss more than two PK sampling time points from Days 1 
through 43 will be replaced.  Subjects not participating in the optional full PK 
assessment will participate in the sparse PK assessment. 

Part 2- Sparse PK blood samples will be collected from approximately 300 (40%) of 
750 subjects (approximately 150 subjects in each arm).  
Detailed PK sampling schedule is presented in Table 8 and Table 9: Schedule of 
Pharmacokinetic Assessments.  

PK samples must be collected predose on the day of sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo administration.  PK samples may be collected at any 
time on non-dosing days.  After collection, allow the blood to clot at room 
temperature for approximately one hour and then centrifuge the blood sample at room 
temperature for 10 minutes (1100-1300g) to obtain serum.  At each time point, 
approximately 2 mL or less blood will be collected.  
Bone Biomarkers
Bone biomarkers will be evaluated in all subjects.  The serum and urine bone biomarkers will 
include BSAP, OC, P1NP, CTX, TRACP-5b and uNTX.  Both serum and urine samples will be 
collected.  
Biomarker serum samples should be consistently collected early morning.  The urine sample 
should not be from the first morning void.  
Bone Imaging
DXA scan to evaluate overall bone health will be performed on approximately 200 subjects at 
select site(s).
Quality of Life Assessments
QoL Assessment (FACIT Fatigue Scale [Version 4]) and LCSS questionnaire will be completed 
by the subject upon arrival at clinic and prior to any study procedures or testing.  The LCSS 
consists of two scales: one for the patient (Patient Scale) and a counterpart for health 
professionals acting as observers (Observer Scale). 
Independent External Radiology Review (Part 2 Only)
At least 3 independent external radiologists (2 reviewers and 1 adjudicator) will perform a 
blinded, independent assessment of response, including the development of progressive disease 
(PD).  
Independent Review Committee (IRC) (Part 2 Only)
The IRC will review the tumor response data (to include results from the central radiologist and 
relevant clinical laboratory and physical examination findings) and the dates of disease 
progression for each subject.  These data reviewed by the IRC will be used in the primary 
analyses ORR, TTP and PFS for the Clinical Study Report.  
Page 256 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
63
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
7.
STUDY POPULATION
Subjects must be receiving their first regimen of first-line platinum-containing chemotherapy, 
given every three weeks, for the treatment of metastatic NSCLC at the time of randomization.  
Subjects must be randomized prior to receiving Cycle 4 of this current first-line platinum-based 
chemotherapy regimen.  Subjects are expected to be eligible to continue to receive ≥ 2 
additional platinum-based chemotherapy cycles while on study treatment.  
Subjects must not have received any other regimens of chemotherapy for the first-line platinum 
containing treatment of metastatic NSCLC prior to the regimen at the time of randomization.  
7.1.
Number of Subjects
This NSCLC platinum-based CIA study will enroll approximately 840 subjects in Part 1 and 
Part 2.  
In Part 1, up to 90 subjects will be randomized to receive one of the following sotatercept (ACE-
011) dose levels, with 10-30 subjects per arm:

Sotatercept (ACE-011) 15.0 mg SC

Sotatercept (ACE-011) 30.0 mg SC

Sotatercept (ACE-011) 45.0 mg SC
and will be stratified by:
1. Baseline Hgb level 

6.5 to < 9.0 g/dL

9.0 to < 11.0 g/dL
2. Type of platinum-based chemotherapy (cisplatin versus carboplatin)
In Part 2, an additional 750 subjects will be randomized to receive either sotatercept (ACE-011), 
at the dose determined in Part 1, or placebo at a ratio of 1:1.  Subjects will be randomized to 
receive either sotatercept (ACE-011) or placebo and will be stratified by:
1. Baseline Hgb level 

6.5 to < 9.0 g/dL

9.0 to < 11.0 g/dL
2. Type of platinum-based chemotherapy (cisplatin versus carboplatin)
3. NSCLC histology (Squamous NSCLC vs. Non-Squamous NSCLC)
4. ECOG Performance Status 0-1 vs. 2
Page 257 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
64
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
7.2.
Inclusion Criteria
Subjects must satisfy the following criteria to be enrolled in the study:
1. Men and women > 18 years of age at the time of signing the informed consent document.
2. Histologically confirmed (cytology or biopsy) non-small cell carcinoma of the lung.
3. Documented metastatic (Stage IV) disease, (including pleural or pericardial effusion
involvement)
4. Measurable or non-measurable disease evaluable by RECIST criteria (Version 1.1)
(Appendix A).
5. All of the following laboratory values:

Hemoglobin ≥ 6.5 to < 11.0 g/dL (≥ 65 to < 110 g/L)

Absolute neutrophil count ≥ 500/mm3

Platelet count ≥ 75,000/mm3 (> 72 hours since prior platelet transfusion) 

Adequate renal function (creatinine clearance ≥ 40mL/min or ≥ 50 mL/min if 
cisplatin concomitantly administered)

Hepatic function (bilirubin < 1.5 x ULN; AST and ALT < 3.0 x ULN and ≤5 ULN for 
subjects with liver metastases)

Corrected calcium within normal limits (WNL), previous hypercalcemia treatment is 
allowed
6. Subjects may have received up to 3 cycles of their first regimen of first line platinum-
based chemotherapy treatment for metastatic NSCLC.  Allowed regimens are:

gemcitabine plus cisplatin or carboplatin ± bevacizumab

pemetrexed plus cisplatin or carboplatin ± bevacizumab

paclitaxel plus carboplatin ± bevacizumab

docetaxel plus cisplatin ± bevacizumab
At randomization subjects are expected to be eligible to continue to receive at least two
additional platinum-based chemotherapy cycles while on study. .
7. ≥ 28 days must have elapsed since previous treatment with ESA
8. ≥ 14 days must have elapsed (prior to Day 1) since the last RBC transfusion and receipt 
of ≤ 2 units of blood in the past 30 days (prior to Day 1)
9. ECOG Performance status of 0 – 2 (Appendix B)  
10. If currently receiving bisphosphonate or denosumab (XGEVA™) therapy for bone 
metastases, must be on a stable dose for ≥ 2 months before Day 1 (ongoing 
bisphosphonate or denosumab therapy is allowed during study provided it is kept at a 
stable level). Bisphosphonate or denosumab therapy may not be started on study.  
Bisphosphonate therapy may be started on study for the treatment of hypercalcemia.  
Page 258 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
65
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
Subjects not currently on bisphosphonates or denosumab must not have received 
bisphosphonates or denosumab within 2 months prior to Day 1.  
11. Females of childbearing potential participating in the study are to use highly effective 
methods of birth control for at least 28 days before starting the study, during study 
participation and for at least 112 days following the last dose of sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo.  
Some highly effective methods of birth control include:

Oral contraceptives, intrauterine device, tubal ligation or a partner with a vasectomy
OR

Two forms of barrier method birth control, e.g., a latex condom PLUS a diaphragm 
with spermicide OR a latex condom PLUS a contraceptive sponge with spermicide.  
If a non-latex condom is used, it cannot be made out of natural (animal) membrane  
Females of childbearing potential must have a negative pregnancy test, with a minimum 
sensitivity of 25 mIU/ml, within 3 days prior to sotatercept (ACE-011) or sotatercept 
(ACE-011)/placebo administration (Day 1).  In addition, subjects must be educated 
concerning measures to be used to prevent pregnancy and potential toxicities.  (A female 
of childbearing potential is a sexually mature woman who has not undergone a 
hysterectomy or bilateral oophorectomy; or who has not been postmenopausal for at least 
24 consecutive months i.e. who has had menses at some time in the preceding 24 
months).  
12. Males must agree to use a latex condom or non-latex condom NOT made of natural 
(animal) membrane during any sexual contact with females of childbearing potential or a 
pregnant female while participating in the study and for at least 112 days following the 
last dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo, even if he has 
undergone a successful vasectomy.  
13. Life expectancy of ≥ 3 months.
14. Is willing to adhere to the study visit schedule, understand and comply with all protocol 
requirements.
15. Understand and voluntarily sign a written informed consent document prior to any study 
related assessments/procedures are conducted.
7.3.
Exclusion Criteria
The presence of any of the following will exclude a subject from enrollment:
1. Subjects who have any Grade > 3 toxicity (according to the currently active minor 
version of the NCI National Cancer Institute Common Terminology for Adverse Events 
[CTCAE] version 4.0 [Appendix C] at the time of screening, including Grade ≥ 3 residual 
adverse events related to either chemotherapy or underlying disease.  Exception: Grade ≥ 
3 hematotoxicity (e.g., asymptomatic anemia, neutropenia and thrombocytopenia) 
occurring during the chemotherapy nadir period and resolving or non- hematological 
events (e.g., nausea, vomiting, fatigue, or muscle or bone/joint pain), occurring during the 
chemotherapy period and resolving.
Page 259 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
66
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
2. Prior radiation therapy to > 20% of the whole skeleton.  Use of palliative radiation if the 
area being treated is < 15% of body surface area with no pelvic radiation or no more than 
10% of the bone marrow reserve is radiated is permitted during subject participation in 
the study, at the discretion of the Investigator.  
3. History of prior regimen(s) of platinum-based chemotherapy for metastatic NSCLC.    
4. CNS metastases (exception: subjects with CNS metastases treated with whole brain 
radiotherapy, gamma knife radiosurgery and/or surgery and stable for at least 2 weeks 
prior to randomization).  
5. Clinically significant pulmonary, endocrine, neurologic, gastrointestinal, hepatic or 
genitourinary disease unrelated to underlying NSCLC.  
6. Subjects with classification of 3 or higher heart failure as classified by the New York 
Heart Association (NYHA) (Appendix D).  
7. History of thrombosis, deep vein thrombosis (DVT), pulmonary emboli (PE), or embolic 
stroke if not stable on anticoagulants and/or one of these events occurring within the past 
6 months.  Local central line thrombosis is allowed.  
8. Diagnosis of a myeloid malignancy or known history of myelodysplasia.  
9. History of second malignancy within 3 years (except excised and cured basal cell 
carcinoma, squamous cell carcinoma of the skin or cervical carcinoma in situ).  
10. Subjects with a recent history (within 14 days of Day 1) of administration of IV 
antibiotics or oral antibiotics (due to post septic episode).  Subjects should be free of 
infection at least 14 days after the last dose of systemic antibiotic treatment (prior to Day 
1).  
11. Uncontrolled hypertension.  If hypertension is considered clinically stable, systolic blood 
pressure (SBP) must be < 150 mmHg or diastolic blood pressure (DBP) must be              
< 100 mmHg.  
12. Known infection with human immunodeficiency virus (HIV).  
13. Known active hepatitis B or C antibody defined by positive serology.  
14. Deficiency in iron (transferrin saturation < 20%), vitamin B12, or RBC folate.  Subjects 
may be re-screened following treatment with supplements and normalization of levels.  
15. History of anemia as a result of inherited hemoglobinopathy such as sickle cell anemia or 
thalassemia.  
16. History of anemia due to autoimmune or hereditary hemolysis; or gastrointestinal 
bleeding occurring within the past 6 months.  
17. Urine protein / creatinine ratio > 1.0.
18. Received treatment with another investigational drug or device within 28 days prior to 
Day 1, or if the half life of the previous product is known, within 5 times the half life 
prior to dosing, whichever may be longer.  
19. Any prior use of sotatercept (ACE-011).  
Page 260 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
67
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
20. Pregnant or lactating females or females planning to become pregnant.  
21. History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant 
proteins or excipients in the investigational product (Refer to the Investigator’s Brochure 
for further information).  
22. Major surgery within 30 days prior to Day 1 (subjects must have completely recovered 
from any previous surgery prior to Day 1).  
Page 261 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
68
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
8.
DESCRIPTION OF STUDY TREATMENTS
8.1.
Description of Investigational Product(s)
Sotatercept (ACE-011) clinical drug product will be provided as a frozen liquid formulation, 
Process IIa, or as a lyophilized powder, Process III.  
Note: Subjects receiving Process IIa clinical drug product will begin to receive Process III 
clinical drug product as soon as it becomes available at the study site. 
Process IIa Clinical Drug Product – Frozen Liquid Formulation:
The clinical drug product consists of sotatercept (ACE-011) in phosphate buffered saline (PBS), 
pH 7.5.  It is supplied as a 1 mL solution of 50 mg/mL sotatercept (ACE-011) in labeled, rubber 
stoppered, 2 mL vials providing 50 mg per vial.  The recommended storage temperature for
sotatercept (ACE-011) Process IIa frozen liquid drug product is -65˚C (colder than -65˚C) until 
thawed for administration.  Vials of sotatercept (ACE-011) frozen liquid must be completely 
thawed (approximately 30 minutes at room temperature) prior to preparation for dosing and must 
be used within six (6) hours of being thawed.  
Process III Clinical Drug Product- Lyophilized Powder:
The clinical drug product consists of sotatercept (ACE-011) in 10 mM citrate buffer, pH 5.8, 8% 
sucrose, and 0.02% polysorbate 80.  It is supplied as a lyophilized powder in labeled, rubber
stoppered, 3-mL glass vials.  The recommended storage temperature for sotatercept (ACE-011)
lyophilized drug product is 2°C to 8°C. Prior to administration, the lyophilized drug product is 
reconstituted with 1 mL water for injection (WFI).  The reconstituted drug product consists of a 
50 mg/mL solution of sotatercept (ACE-011).  The reconstituted sotatercept (ACE-011), in its 
original container closure system, may be held for up to 6 hours at 2°C to 8°C.
Placebo (Part 2 Only):
In Part 2, the sotatercept (ACE-011) placebo to be used in the study will be sterile normal saline 
(0.9% sodium chloride for injection) administered as a SC injection.  Sterile, normal saline will 
be supplied by the investigational site’s pharmacy.  The manufacturer’s directions for placebo 
storage and handling are to be followed, as are standard clinical practices for ensuring sterility of 
the placebo.  
8.2.
Treatment Administration and Schedule
Sotatercept (ACE-011) or placebo will be administered as a SC injection to subjects by the study 
staff at the clinical site and will be documented in the study source record.  Subcutaneous 
injections will be given in the upper arm, abdomen, or thigh.  
At the time of randomization all subjects must be receiving their first-line regimen of platinum-
containing chemotherapy, given every three weeks, for the treatment of metastatic NSCLC.  
Subjects will be randomized to this study during the time period in which they are receiving 
Cycle 1 to Cycle 3 of their first regimen of first-line platinum-based chemotherapy.  Subjects 
must not have received any prior regimens of platinum-based chemotherapy for metastatic 
NSCLC.  
Page 262 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
69
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
Allowed concomitant platinum-based chemotherapy regimens are:

gemcitabine plus cisplatin or carboplatin  ± bevacizumab

pemetrexed plus cisplatin or carboplatin ± bevacizumab

paclitaxel plus carboplatin ± bevacizumab

docetaxel plus cisplatin ± bevacizumab
Investigative sites will utilize commercial supply of these medications.  
Subjects may receive 4-6 cycles of the allowed platinum-based regimen selected by the 
Investigator.  Up to 2 additional cycles (8 total cycles) of platinum-based chemotherapy may be 
given as determined by cancer response.  The platinum-based tumor therapy may be revised at 
the discretion of the Investigator for toxicity reasons only.  
While on treatment subjects will be allowed to receive maintenance therapy with a pemetrexed
or erlotinib-containing regimen when indicated. 
Subjects must be given sotatercept (ACE-011) or sotatercept (ACE-011)/placebo prior to 
chemotherapy administration on the dose administration days.  
In Part 1 and Part 2, sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dosing may 
occur on different weeks of the chemotherapy cycle due to the subjects’ Hgb.  Dose delays of 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo and/or dose delays of chemotherapy 
may occur.  
8.2.1.
Selection of Dose for the Study
In Part 1, subjects will be randomized to one of the following sotatercept (ACE-011) dose 
levels, with 10-30 subjects per arm:

Sotatercept (ACE-011) 15.0 mg SC

Sotatercept (ACE-011) 30.0 mg SC

Analysis of safety data will be performed following the treatment of at least 10 
subjects at the 15.0 mg dose level and 10 subjects at the 30.0 mg dose level, with at 
least of one dose of sotatercept (ACE-011), plus a 12-week follow-up period from 
first dose.  Following this analysis, the addition of a third dose level:

Sotatercept (ACE-011) 45.0 mg SC
to the randomization schema will be determined.
Each dose level will be administered every 42 days for up to four doses.  
The following are decision rules for dose determination in Part 1 in order to move forward to 
Part 2:

After completion of two doses of sotatercept (ACE-011), a hematopoietic response in 
approximately 70% of subjects, in at least one or more treatment arms.  

Hematopoietic response is defined as an increase in Hgb of ≥ 1.0 g/dL above the 
study baseline value for 4 consecutive weeks, in the absence of RBC transfusions 
Page 263 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
70
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
and/or ESAs.  In order to determine the optimal dose of sotatercept (ACE-011) to be 
used in Part 2, evaluation of hematopoietic response will be determined from 
sotatercept (ACE-011) dose 1/day 1 through and including dose 2/day 43 (prior to 
dose 3).  

In addition to the hematopoietic response, safety profile, dose modifications and 
extent of exposure will be taken into account for dose level selection for Part 2.  
Hematopoietic response will be determined by laboratory analysis.  
In Part 2, subjects will be randomized to receive either sotatercept (ACE-011) (at the dose 
determined in Part 1) or placebo.  
8.2.2.
Selection and Timing of Dosing for Each Subject
Subjects will be randomized to receive sotatercept (ACE-011) or sotatercept (ACE-011)/placebo 
starting on Day 1 (one SC dose every 42 days) and continuing during the six-month (Part 1) or 
nine-month (Part 2) Treatment Period, as outlined in the Table of Events (see Section 5).  
In Part 1, subjects will be randomized to receive one of three dose levels of sotatercept (ACE-
011), with 10-30 subjects per arm.  In Part 2, 750 subjects will be randomized to receive 
sotatercept (ACE-011) or placebo at a ratio of 1:1.  
Each subject will return to the site on each scheduled clinic visit.  During the Treatment Period,
subjects will receive sotatercept (ACE-011) or sotatercept (ACE-011)/placebo every 42 days as 
determined by Hgb levels and randomization schedule.  Hemoglobin levels and reticulocyte 
counts will be repeated weekly after the first dose of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo then at 7, 14 and 28 days after each subsequent dose of sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo.  
The first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo should be given 
within 7 days prior to or within 7 days of administration of a platinum-based 
chemotherapy cycle.  Subsequent doses of Sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo can be administered at any time point during the chemotherapy cycle. 
Administration of subsequent cycles of chemotherapy, including dose reductions and dose 
delays, should not affect the sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dosing 
schedule, unless determined to be necessary by the Investigator.  If there is a chemotherapy dose 
delay, sotatercept (ACE-011) or sotatercept (ACE-011)/placebo administration does not need to 
be delayed until start of next chemotherapy cycle.  
If sotatercept (ACE-011) or sotatercept (ACE-011)/placebo is administered on the same day as 
chemotherapy, sotatercept (ACE-011) or sotatercept (ACE-011)/placebo should be given prior 
to chemotherapy administration.
Following completion of the Treatment Period, subjects who enter the Post Treatment Follow-
Up Period will be followed for 6 months from their last dose of sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo.  Visits will occur every month.  All subjects will continue to be 
followed for PFS up to 12 months from their first dose of sotatercept (ACE-011) or sotatercept 
(ACE-011)/placebo, or until progression of their NSCLC, whichever comes first.  
Page 264 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
71
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
Subjects will be discontinued from the study treatment for reasons listed in Section 8.2.3 of the 
protocol, for unacceptable toxicity, or for progression of NSCLC that requires the initiation of 
another treatment.  
Following the Study Discontinuation Visit, subjects will be contacted monthly and survival data 
collected for an additional 12 months (up to 24 months following the subject’s first dose of 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo).  
8.2.3.
Discontinuation
Treatment Discontinuation
Subjects will be discontinued from Study Treatment due to the following:

Adverse events(s)

Hypertension ≥Grade 3 – defined as Stage 2 hypertension (SBP ≥160 mm Hg or
DBP ≥100mm Hg) confirmed by two measurements obtained five minutes apart; 
medical intervention indicated; more than one drug or more intensive therapy than 
previously used indicated or medically significant hypertension which cannot be 
adequately controlled with antihypertensive therapy.

Any AE > Grade 2 assessed to be related to sotatercept (ACE-011) therapy

Any persistent AE > Grade 1 considered to be related to sotatercept (ACE-011)
treatment and causing a subject to miss three months sotatercept (ACE-011)
therapy 

Any thromboembolic event > Grade 2 

Elevated Hgb > 15.0 g/dL (sustained for a 7 day period, confirmed by laboratory 
assessment)

Urine protein / creatinine ratio > 1.0 or > 2.0 (if bevacizumab [Avastin®] is 
concomitantly administered)

Persistent hematuria ≥Grade 2 - defined as symptomatic; urinary catheter or 
bladder irrigation indicated; limiting instrumental activities of daily living, and 
persisting for one week.

Lack of sotatercept (ACE-011) therapeutic effect, defined as < 1.0 g/dL increase in 
Hgb following two doses of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo

Concomitant use of ESAs – In Part 1 if administered at any time and in Part 2 if 
administered < 4 months from first dose of study treatment.  

Sotatercept (ACE-011) or Sotatercept (ACE-011)/placebo Dose Modifications

In Part 1 and Part 2:  A second Hgb increase of ≥3.0 g/dL following a two level 
dose reduction due to a Hgb increase ≥3.0 g/dL 

In Part 2:  > 3 dose reductions and/or delays

Disease Progression of NSCLC

Withdrawal of consent
Page 265 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
72
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011

Death

Lost to follow-up

Protocol violation
The reason for treatment discontinuation should be recorded in the eCRF and in the source 
documents.  
Study Discontinuation:  
The following events are considered sufficient reasons for discontinuing a subject from the 
study:

Completed study, per protocol (subject has completed six- to nine- month Treatment 
Period plus up to six-month Post Treatment Follow-Up Period including one year 
tumor assessment to determine TTP and PFS).  Note:  Survival data will continue to 
be collected for up to 24 months from first dose of study treatment.  

Withdrawal of consent

Death

Lost to follow-up
The following events may be considered sufficient reasons for discontinuing a subject from the 
study:

Adverse events(s)

Disease progression of NSCLC

Protocol violation
The reason for study discontinuation should be recorded in the eCRF and in the source 
documents.  The Investigator must notify the Medical Monitor immediately when a subject has 
been discontinued/ withdrawn due to an AE (any unacceptable toxicity).  All subjects who are 
withdrawn from the study should complete the tests and evaluations scheduled for Study 
Discontinuation at the time of withdrawal.  
8.3.
Method of Treatment Assignment
All subjects who qualify for the study will be randomly enrolled into the study and receive up to 
4 doses of sotatercept (ACE-011) in Part 1.  In Part 2, subjects will be randomized at a ratio of 
1:1 and receive up to 4 doses of study treatment and may receive 2 additional doses of 
sotatercept (ACE-011)/placebo, if clinically indicated, at the discretion of the Investigator.  A 
unique multi-digit subject identification number will be assigned by IVRS to each subject 
entering the Treatment Period.  
8.4.
Packaging and Labeling
The label(s) for investigational product (IP) will include Sponsor name, address and telephone 
number, the protocol number, IP name, dosage form and strength (where applicable), amount of 
IP per container, lot number, expiry date (where applicable), medication identification/kit 
Page 266 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
73
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
number (if applicable), dosing instructions, storage conditions, and required caution statements 
and/or regulatory statements as applicable.  Additional information may be included on the label 
as applicable per local regulations.  
8.5.
Investigational Product Accountability And Disposal
Accountability for sotatercept (ACE-011) is the responsibility of the Investigator.  
Investigational clinical supplies must be received by a designated person at the clinical site and 
kept in a secured location.  The investigational site must maintain accurate records demonstrating 
dates and amounts of sotatercept (ACE-011) received, to whom it was administered (subject-by-
subject accounting), and accounts of any sotatercept (ACE-011) accidentally or deliberately 
destroyed or returned.  Unless otherwise notified, all vials of sotatercept (ACE-011), both used 
and unused, must be saved for drug accountability.  The used vials may be discarded, per the 
institution’s standard practice, after drug accountability has been completed by the monitor.  The 
Investigator must return all unused vials of sotatercept (ACE-011) to the Sponsor at the end of 
the study, or the sotatercept (ACE-011) may be destroyed at the clinical site with the permission 
of the Sponsor.  For either scenario, the outcome must be documented on the drug accountability 
log.  The Sponsor will provide direction for the outcome of all unused vials.  
Celgene will instruct the Investigator on the return, disposal and/or destruction of investigational 
medicinal product.  
8.6.
Investigational Product Compliance
Accurate recording of all IP administration will be made in the appropriate section of the 
subject’s eCRF and source documents.  
The Investigator or designee is responsible for accounting for all IP that is administered during 
the course of the study.  
Page 267 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
74
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
9.
CONCOMITANT MEDICATIONS AND PROCEDURES
9.1.
Permitted Concomitant Medications and Procedures
General concomitant medication usage
During screening, and during the study, subjects may take only stable doses of medications for 
chronic conditions that are not specifically excluded by the protocol (see Sections 7.2 and 7.3
Inclusion Criteria and Exclusion Criteria).  The Medical Monitor should be consulted by the 
Investigator if there are any concerns about what constitutes a stable dose or what is a chronic 
condition.  Concomitant medications will be recorded on the subject’s eCRF throughout the 
course of the study.  
Concomitant therapies considered as supportive care are acceptable while participating in this 
study including growth colony stimulating factors (G-CSF), anti-emetics to limit chemotherapy-
related nausea and vomiting and palliative radiation and bisphosphonates (Refer to Inclusion 
Criterion, Section 7.2) for bone metastases.  Additionally, the study site should use its standard 
of care regarding hydration and the minimization of nephrotoxicity prior to/following the 
administration of platinum-based regimens.  
Concomitant medication for anemia
Concurrent therapy with a new prescription medication related to treatment of anemia during the 
course of the study must first be discussed with the Medical Monitor prior to administration, 
unless appropriate medical care necessitates that medication should begin before the Medical 
Monitor can be consulted.  
Iron supplementation
Iron supplementation within 7 days of Day 1 (besides an oral general multivitamin with iron) 
will not be allowed.  If a subject becomes iron deficient during study treatment (ferritin < 100 
ng/mL [< 224.7 pmol/L] or transferrin saturation < 20%), treatment with iron supplementation is 
at the discretion of the Investigator.  
Erythropoiesis-stimulating agents (ESAs)
The use of an ESA is not allowed in Part 1 of the study; however, ESAs are allowed in 
Part 2 only after a subject has received at least 4 months of study treatment.  The use of 
ESAs will need to result in immediate notification to the study sponsor and Medical Monitor, as
well as to the unblinded clinical site pharmacist, so that no further dosing with sotatercept 
(ACE-011) in that study subject will occur.  Subjects will not be unblinded.  If treatment 
with ESAs is required in the opinion of the Investigator, the ESA label instructions are to be 
strictly followed.  
In Part 1, all subjects who receive an ESA will be discontinued from the study treatment period 
and continue to the post treatment follow-up period. In Part 2, subjects who receive an ESA at < 
4 months from their first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo will
be discontinued from the study treatment period and continue to the post treatment follow-up 
period.  Subjects who receive an ESA at ≥ 4 months from their first dose of sotatercept (ACE-
011)/placebo will continue in the treatment period.  The unblinded pharmacist will ensure that 
Page 268 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
75
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
subjects randomized to receive treatment with sotatercept (ACE-011) are changed over to 
receive treatment with placebo.  Subjects randomized to treatment with placebo will
continue to receive placebo.  
RBC transfusions
Concurrent treatment for CIA with blood transfusions is recommended when Hgb value is 
< 8 g/dL or at the discretion of the Investigator if the Hgb value is ≥8 g/dL and associated with 
anemia symptoms such as hemodynamic or pulmonary compromise requiring treatment.  If an 
RBC transfusion is given to a subject during the Treatment Period, sotatercept (ACE-011) should 
be administered no sooner than 7 days from the date of the RBC transfusion.  
9.2.
Prohibited Concomitant Medications and Procedures
No concurrent treatments with any other investigational agent are allowed.  Bisphosphonate 
therapy (see Section 7.2), other than for the treatment of hypercalcemia, must not be started on 
study.  
9.3.
Required Concomitant Medications and Procedures
Not applicable.  
Page 269 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
76
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
10.
STATISTICAL ANALYSES
10.1.
Overview
This is a single-blind, randomized, phase 2a, dose-ranging study of sotatercept (ACE-011)
therapy followed by a phase 2b/3, double-blind, randomized, placebo-controlled study of 
sotatercept (ACE-011) for CIA in subjects with metastatic NSCLC treated with platinum-based 
chemotherapeutic regimens.  An IVRS will be utilized to ensure an equal weight central 
randomization based on a permuted-block randomization method according to stratification 
factors defined in Section 4.1 Study Design.  In Part 1, subjects will be randomized to one of 
three doses of sotatercept (ACE-011) plus platinum-based chemotherapy.  In Part 2, subjects 
will be randomized to placebo or the selected sotatercept (ACE-011) dose determined from Part 
1 plus platinum-based chemotherapy.  Data from Part 1 will not be combined with data from Part 
2 in all safety and efficacy analyses. 
A DMC will be used to monitor the study conduct.  
10.2.
Study Population Definitions

Three study populations will be used for analyses.  

The Intent-to-Treat (ITT) Population – All randomized subjects.  

Safety Population – All subjects who take at least one dose of study medication.  

Efficacy Evaluable (EE) Population – All ITT subjects who take at least one dose of 
study medication and have baseline and at least one post-baseline efficacy assessment 
without major protocol deviation.  
10.3.
Sample Size and Power Considerations
In Part 1, up to 90 subjects will be randomized among three dosing groups.  This sample size is 
for the purpose of hypothesis generation.  However, it would allow approximately 80% power to 
detect an effect size of 0.33 using a 2 degrees of freedom Chi-Square Test with a two-sided 
significance level (alpha) of 0.05.  
In Part 2, subjects will be enrolled in two stages.  In the first stage, approximately 180 subjects 
will be randomized in a 1:1 ratio to the selected sotatercept (ACE-011) dose group or placebo 
group.  An interim analysis of transfusion rate will be performed after these 180 subjects have 
received at least two doses of sotatercept (ACE-011)/placebo, and have been followed for at least 
4 months from randomization.  A Data Monitoring Committee will review the results and 
provide recommendations on continuing or stopping the study. Based on the results of the 
futility analysis, further enrollment in the second stage of Part 2 of the study could be continued.  
Upon recommendation to continue the study, an additional 570 subjects will be subsequently 
randomized in the second stage.  The total sample size of 750 subjects in Part 2 (first plus second 
stage) would allow observation of at least 536 deaths and thus at least 80% power to exclude 
more than 15% hazard increase in the sotatercept (ACE-011) arm compared with the placebo 
arm at one-sided significance level of 0.025, i.e., rejecting hazard ratio (Placebo:sotatercept 
Page 270 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
77
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
[ACE-011]) of 0.87,  assuming the sotatercept (ACE-011) arm actually reduces at least 10% 
hazard, i.e., true hazard ratio (Placebo:sotatercept [ACE-011]) of 1.11.  
10.4.
Background and Demographic Characteristics
Subjects’ age, height, weight, and baseline characteristics will be summarized using descriptive 
statistics by treatment arm, while gender, race and other categorical variables will be provided 
using frequency tabulations.  Medical history data will be summarized using frequency 
tabulations by system organ class and preferred term.  
10.5.
Subject Disposition
Subject disposition (analysis population allocation, entered, discontinued, along with primary 
reason for discontinuation) will be summarized using frequency and percent by treatment arm.  
A summary of subjects enrolled by site will be provided.  Protocol deviations will be 
summarized using frequency tabulations.  
10.6.
Efficacy Analysis
In Part 1, the primary endpoint will be the hematopoietic response defined as an increase in Hgb 
of ≥ 1.0 g/dL above the study baseline value for 28 consecutive days, in the absence of RBC 
transfusions and/or ESAs.  The analysis will be based on the EE population.  The proportion of 
subjects with hematopoietic response will be estimated and a Chi-square test will be performed 
to compare response rates across treatment groups.  
In Part 2, the primary endpoint will be rate of RBC transfusion within 4 months following the 
date of randomization.  It will be estimated based on Kaplan-Meier method for time to the first 
RBC transfusion.  The analysis will be based on ITT population and will be conducted according 
to the approximate timeline as described in Section 10.8.  Subjects who have documented RBC 
transfusion(s) from randomization until the last dose of concomitant platinum-based 
chemotherapy plus 30 days or from the initiation date of non-platinum-based chemotherapy, 
whichever is earlier, will be considered as having the event on the date of first RBC transfusion. 
Subjects who are discontinued from study treatment due to reasons other than disease 
progression or death will be considered as having the event on the date of study treatment 
discontinuation, or the last dose date of platinum-based chemotherapy plus 30 days or the 
initiation date of non-platinum-based chemotherapy, whichever is earliest. Subjects who 
discontinue from study treatment due to disease progression or death will be censored on the date 
of study treatment discontinuation, or the last dose date of platinum-based chemotherapy plus 30 
days or the initiation date of non-platinum-based chemotherapy, whichever is earliest. Otherwise 
subjects will be censored on the date of last contact, or on the date of last dose of concomitant 
platinum-based chemotherapy plus 30 days or on the initiation date of non-platinum-based 
chemotherapy, whichever is earliest.  The comparison on the distribution difference between the 
treatment groups will be based on the stratified log-rank test, and the associated hazard ratio and 
95% confidence interval will be provided using Cox proportional hazard model. The proportion 
of subjects receiving a transfusion based on Kaplan-Meier estimates at specific time points will 
also be provided by treatment arms. 
Page 271 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
78
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
As secondary endpoints for Part 2 of the study, time to progression, progression free survival and 
overall survival will be analyzed based on the ITT population.  
Time to progression (TTP) is defined as the time between the randomization date and date of 
disease progression. Disease progression is based on the IRC reviewed progression date.  If 
a subject dies due to reasons other than disease progression, the subject will be censored at the 
death date.  If a subject does not have disease progression, then the subject will be censored at 
the last tumor assessment (prior to or on the first day of the first subsequent antitumor therapy).  
Progression free survival (PFS) is defined as the time between the randomization and disease 
progression or death.  Disease progression is based on the IRC reviewed progression date.  
Subjects who progressed or died will be considered to have had an event, except if this event 
occurs after the start of subsequent antitumor therapy, in which case the subject is censored at the 
time of last tumor assessment prior to or on the first day of the first subsequent antitumor 
therapy.  The date of progression is taken as the earliest date of:  Date of PD as evaluation of 
response, date of new lesion on tumor measurements page, death date, if death is caused by PD, 
treatment termination date if reason is PD, progression date as documented on treatment 
termination page, progression date as documented on the follow-up visit page.  Subjects who did 
not progress nor died (lost to follow-up or still being treated without documented disease 
progression or started subsequent antitumor therapy) will be censored at the date of the last 
tumor assessment prior to or on the first day of the first subsequent antitumor therapy.  PFS 
based on investigators’ assessment will also be analyzed.  
Overall survival (OS) is defined as the time between the randomization and death.  A subject
who dies, regardless of the cause of death, will be considered to have had an event.  All subjects 
who are lost to the follow-up prior to the end of the trial or who are withdrawn from the trial will 
be censored at the time of last contact.  Subjects who are still being treated will be censored at 
the last available date where the subject is known to be alive.  
For TTP, PFS and OS, Kaplan-Meier method will be used to estimate the distribution function, 
six-month and one-year survival rates, as well as the medians and 95% confidence intervals will 
be provided.  The stratified log rank test will be used to compare the distributions of TTP, PFS 
and OS respectively.  The stratification factors are described in Section 4.1 .  The associated 
hazard ratios and confidence intervals will be provided using stratified Cox proportional hazard 
model respectively for each endpoint.  
Sensitivity analyses will be performed on TTP, PFS, and efficacy analyses will also be 
performed using EE population.  Data listings will be provided for all relevant data collected 
during the studies.  Further details will be included in the Statistical Analysis Plan.  
10.7.
Safety Analysis
All safety subjects will be used for safety analyses.  Sotatercept (ACE-011) exposure will be 
summarized.  Adverse events, vital sign measurements, clinical laboratory information, ECG 
interpretations, and concomitant medications will be tabulated and summarized by study part and 
treatment arm.  The incidence of AEs will be summarized by severity grade based on the NCI 
CTCAE version 4.0 (current active minor version).  Serious adverse events (SAE), deaths and 
AEs leading to dose modifications and study treatment discontinuation will be summarized.  
Page 272 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
79
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
Safety information obtained during the Post Treatment Follow-Up Period during each segment 
will be incorporated into these analyses.  
10.8.
Interim Analysis
There are two interim analyses planned for this study.  At the first interim analysis, the 
transfusion rate result will be used for go/no go decision, and overall survival will also be 
analyzed.  At the second interim analysis, only the overall survival will be analyzed.  
The first interim analysis on transfusion rate will be conducted after the first 180 eligible subjects 
randomized in Part 2 of the study (stage 1) who have received at least two doses of sotatercept 
(ACE-011)/placebo, have been followed for at least 4 months from randomization.  This sample 
size would allow at least 90% power to detect a 15% difference between two arms (sotatercept 
[ACE-011] arm 15% vs. placebo 30%) in 4 month transfusion rates at two-sided 5% significance 
level based on the stratified log rank test and the assumption of exponential distribution for time 
to RBC transfusion.  If the p-value at the interim analysis does exceed significance level of 0.05, 
the result will be considered as lack of efficacy.  If the p-value is less than or equal to 0.05, 
additional subjects will be enrolled and the study will move on to the Part 2; however, the futility 
analysis result based on RBC transfusion rate may be up to DMC evaluation.  For superiority, 
Type I error 0.0001 will be spent at this interim for transfusion rate, and the remaining 0.0499 
will be spent at the final analysis after 750 subjects being enrolled.  
Overall survival will also be analyzed at this interim, Type I error spending will be based on 
O’Brien and Fleming Boundary.  
The second interim analysis will be performed when approximately 265 deaths are observed in 
Part 2.  Type I error spending will be based on O’Brien and Fleming boundary.  
The final analysis will be performed when approximately 536 deaths are observed in Part 2.  
10.9.
Other Topics
Pharmacokinetic Analysis
Approximately 10 subjects will be enrolled for full PK sampling in each treatment cohort of Part 
1.  For this portion of the study, subjects who miss more than two PK sampling time points from 
Days 1 through 43 will be replaced.  
Noncompartmental PK parameters for sotatercept (ACE-011), such as tmax, Cmax, AUC42, CL/F, 
Vz/F, and t1/2,z, will be estimated for subjects providing full PK samples.  Dose proportionality 
will be assessed by regression analysis using the exposure data after the first dose.  Descriptive 
statistics will be provided for plasma concentrations and PK parameters.  
In exploratory population PK analysis, covariates to be tested may include type of chemotherapy, 
the presence of anti-sotatercept (ACE-011) antibodies, demographics (age, race, gender, and 
body weight), markers for hepatic and renal function, and other factors as deemed appropriate.  
Both full and sparse PK data will be included for population PK analyses.  
The relationship between sotatercept (ACE-011) exposure and response (hematology, 
biomarkers, and other clinical outcomes as appropriate) will be explored.  
Page 273 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
80
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
10.10.
Data Monitoring Committee (DMC)
A DMC will review safety and efficacy data to ensure the protection of study subjects.  The 
DMC will receive periodic updates of all serious treatment-related toxicities and SAEs leading to 
deaths from all causes. The first planned review by the DMC will be conducted following the 
randomization and treatment of twenty subjects.  The DMC will continue to monitor safety on an 
ongoing basis including recommendation of sotatercept (ACE-011) dose selection for Part 2.  
The first interim analysis will be conducted after the first 180 eligible subjects in Part 2 of the 
study (stage 1) have been followed for at least 4 months for RBC transfusion rate.  The second 
interim analysis will be performed when approximately 265 deaths are observed in Part 2.  The 
final analysis will be performed when approximately 536 deaths are observed in Part 2.  
Ad hoc meetings will be scheduled as needed.  
The DMC will have a consultative role with respect to the Sponsor. The Sponsor will make the 
final decision regarding the recommendation proposed by the committee. A separate DMC 
charter will detail the activities of this committee.  
Page 274 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
81
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
11.
ADVERSE EVENTS
11.1.
Monitoring, Recording and Reporting of Adverse Events
An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen 
in a subject during the course of a study.  It may be a new intercurrent illness, a worsening 
concomitant illness, an injury, or any concomitant impairment of the subject’s health, including 
laboratory test values (as specified by the criteria below), regardless of etiology.  Any worsening 
(i.e., any clinically significant adverse change in the frequency or intensity of a pre-existing 
condition) should be considered an AE.  A diagnosis or syndrome should be recorded on the AE 
page of the eCRF rather than the individual signs or symptoms of the diagnosis or syndrome.  
An overdose, accidental or intentional, whether or not it is associated with an AE, or abuse, 
withdrawal, sensitivity or toxicity to an investigational product should be reported as an AE.  If 
an overdose is associated with an AE, the overdose and AE should be reported as separate terms.  
All subjects will be monitored for AEs during the study.  Assessments may include monitoring 
of any or all of the following parameters:  the subject’s clinical symptoms, laboratory, 
pathological, radiological or surgical findings, physical examination findings, or other 
appropriate tests and procedures.  
All AEs will be recorded by the Investigator from the time the subject signs informed consent to 
at least 42 days after the last dose of IP.  The AEs and SAEs will be recorded on the AE page of 
the eCRF and in the subject’s source documents.  All SAEs must be reported to Celgene Drug 
Safety immediately (i.e., within 24 hours of the Investigator’s knowledge of the event) by 
facsimile, or other appropriate method, using the SAE Report Form, or approved equivalent 
form.  After 42 days post last dose, only AEs assessed as related to study treatment are to be 
reported.  
11.2.
Evaluation of Adverse Events
A qualified Investigator will evaluate all AEs as to:  
11.2.1.
Seriousness 
An SAE is any AE occurring at any dose that:

Results in death;

Is life-threatening (i.e., in the opinion of the Investigator, the subject is at immediate 
risk of death from the AE);

Requires inpatient hospitalization or prolongation of existing hospitalization 
(hospitalization is defined as an inpatient admission, regardless of length of stay);

Results in persistent or significant disability/incapacity (a substantial disruption of the 
subject’s ability to conduct normal life functions);

Is a congenital anomaly/birth defect;

Constitutes an important medical event.  
Page 275 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
82
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
Important medical events are defined as those occurrences that may not be immediately life 
threatening or result in death, hospitalization, or disability, but may jeopardize the subject or 
require medical or surgical intervention to prevent one of the other outcomes listed above.  
Medical and scientific judgment should be exercised in deciding whether such an AE should be 
considered serious.  
Events not considered to be SAEs are hospitalizations for:

A standard procedure for protocol therapy administration.  However, hospitalization 
or prolonged hospitalization for a complication of therapy administration will be 
reported as an SAE.  

Routine treatment or monitoring of the studied indication not associated with any 
deterioration in condition.  

The administration of blood or platelet transfusion as routine treatment of studied 
indication.  However, hospitalization or prolonged hospitalization for a complication 
of such transfusion remains a reportable SAE.  

A procedure for protocol/disease-related investigations (e.g., surgery, scans, 
endoscopy, sampling for laboratory tests, bone marrow sampling).  However, 
hospitalization or prolonged hospitalization for a complication of such procedures 
remains a reportable SAE.  

Hospitalization or prolongation of hospitalization for technical, practical, or social 
reasons, in absence of an AE.  

A procedure that is planned (i.e., planned prior to starting of treatment on study); 
must be documented in the source document and the eCRF.  Hospitalization or 
prolonged hospitalization for a complication remains a reportable SAE.  

An elective treatment of a pre-existing condition unrelated to the studied indication.  

Emergency outpatient treatment or observation that does not result in admission, 
unless fulfilling other seriousness criteria above.  
If an AE is considered serious, both the AE page/screen of the eCRF and the SAE Report Form 
must be completed.  
For each SAE, the Investigator will provide information on severity, start and stop dates, 
relationship to IP, action taken regarding IP, and outcome.  
11.2.2.
Severity / Intensity
For both AEs and SAEs, the Investigator must assess the severity /intensity of the event.  
The severity of AEs will be graded based upon the subject’s symptoms according to the current 
active minor version of National Cancer Institute (NCI) Common Terminology Criteria for 
Adverse Events (CTCAE, Version 4.0); 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
Page 276 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
83
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
AEs that are not defined in the NCI CTCAE should be evaluated for severity according to the 
following scale:
Grade 1 = Mild – transient or mild discomfort; no limitation in activity; no medical 
intervention/therapy required
Grade 2 = Moderate – mild to moderate limitation in activity, some assistance may be needed; no 
or minimal medical intervention/therapy required
Grade 3 = Severe – marked limitation in activity, some assistance usually required; medical 
intervention/therapy required, hospitalization is possible
Grade 4 = Life threatening – extreme limitation in activity, significant assistance required; 
significant medical intervention/therapy required, hospitalization or hospice care probable
Grade 5 = Death – the event results in death
The term “severe” is often used to describe the intensity of a specific event (as in mild, moderate 
or severe myocardial infarction); the event itself, however, may be of relatively minor medical 
significance (such as severe headache).  This criterion is not the same as “serious” which is 
based on subject/event outcome or action criteria associated with events that pose a threat to a 
subject’s life or functioning.  
Seriousness, not severity, serves as a guide for defining regulatory obligations.  
11.2.3.
Causality 
The Investigator must determine the relationship between the administration of IP and the 
occurrence of an AE/SAE as Not Suspected or Suspected as defined below:
Not Suspected:
The temporal relationship of the adverse event to IP 
administration makes a causal relationship unlikely or 
remote, or other medications, therapeutic interventions, or 
underlying conditions provide a sufficient explanation for the 
observed event.
Suspected:
The temporal relationship of the adverse event to IP 
administration makes a causal relationship possible, and other 
medications, therapeutic interventions, or underlying conditions 
do not provide a sufficient explanation for the observed event.
If an event is assessed as suspected of being related to a comparator, ancillary or additional IP 
that has not been manufactured or provided by Celgene, please provide the name of the 
manufacturer when reporting the event.  
11.2.4.
Duration
For both AEs and SAEs, the Investigator will provide a record of the start and stop dates of the 
event.
Page 277 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
84
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
11.2.5.
Action Taken
The Investigator will report the action taken with IP as a result of an AE or SAE, as applicable 
(e.g., discontinuation or reduction of IP, as appropriate) and report if concomitant and/or 
additional treatments were given for the event. 
11.2.6.
Outcome
All SAEs that have not resolved upon discontinuation of the subject’s participation in the study 
must be followed until recovered, recovered with sequelae, not recovered (death due to another 
cause) or death (due to the SAE).  
11.3.
Abnormal Laboratory Values
An abnormal laboratory value is considered to be an AE if the abnormality:

Results in discontinuation from the study;

Requires treatment, modification/ interruption (delay) of IP dose, or any other 
therapeutic intervention; or

Is judged to be of significant clinical importance.  
Regardless of severity grade, only laboratory abnormalities that fulfill a seriousness criterion 
need to be documented as an SAE.  
If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis 
or syndrome should be recorded on the AE page/screen of the eCRF.  If the abnormality was not 
a part of a diagnosis or syndrome, then the laboratory abnormality should be recorded as the AE.  
11.4.
Pregnancy
11.4.1.
Females of Childbearing Potential
Pregnancies and suspected pregnancies (including a positive pregnancy test regardless of age or 
disease state) of a female subject occurring while the subject is on IP, or within 112 days of the 
subject’s last dose of IP, are considered immediately reportable events.  IP is to be discontinued 
immediately.  The pregnancy, suspected pregnancy, or positive pregnancy test must be reported 
to Celgene Drug Safety immediately by facsimile, or other appropriate method, using the 
Pregnancy Initial Report Form, or approved equivalent form.  
The female subject should be referred to an obstetrician-gynecologist or another appropriate 
healthcare professional for further evaluation.  
The Investigator will follow the female subject until completion of the pregnancy, and must 
notify Celgene Drug Safety immediately about the outcome of the pregnancy (either normal or 
abnormal outcome) using the Pregnancy Follow-up Report Form, or approved equivalent form.  
If the outcome of the pregnancy was abnormal (e.g., spontaneous or therapeutic abortion), the 
Investigator should report the abnormal outcome as an AE.  If the abnormal outcome meets any 
of the serious criteria, it must be reported as an SAE to Celgene Drug Safety immediately by 
facsimile, or other appropriate method, within 24 hours of the Investigator’s knowledge of the 
event) using the SAE Report Form, or approved equivalent form.  
Page 278 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
85
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
All neonatal deaths that occur within 28 days of birth should be reported, without regard to 
causality, as SAEs.  In addition, any infant death after 28 days that the Investigator suspects is 
related to the in utero exposure to the IP should also be reported to Celgene Drug Safety 
immediately by facsimile, or other appropriate method, within 24 hours of the Investigator’s 
knowledge of the event using the SAE Report Form, or approved equivalent form.  
11.4.2.
Male Subjects
If a female partner of a male subject taking investigational product becomes pregnant, the male 
subject taking IP should notify the Investigator, and the pregnant female partner should be 
advised to call their healthcare provider immediately.  
11.5.
Immediate Reporting of Serious Adverse Events
Any AE that meets any criterion for an SAE requires the completion of an SAE Report Form in 
addition to being recorded on the AE page/screen of the eCRF.  All SAEs must be reported to 
Celgene Drug Safety immediately (i.e., within 24 hours of the Investigator’s knowledge of the 
event) by facsimile, or other appropriate method, using the SAE Report Form, or approved 
equivalent form.  This instruction pertains to initial SAE reports as well as any follow-up reports.  
The Investigator is required to ensure that the data on these forms is accurate and consistent.  
This requirement applies to all SAEs (regardless of relationship to IP) that occur during the study 
from the time the subject signs informed consent up to 42 days after the last dose of IP, and those 
made known to the Investigator at anytime thereafter that are suspected of being related to IP.  
SAEs occurring prior to treatment will be captured.  
The SAE report should provide a detailed description of the SAE and include summaries of 
hospital records and other relevant documents.  If a subject died and an autopsy has been 
performed, copies of the autopsy report and death certificate are to be sent to Celgene Drug 
Safety as soon as these become available.  Any follow-up data will be detailed in a subsequent
SAE Report Form, or approved equivalent form, and sent to Celgene Drug Safety.  
Where required by local legislation, the Investigator is responsible for informing the Institutional 
Review Board (IRB)/Ethics Committee (EC) of the SAE and providing them with all relevant 
initial and follow-up information about the event.  The Investigator must keep copies of all SAE 
information on file including correspondence with Celgene and the IRB/EC.  
11.5.1.
Safety Queries
Queries pertaining to SAEs will be communicated from Celgene Drug Safety to the site via 
facsimile or electronic mail.  The response time is expected to be no more than five (5) business 
days.  Urgent queries (e.g., missing causality assessment) may be handled by phone.  
11.6.
Expedited Reporting of Adverse Events
For the purpose of regulatory reporting, Celgene Drug Safety will determine the expectedness of 
events suspected of being related to sotatercept (ACE-011) based on the Investigator Brochure.  
For countries within the European Economic Area (EEA), Celgene or its authorized 
representative will report in an expedited manner to Regulatory Authorities and Ethics 
Committees concerned, suspected unexpected serious adverse reactions (SUSARs) in accordance 
Page 279 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
86
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
with Directive 2001/20/EC and the Detailed Guidance on collection, verification and 
presentation of adverse reaction reports arising from clinical trials on investigational products for 
human use (ENTR/CT3) and also in accordance with country-specific requirements.  
Celgene or its authorized representative shall notify the Investigator of the following 
information:

Any AE suspected of being related to the use of IP in this study or in other studies 
that is both serious and unexpected (i.e., SUSAR);

Any finding from tests in laboratory animals that suggests a significant risk for 
human subjects including reports of mutagenicity, teratogenicity, or carcinogenicity.  
Where required by local legislation, the Investigator shall notify his/her IRB/EC promptly of 
these new serious and unexpected AE(s) or significant risks to subjects.  
The Investigator must keep copies of all pertinent safety information on file including 
correspondence with Celgene and the IRB/EC.  (See Section 15.3 for record retention 
information).  
Celgene Drug Safety Contact Information:
For Local Drug Safety Affiliate Office contact information, please refer to the Serious Adverse 
Event Report Form / Completion Guidelines or to the Pregnancy Report Form / Completion 
Guidelines.  
Page 280 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
87
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
12.
DISCONTINUATIONS
Please refer to Section 8.2.3.  
Stopping Rules
In addition to Celgene routine pharmacovigilance surveillance, a DMC will review unblinded 
data on a regular basis (mainly grade 3 or 4 toxicities, SAEs and subject deaths).  Any relevant 
imbalance in toxic deaths, related SAEs or detrimental survival would be considered for study 
discontinuation.  
Page 281 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
88
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
13.
EMERGENCY PROCEDURES
13.1.
Emergency Contact
In emergency situations, the Investigator should contact the responsible Clinical Research 
Physician/Medical Monitor or designee by telephone at the number(s) listed on the Emergency 
Contact Information page of the protocol (after title page).  
In the unlikely event that the Clinical Research Physician/Medical Monitor or designee cannot be 
reached, please contact the global Emergency Call Center by telephone at the number listed on 
the Emergency Contact Information page of the protocol (after title page).This global Emergency 
Call Center is available 24 hours a day and 7 days a week.  The representatives are responsible 
for obtaining your call-back information and contacting the on call Celgene/CRO Medical 
Monitor, who will then contact you promptly.  
Note:  The back-up 24 hour global emergency contact call center should only be used if you are 
not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls.  
13.2.
Emergency Identification of Investigational Products
In both Part 1 and Part 2 the blind must not be broken during the course of the study unless in the 
opinion of the Investigator, it is absolutely necessary to safely treat the subject.  If it is medically 
imperative to know what IP the subject is receiving, the Investigator or authorized person should 
call IVRS for unblinded dose information, etc.  However, every effort should be made to contact 
the Clinical Research Physician/Medical Monitor prior to breaking the blind.  Contact or 
attempted contact with the Clinical Research Physician/Medical Monitor as well as the reason 
for breaking the blind must be documented in the source documents.  
Page 282 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
89
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
14.
REGULATORY CONSIDERATIONS
14.1.
Good Clinical Practice
The procedures set out in this study protocol pertaining to the conduct, evaluation, and 
documentation of this study are designed to ensure that Celgene, its authorized representative, 
and Investigator abide by Good Clinical Practice (GCP), as described in International 
Conference on Harmonization (ICH) Guideline E6 and in accordance with the general ethical 
principles outlined in the Declaration of Helsinki.  The study will receive approval from an 
IRB/EC prior to commencement.  The Investigator will conduct all aspects of this study in 
accordance with applicable national, state, and local laws of the pertinent regulatory authorities.  
14.2.
Investigator Responsibilities
Investigator responsibilities are set out in the ICH Guideline for Good Clinical Practice and in 
the local regulations.  Celgene staff or an authorized representative will evaluate and approve all 
Investigators who in turn will select their staff.  
The Investigator should ensure that all persons assisting with the study are adequately informed 
about the protocol, amendments, study treatments, as well as study-related duties and functions.  
The Investigator should maintain a list of Sub-investigators and other appropriately qualified 
persons to whom he or she has delegated significant study-related duties.  
The Investigator is responsible for keeping a record of all subjects who sign an informed consent 
document and are screened for entry into the study.  Subjects who fail screening must have the 
reason(s) recorded in the subject’s source documents.  
The Investigator, or a designated member of the Investigator’s staff, must be available during 
monitoring visits to review data, resolve queries and allow direct access to subject records (e.g., 
medical records, office charts, hospital charts, and study-related charts) for source data 
verification.  The Investigator must ensure timely and accurate completion of eCRFs and queries.  
14.3.
Subject Information and Informed Consent
The Investigator must obtain informed consent of a legal representative prior to any study related 
procedures.  
Documentation that informed consent occurred prior to the study subject’s entry into the study 
and of the informed consent process should be recorded in the study subject’s source documents 
including the date.  The original informed consent document signed and dated by the study 
subject and by the person consenting the study subject prior to the study subject’s entry into the 
study, must be maintained in the Investigator’s study files and a copy given to the study subject.  
In addition, if a protocol is amended and it impacts on the content of the informed consent, the 
informed consent document must be revised.  Study subjects participating in the study when the 
amended protocol is implemented must be re-consented with the revised version of the informed 
consent document.  The revised informed consent document signed and dated by the study 
subject and by the person consenting the study subject must be maintained in the Investigator’s 
study files and a copy given to the study subject.  
Page 283 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
90
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
14.4.
Confidentiality
Celgene affirms the subject's right to protection against invasion of privacy and to be in 
compliance with ICH and other local regulations (whichever is most stringent).  Celgene requires 
the Investigator to permit Celgene's representatives and, when necessary, representatives from 
regulatory authorities, to review and/or copy any medical records relevant to the study in 
accordance with local laws.  
Should direct access to medical records require a waiver or authorization separate from the 
subject’s signed informed consent document, it is the responsibility of the Investigator to obtain 
such permission in writing from the appropriate individual.  
14.5.
Protocol Amendments
Any amendment to this protocol must be approved by the Celgene Clinical Research 
Physician/Medical Monitor.  Amendments will be submitted to the IRB/EC for written approval.  
Written approval must be obtained before implementation of the amended version occurs.  The 
written signed approval from the IRB/EC should specifically reference the Investigator name, 
protocol number, study title and amendment number(s) that is applicable.  Amendments that are 
administrative in nature do not require IRB/IEC approval but will be submitted to the IRB/IEC 
for information purposes.  
14.6.
Institutional Review Board/Independent Ethics Committee Review 
and Approval
Before the start of the study, the study protocol, informed consent document, and any other 
appropriate documents will be submitted to the IRB/EC with a cover letter or a form listing the 
documents submitted, their dates of issue, and the site (or region or area of jurisdiction, as 
applicable) for which approval is sought.  If applicable, the documents will also be submitted to 
the authorities in accordance with local legal requirements.  
Investigational Product can only be supplied to an Investigator by Celgene or its authorized 
representative after documentation on all ethical and legal requirements for starting the study has 
been received by Celgene or its authorized representative.  This documentation must also include 
a list of the members of the IRB/EC and their occupation and qualifications.  If the IRB/EC will 
not disclose the names, occupations and qualifications of the committee members, it should be 
asked to issue a statement confirming that the composition of the committee is in accordance 
with GCP.  For example, the IRB General Assurance Number may be accepted as a substitute for 
this list.  Formal approval by the IRB/EC should mention the protocol title, number, amendment 
number (if applicable), study site (or region or area of jurisdiction, as applicable), and any other 
documents reviewed.  It must mention the date on which the decision was made and must be 
officially signed by a committee member.  Before the first subject is enrolled in the study, all 
ethical and legal requirements must be met.  
The IRB/EC and, if applicable, the authorities, must be informed of all subsequent protocol 
amendments in accordance with local legal requirements.  Amendments must be evaluated to 
determine whether formal approval must be sought and whether the informed consent document 
should also be revised.  
Page 284 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
91
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
The Investigator must keep a record of all communication with the IRB/EC and, if applicable, 
between a Coordinating Investigator and the IRB/EC.  This statement also applies to any 
communication between the Investigator (or Coordinating Investigator, if applicable) and 
regulatory authorities.  
Any advertisements used to recruit subjects for the study must be reviewed by Celgene and the 
IRB/EC prior to use.  
14.7.
Ongoing Information for Institutional Review Board / Ethics 
Committee
If required by legislation or the IRB/EC, the Investigator must submit to the IRB/EC:

Information on serious or unexpected adverse events as soon as possible; 

Periodic reports on the progress of the study;

Deviations from the protocol or anything that may involve added risk to subjects.  
14.8.
Closure of the Study
Celgene reserves the right to terminate this study at any time for reasonable medical or 
administrative reasons.  Any premature discontinuation will be appropriately documented 
according to local requirements (e.g., IRB/EC, regulatory authorities, etc...).  
In addition, the Investigator or Celgene has the right to discontinue a single site at any time 
during the study for medical or administrative reasons such as:

Unsatisfactory enrollment;

GCP noncompliance;

Inaccurate or incomplete data collection;

Falsification of records;

Failure to adhere to the study protocol.  
Page 285 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
92
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
15.
DATA HANDLING AND RECORDKEEPING 
15.1.
Data/Documents
The Investigator must ensure that the records and documents pertaining to the conduct of the 
study and the distribution of the investigational product are complete, accurate, filed and 
retained.  Examples of source documents include:  hospital records; clinic and office charts; 
laboratory notes; memoranda; subject’s diaries or evaluation checklists; dispensing records; 
recorded data from automated instruments; copies or transcriptions certified after verification as 
being accurate copies; microfiche; x-ray film and reports; and records kept at the pharmacy, and 
the laboratories, as well as copies of eCRFs or CD-ROM.  
15.2.
Data Management
Data will be collected via an electronic data capture (EDC) system rather than paper. Data will 
be entered into the clinical database as per Celgene SOPs.  These data will be electronically 
verified through use of on-line checks during data entry, and through programmed edit checks
specified by the clinical team. The Clinical team and investigational site personnel will be 
alerted of discrepant data by the functionality of the system. Resolutions to these issues will be 
reflected in the database. An audit trail within the system will track all changes made to the data.  
15.3.
Record Retention
Essential documents must be retained by the Investigator for a minimum of 2 years after the last 
approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region, or at least 2 years have elapsed since the 
formal discontinuation of clinical development of the IP.  The Investigator must retain these 
documents for the time period described above or according to local laws or requirements, 
whichever is longer.  Essential documents include, but are not limited to, the following:

Signed informed consent documents for all subjects;

Subject identification code list, screening log (if applicable), and enrollment log;

Record of all communications between the Investigator and the IRB/EC;

Composition of the IRB/EC;

Record of all communications between the Investigator, Celgene, and their authorized 
representative(s);

List of Sub-investigators and other appropriately qualified persons to whom the 
Investigator has delegated significant study-related duties, together with their roles in 
the study, curriculum vitae, and their signatures;

Copies of CRFs (if paper) and of documentation of corrections for all subjects;

IP accountability records;

Record of any body fluids or tissue samples retained;
Page 286 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
93
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011

All other source documents (subject records, hospital records, laboratory records, 
etc.); 

All other documents as listed in Section 8 of the ICH consolidated guideline on GCP 
(Essential Documents for the Conduct of a Clinical Trial).  
The Investigator must notify Celgene if he/she wishes to assign the essential documents to 
someone else, remove them to another location or is unable to retain them for a specified period.  
The Investigator must obtain approval in writing from Celgene prior to destruction of any 
records.  If the Investigator is unable to meet this obligation, the Investigator must ask Celgene 
for permission to make alternative arrangements.  Details of these arrangements should be 
documented.  
All study documents should be made available if required by relevant health authorities.  
Investigator/Institution should take measures to prevent accidental or premature destruction of 
these documents.  
Page 287 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
94
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
16.
QUALITY CONTROL AND QUALITY ASSURANCE
All aspects of the study will be carefully monitored by Celgene or its authorized representative 
for compliance with applicable government regulations with respect to current GCP and standard 
operating procedures.  
16.1.
Study Monitoring and Source Data Verification
Celgene ensures that appropriate monitoring procedures are performed before, during and after 
the study.  Before the study is initiated at a site visit or at an investigator meeting, all aspects of 
the study are reviewed with the Investigator and the staff.  Prior to enrolling subjects into the 
study, a Celgene representative will review the protocol, eCRFs, procedures for obtaining 
informed consent, record keeping, and reporting of AEs/SAEs with the Investigator.  Monitoring 
will include on-site visits with the Investigator and his/her staff as well as any appropriate 
communications by mail, email, fax, or telephone.  At each monitoring visit, the facilities, 
investigational product storage area, eCRFs, subject’s source documents, and all other study 
documentation will be inspected/reviewed by the Celgene representative for accuracy, adherence 
to the protocol and Good Clinical Practice.  
Accuracy will be checked by performing source data verification that is a direct comparison of 
the entries made onto the eCRFs against the appropriate source documentation.  Any resulting 
discrepancies will be reviewed with the Investigator and/or his/her staff.  Any necessary 
corrections will be made directly to the eCRFs or via queries by the Investigator and/or his/her 
staff.  Monitoring procedures require that informed consents, adherence to inclusion/exclusion 
criteria and documentation of SAEs and their proper recording be verified.  Additional 
monitoring activities may be outlined in a study-specific monitoring plan.  
16.2.
Audits and Inspections
In addition to the routine monitoring procedures, a Good Clinical Practice Quality Assurance 
unit exists within Celgene.  Representatives of this unit will conduct audits of clinical research 
activities in accordance with Celgene SOPs to evaluate compliance with Good Clinical Practice 
guidelines and regulations.  
The Investigator is required to permit direct access to the facilities where the study took place, 
source documents, eCRFs and applicable supporting records of study subject participation for 
audits and inspections by IRB/IECs, regulatory authorities (e.g., FDA, EMEA, Health Canada) 
and company authorized representatives.  The Investigator should make every effort to be 
available for the audits and/or inspections.  If the Investigator is contacted by any reulatory 
authority regarding an inspection, he/she should contact Celgene immediately.  
Page 288 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
95
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
17.
PUBLICATIONS
The results of this study may be published in a medical publication, journal, or may be used for 
teaching purposes.  Additionally, this study and its results may be submitted for inclusion in all 
appropriate health authority study registries, as well as publication on health authority study 
registry websites, as required by local health authority regulations.  Selection of first authorship 
will be based on several considerations, including, but not limited to study participation, 
contribution to the protocol development, and analysis and input into the manuscript, related 
abstracts, and presentations in a study.
Page 289 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
96
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
18.
REFERENCES
Chantry A, Heath D, Mulivor A, Coulton L, Evans H, Abdul N, Werner ED, Bouxsein ML, 
Pearsall RS, Seehra J, Vanderkerken K, and Croucher PI.  Inhibiting activin-A signalling 
stimulates bone formation, prevents tumor-induced osteolytic bone destruction and blocks bone 
metastasis.  Submitted 2008.  
Chen Y-G, Lui HM, Lin S-L, Lee JM, and Ying S-Y.  Regulation of cell proliferation, apoptosis, 
and carcinogenesis by activin.  Exp Biol Med 2002; 227: 75-87.  
Dang TP, Carbone DP:  Cancer of the Lung, in DeVita, VT, Hellman S, Rosenberg SA (eds): 
Cancer: Principles & Practice of Oncology, 8th edition, Philadelphia, PA. Lippincott Williams & 
Wilkens, 2008, 887-971.  
Functional Assessment of Chronic Illness Therapy-Fatigue, FACIT-F Version 4. 
http://www.facit.org/qview/qlist.aspx, last accessed 21Jul2010.
Groopman JE, Itri LM.  Chemotherapy-Induced Anemia in Adults:  Incidence and Treatment.  
Journal of the National Cancer Institute 1999, 91, 1616-1634.  
Hollen PJ, Gralla RJ, Kris MG ‘Lung Cancer Symptom Scale (LCSS)’, Administration, Scoring 
and Procedures Manual, (1995) Ver.1.1.  
Hong WK, Tsao AS, in Lung Carcinoma: Tumors of the Lungs: Merck Manuals Online Medical 
Library for Healthcare Professionals, 2008. 
http://www.merck.com/mmpe/print/sec05/ch062/ch062b.html
Lotinun S, Fajardo RJ, Pearsall RS, Bouxsein ML, and Baron R.  A soluble activin receptor type 
IIA fusion protein, ACE-011, increases bone mass by stimulating bone formation and inhibiting 
bone resorption in cynomolgus monkeys.  ASBMR 30th annual meeting, 2008.  
Mathews LS.  Activin receptors and cellular signaling by the receptor serine kinase family.  
Endocr Rev 1994; 15: 310-25.  
Murata M, Onomichi K, Eto Y, Shibai H, and Muramatsu M.  Expression of erythroid 
differentiation factor (EDF) in Chinese hamster ovary cells.  Biochem Biophys Res Commun
1988; 151: 230-5.  
Nakao K, Kosaka M and Saito S.  Effects of erythroid differentiation factor (EDF) on 
proliferation and differentiation of human hematopoietic progenitors.  Exp Hematol 1991; 19: 
1090-5.  
National Heart, Lung, and Blood Institute, National Institutes of Health.  New York Heart 
Association Classification. 2008.  
NCCN Clinical Practice Guidelines in Oncology:  Cancer and Chemotherapy Induced Anemia, 
V.2. 2010 http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf; 2009.  
Non-small Cell Lung cancer Collaborative Group ‘Chemotherapy in non-small cell lung cancer:  
a meta-analysis using updated data on individual patients from 52 randomized clinical trials’, 
British Medical Journal 1995 vol. 311, no.7010, 899-909.  
Page 290 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
97
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
Oken, MM., Creech, R.H., Tormey, D.C., et. al.  Toxicity And Response Criteria Of The Eastern 
Cooperative Oncology Group.  Am J Clin Onco 1982; 5:649-655.  
Parker SL, Tong T, Bolden S, et. al.  Cancer statistics, 1997.  CA Cancer J Clin, 1997, 47, no. 1, 
5-27.  
Pearsall RS, Canalis E, Cornwall-Brady M, Underwood KW, Haigis B, Ucran J, Kumar R, Pobre 
E, Grinberg A, Werner ED, Glatt V, Stadmeyer L, Smith D, Seehra J, and Bouxsein ML.  A 
soluble activin type IIA receptor induces bone formation and improves skeletal integrity.  Proc 
Natl Acad Sci USA 2008, 105: 7082-7.  
Perrien DS, Akel NS, Edwards PK, et. al.  Inhibin A is an endocrine stimulator of bone mass and 
strength.  Endocrinology 2007; 148: 1654-65.  
Rivier J, Spiess J, McClintock R, Vaughan J and Vale W.  Purification and partial 
characterization of inhibin from porcine follicular fluid.  Biochem Biophys Res Commun 1985; 
133: 120-7.  
Rossi A, Maione P, Gridelli C Cetuximab in advanced non-small cell lung cancer.  Critical 
Reviews in Oncology/Hematology, 2006 59, 139-149.  
Ruckle J, Jacobs M, Kramer W, et. al.  A single-dose, randomized, double-blind, placebo-
controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women.  J Bone Miner Res
2009; 24 (4): 744-52.  
Sandler A, Gray R, Perry M, et al Paclitaxel-Carboplatin alone or with Bevacizumab for Non 
Small Cell Lung Cancer, NEJM, 2006 vol.355, no.24, 2542-50.  
Scagliotti G, Parikh P, von Pawel J, et al Phase III Study Comparing Cisplatin Plus Gemcitabine 
With Cisplatin Plus Pemetrexed in Chemotherapy-Naïve patients With Advanced-Stage Non-
Small-Cell Lung Cancer, JCO, 2008, 26 (21): 3543-51.  
Schiller J, Harrington D, Belani C, et al Comparison of Four Chemotherapy Regimens for 
Advanced Non-Small-Cell Lung Cancer.  N Engl J Med 2002; 346:92-98.  
Seder C, Hartojo W, Lin L, et al Upregulated INHBA Expression May Promote Cell 
Proliferation and Is Associated with Poor Survival in Lung Adenocarcinoma, Neoplasia, 2009, 
11: 388-396.  
Shedden K, Taylor J, Enkemann S, et al Gene Expression-Based Survival prediction in Lung 
Adenocarcinoma: A Multi-Site, Blinded Validation Study: Director’s Challenge Consortium for 
the Molecular Classification of Lung Adenocarcinoma, Nat Med, 2008, 14 (8): 822-827.  
Shiozaki M, Sakai R, Tabuchi M, et. al.  Evidence for the participation of endogenous activin 
A/erythroid differentiation factor in the regulation of erythropoiesis.  Proc Natl Acad Sci USA
1992; 89: 1553-6.  
Shiozaki M, Sakai R, Tabuchi M, et. al.  In vivo treatment with erythroid differentiation factor 
(EDF/activin A) increases erythroid precursors (CFU-E and BFU-E) in mice.  Biochem Biophys 
Res Commun 1989; 165: 1155-61.  
Vansteenkiste J, Pirker R, Massuti B, et. al.  Double-Blind, Placebo-Controlled, Randomized 
Phase III Trial of Darbepoetin Alfa in Lung Cancer Patients Receiving Chemotherapy.  Journal 
of the National Cancer Institute, 2002, 94: 16: 1211-1220.  
Page 291 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
98
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
Woodruff TK.  Regulation of cellular and system function by activin.  Biochem Pharmacol 1998; 
55: 953-63.  
Ying S-Y.  Inhibins, activins, and follistatins:  gonadal proteins modulating the secretion of 
follicle-stimulating hormone.  Endocrine Rev 1988; 9: 267-93.  
Page 292 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
99
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
19.
APPENDICES
Appendix A:  Response Evaluation Criteria in Solid Tumors
Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Terms
Definition
Measurable disease
The presence of at least one measurable lesion by CT or MRI.  If the measurable 
disease is restricted to a solitary lesion, its neoplastic nature should be confirmed by 
cytology/histology.  
All measurements should be taken and recorded in metric notation, using a ruler or 
calipers.  All baseline evaluations should be performed as closely as possible to the 
beginning of treatment and never more than 4 weeks before the beginning of the 
treatment. 
Measurable lesions
Lesions that can be accurately measured in least one dimension by CT scan with 
longest diameter > 10 mm (CT scan thickness no greater than 5 mm).  
The same method of assessment and the same technique should be used to characterize 
each identified and reported lesion at baseline and during follow-up. 
Non-measurable lesion
All other lesions, including small lesions (longest diameter <10mm or pathological 
lymph nodes with P10 to <15mm short axis) as well as truly non-measurable lesions.  
Lesions considered truly non-measurable include:  leptomeningeal disease, ascites, 
pleural or pericardial effusion, inflammatory breast disease, lymphangitic involvement 
of skin or lung, abdominal masses/abdominal organomegaly identified by physical 
exam that is not measurable by reproducible imaging techniques.
RECIST Criteria-Response Evaluation
Evaluation of target lesions
Complete Response (CR)
Disappearance of all target lesions.  
Any pathological lymph nodes (whether target or non-target) must have 
reduction in short axis to <10 mm.
Partial Response (PR):
At least a 30% decrease in the sum of diameters of target lesions, taking as 
reference the baseline sum diameters.
Stable Disease (SD):
Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify 
for PD, taking as reference the smallest sum diameters while on study.
Progressive Disease (PD):
At least a 20% increase in the sum of diameters of target lesions, taking as 
reference the smallest sum on study (this includes the baseline sum if that is the 
smallest on study).  In addition to the relative increase of 20%, the sum must 
also demonstrate an absolute increase of at least 5 mm.  
(Note:  the appearance of one or more new lesions is also considered 
progression).
Page 293 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
100
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
RECIST Criteria-Response Evaluation (continued)
Evaluation of non-target 
lesions
Complete Response (CR):
Disappearance of all non-target lesions and normalisation of tumour marker 
level.  All lymph nodes must be non-pathological in size (<10mm short 
axis).
Non-CR/Non-PD
Persistence of one or more non-target lesion(s) and/or maintenance of 
tumour marker level above the normal limits.
Progressive Disease (PD): 
Unequivocal progression (see comments below) of existing non-target 
lesions.  
(Note:  the appearance of one or more new lesions is also considered 
progression).
Evaluation of best overall response
The best overall response is the best response recorded from the start of the 
treatment until disease progression/recurrence (taking as reference for PD 
the smallest measurements recorded since the treatment started).  In general, 
the patient's best response assignment will depend on the achievement of 
both measurement and confirmation criteria.  
Patients with a global deterioration of health status requiring discontinuation 
of treatment without objective evidence of disease progression at that time 
should be classified as having “symptomatic deterioration”.  Every effort 
should be made to document the objective progression even after 
discontinuation of treatment.  
In some circumstances it may be difficult to distinguish residual disease 
from normal tissue.  When the evaluation of complete response depends on 
this determination, it is recommended that the residual lesion be investigated 
(fine needle aspirate/biopsy) to confirm the complete response status.  
Source:  Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R,  Dancey J, Arbuck S, Gwyther S, 
Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R,  Lacombe D, Verweij J.  New response evaluation 
criteria in solid tumours:  Revised RECIST guideline (version 1.1)  (2009).  European Journal of Cancer 45, 228-
247.  
Page 294 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
101
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
Appendix B:  ECOG Performance Status Scale 
The ECOG scale (Oken, 1982) is used to assess a patient’s quality of life in an evaluation by a 
health professional of the daily activities and how the activities are affected by the disease of the 
patient.  
Table 10:
ECOG Performance Status Scale
Score
Description
0
Fully active, able to carry on all pre-disease performance without restriction
1
Restricted in physically strenuous activity but ambulatory and able to carry out work of 
a light or sedentary nature, e.g., light housework, office work.
2
Ambulatory and capable of all self-care but unable to carry out any work activities.  Up 
and about more than 50% of waking hours.
3
Capable of only limited self-care, confined to bed or chair more than 50% of waking 
hours.
4
Completely disabled.  Cannot carry on any self-care.  Totally confined to bed or chair
5
Dead
Page 295 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
102
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
Appendix C:  National Cancer Institute (NCI) Common Terminology Criteria 
for Adverse Events (CTCAE) Version 4.0
Currently active minor version of NCI CTCAE, Version 4.0:
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
Page 296 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
103
ACE-011-NSCL-001 1.0 FINAL: 22MAR 2011
Appendix D:  New York Heart Association - Classification of Heart Failure
Table 11:
Classification of Heart Failure
Class
Symptoms
Class 1
No limitation of activities.  No symptoms from ordinary activities
Class 2
Mild limitation of activity.  Comfortable with rest or mild exertion
Class 3
Marked limitation of activity and be comfortable only at rest
Class 4
Complete rest, confined to bed or chair; any physical activity brings on discomfort and 
symptoms occur at rest
Page 297 of 791
088VGY

088VGY

088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
3
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
1.
JUSTIFICATION FOR AMENDMENT
Significant changes included in this amendment are summarized below.  These changes were 
based on feedback obtained from investigators/sites, key opinion leaders and internal 
discussions:
In Part 1-
1. Modified to expand eligible tumor types to include the following metastatic solid tumor
types where the standard of care is platinum-based chemotherapy-
metastatic non-small cell lung cancer (NSCLC)
metastatic small cell lung cancer
metastatic bladder cancer
metastatic head and neck cancer 
metastatic endometrial/cervical cancer 
2. Modified to remove single-blind and add open-label of ACE-011 (sotatercept) dose 
levels.
3. Modified to allow for sparse PK in a subset of subjects not participating in the full PK 
analysis.
4. Modified to remove archival tumor tissue analysis.
5.
Modified to allow any platinum-based regimen approved for the specific metastatic solid 
tumor type.
In Part 1 and Part 2
6. Modified to add Medical Monitor mobile phone number.
7. Revised screening period for tumor assessment from 6 weeks to ‘as per standard of care 
at the study site ’. 
8. Clarification of data collection history of prior use of erythropoietic stimulating agents 
and red blood cell transfusion. 
9. Removal of trailing zero’s from sotatercept (ACE-011) doses (i.e., 15.0 mg replaced with 
15 mg, etc.).  
10. Further clarification of criteria to be met to determine addition of  sotatercept (ACE-011) 
45 mg dose level in Part 1  - the analysis of safety data following the treatment of at least 
10 subjects at the 15 mg dose level and 10 subjects at the 30 mg dose level, with each 
subject having received a minimum of one dose of sotatercept (ACE-011) and completion 
of a 12 week follow-up period from the first dose and the subsequent decision to add a 
third dose level of 45 mg to the randomization schema. 
11. Modified to include that concentration of sotatercept (ACE-011) may be determined in 
anti-drug (sotatercept) antibody samples.
12. Modified to describe PK parameters to be measured.
Page 300 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
4
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
13. Discontinuation of study treatment- Clarification of definition of lack of sotatercept 
(ACE-011) therapeutic effect in Part 1 and Part 2 of the study and timeframe in which 
assessment should be performed.
14. Clarification of QoL Assessments to specify that all subjects will complete the FACIT 
Fatigue Scale [Version 4] and only subjects with NSCLC will complete the LCSS.
15. Modified to allow first dose of ACE-011 to be administered at any time during 
chemotherapy cycle versus +/- seven days.
16. Modified to allow bisphosphonate and denosumab therapy.
17. Objectives -
Revised to include specific metastatic solid tumor types in Part 1 and only metastatic 
NSCLC in Part 2 of the study. 
18. Additional clarification to describe the primary objective of transfusion rate following 
initiation of sotatercept (ACE-011)/placebo in Part 2.
19. Introduction- Revised to include: 
a.
Additional selected solid metastatic tumors in Part 1.
b. Detailed description of Part 2.
c.
Additional detail in Chemotherapy Induced Anemia, Treatment of Chemotherapy 
Induced Anemia and Sotatercept (ACE-011) Chemotherapy Induced Anemia 
Sections
20. Revision of Sotatercept (ACE-011) and Pharmacology sections to add and clarify 
preclinical data.  
21. Potential Risks for Human Use-
a.
Clarification that liver enzymes will be monitored in this study
b. Correction of typographical error- Based on the safety data from the two 
completed phase 1 studies, single doses of ACE-011 up to 3.0 mg/kg IV and 
multiple doses of ACE-011 up to 0.3 mg/kg SC were generally well-tolerated in 
healthy postmenopausal women.
22. Endpoints
a.
Clarification that hematopoietic response will be assessed by laboratory analysis 
of hemoglobin.
b. Revised to include additional Lung Cancer Symptom Scale references. 
c.
Clarification that archival tumor tissue analysis will occur only in Part 2 of the 
study.
23. Study Design- Clarification of treatment period timeframe for up to 4 doses of sotatercept 
(ACE-011) in Part 1 and up to 6 doses of sotatercept (ACE-011)/placebo in Part 2 of the 
study.
24. Sotatercept (ACE-011) Dose Modification, Reduction and Escalation Rules-
Page 301 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
5
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
Confirmed sotatercept (ACE-011) dose ‘delay’ as > 4 days and correction of 
typographical error: A delayed sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo dose is defined as a dose administered > 4 days from the planned 
dosing date (due to Hgb ≥ 11.0 g/dL, hypertension > SBP 150 mmHg and > DBP 
100 mmHg and/or sotatercept (ACE-011) related toxicity. 
25. Clarification of study design rationale describing clinical and nonclinical experience.
26. Revision of Schedule of Assessments
a.
Revised screening period for tumor assessment from 6 weeks to ‘as per standard 
of care at the study site ’.
b. Modified collection of ‘NSCLC history’ to ‘cancer history’.
c.
Clarification that Activin A and other proteins/biomarkers will be assessed in 
serum.
d. Modified archival tumor tissue collection to optional.
e.
Clarification that dual energy X-ray Absorptiometry (DXA) scan includes lumbar 
spine and hip.
f.
Modified for sparse PK blood collection in a subset of subjects not participating 
in full PK in Part 1.
g. Modified to allow first dose of ACE-011 to be administered at any time during a 
chemotherapy cycle versus +/- seven days.
h. Clarification of QoL Assessments to specify that all subjects will complete the 
FACIT Fatigue Scale [Version 4] and only subjects with NSCLC will complete 
the LCSS.
27. Revision of Inclusion Criteria:
a.
Revised to include selected metastatic solid tumor types treated with platinum-
based chemotherapy in Part 1.
b. Modified to allow up to 4 prior cycles of first line platinum-based chemotherapy 
at randomization.
c.
Part 1- Modified to allow any platinum-based regimen approved for the specific 
metastatic solid tumor type.
d. Part 2- Modified to include the following allowed regimens for the treatment of 
NSCLC:
i. gemcitabine plus cisplatin or carboplatin ± bevacizumab
ii. pemetrexed plus cisplatin or carboplatin ± bevacizumab
iii. taxanes plus cisplatin or carboplatin ± bevacizumab
e.
Modified to allow prior and concurrent bisphosphonate or denosumab 
(XGEVA™) therapy for bone metastases.  
28. Revision of Exclusion Criteria:
Page 302 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
6
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
a.
Revised to include selected metastatic solid tumor types treated with platinum-
based chemotherapy in Part 1.
b. Revised to clarify acceptable history of prior platinum-based chemotherapy.
29. Clarification that subjects may receive maintenance therapy while on study treatment.
30. Modified to clarify role of unblinded pharmacist based on removal of single-blind in  
Part 1 of the study. 
Other administrative changes (e.g., revisions to the reference section, protocol template section 
updates, correction of typographical errors, editorial changes, etc.) were also incorporated and 
are outlined in Section 2 Itemized Changes.
Page 303 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
7
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
2.
ITEMIZED CHANGES
2.1.
Title Page (page 1)
Original Text:
A SINGLE-BLIND, RANDOMIZED, PHASE 2A, DOSE-
RANGING STUDY (PART 1) OF SOTATERCEPT 
(ACE-011) THERAPY FOLLOWED BY A PHASE 2B/3, 
DOUBLE-BLIND, RANDOMIZED, PLACEBO-
CONTROLLED STUDY (PART 2) OF SOTATERCEPT
(ACE-011) FOR CHEMOTHERAPY-INDUCED ANEMIA 
IN SUBJECTS WITH METASTATIC NON-SMALL CELL 
LUNG CANCER TREATED WITH FIRST-LINE 
PLATINUM-BASED CHEMOTHERAPEUTIC 
REGIMENS
Revised Text:
A SINGLE-BLIND,AN OPEN-LABEL, RANDOMIZED, 
PHASE 2A, DOSE- RANGING STUDY (PART 1) OF 
SOTATERCEPT (ACE-011) THERAPYFOR 
CHEMOTHERAPY-INDUCED ANEMIA IN SUBJECTS 
WITH SELECTED METASTATIC SOLID TUMORS
TREATED WITH PLATINUM-BASED 
CHEMOTHERAPEUTIC REGIMENS FOLLOWED BY A 
PHASE 2B/3, DOUBLE-BLIND, RANDOMIZED, 
PLACEBO-CONTROLLED STUDY (PART 2) OF 
SOTATERCEPT (ACE-011) FOR CHEMOTHERAPY-
INDUCED ANEMIA IN SUBJECTS WITH METASTATIC 
NON-SMALL CELL LUNG CANCER TREATED WITH 
FIRST-LINE PLATINUM-BASED 
CHEMOTHERAPEUTIC REGIMENS
Page 304 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
8
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
Rationale:
Modified to expand study population in Part 1 of the study to include selected metastatic solid 
tumor types treated with first-line platinum-based chemotherapy.
Page 305 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
9
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
2.2.
Section:  MEDICAL MONITOR / EMERGENCY CONTACT 
INFORMATION, (page 2)
Original Text:
Contact Information:
Revised Text:
Contact Information:
Rationale:
Revised to add Celgene medical monitor’s mobile telephone number. 
Page 306 of 791
PPD
PPD
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
10
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
2.3.
Section:  Protocol Summary (pages 6-12)
Original Text:
Protocol Summary
Study Title
A single-blind, randomized, phase 2a, dose-ranging study (Part 1) of sotatercept (ACE-011) 
therapy followed by a phase 2b/3, double-blind, randomized, placebo-controlled study (Part 2) 
of sotatercept (ACE-011) for chemotherapy-induced anemia in subjects with metastatic non-
small cell lung cancer treated with first-line platinum-based chemotherapeutic regimens.  
Indication
Chemotherapy Induced Anemia (CIA) in Subjects with Metastatic Non-Small Cell Lung Cancer 
(NSCLC).  
Objectives
The primary objectives are:
Part 1:  To determine an effective dose of sotatercept (ACE-011) showing a 
hematopoietic response in the treatment of CIA in metastatic NSCLC subjects.  
Part 2:  To assess transfusion rate following initiation of sotatercept (ACE-
011)/placebo treatment.  
The secondary objectives are:
Part 1 and Part 2:
To estimate the effect of sotatercept (ACE-011) treatment on objective response rate 
(ORR), time to progression (TTP), progression free survival (PFS) and overall 
survival (OS) in metastatic NSCLC subjects with CIA.  
To evaluate the safety and tolerability of sotatercept (ACE-011) treatment in 
metastatic NSCLC subjects with CIA.  
To determine the pharmacokinetics (PK) of sotatercept (ACE-011) in subjects with 
metastatic NSCLC receiving platinum-based chemotherapy.  
_  _  _  _  _  _ _  _  _  _
To evaluate the effect of sotatercept (ACE-011) treatment on the quality of life (QoL) 
of NSCLC subjects with CIA.  
_  _  _  _  _  _  _  _  _  _
The exploratory objectives are:
Part 1 and Part 2:

To estimate the effect of sotatercept (ACE-011) treatment on bone metabolism in 
NSCLC subjects with CIA.  
_  _  _  _  _  _  _  _  _  _
Page 307 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
11
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011

To evaluate the expression of Activin A and other proteins/biomarkers in archival 
tumor tissue.
_  _  _  _  _  _  _  _  _  _
Study Design
This is a single-blind, randomized, phase 2a, dose-ranging study (Part 1) of sotatercept (ACE-
011) therapy followed by a phase 2b/3, double-blind, randomized, placebo-controlled study 
(Part 2) of sotatercept (ACE-011) for CIA subjects with metastatic non-small cell lung cancer 
treated with first-line platinum-based chemotherapeutic regimens.  
The study will consist of two parts:
Part 1 is a dose-finding segment in which up to approximately 90 subjects will be randomized to 
one of three sotatercept (ACE-011) dose treatment arms.  The primary objective is to determine 
an effective dose of sotatercept (ACE-011) showing a hematopoietic response in the treatment of 
CIA in metastatic NSCLC subjects.  The sample size is for the purpose of hypothesis generation; 
however, it would allow approximately 80% power to detect an effect size of 0.33 using a 2 
degrees of freedom Chi-Square Test with a significance level (alpha) of 0.05.  
Part 2 is the phase 2b/3 double-blind, randomized, placebo-controlled segment of the study and 
will be performed in two stages.
_  _  _  _  _  _  _  _  _  _
Study Population
At the time of randomization, all subjects must be receiving their first regimen of  first-line 
platinum-containing chemotherapy, given every three weeks, for the treatment of metastatic 
NSCLC. Subjects may have already received up to 3 cycles and must be randomized prior to 
receiving Cycle 4 of this current first-line platinum-based regimen to be eligible for the study.  It 
is  expected that subjects be eligible to continue to receive ≥ 2 additional platinum-based 
chemotherapy cycles while on study treatment.  
Subjects must not have received any other regimens of chemotherapy for the first-line platinum 
containing treatment of metastatic NSCLC prior to the regimen at the time of randomization. 
_  _  _  _  _  _  _  _  _  _
Screening Period (28 days):
Potential study subjects will sign an informed consent form prior to undergoing any study-related 
procedures.  Subjects will undergo screening for protocol eligibility within 28 days of 
randomization, as outlined in the Table of Events, Section 5.  Note: Screening period tumor 
assessments should be performed within six weeks prior to randomization.  
_  _  _  _  _  _  _  _  _  _
Prior erythropoietic stimulating agent (ESA) treatment history starting from initial diagnosis of 
NSCLC and red blood cell (RBC) transfusion history starting from diagnosis of metastatic 
NSCLC at a minimum of up to two months prior to randomization will be collected.
_  _  _  _  _  _  _  _  _  _
Page 308 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
12
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
Treatment Period (up to 6-9 months):  
_  _  _  _  _  _  _  _  _  _
In Part 1 (the dose-ranging portion of the study), subjects who meet all eligibility criteria will be 
randomized to receive one of the following sotatercept (ACE-011) dose levels, with 10-30 
subjects per arm:
Sotatercept (ACE-011) 15.0 mg SC
Sotatercept (ACE-011) 30.0 mg SC
Analysis of safety data will be performed following the treatment of at least 10 subjects at the 
15.0 mg dose level and 10 subjects at the 30.0 mg dose level, with each subject having received 
at least of one dose of sotatercept (ACE-011), plus a 12-week follow-up period from first dose.  
Following this analysis, the addition of a third dose level:
Sotatercept (ACE-011) 45.0 mg SC
to the randomization schema will be determined.
_  _  _ _  _  _  _  _  _  _
Evaluation of hemoglobin response decision status will be completed after dosing arms have 
separately enrolled up to 30 subjects, as needed, to determine the optimal dose for Part 2.  
_  _  _  _  _  _  _  _  _  _
In Part 2, a total of 750 subjects will be randomized to receive either sotatercept (ACE-011) or 
placebo, at a ratio of 1:1:
_  _  _  _  _  _  _  _  _  _
In Part 1, full PK blood samples will be collected to evaluate the full PK profile of sotatercept 
(ACE-011) from approximately 30 subjects at select centers, in approximately 10 subjects for 
each sotatercept (ACE-011) dose group.  In subjects participating in the full PK assessment, 
RBC, Hgb, and reticulocyte counts will be collected at each PK time point (excluding the 4-hour
time point on Day 1) from Day 1 to Day 43 after the first dose.  Subjects not participating in the 
optional full PK assessment will participate in the sparse PK assessment.  
In Part 2, the sparse PK assessment will be performed in approximately 300 (40%) of 750 
subjects (approximately 150 subjects in each arm).  
_  _  _  _  _  _  _  _  _  _
Subjects will be discontinued from Study Treatment due to the following:
_  _  _  _  _  _  _  _  _  _
Lack of sotatercept (ACE-011) therapeutic effect, defined as < 1.0 g/dL increase in 
Hgb following two doses of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo.  
_  _  _  _  _  _  _  _  _  _
Disease progression of NSCLC
Page 309 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
13
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
_  _  _  _  _  _  _  _  _  _
Post Treatment Follow-Up Period (monthly visits for up to 6 months)
_  _  _  _  _  _  _  _  _  _
The following events may be considered sufficient reasons for discontinuing a subject from the 
study:
_  _  _  _  _  _  _  _  _  _
Disease progression of NSCLC
_  _  _  _  _  _  _  _  _  _
Overview of Safety Assessments
_  _  _  _  _  _  _  _  _  _
QoL Assessment (FACIT Fatigue Scale [Version 4]) and Lung Cancer Symptom 
Scale (LCSS) questionnaire.  
Revised Text:
Study Title
An open-label, single-blind, randomized, phase 2a, dose- ranging study (Part 1) of sotatercept 
(ACE--011) therapyfor chemotherapy-induced anemia in subjects with selected metastatic solid 
tumors treated with platinum-based chemotherapeutic regimens followed by a phase 2b/3, 
double-blind, randomized, placebo-controlled study (Part 2) of sotatercept (ACE-011) for 
chemotherapy-induced anemia in subjects with metastatic non-small cell lung cancer treated with 
first-line platinum-based chemotherapeutic regimens.
Indication
Chemotherapy Induced Anemia (CIA) in Subjects with Metastatic Non-Small Cell Lung Cancer
Solid Tumors
Part 1 – Solid tumors, including metastatic non-small cell lung cancer (NSCLC), metastatic 
small cell lung cancer, metastatic bladder cancer, metastatic head and neck cancer, and
metastatic endometrial/cervical cancer, where the standard of care is first-line platinum-based 
chemotherapy.  No solid tumors other than those tumor types listed above should be considered 
for this study.  
Part 2 - Metastatic NSCLC.
Objectives
The primary objectives are:
Part 1:  To determine an effectivea dose of sotatercept (ACE-011) showing that 
results in a hematopoietic response in for the treatment of CIA in metastatic NSCLC 
subjects. with selected metastatic solid tumors treated with platinum-based
chemotherapeutic regimens.
Page 310 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
14
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
Part 2:  To assess transfusion rate following initiation of sotatercept (ACE-
011)/placebo treatment) treatment versus placebo in subjects with CIA who have 
metastatic NSCLC treated with first-line platinum-based chemotherapeutic regimens.  
The secondary objectives are:
Part 1 and Part 2:
To estimate the effect of sotatercept (ACE-011) treatment on objective response rate 
(ORR), time to progression (TTP), progression free survival (PFS) and overall 
survival (OS) in metastatic NSCLC subjects with CIA.  ).

To evaluate the safety and tolerability of sotatercept (ACE-011) treatment in 
metastatic NSCLC subjects with CIA. ).
To determine the pharmacokinetics (PK) of sotatercept (ACE-011) in subjects with 
metastatic NSCLC receiving platinum-based chemotherapy.  
_  _  _  _  _  _  _  _  _  _

To evaluate the effect of sotatercept (ACE-011) treatment on the quality of life 
(QoL) of NSCLC subjects with CIA. ).
_  _  _  _  _  _  _  _  _  _
The exploratory objectives are:
Part 1 and Part 2:

To estimate the effect of sotatercept (ACE-011) treatment on bone metabolism in 
NSCLC subjects with CIA.
_  _  _  _  _  _  _  _  _  _

To evaluate the expression of Activin A and other proteins/biomarkers in archival 
tumor tissue (Part 2 only). 
_  _  _  _  _  _  _  _  _  _
Study Design
This is an open-label, single-blind, randomized, phase 2a, dose-ranging study (Part 1) of 
sotatercept (ACE-011) therapy for CIA in subjects with metastatic solid tumors treated with 
platinum-based chemotherapeutic regimens followed by a phase 2b/3, double-blind, randomized, 
placebo-controlled study (Part 2) of sotatercept (ACE-011) therapy for CIA in subjects with 
metastatic non-small cell lung cancer treated with first-line platinum-based chemotherapeutic 
regimens.  
The study will consist of two parts:
Part 1 is a dose-finding segment in which up to approximately 90 subjects will be randomized to 
one of three sotatercept (ACE-011) dose treatment arms.  The primary objective is to determine 
an effective dose of sotatercept (ACE-011) that results inshowing a hematopoietic response in 
the treatment of CIA in subjects with metastatic NSCLC subjects.solid tumors treated with 
Page 311 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
15
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
platinum-based chemotherapy.  The sample size is for the purpose of hypothesis generation; 
however, it would allow approximately 80% power to detect an effect size of 0.33 using a 2 
degrees of freedom Chi-Square Test with a significance level (alpha) of 0.05.  
Part 2 is the phase 2b/3 double-blind, randomized, placebo-controlled segment of the study and 
will be performed in two stages. Its primary objective is to determine the transfusion rate 
following initiation of sotatercept (ACE-011) treatment versus placebo in subjects with CIA who 
have metastatic NSCLC treated with first-line platinum-based chemotherapeutic regimens.
_  _  _  _  _  _  _  _  _  _
Study Population
At the time of randomization, all subjects must be receiving their first regimen of first-line 
platinum-containing based chemotherapy , given every three weeks, for the treatment of one of 
the selected metastatic NSCLC. solid tumor types which include: metastatic non-small cell lung 
cancer (NSCLC), metastatic small cell lung cancer, metastatic bladder cancer, metastatic head 
and neck cancer , and metastatic endometrial/cervical cancer.  Subjects may have already 
received up to 34 cycles of this current platinum-based regimen and must be randomized prior to 
receiving Cycle 4 of this current first-line platinum-based regimen to be eligible for the study.5..  
It is expected that subjects be eligible to continue to receive ≥ 2 additional platinum-based 
chemotherapy cycles while on study treatment.  
Subjects must not have received any other platinum containing regimens of chemotherapy for the 
first-line platinum containing treatment of a metastatic NSCLCsolid tumor prior to the regimen 
they are receiving at the time of randomization.  
_  _  _  _  _  _  _  _  _  _
Screening Period (28 days):
Potential study subjects will sign an informed consent form prior to undergoing any study-related 
procedures.  Subjects will undergo screening for protocol eligibility within 28 days prior to of
randomization, as outlined in the Table of Events, Section 5.  Note: Screening period tumor 
assessments should be performed within six weeks or as per standard care at the study site prior 
to randomization.  
_  _  _  _  _  _  _  _  _  _
Prior erythropoietic stimulating agent (ESA) treatment history starting from initial diagnosis of 
NSCLCselected solid tumor types and red blood cell (RBC) transfusion history starting from 
diagnosis of metastatic NSCLCdisease, at a minimum of up to two months prior to 
randomization will be collected.  
_  _  _  _  _  _  _  _  _  _
Treatment Period (up to 6-9 months):  
_  _  _  _  _  _  _  _  _  _
Page 312 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
16
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
In Part 1 (the dose-ranging portion of the study), subjects with selected metastatic solid tumor
types who meet all eligibility criteria will be randomized to receive one of the following 
sotatercept (ACE-011) dose levels, with 10-30 subjects per arm:
Sotatercept (ACE-011) 15.0 mg SC
Sotatercept (ACE-011) 30.0 mg SC
Analysis of safety data will be performed following the treatment of at least 10 subjects at the 
15.0 mg dose level and 10 subjects at the 30.0 mg dose level, with each subject having received 
at leasta minimum of  one dose of sotatercept (ACE-011), plus) and completed a 12-week 
follow-up period from the first dose.  Following this analysis, the addition of a third dose level:
Following this analysis, the addition of a third dose level:
Sotatercept (ACE-011) 45.0 mg SC
to the randomization schema will be determined.
_  _  _  _  _  _  _  _  _  _
Evaluation of hemoglobin response decision status will be completed after dosing arms have 
separately enrolled up to 30 subjects, as needed, to determine the optimalsotatercept (ACE-011)
dose for Part 2.  
_  _  _  _  _  _  _  _  _  _
In Part 2, a total of 750 subjects with metastatic NSCLC will be randomized to receive either 
sotatercept (ACE-011) or placebo, at a ratio of 1:1:
_  _  _  _  _  _  _  _  _  _
In Part 1, full PK blood samples will be collected to evaluate the full PK profile of sotatercept 
(ACE-011) from approximately 30 subjects at select centers, in approximately 10 subjects for 
each sotatercept (ACE-011) dose group.  In subjects participating in the full PK assessment, 
RBC, Hgb, and reticulocyte counts will be collected at each PK time point (excluding the 4-hour 
time point on Day 1) from Day 1 to Day 43 after the first dose.  Subjects not participating in the 
optional full PK assessment willmay participate in the sparse PK assessment.  In Part 2, blood 
samples will be collected for the sparse PK assessment that will be performed in approximately 
300 (40%) of 750 subjects (approximately 150 subjects in each arm).  
For subjects who do not participate in either Part 1 full or sparse PK assessments or Part 2 sparse 
PK assessments, the ACE-011 (sotatercept) concentration may be determined in their anti-
sotatercept antibody samples to assist in the evaluation of immunogenicity, as well as PK.
_  _  _  _  _  _  _  _  _  _
Subjects will be discontinued from Study Treatment due to the following:
_  _  _  _  _  _  _  _  _  _

LackIn Part 1, lack of sotatercept (ACE-011) therapeutic effect, defined as < 1.0 
g/dL increase in Hgb from baseline following three dose escalations.  In Part 2, lack 
of sotatercept (ACE-011) therapeutic effect, defined as < 1.0 g/dL increase in Hgb 
Page 313 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
17
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
from baseline following two doses of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo. (Dose 1/ Day 1 through and including Dose 2/Day 43, prior to Dose 3).
_  _  _  _  _  _  _  _  _  _
Disease progression of NSCLC
_  _  _  _  _  _  _  _  _  _
Post Treatment Follow-Up Period (monthly visits for up to 6 months)
_  _  _  _  _  _  _  _  _  _
The following events may be considered sufficient reasons for discontinuing a subject from the 
study:
_  _  _  _  _  _  _  _  _  _
Disease progression of NSCLC
_  _  _  _  _  _  _  _  _  _
Overview of Safety Assessments
_  _  _  _  _  _  _  _  _  _
QoL Assessment (FACIT Fatigue Scale [Version 4]) and– all subjects 

Lung Cancer Symptom Scale (LCSS) questionnaire. – subjects with NSCLC
Rationale:
Modified to:

Include subjects with selected metastatic solid tumor types in Part 1 and specify 
metastatic NSCLC subjects in Part 2 of the study 

Provide clarification of primary objective of Part 2 of the study

Modified to increase the number of allowed prior cycles of first-line platinum-based 
chemotherapy to 4 and allow subjects with selected metastatic solid tumor types in Part 1 
of the study 

Expand acceptable time period for screening tumor assessment to align with standard of 
care per site

Clarification of criteria for analysis of safety data from the 15 and 30 mg sotatercept 
(ACE-011) dose levels to determine the addition of the 45 mg sotatercept (ACE-011) 
dose level  

Delete term ‘optimal’ to describe sotatercept dose determined in Part 1 to be administered 
in Part 2 

Clarify that sparse PK in Part 1 is optional

Include that concentration of sotatercept (ACE-011) may be determined in anti-drug 
(sotatercept) antibody samples.
Page 314 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
18
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011

Clarify assessment of  sotatercept (ACE-011) therapeutic effect in Part 1 and Part 2 of the 
study and provide the timeframe in which assessment should be performed

Clarify FACIT Fatigue Scale to be performed on all subjects

Clarify LCSS questionnaire to be performed only on subjects with NSCLC
Page 315 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
19
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
2.4.
Section 1:  Introduction (pages 18-33)
Original Text:
This is a single-blind, randomized, phase 2a, dose-ranging study of sotatercept (ACE-011) 
therapy followed by a phase 2b/3, double-blind, randomized, placebo-controlled study of 
sotatercept (ACE-011) for chemotherapy-induced anemia (CIA) in subjects with metastatic non-
small cell lung cancer (NSCLC) treated with platinum-based chemotherapeutic regimens.  The 
study will consist of two parts.  Part 1 is a dose finding segment in which up to 90 subjects will 
be randomized to one of three sotatercept (ACE-011) dose treatment arms.  Continuous 
monitoring of safety data will be conducted, including the review of Part 1 data to define the 
recommended sotatercept (ACE-011) dose to be used in Part 2, the phase 2b/3, double-blind, 
randomized placebo-controlled segment of the study.  
Part 2 will be performed in two stages. In the first stage approximately 180 subjects will be 
randomized to receive sotatercept (ACE-011), at the dose determined from Part 1, or placebo at a 
ratio of 1:1.  An interim futility assessment based on transfusion rate at 4 months will be 
performed as described in Section 10.8.  It is expected that accrual will continue during the 
interim assessment period, with up to an additional 570 subjects randomized to achieve full study 
accrual.
_  _  _  _  _  _  _  _  _  _
Treatment of Chemotherapy-Induced Anemia
Chemotherapy-induced anemia is an area of unmet medical need.  Erythropoiesis-stimulating 
agents can successfully mitigate transfusion need in a proportion of these patients, but concerns 
have emerged regarding apparent negative effects on survival and/or tumor progression in certain 
patient populations.  
Patients with cancer receiving multi-cycle chemotherapy are frequently anemic.  The etiology of 
CIA is multifactorial, resulting from the myelosuppressive effects of chemotherapy and the 
decrease in the production of the bone-marrow-stimulating hormone erythropoietin due to 
repeated cycles of chemotherapy (Vansteenkiste, 2002).  
The current treatment options for CIA include blood transfusion and ESAs.  However, the blood 
transfusion involves the risk of complications (such as potential transmission of infectious 
disease, alloimmunization, allergic reactions, hemolytic reactions, iron and circulatory overload, 
and possible immunosuppression) for the patient, and donor blood is a limited resource.  The 
practice of offering blood transfusions to cancer patients in chemotherapy has therefore been 
rather restricted, generally reserved for emergencies, and severely anemic patients with serious 
symptoms.  
Erythropoiesis-stimulating agents have been approved for treating CIA.  Clinical studies have 
demonstrated that ESAs can successfully mitigate transfusion need in a proportion of these 
patients; however, new concerns have emerged regarding apparent negative effects on survival 
and/or tumor progression in certain patient populations.  In the pivotal Aranesp study for CIA in 
NSCLC, 27 % of patients were transfused with Packed Red Blood Cells (PRBC’s) at 4 months 
vs. 52% in the placebo arm.  In a subsequent recent Phase III study of pemetrexed (Alimta®) plus 
cisplatin vs. gemcitabine plus cisplatin where all first-line NSCLC patients with anemia or not 
Page 316 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
20
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
were enrolled, 16.1% vs 27.3% of patients respectively were transfused with PRBC’s during that 
study (Scagliotti, 2008). 
Chemotherapy-induced anemia is a significant problem for patients with cancer, causing fatigue 
and reducing quality-of-life (QoL).  Treatment with sotatercept (ACE-011) resulted in increased 
HCT, Hgb and absolute red cell number in both nonclinical and clinical studies.  The rapid and 
sustained increases in Hgb and HCT levels were observed in two Phase 1 studies in healthy 
volunteers, as well as in a Phase 2a study for multiple myeloma (MM). The ability for sotatercept 
(ACE-011) to rapidly increase and sustain Hgb levels in anemic subjects supports the clinical 
development of ACE-011 for the treatment of CIA.  
Activin Biology
_  _  _  _  _  _  _  _  _  _
The activin signaling pathway has been shown to induce terminal erythroid differentiation in 
some preclinical models.  Inhibition of activin may indirectly lead to increases in proliferation of 
the erythroid lineage.  Based on its pharmacologic effects, sotatercept (ACE-011) is being 
developed for the treatment of anemia associated with a variety of disorders, such as in chronic 
renal failure and CIA.  
_  _  _  _  _  _  _  _  _  _
Sotatercept (ACE-011)
(text not previously present)
_  _  _  _  _  _  _  _  _  _
Pharmacology Studies
The data demonstrate that RAP-011 treatment acts to decrease the incidence of MDA-MB-231 
metastasis to bone and may also play a role in inhibiting tumor growth in the bone marrow 
environment.  Furthermore, in the presence of tumor cells, RAP-011 is able to prevent lytic 
disease through an anabolic mechanism of bone formation.  Lastly, inhibition of tumor growth 
and metastasis with RAP-011 leads to a greater than 25% survival benefit in this model.  
_  _  _  _  _  _  _  _  _  _
The effect of this activin antagonist on the inhibition of bone formation and osteoblast function 
in myeloma bone disease was investigated in 5T2MM murine myeloma cells isolated from the 
bone marrow of disease bearing animals.  
_  _  _  _  _  _  _  _  _  _
In addition, the RAP-011 was highly effective in restoring bone mineral density (BMD) when 
administered therapeutically in a murine model of postmenopausal osteoporosis.  RAP-011 has 
also been shown to increase trabecular bone density in normal mice.  
_  _  _  _  _  _  _  _  _  _
In addition, in the MCF-7 model, a 60% reduction in tumor weight was observed in the RAP-011 
treated mice.  
_  _  _  _  _  _  _  _  _  _
Page 317 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
21
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
Table 4:
Number of Subjects with an Increase in Hgb from Baseline at Any Time and 
Sustained for Greater Than or Equal To 28 Days
Increase in Hgb
Dose Sotatercept (ACE-011)/Placebo
mg/kg
N=8
0.3 mg/kg
N=8
0.5 mg/kg
N=8
Placebo
N=6
Overall
N=30
≥ 1.0 g/dL
4
3
7
2
16
≥ 1.5 g/dL
2
3
3
1
9
≥ 2.0 g/dL
1
3
2
0
6
_  _  _  _  _  _  _  _  _  _
Potential Risks for Human Use
_  _  _  _  _  _  _  _  _  _
The most significant toxicity findings are listed below:  
_  _  _  _  _  _  _  _  _  _
Elevations in liver enzymes (alanine aminotransferase [ALT], aspartate 
aminotransferase [AST], and/or alkaline phosphatase), as well as triglycerides, were 
observed sporadically in rats and monkeys treated with sotatercept (ACE-011).  There 
were no histological correlates in the liver, and often a dose-response relationship was 
not observed.  The relevance of these findings to sotatercept (ACE-011) treatment is 
uncertain; however, these endpoints will continue to be monitored in the clinic.  
Revised Text:
This is an open-label, single-blind, randomized, phase 2a, dose-ranging study of sotatercept 
(ACE-011) therapy for chemotherapy-induced anemia (CIA) in subjects with selected metastatic 
solid tumors treated with platinum-based chemotherapeutic agents followed by a phase 2b/3, 
double-blind, randomized, placebo-controlled study of sotatercept (ACE-011) therapy for 
chemotherapy-induced anemia (CIA) in subjects with metastatic non-small cell lung cancer 
(NSCLC) treated with platinum-based chemotherapeutic regimens.  The study will consist of two 
parts.  Part 1 is a dose finding segment in which up to 90 subjects with selected metastatic solid 
tumor types treated with platinum-based chemotherapy will be randomized to one of three 
sotatercept (ACE-011) dose treatment arms.  Continuous monitoring of safety data will be 
conducted, including the review of Part 1 data to deftermine  the recommended sotatercept 
(ACE-011) dose to be used in Part 2, the phase 2b/3, double-blind, randomized placebo-
controlled segment of the study.  
  Part 2 will be performed in two stages. Part 2 will include only subjects with metastatic 
NSCLC and will be performed in two stages. Its primary objective is to determine the 
transfusion rate following initiation of sotatercept (ACE-011) treatment versus placebo in 
subjects with CIA who have metastatic NSCLC treated with first-line platinum-based 
chemotherapeutic regimens.
In the first stage approximately 180 subjects will be randomized to receive sotatercept (ACE-
011), at the dose determined from Part 1, or placebo at a ratio of 1:1.  An interim futility 
Page 318 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
22
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
assessment based on transfusion rate at 4 months will be performed as described in Section 10.8.  
It is expected that accrual will continue during the interim assessment period.  Based on the 
results of the futility analysis and upon recommendation to continue the study, with up to an 
additional 570 subjects will be randomized in the second stage of Part 2, to achieve full study 
accrual.
_  _  _  _  _  _  _  _  _  _
Chemotherapy-Induced Anemia
Chemotherapy-induced anemia (CIA) is an area of unmet medical need. It is a significant 
problem for patients with cancer, causing fatigue and reducing quality-of-life (QoL).   
Patients with cancer receiving multi-cycle chemotherapy are frequently anemic.  The etiology of 
CIA is multifactorial, resulting from the myelosuppressive effects of chemotherapy and the 
decrease in the production of the bone-marrow-stimulating hormone erythropoietin due to 
repeated cycles of chemotherapy (Vansteenkiste, 2002). The incidence and severity of 
chemotherapy-induced anemia (CIA) is further dependent on a variety of factors, such as the 
type, schedule, and intensity of chemotherapy administered, and whether the patient has received 
prior myelosuppressive chemotherapy and/or radiation therapy (Groopman, 1999).  Platinum-
based treatments (eg, cisplatin and carboplatin), commonly used in lung, ovarian, and head and 
neck cancers, are well known to induce anemia due to combined bone marrow and kidney 
toxicity.  Antimicrotubular agents (eg, taxanes and vinorelbine) and camptothecins (eg, 
irinotecan and topotecan) are also considered particularly myelosuppressive (Groopman, 1999).  
Dose intensity, the increasingly widespread practice of administering higher doses of 
chemotherapy over a shorter period of time, is also associated with an increased risk of 
myelosuppression
The association between uncorrected anemia before or during chemotherapy and poorer patients’ 
outcomes has been reported in several studies (Grogan, 1999; Laurie, 2006; MacRae, 2002; 
Obermair, 2003).  Anemia can lead to a multitude of symptoms (eg, fatigue, tachycardia, 
cognitive impairment, shortness of breath, depression, and dizziness) and may also have an 
adverse impact on co-morbid conditions, such as cardiac and pulmonary disease.  The most 
common patient complaints are dyspnea on exertion and chronic fatigue, which may interfere 
with a patient’s ability to perform normal daily activities (Groopman, 1999).  A key 
differentiating characteristic of cancer-related fatigue versus fatigue in healthy individuals is its 
likelihood of persistence at rest (National Comprehensive Cancer Network, 2008)  In various 
published surveys, fatigue has been represented as a symptom that has affected patients’ 
everyday life the most and has been linked to changes in employment status among patients and 
even caregivers (Schwartz, 2007).  The association between Hgb levels and fatigue is well 
documented, with one analysis of 5 randomized trials linking an increase in Hgb concentrations 
of at least 2 g/dL with an improvement in fatigue, and consequently, in energy, ability to perform 
usual activities, and overall health (Cella, 2004).
In looking at the impact of CIA on survival, a meta-analysis of 60 clinical studies found a 65% 
increase in the risk of death and a shortened survival time among patients with cancer and 
anemia compared with patients without anemia (Carlos, 2001).  The increased relative risk of 
death was particularly evident in patients with head and neck cancer (75%), a finding that also is 
supported by other retrospective studies.  Tumor hypoxia, resulting from the reduced oxygen-
Page 319 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
23
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
carrying capacity of blood in patients with anemia, has been hypothesized to be a major 
contributor to reduced survival.  Several studies have shown that tumor hypoxia also reduces the 
effectiveness of radiotherapy and chemotherapy, and is associated with tumor progression 
(Aapro, 2006).
Treatment of Chemotherapy-Induced Anemia
The current treatment options for CIA include blood transfusion and erythropoiesis-stimulating 
agents (ESAs).  However, blood transfusion involves the risk of complications (such as potential 
transmission of infectious disease, alloimmunization, allergic reactions, hemolytic reactions, iron 
and circulatory overload, and possible immunosuppression) for the patient, and donor blood is a 
limited resource.  The practice of offering blood transfusions to cancer patients receiving
chemotherapy has therefore been rather restricted, generally reserved for emergencies, and 
severely anemic patients with serious symptoms.  
Erythropoiesis-stimulating agents have been approved for treating CIA.  However, the past five 
years has seen a major change in the use of ESAs for cancer related and chemotherapy induced 
anemia. Clinical studies have demonstrated that ESAs can successfully mitigate transfusion need 
in a proportion of these patients; however, new concerns have emerged regarding apparent 
negative effects on survival and/or tumor progression in certain patient populations. 
Retrospective statistical analysis in one study in head and neck cancer patients, and two studies 
with adjuvant breast cancer revealed substantial safety concerns of increased thromboembolic 
events, and decreased PFS and overall survival.  
Sotatercept (ACE-011) Treatment of Chemotherapy-Induced Anemia
Treatment with sotatercept (ACE-011) resulted in increased HCT, Hgb and absolute red cell 
number in both nonclinical and clinical studies.  The rapid and sustained increases in Hgb and 
HCT levels were observed in two phase 1 studies in healthy volunteers, as well as in a phase 2a 
study in multiple myeloma (MM) subjects. The ability for sotatercept (ACE-011) to rapidly 
increase and sustain Hgb levels in anemic subjects supports the clinical development of ACE-
011 for the treatment of CIA.  
In a phase 1 single-dose and multiple-dose studies of sotatercept in postmenopausal women 
(Studies A011-01 and A011-02, respectively), and in a phase 2 study in subjects with osteolytic 
lesions associated with MM that examined concurrent administration of sotatercept with 
melphalan, prednisolone, and thalidomide (MPT) anti-myeloma therapy, increases in Hgb, RBC 
count and HCT were observed following sotatercept treatment, and these increases remained 
detectable throughout the course of study.  The observed Hgb, RBC count, and HCT effects of 
sotatercept were dose-dependent and time-dependent.  These phase 1 and phase 2 clinical data 
are consistent with the increased hematologic parameters observed in nonclinical studies, The 
results from the three completed clinical studies A011-01, A011-02, and A011-04 are 
summarized in Summary of Clinical Experience.  
The mechanism of action of sotatercept with regards to increased RBC counts is not known; 
however, the mechanism of action for the hematopoietic effect of sotatercept may be different 
than that of ESAs, as some level of erythrocyte stimulatory effect was observed in the presence 
Page 320 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
24
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
of anti-EPO antibodies in one nonclinical study.  As such, sotatercept may provide a unique 
clinical profile with a favorable benefit-risk profile in the chemotherapy-induced anemia patient 
population, thereby addressing some of the unmet medical needs in chemotherapy-induced 
anemia treatment.
_  _  _  _  _  _  _  _  _  _
Treatment of Chemotherapy-Induced Anemia
Chemotherapy-induced anemia is an area of unmet medical need.  Erythropoiesis-stimulating 
agents can successfully mitigate transfusion need in a proportion of these patients, but concerns 
have emerged regarding apparent negative effects on survival and/or tumor progression in certain 
patient populations.  
Patients with cancer receiving multi-cycle chemotherapy are frequently anemic.  The etiology of 
CIA is multifactorial, resulting from the myelosuppressive effects of chemotherapy and the 
decrease in the production of the bone-marrow-stimulating hormone erythropoietin due to 
repeated cycles of chemotherapy (Vansteenkiste, 2002).  
The current treatment options for CIA include blood transfusion and ESAs.  However, the blood 
transfusion involves the risk of complications (such as potential transmission of infectious 
disease, alloimmunization, allergic reactions, hemolytic reactions, iron and circulatory overload, 
and possible immunosuppression) for the patient, and donor blood is a limited resource.  The 
practice of offering blood transfusions to cancer patients in chemotherapy has therefore been 
rather restricted, generally reserved for emergencies, and severely anemic patients with serious 
symptoms.  
Erythropoiesis-stimulating agents have been approved for treating CIA.  Clinical studies have 
demonstrated that ESAs can successfully mitigate transfusion need in a proportion of these 
patients; however, new concerns have emerged regarding apparent negative effects on survival 
and/or tumor progression in certain patient populations. In the pivotal Aranesp (darbepoetin 
alfa) study for CIA in NSCLC, 27 % of patients were transfused with Packed Red Blood 
Cellspacked red blood cells (PRBC’s) at 4 months vs.versus 52% in the placebo arm.  In a 
subsequent recent Phase III study of pemetrexed (Alimta®) plus cisplatin vs. gemcitabine plus 
cisplatin where all first-line NSCLC patients with anemia or not were enrolled, 16.1% vs 27.3% 
of patients respectively were transfused with PRBC’s during that study (Scagliotti, 2008). 
Chemotherapy-induced anemia is a significant problem for patients with cancer, causing fatigue 
and reducing quality-of-life (QoL).  Treatment with sotatercept (ACE-011) resulted in increased 
HCT, Hgb and absolute red cell number in both nonclinical and clinical studies.  The rapid and 
sustained increases in Hgb and HCT levels were observed in two Phase 1 studies in healthy 
volunteers, as well as in a Phase 2a study for multiple myeloma (MM). The ability for sotatercept 
(ACE-011) to rapidly increase and sustain Hgb levels in anemic subjects supports the clinical 
development of ACE-011 for the treatment of CIA.  
Activin Biology
_  _  _  _  _  _  _  _  _  _
Page 321 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
25
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
The activin signaling pathway has been shown to induce terminal erythroid differentiation in 
some preclinical models.  Inhibition of activin may indirectly lead to increases in proliferation or 
differentiation of the erythroid lineage.  Based on its pharmacologic effects, sotatercept (ACE-
011) is being developed for the treatment of anemia associated with a variety of disorders, such 
as in chronic renal failure and CIA.  
_  _  _  _  _  _  _  _  _  _
Sotatercept (ACE-011)
_  _  _  _  _  _  _  _  _  _
Both ACE-011 and RAP-011 bind with high affinity to activin A/B, GDF-11 and, with slightly 
lower affinity, to BMP-10.
_  _  _  _  _  _  _  _  _  _
Pharmacology Studies
The data demonstratesuggest that RAP-011 treatment acts tomay decrease the incidence of 
MDA-MB-231 metastasis to bone and may also play a role in inhibiting tumor growth in the 
bone marrow environment.  Furthermore, in the presence of tumor cells, RAP-011 is able to 
prevent lytic disease through an anabolic mechanism of bone formation.  Lastly, inhibition of 
tumor growth and metastasistreatment with  RAP-011 leads to a greater thanresulted in an 
approximately 25% survival benefit in this model.  
_  _  _  _  _  _  _  _  _  _
The effect of this activin antagonist on the inhibition of bone formation and osteoblast function 
in myeloma bone disease was investigated in 5T2MM murine myeloma cells isolated from the 
bone marrow of disease bearing animals..  
_  _  _  _  _  _  _  _  _  _
In addition, the RAP-011 was highly effective in restoring bone mineral density (BMD) when 
administered therapeutically in a murine model of postmenopausal osteoporosis.  RAP-011 has 
also been shown to increase trabecular bone density in normal mice.  
_  _  _  _  _  _  _  _  _  _
In addition, in the MCF-7 model, a 60% reduction in tumor weight was observed in the RAP-011 
treated mice.  
_  _  _  _  _  _  _  _  _  _
Page 322 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
26
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
Table 4:
Number of Subjects with an Increase in Hgb from Baseline at Any Time and 
Sustained for Greater Than or Equal To 28 Days
Increase in Hgb
Dose Sotatercept (ACE-011)/Placebo
0.1 mg/kg
N=8
0.3 mg/kg
N=8
0.5 mg/kg
N=8
Placebo
N=6
Overall
N=30
≥ 1.0 g/dL
4
3
7
2
16
≥ 1.5 g/dL
2
3
3
1
9
≥ 2.0 g/dL
1
3
2
0
6
_  _  _  _  _  _  _  _  _  _
Potential Risks for Human Use
_  _  _  _  _  _  _  _  _  _
The most significant toxicity findings are listed below:  
Elevations in liver enzymes (alanine aminotransferase [ALT], aspartate 
aminotransferase [AST], and/or alkaline phosphatase), as well as triglycerides, were 
observed sporadically in rats and monkeys treated with sotatercept (ACE-011).  There 
were no histological correlates in the liver, and often a dose-response relationship was 
not observed.  The relevance of these findings to sotatercept (ACE-011) treatment is 
uncertain; however, these endpoints liver enzymes will continue to be monitored in 
the clinic.this study.
Rationale:
Modified to:

Include subjects with specific metastatic solid tumor types in Part 1 and clarify the two 
stages in Part 2 of the study.

Revise and add Chemotherapy-Induced Anemia, Treatment of Chemotherapy-Induced 
Anemia and Sotatercept (ACE-011) Treatment of Chemotherapy-Induced Anemia 
sections to provide additional solid tumor type and chemotherapy-induced anemia 
background data.   

Provide additional description of Sotatercept (ACE-011) and Activin Biology.

Clarify results of pharmacology studies.

Include missing dose level in Table 4.

Clarify the continued monitoring of liver enzymes.
Page 323 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
27
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
2.5.
Section 2.1:  Primary Objective (page 34)
Original Text:
Part 1:  To determine an effective dose of sotatercept (ACE-011) showing a 
hematopoietic response in the treatment of CIA in metastatic NSCLC subjects.  
Part 2:  To assess transfusion rate following initiation of sotatercept (ACE-011) 
treatment.  
Revised Text:
Part 1:  To determine an effectivea dose of sotatercept (ACE-011) showing that 
results in a hematopoietic response in for the treatment of CIA in metastatic NSCLC 
subjects. with selected metastatic solid tumors treated with platinum-based
chemotherapeutic regimens.
Part 2:  To assess transfusion rate following initiation of sotatercept (ACE-011) 
treatment. versus placebo in subjects with CIA who have metastatic NSCLC treated 
with first-line platinum-based chemotherapeutic regimens.
Rationale:
Modified to include subjects with selected metastatic solid tumor types in Part 1 and specify 
metastatic NSCLC subjects in Part 2 of the study. 
Page 324 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
28
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
2.6.
Section 2.2:  Secondary Objectives (page 34)
Original Text:
Part 1 and Part 2:
To estimate the effect of sotatercept (ACE-011) treatment on objective response rate 
(ORR), time to progression (TTP), progression free survival (PFS) and overall 
survival (OS) in metastatic NSCLC subjects with CIA.  
To evaluate the safety and tolerability of sotatercept (ACE-011) treatment in 
metastatic NSCLC subjects with CIA.  
To determine the PK of sotatercept (ACE-011) in subjects with metastatic NSCLC 
receiving platinum-based chemotherapy.  
_  _  _  _  _  _  _  _  _  _

To evaluate the effect of sotatercept (ACE-011) treatment on the quality of life 
(QoL) of NSCLC subjects with CIA.  
Revised Text:
Part 1 and Part 2:
To estimate the effect of sotatercept (ACE-011) treatment on objective response rate 
(ORR), time to progression (TTP), progression free survival (PFS) and overall 
survival (OS) in metastatic NSCLC subjects with CIA.  

To evaluate the safety and tolerability of sotatercept (ACE-011) treatment in 
metastatic NSCLC subjects with CIA.  

To determine the PK of sotatercept (ACE-011) in subjects with metastatic NSCLC 
receiving platinum-based chemotherapy.  
_  _  _  _  _  _  _  _  _  _
To evaluate the effect of sotatercept (ACE-011) treatment on the quality of life (QoL) 
of NSCLC subjects with CIA. 
Rationale:
Modified to not specify subjects with metastatic NSCLC only.
Page 325 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
29
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
2.7.
Section 2.3:  Exploratory Objectives (page 34)
Original Text:
Part 1 and Part 2:
To estimate the effect of sotatercept (ACE-011) treatment on bone metabolism in 
NSCLC subjects with CIA.  

To evaluate the expression of Activin A and other proteins/biomarkers in archival 
tumor tissue.
Revised Text:
Part 1 and Part 2:
To estimate the effect of sotatercept (ACE-011) treatment on bone metabolism in 
NSCLC subjects with CIA.  

To evaluate the expression of Activin A and other proteins/biomarkers in archival 
tumor tissue (Part 2 only).
Rationale:
Modified to:
Remove subjects with metastatic NSCLC only.
Clarify that archival tumor tissue analysis will occur only in Part 2 of the study. 
Page 326 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
30
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
2.8.
Section 3.1:  Primary Endpoint(s) (page 35)
Original Text:
_  _  _  _  _  _  _  _  _  _

Hematopoietic response is defined as an increase in Hgb of ≥ 1.0 g/dL above the 
study baseline value for 28 consecutive days, in the absence of RBC transfusions 
and/or ESAs.  In order to determine the optimal dose of sotatercept (ACE-011) to be 
used in Part 2, evaluation of hematopoietic response will be determined from 
sotatercept (ACE-011) Dose 1/ Day 1 through and including Dose 2/Day 43 (prior to 
Dose 3).  
_  _  _  _  _  _  _  _  _  _
Hematopoietic response will be determined by laboratory analysis.  
Revised Text:
_  _  _  _  _  _  _  _  _  _

Hematopoietic response is defined as an increase in Hgb of ≥ 1.0 g/dL above the 
study baseline value for 28 consecutive days, in the absence of RBC transfusions 
and/or ESAs.  In order to determine the optimal dose of sotatercept (ACE-011) to be 
used in Part 2, evaluation of hematopoietic response will be determined from 
sotatercept (ACE-011) Dose 1/ Day 1 through and including Dose 2/Day 43 (prior to 
Dose 3).  
_  _  _  _  _  _  _  _  _  _
Hematopoietic response will be determined by laboratory analysis. of hemoglobin levels.  
Rationale:
Modified to:
Delete term ‘optimal’ to describe sotatercept dose determined in Part 1 to be administered in 
Part 2. 
Clarify how hematopoietic response will be determined. 
Page 327 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
31
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
2.9.
Section 3.2:  Secondary Endpoint(s) (page 35)
Original Text:

QoL assessment (FACIT Fatigue Scale [Version 4]) and LCSS questionnaire (Hollen, 
1995)
Revised Text:

QoL assessment (FACIT Fatigue Scale [Version 4]) and LCSS questionnaire (Hollen, 
1993 ; Hollen, 1994a ; Hollen, 1994b; Hollen, 1995)
Rationale:
Modified to include additional Lung Cancer Symptom Scale references.
2.10.
Section 3.3:  Exploratory Endpoint(s) (page 36)
Original Text:

Expression of Activin A and other protein/biomarkers related to sotatercept (ACE-
011) mechanism of action in blood (including myostatin and follistatin) and in 
archival tumor tissue in the NSCLC population.
Revised Text:

Expression of Activin A and other protein/biomarkers related to sotatercept (ACE-
011) mechanism of action in blood (including myostatin and follistatin) and in 
archival tumor tissue in the NSCLC population(Part 2 only).
Rationale:
Modified to provide clarification that archival tumor tissue analysis will occur only in Part 2 of 
the study.  
2.11.
Section 4.1:  Study Design (pages 37-39)
Original Text:
This is a single-blind, randomized, phase 2a, dose-ranging study of sotatercept (ACE-011) 
therapy followed by a phase 2b/3, double-blind, randomized, placebo-controlled study of 
sotatercept (ACE-011) for CIA in subjects with metastatic NSCLC treated with platinum-based 
chemotherapeutic regimens.  
The study will consist of two parts.  Part 1 is a dose finding segment in which subjects will be 
randomized to one of three sotatercept (ACE-011) dose treatment arms.  Continuous monitoring 
of safety data will be conducted, including the review of Part 1 data to define the recommended 
sotatercept (ACE-011) dose to be used in Part 2, the phase 2b/3, double-blind, randomized 
placebo-controlled segment of the study.  
_  _  _  _  _  _  _  _  _  _
Page 328 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
32
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
Part 1 is planned to be conducted at selected US sites. The study will be extended to additional 
global sites for the conduct of Part 2.
_  _  _  _  _  _  _  _  _  _
Three starting sotatercept (ACE-011) dose levels, 15.0, 30.0, and 45.0 mg, were selected for Part 
1 of the study. Up to approximately 90 subjects will be randomized to one of the following 
sotatercept (ACE-011) dose levels, with 10-30 subjects per arm:
Sotatercept (ACE-011) 15.0 mg SC
Sotatercept (ACE-011) 30.0 mg SC
Analysis of safety data will be performed following the treatment of at least 10 subjects at the 
15.0 mg dose level and 10 subjects at the 30.0 mg dose level, with each subject having received 
at least of one dose of sotatercept (ACE-011), plus a 12-week follow-up period from first dose.  
Following this analysis, the addition of a third dose level:
Sotatercept (ACE-011) 45.0 mg SC
to the randomization schema will be determined.
Each dose level will be administered every 42 days for four doses.  
In Part 2, a total of 750 subjects will be randomized to receive either sotatercept (ACE-011) (at 
the dose determined in Part 1) or placebo, at a ratio of 1:1:
_  _  _  _  _  _  _  _  _  _
The Treatment Period for Part 1 is up to approximately six months and for Part 2 up to nine 
months.  Subjects who enter the Post Treatment Follow-Up Period will be followed for up to 6 
months from their last dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.  All 
subjects will continue to be followed for TTP and PFS up to 12 months from their first dose of 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo or until progression of their NSCLC, 
whichever comes first.  
_  _  _  _  _  _  _  _  _  _
At the time of randomization all subjects must be receiving their first regimen of  first-line 
platinum-containing chemotherapy, given every three weeks, for the treatment of metastatic 
NSCLC.  Subjects may have already received up to 3 cycles of this first-line platinum-based 
regimen to be eligible for the study.  Subjects are expected to  be eligible to continue to receive ≥ 
2 additional platinum-based chemotherapy cycles while on study treatment prior to initiating any 
maintenance chemotherapy for the treatment of metastatic NSCLC. 
Revised Text:
This is an open-label, single-blind, randomized, phase 2a, dose-ranging study (Part 1) of 
sotatercept (ACE-011) therapy in subjects with selected metastatic solid tumors types treated 
with platinum-based chemotherapeutic regimens followed by a phase 2b/3, double-blind, 
randomized, placebo-controlled study of sotatercept (ACE-011) therapy for CIA in subjects with 
metastatic NSCLC treated with platinum-based chemotherapeutic regimens.  
Page 329 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
33
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
The study will consist of two parts.  Part 1 is a dose finding segment in which subjects with 
selected metastatic solid tumor types will be randomized to one of three sotatercept (ACE-011) 
dose treatment arms.  Continuous monitoring of safety data will be conducted, including the 
review of Part 1 data to deftermine the recommended sotatercept (ACE-011) dose to be used in 
Part 2, the phase 2b/3, double-blind, randomized placebo-controlled segment of the study. in 
subjects with metastatic NSCLC.  
_  _  _  _  _  _  _  _  _  _
Part 1 is planned to be conducted at selected US sites and.  The study will be extended to 
additional global sites for the conduct of Part 2.
_  _  _  _  _  _  _  _  _  _
Three starting sotatercept (ACE-011) dose levels, 15.0, 30.0, and 45.0 mg, were selected for Part 
1 of the study. Up to approximately 90 subjects with selected metastatic solid tumor types will 
be randomized to one of the following sotatercept (ACE-011) dose levels, with 10-30 subjects 
per arm:
Sotatercept (ACE-011) 15.0 mg SC
Sotatercept (ACE-011) 30.0 mg SC
Analysis of safety data will be performed following the treatment of at least 10 subjects at the 
15.0 mg dose level and 10 subjects at the 30.0 mg dose level, with each subject having received 
at leasta minimum of one dose of sotatercept (ACE-011), plus) and completed a 12-week 
follow-up period from the first dose.  Following this analysis, the addition of a third dose level:
Following this analysis, the addition of a third dose level:
Sotatercept (ACE-011) 45.0 mg SC
to the randomization schema will be determined.
Each dose level will be administered every 42 days for a total of four doses.  
In Part 2, a total of 750 subjects with metastatic NSCLC will be randomized to receive either 
sotatercept (ACE-011) (at the dose determined in Part 1) or placebo, at a ratio of 1:1:
_  _  _  _  _  _  _  _  _  _
The Treatment Period for Part 1 is up to approximately six months, which includes up to 4 doses 
of sotatercept (ACE-011) and for Part 2 up to approximately nine months., which includes up to 
6 doses of sotatercept (ACE-011/placebo).  Subjects who enter the Post Treatment Follow-Up 
Period will be followed for up to 6 months from their last dose of sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo.  All subjects will continue to be followed for TTP and PFS up to 
12 months from their first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo or 
until progression of their NSCLCmetastatic disease, whichever comes first.  
_  _  _  _ _  _  _  _  _  _
At the time of randomization, all subjects must be receiving their first regimen of first-line 
platinum-containing based chemotherapy, given every three weeks, for the treatment of a 
metastatic NSCLC.solid tumor.  Subjects may have already received up to 34 cycles of this first-
Page 330 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
34
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
linecurrent platinum-based regimen toand must be eligible for the study.  Subjects are 
randomized prior to receiving Cycle 5.  It is expected to that subjects be eligible to continue to 
receive ≥ 2 additional platinum-based chemotherapy cycles while on study treatment prior to 
initiating any maintenance .  
Subjects must not have received any other platinum containing regimens of chemotherapy for the 
first-line treatment of a metastatic NSCLC.solid tumor prior to the regimen they are receiving at 
the time of randomization. 
Rationale:
Modified to:

Include subjects with selected metastatic solid tumor types in Part 1 of the study

Delete participation of US sites only in Part 1 of the study.

Clarify the criteria for analysis of safety data from the 15 and 30 mg sotatercept (ACE-
011) dose levels to determine the addition of the 45 mg sotatercept (ACE-011) dose 
level.  

Increase the number of allowed prior cycles of first-line platinum-based chemotherapy to 
4 and allow subjects with metastatic tumors in Part 1 of the study.
Page 331 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
35
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
2.12.
Section 4.1.1:  Sotatercept (ACE-011) Dose Modification, Reduction 
and Escalation Rules (pages 40-43)
Original Text:
3Sotatercept (ACE-011)or sotatercept (ACE-011)/placebo should be delayed until Hgb is < 11g/dL and 
hypertension < SBP 150mm Hg and < DBP 100 mm Hg..  Dosing can commence at ≥7 days after the originally 
planned sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dose that was delayed.  Subsequent sotatercept 
(ACE-011) or sotatercept (ACE-011)/placebo doses will then begin 42 days following this revised treatment dose 
date. 
A delayed sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dose is defined as a dose not administered > 4 
days from the planned dosing date (due to Hgb ≥11.0 g/dL, hypertension < SBP 150mm Hg and < DBP 100 mm 
Hg and/or sotatercept (ACE-011) related toxicity).  
_  _  _  _  _  _  _  _  _  _
Table 5:
Sotatercept (ACE-011) and Sotatercept (ACE-011)/Placebo Dose Reduction 
Levels
_  _  _  _  _  _  _  _  _  _
Dose Schedule
Sotatercept (ACE-011) or
Sotatercept (ACE-011)/placebo
Dose Reduction*
#1
Dose Reduction*
#2
Dose Reduction*
#3
Every 42 days-
45.0 mg
38.0 mg
33.0 mg
28.0 mg
Every 42 days-
30.0 mg
26.0 mg
22.0 mg
18.0 mg
Every 42 days-
15.0 mg
13.0 mg
11.0 mg
9.0 mg
*Note:  Any Hgb increase of ≥3.0 g/dL will require a subsequent sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo dose reduction of two dose levels.  A second Hgb increase of ≥3.0 g/dL, sustained for 28 days, 
following a two-level dose reduction will require the subject discontinue from study treatment.  
_  _  _  _  _  _  _  _  _  _
Dose reduction steps and the subsequent administration of the reduced dose(s) of sotatercept 
(ACE-011) or sotatercept (ACE-011)/placebo will be conducted in a manner that will preserve 
the blinded status of the original treatment group of each subject.  In Part 2, subjects in the 
placebo group who are designated by their treating physician to undergo dose reduction will 
continue to receive placebo.  
_  _  _  _  _  _  _  _  _  _
Page 332 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
36
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
Table 6:
Sotatercept (ACE-011) Dose Escalation Levels (Part 1 Only) 
Dose Schedule
Sotatercept (ACE-
011)
Dose Increase  #1
Dose Increase  #2
Dose Increase #3
Every 42 days-
45.0 mg
50.0 mg
55.0 mg
61.0 mg
Every 42 days-
30.0 mg
33.0 mg
36.0 mg
40.0 mg
Every 42 days-
15.0 mg
17.0 mg
20.0 mg
23.0 mg
Dose increase steps and the subsequent administration of the increased dose(s) of sotatercept 
(ACE-011) will be conducted in a manner that will preserve the blinded status of the original 
treatment group of each subject.  
Revised Text:
3Sotatercept (ACE-011) or sotatercept (ACE-011)/placebo should be delayed until Hgb is < 11g/dL and 
hypertension < SBP 150mm Hg and < DBP 100 mm Hg...  Dosing can commence at ≥7 days after the originally 
planned sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dose that was delayed.  Subsequent sotatercept 
(ACE-011) or sotatercept (ACE-011)/placebo doses will then begin 42 days following this revised treatment dose 
date.  
A delayed sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dose is defined as a dose not administered > 4 
days from the planned dosing date (due to Hgb ≥11.0 g/dL, hypertension <> SBP 150 mmHg and <> DBP 100 
mmHg and/or sotatercept (ACE-011) related toxicity).  
_  _  _  _  _  _  _  _  _  _
Table 5:
Sotatercept (ACE-011) and Sotatercept (ACE-011)/Placebo Dose Reduction 
Levels
_  _  _  _  _  _  _  _  _  _
Dose Schedule
Sotatercept (ACE-011) or
Sotatercept (ACE-011)/placebo
Dose Reduction*
#1
Dose Reduction*
#2
Dose Reduction*
#3
Every 42 days-
45.0 mg
38.0 mg
33.0 mg
28.0 mg
Every 42 days-
30.0 mg
26.0 mg
22.0 mg22mg
18.0 mg
Every 42 days-
15.0 mg
13.0 mg
11.0 mg
9.0 mg
*Note:  Any Hgb increase of ≥3.0 g/dL sustained for a 28 day period since last doing day will require a subsequent 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dose reduction of two dose levels.  A second Hgb 
increase of ≥3.0 g/dL, sustained for 28 days, following a two-level dose reduction will require the subject 
discontinue from study treatment.
Page 333 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
37
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
_  _  _  _  _  _  _  _  _  _
DoseIn Part 2, dose reduction steps and the subsequent administration of the reduced dose(s) of 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo will be conducted in a manner that will 
preserve the blinded status of the original treatment group of each subject.  In Part 2,S subjects in 
the placebo group who are designated by their treating physician to undergo dose reduction will 
continue to receive placebo.  
_  _  _  _  _  _  _  _  _  _
Table 6:
Sotatercept (ACE-011) Dose Escalation Levels (Part 1 Only) 
Dose Schedule
Sotatercept (ACE-
011)
Dose Increase  #1
Dose Increase  #2
Dose Increase #3
Every 42 days-
45.0 mg
50.0 mg
55.0 mg
61.0 mg
Every 42 days-
30.0 mg
33.0 mg
36.0 mg
40.0 mg
Every 42 days-
15.0 mg
17.0 mg
20.0 mg
23.0 mg
_  _  _  _  _  _  _  _  _  _
Dose increase steps and the subsequent administration of the increased dose(s) of sotatercept 
(ACE-011) will be conducted in a manner that will preserve the blinded status of the original 
treatment group of each subject.  
Rationale:
Modified to:

Correct typographical error – blood pressure measurements.

Remove sotatercept (ACE-011) trailing zeros.

Remove references to single-blind in Part 1.
Page 334 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
38
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
2.13.
Section 4.2:  Study Design Rationale (page 43)
Original Text:
The A011-01, A011-02 and A011-04 studies have shown that dosing with sotatercept (ACE-011) 
resulted in a significant increase in hematopoietic parameters, beginning rapidly and sooner than 
would be expected from a stimulation of the erythropoietic effect by an ESA.  This fact, as well 
as the fairly rapid and persistent elevation in the relative Hgb, HCT, and RBC counts of the 
majority of subjects from each dose of sotatercept (ACE-011), suggests an entirely novel 
mechanism of RBC production.  
Revised Text:
The A011-01, A011-02 and A011-04 studies have shown that dosing with sotatercept (ACE-011) 
resulted in a significant increaserapid, sustained and dose-dependent increases in hematopoietic 
parameters, beginning rapidly and sooner(Hgb, HCT and RBC counts) which occurred earlier 
than would be expected from a stimulation of the erythropoietic effect erythropoiesis by an ESA.  
This fact, as well as the fairly rapid and persistent elevation observation, couple with nonclinical 
data demonstrating some level of erythrocyte stimulatory effect in the relative Hgb, HCT, and 
RBC counts of the majoritypresence of subjects from each doseanti-erthyropoietin (EPO) 
antibodies, suggests that the hematopoieitc effect of sotatercept (ACE-011), suggests an entirely 
novel mechanismis different from that of RBC production.  ESAs. 
Rationale:
Revised to clarify prior clinical and non-clinical findings in support of study design rationale. 
Page 335 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
39
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
2.14.
Section 4.3:  Study Duration (page 46)
Original Text:
To evaluate sequence and study timelines, please see the Table of Events (see Section 5).  
Approximately 60-90 subjects in Part 1 and 750 subjects in Part 2 will be randomized prior to 
receiving the fourth cycle of platinum-based chemotherapy for metastatic NSCLC.  Each subject 
will be on the study for approximately 12 – 15 months (including the Screening Period, the 
Treatment Period, and the Post Treatment Follow-Up Period).  The Treatment Period is 
approximately 6 to 9 months (four to six doses every 42 days) with a Post Treatment Follow-Up 
Period of six months from the subjects’ last dose of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo.  Subjects who discontinue treatment early will still continue to the Post Treatment 
Follow-Up Period for six months from their last dose of sotatercept (ACE-011) or sotatercept 
(ACE-011)/placebo.  
All subjects will continue to be followed for TTP and PFS up to 12 months from their first dose 
of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo or until progression of their NSCLC, 
whichever comes first.  All subjects will continue to be followed for survival up to 24 months 
from their first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.
Revised Text:
To evaluate sequence and study timelines, please see the Table of Events (see Section 5).  
Approximately 60-90 subjects with selected metastatic solid tumor types in Part 1 and 750 
subjects with metastatic NSCLC in Part 2 will be randomized prior to receiving the fourifth cycle 
of platinum-based chemotherapy for metastatic NSCLC...  Each subject will be on the study for 
approximately 12 – 15 months (including the Screening Period, the Treatment Period, and the 
Post Treatment Follow-Up Period).  The Treatment Period is approximately 6 to 9 months (four 
to six doses of sotatercept [ACE-011] every 42 days) with a Post Treatment Follow-Up Period of 
six months from the subjects’ last dose of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo.  Subjects who discontinue treatment early will still continue to the Post Treatment 
Follow-Up Period for six months from their last dose of sotatercept (ACE-011) or sotatercept 
(ACE-011)/placebo.  
All subjects will continue to be followed for TTP and PFS up to 12 months from their first dose 
of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo or until progression of their 
NSCLCmetastatic disease, whichever comes first.  All subjects will continue to be followed for 
survival up to 24 months from their first dose of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo.
Rationale:
Modified to:

Include subjects with selected metastatic solid tumor types in Part 1 of the study.

Modified to increase the number of allowed prior cycles of first-line platinum-based 
chemotherapy to 4 cycles.
Page 336 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
40
ACE-011-NSCL-001 2.0 FINAL: 27 JUN 2011
2.15.
Section 5:  Table Of Events (pages 47-52)
Original Text:
Table 7:
Sotatercept (ACE-011) NSCLC Schedule of Assessments
Treatment Period
Screening 
Period
Sotatercept (ACE-011)
Dose 1 Schedule
(± 3 days)
Sotatercept (ACE-011)
Subsequent
Doses 2  through 6 Schedule
(± 3 days)
Post Treatment Follow-Up Period
(± 1 week)
Survival
(±1wk)
Assessments
Day -28
to
Day -1
D1
D8
D15 D22 D29
D43/
D1
D8
D15 D29
D43 
Post Last 
Dose/End 
of Study 
Txt
1
Month
2
Month
3
Month
4
Month
5
Month
6
Month/
Study
DCu
Survival
_  _  _  _  _  _  _  _  _  _
Activin A and other proteins/biomarkers 
in Blood (pre-dose study treatment in a 
subset of subjects)
X
X
X
X
_  _  _  _  _  _  _  _  _  _
Activin and other proteins/biomarkers in 
archival tumor tissue
X
_  _  _  _  _  _  _  _  _  _
Tumor Assessmentso
X
< Every 9 weeks ± 1 week or per standard of care at study site
_  _  _  _  _  _  _  _  _  _
aInclude NSCLC history, date of original diagnosis, clinical stage at Screening and date of metastases and metastatic site involvement.  Record prior ESA history, 
starting at diagnosis of NSCLC.  Record RBC transfusion history, starting from diagnosis of metastatic NSCLC, at a minimum of two months prior to 
randomization.  
_  _  _  _  _  _  _  _  _  _
mDual Energy X-ray Absorptiometry (DXA) scan to evaluate overall health on approximately 200 subjects at selected US site(s).  Performed at Screening, and 
Month 3 during the Post Treatment Follow-Up Period.  
Page 337 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
41
ACE-011-NSCL-001 2.0 FINAL: 27 JUN 2011
nPharmacokinetics (Part 1):  Blood samples will be collected to evaluate the blood or serum concentrations of sotatercept (ACE-011).  Approximately 10 
subjects at each sotatercept (ACE-011) dose level, 15.0, 30.0 and 45.0 mg, will have full PK sampling.  In addition, RBC, Hgb, and reticulocyte counts will be 
collected at each time point (excluding the 4-hour time point on Day 1) from Day 1 to Day 43 after the first dose within the full PK assessment.  Subjects not 
participating in the optional full PK assessment will participate in the sparse PK assessment.  
_  _  _  _  _  _  _  _  _  _
oTumor assessments:  Screening period tumor assessments may be performed up to six weeks prior to randomization.  Also, historical tumor assessment data, 
from prior to the initiation of platinum-based chemotherapy through the screening period, will be collected.  Following randomization, tumor assessments will 
be performed at a maximum of every 9 weeks (± 7 days) or per standard of care at the study site, starting from the date of the previous (screening period) tumor 
assessment and following the chemotherapy schedule.  
pQoL assessments, FACIT Fatigue Scale (Version 4) and LCSS questionnaire, to be completed by the subject upon arrival at clinic and prior to any study 
procedures or testing at all visits, as indicated in the schedule, and at Study Discontinuation/One-Year Follow-Up Visit.  
qSotatercept (ACE-011) or sotatercept (ACE-011)/placebo dosing repeats every 42 days and will start after the subject begins an every 3 week platinum-based 
chemotherapy regimen.  The first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo should be given within 7 days prior to or within 7 days 
following Day 1 of a platinum-based chemotherapy cycle.  Subsequent doses of Sotatercept (ACE-011) or sotatercept (ACE-011)/placebo can be 
administered at any time point during the chemotherapy cycle. 
_  _  _  _  _  _  _  _  _  _
If sotatercept (ACE-011) or sotatercept (ACE-011)/placebo is administered on the same day as chemotherapy, sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo should be given prior to chemotherapy administration.
_  _  _  _  _  _  _  _  _  _
rEvery 3-week platinum-based chemotherapy is to be administered based on guidelines for administration according to manufacturer’s 
recommendations and standard clinical practice.  Type of chemotherapy and dosing will be recorded.  If sotatercept (ACE-011) or
sotatercept (ACE-011)/placebo is administered on the same day as chemotherapy, sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo should be given prior to chemotherapy administration.
Page 338 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
42
ACE-011-NSCL-001 2.0 FINAL: 27 JUN 2011
Table 8:
Schedule of Pharmacokinetic Assessments (Part 1)
_  _  _  _  _  _  _  _  _  _
dTo be collected in other subjects.  
Page 339 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
43
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
Revised Text:
Table 7:
Sotatercept (ACE-011) NSCLC Schedule of Assessments 
Treatment Period
Screening 
Period
Sotatercept (ACE-011)
Dose 1 Schedule
(± 3 days)
Sotatercept (ACE-011)
Subsequent
Doses 2  through 6 Schedule
(± 3 days)
Post Treatment Follow-Up Period
(± 1 week)
Survival
(±1wk)
Assessments
Day -28
to
Day -1
D1
D8
D15 D22 D29
D43/
D1
D8
D15 D29
D43 
Post Last 
Dose/End 
of Study 
Txt
1
Month
2
Month
3
Month
4
Month
5
Month
6
Month/
Study
DCu
Survival
_  _  _  _  _  _  _  _  _  _
Activin A and other proteins/biomarkers 
in blood (serum) (pre-dose study 
treatment in a subset of subjects)
X
X
X
X
_  _  _  _  _  _  _  _  _  _
Activin and other proteins/biomarkers in 
archival tumor tissue (Part 2 only -
optional)
X
_  _  _  _  _  _  _  _  _  _
Tumor Assessmentso
XXo
< Every 9 weeks ± 1 week or as per standard of care at study site
_  _  _  _  _  _  _  _  _  _
aInclude NSCLCcancer history, date of original diagnosis, clinical stage at Screening and date of metastases and metastatic site involvement.  Record prior ESA 
history, starting at selected solid tumor diagnosis of NSCLC.  Record RBC transfusion history, starting from diagnosis of metastatic NSCLCdisease, at a 
minimum of two months prior to randomization.  
_  _  _  _  _  _  _  _  _  _
mDual Energy X-ray Absorptiometry (DXA) scanof lumbar spine and hip to evaluate overall health on approximately 200 subjects at selected US site(s).  
Performed at Screening, and Month 3 during the Post Treatment Follow-Up Period.  
Page 340 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
44
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
nPharmacokinetics (Part 1):  Blood samples will be collected to evaluate the blood or serum concentrations of sotatercept (ACE-011).  Approximately 10 
subjects at each sotatercept (ACE-011) dose level, 15.0, 30.0 and 45.0 mg, will have full PK sampling.  In addition, RBC, Hgb, and reticulocyte counts will be 
collected at each time point (excluding the 4-hour time point on Day 1) from Day 1 to Day 43 after the first dose within the full PK assessment.  Subjects not 
participating in the optional full PK assessment willmay participate in the sparse PK assessment.  
_  _  _  _  _  _  _  _  _  _
oTumor assessments:  Screening period tumor assessments may be performed up to within six weeks or as per study site standard of care prior to randomization.  
Also, historical tumor assessment data, from prior to the initiation of platinum-based chemotherapy through the screening period, will be collected.  Following 
randomization, tumor assessments will be performed at a maximum of≤every 9 weeks (± 7 days) or per standard of care at the study site, starting from the date of 
the previous (screening period) tumor assessment and following the chemotherapy schedule.  
pQoL assessments, FACIT Fatigue Scale (Version 4) – all subjects and LCSS questionnaire – only subjects with NSCLC, to be completed by the subject upon 
arrival at clinic and prior to any study procedures or testing at all visits, as indicated in the schedule, and at Study Discontinuation/One-Year Follow-Up Visit.  
qSotatercept (ACE-011) or sotatercept (ACE-011)/placebo dosing repeats every 42 days and will start after the subject begins an every 3 week, platinum-based 
chemotherapy regimen.  The first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo shouldmay be given within 7 days prior to or within 7 
daysat any time following Day 1the first dose of afirst-line platinum-based chemotherapy cycle.  Subsequent doses of Sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo can be administered at any time point during the chemotherapy cycle. 
_  _  _  _  _  _  _  _  _  _
If sotatercept (ACE-011) or sotatercept (ACE-011)/placebo is administered on the same day as chemotherapy, sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo should be given prior to chemotherapy administration.
rEvery 3-week platinum
r Platinum-based chemotherapy is to be administered based on guidelines for administration according to manufacturer’s recommendations and standard 
clinical practice.  Type of chemotherapy and dosing will be recorded.  If sotatercept (ACE-011) or sotatercept (ACE-011)/placebo is administered on the same 
day as chemotherapy, sotatercept (ACE-011) or sotatercept (ACE-011)/placebo should be given prior to chemotherapy administration.
Page 341 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
45
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
Table 8:
Schedule of Pharmacokinetic Assessments (Part 1)
_  _  _  _  _  _  _  _  _  _
dTo be collected in other subjects. participating in sparse PK sampling and not participating in full PK sampling.  
Rationale:
Modified to:

Clarify that archival tumor tissue analysis will occur only in Part 2 of the study and will 
be optional. 

Include subjects with selected metastatic solid tumor types in Part 1 of the study.

Clarify sites of DXA scan.

Clarify that sparse PK in Part 1 is optional.

Expand acceptable time period for screening tumor assessment to align with standard of 
care per site.

Clarify FACIT Fatigue Scale to be performed on all subjects..

Clarify LCSS questionnaire to be performed only on subjects with NSCLC.

Allow administration of the first dose of sotatercept (ACE-011) at any time during a 
chemotherapy cycle dependent upon hemoglobin level.   

Allow administration of sotatercept (ACE-011) before or after chemotherapy 
administration.

Clarify sparse PK sampling in Part 1.
Page 342 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
46
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
2.16.
Section 6:  Procedures (pages 55-62)
Original Text:
Screening Period (Day -28 to Day -1)
Prior to screening, subjects must sign an informed consent.  Potentially protocol-eligible subjects 
will be evaluated for the inclusion and exclusion criteria for the Treatment Period of this study.  
All screening assessments must be completed within 28 days prior to randomization.  Screening 
period tumor assessments and tumor evaluation documentation, as per RECIST criteria (Version 
1.1) (Appendix A), must be performed within 6 weeks prior to randomization.  Historical tumor 
assessment data, from prior to the initiation of platinum-based chemotherapy through the 
screening period, will be collected.  Hematology and chemistry laboratory assessments should be 
performed within 14 days of randomization.  
The assessments and procedures that will be performed during the Screening Period are outlined 
in the Table of Events (see Section 5) and include:
_  _  _  _  _  _  _  _  _  _
NSCLC history, including date of original diagnosis, histopathology, clinical stage at 
screening, date of metastatic stage and site involvement
Prior ESA treatment history starting from initial diagnosis of NSCLC
RBC transfusion history starting from diagnosis of metastatic NSCLC at a minimum 
of up two months prior to randomization
_  _  _  _  _  _  _  _  _  _
Bone imaging – DXA scan
Tumor Assessment - Screening period tumor assessments and tumor evaluation 
documentation, as per RECIST criteria (Version 1.1), must be performed within 6 
weeks prior to randomization to this study.  Also, historical tumor assessment data, 
from prior to the initiation of platinum based chemotherapy through the screening 
period, will be collected.  
QoL Assessment (FACIT Fatigue Scale [Version 4]) and LCSS questionnaire  
_  _  _  _  _  _  _  _  _  _
Treatment Period (Day 1/Dose 1 of study treatment to Day 43 post last study treatment 
dose)
Results from screening evaluations must be reviewed prior to randomization to confirm subject 
eligibility.  
In Part 1 (the dose-ranging portion of the study), subjects who meet all eligibility criteria will be 
randomized by a single-blind procedure utilizing IVRS to receive one of the following 
sotatercept (ACE-011) dose levels, with 10-30 subjects per arm:
Sotatercept (ACE-011) 15.0 mg SC
Sotatercept (ACE-011) 30.0 mg SC
Page 343 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
47
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
Analysis of safety data will be performed following the treatment of at least 10 subjects at the 
15.0 mg dose level and 10 subjects at the 30.0 mg dose level, with each subject having received 
at least of one dose of sotatercept (ACE-011), plus a 12-week follow-up period from first dose.  
Following this analysis, the addition of a third dose level:
Sotatercept (ACE-011) 45.0 mg SC
to the randomization schema will be determined.
_  _  _ _  _  _  _  _  _  _
In Part 2, the Treatment Period will last approximately 6 to 9 months, where subjects 
randomized to sotatercept (ACE-011)/Placebo will receive treatment on Day 1 every 42 days for 
a planned 4 doses with an additional two doses of sotatercept (ACE-011)/placebo allowable, at 
the discretion of the Investigator, for a total of up to 6 doses.  
_  _  _  _  _  _  _  _  _  _
The assessments and procedures that will be performed during the Treatment Period are outlined 
in the Table of Events (see Section 5).  
_  _  _  _  _  _  _  _  _  _

Activin A and other sotatercept (ACE-011)-related proteins/biomarkers

in blood, including myostatin and follistatin:
o
pre- dose on Day 1 and Day 8 after first dose of sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo
o
pre-dose on Day 1 subsequent dosing visits

in archival tumor tissue
_  _  _  _  _  _  _  _  _  _
Tumor Assessment and Response Evaluation, as per RECIST criteria (Version 1.1), 
(performed ≥ every 9 weeks ± one week or per standard of care at the study site, 
starting from the previous [screening] tumor assessment) and following the 
chemotherapy schedule
_  _  _  _  _  _  _  _  _  _
QoL Assessment (FACIT Fatigue Scale (Version 4)) and LCSS questionnaire
_  _  _  _  _  _  _  _  _  _
Post Treatment Follow-Up Period (Day 43 post last dose of study treatment to six months 
post last dose of study treatment)
_  _  _  _  _  _  _  _  _  _
The assessments and procedures that will be performed during this period are outlined in the 
Table of Events (see Section 5) and include:
_  _  _  _  _  _  _  _  _  _
Page 344 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
48
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
Tumor Assessment and Response Evaluation, as per RECIST criteria (Version 1.1), 
(performed ≥ every 9 weeks ± one week or per standard of care at the study site, 
and following the chemotherapy schedule
QoL Assessment (FACIT Fatigue Scale (Version 4)) and LCSS questionnaire
_  _  _  _  _  _  _  _  _  _
Study Discontinuation
_  _  _  _  _  _  _  _  _  _
The assessments and procedures that will be performed during the Study Discontinuation Visit 
are outlined in the Table of Events (see Section 5) and include:
QoL Assessment (FACIT Fatigue Scale (Version 4)) and LCSS questionnaire 
_  _  _  _  _  _  _  _  _  _

Reporting of adverse events (only AE/SAE assessed related to study treatment are to 
be reported)
_  _  _  _  _  _  _  _  _  _
Exploratory Biomarkers
Analyses will be undertaken to evaluate the expression of Activin A and other 
proteins/biomarkers related to sotatercept (ACE-011) mechanism of action in blood (including 
myostatin and follistatin) and in archival tumor tissue in the NSCLC population in a subset of 
subjects.  
_  _  _  _  _  _  _  _  _  _
Pharmacokinetics
Part 1 - Full PK blood samples will be collected to evaluate the full PK profile of 
sotatercept (ACE-011) from approximately 30 subjects at select centers 
(approximately 10 subjects for each sotatercept [ACE-011] dose group).  For full PK 
sampling, subjects who miss more than two PK sampling time points from Days 1 
through 43 will be replaced.  Subjects not participating in the optional full PK 
assessment will participate in the sparse PK assessment.  

Part 2- Sparse PK blood samples will be collected from approximately 300 (40%) of 
750 subjects (approximately 150 subjects in each arm).  
_  _  _  _  _  _  _  _  _  _
Bone Imaging
_  _  _  _  _  _  _  _  _  _
Quality of Life Assessments
QoL Assessment (FACIT Fatigue Scale [Version 4]) and LCSS questionnaire will be completed 
by the subject upon arrival at clinic and prior to any study procedures or testing.  The LCSS 
Page 345 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
49
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
consists of two scales: one for the patient (Patient Scale) and a counterpart for health 
professionals acting as observers (Observer Scale). 
Revised Text:
Screening Period (Day -28 to Day -1)
Prior to screening, subjects must sign an informed consent.  Potentially protocol-eligible subjects 
will be evaluated for the inclusion and exclusion criteria for the Treatment Period of this study.  
All screening assessments must be completed within≤28 days prior to randomization.  Screening 
period tumor assessments and tumor evaluation documentation, as per RECIST criteria (Version 
1.1) (Appendix A), must be performed within 6 weeks prior to randomization. or as per study 
site standard of care.  Historical tumor assessment data, from prior to the initiation of platinum-
based chemotherapy through the screening period, will be collected.  Hematology and chemistry 
laboratory assessments should be performed within≤14 days of randomization.  
The assessments and procedures that will be performed during the Screening Period are outlined 
in the Table of Events (see Section 5) and include:
_  _  _  _  _  _  _  _  _  _
NSCLCCancer history, including date of original diagnosis, histopathology, clinical 
stage at screening, date of metastatic stage and site involvement
Prior ESA treatment history starting from initial diagnosis of NSCLCone of the
selected solid tumors
RBC transfusion history starting from diagnosis of metastatic NSCLCdisease at a 
minimum of up two months prior to randomization
_  _  _  _  _  _  _  _  _  _
Bone imaging – DXA scan (optional at selected sites)
Tumor Assessment - Screening period tumor assessments and tumor evaluation 
documentation, as per RECIST criteria (Version 1.1), must be performed within 6 
weeks or as per study site standard of care prior to randomization to this study..  Also, 
historical tumor assessment data, from prior to the initiation of platinum based 
chemotherapy through the screening period, will be collected.  
QoL Assessment (FACIT Fatigue Scale [Version 4]) and – all subjects
LCSS questionnaire – only subjects with NSCLC  
_  _  _  _  _  _  _  _  _  _
Treatment Period (Day 1/Dose 1 of study treatment to Day 43 post last study treatment 
dose)
Results from screening evaluations must be reviewed prior to randomization to confirm subject 
eligibility.  
Page 346 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
50
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
In Part 1 (the dose-ranging portion of the study), subjects who meet all eligibility criteria will be 
randomized by a single-blind procedure utilizing IVRS to receive one of the following 
sotatercept (ACE-011) dose levels, with 10-30 subjects per arm:
Sotatercept (ACE-011) 15.0 mg SC
Sotatercept (ACE-011) 30.0 mg SC
Analysis of safety data will be performed following the treatment of at least 10 subjects at the 
15.0 mg dose level and 10 subjects at the 30.0 mg dose level, with each subject having received 
at leasta minimum of  one dose of sotatercept (ACE-011), plus) and completed a 12-week 
follow-up period from the first dose. Following this analysis, the addition of a third dose level:
Following this analysis, the addition of a third dose level:
Sotatercept (ACE-011) 45.0 mg SC
to the randomization schema will be determined.
_  _  _  _  _  _  _  _  _  _
In Part 2, the Treatment Period will last approximately 6 to 9 months, where subjects 
randomized to sotatercept (ACE-011)/Placebo will receive treatment on Day 1 every 42 days for 
a planned 4 doses with an additional two2 doses of sotatercept (ACE-011)/placebo allowable, at 
the discretion of the Investigator, for a total of up to 6 doses.  
_  _  _  _  _  _  _  _  _  _
The assessments and procedures that will be performed during the Treatment Period are outlined 
in the Table of Events (see Section 5).  
_  _  _  _  _  _  _  _  _  _
Activin A and other sotatercept (ACE-011)-related proteins/biomarkers

in blood, including myostatin and follistatin:
o
pre- dose on Day 1 and Day 8 after first dose of sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo
o
pre-dose on Day 1 subsequent dosing visits
in archival tumor tissue (Part 2 only)
_  _  _  _  _  _  _  _  _  _

Tumor Assessment and Response Evaluation, as per RECIST criteria (Version 1.1), 
(performed ≥≤every 9 weeks ± one week or per standard of care at the study site, 
starting from the previous [screening] tumor assessment) and following the 
chemotherapy schedule
_  _  _  _  _  _  _  _  _  _
QoL Assessment (FACIT Fatigue Scale ([Version 4)) and LCSS questionnaire]) – all 
subjects
LCSS questionnaire – only subjects with NSCLC  
Page 347 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
51
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
_  _  _  _  _  _  _  _  _  _
Post Treatment Follow-Up Period (Day 43 post last dose of study treatment to six months 
post last dose of study treatment)
_  _  _  _  _  _  _  _  _  _
The assessments and procedures that will be performed during this period are outlined in the 
Table of Events (see Section 5) and include:
Tumor Assessment and Response Evaluation, as per RECIST criteria (Version 1.1), 
(performed ≥≤every 9 weeks ± one week or as per standard of care at the study 
site, and following the chemotherapy schedule
QoL Assessment (FACIT Fatigue Scale (Version 4)) and LCSS questionnaire– all 
subjects
LCSS questionnaire – subjects with NSCLC  
_  _  _  _  _  _  _  _  _  _
Study Discontinuation 
_  _  _  _  _  _  _  _  _  _
The assessments and procedures that will be performed during the Study Discontinuation Visit 
are outlined in the Table of Events (see Section 5) and include:
_  _  _  _  _  _  _  _  _  _
QoL Assessment (FACIT Fatigue Scale (Version 4)) and– all subjects 

LCSS questionnaire – only subjects with NSCLC 
_  _  _  _  _  _  _  _  _  _

Reporting of adverse events (only AE/SAE assessed related to study treatment are to 
be reported)

Evaluation and reporting of all AEs regardless of causality (up to 6 weeks after last 
dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo).  After 6 weeks 
post last dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo, only AEs 
assessed as related to sotatercept (ACE-011) or sotatercept (ACE-011)/placebo or 
study related procedures are to be reported.
_  _  _  _  _  _  _  _  _  _
Exploratory Biomarkers
Analyses will be undertaken to evaluate the expression of Activin A and other 
proteins/biomarkers related to sotatercept (ACE-011) mechanism of action in blood 
(including myostatin and follistatin) and in archival tumor tissue in the NSCLC population in
a subset of subjects. (Part 2 only).  
_  _  _  _  _  _  _  _  _  _
Page 348 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
52
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
Pharmacokinetics

Part 1 - Full PK bloodBlood samples will be collected to evaluate the full PK profile 
of sotatercept (ACE-011) from approximately 30 subjects at select centers 
(approximately 10 subjects for each sotatercept [ACE-011] dose group).  For full PK 
sampling, subjects who miss more than two PK sampling time points from Days 1 
through 43 will be replaced.  Subjects not participating in the optional full PK 
assessment willmay participate in the sparse PK assessment. 

Part 2- Sparse PK blood samples will be collected from approximately 300 (40%) of 
750 subjects (approximately 150 subjects in each arm).  
For subjects who do not participate in either Part 1 full or sparse PK assessments or in Part 2 
sparse PK assessments, the ACE-011 (sotatercept) concentration may be determined in their anti-
sotatercept antibody samples to assist in the evaluation of immunogenicity, as well as PK.
_  _  _  _  _  _  _  _  _  _
Bone Imaging - optional
_  _  _  _  _  _  _  _  _  _
Quality of Life Assessments
QoL Assessment (FACIT Fatigue Scale [Version 4]) will be completed by all subjects and LCSS 
questionnaire will be completed for subjects with NSCLC.  Each assessment will be completed 
by the subject upon arrival at clinic and prior to any study procedures or testing.  The LCSS 
consists of two scales: one for the patient (Patient Scale) and a counterpart for health 
professionals acting as observers (Observer Scale). 
Rationale:
Modified to:

Clarify screening period.

Expand acceptable time period for screening tumor assessment to align with standard of 
care per site.

Include subjects with selected metastatic solid tumor types in Part 1 of the study.

Clarify collection of RBC transfusion data.   

Clarify DXA scanning is optional.

Clarify FACIT Fatigue Scale will be performed on all subjects.

Clarify LCSS questionnaire to be performed only for subjects with NSCLC.

Clarify collection of adverse event data at study discontinuation visit.

Clarify criteria for analysis of safety data from the 15 and 30 mg sotatercept (ACE-011) 
dose levels to  determine the addition of the 45 mg sotatercept (ACE-011) dose level.

Add editorial revision –  ‘two’ to ‘2’.
Page 349 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
53
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011

Clarify that archival tumor tissue analysis will occur only in Part 2 of the study. 

Deleted redundant wording – ‘ Full PK blood’.

Clarify that sparse PK in Part 1 is optional.

Clarify that concentration of sotatercept (ACE-011) may be determined in anti-drug 
(sotatercept) antibody samples.
Page 350 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
54
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
2.17.
Section 7:  Study Population (page 63)
Original Text:
Subjects must be receiving their first regimen of first-line platinum-containing chemotherapy, 
given every three weeks, for the treatment of metastatic NSCLC at the time of randomization.  
Subjects must be randomized prior to receiving Cycle 4 of this current first-line platinum-based 
chemotherapy regimen.  Subjects are expected to  be eligible to continue to receive ≥ 2 
additional platinum-based chemotherapy cycles while on study treatment.  
Subjects must not have received any other regimens of chemotherapy for the first-line platinum 
containing treatment of metastatic NSCLC prior to the regimen at the time of randomization.  
Revised Text:
Subjects must be receiving their first regimen of first-line platinum-containing chemotherapy , 
given every three weeks, for the treatment of a selected metastatic NSCLCsolid tumor at the time 
of randomization: metastatic NSCLC, metastatic small cell lung cancer, metastatic bladder 
cancer, metastatic head and neck cancer, and metastatic endometrial/cervical cancer, where the 
standard of care is first-line platinum-based chemotherapy. Subjects may have already received 
up to 4 cycles of this current platinum-based regimen and must be randomized prior to receiving 
Cycle 4 of this current first-line platinum-based chemotherapy regimen.  Subjects are5.  It is
expected to that subjects be eligible to continue to receive ≥ 2 additional platinum-based 
chemotherapy cycles while on study treatment.  
Subjects must not have received any other regimens of platinum containing chemotherapy for the 
first-line platinum containing treatment of metastatic NSCLCsolid tumors prior to the regimen 
they are receiving at the time of randomization.  
Rationale:
Modified to increase the number of allowed prior cycles of first-line platinum-based 
chemotherapy to 4 and allow subjects with selected metastatic solid tumor types in Part 1 of the 
study. 
Page 351 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
55
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
2.18.
Section 7.1:  Number of Subjects (page 63)
Original Text:
This NSCLC platinum-based CIA study will enroll approximately 840 subjects in Part 1 and 
Part 2.  
_  _  _  _  _  _  _  _  _  _
In Part 2, an additional 750 subjects will be randomized to receive either sotatercept (ACE-011), 
at the dose determined in Part 1, or placebo at a ratio of 1:1.  Subjects will be randomized to 
receive either sotatercept (ACE-011) or placebo and will be stratified by:
Revised Text:
This NSCLC platinum-based CIA study will enroll approximately 840 subjects, approximately 
90 subjects with selected metastatic solid tumor types in Part 1 and 750 subjects with metastatic 
NSCLC in Part 2.  
_  _  _  _  _  _  _  _  _  _
In Part 2, an additional 750 subjects will be randomized to receive either sotatercept (ACE-011), 
at the dose determined in Part 1, or placebo at a ratio of 1:1.  Subjects will be randomized to 
receive either sotatercept (ACE-011) or placebo andSubjects will be stratified by:
Rationale:
Modified to:

Include subjects with selected metastatic solid tumor types in Part 1.

Delete redundant wording.
Page 352 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
56
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
2.19.
Section 7.2:  Inclusion Criteria (page 64)
Original Text:
Subjects must satisfy the following criteria to be enrolled in the study:
_  _  _  _  _  _  _  _  _  _
2. Histologically confirmed (cytology or biopsy) non-small cell carcinoma of the lung.
3. Documented metastatic (Stage IV) disease, (including pleural or pericardial effusion 
involvement) 
_  _  _  _  _  _  _  _  _  _
5. All of the following laboratory values:
_  _  _  _  _  _  _  _  _  _
Hepatic function (bilirubin < 1.5 x ULN; AST and ALT < 3.0 x ULN and ≤5 ULN for 
subjects with liver metastases)
_  _  _  _  _  _  _  _  _  _
6. Subjects may have received up to 3 cycles of their first regimen of  first line platinum-
based chemotherapy treatment for metastatic NSCLC.  Allowed regimens are:
gemcitabine plus cisplatin or carboplatin ± bevacizumab
pemetrexed plus cisplatin or carboplatin ± bevacizumab
paclitaxel plus carboplatin ± bevacizumab
docetaxel plus cisplatin ± bevacizumab
At randomization subjects are expected to  be eligible to continue to receive at least two 
additional platinum-based chemotherapy cycles while on study. .
_  _  _  _  _  _  _  _  _  _
10. If currently receiving bisphosphonate or denosumab (XGEVA™) therapy for bone 
metastases, must be on a stable dose for ≥ 2 months before Day 1 (ongoing 
bisphosphonate or denosumab therapy is allowed during study provided it is kept at a 
stable level). Bisphosphonate or denosumab therapy may not be started on study.  
Bisphosphonate therapy may be started on study for the treatment of hypercalcemia.  
Subjects not currently on bisphosphonates or denosumab must not have received 
bisphosphonates or denosumab within 2 months prior to Day 1.  
Revised Text:
Subjects must satisfy the following criteria to be enrolled in the study:
_  _  _  _  _  _  _  _
2. Part 1 - Histologically confirmed (cytology or biopsy) solid tumor malignancy, including
metastatic non-small cell lung cancer (NSCLC), metastatic small cell lung cancer,  
Page 353 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
57
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
metastatic bladder cancer, metastatic head and neck cancer, and metastatic 
endometrial/cervical cancer , where the standard of care is platinum-based chemotherapy.
Part 2 - Histologically confirmed (cytology or biopsy) non-small cell lung cancer.
carcinoma of the lung.
3. Documented metastatic (Stage IV) disease, (including pleural or pericardial effusion 
involvement)
_  _  _  _  _  _  _  _  _  _
5. All of the following laboratory values:
_  _  _  _  _  _  _  _  _  _
Hepatic function (bilirubin < 1.5 x ULN; AST and ALT < 3.0 x ULN and ≤ 5.0 ULN 
for subjects with liver metastases)
_  _  _  _  _  _  _  _  _  _
6. Subjects may have received up to 34 cycles of their first regimen of first line platinum-
based chemotherapy treatment. 

For Part 1- any platinum-based regimen approved for the specific indication
For Part 2 -allowed regimens for the treatment of metastatic NSCLC .  Allowed 
regimens are:
o gemcitabine plus cisplatin or carboplatin ± bevacizumab
o pemetrexed plus cisplatin or carboplatin ± bevacizumab
paclitaxelotaxanes plus cisplatin or carboplatin ± bevacizumab
docetaxel plus cisplatin ± bevacizumab
At randomization, subjects are expected to be eligible to continue to receive at least two 
additional platinum-based chemotherapy cycles while on study. .
_  _  _  _  _  _  _  _  _  _
10. If currently receiving bisphosphonate or denosumab (XGEVA™) therapy for bone 
metastases, must be on a stable dose for ≥ 2 months before Day 1 (ongoing 
bisphosphonate or denosumab therapy is allowed during study provided it is kept at a 
stable level). Bisphosphonate or denosumab therapy may not be started on study.  
Bisphosphonate therapy may be started on study for the treatment of hypercalcemia.  
Subjects not currently on bisphosphonates or denosumab must not have received 
bisphosphonates or denosumab within 2 months prior to Day 1.  
Rationale:
Modified to:

Include subjects with selected metastatic solid tumor types in Part 1 of the study.
Page 354 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
58
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011

Correction of hepatic function typographical error.

Increase the number of allowed prior cycles of first-line platinum-based chemotherapy to 
4 cycles.

Expand the type of platinum-based regimens allowed in Part 1 of the study.

Clarify the types of platinum-based regimens allowed in Part 2 of the study.

Include use of bisphosphonates and denosumab for bone metastases to be consistent with 
standard of care and treatment practices.
Page 355 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
59
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
2.20.
Section 7.3:  Exclusion Criteria (pages 65-67)
Original Text:
The presence of any of the following will exclude a subject from enrollment:
_  _  _  _  _  _  _  _  _  _
3. History of prior regimen(s) of platinum-based chemotherapy for metastatic NSCLC.    
_  _  _  _  _  _  _  _  _  _
5. Clinically significant pulmonary, endocrine, neurologic, gastrointestinal, hepatic or 
genitourinary disease unrelated to underlying NSCLC.  
Revised Text:
The presence of any of the following will exclude a subject from enrollment:
_  _  _  _  _  _  _  _  _  _
3. History of prior regimen(s) of platinum-based chemotherapy for metastatic NSCLC.  
disease and/or history of adjuvant platinum-based chemotherapy with last dose received 
less than six months prior to the start of current first-line platinum-based chemotherapy 
for metastatic disease.  
_  _  _  _  _  _  _  _  _  _
5. Clinically significant pulmonary, endocrine, neurologic, gastrointestinal, hepatic or 
genitourinary disease unrelated to underlying NSCLCmalignancy.  
Rationale: Modified to include selected metastatic solid tumor types in Part 1 of the study and 
clarify acceptable history of prior adjuvant platinum-based chemotherapy.
Page 356 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
60
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
2.21.
Section 8.2:  Treatment Administration and Schedule (pages 68-69)
Original Text:
At the time of randomization all subjects must be receiving their first-line regimen of platinum-
containing chemotherapy, given every three weeks, for the treatment of metastatic NSCLC.  
Subjects will be randomized to this study during the time period in which they are receiving 
Cycle 1 to Cycle 3 of their first regimen of first-line platinum-based chemotherapy.  Subjects 
must not have received any prior regimens of platinum-based chemotherapy for metastatic 
NSCLC.  
Allowed concomitant platinum-based chemotherapy regimens are:
_  _  _  _  _  _  _  _  _  _
paclitaxel plus carboplatin ± bevacizumab
docetaxel plus cisplatin  ± bevacizumab
_  _  _  _  _  _  _  _  _  _
The platinum-based tumor therapy may be revised at the discretion of the Investigator for 
toxicity reasons only.  
While on treatment subjects will be allowed to receive maintenance therapy with a pemetrexed 
or erlotinib-containing regimen when indicated. 
Subjects must be given sotatercept (ACE-011) or sotatercept (ACE-011)/placebo prior to 
chemotherapy administration on the dose administration days.  
Revised Text:
At the time of randomization all subjects must be receiving their first-line regimen of platinum-
containing chemotherapy, given every three weeks, for the treatment of a metastatic 
NSCLC.solid tumor.  Subjects will be randomized to this study during the time period in which 
they are receiving Cycle 1 tothrough Cycle 34 of their first this regimen of first-line platinum-
based chemotherapy..  Subjects must not have received any prior regimens of first line platinum-
based chemotherapy for a metastatic NSCLC.solid tumor..  
Allowed concomitant platinum-based chemotherapy regimens are:
For Part 1- any platinum-based regimen approved for the specific indication
For Part 2 -allowed regimens for the treatment of metastatic NSCLC are:
_  _  _  _  _  _  _  _  _  _
paclitaxelotaxanes plus cisplatin or carboplatin ± bevacizumab
docetaxel plus cisplatin  ± bevacizumab
_  _  _  _  _  _  _  _  _  _
The platinum Platinum-based tumor therapy may be revised at the discretion of the Investigator 
for toxicity reasons only.  
Page 357 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
61
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
While on study treatment subjects will be allowed to receive maintenance therapy with a 
pemetrexed or erlotinib-containing regimen when indicated. 
Subjects must be given sotatercept (ACE-011) or sotatercept (ACE-011)/placebo prior to 
chemotherapy administration on the dose administration days.  
Rationale:
Modified to:

Include selected metastatic solid tumor types in Part 1 of the study.

Increase the number of allowed prior cycles of first-line platinum-based chemotherapy to 
4 cycles.

Expand the type of platinum-based regimens allowed in Part 1 of the study.

Clarify the types of platinum-based regimens allowed in Part 2 of the study.

Make editorial correction.

Clarify that maintenance therapy is allowed while subject is on study treatment.
Page 358 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
62
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
2.22.
Section 8.2.1:  Selection of Dose for the Study (pages 69-70)
Original Text:
_  _  _  _  _  _  _  _  _  _
Analysis of safety data will be performed following the treatment of at least 10 
subjects at the 15.0 mg dose level and 10 subjects at the 30.0 mg dose level, with at 
least of one dose of sotatercept (ACE-011), plus a 12-week follow-up period from 
first dose.  
_  _  _  _  _  _  _  _  _  _

Hematopoietic response is defined as an increase in Hgb of ≥ 1.0 g/dL above the 
study baseline value for 28 consecutive days, in the absence of RBC transfusions 
and/or ESAs.  In order to determine the optimal dose of sotatercept (ACE-011) to be 
used in Part 2, evaluation of hematopoietic response will be determined from 
sotatercept (ACE-011) Dose 1/ Day 1 through and including Dose 2/Day 43 (prior to 
Dose 3).  
_  _  _  _  _  _  _  _  _  _
Hematopoietic response will be determined by laboratory analysis.  
Revised Text:
_  _  _  _  _  _  _  _  _  _
Analysis of safety data will be performed following the treatment of at least 10 subjects at the 
15.0 mg dose level and 10 subjects at the 30.0 mg dose level, with at leasteach subject having 
received a minimum of one dose of sotatercept (ACE-011), plus) and completed a  12-week 
follow-up period from the first dose.  
_  _  _  _  _  _  _  _  _  _

Hematopoietic response is defined as an increase in Hgb of ≥ 1.0 g/dL above the 
study baseline value for 28 consecutive days, in the absence of RBC transfusions 
and/or ESAs.  In order to determine the optimal dose of sotatercept (ACE-011) to be 
used in Part 2, evaluation of hematopoietic response will be determined from 
sotatercept (ACE-011) Dose 1/ Day 1 through and including Dose 2/Day 43 (prior to 
Dose 3).  
_  _  _  _  _  _  _  _  _  _
Hematopoietic response will be determined by laboratory analysis of hemoglobin levels.  
_  _  _  _  _  _  _  _  _  _
Rationale:
Modified to:
Clarify criteria for analysis of safety data from the 15 and 30 mg sotatercept (ACE-011) dose 
levels to determine the addition of the 45 mg sotatercept (ACE-011) dose level.  
Page 359 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
63
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
Delete term ‘optimal’ to describe sotatercept dose determined in Part 1 to be administered in 
Part 2. 
Clarify how hematopoietic response will be determined. 
Page 360 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
64
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
2.23.
Section 8.2.2:  Selection and Timing of Dosing for Each Subject
(pages 70-71)
Original Text:
_  _  _  _  _  _  _  _  _  _
The first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo should be given 
within 7 days prior to or within 7 days of administration of a platinum-based 
chemotherapy cycle.  Subsequent doses of Sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo can be administered at any time point during the chemotherapy cycle. 
_  _  _  _  _  _  _  _  _  _
If sotatercept (ACE-011) or sotatercept (ACE-011)/placebo is administered on the same day as 
chemotherapy, sotatercept (ACE-011) or sotatercept (ACE-011)/placebo should be given prior 
to chemotherapy administration.
Following completion of the Treatment Period, subjects who enter the Post Treatment Follow-
Up Period will be followed for 6 months from their last dose of sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo.  Visits will occur every month.  All subjects will continue to be 
followed for PFS up to 12 months from their first dose of sotatercept (ACE-011) or sotatercept 
(ACE-011)/placebo, or until progression of their NSCLC, whichever comes first.  
Subjects will be discontinued from the study treatment for reasons listed in Section 8.2.3 of the 
protocol, for unacceptable toxicity, or for progression of NSCLC that requires the initiation of 
another treatment.  
Revised Text:
_  _  _  _  _  _  _  _  _  _
The first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo shouldcan be 
administered given within 7 days prior to or within 7 days of at any time after the first cycle 
and prior to the fifth cycle of first-line platinum-based chemotherapy cycle.  Subsequent 
doses of Sotatercept (ACE-011) or sotatercept (ACE-011)/placebo can be administered at any 
time point during the chemotherapy cycle. 
_  _  _  _  _  _  _  _  _  _
If sotatercept (ACE-011) or sotatercept (ACE-011)/placebo is administered on the same day as 
chemotherapy, sotatercept (ACE-011) or sotatercept (ACE-011)/placebo should be given prior 
to chemotherapy administration.
Following completion of the Treatment Period, subjects who enter the Post Treatment Follow-
Up Period will be followed for 6 months from their last dose of sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo.  Visits will occur every month.  All subjects will continue to be 
followed for PFS up to 12 months from their first dose of sotatercept (ACE-011) or sotatercept 
(ACE-011)/placebo, or until progression of their NSCLCmetastatic disease, whichever comes 
first.  
Page 361 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
65
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
Subjects will be discontinued from the study treatment for reasons listed in Section 8.2.3 of the 
protocol, for unacceptable toxicity, or for progression of NSCLCmetastatic disease that requires 
the initiation of another treatment.  
Rationale:
Modified to:

Allow administration of the first dose of sotatercept (ACE-011) at any time during a 
chemotherapy cycle dependent upon hemoglobin level.   

Allow administration of sotatercept (ACE-011) before or after chemotherapy 
administration.

Include metastatic solid tumor progression as a reason for Study Treatment 
Discontinuation.
Page 362 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
66
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
2.24.
Section 8.2.3:  Discontinuation (pages 71-72)
Original Text:
Treatment Discontinuation
_  _  _  _  _  _  _  _  _  _
Subjects will be discontinued from Study Treatment due to the following:
_  _  _  _  _  _  _  _  _  _
Lack of sotatercept (ACE-011) therapeutic effect, defined as < 1.0 g/dL increase in 
Hgb following two doses of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo
_  _  _  _  _  _  _  _  _  _
Disease Progression of NSCLC
_  _  _  _  _  _  _  _  _  _
Study Discontinuation:  
_  _  _  _  _  _  _  _  _  _
The following events may be considered sufficient reasons for discontinuing a subject from the 
study:
_  _  _  _  _  _  _  _  _  _
Disease progression of NSCLC
Revised Text:
Treatment Discontinuation
_  _  _  _  _  _  _  _  _  _
Subjects will be discontinued from Study Treatment due to the following:
_  _  _  _  _  _  _  _  _  _

LackIn Part 1, lack of sotatercept (ACE-011) therapeutic effect, defined as < 1.0 
g/dL increase in Hgb from baseline following three dose escalations.  In Part 2, lack 
of sotatercept (ACE-011) therapeutic effect, defined as < 1.0 g/dL increase in Hgb 
from baseline following two doses of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo. (Dose 1/ Day 1 through and including Dose 2/Day 43, prior to Dose 3).
_  _  _  _  _  _  _  _  _  _
Disease Progression of NSCLC
_  _  _  _  _  _  _  _  _  _
Study Discontinuation:  
_  _  _  _  _  _  _  _  _  _
Page 363 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
67
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
The following events may be considered sufficient reasons for discontinuing a subject from the 
study:
_  _  _  _  _  _  _  _  _  _
Disease progression of NSCLC
Rationale:
Modified to:

Clarify assessment of  sotatercept (ACE-011) therapeutic effect in Part 1 and Part 2 of the 
study and provide the timeframe in which assessment should be performed.

Include metastatic solid tumor progression in rules for Study Treatment and Study 
Discontinuation.
Page 364 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
68
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
2.25.
Section 9.1:  Permitted Concomitant Medications and Procedures
(pages 74-75)
Original Text:
General concomitant medication usage
_  _  _  _  _  _  _  _  _  _
Concomitant therapies considered as supportive care are acceptable while participating in this 
study including growth colony stimulating factors (G-CSF), anti-emetics to limit chemotherapy-
related nausea and vomiting and palliative radiation and bisphosphonates (Refer to Inclusion 
Criterion, Section 7.2) for bone metastases.  
_  _  _  _  _  _  _  _  _  _
Erythropoiesis-stimulating agents (ESAs)
The use of an ESA is not allowed in Part 1 of the study; however, ESAs are allowed in 
Part 2 only after a subject has received at least 4 months of study treatment.  The use of 
ESAs will need to result in immediate notification to the study sponsor and Medical Monitor, as
well as to the unblinded clinical site pharmacist, so that no further dosing with sotatercept 
(ACE-011) in that study subject will occur.  Subjects will not be unblinded.  
_  _  _  _  _  _  _  _  _  _
In Part 2, subjects who receive an ESA at < 4 months from their first dose of sotatercept (ACE-
011) or sotatercept (ACE-011)/placebo will be discontinued from the study treatment period and 
continue to the post treatment follow-up period.  Subjects who receive an ESA at ≥ 4 months 
from their first dose of sotatercept (ACE-011)/placebo will continue in the treatment period.  
The unblinded pharmacist will ensure that subjects randomized to receive treatment with 
sotatercept (ACE-011) are changed over to receive treatment with placebo.  Subjects 
randomized to treatment with placebo will continue to receive placebo.  
RBC transfusions
_  _  _  _  _  _  _  _  _  _
If an RBC transfusion is given to a subject during the Treatment Period, sotatercept (ACE-011) 
should be administered no sooner than 7 days from the date of the RBC transfusion.  
Revised Text:
General concomitant medication usage
_  _  _  _  _  _  _  _  _  _
Concomitant therapies considered as supportive care are acceptable while participating in this 
study including growth colony stimulating factors (G-CSF), anti-emetics to limit chemotherapy-
related nausea and vomiting and palliative radiation and , bisphosphonates and denosumab 
(Refer to Inclusion Criterion, Section 7.2) for bone metastases.  
_  _  _  _  _  _  _  _  _  _
Page 365 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
69
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
Erythropoiesis-stimulating agents (ESAs)
The use of an ESA is not allowed in Part 1 of the study; however, ESAs are allowed in 
Part 2 only after a subject has received at least 4 months of study treatment.  The use of 
ESAs will need to result in immediate notification to the study sponsor and Medical Monitor, as
well as to the unblinded clinical site pharmacist, so that no further dosing with sotatercept 
(ACE-011) in that study subject will occur.  Subjects will not be unblinded. 
_  _  _  _  _  _  _  _  _  _
In Part 2, subjects who receive an ESA at < 4 months from their first dose of sotatercept (ACE-
011) or sotatercept (ACE-011)/placebo will be discontinued from the study treatment period and 
continue to the post treatment follow-up period.  Subjects who receive an ESA at ≥ 4 months 
from their first dose of sotatercept (ACE-011)/placebo will continue in the treatment period. as 
follows:  The unblinded pharmacist will ensure that subjects randomized to receive 
treatment with sotatercept (ACE-011) are changed over to receive treatment with placebo.  
Subjects randomized to treatment with placebo will continue to receive placebo.  The 
investigator, site personnel and subject will remain blinded. 
RBC transfusions
_  _  _  _  _  _  _  _  _  _
If an RBC transfusion is given to a subject during the Treatment Period, sotatercept (ACE-011) 
should be administered no sooner than >7 days from the date of the RBC transfusion. 
Rationale:
Modified to:

Include use of bisphosphonates and denosumab for bone metastases to be consistent with 
standard of care and treatment practices.

Clarify blinding procedures in Part 2 following treatment with ESAs.

Clarify allowed timing of sotatercept (ACE-011) dosing following RBC transfusion.    
Page 366 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
70
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
2.26.
Section 10.1:  Overview (page 76)
Original Text:
This is a single-blind, randomized, phase 2a, dose-ranging study of sotatercept (ACE-011) 
therapy followed by a phase 2b/3, double-blind, randomized, placebo-controlled study of 
sotatercept (ACE-011) for CIA in subjects with metastatic NSCLC treated with platinum-based 
chemotherapeutic regimens.  
Revised Text:
This is an open-label, randomized, phase 2a, dose-ranging study of sotatercept (ACE-011) 
therapy for chemotherapy-induced anemia (CIA) in subjects with selected metastatic solid tumor 
types treated with platinum-based chemotherapeutic agents followed by a phase 2b/3, double-
blind, randomized, placebo-controlled study of sotatercept (ACE-011) therapy for 
chemotherapy-induced anemia (CIA) in subjects with metastatic non-small cell lung cancer 
(NSCLC) treated with platinum-based chemotherapeutic regimens. This is a single-blind, 
randomized, phase 2a, dose-ranging study of sotatercept (ACE-011) therapy followed by a phase 
2b/3, double-blind, randomized, placebo-controlled study of sotatercept (ACE-011) for CIA in 
subjects with metastatic NSCLC treated with platinum-based chemotherapeutic regimens.  
Rationale:
Modified to include selected metastatic solid tumor types, remove single-blind and add open-
label in Part 1 of the study.
2.27.
Section 10.9:  Other Topics (page 80)
Original Text
Pharmacokinetic Analysis
Approximately 10 subjects will be enrolled for full PK sampling in each treatment cohort of Part 
1.  For this portion of the study, subjects who miss more than two PK sampling time points from 
Days 1 through 43 will be replaced.  
Noncompartmental PK parameters for sotatercept (ACE-011), such as tmax, Cmax, AUC42, CL/F, 
Vz/F, and t1/2,z, will be estimated for subjects providing full PK samples.  Dose proportionality 
will be assessed by regression analysis using the exposure data after the first dose.  Descriptive 
statistics will be provided for plasma concentrations and PK parameters.  
Revised Text:
Pharmacokinetic Analysis
Approximately 10 subjects will be enrolled for full PK sampling in each treatment cohort of Part 
1.  For this portion of the study, subjects who miss more than two PK sampling time points from 
Days 1 through 43 will be replaced.  
Noncompartmental PK parameters for sotatercept (ACE-011), such as tmax, Cmax, AUC42, CL/F, 
Vz/F, and t1/2,z, will be estimated for subjects providing full PK samples.  Dose proportionality 
Page 367 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
71
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
will be assessed by regression analysis using the exposure data after the first dose.  Descriptive 
statistics will be provided for plasma concentrations and PK parameters.
Rationale:
Revision of PK parameters to be measured. 
Page 368 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
72
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
2.28.
Section 11.1:  Monitoring, Recording, and Reporting of Adverse 
Events (page 81)
2.29.
Original Text:
All AEs will be recorded by the Investigator from the time the subject signs informed consent to 
at least 42 days after the last dose of IP.  The AEs and SAEs will be recorded on the AE page of 
the eCRF and in the subject’s source documents.  All SAEs must be reported to Celgene Drug 
Safety immediately (i.e., within 24 hours of the Investigator’s knowledge of the event) by 
facsimile, or other appropriate method, using the SAE Report Form, or approved equivalent 
form.  After 42 days post last dose, only AEs assessed as related to study treatment are to be 
reported.  
Revised Text:
All AEs will be recorded by the Investigator from the time the subject signs informed consent to 
at least 42 days after the last dose of IP.  The AEs and SAEs will be recorded on the AE page of 
the eCRF and in the subject’s source documents.  All SAEs must be reported to Celgene Drug 
Safety immediately (i.e., within 24 hours of the Investigator’s knowledge of the event) by 
facsimile, or other appropriate method, using the SAE Report Form, or approved equivalent 
form.  After 42 days post last dose, only AEs assessed as related to study treatment are to be 
reported.  
Rationale:
Updated in alignment with current protocol template.
2.30.
Section 11.5:  Immediate Reporting of Serious Adverse Events 
Adverse Events (page 85)
Original Text:
Any AE that meets any criterion for an SAE requires the completion of an SAE Report Form in 
addition to being recorded on the AE page/screen of the eCRF.  All SAEs must be reported to 
Celgene Drug Safety immediately (i.e., within 24 hours of the Investigator’s knowledge of the 
event) by facsimile, or other appropriate method, using the SAE Report Form, or approved 
equivalent form.  This instruction pertains to initial SAE reports as well as any follow-up reports.  
Revised Text:
Any AE that meets any criterion for an SAE requires the completion of an SAE Report Form in 
addition to being recorded on the AE page/screen of the eCRF.  All SAEs must be reported to 
Celgene Drug Safety immediately (i.e., within 24 hours of the Investigator’s knowledge of the 
event) by facsimile, or other appropriate method, using the SAE Report Form, or approved 
equivalent form.  This instruction pertains to initial SAE reports as well as any follow-up reports.  
Page 369 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
73
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
Rationale:
Updated in alignment with current protocol template.
2.31.
Section 18:  References (pages 96-98)
Original Text:
Chantry A, Heath D, Mulivor A, Coulton L, Evans H, Abdul N, Werner ED, Bouxsein ML, 
Pearsall RS, Seehra J, Vanderkerken K, and Croucher PI.  Inhibiting activin-A signalling 
stimulates bone formation, prevents tumor-induced osteolytic bone destruction and blocks bone 
metastasis.  Submitted 2008.  
Revised Text:
Aapro M, Vaupel P.  Erythropoietin:  effects on life expectancy in patients with cancer-related 
anemia.  Curr Med Res Opin. 2006; 22(suppl 4):5-13.
Carlos JJ, Salas M, Ward A, et al.  Anemia as an independent prognostic factor for survival in 
patients with cancer:  a systemic, quantitative review.  Cancer.  2001; 91:2214-2221.
Cella D, Kallich J, McDermott A, et al.  The longitudinal relationship of hemoglobin, fatigue, 
and quality of life in anemic cancer patients:  results from five randomized clinical trials.  Ann 
Oncol. 2004; 15:979-986.
Chantry A, Heath D, Mulivor A, Coulton L, Evans H, Abdul N, Werner ED, Bouxsein ML, 
Pearsall RS, Seehra J, Vanderkerken K, and Croucher PI.  Inhibiting activin-A signalling 
stimulates bone formation, prevents tumor-induced osteolytic bone destruction and blocks bone 
metastasis. J Bone Miner Res 2010; 25 (12), 2633-46,1. Erroatum in J Bone Miner Res 2011; 26 
(2), 439 Submitted 2008.
_  _  _  _  _  _  _  _  _  _
Grogan M, Thomas GM, Melamed I, et al.  The importance of hemoglobin levels during 
radiotherapy for carcinoma of the cervix.  Cancer.  1999; 86:1528-1536.
_  _  _  _  _  _  _  _  _  _
Hollen, PJ, Gralla, RJ, Kris, MG, and Potanovich, LM. Quality of life assessment in individuals 
with lung cancer:  Testing the Lung Cancer Symptom Scale (LCSS).  European Journal of 
Cancer, 1993; 29A, S51-S58.
Hollen, PJ, Gralla, RJ, Kris, MG, & Cox, C. Quality of life during clinical trials:  Conceptual 
model for the Lung Cancer Symptom Scale (LCSS).  Supportive Care in Cancer, 1994a; 2, 213-
222.
Hollen, PJ, Gralla, RJ, Kris, MG, Cox, C, Belani, CP, Grunberg, SM, Crawford, J, and Neidhart, 
JA. Measurement of quality of life in patients with lung cancer in multicenter trials of new 
Page 370 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
74
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
therapies:  Psychometric assessment of the Lung Cancer Symptom Scale.  Cancer, 1994b; 73, 
2087-98.
Hollen, PJ, Gralla, RJ, Kris, MG, Eberly, SW, and Cox, C.  Normative data and trends in quality 
of life from the Lung Cancer Symptom Scale (LCSS).  Supportive Care in Cancer, 1999; 7, 140-
148.
_  _  _  _  _  _  _  _  _  _
Laurie SA, Jeyabalan N, Nicholas G, Dahrouge S.  Association between anemia arising during 
therapy and outcomes of chemoradiation for limited small-cell lung cancer.  J Thorac Oncol.  
2006;146-151.
_  _  _  _  _  _  _  _  _  _
MacRae R, Shyr Y, Jonson D, Choy H.  Declining hemoglobin Turing chemoradiotherapy for 
locally advanced non-small cell lung cancer is significant.  Radiother Oncol. 2002;64:37-40.
_  _  _  _  _  _  _  _  _  _
Obermair A, Cheuk R, Horwood K, et al.  Anemia before and during concurrent 
chemoradiotherapy in patients with cervical carcinoma:  effect on progression-free survival.  Int 
J Gynecol Cancer. 2003; 13:633-639.
_  _  _  _  _  _  _  _  _  _
Schwartz RN.  Anemia in patients with cancer:  incidence, causes, impact, management, and use 
of treatment guidelines and protocols.  Am J Health Syst Pharm.  2007; 64 (suppl 2):S5-S13.  
Page 371 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
75
ACE-011-NSCL-001 2.0 FINAL:  27 JUN 2011
Rationale:
References added provide additional information for:

Addition of selected metastatic solid tumor types in Part 1 of the study.

Chemotherapy-induced anemia.

QoL- Lung Cancer Symptom Scale Assessment.
Reference updated to include publishing details.
Page 372 of 791
088VGY

088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
2
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
MEDICAL MONITOR / EMERGENCY CONTACT INFORMATION
Contact Information:
Note:  The back-up 24 hour global emergency contact call center should only be used if you 
are not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls  
Back-up 24 Hour Global Emergency Contact Call Center: 
Page 374 of 791
PPD
PPD
088VGY

088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
4
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
SITE PRINCIPAL INVESTIGATOR SIGNATURE PAGE
Signature of Site Principal Investigator
dd mmm yyyy
Printed Name of Site Principal Investigator 
Institution Name:_______________________________________
By my signature, I agree to personally supervise the conduct of this study at my study 
site and to ensure its conduct is in compliance with the protocol, informed consent, 
Institutional Review Board (IRB)/Ethics Committee (EC) procedures, instructions from 
Celgene representatives, the Declaration of Helsinki, ICH Good Clinical Practices 
Guidelines, and local regulations governing the conduct of clinical studies.
Page 376 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
5
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
COORDINATING PRINCIPAL INVESTIGATOR SIGNATURE PAGE
Signature of Coordinating Principal Investigator
dd mmm yyyy
Printed Name of Coordinating Principal Investigator 
Institution Name:_______________________________________
By my signature, I agree the protocol has been written to comply with ICH Good 
Clinical Practices guidelines and agree to offer guidance throughout the study as 
needed.
Page 377 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
6
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
PROTOCOL SUMMARY
Study Title
An open-label randomized, phase 2a, dose-ranging study (Part 1) of sotatercept (ACE-011) for 
chemotherapy-induced anemia in subjects with selected metastatic solid tumors treated with 
platinum-based chemotherapeutic regimens followed by a phase 2b/3, double-blind, randomized, 
placebo-controlled study (Part 2) of sotatercept (ACE-011) for chemotherapy-induced anemia in 
subjects with metastatic non-small cell lung cancer treated with first-line platinum-based 
chemotherapeutic regimens.
Indication
Chemotherapy Induced Anemia (CIA) in Subjects with Metastatic Solid Tumors
Part 1 – Solid tumors, including metastatic non-small cell lung cancer (NSCLC), metastatic
small cell lung cancer, metastatic bladder cancer, metastatic head and neck cancer, and 
metastatic endometrial/cervical cancer, where the standard of care is first-line platinum-based 
chemotherapy.  No solid tumors other than those tumor types listed above should be considered 
for this study.   
Part 2 - Metastatic NSCLC.
Objectives
The primary objectives are:

Part 1:  To determine a dose of sotatercept (ACE-011) that results in a hematopoietic 
response for the treatment of CIA in subjects with selected metastatic solid tumors 
treated with platinum-based chemotherapeutic regimens.  

Part 2:  To assess transfusion rate following initiation of sotatercept (ACE-011) 
treatment versus placebo in subjects with CIA who have metastatic NSCLC treated 
with first-line platinum-based chemotherapeutic regimens.  
The secondary objectives are:
Part 1 and Part 2:

To estimate the effect of sotatercept (ACE-011) treatment on objective response rate 
(ORR), time to progression (TTP), progression free survival (PFS) and overall 
survival (OS).

To evaluate the safety and tolerability of sotatercept (ACE-011).

To determine the pharmacokinetics (PK) of sotatercept (ACE-011) in subjects 
receiving platinum-based chemotherapy.  

To evaluate the hematopoietic response and its duration associated with sotatercept 
(ACE-011) treatment.  

To evaluate the effect of sotatercept (ACE-011) treatment on the quality of life 
(QoL).
Page 378 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
7
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
The exploratory objectives are:
Part 1 and Part 2:

To estimate the effect of sotatercept (ACE-011) treatment on bone metabolism

To explore the relationship between sotatercept (ACE-011) exposure and response 
(hematology, biomarkers, and other clinical outcomes as appropriate).  

To evaluate the expression of Activin A and other proteins/biomarkers (including 
myostatin and follistatin) related to sotatercept (ACE-011) mechanism of action in 
blood.

To evaluate the expression of Activin A and other proteins/biomarkers in archival 
tumor tissue (Part 2 only). 

To assess renal function biomarkers
Study Design
This is an open-label, randomized, phase 2a, dose-ranging study (Part 1) of sotatercept (ACE-
011) therapy for CIA in subjects with selected metastatic solid tumors treated with platinum-
based chemotherapeutic regimens followed by a phase 2b/3, double-blind, randomized, placebo-
controlled study (Part 2) of sotatercept (ACE-011) therapy for CIA in subjects with metastatic 
non-small cell lung cancer treated with first-line platinum-based chemotherapeutic regimens.  
The study will consist of two parts:
Part 1 is a dose-finding segment in which up to approximately 90 subjects will be randomized to 
one of three sotatercept (ACE-011) dose treatment arms.  The primary objective is to determine a 
dose of sotatercept (ACE-011) that results in a hematopoietic response in the treatment of CIA in 
subjects with selected metastatic solid tumors treated with platinum-based chemotherapy.  The 
sample size is for the purpose of hypothesis generation; however, it would allow approximately 
80% power to detect an effect size of 0.33 using a 2 degrees of freedom Chi-Square Test with a 
significance level (alpha) of 0.05.  
Part 2 is the phase 2b/3 double-blind, randomized, placebo-controlled segment of the study and 
will be performed in two stages. Its primary objective is to determine the transfusion rate 
following initiation of sotatercept (ACE-011) treatment versus placebo in subjects with CIA who 
have metastatic NSCLC treated with first-line platinum-based chemotherapeutic regimens.
In the first stage, approximately 180 subjects will be randomized to receive sotatercept (ACE-
011), at the dose determined from Part 1, or placebo at a ratio of 1:1.  An interim futility 
assessment based on transfusion rate at 4 months will be performed as described in Section 10.8.
It is expected that accrual will continue during the interim assessment period, with up to an 
additional 570 subjects randomized to achieve full study accrual.  
During Part 2 (first and second stage) overall survival will be assessed.  The total sample size of 
750 subjects will allow observation of at least 536 deaths and thus, at least 80% power to exclude 
more than 15% hazard increase in the sotatercept (ACE-011) arm compared with the placebo 
arm at one-sided significance level of 0.025, i.e., rejecting hazard ratio (Placebo:sotatercept 
[ACE-011]) of 0.87, assuming the sotatercept (ACE-011) arm actually reduces at least 10% 
hazard, i.e., true hazard ratio (Placebo:sotatercept [ACE-011]) of 1.11.  
Page 379 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
8
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
A Data Monitoring Committee (DMC) will monitor the conduct of the study.  
Study Population
At the time of randomization, all subjects must be receiving their first regimen of first-line 
platinum-based chemotherapy, given every three weeks, for the treatment of one of the selected
metastatic solid tumor types, which include: metastatic non-small cell lung cancer (NSCLC), 
metastatic small cell lung cancer, metastatic bladder cancer, metastatic head and neck cancer, 
and metastatic endometrial/cervical cancer.  Subjects may have already received up to 4 cycles 
of this current platinum-based regimen and must be randomized prior to receiving Cycle 5.  It is
expected that subjects be eligible to continue to receive ≥ 2 additional platinum-based 
chemotherapy cycles while on study treatment.  
Subjects must not have received any other platinum containing regimens of chemotherapy for the 
first-line treatment of a metastatic solid tumor prior to the regimen they are receiving at the time 
of randomization.  
Length of Study and Study Treatments
This study will consist of the following consecutive periods:  Screening, Treatment Period, Post 
Treatment Follow-Up Period, and Survival Follow-Up Period.  Study treatment is defined as 
sotatercept (ACE-011) in Part 1 and sotatercept (ACE-011)/placebo in Part 2.  
Screening Period (28 days):
Potential study subjects will sign an informed consent form prior to undergoing any study-related 
procedures.  Subjects will undergo screening for protocol eligibility within 28 days prior to
randomization, as outlined in the Table of Events, Section 5.  Note: Screening period tumor 
assessments should be performed within six weeks or as per standard care at the study site prior 
to randomization.  Also, historical tumor assessment data, from prior to the initiation of 
platinum-based chemotherapy through the Screening Period, will be collected and used for 
assessment of tumor response.  
Prior erythropoietic stimulating agent (ESA) treatment history starting from initial diagnosis of 
selected solid tumor types and red blood cell (RBC) transfusion history starting from diagnosis 
of metastatic disease, at a minimum of up to two months prior to randomization will be collected.  
All females of childbearing potential (FCBP) participating in the study are to use highly effective 
methods of birth control during the Screening Period, for at least 28 days before starting the 
study.  Some highly effective methods of birth control include:

Oral contraceptives, intrauterine device, tubal ligation or a partner with a vasectomy
OR

Two forms of barrier method birth control, e.g., a latex condom PLUS a diaphragm 
with spermicide OR a latex condom PLUS a contraceptive sponge with spermicide.  
If a non-latex condom is used, it cannot be made out of natural (animal) membrane.  
Treatment Period (up to 6-9 months):  
The Treatment Period is approximately six months (four doses of study treatment given on Day
1, every 42 days), two additional sotatercept (ACE-011)/placebo doses may be given only in 
Part 2, at the discretion of the Investigator.  
Page 380 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
9
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
In Part 1 (the dose-ranging portion of the study), subjects with selected metastatic solid tumor
types who meet all eligibility criteria will be randomized to receive one of the following 
sotatercept (ACE-011) dose levels, with 10-30 subjects per arm:

Sotatercept (ACE-011) 15 mg SC

Sotatercept (ACE-011) 30 mg SC
Analysis of safety data will be performed following the treatment of at least 10 subjects at the 15 
mg dose level and 10 subjects at the 30 mg dose level, with each subject having received a 
minimum of one dose of sotatercept (ACE-011) and completed a 12-week follow-up period from 
the first dose.  
Following this analysis, the addition of a third dose level:

Sotatercept (ACE-011) 45 mg SC
to the randomization schema will be determined.
Each dose level will be administered every 42 days for up to four doses.  
The effective dose of sotatercept (ACE-011) is defined as follows:
An increase in hemoglobin (Hgb) of ≥ 1.0 g/dL above the study baseline value for 4 
consecutive weeks during the first two doses of sotatercept (ACE-011) (Dose 1/Day 1 
through and including Dose 2/Day 43 [prior to Dose 3]), in approximately 70% of subjects, 
in at least one or more treatment arms (in the absence of RBC transfusions and/or ESAs).  
Evaluation of hemoglobin response decision status will be completed after dosing arms have 
separately enrolled up to 30 subjects, as needed, to determine the sotatercept (ACE-011) dose for
Part 2.  
In addition to the hematopoietic response, the safety profile, dose modifications and extent of 
exposure in each dosing level will be taken into account to determine the study dose to be used in 
Part 2.  
In Part 2, a total of 750 subjects with metastatic NSCLC will be randomized to receive either 
sotatercept (ACE-011) or placebo, at a ratio of 1:1:

375 subjects will receive sotatercept (ACE-011) (at the dose determined in Part 1)

375 subjects will receive placebo
Each dose of sotatercept (ACE-011) or placebo will be administered every 42 days for four 
doses.  Up to two additional doses (in Part 2 only) may be given at the discretion of the 
Investigator.  
Part 2 will be performed in two stages. In the first stage, approximately 180 subjects will be 
randomized to receive sotatercept (ACE-011) (at the dose determined from Part 1) or placebo at 
a ratio of 1:1.  An interim futility assessment based on transfusion rate at 4 months will be 
performed as described in Section 10.8. It is expected that accrual will continue during the 
interim assessment period, with up to an additional 570 subjects randomized to achieve full study 
accrual.  
Page 381 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
10
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
During the Treatment Period, subjects will be assessed for hematopoietic response, transfusion 
need, safety and tumor response.  The severity of AEs will be graded according to the currently 
active minor version of the National Cancer Institute Common Terminology Criteria for Adverse 
Events (NCI CTCAE) version 4.0.  
Concurrent treatment for CIA with blood transfusions is recommended when Hgb value is 
< 8 g/dL or at the discretion of the Investigator if the Hgb value is ≥8 g/dL and associated with 
anemia symptoms such as hemodynamic or pulmonary compromise requiring treatment.  If an 
RBC transfusion is given to a subject during the Treatment Period, sotatercept (ACE-011) should 
be administered > 7 days from the date of the RBC transfusion.
In Part 1, blood samples will be collected to evaluate the full PK profile of sotatercept (ACE-
011) from approximately 30 subjects at select centers, in approximately 10 subjects for each 
sotatercept (ACE-011) dose group.  In subjects participating in the full PK assessment, RBC, 
Hgb, and reticulocyte counts will be collected at each PK time point (excluding the 4-hour time
point on Day 1) from Day 1 to Day 43 after the first dose.  Subjects not participating in the 
optional full PK assessment may participate in the sparse PK assessment.  In Part 2, blood 
samples will be collected for the sparse PK assessment that will be performed in approximately 
300 (40%) of 750 subjects (approximately 150 subjects in each arm).  
For subjects who do not participate in either Part 1 full or sparse PK assessments or Part 2 sparse 
PK assessments, the ACE-011 (sotatercept) concentration may be determined in their anti-
sotatercept antibody samples to assist in the evaluation of immunogenicity, as well as PK.
Subjects will be discontinued from Study Treatment due to the following:

Adverse events(s)

Hypertension ≥Grade 3 – defined as Stage 2 hypertension (systolic blood 
pressure [SBP] ≥160 mmHg or diastolic blood pressure [DBP] ≥100mmHg), 
confirmed by two measurements obtained five minutes apart; medical 
intervention indicated; more than one drug or more intensive therapy than 
previously used indicated or medically significant hypertension which cannot be 
adequately controlled with antihypertensive therapy. Any AE > Grade 2 assessed 
to be related to sotatercept (ACE-011) therapy

Any persistent AE > Grade 1 considered to be related to sotatercept (ACE-011)
treatment and causing a subject to miss three months of sotatercept (ACE-011)
therapy

Any thromboembolic event > Grade 2 

Elevated Hgb > 15.0 g/dL (sustained for a 7 day period, confirmed by laboratory 
assessment)

Urine protein / creatinine ratio > 1.0 or > 2.0 (if bevacizumab [Avastin®] is 
concomitantly administered)

Persistent hematuria ≥Grade 2 - defined as symptomatic; urinary catheter or 
bladder irrigation indicated; limiting instrumental activities of daily living, and 
persisting for one week. 
Page 382 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
11
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011

In Part 1, lack of sotatercept (ACE-011) therapeutic effect, defined as < 1.0 g/dL 
increase in Hgb from baseline following three dose escalations. In Part 2, lack of 
sotatercept (ACE-011) therapeutic effect, defined as < 1.0 g/dL increase in Hgb from 
baseline following two doses of sotatercept (ACE-011)/placebo (Dose 1/ Day 1 
through and including Dose 2/Day 43, prior to Dose 3).  

Concomitant use of ESAs – In Part 1 if administered at any time and in Part 2 if 
administered < 4 months from first dose of study treatment. 

Sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dose modifications

In Part 1 and Part 2:  A second Hgb increase of ≥3.0 g/dL following a two-level 
dose reduction due to a Hgb increase ≥3.0 g/dL 

In Part 2:  > 3 dose reductions and/or delays

Disease progression 

Withdrawal of consent

Death

Lost to follow-up

Protocol violation
The reason for treatment discontinuation should be recorded in the eCRF and in the source 
documents.  
Post Treatment Follow-Up Period (monthly visits for up to 6 months)
Subjects who enter the Post Treatment Follow-Up Period will be followed monthly for up to 6 
months from their last dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.  All 
subjects will continue to be followed for TTP and PFS up to one year from their first dose of 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo or until progression of their NSCLC, 
whichever comes first.  
The following events are considered sufficient reasons for discontinuing a subject from the 
study:

Completed study, per protocol (subject has completed six- to nine- month Treatment 
Period plus up to six-month Post Treatment Follow-Up Period including one year 
tumor assessment to determine TTP and PFS).  Note: Survival data will continue to 
be collected for up to 24 months from first dose of study treatment.  

Withdrawal of consent

Death

Lost to follow-up
The following events may be considered sufficient reasons for discontinuing a subject from the 
study:

Adverse event(s)
Page 383 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
12
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011

Disease progression 

Protocol violation
Survival Follow-up Period (monthly for up to 24 months after first dose of sotatercept 
(ACE-011) or sotatercept (ACE-011)/placebo)
In both Part 1 and Part 2, survival data will be collected monthly via telephone contact for up to 
24 months following the subject’s first dose of sotatercept (ACE-011) (Part 1) or sotatercept 
(ACE-011)/placebo (Part 2).  Collection of survival data will begin following Study 
Discontinuation Visit.  

Overall survival

Post-Treatment Anti-Neoplastic Therapy
Overview of Efficacy Assessments

Serum hematology, absolute reticulocyte counts

Serum iron, total iron binding capacity (TIBC), transferrin and serum ferritin

Serum erythropoietin

Tumor Assessments

Documentation of concomitant RBC transfusions
Overview of Safety Assessments

Informed consent

Assessment of inclusion / exclusion criteria

Complete medical history including history of cardiac and thromboembolic events

Vital signs including height, weight, heart rate, seated systolic and diastolic blood 
pressure, and temperature.  

AE(s)

12-lead electrocardiogram (ECG)  

Medically supervised pregnancy testing

Clinical laboratory evaluations (serum chemistry, hematology, absolute reticulocyte 
count, creatinine clearance, serum iron, total iron binding capacity, transferrin and 
serum ferritin, serum erythropoietin, Vitamin B12, serum RBC folate levels, 
urinalysis, FSH, LH, dihyroepiandosterone, estrogen, estradiol, testosterone and
serum thyroid-stimulating hormone).  

QoL Assessment (FACIT Fatigue Scale [Version 4]) – all subjects

Lung Cancer Symptom Scale (LCSS) questionnaire – subjects with NSCLC 

Documentation of concomitant medications / procedures.  
Page 384 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
13
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
Overview of Exploratory Assessments

Bone or other potential mechanistic or disease-related proteins/biomarkers 

DXA scan

Renal function biomarkers 
Page 385 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
14
TABLE OF CONTENTS
TITLE PAGE..............................................................................................................................1
PROTOCOL SUMMARY ..........................................................................................................6
1.
INTRODUCTION..................................................................................................19
2.
STUDY OBJECTIVES...........................................................................................36
2.1.
Primary Objective...................................................................................................36
2.2.
Secondary Objectives .............................................................................................36
2.3.
Exploratory Objectives ...........................................................................................36
3.
STUDY ENDPOINTS............................................................................................37
3.1.
Primary Endpoint(s) ...............................................................................................37
3.2.
Secondary Endpoint(s)............................................................................................37
3.3.
Exploratory Endpoint(s)..........................................................................................38
4.
OVERALL STUDY DESIGN ................................................................................39
4.1.
Study Design ..........................................................................................................39
4.1.1.
Sotatercept (ACE-011) Dose Modification, Reduction and Escalation Rules...........43
4.2.
Study Design Rationale ..........................................................................................46
4.2.1.
Fixed Dose .............................................................................................................46
4.2.2.
Dosing Schedule.....................................................................................................47
4.2.3.
Starting Dose Levels in Part 1.................................................................................47
4.2.4.
Evaluation of Dosing Schema via Modeling/Simulation .........................................48
4.3.
Study Duration .......................................................................................................49
5.
TABLE OF EVENTS.............................................................................................50
6.
PROCEDURES......................................................................................................58
7.
STUDY POPULATION.........................................................................................67
7.1.
Number of Subjects ................................................................................................67
7.2.
Inclusion Criteria....................................................................................................68
7.3.
Exclusion Criteria...................................................................................................69
8.
DESCRIPTION OF STUDY TREATMENTS........................................................72
8.1.
Description of Investigational Product(s)................................................................72
8.2.
Treatment Administration and Schedule .................................................................72
8.2.1.
Selection of Dose for the Study...............................................................................73
8.2.2.
Selection and Timing of Dosing for Each Subject ...................................................74
Page 386 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
15
8.2.3.
Discontinuation ......................................................................................................75
8.3.
Method of Treatment Assignment...........................................................................76
8.4.
Packaging and Labeling..........................................................................................76
8.5.
Investigational Product Accountability And Disposal .............................................77
8.6.
Investigational Product Compliance........................................................................77
9.
CONCOMITANT MEDICATIONS AND PROCEDURES....................................78
9.1.
Permitted Concomitant Medications and Procedures...............................................78
9.2.
Prohibited Concomitant Medications and Procedures..............................................79
9.3.
Required Concomitant Medications and Procedures................................................79
10.
STATISTICAL ANALYSES..................................................................................80
10.1.
Overview................................................................................................................80
10.2.
Study Population Definitions ..................................................................................80
10.3.
Sample Size and Power Considerations...................................................................80
10.4.
Background and Demographic Characteristics........................................................81
10.5.
Subject Disposition.................................................................................................81
10.6.
Efficacy Analysis....................................................................................................81
10.7.
Safety Analysis.......................................................................................................82
10.8.
Interim Analysis .....................................................................................................83
10.9.
Other Topics...........................................................................................................83
10.10.
Data Monitoring Committee (DMC).......................................................................84
11.
ADVERSE EVENTS..............................................................................................85
11.1.
Monitoring, Recording and Reporting of Adverse Events .......................................85
11.2.
Evaluation of Adverse Events.................................................................................85
11.2.1.
Seriousness.............................................................................................................85
11.2.2.
Severity / Intensity..................................................................................................86
11.2.3.
Causality ................................................................................................................87
11.2.4.
Duration .................................................................................................................87
11.2.5.
Action Taken..........................................................................................................88
11.2.6.
Outcome.................................................................................................................88
11.3.
Abnormal Laboratory Values..................................................................................88
11.4.
Pregnancy...............................................................................................................88
11.4.1.
Females of Childbearing Potential ..........................................................................88
11.4.2.
Male Subjects.........................................................................................................89
Page 387 of 791
088VGY

088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
17
LIST OF TABLES
Table 1:
A011-02:  A Phase 1b Study in Healthy Postmenopausal Women, 
Hemoglobin Evaluation ..........................................................................................28
Table 2:
Summary of Adverse Events Reported in Greater Than or Equal To 5 
Percent of Patients Overall......................................................................................31
Table 3:
Summary of SAEs Reported...................................................................................32
Table 4:
Number of Subjects with an Increase in Hgb from Baseline at Any Time and 
Sustained for Greater Than or Equal To 28 Days ....................................................32
Table 5:
Sotatercept (ACE-011) and Sotatercept (ACE-011)/Placebo Dose Reduction 
Levels.....................................................................................................................45
Table 6:
Sotatercept (ACE-011) Dose Escalation Levels (Part 1 Only) .................................46
Table 7:
Sotatercept (ACE-011) Schedule of Assessments....................................................50
Table 8:
Schedule of Pharmacokinetic Assessments (Part 1).................................................56
Table 9:
Schedule of Pharmacokinetic Assessments (Part 2).................................................57
Table 10:
ECOG Performance Status Scale ..........................................................................105
Table 11:
Classification of Heart Failure ..............................................................................107
Page 389 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
18
LIST OF FIGURES
Figure 1:
Study Design ..........................................................................................................42
Figure 2:
Simulated Hemoglobin Response in the Hypothetical Anemic Population .............48
Page 390 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
19
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
1.
INTRODUCTION
This is an open-label, randomized, phase 2a, dose-ranging study of sotatercept (ACE-011)
therapy for chemotherapy-induced anemia (CIA) in subjects with selected metastatic solid 
tumors treated with platinum-based chemotherapeutic agents followed by a phase 2b/3, double-
blind, randomized, placebo-controlled study of sotatercept (ACE-011) therapy for 
chemotherapy-induced anemia (CIA) in subjects with metastatic non-small cell lung cancer 
(NSCLC) treated with platinum-based chemotherapeutic regimens.  The study will consist of two 
parts.  Part 1 is a dose finding segment in which up to 90 subjects with selected metastatic solid 
tumor types treated with platinum-based chemotherapy will be randomized to one of three 
sotatercept (ACE-011) dose treatment arms.  Continuous monitoring of safety data will be 
conducted, including the review of Part 1 data to determine the sotatercept (ACE-011) dose to be 
used in Part 2, the phase 2b/3, double-blind, randomized placebo-controlled segment of the 
study.  
Part 2 will include only subjects with metastatic NSCLC and will be performed in two stages.  
Its primary objective is to determine the transfusion rate following initiation of sotatercept 
(ACE-011) treatment versus placebo in subjects with CIA who have metastatic NSCLC treated 
with first-line platinum-based chemotherapeutic regimens.
In the first stage approximately 180 subjects will be randomized to receive sotatercept (ACE-
011), at the dose determined from Part 1, or placebo at a ratio of 1:1.  An interim futility 
assessment based on transfusion rate at 4 months will be performed as described in Section 10.8.  
It is expected that accrual will continue during the interim assessment period.  Based on the 
results of the futility analysis and upon recommendation to continue the study, up to an 
additional 570 subjects will be randomized in the second stage of Part 2, to achieve full study 
accrual.
A Data Monitoring Committee (DMC) will monitor the conduct of the study. 
Sotatercept (ACE-011) (ActRIIA-IgG1Fc) is a human fusion protein consisting of the 
extracellular domain (ECD) of activin receptor IIA (ActRIIA) linked to the human IgG1 Fc 
domain, which includes the heavy chain hinge and constant domains, CH2 and CH3.  
The chemical structure of sotatercept (ACE-011) is composed of a disulfide-linked, glycosylated, 
dimeric protein.  Sotatercept (ACE-011) competes with the activin receptor IIA and binds a 
number of TGF-β superfamily ligands including activin, GDF-11, BMP-10, GDF-3 and 
myostatin (growth differentiation factor [GDF]-8).  
In both a single and a multiple dose phase 1 study of sotatercept (ACE-011) in healthy volunteer, 
postmenopausal women, a dose and time dependent increase in hemoglobin (Hgb) and 
hematocrit (HCT), and red blood cell (RBC) levels were observed following sotatercept (ACE-
011) treatment and remained elevated over the course of study.  
Although the mechanism(s) underlying the stimulation effect of sotatercept (ACE-011) on 
erythropoiesis are not yet fully understood, the result of clinical experience showed a rapid and 
sustainable increase in mature erythrocytes released into circulation.  The sotatercept (ACE-011) 
proposed mechanism of action may be different than that of known erythropoiesis-stimulating 
agents (ESAs) and may provide a different clinical profile in the treatment of CIA.  
Page 391 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
20
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
This study will provide information on the pharmacodynamic properties regarding the ability of 
sotatercept (ACE-011) to increase Hgb in subjects with CIA.  
Chemotherapy-Induced Anemia
Chemotherapy-induced anemia (CIA) is an area of unmet medical need. It is a significant 
problem for patients with cancer, causing fatigue and reducing quality of life (QoL).  
Patients with cancer receiving multi-cycle chemotherapy are frequently anemic.  The etiology of 
CIA is multifactorial, resulting from the myelosuppressive effects of chemotherapy and the 
decrease in the production of the bone-marrow-stimulating hormone erythropoietin due to 
repeated cycles of chemotherapy (Vansteenkiste, 2002). The incidence and severity of 
chemotherapy-induced anemia (CIA) is further dependent on a variety of factors, such as the 
type, schedule, and intensity of chemotherapy administered, and whether the patient has received 
prior myelosuppressive chemotherapy and/or radiation therapy (Groopman, 1999).  Platinum-
based treatments (eg, cisplatin and carboplatin), commonly used in lung, ovarian, and head and 
neck cancers, are well known to induce anemia due to combined bone marrow and kidney 
toxicity.  Antimicrotubular agents (eg, taxanes and vinorelbine) and camptothecins (eg, 
irinotecan and topotecan) are also considered particularly myelosuppressive (Groopman, 1999).  
Dose intensity, the increasingly widespread practice of administering higher doses of 
chemotherapy over a shorter period of time, is also associated with an increased risk of 
myelosuppression
The association between uncorrected anemia before or during chemotherapy and poorer patients’ 
outcomes has been reported in several studies (Grogan, 1999; Laurie, 2006; MacRae, 2002; 
Obermair, 2003).  Anemia can lead to a multitude of symptoms (eg, fatigue, tachycardia, 
cognitive impairment, shortness of breath, depression, and dizziness) and may also have an 
adverse impact on co-morbid conditions, such as cardiac and pulmonary disease.  The most 
common patient complaints are dyspnea on exertion and chronic fatigue, which may interfere 
with a patient’s ability to perform normal daily activities (Groopman, 1999).  A key 
differentiating characteristic of cancer-related fatigue versus fatigue in healthy individuals is its 
likelihood of persistence at rest (National Comprehensive Cancer Network, 2008)  In various 
published surveys, fatigue has been represented as a symptom that has affected patients’ 
everyday life the most and has been linked to changes in employment status among patients and 
even caregivers (Schwartz, 2007).  The association between Hgb levels and fatigue is well 
documented, with one analysis of 5 randomized trials linking an increase in Hgb concentrations 
of at least 2 g/dL with an improvement in fatigue, and consequently, in energy, ability to perform 
usual activities, and overall health (Cella, 2004).
In looking at the impact of CIA on survival, a meta-analysis of 60 clinical studies found a 65% 
increase in the risk of death and a shortened survival time among patients with cancer and 
anemia compared with patients without anemia (Carlos, 2001). The increased relative risk of 
death was particularly evident in patients with head and neck cancer (75%), a finding that also is
supported by other retrospective studies.  Tumor hypoxia, resulting from the reduced oxygen-
carrying capacity of blood in patients with anemia, has been hypothesized to be a major 
contributor to reduced survival.  Several studies have shown that tumor hypoxia also reduces the 
effectiveness of radiotherapy and chemotherapy, and is associated with tumor progression 
(Aapro, 2006).
Page 392 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
21
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
Treatment of Chemotherapy-Induced Anemia
The current treatment options for CIA include blood transfusion and erythropoiesis-stimulating 
agents (ESAs).  However, blood transfusion involves the risk of complications (such as potential 
transmission of infectious disease, alloimmunization, allergic reactions, hemolytic reactions, iron 
and circulatory overload, and possible immunosuppression) for the patient, and donor blood is a 
limited resource.  The practice of offering blood transfusions to cancer patients receiving
chemotherapy has therefore been rather restricted, generally reserved for emergencies, and 
severely anemic patients with serious symptoms.  
Erythropoiesis-stimulating agents have been approved for treating CIA.  However, the past five 
years has seen a major change in the use of ESAs for cancer related and chemotherapy induced 
anemia. Clinical studies have demonstrated that ESAs can successfully mitigate transfusion need
in a proportion of these patients; however, new concerns have emerged regarding apparent 
negative effects on survival and/or tumor progression in certain patient populations. 
Retrospective statistical analysis in one study in head and neck cancer patients, and two studies 
with adjuvant breast cancer revealed substantial safety concerns of increased thromboembolic 
events, and decreased PFS and overall survival.  
Sotatercept (ACE-011) Treatment of Chemotherapy-Induced Anemia
Treatment with sotatercept (ACE-011) resulted in increased HCT, Hgb and absolute red cell 
number in both nonclinical and clinical studies.  The rapid and sustained increases in Hgb and 
HCT levels were observed in two phase 1 studies in healthy volunteers, as well as in a phase 2a 
study in multiple myeloma (MM) subjects. The ability for sotatercept (ACE-011) to rapidly 
increase and sustain Hgb levels in anemic subjects supports the clinical development of ACE-
011 for the treatment of CIA.  
In a phase 1 single-dose and multiple-dose studies of sotatercept in postmenopausal women 
(Studies A011-01 and A011-02, respectively), and in a phase 2 study in subjects with osteolytic 
lesions associated with MM that examined concurrent administration of sotatercept with 
melphalan, prednisolone, and thalidomide (MPT) anti-myeloma therapy, increases in Hgb, RBC 
count and HCT were observed following sotatercept treatment, and these increases remained 
detectable throughout the course of study.  The observed Hgb, RBC count, and HCT effects of 
sotatercept were dose-dependent and time-dependent.  These phase 1 and phase 2 clinical data 
are consistent with the increased hematologic parameters observed in nonclinical studies, The 
results from the three completed clinical studies A011-01, A011-02, and A011-04 are 
summarized in Summary of Clinical Experience
.  
The mechanism of action of sotatercept with regards to increased RBC counts is not known; 
however, the mechanism of action for the hematopoietic effect of sotatercept may be different 
than that of ESAs, as some level of erythrocyte stimulatory effect was observed in the presence 
of anti-EPO antibodies in one nonclinical study.  As such, sotatercept may provide a unique 
clinical profile with a favorable benefit-risk profile in the chemotherapy-induced anemia patient 
population, thereby addressing some of the unmet medical needs in chemotherapy-induced 
anemia treatment.
Page 393 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
22
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
Non-Small Cell Lung Cancer Current Therapy Status
Lung cancer is the leading cause of cancer death in the world, accounting for 32% of cancer 
deaths in males and 25% in females, affecting approximately 171,000 people annually in the US 
(Parker, 1997; Sandler, 2006) and more than 200,000 people in Europe (Rossi, 2006).  Of these 
patients, approximately 85% have NSCLC, including squamous carcinoma, adenocarcinoma and 
large cell carcinoma (Rossi, 2006; Sandler, 2006).  These histologies are typically classified 
together because the approaches to diagnosis, staging and prognosis, and treatment are similar.  
Patients are often diagnosed with an advanced stage of disease.  Studies of advanced NSCLC 
patients treated with platinum-based chemotherapy report a one year survival rate that ranges 
from 30% to 43% and a median survival that ranges from seven to ten months (Dang, 2008).  
The 5-year survival rate of patients with NSCLC varies by stage, from 60% to 70% for patients 
with stage I disease to < 1% for patients with stage IV disease (Hong, 2008).  Patients having 
stage IIIb/IV NSCLC are not considered to be candidates for curative resection surgery or 
radiation, and radiation therapy is primarily used as palliative treatment in advanced stages of 
NSCLC.  
The role of chemotherapy is now well established as the recommended treatment of advanced 
NSCLC (Non-small Cell Lung Cancer Collaborative, Group 1995).  The current globally 
accepted standard of treatment for NSCLC is platinum-based combination therapy.  In advanced-
stage (stage IIB or IV) NSCLC, doublet combinations of platinum compounds (cisplatin or 
carboplatin) with gemcitabine (Gemzar®), vinorelbine, taxanes (paclitaxel or docetaxel) or 
pemetrexed are reference regimens.  When compared head-to-head in phase 3 studies, these 
doublets have shown comparable efficacy, in regards to overall survival (Schiller, 2002) with 
differences in toxicity profiles (Schiller, 2002).  When administered in a 3-week schedule, 
cisplatin plus gemcitabine, or cisplatin plus pemetrexed are effective and are widely used 
regimens for first-line treatment of NSCLC.  A recent phase 3 study in NSCLC compared 
cisplatin plus gemcitabine with cisplatin plus pemetrexed (Scagliotti, 2008).  Both had similar 
efficacy, with cisplatin plus pemetrexed having better tolerability and more convenient 
administration than cisplatin/gemcitabine.  This study was also the first prospective phase 3
study in NSCLC to show a survival difference based on histologic type (non-squamous benefited 
from pemetrexed plus cisplatin).  Drug-related grade (G) 3 or 4 anemia was at the rate of 6% for 
cisplatin/pemetrexed versus 10% for cisplatin/gemcitabine.  The incidence of RBC transfusion 
was 16.1% versus 27.3% and administration of erythropoietic agents 10.4% versus 18.1% 
respectively.  There was no significant difference between treatment arms in the incidence of or 
reason for deaths (7%).  
In the pivotal Aranesp (darbepoetin alfa) study for CIA in NSCLC, 27 % of patients were 
transfused with packed red blood cells (PRBC’s) at 4 months versus 52% in the placebo arm.  
Activin Biology
The activins (A-E) are a group of proteins that form dimers and heterodimers.  All are part of the 
TGF-β protein superfamily.  The first described activin, Activin A was initially identified as a 
gonadal differentiation factor involved in modulating follicle stimulating hormone (FSH) 
secretion from the pituitary (Ying, 1988).  Subsequently, the pleiotropic nature of Activin A has 
become more apparent (Woodruff, 1998).  There is a growing body of data suggesting a role for 
activins in bone remodeling, specifically as a negative regulator of bone growth (Perrien, 2007).  
Page 394 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
23
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
Before the two molecules were shown to be identical (Rivier, 1985), Activin A was also initially 
described as erythroid differentiation factor (EDF), effecting the maturation and differentiation 
of RBCs (Murata, 1988).  The mechanism(s) by which Activin A influences erythropoiesis 
remains under investigation and, in fact, there are data from in vitro and in vivo studies that 
support erythropoiesis-stimulatory (Shiozaki, 1992; Shiozaki; 1989) and erythropoiesis-
inhibitory effects (Nakao, 1991).  
At the cellular level, the activins bind initially to the high-affinity Type II receptor (ActRIIA).  
The ligand-bound ActRIIA then recruits the low-affinity Type I receptor (ActRIA or ALK-4).  
The receptor heterocomplex, through its cytoplasmic protein kinase activity, then activates the 
Smad signal cascade to eventually influence nuclear transcriptional factors (Chen, 2002; 
Mathews, 1994).  The competitive binding of activins in the blood by the sotatercept (ACE-011)
soluble fusion protein can result in inhibition of the ActRIIA receptor signaling pathway by 
impeding biological processes attributed to these pleiotropic proteins.  
The activin signaling pathway has been shown to induce terminal erythroid differentiation in 
some preclinical models.  Inhibition of activin may indirectly lead to increases in proliferation or 
differentiation of the erythroid lineage.  Based on its pharmacologic effects, sotatercept (ACE-
011) is being developed for the treatment of anemia associated with a variety of disorders, such 
as in chronic renal failure and CIA.  
In a retrospective study (Seder, 2009) activin immunoreactivity was found in 78% of lung 
adenocarcinomas surveyed (n=164).  Expression ranged from moderate in the majority of 
individuals to high in approximately 19.7% of samples evaluated.  Gene expression analysis was 
also used to measure activin mRNA in 86 lung adenocarcinomas and 10 normal lung samples.  
An average of three-fold more activin transcript was detected in diseased tissue relative to 
normal samples and particularly high levels of overexpression were associated with worse 
overall survival in stage I patients with NSCLC.  
Additionally, in the NIH “directors challenge” study for NSCLC adenocarcinoma (Shedden, 
2008), 3 of the 12 molecular subgroups, including the subgroup with the worst survival 
prognosis, demonstrated overexpression of Activin A.  Thus, overexpression of activin may play 
a role in NSCLC tumor progression.  
Sotatercept (ACE-011)
Sotatercept (ACE-011) (ActRIIA-IgG1Fc) is a human fusion protein consisting of the 
extracellular domain (ECD) of activin receptor IIA (ActRIIA) linked to the human IgG1 Fc 
domain, which includes the heavy chain hinge and constant domains, CH2 and CH3.  The ECD
sequence of ActRIIA is completely conserved among numerous species including mouse, rat, 
cynomolgus monkey and humans, thus mouse, rat and cynomolgus monkeys have been 
considered relevant species for nonclinical evaluation of sotatercept (ACE-011).  However, in 
order to reduce the potential immunogenicity of the human molecule, sotatercept (ACE-011), 
and to maximize the opportunity to maintain exposures in chronic models, a murine surrogate 
molecule was constructed by exchanging the human immunoglobulin Fc sequence portion of 
sotatercept (ACE-011) with its murine IgG2a homolog.  The resultant construct is referred to as 
RAP-011 (ActRIIA-mIgG2aFc), and is described in the pharmacology studies below.  Both 
ACE-011 and RAP-011 bind with high affinity to activin A/B, GDF-11 and, with slightly lower 
affinity, to BMP-10.
Page 395 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
24
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
Pharmacology Studies
RAP-011 was evaluated in a broad range of animal pharmacology studies to assess the effects of 
inhibition of Activin A on the biological processes attributed to that regulatory protein.  RAP-
011 has been shown to have significant effects on the red cell compartment.  RAP-011 treatment 
of mice at 10, 30 and 50 mg/kg by intraperitoneal injection (IP) twice per week for 3 months 
resulted in a 16-26% increase in RBC counts compared to control animals.  Rats treated with 
sotatercept (ACE-011) at 0.3, 3 and 30 mg/kg once per week for 3 months showed RBC count 
increases of 6-15% over control animals.  Finally, in cynomolgus monkeys treated with 10, 30 or 
50 mg/kg of sotatercept (ACE-011) twice per month for 3 months, there was a 21-24% increase 
in RBC counts compared to control animals.  In this study, the RBC count increase was apparent 
as early as 2 weeks following the initial dose of sotatercept (ACE-011).  
RAP-011 administered at 10 mg/kg to mice three days prior to administration of paclitaxel at 30 
mg/kg was sufficient to prevent decreases in RBC parameters typically seen three days later.  
Mice receiving paclitaxel alone had decreased HCT levels from 43% to 38% three days 
following treatment.  RAP-011 administered three days prior to paclitaxel injection was 
sufficient to keep the HCT levels above 42% at three days and up to two weeks following 
paclitaxel administration.  Therefore, prophylactic treatment with RAP-011 was able to prevent 
paclitaxel-induced anemia in mice.  
RAP-011 has also been shown to significantly increase bone mineral density (BMD) and 
strength in normal animals and in a variety of animal models of bone loss (Chantry, 2008; 
Lotinun, 2008; Pearsall, 2008).  In a murine ovariectomy (OVX)-induced model of osteopenia, 
RAP-011 (10 mg/kg intravenous [IV], twice per week x 12 weeks) increased trabecular BMD > 
25% in 6-12 weeks compared to the phosphate buffered saline (PBS)-treated controls (p<0.002).  
RAP-011 treatment was able to reverse the accelerated bone loss associated with ovariectomy.  
As expected, sham-operated (SHAM) mice (i.e., intact ovaries) started the study with a greater 
trabecular BMD than OVX mice.  PBS-treated SHAM mice showed a 10% decrease in 
trabecular BMD after 12 weeks of treatment compared to baseline, while SHAM-RAP-011 mice 
had a 32% increase in trabecular BMD over the same period.  These data demonstrate that RAP-
011 is able to increase trabecular BMD in both the normal state and in a model of established 
bone loss.  The femurs of both the RAP-011 treated OVX and SHAM mice showed statistically 
significant increases in all measured parameters of bone strength (i.e., maximum load, stiffness, 
energy, ultimate strength, and elastic modulus).  In summary, treatment with RAP-011 produced 
bone of superior quality consistent with an anabolic agent.  
RAP-011 was evaluated in a mouse model of skeletal metastasis using luciferase-tagged, human 
MDA-MB-231 breast cancer cells (estrogen receptor negative).  Mice were pretreated for 2 
weeks with RAP-011 (10 mg/kg, biweekly, subcutaneous [SC]) prior to intracardiac injection of 
tumor cells.  Treatment with RAP-011 was continued for an additional 5 weeks following tumor 
implantation.  A parallel study was conducted to examine the effect of RAP-011 treatment, as 
described above, on survival of MDA-MB-231 bearing mice.  
The data suggest that RAP-011 treatment may decrease the incidence of MDA-MB-231 
metastasis to bone and may also play a role in inhibiting tumor growth in the bone marrow 
environment.  Furthermore, in the presence of tumor cells, RAP-011 is able to prevent lytic 
disease through an anabolic mechanism of bone formation.  Lastly, treatment with RAP-011 
resulted in an approximately 25% survival benefit in this model.  
Page 396 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
25
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
RAP-011 was also evaluated in osteolytic bone disease of multiple myeloma.  Multiple myeloma 
is associated with the development of bone disease characterised by increased osteoclast activity 
and a suppression of osteoblastic bone formation.  
Results obtained in the 5T2MM murine model demonstrated that RAP-011 could prevent the 
development of osteolytic bone disease in a preventative setting.  
5T2MM cells promoted the development of osteolytic bone lesions (p<0.001), a reduction in 
trabecular volume (p<0.001) and cortical volume (p<0.005).  RAP-011 completely prevented 
5T2MM-induced decreases in trabecular volume and number in both tibia (p<0.001 and p<0.01), 
femur (p<0.001 and p<0.001) and vertebrae (p<0.01 and p<0.01) when compared to vehicle 
treated mice.  Bone volume was 19% higher in the tibia, 35% higher in the femur and 12% 
higher in vertebrae of RAP-011 treated mice than naïve non-tumour bearing mice.  
This study showed that, in the preclinical murine model for myeloma, RAP-011 stimulates bone 
formation by increasing osteoblast perimeter and number, mineralisation and bone formation rate 
but had no effect on osteoclast activity.  RAP-011 also appeared to inhibit tumor growth as 
demonstrated by decreased serum M protein, indicative of decreased tumor burden.  
The efficacy of RAP-011 was also examined in two orthotopic metastatic models of breast 
cancer using luciferase-tagged human MCF-7 and MDA-MB-231 breast cancer cells (estrogen 
receptor positive and negative, respectively).  Mice were pretreated for 2 weeks with RAP-011 
(10 mg/kg, biweekly, SC) prior to the intra-cardiac implantation of tumor cells into female nude 
mice.  Treatment with RAP-011 was continued for an additional 7 weeks following tumor 
implantation at which time mice were sacrificed and assessed for tumor burden.  RAP-011 either 
modestly decreased the tumor burden (in the case of mice bearing MCF-7 tumors) or delayed 
tumor growth by approximately 3 weeks (MDA-MB-231 model) as measured by bio-
luminescence.  
The ability of RAP-011 to repair osteolytic lesions caused by metastatic disease was investigated 
in mice.  In this model, MDA-MB-231-Luc cells were intratibially implanted in athymic nude 
mice to mimic bone metastasis.  Mice were treated with a chemotherapy regimen of paclitaxel 
(20 mg/kg, IP, every three days) starting seven days after tumor injection and continuing for the 
duration of the study.  On study day 42, mice with detectable but minimal tumor burden, as 
measured by bioluminescent imaging, were divided into two groups and treated with either 
RAP-011 (10 mg/kg, SC, biweekly) or vehicle.  Prior to dosing, μCT scans of the tumor bearing 
tibia were conducted to identify osteolytic lesions.  RAP-011 treatment continued for four weeks 
(to study day 70) and a final μCT scan of the tibia was performed.  On study day 70 there was a 
trend toward decreased number and size of osteolytic lesions in RAP-011-treated mice compared 
to control animals.  While osteolytic disease (most likely related to tumor burden) did progress in 
some of the treated mice, the majority of mice treated receiving RAP-011 developed less severe 
or no bone lesions compared to the untreated group.  Finally, treated animals also demonstrated 
an increased HCT, confirming the ability of RAP-011 to prevent CIA.  To summarize, treatment 
with RAP-011 has the ability to inhibit osteolytic lesions caused by tumors and to build new 
bone after cytotoxic chemotherapy with paclitaxel.  
Toxicology
Sotatercept (ACE-011) has been evaluated for toxicological effects in two species, Sprague-
Dawley rats and cynomolgus monkeys.  The dose levels ranged from 0.3 to 30 mg/kg in rats and 
Page 397 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
26
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
from 1 to 50 mg/kg in monkeys.  These dose ranges were designed to support phase 1a single-
dose levels of 0.01 to 3.0 mg/kg IV and phase 1b multiple doses of 0.1 to 2 mg/kg (monthly, 
SC).  Weekly (rat and IV monkey studies) or every 2 week (SC monkey studies) dosing in 
animals was designed to provide continuous, but fluctuating serum concentrations of sotatercept 
(ACE-011), which would be mimicked by a one-month dosing interval in humans.  
Test article related hematological (increase in RBC parameters) and reproductive (epididymal 
granulomas, testicular degeneration, decreased sperm counts and motility, and change in 
ovarian/uterine weights) findings were expected pharmacodynamic effects of ActRIIA signal 
inhibition, likely mediated via modulation of erythropoiesis and FSH secretion, respectively.  
Unique to rats were adrenocortical and pancreatic findings.  Neither finding was associated with 
any clinical signs of adrenocortical (anorexia, weakness, gastrointestinal disturbances, serum 
electrolyte disturbances) or pancreatic (abnormal stool, weight loss) insufficiency.  Kidney 
findings include membranoproliferative glomerulonephritis and/or tubulointerstitial nephritis in 
rats and monkeys.  The glomerulonephritis was presumed to be due to anti-sotatercept (ACE-
011) antibody deposition in the kidneys.  This presumption is supported by a robust anti-drug 
antibody response observed in rats.  However, high plasma concentrations of sotatercept (ACE-
011) in monkeys likely interfered with the immunogenicity assay, so the true incidence of anti-
drug antibodies is unknown in this species.  
The no-observed-adverse effects levels (NOAELs) from the 3 month SC studies were 3 and 30 
mg/kg in rats and monkeys, respectively.  Since the kidney findings were observed at all dose 
levels, the NOAEL from the 6 month monkey study is < 10 mg/kg.  A 9-month monkey study to 
evaluate the effects of lower concentrations of sotatercept (ACE-011) has been completed (refer 
to Potential Risks for Human Use).  
Summary of Clinical Experience
A011-01:  A Phase 1a Study in Healthy Postmenopausal Women (Single Dose)
Sotatercept (ACE-011) was first studied in a randomized, phase 1a, single dose, dose escalation 
study in healthy, postmenopausal females (Ruckle, 2009).  Sotatercept (ACE-011) was diluted in 
normal saline administered as an IV infusion (over approximately 1 hour) or as a SC injection on 
Day 1.  Dose levels were 0.01, 0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg IV and 0.03 and 0.1 mg/kg SC.  
A total of 48 subjects were enrolled; 5 active and 1 placebo at each of the IV and SC dose levels.  
All subjects were followed for 4 months following a single dose administration.  
The pharmacokinetics (PK) of sotatercept (ACE-011) was linear.  The overall mean exposure 
(AUC) was proportional to doses (0.01-3 mg/kg IV, 0.03-0.1 mg/kg SC).  Across IV doses 
ranging from 0.1 through 3.0 mg/kg, the mean clearance (CL) ranged from 0.092 to 0.128 
mL/h/kg, the volume of distribution ranged from 73.7 to 110 mL/kg, and the mean terminal half 
life in serum (t1/2, z) ranged from 23.7 to 31.8 days, with no apparent dependence on dose.  After 
SC administration of 0.03 and 0.1 mg/kg, sotatercept (ACE-011) was completely absorbed, and 
the mean t1/2, z was approximately 30 days, with no apparent dependence on dose.  
The most commonly occurring treatment-emergent adverse events (AEs; i.e., those occurring in 
more than 1 subject in any treatment group) were headache, infusion site reaction, injection site 
hemorrhage, and toothache.  The majority of the injection site reactions and injection site 
hemorrhages were in the first IV cohort and were related to infiltration of the IV site.  The 
majorities of treatment-emergent AEs was mild in severity and were judged to be unrelated to 
Page 398 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
27
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
sotatercept (ACE-011).  No deaths, serious AEs (SAEs), or AEs leading to discontinuation were 
reported.  Changes in RBCs, Hgb, reticulocytes, liver function tests, glucose, uric acid, amylase 
and lipase occurred in some subjects.  Mild, transient elevations in pancreas enzymes, liver 
enzymes, or glucose were reported as AEs in five subjects.  
There were no clinically significant changes from baseline in vital signs, physical examination, 
endocrine function, or electrocardiogram (ECG) data.  Preservation of adrenal cortical function 
was monitored through evaluation of serum electrolytes (sodium and potassium levels) and 
through cortisol response to adrenocorticotropic hormone (ACTH) stimulation.  
No clinically significant findings were observed at doses up to 3.0 mg/kg IV, and sotatercept 
(ACE-011) was well tolerated in healthy, postmenopausal female volunteers in single dose levels 
up to 0.1 mg/kg SC and 3.0 mg/kg IV, the highest dose levels tested in this study.  
A011-02:  A Phase 1b Study in Healthy Postmenopausal Women (Multiple Dose)
Sotatercept (ACE-011) was studied in a phase 1b, single-center, randomized, double-blind, 
placebo-controlled, multi-dose, dose-escalating study to evaluate the safety, tolerability and 
pharmacodynamics of sotatercept (ACE-011) in healthy postmenopausal women.  Four cohorts 
of 10 subjects each were planned at the following dose levels:  0.1, 0.3, 1.0, and 2.0 mg/kg 
administered SC.  Within each cohort, subjects were to be randomized to either active or placebo 
treatment in an 8:2 ratio.  Subjects were to receive one SC injection of sotatercept (ACE-011) or 
placebo every 28 days for a total of 4 doses.  All subjects were to be followed for 12 weeks after 
the last dose.  
The treatment phase of the study was terminated early after a dose-limiting pharmacodynamic 
effect was observed.  While on study, one subject in the 1.0 mg/kg cohort experienced an SAE of 
progressive and persistent hypertension that was attributed to a rapid and significant rise in Hgb
levels, up to 20 g/dL and HCT levels, up to 57.3%.  Due to symptoms of headaches, nausea, eye 
pain, dizziness and vomiting approximately one week following the second dose, the subject was 
hospitalized for monitoring and evaluation of her hypertension.  The head MRI, fundoscopy, and 
ECG performed were reported as normal and headache symptoms resolved following corrective 
treatment by phlebotomy.  The SAE resolved and the subject was discharged from the hospital 
the following day.  The hypertension was monitored closely and managed initially with 
antihypertensive medication.  The hypertension resolved by the end of the study without need of 
any antihypertensive medication.  The subject received aspirin prophylactically until the end of 
the study and continued taking ibuprofen as needed for headaches.  Further details can be found 
in the Investigator’s Brochure.  
Based on the magnitude of the hematopoietic response, the Sponsor suspended dose escalation to 
the 2.0 mg/kg dose level and further dosing in all cohorts as a result of this dose-limiting 
pharmacodynamic effect at the 1.0 mg/kg dose level.  In total, 31 subjects were enrolled and 
treated.  Dose levels of sotatercept (ACE-011) administered included 0.1, 0.3, and 1.0 mg/kg 
(Cohorts 1, 2, and 3 respectively).  All subjects randomized to active treatment in Cohort 1 
received all 4 planned doses of sotatercept (ACE-011).  Due to early discontinuation of study 
drug, subjects randomized to active treatment in Cohort 2 received 3 doses of sotatercept (ACE-
011), and subjects randomized to active treatment in Cohort 3 received 2 doses of sotatercept 
(ACE-011).  Subjects randomized to placebo treatment received between 1 and 4 doses of study 
treatment.  
Page 399 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
28
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
In the analysis of the data, after the administration of the first dose, a dose and time dependent 
increase in Hgb, HCT, and RBC values were observed (see Table 1 below for changes in Hgb 
levels):
Table 1:
A011-02:  A Phase 1b Study in Healthy Postmenopausal Women, 
Hemoglobin Evaluation
Evaluation Time Point
Mean Change from Baseline (g/dL)
Placebo
N=7a
Sotatercept 
(ACE-011)
0.1 mg/kg
N=8
Sotatercept 
(ACE-011)
0.3 mg/kg
N=8
Sotatercept 
(ACE-011)
1.0 mg/kg
N=8
Baseline Mean, pre-Dose 1
13.20
13.11
13.30
12.71
Day 8
0.17
0.68
0.85
1.21
Day 15
-0.27
0.43
0.44
1.75
Day 29
0.27
0.61
1.21
2.68b
Day 36
0.56
0.64
1.89
2.96
Day 43
-0.02
0.89
1.21
2.85
Day 57
0.27
1.28
1.64b
2.09
Day 64
0.53
1.11
2.49
2.21
Day 71
-0.10
1.34
2.09
1.66
Day 85
0.38
1.18b
2.55
1.86
Day 92
0.00c
1.04
1.60c
3.80c
Day 99
-0.20
1.21
3.20c
1.28c
Day 113
-0.02
1.30
1.29
1.04
Day 141
0.30
0.95
0.34
2.30
Day 169
0.20c
0.06
-
2.00c
aThe number of placebo subjects with data decreases over time as a result of the early discontinuation of the study 
(i.e., there were placebo subjects in each dosing cohort).  There were seven placebo subjects with data at baseline, 
Days 8, 15, and 36; six subjects with data at Days 29, 43, 57, and 85; five subjects with data on Days 71 and 113; 
four subjects with data on Day 64; three subjects with data on Day 141; two subjects with data on Day 99; and one 
subject with data on Days 92 and 169.  
bNumber of doses administered per treatment group:  0.1 mg/kg 4 doses; 0.3 mg/kg 3 doses; 1.0 mg/kg 2 doses.  
Data beyond this study day are considered follow-up results.  
cn=1
Other than the serious case of Hgb increase, no life-threatening events were reported.  The most 
notable AEs were those related to increases in hematologic laboratory measures in the 1.0 mg/kg 
dose group:  HCT, Hgb, and RBC count.  The AEs of increased Hgb and/or HCT were reported 
for seven of the eight subjects in this dose group.  These events were reported as mild or 
moderate elevations; all were considered probably related to study drug treatment.  Three of the 
Page 400 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
29
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
subjects in the 1.0 mg/kg group with elevated Hgb levels underwent phlebotomies and all Hgb 
elevations were resolved by the end of the follow-up period.  No erythroid lineage AEs were 
reported in the 0.1 or 0.3 mg/kg treatment groups.  
Paresthesia and dizziness were reported more frequently in the sotatercept (ACE-011) groups, 
though the events were < G 2 and generally not considered drug related.  Other frequently 
reported events (e.g. fatigue, upper respiratory infection) did not appear to increase with dose 
and were generally mild.  
Hemoglobin levels for all subjects with elevations had returned to within normal limits by the 
end of the study.  
Adrenal cortical function was monitored through evaluation of serum electrolytes (sodium and 
potassium levels) and through cortisol response to adrenocorticotropic hormone (ACTH) 
stimulation.  All ACTH simulation test results were normal.  
The PK of sotatercept (ACE-011) were linear after SC administration.  Both AUC28d and Cmax 
were proportional to dose from 0.1 to 1 mg/kg following the first SC administration.  The t1/2, z 
of sotatercept (ACE-011) following the last dose in all three dose groups was identical, with 
mean t1/2, z being approximately 23 days.  Based on the one-compartmental modeling, the mean 
CL/F ranged from 3.05 to 3.90 mL/d/kg, the mean Vz/F ((apparent) volume of distribution) 
ranged from 97.47 to 103.03 mL/kg, with no apparent dependence on dose.  
Bone mineral density was assessed by dual-energy X-ray absorptiometry (DXA).  A dose-
dependent increase in the BMD of the total hip from baseline to end of study was observed, with 
a significant and rapid increase of 2.4% in the 1.0 mg/kg dose group, compared to a 0.7% 
decrease in the placebo group.  BMD results for lumbar spine showed slight increases of 0.4% to 
1.0% from baseline to study end in all active treatment groups, compared with a 0.5% decrease 
in the placebo group.  
A011-04:  A Phase 2a Study in Patients with Osteolytic Lesions of Multiple Myeloma / 
Preliminary Results
Study A011-04 is a phase 2a, multi-center, randomized, multiple-dose study to evaluate the 
safety, tolerability and efficacy of sotatercept (ACE-011) in subjects with osteolytic lesions of 
multiple myeloma (MM).  
In this study, subjects were randomized in a 4:1 ratio to one of three dose levels of sotatercept 
(ACE-011) (0.1, 0.3 and 0.5 mg/kg) or placebo, administered to subjects every 28 days by SC 
injection, for up to four doses over a 3-month period. Sotatercept (ACE-011) was evaluated in 
combination with the anti-myeloma therapy of melphalan (4 mg/m2 on days 1-7), prednisolone 
(40 mg/m2 on days 1-7) and thalidomide (100 mg per day) (MPT). The sites, Sponsor and 
Sponsor representatives were blinded to treatment assignment.  
Thirty subjects were randomized and received at least one dose of study medication:  6 subjects
received placebo, 8 subjects received 0.1 mg/kg sotatercept (ACE-011), 8 subjects received 0.3 
mg/kg sotatercept (ACE-011), and 8 subjects received 0.5 mg/kg sotatercept (ACE-011).  
Twenty six (86.7%) subjects completed the study.  One subject in the 0.1 mg/kg dose group and 
one subject in the 0.5 mg/kg dose group discontinued due to AEs.  One subject in the 0.1 mg/kg 
dose group withdrew consent and was discontinued, and one subject in the 0.3 mg/kg dose group 
was discontinued at the request of the investigator.  
Page 401 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
30
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
In this study, 50.0% of subjects were female and the mean (range) age was 60.9 (41 to 79) years.  
The mean time since diagnosis of MM was 3.3 years, the majority of subjects had stage III 
disease at screening (83.3%) and had received prior chemotherapy (93.3%).  Approximately
43.3% of subjects were receiving bisphosphonates at screening, which continued during the 
study.  
Fourteen out of 24 subjects (58%) who received study treatment (sotatercept [ACE-011]) did 
receive 3 doses or more (4 out of 8 subjects in the 0.5 mg/kg dose level, 5 out of 8 subjects in the 
0.3 mg/kg dose level and 5 out of 8 subjects in the 0.1 mg/kg dose level).  
Safety:  Overall, 22 (91.7%) subjects receiving sotatercept (ACE-011) and 4 (66.7%) subjects
receiving placebo reported at least one AE.  Among subjects receiving sotatercept (ACE-011), 
AEs were reported in 87.5%, 87.5%, and 100% of subjects in the 0.1 mg/kg, 0.3 mg/kg, and 0.5 
mg/kg dosing cohorts, respectively.  Treatment-related AEs (i.e., those assessed by the 
Investigator as possibly, probably, or definitely related to treatment) were reported by 21 
(87.5%) subjects receiving sotatercept (ACE-011) and 4 (66.7%) receiving placebo.  Most 
subjects had AEs that were assessed as related to MPT:  21 (87.5%) subjects receiving 
sotatercept (ACE-011) and 4 (66.7%) subjects receiving placebo.  No AEs were assessed by the 
Investigator as related to the study medication alone (sotatercept (ACE-011) or placebo).  Two 
subjects had AEs assessed as possibly or probably related to study drug and possibly or probably 
related to MPT, one subject in the 0.1 mg/kg sotatercept (ACE-011) dose group (increased blood 
pressure; sudden death) and one subject in the 0.5 mg/kg sotatercept (ACE-011) dose group 
(hypertension).  Four subjects had SAEs, 1 (12.5%) subject in the 0.1 mg/kg sotatercept (ACE-
011) group and 3 (37.5%) subjects in the 0.5 mg/kg sotatercept (ACE-011) group.  Three 
subjects had SAEs that were assessed as treatment-related.  Of the 3 treatment-related SAEs, 2 
SAEs were assessed as possibly related to MPT and unrelated to sotatercept (ACE-011), and 1 
SAE (sudden death) was assessed as probably related to MPT and possibly related to sotatercept 
(ACE-011).  One subject in the 0.5 mg/kg sotatercept (ACE-011) dose group discontinued study 
drug due to episodes of atrial fibrillation assessed as possibly related to MPT and unrelated to 
sotatercept (ACE-011).  
Table 2 summarizes the most frequent AEs ≥5% in all treatment groups and Table 3 is a 
summary of SAEs reported.  
Page 402 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
31
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
Table 2:
Summary of Adverse Events Reported in Greater Than or Equal To 5
Percent of Patients Overall
Sotatercept (ACE-011) Treatment Group
Preferred 
Terma
Placebo
(N=6)
0.1 mg/kg
(N=8)
0.3 mg/kg
(N=8)
0.5 mg/kg
(N=8)
All Sotatercept
(ACE-011)
(N=24)
Any 
Grade
Grade ≥3
Any 
Grade
Grade ≥3
Any 
Grade
Grade ≥3
Any 
Grade
Grade ≥3 Any Grade Grade ≥3
Neutropenia
4 (66.7%) 1 (16.7%) 4 (50.0%) 2 (25.0%) 6 (75.0%) 2 (25.0%) 6 (75.0%) 3 (37.5%) 16 (66.7%) 7 (29.2%)
Leukopenia
0
0
3 (37.5%) 1 (12.5%) 1 (12.5%) 0
1 (12.5%) 1 (12.5%) 5 (20.8%)
2 (8.3%)
Granulo-
cytopenia
0
0
2 (25.0%) 1 (12.5%) 1 (12.5%) 1 (12.5%) 1 (12.5%) 1 (12.5%) 4 (16.7%)
3 (12.5%)
Anaemia
0
0
1 (12.5%) 1 (12.5%) 1 (12.5%) 1 (12.5%) 2 (25.0%) 1 (12.5%) 4 (16.7%)
3 (12.5%)
Respiratory 
tract 
infection
0
0
1 (12.5%) 1 (12.5%) 1 (12.5%) 0
1 (12.5%) 0
3 (12.5%)
1 (4.2%)
Thrombo-
cytopenia
0
0
1 (12.5%) 0
0
0
2 (25.0%) 1 (12.5%) 3 (12.5%)
1 (4.2%)
Pyrexia
0
0
1 (12.5%) 0
1 (12.5%) 0
1 (12.5%) 0
3 (12.5%)
0
Blood 
pressure 
increased
0
0
1 (12.5%)*1 (12.5%)*0
0
1 (12.5%) 0
2 (8.3%)
1 (4.2%)
Bronchitis
1 (16.7%) 0
0
0
1 (12.5%) 0
1 (12.5%) 0
2 (8.3%)
0
Compression 
fracture
0
0
0
0
1 (12.5%) 0
1 (12.5%) 0
2 (8.3%)
0
Pathological 
fracture
0
0
1 (12.5%) 0
0
0
1 (12.5%) 1 (12.5%) 2 (8.3%)
1 (4.2%)
aAdverse events were those that were treatment-emergent, defined as newly acquired or worsened during or after 
administration of first dose of study medication. A patient with multiple occurrences of an AE counted only once 
under each preferred term.  
*Indicates the adverse event was assessed by the investigator as related (possibly, probably, or definitely) to study 
drug (sotatercept (ACE-011) or placebo).  
Page 403 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
32
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
Table 3:
Summary of SAEs Reported
Study Treatment
Age (y) / 
Sex / Race
Preferred Term
(Verbatim Term)
[Severity / Gradea]
Study Dayb
at Onset
Outcome
(duration)
Relationship to Study 
Treatment
0.1 mg/kg 
Sotatercept 
(ACE-011) and 
MPT
Sudden death
(sudden death)
103
Death
Sotatercept (ACE-011):  
possibly
MPT:  probably
0.5 mg/kg 
Sotatercept 
(ACE-011) and 
MPT
Pain in extremity
(pain in leg)
[severe / G 3]
128
Ongoing at 
end of study
Sotatercept (ACE-011):  not 
related
MPT:  not related
Pathological fracture
(pathological fracture of 
femur)
[severe / G 3]
130
Ongoing at 
end of study
Sotatercept (ACE-011):  not 
related
MPT:  not related
0.5 mg/kg 
Sotatercept 
(ACE-011) and 
MPT
Pneumonia
(pneumonia)
[moderate / G 2]
9
Resolved
(12 days)
Sotatercept (ACE-011):  not 
related
MPT:  possibly
0.5 mg/kg 
Sotatercept 
(ACE-011) and 
MPT
Atrial fibrillation
(atrial fibrillation)
[life-threatening / G 4]
6
Resolved
(1 day)
Sotatercept (ACE-011):  not 
related
MPT:  possibly
F= female; M = male; MPT = melphalan, prednisolone, and thalidomide; NCI CTCAE, v3.0 = National Cancer 
Institute Common Terminology Criteria for Adverse Events, version 3.0; y = years
abased on NCI CTCAE, v3.0.  
bRelative to first dose of study drug.  
Following analysis of the central laboratory data, increases in Hgb values were observed within 
28 days after administration of the first dose of sotatercept (ACE-011)/placebo and sustained for 
≥ 28 days from baseline at any time as presented in Table 4.  
Table 4:
Number of Subjects with an Increase in Hgb from Baseline at Any Time and 
Sustained for Greater Than or Equal To 28 Days
Increase in Hgb
Dose Sotatercept (ACE-011)/Placebo
0.1 mg/kg
N=8
0.3 mg/kg
N=8
0.5 mg/kg
N=8
Placebo
N=6
Overall
N=30
≥ 1.0 g/dL
4
3
7
2
16
≥ 1.5 g/dL
2
3
3
1
9
≥ 2.0 g/dL
1
3
2
0
6
Taken together, these data, suggest a beneficial pharmacodynamic effect of sotatercept (ACE-
011) on erythropoiesis in a patient population with cancer CIA.  
Potential Risks for Human Use
Nonclinical studies to determine the safety of sotatercept (ACE-011) have been conducted in 
cynomolgus monkeys and Sprague-Dawley rats.  Many of the observed effects in these studies 
Page 404 of 791
PPD
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
33
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
were as a result of the expected biologic activity of activin inhibition and can be summarized as a 
dose-dependent decrease in sperm count and motility secondary to FSH suppression as well as 
reversible increases in RBC parameters due to the effects on erythroid differentiation factor 
(activin).  
The most significant toxicity findings are listed below:  

Hematological findings (increase in RBC parameters – RBCs, Hgb, HCT) were 
observed across all studies.  Associated with the increase in RBC parameters were 
increases in reticulocytes and decreases in mean corpuscular hemoglobin (MCH) and 
mean corpuscular hemoglobin concentration (MCHC).  The increase in RBC 
parameters is an anticipated effect of sotatercept (ACE-011) treatment and is being 
targeted as a therapeutic intervention for conditions associated with anemia.  

In the 6- and 9-month monkey studies, glomerulonephritis and/or tubulointerstitial 
nephritis were observed in monkeys administered ≥ 10 mg/kg administered 
subcutaneously (SC) every 2 or 4 weeks. At 2.6 mg/kg administered SC every 4 
weeks for 9 months, kidney findings were limited to a single incidence of 
tubulointerstitial nephritis. The NOAEL in the 9-month study was considered to be 1 
mg/kg every 4 weeks. Serum exposure in monkeys at the 1 mg/kg dose is estimated 
to be ~1.3-fold greater than the projected serum exposure in humans at the maximum 
proposed human dose of 61 mg every 6 weeks.  In the single- and multiple-dose 
studies in healthy postmenopausal women, there have been no changes in serum 
chemistry or urinalysis profiles suggestive of kidney injury. Subjects administered 
sotatercept (ACE-011) should continue to be closely monitored.  

In the 9-month monkey study, treatment-related findings in the choroid plexus 
included:  perivascular accumulations of foamy macrophages and intimal thickening 
of small arteries and arterioles primarily at 10 mg/kg administered every 2 weeks as 
well as an increased incidence of small, focal aggregates of mononuclear 
inflammatory cells at all dosages. Findings at 1 mg/kg were limited to mononuclear 
cell infiltrates and were not adverse. 

Adrenal gland congestion or necrosis was observed in rats but not in monkeys.  The 
finding was more pronounced in female rats and appeared following either one month 
of IV dosing or 3 months of SC dosing.  Although the current data suggest adrenal 
toxicity may be specific to rats, the relevance of the adrenal findings to humans is 
uncertain.  

Elevations in liver enzymes (alanine aminotransferase [ALT], aspartate 
aminotransferase [AST], and/or alkaline phosphatase), as well as triglycerides, were 
observed sporadically in rats and monkeys treated with sotatercept (ACE-011).  There 
were no histological correlates in the liver, and often a dose-response relationship was 
not observed.  The relevance of these findings to sotatercept (ACE-011) treatment is 
uncertain; however, liver enzymes will continue to be monitored in this study. 
Page 405 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
34
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011

Pregnancy and Lactation

Due to the potential for effects on hormones in the pituitary, including FSH, in 
addition to possible direct effects on fetus, there may be potential effects on the 
fetus. Delays in fetal development (decreased fetal weights and delays in 
ossification) were observed at doses ≥15 mg/kg (15-fold greater on a mg/kg basis 
than the maximum proposed human dose of 60 mg every 6 weeks assuming a 60 
kg person). In addition, at 50 mg/kg (100-fold the maximum proposed human 
dose), there was an increase in late fetal death coupled with an overall increase in 
post implantation loss and a reduction in live litter size, as well as an increase in 
the incidence of developmental variations of supernumerary ribs with 
corresponding increases and decreases in thoracic and lumbar vertebrae, 
respectively. No fetal malformations were observed in this study at dosages up to 
50 mg/kg. The NOAEL for embryofetal development effects was 5 mg/kg 
(~5-fold greater than the maximum proposed human dose of 60 mg every 6 weeks 
assuming a 60 kg person) based on reduced fetal weights and associated delays in 
ossification. Although the risks for embryofetal development effects are 
considered relatively low given the large safety margins, precautions should still 
be taken to protect females of childbearing potential. Nonclinical studies on 
breast milk have not been done.  

If sotatercept (ACE-011) is taken during pregnancy, a teratogenic effect in 
humans cannot be ruled out.  Therefore, all sotatercept (ACE-011) protocols 
describe pregnancy prevention requiring females of child-bearing potential to use 
highly effective methods of birth control.  In addition, since it is unknown if 
sotatercept (ACE-011) is found in breast milk, breast feeding is prohibited in all 
protocols.  

Fertility

In male rats, sperm granulomas and testicular degeneration were observed 
histologically.  In addition, sperm analysis revealed a reduction in sperm counts 
and motility as well as sperm fragmentation in isolated animals (2/10 males) at 
doses of 30 mg/kg IV.  Sperm fragmentation was also noted in 2/5 males 
administered 10 mg/kg IV at the end of the recovery period.  Overall, there was 
some evidence of recovery (motility similar to controls) at the end of the 4-week 
recovery period.  There was no evidence of a treatment-related impact on 
reproductive organs (testes, ovary, uterus) of monkeys in the toxicity studies; 
however, the monkeys on these studies, were too immature to fully assess the 
potential impact on reproductive organs.  The NOAEL for reproductive effects 
(testicular or ovarian) was 1 mg/kg IV.  Serum exposure (AUC28d) in rats at the 
NOAEL was estimated to be ~ 8,000 µg·hr/mL based on the single-dose IV 
pharmacokinetic study in rats (Report TR148), ~ 2-fold greater than the serum 
exposure observed in humans at the maximum proposed dose of 60 mg every 6 
weeks (estimated AUC28d ~ 4548 μg·hr/mL). 
Page 406 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
35
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011

In summary, in view of the potential risks sotatercept (ACE-011) treatment has on 
fertility, sotatercept (ACE-011) is targeted toward patient groups for whom the 
potential benefits outweigh the perceived risks.  
Because of the potential risks sotatercept (ACE-011) treatment has on fertility, sotatercept (ACE-
011) was first studied in healthy postmenopausal in two completed phase 1 clinical trials.  In 
addition, due to the potential for effects on hormones in the pituitary, levels of growth hormone, 
ACTH, and thyroid stimulating hormone (TSH) were monitored closely in the phase 1 studies.  
Completed studies in humans carried out in postmenopausal females showed a dose-dependent 
decrease in circulating levels of FSH, with mean levels in the multi-dose study in the two higher 
dose groups remaining below baseline at study end.  FSH will continue to be evaluated in 
ongoing studies.  No abnormal effects of sotatercept (ACE-011) on growth hormone, ACTH, and 
TSH and kidney toxicities were observed.  
Based on the safety data from the two completed phase 1 studies, single doses of sotatercept 
(ACE-011) up to 3.0 mg/kg IV and multiple doses of sotatercept (ACE-011) up to 0.3 mg/kg SC 
were generally well-tolerated in healthy postmenopausal women.  Consistent with observations 
from nonclinical safety studies, many of the observed pharmacodynamic effects in the phase 1 
clinical studies could be attributed to the expected biologic activity of activin inhibition, i.e., 
dose-dependent decrease in circulating levels of FSH, and transient, reversible effects on RBC 
parameters.  In Study A011-02 one subject experienced persistent, progressive hypertension and 
headaches approximately 1 week following her second dose of 1.0 mg/kg sotatercept (ACE-011)
SC that were attributed to a rapid and significant rise in Hgb levels.  The hypertension was 
reported as an SAE.  
In regards to the above safety concerns, appropriate vitals, hematologic, clinical chemistry and 
endocrine testing will be closely monitored in this clinical study.  There may be an effect of 
delayed wound healing, thus subjects with major surgeries within 30 days prior to study 
initiation will be excluded.  As with all biologics there is the potential for anti-drug antibodies 
that can be associated with increased drug clearance and hypersensitivity reactions.  Although no 
current evidence of neutralizing anti-drug antibodies formation was seen in two completed phase 
1 clinical trials, anti-drug antibody formation will be monitored in this clinical study.  
Please refer to the Investigator Brochure for further detailed information on the available 
pharmacology, toxicology, drug metabolism, clinical studies and AE profile of sotatercept 
(ACE-011).  
Page 407 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
36
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
2.
STUDY OBJECTIVES
2.1.
Primary Objective

Part 1:  To determine a dose of sotatercept (ACE-011) that results in a hematopoietic 
response for the treatment of CIA in subjects with selected metastatic solid tumors 
treated with platinum-based chemotherapeutic regimens.

Part 2:  To assess transfusion rate following initiation of sotatercept (ACE-011)
treatment versus placebo in subjects with CIA who have metastatic NSCLC treated 
with first-line platinum-based chemotherapeutic regimens.
2.2.
Secondary Objectives
Part 1 and Part 2:

To estimate the effect of sotatercept (ACE-011) treatment on objective response rate 
(ORR), time to progression (TTP), progression free survival (PFS) and overall 
survival (OS). To evaluate the safety and tolerability of sotatercept (ACE-011). To 
determine the PK of sotatercept (ACE-011) in subjects receiving platinum-based 
chemotherapy.  

To evaluate the hematopoietic response and its duration associated with sotatercept 
(ACE-011) treatment.  

To evaluate the effect of sotatercept (ACE-011) treatment on the quality of life 
(QoL).
2.3.
Exploratory Objectives
Part 1 and Part 2:

To estimate the effect of sotatercept (ACE-011) treatment on bone metabolism To 
explore the relationship between sotatercept (ACE-011) exposure and response 
(hematology, biomarkers, and other clinical outcomes as appropriate).  

To evaluate the expression of Activin A and other proteins/biomarkers (including 
myostatin and follistatin) related to sotatercept (ACE-011) mechanism of action in 
blood.

To evaluate the expression of Activin A and other proteins/biomarkers in archival 
tumor tissue (Part 2 only).

To assess renal function biomarkers
Data from exploratory objectives may not be included in the Clinical Study Report.  
Page 408 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
37
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
3.
STUDY ENDPOINTS
3.1.
Primary Endpoint(s)
Part 1: Dose Finding
The following are decision rules for dose determination in Part 1 in order to move forward to 
Part 2:

After completion of two doses of sotatercept (ACE-011), a hematopoietic response in 
approximately 70% of subjects, in at least one or more treatment arms.  

Hematopoietic response is defined as an increase in Hgb of ≥ 1.0 g/dL above the 
study baseline value for 28 consecutive days, in the absence of RBC transfusions 
and/or ESAs.  In order to determine the dose of sotatercept (ACE-011) to be used in 
Part 2, evaluation of hematopoietic response will be determined from sotatercept 
(ACE-011) Dose 1/ Day 1 through and including Dose 2/Day 43 (prior to Dose 3).  

In addition to the hematopoietic response, the safety profile, dose modifications and 
extent of exposure in each dosing level will be taken into account to determine the 
study dose to be used in Part 2.  
Hematopoietic response will be determined by laboratory analysis of hemoglobin levels.  
Part 2:  Phase 2b/3 Double-Blind

Rate of RBC transfusion within four months following the date of randomization to 
sotatercept (ACE-011)/placebo treatment
3.2.
Secondary Endpoint(s)

Safety (type, frequency, and severity [National Cancer Institute (NCI) Common 
Terminology for Adverse Events (CTCAE) current active minor version 4.0] of 
adverse events

TTP 

PFS (including at 6 and 12 months)

OS (at 12 months and up to 24 months)

ORR

Duration of hematopoietic response

Sotatercept (ACE-011) concentration in serum 

Non-compartmental PK parameters for sotatercept (ACE-011) (Part 1 only)

QoL assessment (FACIT Fatigue Scale [Version 4]) and LCSS questionnaire (Hollen,
1993 ; Hollen, 1994a ; Hollen, 1994b; Hollen, 1995)
Page 409 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
38
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
3.3.
Exploratory Endpoint(s)

Change in serum and urine bone biomarkers, including osteocalcin (OC), serum bone 
specific alkaline phosphatase (BSAP), procollagen type 1 N-terminal propeptide 
(P1NP), C-terminal type 1 collagen telopeptide (CTX) and tartrate-resistant acid 
phosphatase isoform-5b (TRACP-5b), the urine bone biomarker (urine N-telopeptide 
[uNTX]) related to activin or sotatercept (ACE-011) mechanism of action  

Change in BMD (DXA scans of lumbar spine and hip)

Time to first symptomatic skeletal related event (SRE) defined as pathologic fracture, 
clinical need for radiation therapy, surgery to bone or spinal cord compression

A population PK model for sotatercept (ACE-011)  

A population pharmacodynamic model describing Hgb response as a function of time, 
sotatercept (ACE-011) exposure, and subject characteristics 

Expression of Activin A and other protein/biomarkers related to sotatercept (ACE-
011) mechanism of action in blood (including myostatin and follistatin) and in 
archival tumor tissue (Part 2 only). 

Change in renal function biomarkers via urinalysis measuring urine albumin / 
creatinine ratio, urine protein / creatinine ratio and other biomarkers of glomerular 
and/or tubular injury - urine kidney injury molecule-1 (KIM-1), urine trefoil factor 3 
(TTF3), urine cystatin C and + or – urine β2-microglobulin
Page 410 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
39
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
4.
OVERALL STUDY DESIGN
4.1.
Study Design 
This is an open-label randomized, phase 2a, dose-ranging study (Part 1) of sotatercept (ACE-
011) therapy in subjects with selected metastatic solid tumor types treated with platinum-based
chemotherapeutic regimens followed by a phase 2b/3, double-blind, randomized, placebo-
controlled study of sotatercept (ACE-011) therapy for CIA in subjects with metastatic NSCLC
treated with platinum-based chemotherapeutic regimens.  
The study will consist of two parts.  Part 1 is a dose finding segment in which subjects with
selected metastatic solid tumor types will be randomized to one of three sotatercept (ACE-011)
dose treatment arms.  Continuous monitoring of safety data will be conducted, including the 
review of Part 1 data to determine the sotatercept (ACE-011) dose to be used in Part 2, the phase 
2b/3, double-blind, randomized placebo-controlled segment of the study in subjects with 
metastatic NSCLC.  
A DMC will monitor the conduct of the study.
Part 1 is planned to be conducted at selected sites and will be extended to additional global sites 
for the conduct of Part 2.  
Study treatment is defined as sotatercept (ACE-011) in Part 1 and sotatercept (ACE-011)/placebo 
in Part 2.  
Three starting sotatercept (ACE-011) dose levels, 15, 30, and 45 mg, were selected for Part 1 of 
the study. Up to approximately 90 subjects with selected metastatic solid tumor types will be 
randomized to one of the following sotatercept (ACE-011) dose levels, with 10-30 subjects per 
arm:

Sotatercept (ACE-011) 15 mg SC

Sotatercept (ACE-011) 30 mg SC
Analysis of safety data will be performed following the treatment of at least 10 subjects at the 15
mg dose level and 10 subjects at the 30 mg dose level, with each subject having received a 
minimum of one dose of sotatercept (ACE-011) and completed a 12-week follow-up period from 
the first dose.  
Following this analysis, the addition of a third dose level:

Sotatercept (ACE-011) 45 mg SC
to the randomization schema will be determined.
Each dose level will be administered every 42 days for a total of four doses.  
In Part 2, a total of 750 subjects with metastatic NSCLC will be randomized to receive either 
sotatercept (ACE-011) (at the dose determined in Part 1) or placebo, at a ratio of 1:1:

375 subjects will receive sotatercept (ACE-011) (at the dose determined in Part 1)

375 subjects will receive placebo
Page 411 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
40
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
Each dose of sotatercept (ACE-011) or placebo will be administered every 42 days for four
doses; two additional doses may be given at the discretion of the Investigator.  
Part 2 will be performed in two stages. In the first stage, approximately 180 subjects will be 
randomized to receive sotatercept (ACE-011), at the dose determined from Part 1, or placebo at a 
ratio of 1:1.  An interim futility assessment based on transfusion rate at 4 months will be 
performed as described in Section 10.8.  It is expected that accrual will continue during the 
interim assessment period, with up to an additional 570 subjects randomized to achieve full study 
accrual. 
The Treatment Period for Part 1 is approximately six months, which includes up to 4 doses of 
sotatercept (ACE-011) and for Part 2 approximately nine months, which includes up to 6 doses 
of sotatercept (ACE-011/placebo).  Subjects who enter the Post Treatment Follow-Up Period
will be followed for up to 6 months from their last dose of sotatercept (ACE-011) or sotatercept 
(ACE-011)/placebo.  All subjects will continue to be followed for TTP and PFS up to 12 months
from their first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo or until 
progression of their metastatic disease, whichever comes first.  
Survival data will be collected monthly for up to 24 months following the subject’s first dose of 
sotatercept (ACE-011) in Part 1 or sotatercept (ACE-011)/placebo in Part 2.  
At the time of randomization, all subjects must be receiving their first regimen of first-line 
platinum-based chemotherapy, given every three weeks, for the treatment of a selected metastatic 
solid tumor.  Subjects may have already received up to 4 cycles of this current platinum-based 
regimen and must be randomized prior to receiving Cycle 5.  It is expected that subjects be 
eligible to continue to receive ≥ 2 additional platinum-based chemotherapy cycles while on study 
treatment.  
Subjects must not have received any other platinum containing regimens of chemotherapy for the 
first-line treatment of a metastatic solid tumor prior to the regimen they are receiving at the time 
of randomization.  
Stratification and randomization will be performed utilizing a validated interactive voice 
response system (IVRS).  

In Part 1, subjects will be randomized to one of three sotatercept (ACE-011) dose levels 
and will be stratified by:
1. Baseline Hgb level 

6.5 to < 9.0 g/dL

9.0 to < 11.0 g/dL
2. Type of platinum-based chemotherapy (cisplatin versus carboplatin)

In Part 2 subjects will be randomized to receive either sotatercept (ACE-011) or placebo 
and will be stratified by:
1. Baseline Hgb level 

6.5 to < 9.0 g/dL

9.0 to < 11.0 g/dL
Page 412 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
41
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
2. Type of platinum-based chemotherapy (cisplatin versus carboplatin)
3. NSCLC histology (Squamous NSCLC vs. Non-Squamous NSCLC)
4. ECOG Performance Status 0-1 vs. 2
Page 413 of 791
088VGY

088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
43
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
4.1.1.
Sotatercept (ACE-011) Dose Modification, Reduction and Escalation Rules
Subjects should have Hgb and blood pressure measured (confirmed by two measurements 
obtained five minutes apart) prior to each dose of study drug.  The Investigator must adhere to 
the following Hgb and blood pressure-based dose modification rules for sotatercept (ACE-011)
or sotatercept (ACE-011)/placebo for the subject’s second dose of study treatment and beyond.  
Sotatercept (ACE-011) Dose Modification Rules:
Hemoglobin < 11g/dL
(per local* lab value) 
Hemoglobin ≥11g/dL
(per local* lab value) 
Hypertension ≥SBP 150 mmHg and ≥DBP 100 mmHg
*Note:  Local laboratory assessments are allowed in cases when timely results are needed (e.g., randomization, 
study treatment and chemotherapy dosing decisions, hematology assessments between clinic visits).  Whenever 
possible a “split” sample should also be forwarded to the central laboratory for analysis. Local laboratory data 
should be collected in the eCRF.  
< 2.0 g/dL increase within a 
dosing period or a ≥ 2.0 g/dL 
increase not sustained for a 28 
day period since last dosing day 
≥ 2.0 g/dL increase sustained for a 
28 day period since last dosing day2
Note: ≥ 3.0 g/dL increase sustained 
for a 28 day period since last dosing 
day requires a two level dose 
reduction.  
< 2.0 g/dL increase within a 
dosing period or a   ≥ 2.0g/dL 
increase not sustained for a 28 
day period since last dosing day
≥ 2.0g/dL increase sustained for a 28 day 
period since last dosing day2
Note: ≥ 3.0g/dL increase sustained for a 28 
day period since last dosing day requires a 
two level dose reduction.  If Hgb is > 15.0 
g/dL, sustained for 7 days, subject is to be 
discontinued from treatment2. 
Dose Delay5
Continue 
Dosing1
(Part 1 only-
Dose Escalation 
Table 6)
Continue Dosing 
with Dose 
Reduction 
Table 5: Sotatercept 
(ACE-011) and 
Sotatercept (ACE-
011)/Placebo Dose 
Reduction Levels
Dose Delay3
Dose Delay 
then, Dose 
Reduction4
Page 415 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
44
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
1If Hgb increase ≥ 1.0 but < 2.0 g/dL, dose remains the same.
For Part 1 only:  if the RBC transfusion was given > 7 days following the previous dose of sotatercept (ACE-011), 
the subsequent dose of sotatercept (ACE-011) will be increased one dose level (Refer to sotatercept (ACE-011)
Dose Escalation Levels- Table 6).  Hemoglobin level must be < 11 g/dL AND hypertension < SBP 150 mmHg and 
< DBP 100 mmHg on the day of dosing.  Sotatercept (ACE-011) should not be administered ≤7 days post RBC 
transfusion.  
For Part 2:  Subjects who have received an RBC transfusion in the past 42 days should continue at the same
sotatercept (ACE-011)/placebo dose if the transfusion was given greater than 7 days from the previous dose of 
sotatercept (ACE-011)/placebo AND the Hgb level is < 11 g/dL AND hypertension is < SBP 150 mmHg and < 
DBP 100 mmHg on the day of dosing.  Sotatercept (ACE-011)/placebo should not be administered ≤7 days post 
RBC transfusion.  
2Hemoglobin increases of > 2 g/dL sustained for a 28 day period since last dosing day should be confirmed on the 
dosing day, 7, 14 , 22 (after first dose of study treatment) and 28 days after dosing, and reviewed in comparison to 
Hgb level on previous dosing day.  Any Hgb increase of ≥3.0 g/dL sustained for 28 days will require a subsequent 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dose reduction of two dose levels (Refer to sotatercept 
(ACE-011) and sotatercept (ACE-011)/Placebo Dose Reduction Levels (Table 5).  A second Hgb increase of ≥3.0 
g/dL sustained for 28 days, following a two level dose reduction, will require the subject discontinue from study 
treatment.  If Hgb is > 15.0 g/dL (sustained for a 7 day period, confirmed by laboratory assessment) subject is to 
be discontinued from treatment.  (See Section 8.2.3 Discontinuation)  
3Sotatercept (ACE-011) or sotatercept (ACE-011)/placebo should be delayed until Hgb is < 11g/dL and 
hypertension < SBP 150mm Hg and < DBP 100 mm Hg.  Dosing can commence at ≥7 days after the originally 
planned sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dose that was delayed.  Subsequent sotatercept 
(ACE-011) or sotatercept (ACE-011)/placebo doses will then begin 42 days following this revised treatment dose
date.  
A delayed sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dose is defined as a dose administered > 4 
days from the planned dosing date (due to Hgb ≥11.0 g/dL, hypertension > SBP 150 mmHg and > DBP 100 
mmHg and/or sotatercept (ACE-011) related toxicity).  
4Sotatercept (ACE-011)or sotatercept (ACE-011)/placebo should be delayed as above in foot note (3), a reduced 
dose as above in foot note (2) of sotatercept (ACE-011) will be administered based on the evaluation of the Hgb
and blood pressure at that time.  
5Sotatercept (ACE-011)or sotatercept (ACE-011)/placebo should be held until hypertension resolves to < SBP 
150mmHg and < DBP 100 mmHg and may then be resumed beginning seven days after the previous planned
scheduled treatment visit as above in foot note (3).  
Page 416 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
45
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
Table 5:
Sotatercept (ACE-011) and Sotatercept (ACE-011)/Placebo Dose Reduction 
Levels
When required, per dose modification rules above, sotatercept (ACE-011) dose(s) in Part 1 and 
sotatercept (ACE-011)/placebo dose(s) in Part 2 should be reduced as follows:  
Dose Schedule
Sotatercept (ACE-011) or
Sotatercept (ACE-011)/placebo
Dose Reduction*
#1
Dose Reduction*
#2
Dose Reduction*
#3
Every 42 days-
45 mg
38 mg
33 mg
28 mg
Every 42 days-
30 mg
26 mg
22 mg
18 mg
Every 42 days-
15 mg
13 mg
11 mg
9 mg
*Note:  Any Hgb increase of ≥3.0 g/dL sustained for a 28 day period since last doing day will require a subsequent 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dose reduction of two dose levels.  A second Hgb
increase of ≥3.0 g/dL, sustained for 28 days, following a two-level dose reduction will require the subject 
discontinue from study treatment.  
Dosing visits are on Day 1 and repeated every 42 days, for four doses.  An additional two doses 
(total of 6 doses) may be given only during Part 2 at the discretion of the Investigator.  
Blood pressure (confirmed by two measurements obtained five minutes apart) and Hgb values 
must be evaluated prior to dosing at each dosing day for consideration in administration of 
sotatercept (ACE-011) and sotatercept (ACE-011)/placebo.  
The dose level for the initial dose reduction will be maintained unless subsequent dose 
reductions need to be administered upon evaluation of the dose modification rules listed above.  
A dose level may not be increased following a dose reduction.  
In Part 2, dose reduction steps and the subsequent administration of the reduced dose(s) of 
sotatercept (ACE-011)/placebo will be conducted in a manner that will preserve the blinded 
status of the original treatment group of each subject.  Subjects in the placebo group who are 
designated to undergo dose reduction will continue to receive placebo.  
Placebo will be administered at the same volume as the corresponding sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo dose reduction.  
Sotatercept (ACE-011) Dose Escalation Levels:
The following dose escalation rules apply for sotatercept (ACE-011) dose(s) in Part 1 only.  
Dose escalations are not allowed in Part 2:

Less than 1.0 g/dL increase in Hgb in response to prior sotatercept (ACE-011) dose

Hgb level must be < 11.0 g/dL and hypertension < SBP 150mmHg and
< DBP 100 mmHg

Dose escalation to begin at next treatment visit 
Page 417 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
46
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011

Sotatercept (ACE-011) should not be administered ≤7 days from the date of RBC 
transfusion.  
Subjects who have received an RBC transfusion should receive a one level dose increase of 
Sotatercept (ACE-011) at the subsequent visit per the escalation table below.  
Table 6:
Sotatercept (ACE-011) Dose Escalation Levels (Part 1 Only) 
Dose Schedule
Sotatercept (ACE-
011)
Dose Increase  #1
Dose Increase  #2
Dose Increase #3
Every 42 days-
45 mg
50 mg
55 mg
61 mg
Every 42 days-
30 mg
33 mg
36 mg
40 mg
Every 42 days-
15 mg
17 mg
20 mg
23 mg
Blood pressure (confirmed by two measurements obtained five minutes apart) and Hgb values 
must be evaluated prior to dosing at each dosing day for consideration in administration of 
sotatercept (ACE-011) and sotatercept (ACE-011)/placebo.  
4.2.
Study Design Rationale
The A011-01, A011-02 and A011-04 studies have shown that dosing with sotatercept (ACE-011)
resulted in a rapid, sustained and dose-dependent increases in hematopoietic parameters, (Hgb, 
HCT and RBC counts) which occurred earlier than would be expected from a stimulation of 
erythropoiesis by an ESA.  This observation, couple with nonclinical data demonstrating some 
level of erythrocyte stimulatory effect in the presence of anti-erthyropoietin (EPO) antibodies, 
suggests that the hematopoietic effect of sotatercept is different from that of ESAs. Treatment of 
subjects with metastatic lung cancer with myelosuppressive platinum-based chemotherapy is 
frequently associated with anemia.  Chemotherapy induced anemia is a significant problem for 
subjects with cancer, causing fatigue and reduced quality of life (Groopman, 1999).  Subjects
with CIA are currently treated with blood transfusion and/or ESAs (NCCN Guidelines, 2009).  
However, with these treatment options CIA is still an area of major medical morbidity.  
Erythropoiesis-stimulating agents can successfully mitigate transfusion need in a proportion of 
these subjects, but concerns have emerged regarding apparent negative effects on survival and/or 
tumor progression in certain patient populations.  
4.2.1.
Fixed Dose
Sotatercept (ACE-011) dose will be fixed at the indicated levels regardless of the subject’s body 
weight.  The fixed dosing approach is supported by an exploratory analysis of the relationship 
between body weight and sotatercept (ACE-011) PK in the previous studies (A011-01, A011-02, 
and A011-04).  In healthy postmenopausal women (Studies A011-01 and A011-02), body weight 
was estimated to explain less than 2.5% of intersubject variability for the two PK parameters 
dictating sotatercept (ACE-011) exposure, clearance and central volume of distribution, 
Page 418 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
47
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
compared to an overall intersubject variability of 17.4% -25.5% for the two parameters.  In MM 
subjects (Study A011-04), body weight had no apparent effect on sotatercept (ACE-011)
exposure.  Because the Hgb response is dependent on sotatercept (ACE-011) exposure and 
because body weight is not a major source for the intersubject variability of sotatercept (ACE-
011) exposure, a fixed dosing approach is considered to be appropriate for the current study.  
4.2.2.
Dosing Schedule
The dosing schedule of once every 42 days (6 weeks) is proposed for the current study.  This 
dosing schedule was chosen by taking into consideration the rapid and prolonged Hgb response 
to sotatercept (ACE-011) as well as the dosing schedule for the platinum-based chemotherapies.  
The Hgb-increasing effect of sotatercept (ACE-011) was usually evident approximately 1 week 
after a SC dose and remained detectable through 6-8 weeks.  In addition, as platinum-based 
chemotherapy is often administered once every 3 weeks, a once every 6 weeks dosing schedule 
allows administration of sotatercept (ACE-011) at the same visit for the chemotherapy, which is 
convenient to both subjects and study sites.  
4.2.3.
Starting Dose Levels in Part 1
Three starting dose levels, 15, 30, and 45 mg, were chosen for Part 1 of the study.  Selection of 
these doses is primarily based on the safety and exposure-response data observed in MM subjects 
under the standard MPT chemotherapy, who received up to four doses of sotatercept (ACE-011)
at 0.1, 0.3, or 0.5 mg/kg (Study A011-04).  In these subjects, sotatercept (ACE-011) had an 
acceptable safety profile and caused exposure-dependent Hgb response.  Further, there was no 
relationship observed between an increase in blood pressure and the maximal sotatercept (ACE-
011) concentration or the maximal Hgb rise within 28 days of the first dose (Report A011-04-
CP).  The three starting dose levels approximate the average doses received by a 70 kg subject 
over a 6-week interval (10.5 mg, 31.5 mg, and 52.5 mg, respectively) in the A011-04 study.  
In Study A011-04, four MM subjects received at least three sotatercept (ACE-011) doses at 0.5 
mg/kg every 4 weeks without a dose interruption, and none of them was reported to have an AE 
related to sotatercept (ACE-011).  In this study, the starting dose level of 45 mg (during the dose 
finding Part 1) will be implemented only after at least 10 subjects at each lower dose level (10 
subjects at the 15 mg dose level and 10 subjects at the 30 mg dose level) have been evaluated as 
well as following DMC review of safety data and assessment of dose effects on Hgb levels.  
In addition, in this study, during the first 6-week treatment period for a 70 kg subject receiving 
the starting dose at 45 mg, the sotatercept (ACE-011) exposure (Cmax, day 1-43 and AUC1-43) is 
projected to be approximately 10% lower than the exposure for the dose regimen of 0.5 mg/kg 
once every 4 weeks.  Afterwards, safety measures (Hgb and blood pressure) will be used to guide 
the adjustment of the second dose and beyond.  Thus, the use of the 45 mg starting dose in the 
current study is not anticipated to significantly compromise subject safety.  
In this study, the 45 mg group will have the highest starting dose, and it may be titrated up to 
61.0 mg for the last dose (Dose 4).  Assuming a 70 kg subject who receives the maximal amount 
of dose during the entire study (i.e., starting at 45 mg followed by dose escalation every 6 weeks 
to 50.0, 55.0, and 61.0 mg for Doses 2, 3, and 4, respectively), the projected cumulative AUC 
during the treatment period (168 days) would be approximately 60% of the steady state AUC 
cumulated during the same period at the NOAEL level of 1 mg/kg (given every 4 weeks for a 
Page 419 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
48
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
total of 6 doses) as reported in the 9-month, repeat-dose toxicity study in monkeys.  The
projected highest Cmax for the current study would be less than 50% of the steady state Cmax in 
the monkey study.  
4.2.4.
Evaluation of Dosing Schema via Modeling/Simulation
The performance of the proposed dosing schema (three fixed starting dose levels, 6-week dosing 
interval, and dose adjustment rules [see Section 4.1.1 for details]) for this study was evaluated 
via PK/pharmacodynamic modeling/simulation.  A tentative mechanistic PK/pharmacodynamic
model for Hgb was developed using PK and Hgb data from healthy postmenopausal women and 
the model was extended to include MM subjects as a sub-population.  The model was required to 
appropriately reproduce the observed PK and Hgb profiles in MM subjects.  Monte Carlo 
simulations of the Hgb response to sotatercept (ACE-011) in a hypothetical anemic population 
(6.5 ≤ baseline Hgb < 11 g/dL; body weight 47 – 108 kg) were performed using the model 
parameterized with preliminary PK and pharmacodynamic parameters from MM subjects.  In 
this simulation analysis, efficacy refers to an Hgb increase > 1 g/dL from the baseline for 28 
consecutive days while safety refers to both the absolute Hgb levels and the rate of Hgb increase.  
The simulation predicts that the desired efficacy would be achieved 6 weeks after the second 
dose in approximately 70% subjects of the 45 mg group and 6 weeks after the last dose in >70% 
subjects of the 30 mg group.  Further, the simulation predicts the Hgb level would be maintained 
under 12 g/dL in 90% subjects and under 13 g/dL in 95% of subjects during the course of the 
study (Figure 2).  No subjects are predicted to have a Hgb level above the upper limit of the 
normal range for Hgb (16 g/dL).  Approximately 6% subjects are predicted to have an Hgb rise 
> 2 g/dL within 28 days of the first dose, mostly from the 45 mg group (4%); however, the 
fraction of subjects with an Hgb rise > 3 g/dL per 28 days is predicted to be similar between the 
three dose groups (approximately 2.5% for each group).  
Figure 2:
Simulated Hemoglobin Response in the Hypothetical Anemic Population
Time (days)
0
50
100
150
200
250
300
Hb (g/dL)
6
8
10
12
14
Time (days)
0
50
100
150
200
250
300
6
8
10
12
14
Time (days)
0
50
100
150
200
250
300
6
8
10
12
14
Starting dose = 15 mg
Starting dose = 30 mg
Starting dose = 45 mg
The middle solid lines represent the median Hgb level.  The top and bottom solid lines represent the Hgb level at 5% 
and 95% percentile, respectively.  The area between 5% and 95% percentiles represents 90% prediction interval.  
The straight dot lines represent the Hgb level of 12 g/dL.  The arrows indicate the dosing time of sotatercept (ACE-
011).  The two level dose reductions upon ≥ 3 g/dL increase sustained for 28 days of a dose (Table 5) was not 
included in the simulation.  
Page 420 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
49
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
4.3.
Study Duration
To evaluate sequence and study timelines, please see the Table of Events (see Section 5).  
Approximately 60-90 subjects with selected metastatic solid tumor types in Part 1 and 750
subjects with metastatic NSCLC in Part 2 will be randomized prior to receiving the fifth cycle of 
platinum-based chemotherapy..  Each subject will be on the study for approximately 12 – 15 
months (including the Screening Period, the Treatment Period, and the Post Treatment Follow-
Up Period).  The Treatment Period is approximately 6 to 9 months (four to six doses of 
sotatercept [ACE-011] every 42 days) with a Post Treatment Follow-Up Period of six months
from the subjects’ last dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.  
Subjects who discontinue treatment early will still continue to the Post Treatment Follow-Up 
Period for six months from their last dose of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo.  
All subjects will continue to be followed for TTP and PFS up to 12 months from their first dose 
of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo or until progression of their
metastatic disease, whichever comes first.  All subjects will continue to be followed for survival 
up to 24 months from their first dose of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo.
Page 421 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
50
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
5.
TABLE OF EVENTS
Table 7:
Sotatercept (ACE-011) Schedule of Assessments
Treatment Period
Screening 
Period
Sotatercept (ACE-011)
Dose 1 Schedule
(± 3 days)
Sotatercept (ACE-011)
Subsequent
Doses 2  through 6 Schedule
(± 3 days)
Post Treatment Follow-Up Period
(± 1 week)
Survival
(±1wk)
Assessments
Day -28
to
Day -1
D1
D8
D15 D22 D29
D43/
D1
D8
D15 D29
D43 
Post Last 
Dose/End 
of Study
Txt
1
Month
2
Month
3
Month
4
Month
5
Month
6
Month/
Study
DCu
Survival
Informed Consent
X
Inclusion/Exclusion Criteria
X
Complete Medical History
X
Cancer History and Prior Therapiesa
X
Prior ESA and RBC transfusion historya
X
X
Clinical visits (*study treatment visit)
X
X*
X
X
X*
X
X
X
X
X
X
X
X
ECOG Performance Status
X
X
X
X
X
X
X
X
X
X
X
X
Vital Signs / Blood Pressureb
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Height (at randomization only)/Weight
X
X
X
X
X
X
X
X
X
X
X
X
X
12-Lead Electrocardiogram (ECG) –
Part 1c
X
X
X
X
X
12-Lead Electrocardiogram (ECG) –
Part 2c
X
X
X
Pregnancy Testingd
X
X
X
X
X
X
X
Xd
Page 422 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
51
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
Table 7:
Sotatercept (ACE-011) Schedule of Assessments (Continued)
Treatment Period
Screening 
Period
Sotatercept (ACE-011)
Dose 1 Schedule
(± 3 days)
Sotatercept (ACE-011)
Subsequent
Doses 2  through 6 Schedule
(± 3 days)
Post Treatment Follow-Up Period
(± 1 week)
Survival
(±1wk)
Assessments
Day -28
to
Day -1
D1
D8
D15 D22 D29
D43/
D1
D8
D15 D29
D43 
Post Last 
Dose/End 
of Study
Txt
1
Month
2
Month
3
Month
4
Month
5
Month
6
Month/
Study
DCu
Survival
Hematologye
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Absolute Reticulocyte Counte
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Serum Chemistryf
X
X
X
X
X
X
X
X
X
X
X
X
X
Serum Creatinine and Creatinine 
Clearanceg
X
X
X
X
X
X
X
X
X
X
X
X
X
Serum Iron, TIBC, Transferrin and Serum 
Ferritin, Vitamin B12 and RBC Folate 
Levelsh
X
Xh
X
Serum Erythropoietin (**Full PK subjects 
post first dose only)i
X
X
X**
X
X** X**
X
Xi
X
X
Urinalysis and Renal Biomarkersj
X
X
X
X
X
X
X
X
X
X
X
X
FSH and LH – Males and Females
X
X
X
X
X
X
X
X
Dihyroepiandosterone and Testosterone 
(Free & Total) - Males Only 
X
X
X
X
X
X
X
X
Estrogen and Estradiol & Menstrual 
Status - Females Only
X
X
X
X
X
X
X
X
TSHk
X
X
Xk
X
Page 423 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
52
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
Table 7:
Sotatercept (ACE-011) Schedule of Assessments (Continued)
Treatment Period
Screening 
Period
Sotatercept (ACE-011)
Dose 1 Schedule
(± 3 days)
Sotatercept (ACE-011)
Subsequent
Doses 2  through 6 Schedule
(± 3 days)
Post Treatment Follow-Up Period
(± 1 week)
Survival
(±1wk)
Assessments
Day -28
to
Day -1
D1
D8
D15 D22 D29
D43/
D1
D8
D15 D29
D43 
Post Last 
Dose/End 
of Study
Txt
1
Month
2
Month
3
Month
4
Month
5
Month
6
Month/
Study
DCu
Survival
Sotatercept (ACE-011) drug antibody test
(pre-dose)
X
X
X
X
X
X
Bone Biomarkers (BSAP, OC, P1NP, 
CTX, TRACP-5b and uNTX)l
(**Full PK subjects post first dose only)
X
X** X**
X** X**
X
X
X
Bone Imaging (DXA)m (Optional in 
Selected Centers)
X
X
Activin A and other proteins/biomarkers 
in blood (serum) (pre-dose study 
treatment in a subset of subjects)
X
X
X
X
Activin and other proteins/biomarkers in 
archival tumor tissue (Part 2 only -
optional)
X
Pharmacokinetics–
Part 1 and Part 2)n
Refer to Table 8 and Table 9 – Schedule of Pharmacokinetic Assessments
Tumor Assessmentso
Xo
< Every 9 weeks or as per standard of care at study site
QoL Assessment
(LCSS and FACIT Fatigue Scale)p
X
X
X
X
X
X
X
X
X
X
X
X
X
Adverse Events
X
All AEs regardless of causality up to 6 weeks (42 days) post last dose of study treatment, after day 43 of last dose 
only AEs assessed as related to study treatment are to be reported
Concomitant Medications
(including ESAs and transfusions)
X
X
X
X
X
X
X
X
X
Page 424 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
53
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
Table 7:
Sotatercept (ACE-011) Schedule of Assessments (Continued)
Treatment Period
Screening 
Period
Sotatercept (ACE-011)
Dose 1 Schedule
(± 3 days)
Sotatercept (ACE-011)
Subsequent
Doses 2  through 6 Schedule
(± 3 days)
Post Treatment Follow-Up Period
(± 1 week)
Survival
(±1wk)
Assessments
Day -28
to
Day -1
D1
D8
D15 D22 D29
D43/
D1
D8
D15 D29
D43 
Post Last 
Dose/End 
of Study
Txt
1
Month
2
Month
3
Month
4
Month
5
Month
6
Month/
Study
DCu
Survival
Concomitant Procedures
X
X
X
X
X
X
X
X
X
Hospitalizations (Record)
X
X
X
X
X
X
X
X
X
Randomization
X
Administer 
Sotatercept (ACE-011)/Perform Drug 
Accountabilityq
X
X
Platinum-based Chemotherapyr
X
Dosing of allowed regimen(s) per standard practice
Maintenance Therapys
Dosing of allowed regimen(s) per standard practice
Overall Survivalv
X
Post Treatment Anti-Neoplastic Therapy
X
X
X
X
X
X
X
X
aInclude cancer history, date of original diagnosis, clinical stage at Screening and date of metastases and metastatic site involvement.  Record prior ESA history,
starting at selected solid tumor diagnosis .  Record RBC transfusion history, starting from diagnosis of metastatic disease, at a minimum of two months prior to 
randomization.  
bVital signs (including heart rate, seated blood pressure, and temperature) will be measured at Screening and all subsequent clinical visits, on Day 29 post 
sotatercept (ACE-011) or sotatercept (ACE-011)/ placebo dose, at Treatment Discontinuation, and at Study Discontinuation.  Blood pressure should be 
confirmed by two measurements obtained five minutes apart Investigators are to report any clinically significant abnormal findings as adverse events.  
Page 425 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
54
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
cECG to be performed as follows:  For Part 1:  At Screening,   Day 1 Dose 1 pre and post sotatercept (ACE-011) dose,  Day 8 post dose 1, every sotatercept 
(ACE-011) dosing Visit (post-dose) and at end of study treatment (day 43 post last dose).  
For Part 2:  At Screening, Day 1 Dose 1 pre and post sotatercept (ACE-011)/placebo dose and at end of study treatment (day 43 post last dose).  
dFemales of childbearing potential (FCBP) only:  A female of childbearing potential is a sexually mature woman who has not undergone a hysterectomy or who 
has not been postmenopausal for at least 24 consecutive months (i.e. who has had menses at some time in the preceding 24 months).  A medically supervised
pregnancy test with a minimum sensitivity of 25mIU/ml must be performed within 3 days prior to the start of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo administration (Day 1) once the subject has been on effective contraception for at least 28 days and be performed within 3 days prior to dose 
administration of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo during the Treatment Period.  Subjects must agree to use highly effective birth 
control measures (e.g., oral contraceptives or two forms of barrier method birth control) during study participation and for at least 112 days following the last 
dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.  Pregnancy test will be performed at Study Discontinuation if date is ≤112 days following 
the last dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.  
eHematology laboratory evaluations (RBC count, Hgb, HCT, WBC count and differential, ANC, MCV, platelet count and reticulocyte count).  Hemoglobin 
should be tested prior to dosing with sotatercept (ACE-011) or sotatercept (ACE-011)/placebo to ensure levels are within normal limits and that sotatercept 
(ACE-011) dose modification rules are followed as outlined in Section 4.1.1.  Any laboratory evaluations may be repeated more frequently if clinically 
indicated.  In addition, RBC, Hgb, and reticulocyte counts will be included at each timepoint within the full PK assessment (Part 1).  
fSerum chemistry laboratory evaluations (sodium, potassium, chloride, CO2 (bicarbonate), calcium, magnesium, phosphorus, BUN, creatinine, glucose, amylase, 
lipase, albumin, total protein, alkaline phosphatase, bilirubin [total and direct], AST/SGOT, ALT/SGPT, LDH and uric acid) if clinically significant any or all 
laboratory evaluations may be reported as AE and repeated more frequently.  
gCreatinine clearance (per Cockcroft-Gault formula) every 2 weeks during the Treatment Period, every month (except month 1) during the Post Treatment 
Follow-Up Period and at study discontinuation .  
hSerum Iron, TIBC, Transferrin, Serum Ferritin, Vitamin B12 and RBC Folate to be performed at Screening, pre-last dose of sotatercept (ACE-011) or
sotatercept (ACE-011)/placebo and end of study treatment (day 43 post last dose).  
iErythropoietin – collected at day 15 following first 2 doses of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.  For full PK assessment, weekly after 
first dose of sotatercept (ACE-011).  
jUrine collection for:  Urine albumin, urine albumin creatinine ratio, urine protein creatinine ratio and other renal biomarkers of glomerular and/or tubular injury.  
kTSH – collected at screening, on Day 1 of only the first and second dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo and at 2 month post-
treatment follow-up visit. 
lBone Biomarkers- Collected for full PK subjects prior to dose 1, weekly following dose 1, prior to dose 2 ,  post last dose day 43 and month 3 post treatment 
follow-up visit.  For all other subjects collected prior to dose 1,  prior to dose 2 ,  post last dose day 43 and month 3 post treatment follow-up visit.  Biomarker 
serum samples should be consistently collected early morning. The urine sample should not be from the first morning void.  
mDual Energy X-ray Absorptiometry (DXA) scan of lumbar spine and hip to evaluate overall health on approximately 200 subjects at selected US site(s).  
Performed at Screening, and Month 3 during the Post Treatment Follow-Up Period.  
Page 426 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
55
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
nPharmacokinetics (Part 1):  Blood samples will be collected to evaluate the blood or serum concentrations of sotatercept (ACE-011).  Approximately 10 
subjects at each sotatercept (ACE-011) dose level, 15, 30 and 45 mg, will have full PK sampling.  In addition, RBC, Hgb, and reticulocyte counts will be 
collected at each time point (excluding the 4-hour time point on Day 1) from Day 1 to Day 43 after the first dose within the full PK assessment.  Subjects not 
participating in the optional full PK assessment may participate in the sparse PK assessment. 
Pharmacokinetics (Part 2):  Sparse PK blood samples will be collected to evaluate the blood or serum concentrations of sotatercept (ACE-011) in 
approximately 300 (40%) of 750 subjects.  Sotatercept (ACE-011) doses 5 and 6 will have pre-dose Day 1 PK (if applicable).  
REFER TO Table 8 and Table 9, SCHEDULE OF PHARMACOKINETIC ASSESSMENTS.  
oTumor assessments:  Screening Period tumor assessments may be performed within six weeks or as per study site standard of care prior to randomization.  Also, 
historical tumor assessment data, from prior to the initiation of platinum-based chemotherapy through the Screening Period, will be collected.  Following 
randomization, tumor assessments will be performed ≤every 9 weeks or per standard of care at the study site, starting from the date of the previous (screening
period) tumor assessment and following the chemotherapy schedule.  
pQoL assessments, FACIT Fatigue Scale (Version 4) – all subjects and LCSS questionnaire – only subjects with NSCLC, to be completed by the subject upon 
arrival at clinic and prior to any study procedures or testing at all visits, as indicated in the schedule, and at Study Discontinuation/One-Year Follow-Up Visit.  
qSotatercept (ACE-011) or sotatercept (ACE-011)/placebo dosing repeats every 42 days and will start after the subject begins an every 3 week platinum-based 
chemotherapy regimen.  The first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo may be given at any time following the first dose of 
first-line platinum-based chemotherapy.  Subsequent doses of Sotatercept (ACE-011) or sotatercept (ACE-011)/placebo can be administered at any time 
point during the chemotherapy cycle. 
Administration of subsequent cycles of chemotherapy, including dose reductions and dose delays, should not affect the sotatercept (ACE-011) or sotatercept 
(ACE-011)/placebo dosing schedule, unless determined to be necessary by the Investigator.  If there is a chemotherapy dose delay, sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo administration does not need to be delayed until start of next chemotherapy cycle. 
rPlatinum-based chemotherapy is to be administered based on guidelines for administration according to manufacturer’s recommendations and standard clinical 
practice.  Type of chemotherapy and dosing will be recorded.  
sPemetrexed or erlotinib maintenance therapy is to be administered based on guidelines for administration according to manufacturer’s recommendations and 
standard clinical practice.  
tDay 43 (6 weeks) post last dose corresponds to the end of Treatment Period.  Subjects who discontinue the sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo Treatment Period early will continue to the Post Treatment Follow-Up Period and be followed for up to 6 months after their last dose of 
sotatercept (ACE-011)/placebo.  
uStudy Discontinuation visit should occur 12 months after starting treatment with sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.
vSurvival data will be collected monthly, via telephone contact, following the Study Discontinuation visit for an additional 12 months (up to 24 months after first 
dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo).  
Page 427 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
56
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
Table 8:
Schedule of Pharmacokinetic Assessments (Part 1)
Scheduled Time
Time relative to 
Sotatercept (ACE-011)
Part 1a,b
Collection 
Windowe
Full PKc
Sparse PKd
Dose 1, D1
pre-Dose 1
X
X
-2  to  0 hour
Dose 1, D1
4 hours after Dose 1
X
X
±1 hour
Dose 1, D5
4 days after Dose 1
X
-
± 1 day
Dose 1, D8
7 days after Dose 1
X
X
± 1 day
Dose 1, D11
10 days after Dose 1
X
-
± 1 day
Dose 1, D15
14 days after Dose 1
X
X
± 1 day
Dose 1, D22
21 days after Dose 1
X
-
± 1 day
Dose 1, D29
28 days after Dose 1
X
X
± 1 day
Dose 1, D36
35 days after Dose 1
X
-
± 1 day
Dose 1, D43 (Dose 2, D1)
pre-Dose 2
X
X
± 2 days
Dose 2, D8
7 days after Dose 2
X
-
± 2 days
Dose 2, D15
14 days after Dose 2
X
-
± 2 days
Dose 2, D43 (Dose 3, D1)
pre-Dose 3
X
X
± 2 days
Dose 3, D8
7 days after Dose 3
X
-
± 2 days
Dose 3, D15
14 days after Dose 3
X
-
± 2 days
Dose 3, D43 (Dose 4, D1)
pre-Dose 4
X
X
± 2 days
Dose 4, D8
7 days after Dose 4
X
-
± 2 days
Dose 4, D15
14 days after Dose 4
X
-
± 2 days
Dose 4, D29
28 days after Dose 4
X
-
± 3 days
Last Dose, D43 
42 days after final dose 
X
X
± 3 days
PTf Follow up, 1 month
72 days after final dose
X
-
± 1 week
PT Follow up, 2 month
102 days after final dose
X
-
± 1 week
PT Follow up, 3 month
132 days after final dose
X
X
± 1 week
PT Follow up, 4 month
162 days after final dose
X
-
± 1 week
PT Follow up, 5 month
192 days after final dose
X
X
± 1 week
a Notes about PK sampling times:

For subjects participating in full PK sampling, RBC, Hgb and reticulocyte counts will be collected at each 
time point (excluding the 4-hour time point on Day 1) from Day 1 to Day 43 post first sotatercept (ACE-
011) dose.  Erythropoietin and bone biomarkers will be collected at D1, D8, D15, D22, D29, and D43 post 
first sotatercept (ACE-011) dose.  If the time points for RBC, Hgb, reticulocyte, erythropoietin and bone 
biomarkers overlap with the time points defined in Table 7, only one sample is required.  

For subjects who discontinue the treatment early, PK blood sample collection will be continued during the 
follow-up period.  
bAt each time point, collect approximately 2 mL of blood.  After collection, allow the blood to clot at room 
temperature for approximately 1 hour and then centrifuge the blood sample at room temperature for 10 min (1100-
1300 g) to obtain serum.  
cTo be collected for approximately 30 subjects (approximately 10 subjects in each dose group).  
dTo be collected in subjects participating in sparse PK sampling and not participating in full PK sampling.  
eFor subjects who participate in full PK sampling only.  The collection window for sparse PK samples will be the 
same as the visit window defined in Table 7.  
fPT = Post Treatment
Page 428 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
57
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
Table 9:
Schedule of Pharmacokinetic Assessments (Part 2)
Scheduled Time
Time relative to 
Sotatercept (ACE-
011)/placebo dose
Sparse PKa,b,c
Collection Windowd
Dose 1, D1
pre-Dose 1
X
-2  to  0 hour
Dose 1, D1
4 hours after Dose 1
X
±1 hour
Dose 1, D8
7 days after Dose 1
X
± 3 day
Dose 1, D15
14 days after Dose 1
X
± 3 day
Dose 1, D29
28 days after Dose 1
X
± 3 day
Dose 1, D43 (Dose 2, D1)
pre-Dose 2
X
± 3 days
Dose 2, D43 (Dose 3, D1)
pre-Dose 3
X
± 3 days
Dose 3, D43 (Dose 4, D1)
pre-Dose 4
X
± 3 days
Dose 4, D43 (Dose 5, D1)
pre-Dose 5 
X
± 3 days
Dose 5, D43 (Dose 6, D1)
pre-Dose 6 
X
± 3 days
PTe Follow up, 3 month
132 days after final dose
X
± 1 week
PT Follow up, 5 month
192 days after final dose
X
± 1 week
a For subjects who discontinue the treatment early, PK blood sample collection will be continued during the follow-
up period.  
bAt each time point, collect approximately 2 mL of blood.  After collection, allow the blood to clot at room 
temperature for approximately 1 hour and then centrifuge the blood sample at room temperature for 10 min (1100-
1300 g) to obtain serum.  
cTo be collected for approximately 300 (40%) of 750 subjects (approximately 150 subjects in each arm).
dExcept for Day 1 (Dose 1, D1), the collection window will be the same as the visit window defined in Table 7.  
ePT = Post Treatment
Page 429 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
58
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
6.
PROCEDURES
Screening Period (Day -28 to Day -1)
Prior to screening, subjects must sign an informed consent.  Potentially protocol-eligible subjects 
will be evaluated for the inclusion and exclusion criteria for the Treatment Period of this study.  
All screening assessments must be completed ≤ 28 days prior to randomization.  Screening 
period tumor assessments and tumor evaluation documentation, as per RECIST criteria (Version 
1.1) (Appendix A), must be performed within 6 weeks prior to randomization or as per study site 
standard of care.  Historical tumor assessment data, from prior to the initiation of platinum-based 
chemotherapy through the screening period, will be collected.  Hematology and chemistry 
laboratory assessments should be performed ≤14 days of randomization.  
The assessments and procedures that will be performed during the Screening Period are outlined 
in the Table of Events (see Section 5) and include:

Informed consent

Assessment of inclusion / exclusion criteria

Complete medical history including history of cardiac, renal and thromboembolic 
events

Cancer history, including date of original diagnosis, histopathology, clinical stage at 
screening, date of metastatic stage and site involvement

Prior ESA treatment history starting from initial diagnosis of one of the selected solid 
tumors

RBC transfusion history starting from diagnosis of metastatic disease at a minimum 
of up two months prior to randomization

ECOG performance status

Vital signs including height, weight, heart rate, seated systolic and diastolic blood 
pressure, and temperature.  

12-lead electrocardiogram (ECG)  

Medically supervised pregnancy test, with a minimum sensitivity of 25 mIU/ml, for
females of childbearing potential (FCBP) to be assessed within 3 days prior to 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo administration

Serum chemistry, hematology, absolute reticulocyte count to be assessed within 14 
days of randomization

Creatinine clearance (per Cockroft-Gault formula) within 14 days prior to study 
treatment administration

Serum iron, total iron binding capacity (TIBC), transferrin and serum ferritin

Vitamin B12 and RBC folate levels
Page 430 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
59
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011

Serum erythropoietin

Urinalysis

FSH (include current menstrual cycle status for pre-menopausal female subjects) and 
LH – both males and females 

Dihyroepiandosterone and Testosterone (free and total) – males only

Estrogen and estradiol – females only

TSH

Bone imaging – DXA scan (optional at selected sites)

Tumor Assessment - Screening period tumor assessments and tumor evaluation 
documentation, as per RECIST criteria (Version 1.1), must be performed within 6
weeks or as per study site standard of care prior to randomization.  Also, historical 
tumor assessment data, from prior to the initiation of platinum based chemotherapy 
through the screening period, will be collected.  

QoL Assessment (FACIT Fatigue Scale [Version 4]) – all subjects

LCSS questionnaire – only subjects with NSCLC  

Documentation of concomitant medications / procedures / hospitalizations

Documentation of concomitant platinum-based chemotherapy
Treatment Period (Day 1/Dose 1 of study treatment to Day 43 post last study treatment 
dose)
Results from screening evaluations must be reviewed prior to randomization to confirm subject 
eligibility.  
In Part 1 (the dose-ranging portion of the study), subjects who meet all eligibility criteria will be 
randomized utilizing IVRS to receive one of the following sotatercept (ACE-011) dose levels, 
with 10-30 subjects per arm:

Sotatercept (ACE-011) 15 mg SC

Sotatercept (ACE-011) 30 mg SC
Analysis of safety data will be performed following the treatment of at least 10 subjects at the 15 
mg dose level and 10 subjects at the 30 mg dose level, with each subject having received a 
minimum of one dose of sotatercept (ACE-011) and completed a 12-week follow-up period from 
the first dose. 
Following this analysis, the addition of a third dose level:

Sotatercept (ACE-011) 45 mg SC
to the randomization schema will be determined.
Each dose level will be administered every 42 days for up to four doses.  
Page 431 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
60
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011

In Part 2, subjects meeting all inclusion and exclusion criteria will enter into the 
Treatment Period and be randomized by a double-blind procedure utilizing IVRS to 
receive sotatercept (ACE-011) or placebo (1:1 ratio).  

A subject will be considered randomized once a unique multi-digit subject 
identification number has been assigned by IVRS.  
Following randomization, subjects will receive SC doses of sotatercept (ACE-011) or sotatercept 
(ACE-011)/placebo every 42 days during the Treatment Period, as specified in the Table of 
Events (see Section 5).  
In Part 1, the Treatment Period will last approximately 6 months, where subjects randomized to 
sotatercept (ACE-011) will receive treatment on Day 1 every 42 days for a planned 4 doses.  
In Part 2, the Treatment Period will last approximately 6 to 9 months, where subjects 
randomized to sotatercept (ACE-011)/Placebo will receive treatment on Day 1 every 42 days for 
a planned 4 doses with an additional 2 doses of sotatercept (ACE-011)/placebo allowable, at the 
discretion of the Investigator, for a total of up to 6 doses.  
The assessments and procedures that will be performed during the Treatment Period are outlined 
in the Table of Events (see Section 5).  

Updated prior ESA and RBC transfusion history which may have occurred between 
the screening visit and randomization

ECOG performance status

Vital signs including weight, heart rate, seated systolic and diastolic blood pressure, 
and temperature

ECG 

Medically supervised pregnancy test, with a minimum sensitivity of 25 mIU/ml, for 
FCBP within 3 days prior to sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo administration.  

Serum chemistry, hematology, absolute reticulocyte count.  

Hematology laboratory evaluations (RBC count, Hgb, HCT, WBC count and 
differential, mean corpuscular volume [MCV], absolute neutrophil count [ANC], 
platelet count and reticulocyte count) will be collected weekly after the first dose 
of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo and at subsequent 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo doses collected at 7, 14
days and 28 days post-dose.

Within full PK assessment, RBC, Hgb and reticulocyte counts are collected at 
each time point; erythropoietin and bone biomarkers at weekly intervals post first 
dose of study treatment.  

Creatinine clearance will be assessed every 14 days.  

Serum iron, total iron binding capacity (TIBC), transferrin and serum ferritin at last 
dose and 43 days after last dose of study treatment
Page 432 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
61
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011

Vitamin B12 and RBC folate levels at last dose and 43 days after last dose of study 
treatment

Serum erythropoietin

Urinalysis

FSH (include current menstrual cycle status for premenopausal female subjects) and 
LH – both males and females 

Dihyroepiandosterone and Testosterone (free and total)– males only 

Estrogen and estradiol – females only 

TSH  

Serum for sotatercept (ACE-011) drug antibody test (pre-dose on the day of 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo administration)

Bone or other potential mechanistic or disease-related proteins/biomarkers 

Activin A and other sotatercept (ACE-011)-related proteins/biomarkers

in blood, including myostatin and follistatin:
o
pre- dose on Day 1 and Day 8 after first dose of sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo
o
pre-dose on Day 1 subsequent dosing visits

in archival tumor tissue (Part 2 only)

Tumor Assessment and Response Evaluation, as per RECIST criteria (Version 1.1), 
(performed ≤every 9 weeks or per standard of care at the study site, starting from the 
previous [screening] tumor assessment) and following the chemotherapy schedule

Pharmacokinetics

QoL Assessment (FACIT Fatigue Scale [Version 4]) – all subjects

LCSS questionnaire – only subjects with NSCLC  

Evaluation and all AE/SAE reporting (regardless of causality)

Documentation of concomitant medications / procedures (including use of ESAs and 
all transfusions) / hospitalizations

Documentation of concomitant platinum-based chemotherapy and/or maintenance 
therapy

Administration of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo at:  Day 1 
every 42 days 
Subjects who discontinue from the Treatment Period early will enter the Post Treatment Follow-
Up Period and be followed for 6 months after their last dose of sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo.  Upon completion of the Post Treatment Follow-Up Period, 
Page 433 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
62
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
subjects will have a discontinuation visit and be followed for survival for up to 24 months from 
their first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.  
Post Treatment Follow-Up Period (Day 43 post last dose of study treatment to six months 
post last dose of study treatment)
Following completion or early discontinuation from the Treatment Period, subjects will enter the 
Post Treatment Follow-Up Period and continue to be followed for 6 months after their last dose 
of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo. Visits will occur every month.  The 
assessments and procedures that will be performed during this period are outlined in the Table of 
Events (see Section 5) and include:

ECOG performance status

Vital signs including weight, heart rate, seated systolic and diastolic blood pressure,
and temperature.  

ECG – end of study treatment (day 43 post last dose)

Medically supervised pregnancy test, with a minimum sensitivity of 25mIU/ml, for 
FCBP

Serum chemistry, hematology, absolute reticulocyte count

Creatinine clearance 

Serum iron, total iron binding capacity (TIBC), transferrin and serum ferritin – end of 
study treatment (at day 43 post last dose)

Vitamin B12 and RBC folate levels – end of study treatment (at day 43 post last dose)

Serum erythropoietin

Urinalysis

FSH (include current menstrual cycle status for pre-menopausal female subjects) and 
LH – both males and females 

Dihyroepiandosterone and Testosterone (free and total)– males only 

Estrogen and estradiol – females only

TSH (at 2 month end of treatment follow-up visit)

Serum for sotatercept (ACE-011) drug antibody test (pre-sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo dose)

Bone or other potential mechanistic or disease-related proteins/biomarkers 

Bone imaging – DXA scan (optional at selected sites-performed at 3 month end of 
treatment follow-up visit)

Activin A and other sotatercept (ACE-011) related proteins/biomarkers, including 
myostatin and follistatin, in blood at 1 month end of treatment follow-up visit)

Pharmacokinetics
Page 434 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
63
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011

Tumor Assessment and Response Evaluation, as per RECIST criteria (Version 1.1), 
(performed ≤every 9 weeks or as per standard of care at the study site, and following 
the chemotherapy schedule

QoL Assessment (FACIT Fatigue Scale (Version 4)) – all subjects

LCSS questionnaire – only subjects with NSCLC  

Evaluation and reporting of all AEs regardless of causality (up to 6 weeks after last 
dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo).  After 6 weeks 
post last dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo, only AEs 
assessed as related to sotatercept (ACE-011) or sotatercept (ACE-011)/placebo or 
study related procedures are to be reported.  

Documentation of concomitant medications / procedures (including use of ESAs and 
all transfusions) / hospitalizations

Post-Treatment Anti-Neoplastic Therapy
Study Discontinuation 
Study Discontinuation is the final scheduled visit for this study and should be performed for all 
enrolled subjects.  
Subjects who discontinue from treatment early will enter the Post Treatment Follow-Up Period 
and be followed for 6 months from their last dose of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo.  Follow-up for twelve months for TTP and PFS will be performed from the 
subject’s first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/Placebo.  Following the 
Study Discontinuation Visit, subjects will be contacted monthly and survival data collected for 
an additional 12 months (up to 24 months following the subject’s first dose of sotatercept (ACE-
011) or sotatercept (ACE-011)/placebo).  
The assessments and procedures that will be performed during the Study Discontinuation Visit 
are outlined in the Table of Events (see Section 5) and include:

ECOG performance status

Vital signs including weight, heart rate, seated systolic and diastolic blood pressure, 
and temperature

Medically supervised pregnancy test, with a minimum sensitivity of 25 mIU/ml, for 
females of childbearing potential (FCBP) – if Study Discontinuation date is ≤ 112 
days following the last dose of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo.  

Serum chemistry, hematology, absolute reticulocyte count

Creatinine clearance 

Urinalysis 

FSH (include current menstrual cycle status for pre-menopausal female subjects) and 
LH – both males and females 

Estrogen and estradiol – females only
Page 435 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
64
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011

Dihyroepiandosterone and Testosterone (free and total) – males only

Tumor Assessment and Response Evaluation, as per RECIST criteria (Version 1.1)
(PFS at 12 months)

QoL Assessment (FACIT Fatigue Scale (Version 4)) – all subjects

LCSS questionnaire – only subjects with NSCLC  

Evaluation and reporting of all AEs regardless of causality (up to 6 weeks after last 
dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo).  After 6 weeks 
post last dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo, only AEs 
assessed as related to sotatercept (ACE-011) or sotatercept (ACE-011)/placebo or 
study related procedures are to be reported.

Documentation of concomitant medications / procedures (including use of ESAs and 
all transfusions) / hospitalizations

Post-Treatment Anti-Neoplastic Therapy
Survival Follow-Up Period:
Monthly collection of survival data will begin following the Study Discontinuation Visit and 
continue for an additional 12 months (up to 24 months after first dose of sotatercept (ACE-011)
or sotatercept (ACE-011)/placebo).  

Overall survival

Post-Treatment Anti-Neoplastic Therapy
Additional Procedure Descriptions:
Central ECG
Part 1 – ECGs will be performed and read per Central ECG vendor.  
Part 2 – ECGs will be performed locally and read per Central ECG vendor.  
Please refer to vendor manual for procedures.  
Clinical Laboratory Evaluations
Clinical laboratory evaluations (serum chemistry, hematology, absolute reticulocyte count, 
creatinine clearance, serum iron, total iron binding capacity, transferrin and serum ferritin, serum 
erythropoietin, vitamin B12, serum RBC folate levels, urinalysis, FSH, LH, 
dihyroepiandosterone, estrogen, estradiol, testosterone and serum thyroid-stimulating hormone)
will be performed by a central laboratory.  
Please refer to vendor manual for procedures.  
Note:  Local laboratory assessments are allowed in cases when timely results are needed (e.g.,
randomization, study treatment and chemotherapy dosing decisions, hematology assessments 
between clinic visits).  Whenever possible a “split” sample should also be forwarded to the 
central laboratory for analysis. Local laboratory data should be collected in the eCRF.  
Page 436 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
65
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
Exploratory Biomarkers
Analyses will be undertaken to evaluate the expression of Activin A and other 
proteins/biomarkers related to sotatercept (ACE-011) mechanism of action in blood (including 
myostatin and follistatin) and in archival tumor tissue in a subset of subjects (Part 2 only).  
Renal function biomarkers via urinalysis measuring urine albumin / creatinine ratio, urine
protein / creatinine ratio and other biomarkers of glomerular and/or tubular injury - urine kidney 
injury molecule-1 (KIM-1), urine trefoil factor 3 (TTF3), urine cystatin C and + or – urine β2-
microglobulin will be evaluated in all subjects.  
Pharmacokinetics

Part 1 -Blood samples will be collected to evaluate the full PK profile of sotatercept 
(ACE-011) from approximately 30 subjects at select centers (approximately 10 
subjects for each sotatercept [ACE-011] dose group).  For full PK sampling, subjects 
who miss more than two PK sampling time points from Days 1 through 43 will be 
replaced.  Subjects not participating in the optional full PK assessment may
participate in the sparse PK assessment. 

Part 2- Sparse PK blood samples will be collected from approximately 300 (40%) of 
750 subjects (approximately 150 subjects in each arm).  
For subjects who do not participate in either Part 1 full or sparse PK assessments or in Part 2 
sparse PK assessments, the ACE-011 (sotatercept) concentration may be determined in their anti-
sotatercept antibody samples to assist in the evaluation of immunogenicity, as well as PK.
Detailed PK sampling schedule is presented in Table 8 and Table 9: Schedule of 
Pharmacokinetic Assessments.  

PK samples must be collected predose on the day of sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo administration.  PK samples may be collected at any 
time on non-dosing days.  After collection, allow the blood to clot at room 
temperature for approximately one hour and then centrifuge the blood sample at room 
temperature for 10 minutes (1100-1300g) to obtain serum.  At each time point, 
approximately 2 mL or less blood will be collected.  
Bone Biomarkers
Bone biomarkers will be evaluated in all subjects.  The serum and urine bone biomarkers will 
include BSAP, OC, P1NP, CTX, TRACP-5b and uNTX.  Both serum and urine samples will be 
collected.  
Biomarker serum samples should be consistently collected early morning.  The urine sample 
should not be from the first morning void.  
Page 437 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
66
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
Bone Imaging - optional
DXA scan to evaluate overall bone health will be performed on approximately 200 subjects at 
select site(s).
Quality of Life Assessments
QoL Assessment (FACIT Fatigue Scale [Version 4]) will be completed by all subjects and LCSS 
questionnaire will be completed for subjects with NSCLC.  Each assessment will be completed 
by the subject upon arrival at clinic and prior to any study procedures or testing.  The LCSS 
consists of two scales: one for the patient (Patient Scale) and a counterpart for health 
professionals acting as observers (Observer Scale). 
Independent External Radiology Review (Part 2 Only)
At least 3 independent external radiologists (2 reviewers and 1 adjudicator) will perform a 
blinded, independent assessment of response, including the development of progressive disease 
(PD).  
Independent Review Committee (IRC) (Part 2 Only)
The IRC will review the tumor response data (to include results from the central radiologist and 
relevant clinical laboratory and physical examination findings) and the dates of disease 
progression for each subject.  These data reviewed by the IRC will be used in the primary 
analyses ORR, TTP and PFS for the Clinical Study Report.  
Page 438 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
67
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
7.
STUDY POPULATION
Subjects must be receiving their first regimen of first-line platinum-containing chemotherapy, 
given, every three weeks, for the treatment of a selected metastatic solid tumor at the time of 
randomization: metastatic NSCLC, metastatic small cell lung cancer, metastatic bladder cancer, 
metastatic head and neck cancer, and metastatic endometrial/cervical cancer, where the standard 
of care is first-line platinum-based chemotherapy. Subjects may have already received up to 4 
cycles of this current platinum-based regimen and must be randomized prior to receiving Cycle 
5.  It is expected that subjects be eligible to continue to receive ≥ 2 additional platinum-based 
chemotherapy cycles while on study treatment.  
Subjects must not have received any other regimens of platinum containing chemotherapy for the 
first-line treatment of metastatic solid tumors prior to the regimen they are receiving at the time 
of randomization.  
7.1.
Number of Subjects
This platinum-based CIA study will enroll approximately 840 subjects, approximately 90 
subjects with selected metastatic solid tumor types in Part 1 and 750 subjects with metastatic 
NSCLC in Part 2.  
In Part 1, up to 90 subjects will be randomized to receive one of the following sotatercept (ACE-
011) dose levels, with 10-30 subjects per arm:

Sotatercept (ACE-011) 15 mg SC

Sotatercept (ACE-011) 30 mg SC

Sotatercept (ACE-011) 45 mg SC
and will be stratified by:
1. Baseline Hgb level 

6.5 to < 9.0 g/dL

9.0 to < 11.0 g/dL
2. Type of platinum-based chemotherapy (cisplatin versus carboplatin)
In Part 2, an additional 750 subjects will be randomized to receive either sotatercept (ACE-011), 
at the dose determined in Part 1, or placebo at a ratio of 1:1.  Subjects will be stratified by:
1. Baseline Hgb level 

6.5 to < 9.0 g/dL

9.0 to < 11.0 g/dL
2. Type of platinum-based chemotherapy (cisplatin versus carboplatin)
3. NSCLC histology (Squamous NSCLC vs. Non-Squamous NSCLC)
4. ECOG Performance Status 0-1 vs. 2
Page 439 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
68
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
7.2.
Inclusion Criteria
Subjects must satisfy the following criteria to be enrolled in the study:
1. Men and women > 18 years of age at the time of signing the informed consent document.
2. Part 1 - Histologically confirmed (cytology or biopsy) solid tumor malignancy, including
metastatic non-small cell lung cancer (NSCLC), metastatic small cell lung cancer, 
metastatic bladder cancer, metastatic head and neck cancer, and metastatic 
endometrial/cervical cancer, where the standard of care is first-line platinum-based 
chemotherapy.
Part 2 - Histologically confirmed (cytology or biopsy) non-small cell lung cancer.
3. Documented metastatic disease
4. Measurable or non-measurable disease evaluable by RECIST criteria (Version 1.1)
(Appendix A).
5. All of the following laboratory values:

Hemoglobin ≥ 6.5 to < 11.0 g/dL (≥ 65 to < 110 g/L)

Absolute neutrophil count ≥ 500/mm3

Platelet count ≥ 75,000/mm3 (> 72 hours since prior platelet transfusion) 

Adequate renal function (creatinine clearance ≥ 40mL/min or ≥ 50 mL/min if 
cisplatin concomitantly administered)

Hepatic function (bilirubin < 1.5 x ULN; AST and ALT < 3.0 x ULN and ≤5.0 ULN 
for subjects with liver metastases)

Corrected calcium within normal limits (WNL), previous hypercalcemia treatment is 
allowed
6. Subjects may have received up to 4 cycles of their first regimen of first line platinum-
based chemotherapy treatment. 

For Part 1- any platinum-based regimen approved for the specific indication

For Part 2 -allowed regimens for the treatment of metastatic NSCLC are:
o
gemcitabine plus cisplatin or carboplatin ± bevacizumab
o
pemetrexed plus cisplatin or carboplatin ± bevacizumab
o
taxanes plus cisplatin or carboplatin ± bevacizumab
At randomization, subjects are expected to be eligible to continue to receive at least two
additional platinum-based chemotherapy cycles while on study.  
7. ≥ 28 days must have elapsed since previous treatment with ESA
8. ≥ 14 days must have elapsed (prior to Day 1) since the last RBC transfusion and receipt 
of ≤ 2 units of blood in the past 30 days (prior to Day 1)
9. ECOG Performance status of 0 – 2 (Appendix B)  
Page 440 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
69
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
10. Females of childbearing potential participating in the study are to use highly effective 
methods of birth control for at least 28 days before starting the study, during study 
participation and for at least 112 days following the last dose of sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo.  
Some highly effective methods of birth control include:

Oral contraceptives, intrauterine device, tubal ligation or a partner with a vasectomy
OR

Two forms of barrier method birth control, e.g., a latex condom PLUS a diaphragm 
with spermicide OR a latex condom PLUS a contraceptive sponge with spermicide.  
If a non-latex condom is used, it cannot be made out of natural (animal) membrane  
Females of childbearing potential must have a negative pregnancy test, with a minimum 
sensitivity of 25 mIU/ml, within 3 days prior to sotatercept (ACE-011) or sotatercept 
(ACE-011)/placebo administration (Day 1).  In addition, subjects must be educated 
concerning measures to be used to prevent pregnancy and potential toxicities.  (A female 
of childbearing potential is a sexually mature woman who has not undergone a 
hysterectomy or bilateral oophorectomy; or who has not been postmenopausal for at least 
24 consecutive months i.e. who has had menses at some time in the preceding 24 
months).  
11. Males must agree to use a latex condom or non-latex condom NOT made of natural 
(animal) membrane during any sexual contact with females of childbearing potential or a 
pregnant female while participating in the study and for at least 112 days following the 
last dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo, even if he has 
undergone a successful vasectomy.  
12. Life expectancy of ≥ 3 months.
13. Is willing to adhere to the study visit schedule, understand and comply with all protocol 
requirements.
14. Understand and voluntarily sign a written informed consent document prior to any study 
related assessments/procedures are conducted.
7.3.
Exclusion Criteria
The presence of any of the following will exclude a subject from enrollment:
1. Subjects who have any Grade > 3 toxicity (according to the currently active minor 
version of the NCI National Cancer Institute Common Terminology for Adverse Events 
[CTCAE] version 4.0 [Appendix C] at the time of screening, including Grade ≥ 3 residual 
adverse events related to either chemotherapy or underlying disease.  Exception: Grade ≥ 
3 hematotoxicity (e.g., asymptomatic anemia, neutropenia and thrombocytopenia) 
occurring during the chemotherapy nadir period and resolving or non- hematological 
events (e.g., nausea, vomiting, fatigue, or muscle or bone/joint pain), occurring during the 
chemotherapy period and resolving.
Page 441 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
70
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
2. Prior radiation therapy to > 20% of the whole skeleton.  Use of palliative radiation if the 
area being treated is < 15% of body surface area with no pelvic radiation or no more than 
10% of the bone marrow reserve is radiated is permitted during subject participation in 
the study, at the discretion of the Investigator.  
3. History of prior regimen(s) of platinum-based chemotherapy for metastatic disease and/or 
history of adjuvant platinum-based chemotherapy with last dose received less than six 
months prior to the start of current first-line platinum-based chemotherapy for metastatic 
disease.  
4. CNS metastases (exception: subjects with CNS metastases treated with whole brain 
radiotherapy, gamma knife radiosurgery and/or surgery and stable for at least 2 weeks 
prior to randomization).  
5. Clinically significant pulmonary, endocrine, neurologic, gastrointestinal, hepatic or 
genitourinary disease unrelated to underlying malignancy.  
6. Subjects with classification of 3 or higher heart failure as classified by the New York 
Heart Association (NYHA) (Appendix D).  
7. History of thrombosis, deep vein thrombosis (DVT), pulmonary emboli (PE), or embolic 
stroke if not stable on anticoagulants and/or one of these events occurring within the past 
6 months.  Local central line thrombosis is allowed.  
8. Diagnosis of a myeloid malignancy or known history of myelodysplasia.  
9. History of second malignancy within 3 years (except excised and cured basal cell 
carcinoma, squamous cell carcinoma of the skin or cervical carcinoma in situ).  
10. Subjects with a recent history (within 14 days of Day 1) of administration of IV 
antibiotics or oral antibiotics (due to post septic episode).  Subjects should be free of 
infection at least 14 days after the last dose of systemic antibiotic treatment (prior to Day 
1).  
11. Uncontrolled hypertension.  If hypertension is considered clinically stable, systolic blood 
pressure (SBP) must be < 150 mmHg or diastolic blood pressure (DBP) must be              
< 100 mmHg.  
12. Known infection with human immunodeficiency virus (HIV).  
13. Known active hepatitis B or C antibody defined by positive serology.  
14. Deficiency in iron (transferrin saturation < 20%), vitamin B12, or RBC folate.  Subjects 
may be re-screened following treatment with supplements and normalization of levels.  
15. History of anemia as a result of inherited hemoglobinopathy such as sickle cell anemia or 
thalassemia.  
16. History of anemia due to autoimmune or hereditary hemolysis; or gastrointestinal 
bleeding occurring within the past 6 months.  
17. Urine protein / creatinine ratio > 1.0.
Page 442 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
71
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
18. Received treatment with another investigational drug or device within 28 days prior to 
Day 1, or if the half life of the previous product is known, within 5 times the half life 
prior to dosing, whichever may be longer.  
19. Any prior use of sotatercept (ACE-011).  
20. Pregnant or lactating females or females planning to become pregnant.  
21. History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant 
proteins or excipients in the investigational product (Refer to the Investigator’s Brochure 
for further information). 
22. Major surgery within 30 days prior to Day 1 (subjects must have completely recovered 
from any previous surgery prior to Day 1).  
Page 443 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
72
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
8.
DESCRIPTION OF STUDY TREATMENTS
8.1.
Description of Investigational Product(s)
Sotatercept (ACE-011) clinical drug product will be provided as a frozen liquid formulation, 
Process IIa, or as a lyophilized powder, Process III.  
Note: Subjects receiving Process IIa clinical drug product will begin to receive Process III 
clinical drug product as soon as it becomes available at the study site. 
Process IIa Clinical Drug Product – Frozen Liquid Formulation:
The clinical drug product consists of sotatercept (ACE-011) in phosphate buffered saline (PBS), 
pH 7.5.  It is supplied as a 1 mL solution of 50 mg/mL sotatercept (ACE-011) in labeled, rubber 
stoppered, 2 mL vials providing 50 mg per vial.  The recommended storage temperature for
sotatercept (ACE-011) Process IIa frozen liquid drug product is -65˚C (colder than -65˚C) until 
thawed for administration.  Vials of sotatercept (ACE-011) frozen liquid must be completely 
thawed (approximately 30 minutes at room temperature) prior to preparation for dosing and must 
be used within six (6) hours of being thawed.  
Process III Clinical Drug Product- Lyophilized Powder:
The clinical drug product consists of sotatercept (ACE-011) in 10 mM citrate buffer, pH 5.8, 8% 
sucrose, and 0.02% polysorbate 80.  It is supplied as a lyophilized powder in labeled, rubber 
stoppered, 3-mL glass vials.  The recommended storage temperature for sotatercept (ACE-011)
lyophilized drug product is 2°C to 8°C. Prior to administration, the lyophilized drug product is 
reconstituted with 1 mL water for injection (WFI).  The reconstituted drug product consists of a 
50 mg/mL solution of sotatercept (ACE-011).  The reconstituted sotatercept (ACE-011), in its 
original container closure system, may be held for up to 6 hours at 2°C to 8°C.
Placebo (Part 2 Only):
In Part 2, the sotatercept (ACE-011) placebo to be used in the study will be sterile normal saline 
(0.9% sodium chloride for injection) administered as a SC injection.  Sterile, normal saline will 
be supplied by the investigational site’s pharmacy.  The manufacturer’s directions for placebo 
storage and handling are to be followed, as are standard clinical practices for ensuring sterility of 
the placebo.  
8.2.
Treatment Administration and Schedule
Sotatercept (ACE-011) or placebo will be administered as a SC injection to subjects by the study 
staff at the clinical site and will be documented in the study source record.  Subcutaneous 
injections will be given in the upper arm, abdomen, or thigh.  
At the time of randomization all subjects must be receiving their first-line regimen of platinum-
containing chemotherapy, given every three weeks, for the treatment of a metastatic solid tumor.  
Subjects will be randomized to this study during the time period in which they are receiving 
Cycle 1 through Cycle 4 of this regimen.  Subjects must not have received any prior regimens of 
first line platinum-based chemotherapy for a metastatic solid tumor.  
Page 444 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
73
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
Allowed concomitant platinum-based chemotherapy regimens are:

For Part 1- any platinum-based regimen approved for the specific indication

For Part 2 -allowed regimens for the treatment of metastatic NSCLC are:
o
gemcitabine plus cisplatin or carboplatin ± bevacizumab
o
pemetrexed plus cisplatin or carboplatin ± bevacizumab
o
taxanes plus cisplatin or carboplatin ± bevacizumab
Investigative sites will utilize commercial supply of these medications.  
Subjects may receive 4-6 cycles of the allowed platinum-based regimen selected by the 
Investigator.  Up to 2 additional cycles (8 total cycles) of platinum-based chemotherapy may be 
given as determined by cancer response. Platinum-based tumor therapy may be revised at the 
discretion of the Investigator for toxicity reasons only.  
While on study treatment subjects will be allowed to receive maintenance therapy with a 
pemetrexed or erlotinib-containing regimen when indicated. 
In Part 1 and Part 2, sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dosing may 
occur on different weeks of the chemotherapy cycle due to the subjects’ Hgb.  Dose delays of 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo and/or dose delays of chemotherapy 
may occur.  
8.2.1.
Selection of Dose for the Study
In Part 1, subjects will be randomized to one of the following sotatercept (ACE-011) dose 
levels, with 10-30 subjects per arm:

Sotatercept (ACE-011) 15 mg SC

Sotatercept (ACE-011) 30 mg SC
Analysis of safety data will be performed following the treatment of at least 10 subjects at the 15 
mg dose level and 10 subjects at the 30 mg dose level, with each subject having received a 
minimum of one dose of sotatercept (ACE-011) and completed a 12-week follow-up period from 
the first dose.  
Following this analysis, the addition of a third dose level:

Sotatercept (ACE-011) 45 mg SC
to the randomization schema will be determined.
Each dose level will be administered every 42 days for up to four doses.  
The following are decision rules for dose determination in Part 1 in order to move forward to 
Part 2:

After completion of two doses of sotatercept (ACE-011), a hematopoietic response in 
approximately 70% of subjects, in at least one or more treatment arms.  

Hematopoietic response is defined as an increase in Hgb of ≥ 1.0 g/dL above the 
study baseline value for 4 consecutive weeks, in the absence of RBC transfusions 
Page 445 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
74
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
and/or ESAs.  In order to determine the dose of sotatercept (ACE-011) to be used in 
Part 2, evaluation of hematopoietic response will be determined from sotatercept 
(ACE-011) dose 1/day 1 through and including dose 2/day 43 (prior to dose 3).  

In addition to the hematopoietic response, safety profile, dose modifications and 
extent of exposure will be taken into account for dose level selection for Part 2.  
Hematopoietic response will be determined by laboratory analysis of hemoglobin levels.  
In Part 2, subjects will be randomized to receive either sotatercept (ACE-011) (at the dose 
determined in Part 1) or placebo.  
8.2.2.
Selection and Timing of Dosing for Each Subject
Subjects will be randomized to receive sotatercept (ACE-011) or sotatercept (ACE-011)/placebo 
starting on Day 1 (one SC dose every 42 days) and continuing during the six-month (Part 1) or 
nine-month (Part 2) Treatment Period, as outlined in the Table of Events (see Section 5).  
In Part 1, subjects will be randomized to receive one of three dose levels of sotatercept (ACE-
011), with 10-30 subjects per arm.  In Part 2, 750 subjects will be randomized to receive 
sotatercept (ACE-011) or placebo at a ratio of 1:1.  
Each subject will return to the site on each scheduled clinic visit.  During the Treatment Period,
subjects will receive sotatercept (ACE-011) or sotatercept (ACE-011)/placebo every 42 days as 
determined by Hgb levels and randomization schedule.  Hemoglobin levels and reticulocyte 
counts will be repeated weekly after the first dose of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo then at 7, 14 and 28 days after each subsequent dose of sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo.  
The first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo can be administered
at any time after the first cycle and prior to the fifth cycle of first-line platinum-based 
chemotherapy.  Subsequent doses of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo 
can be administered at any time point during the chemotherapy cycle. 
Administration of subsequent cycles of chemotherapy, including dose reductions and dose 
delays, should not affect the sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dosing 
schedule, unless determined to be necessary by the Investigator.  If there is a chemotherapy dose 
delay, sotatercept (ACE-011) or sotatercept (ACE-011)/placebo administration does not need to 
be delayed until start of next chemotherapy cycle.  
Following completion of the Treatment Period, subjects who enter the Post Treatment Follow-
Up Period will be followed for 6 months from their last dose of sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo.  Visits will occur every month.  All subjects will continue to be 
followed for PFS up to 12 months from their first dose of sotatercept (ACE-011) or sotatercept 
(ACE-011)/placebo, or until progression of their metastatic disease, whichever comes first.  
Subjects will be discontinued from the study treatment for reasons listed in Section 8.2.3 of the 
protocol, for unacceptable toxicity, or for progression of metastatic disease that requires the 
initiation of another treatment.  
Page 446 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
75
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
Following the Study Discontinuation Visit, subjects will be contacted monthly and survival data 
collected for an additional 12 months (up to 24 months following the subject’s first dose of 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo).  
8.2.3.
Discontinuation
Treatment Discontinuation
Subjects will be discontinued from Study Treatment due to the following:

Adverse events(s)

Hypertension ≥Grade 3 – defined as Stage 2 hypertension (SBP ≥160 mmHg or
DBP ≥100mmHg) confirmed by two measurements obtained five minutes apart; 
medical intervention indicated; more than one drug or more intensive therapy than 
previously used indicated or medically significant hypertension which cannot be 
adequately controlled with antihypertensive therapy. 

Any AE > Grade 2 assessed to be related to sotatercept (ACE-011) therapy

Any persistent AE > Grade 1 considered to be related to sotatercept (ACE-011)
treatment and causing a subject to miss three months sotatercept (ACE-011)
therapy 

Any thromboembolic event > Grade 2 

Elevated Hgb > 15.0 g/dL (sustained for a 7 day period, confirmed by laboratory 
assessment)

Urine protein / creatinine ratio > 1.0 or > 2.0 (if bevacizumab [Avastin®] is 
concomitantly administered)

Persistent hematuria ≥Grade 2 - defined as symptomatic; urinary catheter or 
bladder irrigation indicated; limiting instrumental activities of daily living, and 
persisting for one week.

In Part 1, lack of sotatercept (ACE-011) therapeutic effect, defined as < 1.0 g/dL 
increase in Hgb from baseline following three dose escalations.  In Part 2, lack of 
sotatercept (ACE-011) therapeutic effect, defined as < 1.0 g/dL increase in Hgb from 
baseline following two doses of sotatercept (ACE-011)/placebo (Dose 1/ Day 1 
through and including Dose 2/Day 43, prior to Dose 3).  

Concomitant use of ESAs – In Part 1 if administered at any time and in Part 2 if 
administered < 4 months from first dose of study treatment.  

Sotatercept (ACE-011) or Sotatercept (ACE-011)/placebo Dose Modifications

In Part 1 and Part 2:  A second Hgb increase of ≥3.0 g/dL following a two level 
dose reduction due to a Hgb increase ≥3.0 g/dL 

In Part 2:  > 3 dose reductions and/or delays

Disease Progression 

Withdrawal of consent
Page 447 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
76
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011

Death

Lost to follow-up

Protocol violation
The reason for treatment discontinuation should be recorded in the eCRF and in the source 
documents.  
Study Discontinuation:  
The following events are considered sufficient reasons for discontinuing a subject from the 
study:

Completed study, per protocol (subject has completed six- to nine- month Treatment 
Period plus up to six-month Post Treatment Follow-Up Period including one year 
tumor assessment to determine TTP and PFS).  Note:  Survival data will continue to 
be collected for up to 24 months from first dose of study treatment.  

Withdrawal of consent

Death

Lost to follow-up
The following events may be considered sufficient reasons for discontinuing a subject from the 
study:

Adverse events(s)

Disease progression 

Protocol violation
The reason for study discontinuation should be recorded in the eCRF and in the source 
documents.  The Investigator must notify the Medical Monitor immediately when a subject has 
been discontinued/ withdrawn due to an AE (any unacceptable toxicity).  All subjects who are 
withdrawn from the study should complete the tests and evaluations scheduled for Study 
Discontinuation at the time of withdrawal.  
8.3.
Method of Treatment Assignment
All subjects who qualify for the study will be randomly enrolled into the study and receive up to 
4 doses of sotatercept (ACE-011) in Part 1.  In Part 2, subjects will be randomized at a ratio of 
1:1 and receive up to 4 doses of study treatment and may receive 2 additional doses of 
sotatercept (ACE-011)/placebo, if clinically indicated, at the discretion of the Investigator.  A 
unique multi-digit subject identification number will be assigned by IVRS to each subject 
entering the Treatment Period.  
8.4.
Packaging and Labeling
The label(s) for investigational product (IP) will include Sponsor name, address and telephone 
number, the protocol number, IP name, dosage form and strength (where applicable), amount of 
IP per container, lot number, expiry date (where applicable), medication identification/kit 
Page 448 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
77
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
number (if applicable), dosing instructions, storage conditions, and required caution statements 
and/or regulatory statements as applicable.  Additional information may be included on the label 
as applicable per local regulations.  
8.5.
Investigational Product Accountability And Disposal
Accountability for sotatercept (ACE-011) is the responsibility of the Investigator.  
Investigational clinical supplies must be received by a designated person at the clinical site and 
kept in a secured location.  The investigational site must maintain accurate records demonstrating 
dates and amounts of sotatercept (ACE-011) received, to whom it was administered (subject-by-
subject accounting), and accounts of any sotatercept (ACE-011) accidentally or deliberately 
destroyed or returned.  Unless otherwise notified, all vials of sotatercept (ACE-011), both used 
and unused, must be saved for drug accountability.  The used vials may be discarded, per the 
institution’s standard practice, after drug accountability has been completed by the monitor.  The 
Investigator must return all unused vials of sotatercept (ACE-011) to the Sponsor at the end of 
the study, or the sotatercept (ACE-011) may be destroyed at the clinical site with the permission 
of the Sponsor.  For either scenario, the outcome must be documented on the drug accountability 
log.  The Sponsor will provide direction for the outcome of all unused vials.  
Celgene will instruct the Investigator on the return, disposal and/or destruction of investigational 
medicinal product.  
8.6.
Investigational Product Compliance
Accurate recording of all IP administration will be made in the appropriate section of the 
subject’s eCRF and source documents.  
The Investigator or designee is responsible for accounting for all IP that is administered during 
the course of the study.  
Page 449 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
78
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
9.
CONCOMITANT MEDICATIONS AND PROCEDURES
9.1.
Permitted Concomitant Medications and Procedures
General concomitant medication usage
During screening, and during the study, subjects may take only stable doses of medications for 
chronic conditions that are not specifically excluded by the protocol (see Sections 7.2 and 7.3
Inclusion Criteria and Exclusion Criteria).  The Medical Monitor should be consulted by the 
Investigator if there are any concerns about what constitutes a stable dose or what is a chronic 
condition.  Concomitant medications will be recorded on the subject’s eCRF throughout the 
course of the study.  
Concomitant therapies considered as supportive care are acceptable while participating in this 
study including growth colony stimulating factors (G-CSF), anti-emetics to limit chemotherapy-
related nausea and vomiting and palliative radiation, bisphosphonates and denosumab (Refer to 
Inclusion Criterion, Section 7.2) for bone metastases.  Additionally, the study site should use its 
standard of care regarding hydration and the minimization of nephrotoxicity prior to/following 
the administration of platinum-based regimens.  
Concomitant medication for anemia
Concurrent therapy with a new prescription medication related to treatment of anemia during the 
course of the study must first be discussed with the Medical Monitor prior to administration, 
unless appropriate medical care necessitates that medication should begin before the Medical 
Monitor can be consulted.  
Iron supplementation
Iron supplementation within 7 days of Day 1 (besides an oral general multivitamin with iron) 
will not be allowed.  If a subject becomes iron deficient during study treatment (ferritin < 100 
ng/mL [< 224.7 pmol/L] or transferrin saturation < 20%), treatment with iron supplementation is 
at the discretion of the Investigator.  
Erythropoiesis-stimulating agents (ESAs)
The use of an ESA is not allowed in Part 1 of the study; however, ESAs are allowed in 
Part 2 only after a subject has received at least 4 months of study treatment.  The use of 
ESAs will need to result in immediate notification to the study sponsor and Medical Monitor, as
well as to the clinical site pharmacist, so that no further dosing with sotatercept (ACE-011) in 
that study subject will occur If treatment with ESAs is required in the opinion of the 
Investigator, the ESA label instructions are to be strictly followed.  
In Part 1, all subjects who receive an ESA will be discontinued from the study Treatment Period 
and continue to the Post Treatment Follow-Up Period. In Part 2, subjects who receive an ESA 
at < 4 months from their first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo 
will be discontinued from the study Treatment Period and continue to the Post Treatment 
Follow-Up Period.  Subjects who receive an ESA at ≥ 4 months from their first dose of 
sotatercept (ACE-011)/placebo will continue in the Treatment Period as follows:  The
unblinded pharmacist will ensure that subjects randomized to receive treatment with 
Page 450 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
79
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
sotatercept (ACE-011) are changed over to receive treatment with placebo.  Subjects 
randomized to treatment with placebo will continue to receive placebo.  The investigator, 
site personnel and subject will remain blinded. 
RBC transfusions
Concurrent treatment for CIA with blood transfusions is recommended when Hgb value is 
< 8 g/dL or at the discretion of the Investigator if the Hgb value is ≥8 g/dL and associated with 
anemia symptoms such as hemodynamic or pulmonary compromise requiring treatment.  If an 
RBC transfusion is given to a subject during the Treatment Period, sotatercept (ACE-011) should 
be administered >7 days from the date of the RBC transfusion.
9.2.
Prohibited Concomitant Medications and Procedures
No concurrent treatments with any other investigational agent are allowed.  Bisphosphonate 
therapy (see Section 7.2), other than for the treatment of hypercalcemia, must not be started on 
study.  
9.3.
Required Concomitant Medications and Procedures
Not applicable.  
Page 451 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
80
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
10.
STATISTICAL ANALYSES
10.1.
Overview
This is an open-label randomized, phase 2a, dose-ranging study of sotatercept (ACE-011) 
therapy for chemotherapy-induced anemia (CIA) in subjects with selected metastatic solid tumor
types treated with platinum-based chemotherapeutic agents followed by a phase 2b/3, double-
blind, randomized, placebo-controlled study of sotatercept (ACE-011) therapy for 
chemotherapy-induced anemia (CIA) in subjects with metastatic non-small cell lung cancer 
(NSCLC) treated with platinum-based chemotherapeutic regimens. An IVRS will be utilized to 
ensure an equal weight central randomization based on a permuted-block randomization method 
according to stratification factors defined in Section 4.1 Study Design.  In Part 1, subjects will 
be randomized to one of three doses of sotatercept (ACE-011) plus platinum-based 
chemotherapy.  In Part 2, subjects will be randomized to placebo or the selected sotatercept 
(ACE-011) dose determined from Part 1 plus platinum-based chemotherapy.  Data from Part 1
will not be combined with data from Part 2 in all safety and efficacy analyses. 
A DMC will be used to monitor the study conduct.  
10.2.
Study Population Definitions

Three study populations will be used for analyses.  

The Intent-to-Treat (ITT) Population – All randomized subjects.  

Safety Population – All subjects who take at least one dose of study medication.  

Efficacy Evaluable (EE) Population – All ITT subjects who take at least one dose of 
study medication and have baseline and at least one post-baseline efficacy assessment 
without major protocol deviation.  
10.3.
Sample Size and Power Considerations
In Part 1, up to 90 subjects will be randomized among three dosing groups.  This sample size is 
for the purpose of hypothesis generation.  However, it would allow approximately 80% power to 
detect an effect size of 0.33 using a 2 degrees of freedom Chi-Square Test with a two-sided 
significance level (alpha) of 0.05.  
In Part 2, subjects will be enrolled in two stages.  In the first stage, approximately 180 subjects 
will be randomized in a 1:1 ratio to the selected sotatercept (ACE-011) dose group or placebo 
group.  An interim analysis of transfusion rate will be performed after these 180 subjects have 
received at least two doses of sotatercept (ACE-011)/placebo, and have been followed for at least 
4 months from randomization.  A Data Monitoring Committee will review the results and 
provide recommendations on continuing or stopping the study. Based on the results of the 
futility analysis, further enrollment in the second stage of Part 2 of the study could be continued.  
Upon recommendation to continue the study, an additional 570 subjects will be subsequently 
randomized in the second stage.  The total sample size of 750 subjects in Part 2 (first plus second 
stage) would allow observation of at least 536 deaths and thus at least 80% power to exclude 
Page 452 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
81
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
more than 15% hazard increase in the sotatercept (ACE-011) arm compared with the placebo 
arm at one-sided significance level of 0.025, i.e., rejecting hazard ratio (Placebo:sotatercept 
[ACE-011]) of 0.87,  assuming the sotatercept (ACE-011) arm actually reduces at least 10% 
hazard, i.e., true hazard ratio (Placebo:sotatercept [ACE-011]) of 1.11.  
10.4.
Background and Demographic Characteristics
Subjects’ age, height, weight, and baseline characteristics will be summarized using descriptive 
statistics by treatment arm, while gender, race and other categorical variables will be provided 
using frequency tabulations.  Medical history data will be summarized using frequency 
tabulations by system organ class and preferred term.  
10.5.
Subject Disposition
Subject disposition (analysis population allocation, entered, discontinued, along with primary 
reason for discontinuation) will be summarized using frequency and percent by treatment arm.  
A summary of subjects enrolled by site will be provided.  Protocol deviations will be 
summarized using frequency tabulations.  
10.6.
Efficacy Analysis
In Part 1, the primary endpoint will be the hematopoietic response defined as an increase in Hgb 
of ≥ 1.0 g/dL above the study baseline value for 28 consecutive days, in the absence of RBC 
transfusions and/or ESAs.  The analysis will be based on the EE population. The proportion of 
subjects with hematopoietic response will be estimated and a Chi-square test will be performed 
to compare response rates across treatment groups.  
In Part 2, the primary endpoint will be rate of RBC transfusion within 4 months following the 
date of randomization.  It will be estimated based on Kaplan-Meier method for time to the first 
RBC transfusion.  The analysis will be based on ITT population and will be conducted according 
to the approximate timeline as described in Section 10.8.  Subjects who have documented RBC 
transfusion(s) from randomization until the last dose of concomitant platinum-based 
chemotherapy plus 30 days or from the initiation date of non-platinum-based chemotherapy, 
whichever is earlier, will be considered as having the event on the date of first RBC transfusion. 
Subjects who are discontinued from study treatment due to reasons other than disease 
progression or death will be considered as having the event on the date of study treatment 
discontinuation, or the last dose date of platinum-based chemotherapy plus 30 days or the 
initiation date of non-platinum-based chemotherapy, whichever is earliest. Subjects who 
discontinue from study treatment due to disease progression or death will be censored on the date 
of study treatment discontinuation, or the last dose date of platinum-based chemotherapy plus 30 
days or the initiation date of non-platinum-based chemotherapy, whichever is earliest. Otherwise 
subjects will be censored on the date of last contact, or on the date of last dose of concomitant 
platinum-based chemotherapy plus 30 days or on the initiation date of non-platinum-based 
chemotherapy, whichever is earliest.  The comparison on the distribution difference between the 
treatment groups will be based on the stratified log-rank test, and the associated hazard ratio and 
95% confidence interval will be provided using Cox proportional hazard model. The proportion 
of subjects receiving a transfusion based on Kaplan-Meier estimates at specific time points will 
also be provided by treatment arms. 
Page 453 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
82
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
As secondary endpoints for Part 2 of the study, time to progression, progression free survival and 
overall survival will be analyzed based on the ITT population.  
Time to progression (TTP) is defined as the time between the randomization date and date of 
disease progression. Disease progression is based on the IRC reviewed progression date.  If 
a subject dies due to reasons other than disease progression, the subject will be censored at the 
death date.  If a subject does not have disease progression, then the subject will be censored at 
the last tumor assessment (prior to or on the first day of the first subsequent antitumor therapy).  
Progression free survival (PFS) is defined as the time between the randomization and disease 
progression or death.  Disease progression is based on the IRC reviewed progression date.  
Subjects who progressed or died will be considered to have had an event, except if this event 
occurs after the start of subsequent antitumor therapy, in which case the subject is censored at the 
time of last tumor assessment prior to or on the first day of the first subsequent antitumor 
therapy.  The date of progression is taken as the earliest date of:  Date of PD as evaluation of 
response, date of new lesion on tumor measurements page, death date, if death is caused by PD, 
treatment termination date if reason is PD, progression date as documented on treatment 
termination page, progression date as documented on the follow-up visit page.  Subjects who did 
not progress nor died (lost to follow-up or still being treated without documented disease 
progression or started subsequent antitumor therapy) will be censored at the date of the last 
tumor assessment prior to or on the first day of the first subsequent antitumor therapy.  PFS 
based on investigators’ assessment will also be analyzed.  
Overall survival (OS) is defined as the time between the randomization and death.  A subject
who dies, regardless of the cause of death, will be considered to have had an event.  All subjects 
who are lost to the follow-up prior to the end of the trial or who are withdrawn from the trial will 
be censored at the time of last contact.  Subjects who are still being treated will be censored at 
the last available date where the subject is known to be alive.  
For TTP, PFS and OS, Kaplan-Meier method will be used to estimate the distribution function, 
six-month and one-year survival rates, as well as the medians and 95% confidence intervals will 
be provided.  The stratified log rank test will be used to compare the distributions of TTP, PFS 
and OS respectively.  The stratification factors are described in Section 4.1 .  The associated 
hazard ratios and confidence intervals will be provided using stratified Cox proportional hazard 
model respectively for each endpoint.  
Sensitivity analyses will be performed on TTP, PFS, and efficacy analyses will also be 
performed using EE population.  Data listings will be provided for all relevant data collected 
during the studies.  Further details will be included in the Statistical Analysis Plan.  
10.7.
Safety Analysis
All safety subjects will be used for safety analyses.  Sotatercept (ACE-011) exposure will be 
summarized.  Adverse events, vital sign measurements, clinical laboratory information, ECG 
interpretations, and concomitant medications will be tabulated and summarized by study part and 
treatment arm.  The incidence of AEs will be summarized by severity grade based on the NCI 
CTCAE version 4.0 (current active minor version).  Serious adverse events (SAE), deaths and 
AEs leading to dose modifications and study treatment discontinuation will be summarized.  
Page 454 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
83
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
Safety information obtained during the Post Treatment Follow-Up Period during each segment 
will be incorporated into these analyses.  
10.8.
Interim Analysis
There are two interim analyses planned for this study.  At the first interim analysis, the 
transfusion rate result will be used for go/no go decision, and overall survival will also be 
analyzed.  At the second interim analysis, only the overall survival will be analyzed.  
The first interim analysis on transfusion rate will be conducted after the first 180 eligible subjects 
randomized in Part 2 of the study (stage 1) who have received at least two doses of sotatercept 
(ACE-011)/placebo, have been followed for at least 4 months from randomization.  This sample 
size would allow at least 90% power to detect a 15% difference between two arms (sotatercept 
[ACE-011] arm 15% vs. placebo 30%) in 4 month transfusion rates at two-sided 5% significance 
level based on the stratified log rank test and the assumption of exponential distribution for time 
to RBC transfusion.  If the p-value at the interim analysis does exceed significance level of 0.05, 
the result will be considered as lack of efficacy.  If the p-value is less than or equal to 0.05, 
additional subjects will be enrolled and the study will move on to the Part 2; however, the futility 
analysis result based on RBC transfusion rate may be up to DMC evaluation.  For superiority, 
Type I error 0.0001 will be spent at this interim for transfusion rate, and the remaining 0.0499 
will be spent at the final analysis after 750 subjects being enrolled.  
Overall survival will also be analyzed at this interim, Type I error spending will be based on 
O’Brien and Fleming Boundary.  
The second interim analysis will be performed when approximately 265 deaths are observed in 
Part 2.  Type I error spending will be based on O’Brien and Fleming boundary.  
The final analysis will be performed when approximately 536 deaths are observed in Part 2.  
10.9.
Other Topics
Pharmacokinetic Analysis
Approximately 10 subjects will be enrolled for full PK sampling in each treatment cohort of Part 
1.  For this portion of the study, subjects who miss more than two PK sampling time points from 
Days 1 through 43 will be replaced.  
Noncompartmental PK parameters for sotatercept (ACE-011), such as tmax, Cmax, AUC42, and 
t1/2,z, will be estimated for subjects providing full PK samples.  Dose proportionality will be 
assessed by regression analysis using the exposure data after the first dose.  Descriptive statistics 
will be provided for plasma concentrations and PK parameters.  
In exploratory population PK analysis, covariates to be tested may include type of chemotherapy, 
the presence of anti-sotatercept (ACE-011) antibodies, demographics (age, race, gender, and 
body weight), markers for hepatic and renal function, and other factors as deemed appropriate.  
Both full and sparse PK data will be included for population PK analyses.  
The relationship between sotatercept (ACE-011) exposure and response (hematology, 
biomarkers, and other clinical outcomes as appropriate) will be explored.  
Page 455 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
84
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
10.10.
Data Monitoring Committee (DMC)
A DMC will review safety and efficacy data to ensure the protection of study subjects.  The 
DMC will receive periodic updates of all serious treatment-related toxicities and SAEs leading to 
deaths from all causes. The first planned review by the DMC will be conducted following the 
randomization and treatment of twenty subjects.  The DMC will continue to monitor safety on an 
ongoing basis including recommendation of sotatercept (ACE-011) dose selection for Part 2.  
The first interim analysis will be conducted after the first 180 eligible subjects in Part 2 of the 
study (stage 1) have been followed for at least 4 months for RBC transfusion rate.  The second 
interim analysis will be performed when approximately 265 deaths are observed in Part 2.  The 
final analysis will be performed when approximately 536 deaths are observed in Part 2.  
Ad hoc meetings will be scheduled as needed.  
The DMC will have a consultative role with respect to the Sponsor. The Sponsor will make the 
final decision regarding the recommendation proposed by the committee. A separate DMC 
charter will detail the activities of this committee.  
Page 456 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
85
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
11.
ADVERSE EVENTS
11.1.
Monitoring, Recording and Reporting of Adverse Events
An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen 
in a subject during the course of a study.  It may be a new intercurrent illness, a worsening 
concomitant illness, an injury, or any concomitant impairment of the subject’s health, including 
laboratory test values (as specified by the criteria below), regardless of etiology.  Any worsening 
(i.e., any clinically significant adverse change in the frequency or intensity of a pre-existing 
condition) should be considered an AE.  A diagnosis or syndrome should be recorded on the AE 
page of the eCRF rather than the individual signs or symptoms of the diagnosis or syndrome.  
An overdose, accidental or intentional, whether or not it is associated with an AE, or abuse, 
withdrawal, sensitivity or toxicity to an investigational product should be reported as an AE.  If 
an overdose is associated with an AE, the overdose and AE should be reported as separate terms.  
All subjects will be monitored for AEs during the study.  Assessments may include monitoring 
of any or all of the following parameters:  the subject’s clinical symptoms, laboratory, 
pathological, radiological or surgical findings, physical examination findings, or other 
appropriate tests and procedures.  
All AEs will be recorded by the Investigator from the time the subject signs informed consent to 
at least 42 days after the last dose of IP.  The AEs and SAEs will be recorded on the AE page of 
the eCRF and in the subject’s source documents.  All SAEs must be reported to Celgene Drug 
Safety immediately within 24 hours of the Investigator’s knowledge of the event by facsimile, or 
other appropriate method, using the SAE Report Form, or approved equivalent form.  After 42
days post last dose, only AEs assessed as related to study treatment are to be reported.  
11.2.
Evaluation of Adverse Events
A qualified Investigator will evaluate all AEs as to:  
11.2.1.
Seriousness 
An SAE is any AE occurring at any dose that:

Results in death;

Is life-threatening (i.e., in the opinion of the Investigator, the subject is at immediate 
risk of death from the AE);

Requires inpatient hospitalization or prolongation of existing hospitalization 
(hospitalization is defined as an inpatient admission, regardless of length of stay);

Results in persistent or significant disability/incapacity (a substantial disruption of the 
subject’s ability to conduct normal life functions);

Is a congenital anomaly/birth defect;

Constitutes an important medical event.  
Page 457 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
86
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
Important medical events are defined as those occurrences that may not be immediately life 
threatening or result in death, hospitalization, or disability, but may jeopardize the subject or 
require medical or surgical intervention to prevent one of the other outcomes listed above.  
Medical and scientific judgment should be exercised in deciding whether such an AE should be 
considered serious.  
Events not considered to be SAEs are hospitalizations for:

A standard procedure for protocol therapy administration.  However, hospitalization 
or prolonged hospitalization for a complication of therapy administration will be 
reported as an SAE.  

Routine treatment or monitoring of the studied indication not associated with any 
deterioration in condition.  

The administration of blood or platelet transfusion as routine treatment of studied 
indication.  However, hospitalization or prolonged hospitalization for a complication 
of such transfusion remains a reportable SAE.  

A procedure for protocol/disease-related investigations (e.g., surgery, scans, 
endoscopy, sampling for laboratory tests, bone marrow sampling).  However, 
hospitalization or prolonged hospitalization for a complication of such procedures 
remains a reportable SAE.  

Hospitalization or prolongation of hospitalization for technical, practical, or social 
reasons, in absence of an AE.  

A procedure that is planned (i.e., planned prior to starting of treatment on study); 
must be documented in the source document and the eCRF.  Hospitalization or 
prolonged hospitalization for a complication remains a reportable SAE.  

An elective treatment of a pre-existing condition unrelated to the studied indication.  

Emergency outpatient treatment or observation that does not result in admission, 
unless fulfilling other seriousness criteria above. 
If an AE is considered serious, both the AE page/screen of the eCRF and the SAE Report Form 
must be completed.  
For each SAE, the Investigator will provide information on severity, start and stop dates, 
relationship to IP, action taken regarding IP, and outcome.  
11.2.2.
Severity / Intensity
For both AEs and SAEs, the Investigator must assess the severity /intensity of the event.  
The severity of AEs will be graded based upon the subject’s symptoms according to the current 
active minor version of National Cancer Institute (NCI) Common Terminology Criteria for 
Adverse Events (CTCAE, Version 4.0); 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
Page 458 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
87
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
AEs that are not defined in the NCI CTCAE should be evaluated for severity according to the 
following scale:
Grade 1 = Mild – transient or mild discomfort; no limitation in activity; no medical 
intervention/therapy required
Grade 2 = Moderate – mild to moderate limitation in activity, some assistance may be needed; no 
or minimal medical intervention/therapy required
Grade 3 = Severe – marked limitation in activity, some assistance usually required; medical 
intervention/therapy required, hospitalization is possible
Grade 4 = Life threatening – extreme limitation in activity, significant assistance required; 
significant medical intervention/therapy required, hospitalization or hospice care probable
Grade 5 = Death – the event results in death
The term “severe” is often used to describe the intensity of a specific event (as in mild, moderate 
or severe myocardial infarction); the event itself, however, may be of relatively minor medical 
significance (such as severe headache).  This criterion is not the same as “serious” which is 
based on subject/event outcome or action criteria associated with events that pose a threat to a 
subject’s life or functioning.  
Seriousness, not severity, serves as a guide for defining regulatory obligations.  
11.2.3.
Causality 
The Investigator must determine the relationship between the administration of IP and the 
occurrence of an AE/SAE as Not Suspected or Suspected as defined below:
Not Suspected:
The temporal relationship of the adverse event to IP 
administration makes a causal relationship unlikely or 
remote, or other medications, therapeutic interventions, or 
underlying conditions provide a sufficient explanation for the 
observed event.
Suspected:
The temporal relationship of the adverse event to IP 
administration makes a causal relationship possible, and other 
medications, therapeutic interventions, or underlying conditions 
do not provide a sufficient explanation for the observed event.
If an event is assessed as suspected of being related to a comparator, ancillary or additional IP 
that has not been manufactured or provided by Celgene, please provide the name of the 
manufacturer when reporting the event.  
11.2.4.
Duration
For both AEs and SAEs, the Investigator will provide a record of the start and stop dates of the 
event.
Page 459 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
88
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
11.2.5.
Action Taken
The Investigator will report the action taken with IP as a result of an AE or SAE, as applicable 
(e.g., discontinuation or reduction of IP, as appropriate) and report if concomitant and/or 
additional treatments were given for the event. 
11.2.6.
Outcome
All SAEs that have not resolved upon discontinuation of the subject’s participation in the study 
must be followed until recovered, recovered with sequelae, not recovered (death due to another 
cause) or death (due to the SAE).  
11.3.
Abnormal Laboratory Values
An abnormal laboratory value is considered to be an AE if the abnormality:

Results in discontinuation from the study;

Requires treatment, modification/ interruption (delay) of IP dose, or any other 
therapeutic intervention; or

Is judged to be of significant clinical importance.  
Regardless of severity grade, only laboratory abnormalities that fulfill a seriousness criterion 
need to be documented as an SAE.  
If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis 
or syndrome should be recorded on the AE page/screen of the eCRF.  If the abnormality was not 
a part of a diagnosis or syndrome, then the laboratory abnormality should be recorded as the AE.  
11.4.
Pregnancy
11.4.1.
Females of Childbearing Potential
Pregnancies and suspected pregnancies (including a positive pregnancy test regardless of age or 
disease state) of a female subject occurring while the subject is on IP, or within 112 days of the 
subject’s last dose of IP, are considered immediately reportable events.  IP is to be discontinued 
immediately.  The pregnancy, suspected pregnancy, or positive pregnancy test must be reported 
to Celgene Drug Safety immediately by facsimile, or other appropriate method, using the 
Pregnancy Initial Report Form, or approved equivalent form.  
The female subject should be referred to an obstetrician-gynecologist or another appropriate 
healthcare professional for further evaluation.  
The Investigator will follow the female subject until completion of the pregnancy, and must 
notify Celgene Drug Safety immediately about the outcome of the pregnancy (either normal or 
abnormal outcome) using the Pregnancy Follow-up Report Form, or approved equivalent form.  
If the outcome of the pregnancy was abnormal (e.g., spontaneous or therapeutic abortion), the 
Investigator should report the abnormal outcome as an AE.  If the abnormal outcome meets any 
of the serious criteria, it must be reported as an SAE to Celgene Drug Safety immediately by 
facsimile, or other appropriate method, within 24 hours of the Investigator’s knowledge of the 
event) using the SAE Report Form, or approved equivalent form.  
Page 460 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
89
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
All neonatal deaths that occur within 28 days of birth should be reported, without regard to 
causality, as SAEs.  In addition, any infant death after 28 days that the Investigator suspects is 
related to the in utero exposure to the IP should also be reported to Celgene Drug Safety 
immediately by facsimile, or other appropriate method, within 24 hours of the Investigator’s 
knowledge of the event using the SAE Report Form, or approved equivalent form.  
11.4.2.
Male Subjects
If a female partner of a male subject taking investigational product becomes pregnant, the male 
subject taking IP should notify the Investigator, and the pregnant female partner should be 
advised to call their healthcare provider immediately.  
11.5.
Immediate Reporting of Serious Adverse Events
Any AE that meets any criterion for an SAE requires the completion of an SAE Report Form in 
addition to being recorded on the AE page/screen of the eCRF.  All SAEs must be reported to 
Celgene Drug Safety immediately within 24 hours of the Investigator’s knowledge of the event 
by facsimile, or other appropriate method, using the SAE Report Form, or approved equivalent 
form.  This instruction pertains to initial SAE reports as well as any follow-up reports.  
The Investigator is required to ensure that the data on these forms is accurate and consistent.  
This requirement applies to all SAEs (regardless of relationship to IP) that occur during the study 
from the time the subject signs informed consent up to 42 days after the last dose of IP, and those 
made known to the Investigator at anytime thereafter that are suspected of being related to IP.  
SAEs occurring prior to treatment will be captured.  
The SAE report should provide a detailed description of the SAE and include summaries of 
hospital records and other relevant documents.  If a subject died and an autopsy has been 
performed, copies of the autopsy report and death certificate are to be sent to Celgene Drug 
Safety as soon as these become available.  Any follow-up data will be detailed in a subsequent 
SAE Report Form, or approved equivalent form, and sent to Celgene Drug Safety.  
Where required by local legislation, the Investigator is responsible for informing the Institutional 
Review Board (IRB)/Ethics Committee (EC) of the SAE and providing them with all relevant 
initial and follow-up information about the event.  The Investigator must keep copies of all SAE 
information on file including correspondence with Celgene and the IRB/EC.  
11.6.
Safety Queries
Queries pertaining to SAEs will be communicated from Celgene Drug Safety to the site via 
facsimile or electronic mail.  The response time is expected to be no more than five (5) business 
days.  Urgent queries (e.g., missing causality assessment) may be handled by phone.  
11.7.
Expedited Reporting of Adverse Events
For the purpose of regulatory reporting, Celgene Drug Safety will determine the expectedness of 
events suspected of being related to sotatercept (ACE-011) based on the Investigator Brochure.  
For countries within the European Economic Area (EEA), Celgene or its authorized 
representative will report in an expedited manner to Regulatory Authorities and Ethics 
Page 461 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
90
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
Committees concerned, suspected unexpected serious adverse reactions (SUSARs) in accordance 
with Directive 2001/20/EC and the Detailed Guidance on collection, verification and 
presentation of adverse reaction reports arising from clinical trials on investigational products for 
human use (ENTR/CT3) and also in accordance with country-specific requirements.  
Celgene or its authorized representative shall notify the Investigator of the following 
information:

Any AE suspected of being related to the use of IP in this study or in other studies 
that is both serious and unexpected (i.e., SUSAR);

Any finding from tests in laboratory animals that suggests a significant risk for 
human subjects including reports of mutagenicity, teratogenicity, or carcinogenicity.  
Where required by local legislation, the Investigator shall notify his/her IRB/EC promptly of 
these new serious and unexpected AE(s) or significant risks to subjects.  
The Investigator must keep copies of all pertinent safety information on file including 
correspondence with Celgene and the IRB/EC.  (See Section 15.3 for record retention 
information).  
Celgene Drug Safety Contact Information:
For Local Drug Safety Affiliate Office contact information, please refer to the Serious Adverse 
Event Report Form / Completion Guidelines or to the Pregnancy Report Form / Completion 
Guidelines.  
Page 462 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
91
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
12.
DISCONTINUATIONS
Please refer to Section 8.2.3.  
Stopping Rules
In addition to Celgene routine pharmacovigilance surveillance, a DMC will review unblinded 
data on a regular basis (mainly grade 3 or 4 toxicities, SAEs and subject deaths).  Any relevant 
imbalance in toxic deaths, related SAEs or detrimental survival would be considered for study 
discontinuation.  
Page 463 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
92
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
13.
EMERGENCY PROCEDURES
13.1.
Emergency Contact
In emergency situations, the Investigator should contact the responsible Clinical Research 
Physician/Medical Monitor or designee by telephone at the number(s) listed on the Emergency 
Contact Information page of the protocol (after title page).  
In the unlikely event that the Clinical Research Physician/Medical Monitor or designee cannot be 
reached, please contact the global Emergency Call Center by telephone at the number listed on 
the Emergency Contact Information page of the protocol (after title page).This global Emergency 
Call Center is available 24 hours a day and 7 days a week.  The representatives are responsible 
for obtaining your call-back information and contacting the on call Celgene/CRO Medical 
Monitor, who will then contact you promptly.  
Note:  The back-up 24 hour global emergency contact call center should only be used if you are 
not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls.  
13.2.
Emergency Identification of Investigational Products
In both Part 1 and Part 2 the blind must not be broken during the course of the study unless in the 
opinion of the Investigator, it is absolutely necessary to safely treat the subject.  If it is medically 
imperative to know what IP the subject is receiving, the Investigator or authorized person should 
call IVRS for unblinded dose information, etc.  However, every effort should be made to contact 
the Clinical Research Physician/Medical Monitor prior to breaking the blind.  Contact or 
attempted contact with the Clinical Research Physician/Medical Monitor as well as the reason 
for breaking the blind must be documented in the source documents.  
Page 464 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
93
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
14.
REGULATORY CONSIDERATIONS
14.1.
Good Clinical Practice
The procedures set out in this study protocol pertaining to the conduct, evaluation, and 
documentation of this study are designed to ensure that Celgene, its authorized representative, 
and Investigator abide by Good Clinical Practice (GCP), as described in International 
Conference on Harmonization (ICH) Guideline E6 and in accordance with the general ethical 
principles outlined in the Declaration of Helsinki.  The study will receive approval from an 
IRB/EC prior to commencement.  The Investigator will conduct all aspects of this study in 
accordance with applicable national, state, and local laws of the pertinent regulatory authorities.  
14.2.
Investigator Responsibilities
Investigator responsibilities are set out in the ICH Guideline for Good Clinical Practice and in 
the local regulations.  Celgene staff or an authorized representative will evaluate and approve all 
Investigators who in turn will select their staff.  
The Investigator should ensure that all persons assisting with the study are adequately informed 
about the protocol, amendments, study treatments, as well as study-related duties and functions.  
The Investigator should maintain a list of Sub-investigators and other appropriately qualified 
persons to whom he or she has delegated significant study-related duties.  
The Investigator is responsible for keeping a record of all subjects who sign an informed consent 
document and are screened for entry into the study.  Subjects who fail screening must have the 
reason(s) recorded in the subject’s source documents.  
The Investigator, or a designated member of the Investigator’s staff, must be available during 
monitoring visits to review data, resolve queries and allow direct access to subject records (e.g., 
medical records, office charts, hospital charts, and study-related charts) for source data 
verification.  The Investigator must ensure timely and accurate completion of eCRFs and queries.  
14.3.
Subject Information and Informed Consent
The Investigator must obtain informed consent of a legal representative prior to any study related 
procedures.  
Documentation that informed consent occurred prior to the study subject’s entry into the study 
and of the informed consent process should be recorded in the study subject’s source documents 
including the date.  The original informed consent document signed and dated by the study 
subject and by the person consenting the study subject prior to the study subject’s entry into the 
study, must be maintained in the Investigator’s study files and a copy given to the study subject.  
In addition, if a protocol is amended and it impacts on the content of the informed consent, the 
informed consent document must be revised.  Study subjects participating in the study when the 
amended protocol is implemented must be re-consented with the revised version of the informed 
consent document.  The revised informed consent document signed and dated by the study 
subject and by the person consenting the study subject must be maintained in the Investigator’s 
study files and a copy given to the study subject.  
Page 465 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
94
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
14.4.
Confidentiality
Celgene affirms the subject's right to protection against invasion of privacy and to be in 
compliance with ICH and other local regulations (whichever is most stringent).  Celgene requires 
the Investigator to permit Celgene's representatives and, when necessary, representatives from 
regulatory authorities, to review and/or copy any medical records relevant to the study in 
accordance with local laws.  
Should direct access to medical records require a waiver or authorization separate from the 
subject’s signed informed consent document, it is the responsibility of the Investigator to obtain 
such permission in writing from the appropriate individual.  
14.5.
Protocol Amendments
Any amendment to this protocol must be approved by the Celgene Clinical Research 
Physician/Medical Monitor.  Amendments will be submitted to the IRB/EC for written approval.  
Written approval must be obtained before implementation of the amended version occurs.  The 
written signed approval from the IRB/EC should specifically reference the Investigator name, 
protocol number, study title and amendment number(s) that is applicable.  Amendments that are 
administrative in nature do not require IRB/IEC approval but will be submitted to the IRB/IEC 
for information purposes.  
14.6.
Institutional Review Board/Independent Ethics Committee Review 
and Approval
Before the start of the study, the study protocol, informed consent document, and any other 
appropriate documents will be submitted to the IRB/EC with a cover letter or a form listing the 
documents submitted, their dates of issue, and the site (or region or area of jurisdiction, as 
applicable) for which approval is sought.  If applicable, the documents will also be submitted to 
the authorities in accordance with local legal requirements.  
Investigational Product can only be supplied to an Investigator by Celgene or its authorized 
representative after documentation on all ethical and legal requirements for starting the study has 
been received by Celgene or its authorized representative.  This documentation must also include 
a list of the members of the IRB/EC and their occupation and qualifications.  If the IRB/EC will 
not disclose the names, occupations and qualifications of the committee members, it should be 
asked to issue a statement confirming that the composition of the committee is in accordance 
with GCP.  For example, the IRB General Assurance Number may be accepted as a substitute for 
this list.  Formal approval by the IRB/EC should mention the protocol title, number, amendment 
number (if applicable), study site (or region or area of jurisdiction, as applicable), and any other 
documents reviewed.  It must mention the date on which the decision was made and must be 
officially signed by a committee member.  Before the first subject is enrolled in the study, all 
ethical and legal requirements must be met.  
The IRB/EC and, if applicable, the authorities, must be informed of all subsequent protocol 
amendments in accordance with local legal requirements.  Amendments must be evaluated to 
determine whether formal approval must be sought and whether the informed consent document 
should also be revised.  
Page 466 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
95
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
The Investigator must keep a record of all communication with the IRB/EC and, if applicable, 
between a Coordinating Investigator and the IRB/EC.  This statement also applies to any 
communication between the Investigator (or Coordinating Investigator, if applicable) and 
regulatory authorities.  
Any advertisements used to recruit subjects for the study must be reviewed by Celgene and the 
IRB/EC prior to use.  
14.7.
Ongoing Information for Institutional Review Board / Ethics 
Committee
If required by legislation or the IRB/EC, the Investigator must submit to the IRB/EC:

Information on serious or unexpected adverse events as soon as possible; 

Periodic reports on the progress of the study;

Deviations from the protocol or anything that may involve added risk to subjects.  
14.8.
Closure of the Study
Celgene reserves the right to terminate this study at any time for reasonable medical or 
administrative reasons.  Any premature discontinuation will be appropriately documented 
according to local requirements (e.g., IRB/EC, regulatory authorities, etc...).  
In addition, the Investigator or Celgene has the right to discontinue a single site at any time 
during the study for medical or administrative reasons such as:

Unsatisfactory enrollment;

GCP noncompliance;

Inaccurate or incomplete data collection;

Falsification of records;

Failure to adhere to the study protocol.  
Page 467 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
96
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
15.
DATA HANDLING AND RECORDKEEPING 
15.1.
Data/Documents
The Investigator must ensure that the records and documents pertaining to the conduct of the 
study and the distribution of the investigational product are complete, accurate, filed and 
retained.  Examples of source documents include:  hospital records; clinic and office charts; 
laboratory notes; memoranda; subject’s diaries or evaluation checklists; dispensing records; 
recorded data from automated instruments; copies or transcriptions certified after verification as 
being accurate copies; microfiche; x-ray film and reports; and records kept at the pharmacy, and 
the laboratories, as well as copies of eCRFs or CD-ROM.  
15.2.
Data Management
Data will be collected via an electronic data capture (EDC) system rather than paper. Data will 
be entered into the clinical database as per Celgene SOPs.  These data will be electronically 
verified through use of on-line checks during data entry, and through programmed edit checks 
specified by the clinical team. The Clinical team and investigational site personnel will be 
alerted of discrepant data by the functionality of the system. Resolutions to these issues will be 
reflected in the database. An audit trail within the system will track all changes made to the data.  
15.3.
Record Retention
Essential documents must be retained by the Investigator for a minimum of 2 years after the last 
approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region, or at least 2 years have elapsed since the 
formal discontinuation of clinical development of the IP.  The Investigator must retain these 
documents for the time period described above or according to local laws or requirements, 
whichever is longer.  Essential documents include, but are not limited to, the following:

Signed informed consent documents for all subjects;

Subject identification code list, screening log (if applicable), and enrollment log;

Record of all communications between the Investigator and the IRB/EC;

Composition of the IRB/EC;

Record of all communications between the Investigator, Celgene, and their authorized 
representative(s);

List of Sub-investigators and other appropriately qualified persons to whom the 
Investigator has delegated significant study-related duties, together with their roles in 
the study, curriculum vitae, and their signatures;

Copies of CRFs (if paper) and of documentation of corrections for all subjects;

IP accountability records;

Record of any body fluids or tissue samples retained;
Page 468 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
97
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011

All other source documents (subject records, hospital records, laboratory records, 
etc.); 

All other documents as listed in Section 8 of the ICH consolidated guideline on GCP 
(Essential Documents for the Conduct of a Clinical Trial).  
The Investigator must notify Celgene if he/she wishes to assign the essential documents to 
someone else, remove them to another location or is unable to retain them for a specified period.  
The Investigator must obtain approval in writing from Celgene prior to destruction of any 
records.  If the Investigator is unable to meet this obligation, the Investigator must ask Celgene 
for permission to make alternative arrangements.  Details of these arrangements should be 
documented.  
All study documents should be made available if required by relevant health authorities.  
Investigator/Institution should take measures to prevent accidental or premature destruction of 
these documents.  
Page 469 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
98
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
16.
QUALITY CONTROL AND QUALITY ASSURANCE
All aspects of the study will be carefully monitored by Celgene or its authorized representative 
for compliance with applicable government regulations with respect to current GCP and standard 
operating procedures.  
16.1.
Study Monitoring and Source Data Verification
Celgene ensures that appropriate monitoring procedures are performed before, during and after 
the study.  Before the study is initiated at a site visit or at an investigator meeting, all aspects of 
the study are reviewed with the Investigator and the staff.  Prior to enrolling subjects into the 
study, a Celgene representative will review the protocol, eCRFs, procedures for obtaining 
informed consent, record keeping, and reporting of AEs/SAEs with the Investigator.  Monitoring 
will include on-site visits with the Investigator and his/her staff as well as any appropriate 
communications by mail, email, fax, or telephone.  At each monitoring visit, the facilities, 
investigational product storage area, eCRFs, subject’s source documents, and all other study 
documentation will be inspected/reviewed by the Celgene representative for accuracy, adherence 
to the protocol and Good Clinical Practice.  
Accuracy will be checked by performing source data verification that is a direct comparison of 
the entries made onto the eCRFs against the appropriate source documentation.  Any resulting 
discrepancies will be reviewed with the Investigator and/or his/her staff.  Any necessary 
corrections will be made directly to the eCRFs or via queries by the Investigator and/or his/her 
staff.  Monitoring procedures require that informed consents, adherence to inclusion/exclusion 
criteria and documentation of SAEs and their proper recording be verified.  Additional 
monitoring activities may be outlined in a study-specific monitoring plan.  
16.2.
Audits and Inspections
In addition to the routine monitoring procedures, a Good Clinical Practice Quality Assurance 
unit exists within Celgene.  Representatives of this unit will conduct audits of clinical research 
activities in accordance with Celgene SOPs to evaluate compliance with Good Clinical Practice 
guidelines and regulations.  
The Investigator is required to permit direct access to the facilities where the study took place, 
source documents, eCRFs and applicable supporting records of study subject participation for 
audits and inspections by IRB/IECs, regulatory authorities (e.g., FDA, EMEA, Health Canada) 
and company authorized representatives.  The Investigator should make every effort to be 
available for the audits and/or inspections.  If the Investigator is contacted by any regulatory 
authority regarding an inspection, he/she should contact Celgene immediately.  
Page 470 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
99
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
17.
PUBLICATIONS
The results of this study may be published in a medical publication, journal, or may be used for 
teaching purposes.  Additionally, this study and its results may be submitted for inclusion in all 
appropriate health authority study registries, as well as publication on health authority study 
registry websites, as required by local health authority regulations.  Selection of first authorship 
will be based on several considerations, including, but not limited to study participation, 
contribution to the protocol development, and analysis and input into the manuscript, related 
abstracts, and presentations in a study.
Page 471 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
100
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
18.
REFERENCES
Aapro M, Vaupel P.  Erythropoietin:  effects on life expectancy in patients with cancer-related 
anemia.  Curr Med Res Opin. 2006; 22(suppl 4):5-13.
Carlos JJ, Salas M, Ward A, et al.  Anemia as an independent prognostic factor for survival in 
patients with cancer:  a systemic, quantitative review.  Cancer.  2001; 91:2214-2221.
Cella D, Kallich J, McDermott A, et al.  The longitudinal relationship of hemoglobin, fatigue, 
and quality of life in anemic cancer patients:  results from five randomized clinical trials.  Ann 
Oncol. 2004; 15:979-986.
Chantry A, Heath D, Mulivor A, Coulton L, Evans H, Abdul N, Werner ED, Bouxsein ML, 
Pearsall RS, Seehra J, Vanderkerken K, and Croucher PI.  Inhibiting activin-A signalling 
stimulates bone formation, prevents tumor-induced osteolytic bone destruction and blocks bone 
metastasis. J Bone Miner Res 2010; 25 (12), 2633-46, Erroatum in J Bone Miner Res 2011; 26 
(2), 439
Chen Y-G, Lui HM, Lin S-L, Lee JM, and Ying S-Y.  Regulation of cell proliferation, apoptosis, 
and carcinogenesis by activin.  Exp Biol Med 2002; 227: 75-87.  
Dang TP, Carbone DP:  Cancer of the Lung, in DeVita, VT, Hellman S, Rosenberg SA (eds): 
Cancer: Principles & Practice of Oncology, 8th edition, Philadelphia, PA. Lippincott Williams & 
Wilkens, 2008, 887-971.  
Functional Assessment of Chronic Illness Therapy-Fatigue, FACIT-F Version 4. 
http://www.facit.org/qview/qlist.aspx, last accessed 21Jul2010.
Grogan M, Thomas GM, Melamed I, et al.  The importance of hemoglobin levels during 
radiotherapy for carcinoma of the cervix.  Cancer.  1999; 86:1528-1536.
Groopman JE, Itri LM.  Chemotherapy-Induced Anemia in Adults:  Incidence and Treatment.  
Journal of the National Cancer Institute 1999, 91, 1616-1634.  
Hollen, PJ, Gralla, RJ, Kris, MG, and Potanovich, LM. Quality of life assessment in individuals 
with lung cancer:  Testing the Lung Cancer Symptom Scale (LCSS).  European Journal of 
Cancer, 1993; 29A, S51-S58.
Hollen, PJ, Gralla, RJ, Kris, MG, & Cox, C. Quality of life during clinical trials:  Conceptual 
model for the Lung Cancer Symptom Scale (LCSS).  Supportive Care in Cancer, 1994a; 2, 213-
222.
Hollen, PJ, Gralla, RJ, Kris, MG, Cox, C, Belani, CP, Grunberg, SM, Crawford, J, and Neidhart, 
JA. Measurement of quality of life in patients with lung cancer in multicenter trials of new 
therapies:  Psychometric assessment of the Lung Cancer Symptom Scale.  Cancer, 1994b; 73, 
2087-98.
Hollen PJ, Gralla RJ, Kris MG ‘Lung Cancer Symptom Scale (LCSS)’, Administration, Scoring 
and Procedures Manual, (1995) Ver.1.1.  
Page 472 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
101
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
Hollen, PJ, Gralla, RJ, Kris, MG, Eberly, SW, and Cox, C.  Normative data and trends in quality 
of life from the Lung Cancer Symptom Scale (LCSS).  Supportive Care in Cancer, 1999; 7, 140-
148.
Hong WK, Tsao AS, in Lung Carcinoma: Tumors of the Lungs: Merck Manuals Online Medical 
Library for Healthcare Professionals, 2008. 
http://www.merck.com/mmpe/print/sec05/ch062/ch062b.html
Laurie SA, Jeyabalan N, Nicholas G, Dahrouge S.  Association between anemia arising during 
therapy and outcomes of chemoradiation for limited small-cell lung cancer.  J Thorac Oncol.  
2006;146-151.
Lotinun S, Fajardo RJ, Pearsall RS, Bouxsein ML, and Baron R.  A soluble activin receptor type 
IIA fusion protein, ACE-011, increases bone mass by stimulating bone formation and inhibiting 
bone resorption in cynomolgus monkeys.  ASBMR 30th annual meeting, 2008.  
MacRae R, Shyr Y, Jonson D, Choy H.  Declining hemoglobin Turing chemoradiotherapy for 
locally advanced non-small cell lung cancer is significant.  Radiother Oncol. 2002;64:37-40.
Mathews LS.  Activin receptors and cellular signaling by the receptor serine kinase family.  
Endocr Rev 1994; 15: 310-25.  
Murata M, Onomichi K, Eto Y, Shibai H, and Muramatsu M.  Expression of erythroid 
differentiation factor (EDF) in Chinese hamster ovary cells.  Biochem Biophys Res Commun
1988; 151: 230-5.  
Nakao K, Kosaka M and Saito S.  Effects of erythroid differentiation factor (EDF) on 
proliferation and differentiation of human hematopoietic progenitors.  Exp Hematol 1991; 19: 
1090-5.  
National Heart, Lung, and Blood Institute, National Institutes of Health.  New York Heart 
Association Classification. 2008.  
NCCN Clinical Practice Guidelines in Oncology:  Cancer and Chemotherapy Induced Anemia, 
V.2. 2010 http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf; 2009.  
Non-small Cell Lung cancer Collaborative Group ‘Chemotherapy in non-small cell lung cancer:  
a meta-analysis using updated data on individual patients from 52 randomized clinical trials’, 
British Medical Journal 1995 vol. 311, no.7010, 899-909.  
Obermair A, Cheuk R, Horwood K, et al.  Anemia before and during concurrent 
chemoradiotherapy in patients with cervical carcinoma:  effect on progression-free survival.  Int 
J Gynecol Cancer. 2003; 13:633-639.
Oken, MM., Creech, R.H., Tormey, D.C., et. al.  Toxicity And Response Criteria Of The Eastern 
Cooperative Oncology Group.  Am J Clin Onco 1982; 5:649-655.  
Parker SL, Tong T, Bolden S, et. al.  Cancer statistics, 1997.  CA Cancer J Clin, 1997, 47, no. 1, 
5-27.  
Pearsall RS, Canalis E, Cornwall-Brady M, Underwood KW, Haigis B, Ucran J, Kumar R, Pobre 
E, Grinberg A, Werner ED, Glatt V, Stadmeyer L, Smith D, Seehra J, and Bouxsein ML.  A 
soluble activin type IIA receptor induces bone formation and improves skeletal integrity.  Proc 
Natl Acad Sci USA 2008, 105: 7082-7.  
Page 473 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
102
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
Perrien DS, Akel NS, Edwards PK, et. al.  Inhibin A is an endocrine stimulator of bone mass and 
strength.  Endocrinology 2007; 148: 1654-65.  
Rivier J, Spiess J, McClintock R, Vaughan J and Vale W.  Purification and partial 
characterization of inhibin from porcine follicular fluid.  Biochem Biophys Res Commun 1985; 
133: 120-7.  
Rossi A, Maione P, Gridelli C Cetuximab in advanced non-small cell lung cancer.  Critical 
Reviews in Oncology/Hematology, 2006 59, 139-149.  
Ruckle J, Jacobs M, Kramer W, et. al.  A single-dose, randomized, double-blind, placebo-
controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women.  J Bone Miner Res
2009; 24 (4): 744-52.  
Sandler A, Gray R, Perry M, et al Paclitaxel-Carboplatin alone or with Bevacizumab for Non 
Small Cell Lung Cancer, NEJM, 2006 vol.355, no.24, 2542-50.  
Scagliotti G, Parikh P, von Pawel J, et al Phase III Study Comparing Cisplatin Plus Gemcitabine 
With Cisplatin Plus Pemetrexed in Chemotherapy-Naïve patients With Advanced-Stage Non-
Small-Cell Lung Cancer, JCO, 2008, 26 (21): 3543-51.  
Schiller J, Harrington D, Belani C, et al Comparison of Four Chemotherapy Regimens for 
Advanced Non-Small-Cell Lung Cancer.  N Engl J Med 2002; 346:92-98.
Schwartz RN.  Anemia in patients with cancer:  incidence, causes, impact, management, and use 
of treatment guidelines and protocols.  Am J Health Syst Pharm.  2007; 64 (suppl 2):S5-S13.  
Seder C, Hartojo W, Lin L, et al Upregulated INHBA Expression May Promote Cell 
Proliferation and Is Associated with Poor Survival in Lung Adenocarcinoma, Neoplasia, 2009, 
11: 388-396.  
Shedden K, Taylor J, Enkemann S, et al Gene Expression-Based Survival prediction in Lung 
Adenocarcinoma: A Multi-Site, Blinded Validation Study: Director’s Challenge Consortium for 
the Molecular Classification of Lung Adenocarcinoma, Nat Med, 2008, 14 (8): 822-827.  
Shiozaki M, Sakai R, Tabuchi M, et. al.  In vivo treatment with erythroid differentiation factor 
(EDF/activin A) increases erythroid precursors (CFU-E and BFU-E) in mice.  Biochem Biophys 
Res Commun 1989; 165: 1155-61.  
Shiozaki M, Sakai R, Tabuchi M, et. al.  Evidence for the participation of endogenous activin 
A/erythroid differentiation factor in the regulation of erythropoiesis.  Proc Natl Acad Sci USA
1992; 89: 1553-6.  
Vansteenkiste J, Pirker R, Massuti B, et. al.  Double-Blind, Placebo-Controlled, Randomized 
Phase III Trial of Darbepoetin Alfa in Lung Cancer Patients Receiving Chemotherapy.  Journal 
of the National Cancer Institute, 2002, 94: 16: 1211-1220.  
Woodruff TK.  Regulation of cellular and system function by activin.  Biochem Pharmacol 1998; 
55: 953-63.  
Ying S-Y.  Inhibins, activins, and follistatins:  gonadal proteins modulating the secretion of 
follicle-stimulating hormone.  Endocrine Rev 1988; 9: 267-93.  
Page 474 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
103
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
19.
APPENDICES
Appendix A:  Response Evaluation Criteria in Solid Tumors
Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Terms
Definition
Measurable disease
The presence of at least one measurable lesion by CT or MRI.  If the measurable 
disease is restricted to a solitary lesion, its neoplastic nature should be confirmed by 
cytology/histology.  
All measurements should be taken and recorded in metric notation, using a ruler or 
calipers.  All baseline evaluations should be performed as closely as possible to the 
beginning of treatment and never more than 4 weeks before the beginning of the 
treatment. 
Measurable lesions
Lesions that can be accurately measured in least one dimension by CT scan with 
longest diameter > 10 mm (CT scan thickness no greater than 5 mm).  
The same method of assessment and the same technique should be used to characterize 
each identified and reported lesion at baseline and during follow-up. 
Non-measurable lesion
All other lesions, including small lesions (longest diameter <10mm or pathological 
lymph nodes with P10 to <15mm short axis) as well as truly non-measurable lesions.  
Lesions considered truly non-measurable include:  leptomeningeal disease, ascites, 
pleural or pericardial effusion, inflammatory breast disease, lymphangitic involvement 
of skin or lung, abdominal masses/abdominal organomegaly identified by physical 
exam that is not measurable by reproducible imaging techniques.
RECIST Criteria-Response Evaluation
Evaluation of target lesions
Complete Response (CR)
Disappearance of all target lesions.  
Any pathological lymph nodes (whether target or non-target) must have 
reduction in short axis to <10 mm.
Partial Response (PR):
At least a 30% decrease in the sum of diameters of target lesions, taking as 
reference the baseline sum diameters.
Stable Disease (SD):
Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify 
for PD, taking as reference the smallest sum diameters while on study.
Progressive Disease (PD):
At least a 20% increase in the sum of diameters of target lesions, taking as 
reference the smallest sum on study (this includes the baseline sum if that is the 
smallest on study).  In addition to the relative increase of 20%, the sum must 
also demonstrate an absolute increase of at least 5 mm.  
(Note:  the appearance of one or more new lesions is also considered 
progression).
Page 475 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
104
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
RECIST Criteria-Response Evaluation (continued)
Evaluation of non-target 
lesions
Complete Response (CR):
Disappearance of all non-target lesions and normalisation of tumour marker 
level.  All lymph nodes must be non-pathological in size (<10mm short 
axis).
Non-CR/Non-PD
Persistence of one or more non-target lesion(s) and/or maintenance of 
tumour marker level above the normal limits.
Progressive Disease (PD): 
Unequivocal progression (see comments below) of existing non-target 
lesions.  
(Note:  the appearance of one or more new lesions is also considered 
progression).
Evaluation of best overall response
The best overall response is the best response recorded from the start of the 
treatment until disease progression/recurrence (taking as reference for PD 
the smallest measurements recorded since the treatment started).  In general, 
the patient's best response assignment will depend on the achievement of 
both measurement and confirmation criteria.  
Patients with a global deterioration of health status requiring discontinuation 
of treatment without objective evidence of disease progression at that time 
should be classified as having “symptomatic deterioration”.  Every effort 
should be made to document the objective progression even after 
discontinuation of treatment.  
In some circumstances it may be difficult to distinguish residual disease 
from normal tissue.  When the evaluation of complete response depends on 
this determination, it is recommended that the residual lesion be investigated 
(fine needle aspirate/biopsy) to confirm the complete response status.  
Source:  Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R,  Dancey J, Arbuck S, Gwyther S, 
Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R,  Lacombe D, Verweij J.  New response evaluation 
criteria in solid tumours:  Revised RECIST guideline (version 1.1)  (2009).  European Journal of Cancer 45, 228-
247.  
Page 476 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
105
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
Appendix B:  ECOG Performance Status Scale 
The ECOG scale (Oken,1982) is used to assess a patient’s quality of life in an evaluation by a 
health professional of the daily activities and how the activities are affected by the disease of the 
patient.  
Table 10:
ECOG Performance Status Scale
Score
Description
0
Fully active, able to carry on all pre-disease performance without restriction
1
Restricted in physically strenuous activity but ambulatory and able to carry out work of 
a light or sedentary nature, e.g., light housework, office work.
2
Ambulatory and capable of all self-care but unable to carry out any work activities.  Up 
and about more than 50% of waking hours.
3
Capable of only limited self-care, confined to bed or chair more than 50% of waking 
hours.
4
Completely disabled.  Cannot carry on any self-care.  Totally confined to bed or chair
5
Dead
Page 477 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
106
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
Appendix C:  National Cancer Institute (NCI) Common Terminology Criteria 
for Adverse Events (CTCAE) Version 4.0
Currently active minor version of NCI CTCAE, Version 4.0:
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
Page 478 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
107
ACE-011-NSCL-001 2.0 FINAL: 27JUN2011
Appendix D:  New York Heart Association - Classification of Heart Failure
Table 11:
Classification of Heart Failure
Class
Symptoms
Class 1
No limitation of activities.  No symptoms from ordinary activities
Class 2
Mild limitation of activity.  Comfortable with rest or mild exertion
Class 3
Marked limitation of activity and be comfortable only at rest
Class 4
Complete rest, confined to bed or chair; any physical activity brings on discomfort and 
symptoms occur at rest
Page 479 of 791
088VGY

088VGY

088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
3
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
1.
JUSTIFICATION FOR AMENDMENT
Significant changes included in this amendment are summarized below.  These changes were 
based on feedback obtained from investigators/sites, key opinion leaders and internal 
discussions:

Modified to expand eligible tumor types to include advanced or metastatic solid tumors
treated with ≥ first–line platinum–based chemotherapy, excluding those solid tumors 
treated with curative intent, in Part 1 of the study.

Modified to confirm only metastatic NSCLC subjects are eligible for Part 2 of the study.

Clarification that subjects must have received at least one cycle of platinum based 
chemotherapy and up to 4 cycles of a regimen administered every 3 weeks OR up to 3 
months of a regimen administered at other intervals. 

Revised to allow subjects to be randomized while receiving maintenance therapy 
following completion of treatment with platinum-based chemotherapy.

Modified to remove all reference to ACE-011 Process IIa Clinical Drug Product - Frozen 
Liquid Formulation.  Only ACE-011 Process III Clinical Drug Product – Lyophilized 
Powder Formulation will be administered in this study.

Expanded allowable concomitant and maintenance therapy with chemotherapeutic and/or 
targeted agents (e.g., pemetrexed, anti-EGFR agents, anti-VEGF agents) which are 
approved for a given tumor type, in addition to platinum-based chemotherapy. 

Clarification of data collection history of prior use of erythropoietic stimulating agents 
and red blood cell transfusion. 

Clarification of timing interval between two blood pressure measurements required to 
assess sotatercept (ACE-011) dosing.

Clarification that subject discontinuation from treatment and/or study due to protocol 
violation will be determined by the Sponsor.

Clarification that monthly survival data can be collected via telephone contact.

Addition of description of accrual and statistical analysis details in Part 2 of the study in 
the Introduction Section.

Clarification of description of sotatercept (ACE-011) as a recombinant human fusion 
protein.

Toxicology and Potential Risks for Human Use – Revision of sections to provide updated 
non-clinical study data and revised safety multiples based on current human exposure 
data and/or projections. 

Correction of typographical error in hypertension measurement criteria determining 
sotatercept (ACE-011) dose delay.

Correction of hemoglobin collection day 21 post first dose of sotatercept (ACE-011).
Page 482 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
4
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011

Revision of Table 7:  Schedule of Assessments:
a.
Footnote ‘a’ - modified to expand eligible tumor types to include advanced solid
tumors and clarify data collection of prior use of erythropoietic stimulating agents 
and red blood cell transfusion.
b. Footnote ‘b’ – clarification of timing interval between two blood pressure 
measurements required to assess sotatercept (ACE-011) dosing.
c.
Footnote ‘e’, ‘f’, ‘g’ – clarification of screening period for hematology, absolute 
reticulocyte, serum chemistry and creatinine clearance assessments. 
d. Footnote ‘q’ – clarification that subjects must have received at least one cycle of
platinum based chemotherapy.
d. Footnote ‘s’ – revised description of allowable concomitant and maintenance 
therapy with chemotherapeutic and/or targeted agents (e.g., pemetrexed, anti-
EGFR agents, anti-VEGF agents). 
e.
Footnote ‘v’ – clarification that monthly survival data can be collected via 
telephone contact.

Revision of Inclusion Criteria:
a.
Modified to expand study population in Part 1 of the study to include advanced or 
metastatic solid tumor types treated with first-line platinum-based chemotherapy, 
excluding those solid tumors treated with curative intent.
b. Clarification that hemoglobin levels ≥ 6.5 to < 11.0 g/dL (≥ 65 to < 110 g/L) must 
be attributed to chemotherapy-induced anemia.
c.
Consolidation of definition of adequate renal function in Inclusion Criteria to 
include urine protein / creatinine ratio.
d. Expand allowable corrected calcium levels.
e.
Clarification that subjects must have received at least one cycle of platinum-based 
chemotherapy and up to 4 cycles of a regimen administered every 3 weeks OR up 
to 3 months of a regimen administered at other intervals OR be receiving 
maintenance therapy following treatment with platinum-based chemotherapy.

Revision of Exclusion Criteria:
a.
Clarification of allowed prior type and setting of platinum-based chemotherapy in 
Part 2 only.
b. Deletion of exclusion of subjects with second malignancy within three years prior 
to randomization due to frequency of second malignancies in these patient 
populations.
c.
Correction of typographical error in blood pressure measurement exclusion.
d. Deletion of urine protein / creatinine ratio exclusion criterion.  Moved to define 
adequate renal function in Inclusion Criteria.

Revision of Section 9 – Concomitant Medications and Procedures:
Page 483 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
5
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
a.
Deletion of reference to Section 7.2, not applicable following Amendment 2.
b. Further clarify when bisphosphonate and denosumab therapy for metastatic bone 
disease is allowed to begin. 
Other administrative changes (e.g., correction of typographical errors, editorial changes, etc.) 
were also incorporated and are outlined in Section 2 Itemized Changes.
Page 484 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
6
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
2.
ITEMIZED CHANGES
Text Modification Key:
Deleted Text
Added Text
Unchanged Text
2.1.
Section:  Title Page (page 1)
Revised Text:
AN OPEN-LABEL RANDOMIZED, PHASE 2A, DOSE-RANGING 
STUDY (PART 1) OF SOTATERCEPT (ACE-011) FOR 
CHEMOTHERAPY-INDUCED ANEMIA IN SUBJECTS WITH 
SELECTEDADVANCED OR METASTATIC SOLID TUMORS 
TREATED WITH PLATINUM-BASED CHEMOTHERAPEUTIC 
REGIMENS FOLLOWED BY A PHASE 2B/3, DOUBLE-BLIND, 
RANDOMIZED, PLACEBO-CONTROLLED STUDY (PART 2) 
OF SOTATERCEPT (ACE-011) FOR CHEMOTHERAPY-
INDUCED ANEMIA IN SUBJECTS WITH METASTATIC NON-
SMALL CELL LUNG CANCER TREATED WITH FIRST-LINE 
PLATINUM-BASED CHEMOTHERAPEUTIC REGIMENS
Rationale:
Modified to:

Expand reference to study population to include advanced or metastatic solid tumor 
types treated with platinum-based chemotherapy.
Page 485 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
7
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
2.2.
Section:  Protocol Summary (pages 6-12)
Revised Text:
Study Title
An open-label randomized, phase 2a, dose-ranging study (Part 1) of sotatercept (ACE-011) for 
chemotherapy-induced anemia in subjects with selectedadvanced or metastatic solid tumors 
treated with platinum-based chemotherapeutic regimens followed by a phase 2b/3, double-blind, 
randomized, placebo-controlled study (Part 2) of sotatercept (ACE-011) for chemotherapy-
induced anemia in subjects with metastatic non-small cell lung cancer treated with first-line 
platinum-based chemotherapeutic regimens.
Indication
Chemotherapy Induced Anemia (CIA) in Subjects with Advanced or Metastatic Solid Tumors
Part 1 – Solid tumors, includingAdvanced or metastatic non-small cell lung cancer (NSCLC), 
metastatic small cell lung cancer, metastatic bladder cancer, metastatic head and neck cancer, 
and metastatic endometrial/cervical cancer, where the standard of care issolid tumors treated 
with ≥first-–line platinum-–based chemotherapy.  No , excluding those solid tumors other than 
those tumor types listed above should be considered for this study.   treated with curative intent.
Part 2 - Metastatic NSCLC.
Objectives
The primary objectives are:
Part 1:  To determine a dose of sotatercept (ACE-011) that results in a hematopoietic 
response for the treatment of CIA in subjects with selectedadvanced or metastatic 
solid tumors treated with platinum-based chemotherapeutic regimens, excluding those 
solid tumors treated with curative intent.  
_  _  _  _  _  _  _  _  _  _  _
Study Design
This is an open-label, randomized, phase 2a, dose-ranging study (Part 1) of sotatercept (ACE-
011) therapy for CIA in subjects with selectedadvanced or metastatic solid tumors treated with 
platinum-based chemotherapeutic regimens followed by a phase 2b/3, double-blind, randomized, 
placebo-controlled study (Part 2) of sotatercept (ACE-011) therapy for CIA in subjects with 
metastatic non-small cell lung cancer treated with first-line platinum-based chemotherapeutic 
regimens.  
The study will consist of two parts:
Part 1 is a dose-finding segment in which up to approximately 90 subjects will be randomized to 
one of three sotatercept (ACE-011) dose treatment arms.  The primary objective is to determine a 
dose of sotatercept (ACE-011) that results in a hematopoietic response in the treatment of CIA in 
subjects with selectedadvanced or metastatic solid tumors treated with platinum-based 
chemotherapy, excluding those solid tumors treated with curative intent.  The sample size is for 
the purpose of hypothesis generation; however, it would allow approximately 80% power to 
Page 486 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
8
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
detect an effect size of 0.33 using a 2 degrees of freedom Chi-Square Test with a significance 
level (alpha) of 0.05.  
_  _  _  _  _  _  _  _  _  _  _
Study Population
At the time of randomization, all in Part 1 and Part 2, subjects must be receiving their first 
regimen of first-line platinum-based chemotherapy, given every three weeks, for the treatment of 
one of the selected metastatic solid tumor types, which include: metastatic non-small cell lung 
cancer (NSCLC), metastatic small cell lung cancer, metastatic bladder cancer, metastatic head 
and neck cancer, and metastatic endometrial/cervical cancer.  Subjects may have already 
received:
at least one cycle and up to 4 cycles (q3w schedule) of this current platinum-
based regimenchemotherapy and must be randomized prior to receiving Cycle 5.  
OR 
at least one cycle and up to 3 months (depending upon regimen) of platinum-
based chemotherapy 
OR 

currently be receiving maintenance therapy following treatment with platinum-
based chemotherapy 
It is expected that subjects be eligible to continue to receive ≥ 2 additional platinum-based 
chemotherapy cycles while on study treatment.  
SubjectsIn Part 1, subjects must have an advanced or metastatic solid tumor treated with ≥ first–
line platinum–based chemotherapy, excluding those solid tumors treated with curative intent. 
In Part 2, subjects must have metastatic NSCLC and must not have received any other regimens 
of platinum containing regimens of chemotherapy for the first-line treatment of a metastatic solid 
tumor prior to the regimen they are receiving at the time of randomization. 
Concomitant or maintenance therapy with chemotherapeutic and/or targeted agents (e.g., 
pemetrexed, anti-EGFR agents, anti-VEGF agents) which are approved for a given tumor type, 
are allowed in addition to platinum-based chemotherapy.
_  _  _  _  _  _  _  _  _  _  _
Screening Period (28 days):
_  _  _  _  _  _  _  _  _  _  _
Prior erythropoietic stimulating agent (ESA) treatment history starting from the initial diagnosis 
of selected solid tumor typesdiagnosis and red blood cell (RBC) transfusion history starting from 
diagnosis of advanced or metastatic disease, at a minimum of up to two months prior to 
randomization will be collected.  
Page 487 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
9
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
Treatment Period (up to 6-9 months):  
_  _  _  _  _  _  _  _  _  _  _
In Part 1 (the dose-ranging portion of the study), subjects with selectedadvanced or metastatic 
solid tumor types who meet all eligibility criteria will be randomized to receive one of the 
following sotatercept (ACE-011) dose levels, with 10-30 subjects per arm:
Sotatercept (ACE-011) 15 mg SC
Sotatercept (ACE-011) 30 mg SC
_  _  _  _  _  _  _  _  _  _  _
In Part 1, blood samples will be collected to evaluate the full PK profile of sotatercept (ACE-
011) from approximately 30 subjects at select centers, in approximately 10 subjects for each 
sotatercept (ACE-011) dose group. investigated.  In subjects participating in the full PK 
assessment, RBC, Hgb, and reticulocyte counts will be collected at each PK time point 
(excluding the 4-hour time point on Day 1) from Day 1 to Day 43 after the first dose.  Subjects 
not participating in the optional full PK assessment may participate in the sparse PK assessment.  
In Part 2, blood samples will be collected for the sparse PK assessment that will be performed in 
approximately 300 (40%) of 750 subjects (approximately 150 subjects in each arm).  
For subjects who do not participate in either Part 1 full or sparse PK assessments or Part 2 
sparse PK assessments, the ACE-011 (sotatercept) concentration may be determined in their anti-
sotatercept antibody samples to assist in the evaluation of immunogenicity, as well as PK.
Subjects will be discontinued from Study Treatment due to the following:
Adverse events(s)
Hypertension ≥Grade 3 – defined as Stage 2 hypertension (systolic blood 
pressure [SBP] ≥160 mmHg or diastolic blood pressure [DBP] ≥100mmHg), 
confirmed by two measurements obtained at least five minutes apart; medical 
intervention indicated; more than one drug or more intensive therapy than 
previously used indicated or medically significant hypertension which cannot be 
adequately controlled with antihypertensive therapy. 
_  _  _  _  _  _  _  _  _  _  _
Urine protein / creatinine ratio > 1.0; or > 2.0 (if bevacizumab [(Avastin®]®) is 
concomitantly administered)
_  _  _  _  _  _  _  _  _  _  _
Concomitant use of ESAs – In Part 1 if administered at any time and in Part 2 if 
administered < 4 months fromafter first dose of study treatment.  
_  _  _  _  _  _  _  _  _  _  _
Protocol violation - as determined by the Sponsor
Page 488 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
10
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
_  _  _  _  _  _  _  _  _  _  _
Post Treatment Follow-Up Period (monthly visits for up to 6 months)
Subjects who enter the Post Treatment Follow-Up Period will be followed monthly for up to 6 
months from their last dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.  All 
subjects will continue to be followed for TTP and PFS up to one year from their first dose of 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo or until progression of their 
NSCLCadvanced or metastatic disease, whichever occurs first.  
The following events are considered sufficient reasons for discontinuing a subject from the 
study:
Completed study, per protocol (subject has completed six- to nine- month Treatment 
Period plus up to six-month Post Treatment Follow-Up Period including one year 
tumor assessment to determine TTP and PFS).  Note:  Survival data will continue to 
be collected for up to 24 months fromafter first dose of study treatment.  
Withdrawal of consent
Death
Lost to follow-up
The following events may be considered sufficient reasons for discontinuing a subject from the 
study, as determined by the Sponsor:
Adverse event(s)
Disease progression 
Protocol violation
Survival Follow-up Period (monthly for up to 24 months after first dose of sotatercept 
(ACE-011) or sotatercept (ACE-011)/placebo)
In both Part 1 and Part 2, survival data will be collected monthly (can be via telephone     
contact) for up to 24 months following the subject’s first dose of sotatercept (ACE-011) (Part 1) 
or sotatercept (ACE-011)/placebo (Part 2).  Collection of survival data will begin following 
Study Discontinuation Visit.  Data to be collected will include:
Overall survival
Post-Treatment Anti-Neoplastic Therapy, if any
Rationale:
Modified to:

Expand study population in Part 1 of the study to include advanced and metastatic solid 
tumor types treated with ≥ first-line platinum-based chemotherapy, excluding those solid 
tumors treated with curative intent.

Confirm only metastatic NSCLC subjects are eligible for Part 2 of the study.
Page 489 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
11
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011

Clarify that subjects must have received at least one cycle of platinum based 
chemotherapy and up to 4 cycles of a regimen administered every 3 weeks OR up to 3 
months of a regimen administered at other intervals. 

Allow subjects to be randomized while receiving maintenance therapy following 
treatment with platinum-based chemotherapy.

Expand allowable concomitant and maintenance therapy with chemotherapeutic and/or 
targeted agents (e.g., pemetrexed, anti-EGFR agents, anti-VEGF agents) which are 
approved for a given tumor type, in addition to platinum-based chemotherapy. 

Clarify prior ESA treatment and RBC transfusion history to be recorded at screening. 

Clarify data collection of prior use of erythropoietic stimulating agents and red blood cell 
transfusion history. 

Clarify timing interval between two blood pressure measurements required to assess 
sotatercept (ACE-011) dosing.

Clarify that subject discontinuation from treatment and study due to protocol violation 
will be determined by the Sponsor.

Clarify that monthly survival data can be collected via telephone contact.

Correct various grammatical and editorial errors in Introduction section.
Page 490 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
12
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
2.3.
Section 1:  Introduction (pages 19-34)
Revised Text:
This is an open-label, randomized, phase 2a, dose-ranging study of sotatercept (ACE-011) 
therapy for chemotherapy-induced anemia (CIA) in subjects with selectedadvanced or metastatic 
solid tumors treated with platinum-based chemotherapeutic agents followed by a phase 2b/3, 
double-blind, randomized, placebo-controlled study of sotatercept (ACE-011) therapy for 
chemotherapy-induced anemia (CIA) in subjects with metastatic non-small cell lung cancer 
(NSCLC) treated with platinum-based chemotherapeutic regimens.  The study will consist of two 
parts.  Part 1 is a dose finding segment in which up to 90 subjects with selectedadvanced or
metastatic solid tumor types treated with platinum-based chemotherapy will be randomized to 
one of three sotatercept (ACE-011) dose treatment arms.  Continuous monitoring of safety data 
will be conducted, including the review of Part 1 data to determine the sotatercept (ACE-011) 
dose to be used in Part 2, the phase 2b/3, double-blind, randomized placebo-controlled segment 
of the study.  
Part 2 will include only subjects with metastatic NSCLC and will be performed in two stages.  
Its primary objective is to determine the transfusion rate following initiation of sotatercept 
(ACE-011) treatment versus placebo in subjects with CIA who have metastatic NSCLC treated 
with first-line platinum-based chemotherapeutic regimens.
In the first stage of Part 2 approximately 180 subjects will be randomized to receive sotatercept 
(ACE-011), at the dose determined from Part 1, or placebo at a ratio of 1:1.  An interim futility 
assessment based on transfusion rate at 4 months will be performed as described in Section 10.8.  
It is expected that accrual will continue during the interim assessment period.  Based on the 
results of the futility analysis and upon recommendation to continue the study, up to an 
additional 570 subjects will be randomized in the second stage of Part 2, to achieve full study 
accrual.
A Data Monitoring Committee (DMC) will monitor the conduct of the study.  
Sotatercept (ACE-011) (ActRIIA-IgG1Fc) is a recombinant human fusion protein consisting of 
the extracellular domain (ECD) of activin receptor IIA (ActRIIA) linked to the human IgG1 Fc 
domain, which includes the heavy chain hinge and constant domains, CH2 and CH3.  
_  _  _  _  _  _  _  _  _  _  _
Sotatercept (ACE-011)
Sotatercept (ACE-011) (ActRIIA-IgG1Fc) is a recombinant human fusion protein consisting of 
the extracellular domain (ECD) of activin receptor IIA (ActRIIA) linked to the human IgG1 Fc 
domain, which includes the heavy chain hinge and constant domains, CH2 and CH3.  The ECD 
sequence of ActRIIA is completely conserved among numerous species including mouse, rat, 
cynomolgus monkey and humans, thus mouse, rat and cynomolgus monkeys have been 
considered relevant species for nonclinical evaluation of sotatercept (ACE-011).  However, in 
order to reduce the potential immunogenicity of the human molecule, sotatercept (ACE-011), 
and to maximize the opportunity to maintain exposures in chronic models, a murine surrogate 
molecule was constructed by exchanging the human immunoglobulin Fc sequence portion of 
Page 491 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
13
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
sotatercept (ACE-011) with its murine IgG2a homolog.  The resultant construct is referred to as 
RAP-011 (ActRIIA-mIgG2aFc), and is described in the pharmacology studies below.  Both 
ACE-011 and RAP-011 bind with high affinity to activin A/B, GDF-11 and, with slightly lower 
affinity, to BMP-10.
_  _  _  _  _  _  _  _  _  _  _
Toxicology
_  _  _  _  _  _  _  _  _  _  _
Test article related hematological (increase in RBC parameters) and reproductive (epididymal 
granulomas, testicular degeneration, decreased sperm counts and motility, and change in 
ovarian/uterine weights) findings were expected pharmacodynamic effects of ActRIIA signal 
inhibition, likely mediated via modulation of erythropoiesis and FSH secretion, respectively.  
Unique to rats were adrenocortical and pancreatic findings.  Neither finding was associated with 
any clinical signs of adrenocortical (anorexia, weakness, gastrointestinal disturbances, serum 
electrolyte disturbances) or pancreatic (abnormal stool, weight loss) insufficiency.  Kidney 
findings include membranoproliferative glomerulonephritis and/or tubulointerstitial nephritis in 
rats and monkeys.  The glomerulonephritis was presumed to be due to anti-sotatercept (ACE-
011) antibody deposition in the kidneys.  This presumption is supported by a robust anti-drug 
antibody response observed in rats as well as demonstration, by immunohistochemistry, of 
immunoglobulin and complement at the site of injury in monkeys, consistent with immune 
complex deposition.  However, high plasma concentrations of sotatercept (ACE-011) in 
monkeys likely interfered with the immunogenicity assay, so the true incidence of anti-drug 
antibodies is unknown in this species.  
The no-observed-adverse effects levels (NOAELs) from the 3 month SC studies were 3 and 30 
mg/kg in rats and monkeys, respectively.  Since the kidney findings were observed at all dose 
levels, the NOAEL from the 6 month monkey study is < 10 mg/kg.  A 9-month monkey study to 
evaluate the effects of lower concentrations of sotatercept (ACE-011) has been completed (refer 
to Potential Risks for Human Use).in rats and monkeys were 3 (3-month study) and 1 mg/kg (9-
month study), respectively.    
_  _  _  _  _  _  _  _  _  _  _
Potential Risks for Human Use
Nonclinical studies to determine the safety of sotatercept (ACE-011) have been conducted in 
cynomolgus monkeys and Sprague-Dawley rats.  Many of the observed effects in these studies 
were as a result of the expected biologic activity of activin inhibitionsotatercept and can be 
summarized as a dose-dependent decrease in sperm count and motility secondary to FSH 
suppression as well as reversible increases in RBC parameters due to the effects on erythroid 
differentiation factor (activin).erythropoiesis.  
Page 492 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
14
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
The most significant toxicity findings are listed below:  
_  _  _  _  _  _  _  _  _  _  _
In the 6- and 9-month monkey studies, glomerulonephritis and/or tubulointerstitial 
nephritis were observed in monkeys administered ≥ 10 mg/kg administered 
subcutaneously (SC) every 2 or 4 weeks. At 2.6 mg/kg administered SC every 4 
weeks for 9 months, kidney findings were limited to a single incidence of 
tubulointerstitial nephritis.  The NOAEL in the 9-month study was considered to be 1 
mg/kg every 4 weeks.  Serum exposure in monkeys at the 1 mg/kg dose is estimated 
to be ~1.34-fold greater than the projected serum exposure in humans at the 
maximum proposed human dose of 61 mg every 6 weeks. in a 50 kg subject.  Because 
sotatercept is a fully human molecule, immunogenicity and, by extension, kidney 
injury is not expected in humans.  In the single- and multiple-dose studies in healthy 
postmenopausal women, there have been no changes in serum chemistry or urinalysis 
profiles suggestive of kidney injury.  Subjects administered sotatercept (ACE-011) 
should continue to be closely monitored.  
In the 9-month monkey study, treatment-related findings in the choroid plexus 
included:  perivascular accumulations of foamy macrophages and intimal thickening 
of small arteries and arterioles primarily at 10 mg/kg administered every 2 weeks as 
well as an increased incidence of small, focal aggregates of mononuclear 
inflammatory cells at all dosages. These changes were also considered related to the 
formation of anti-drug antibodies. Findings at 1 mg/kg were limited to mononuclear 
cell infiltrates and were not considered adverse. 
_  _  _  _  _  _  _  _  _  _  _
Pregnancy and Lactation
Due to the potential for effects on hormones in the pituitary, including FSH, in 
addition to possible direct effects on fetus, there may be potential effects on the 
fetus. Delays in fetal development (decreased fetal weights and delays in 
ossification) were observed in rats at doses ≥15 mg/kg (152.8-fold greater on a 
mg/kg basisexposure than the projected exposure at the maximum proposed 
human dose of 6061 mg every 6 weeks assumingin a 6050 kg personsubject). In 
addition, at 50 mg/kg (1004.7-fold the exposure at the maximum proposed human 
dose), there was an increase in late fetal death coupled with an overall increase in 
post implantation loss and a reduction in live litter size, as well as an increase in 
the incidence of developmental variations of supernumerary ribs with 
corresponding increases and decreases in thoracic and lumbar vertebrae, 
respectively. No fetal malformations were observed in this study at dosages up to 
50 mg/kg. The NOAEL for embryofetal development effects was 5 mg/kg 
(~(1.5-fold greater exposure than the exposure at the maximum proposed human 
dose of 601 mg every 6 weeks assumingin a 6050 kg personsubject) based on 
reduced fetal weights and associated delays in ossification. Although the risks for 
embryofetal
Page 493 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
15
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
In an embryo-fetal development effects are considered relatively low givenstudy
in rabbits, post implantation loss was increased and average litter size and live 
fetuses were reduced at 15 and 50 mg/kg. In addition, fetal body weights were 
reduced in all sotatercept dosage groups. Abortions occurred in one rabbit in the 
large safety margins, precautions5 mg/kg dosage group and two rabbits in the 50 
mg/kg dosage group. Based on these findings, an NOAEL was not identified in 
this study and was therefore less than 5 mg/kg (<1.2-fold greater exposure than 
the exposure at the maximum proposed human dose of 61 mg every 6 weeks in a 
50 kg subject) 
Precautions should still be taken to protect females of childbearing potential.
Nonclinical studies on breast milk have not been done.  
_  _  _  _  _  _  _  _  _  _  _
Fertility
In male rats, sperm granulomas and testicular degeneration were observed 
histologically.  In addition, sperm analysis revealed a reduction in sperm counts 
and motility as well as sperm fragmentation in isolated animals (2/10 males) at 
doses of 30 mg/kg IV.  Sperm fragmentation was also noted in 2/5 males 
administered 10 mg/kg IV at the end of the recovery period.  Overall, there was 
some evidence of recovery (motility similar to controls) at the end of the 4-week 
recovery period.  There was no evidence of a treatment-related impact on 
reproductive organs (testes, ovary, uterus) of monkeys in the toxicity studies; 
however, the monkeys on these studies, were too immature to fully assess the 
potential impact on reproductive organs.  The NOAEL for reproductive effects 
(testicular or ovarian) was 1 mg/kg IV.  Serum exposure (AUC28d) in rats at the 
NOAEL was estimated to be ~ 8,000 µg·hr/mL based on the single-dose IV 
pharmacokinetic study in rats (Report TR148), ~ 2-fold greater than the serum 
exposure observed in humans at the maximum proposed dose of 601 mg every 6 
weeks (estimated AUC28d ~ 45248 μg·hr/mL in a 50 kg subject).  
Rationale:
Modified to:

Expand study population in Part 1 of the study to include advanced and metastatic solid 
tumor types treated with ≥ first-line platinum-based chemotherapy, excluding those solid 
tumors treated with curative intent.

Include additional description of accrual and statistical analysis details in Part 2 of the 
study.

Add description of sotatercept (ACE-011) as a recombinant human fusion protein.

Incorporate updated toxicology and non-clinical study data and revised safety multiples 
based on current human exposure data and/or projections. 
Page 494 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
16
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
2.4.
Section 2:  Study Objectives (page 36)
Revised Text:
2.1.
Primary Objective
Part 1:  To determine a dose of sotatercept (ACE-011) that results in a hematopoietic 
response for the treatment of CIA in subjects with selectedadvanced or metastatic 
solid tumors treated with platinum-based chemotherapeutic regimens., excluding 
those solid tumors treated with curative intent,.
Rationale:
Modified to:

Expand study population in Part 1 of the study to include advanced and metastatic solid 
tumor types treated with ≥ first-line platinum-based chemotherapy, excluding those solid 
tumors treated with curative intent.
Page 495 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
17
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
2.5.
Section 4:  Overall Study Design (pages 39-40)
Revised Text:
4.1.
Study Design 
This is an open-label randomized, phase 2a, dose-ranging study (Part 1) of sotatercept (ACE-
011) therapy in subjects with selectedadvanced or metastatic solid tumor types treated with 
platinum-based chemotherapeutic regimens followed by a phase 2b/3, double-blind, randomized, 
placebo-controlled study of sotatercept (ACE-011) therapy for CIA in subjects with metastatic 
NSCLC treated with platinum-based chemotherapeutic regimens.  
The study will consist of two parts.  Part 1 is a dose finding segment in which subjects with 
selected advanced or metastatic solid tumor types will be randomized to one of three sotatercept 
(ACE-011) dose treatment arms.  Continuous monitoring of safety data will be conducted, 
including the review of Part 1 data to determine the sotatercept (ACE-011) dose to be used in 
Part 2, the phase 2b/3, double-blind, randomized placebo-controlled segment of the study in 
subjects with metastatic NSCLC.  
A DMC will monitor the conduct of the study. 
Part 1 is planned to be conducted at selected sites and will be extended to additional global sites 
for the conduct of Part 2.  
Study treatment is defined as sotatercept (ACE-011) in Part 1 and sotatercept (ACE-
011)/placebo in Part 2.  
Three starting sotatercept (ACE-011) dose levels, 15, 30, and 45 mg, were selected for Part 1 of 
the study. Up to approximately 90 subjects with selectedadvanced or metastatic solid tumor 
types will be randomized to one of the following sotatercept (ACE-011) dose levels, with 10-30 
subjects per arm:
Sotatercept (ACE-011) 15 mg SC
Sotatercept (ACE-011) 30 mg SC
_  _  _  _  _  _  _  _  _  _  _
The Treatment Period for Part 1 is approximately six months, which includes up to 4 doses of 
sotatercept (ACE-011) and for Part 2 approximately nine months, which includes up to 6 doses 
of sotatercept (ACE-011/placebo).  Subjects who enter the Post Treatment Follow-Up Period 
will be followed for up to 6 months from their last dose of sotatercept (ACE-011) or sotatercept 
(ACE-011)/placebo.  All subjects will continue to be followed for TTP and PFS up to 12 months 
from their first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo or until 
progression of their advanced or metastatic disease, whichever occurs first.  
Survival data will be collected monthly for up to 24 months following the subject’s first dose of 
sotatercept (ACE-011) in Part 1 or sotatercept (ACE-011)/placebo in Part 2.  
Page 496 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
18
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
At the time of randomization, all in Part 1 and Part 2, subjects must be receiving their first 
regimen of first-line platinum-based chemotherapy, given every three weeks, for the treatment of 
a selected metastatic solid tumor.  Subjects may have already received:
at least one cycle and up to 4 cycles (q3w schedule) of this current platinum-
based regimenchemotherapy and must be randomized prior to receiving Cycle 5.  
OR 
at least one cycle and up to 3 months (depending upon regimen) of platinum-
based chemotherapy 
OR 

currently be receiving maintenance therapy following treatment with platinum-
based chemotherapy 
It is expected that subjects be eligible to continue to receive ≥ 2 additional platinum-based 
chemotherapy cycles while on study treatment.  
SubjectsIn Part 1, subjects must have an advanced or metastatic solid tumor treated with ≥ first–
line platinum–based chemotherapy, excluding those solid tumors treated with curative intent. 
In Part 2, subjects must have metastatic NSCLC and must not have received any other regimens 
of platinum containing regimens of chemotherapy for the first-line treatment of a metastatic solid 
tumor prior to the regimen they are receiving at the time of randomization.  
Rationale:
Modified to:

Expand study population in Part 1 of the study to include advanced and metastatic solid 
tumor types treated with ≥ first-line platinum-based chemotherapy, excluding those solid 
tumors treated with curative intent.

Clarify that subjects must have received at least one cycle of platinum based 
chemotherapy and up to 4 cycles of a regimen administered every 3 weeks OR up to 3 
months of a regimen administered at other intervals. 

Allow subjects to be randomized while receiving maintenance therapy following 
treatment with platinum-based chemotherapy.

Confirm that only subjects with metastatic NSCLC are eligible for Part 2 of the study.
Page 497 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
19
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
2.6.
Section 4.1.1:  Sotatercept (ACE-011) Dose Modification, Reduction 
and Escalation Rules (pages 43-45)
Revised Text:
(Appears on following page.)
Page 498 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
20
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
Subjects should have Hgb and blood pressure measured (confirmed by two measurements 
obtained at least five minutes apart) prior to each dose of study drug.  The Investigator must 
adhere to the following Hgb and blood pressure-based dose modification rules for sotatercept 
(ACE-011) or sotatercept (ACE-011)/placebo for the subject’s second dose of study treatment 
and beyond.  
Sotatercept (ACE-011) Dose Modification Rules:
Hemoglobin < 11g/dL
(per local* lab value) 
Hemoglobin ≥ 11g/dL
(per local* lab value) 
Hypertension ≥ SBP 150 mmHg andor ≥DBP 100 mmHg
*Note:  Local laboratory assessments are allowed in cases when timely results are needed (e.g., randomization, 
study treatment and chemotherapy dosing decisions, hematology assessments between clinic visits).  Whenever 
possible a “split” sample should also be forwarded to the central laboratory for analysis. Local laboratory data 
should be collected in the eCRF.  
< 2.0 g/dL increase within a 
dosing period or a ≥ 2.0 g/dL 
increase not sustained for a 28 
day period since last dosing day 
≥ 2.0 g/dL increase sustained for a 
28 day period since last dosing day2
Note: ≥ 3.0 g/dL increase sustained 
for a 28 day period since last dosing 
day requires a two level dose 
reduction.  
< 2.0 g/dL increase within a 
dosing period or a   ≥ 2.0g/dL 
increase not sustained for a 28 
day period since last dosing day
≥ 2.0g/dL increase sustained for a 28 day 
period since last dosing day2
Note: ≥ 3.0g/dL increase sustained for a 28 
day period since last dosing day requires a 
two level dose reduction.  If Hgb is > 15.0 
g/dL, sustained for 7 days, subject is to be 
discontinued from treatment2. 
Dose Delay5
Continue 
Dosing1
(Part 1 only-
Dose Escalation 
Table 6)
Continue Dosing 
with Dose 
Reduction 
Table 5: Sotatercept 
(ACE-011) and 
Sotatercept (ACE-
011)/Placebo Dose 
Reduction Levels
Dose Delay3
Dose Delay 
then, Dose 
Reduction4
Page 499 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
21
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
1If Hgb increase ≥ 1.0 but < 2.0 g/dL, dose remains the same.
For Part 1 only:  if the RBC transfusion was given > 7 days following the previous dose of sotatercept (ACE-011), 
the subsequent dose of sotatercept (ACE-011) will be increased one dose level (Refer to sotatercept (ACE-011) 
Dose Escalation Levels- Table 6).  Hemoglobin level must be < 11 g/dL AND hypertension < SBP 150 mmHg and 
< DBP 100 mmHg on the day of dosing.  Sotatercept (ACE-011) should not be administered ≤7 days post RBC 
transfusion.  
For Part 2:  Subjects who have received an RBC transfusion in the past 42 days should continue at the same
sotatercept (ACE-011)/placebo dose if the transfusion was given greater than 7 days from the previous dose of 
sotatercept (ACE-011)/placebo AND the Hgb level is < 11 g/dL AND hypertension is < SBP 150 mmHg and < 
DBP 100 mmHg on the day of dosing.  Sotatercept (ACE-011)/placebo should not be administered ≤7 days post 
RBC transfusion.  
2Hemoglobin increases of > 2 g/dL sustained for a 28 day period since last dosing day should be confirmed on the 
dosing day, 7, 14 , 2221 (after first dose of study treatment) and 28 days after dosing, and reviewed in comparison 
to Hgb level on previous dosing day.  Any Hgb increase of ≥3.0 g/dL sustained for 28 days will require a 
subsequent sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dose reduction of two dose levels (Refer to 
sotatercept (ACE-011) and sotatercept (ACE-011)/Placebo Dose Reduction Levels (Table 5).  A second Hgb 
increase of ≥ 3.0 g/dL sustained for 28 days, following a two level dose reduction, will require the subject 
discontinue from study treatment.  If Hgb is > 15.0 g/dL (sustained for a 7 day period, confirmed by laboratory 
assessment) subject is to be discontinued from treatment.  (See Section 8.2.3 Discontinuation)  
3Sotatercept (ACE-011) or sotatercept (ACE-011)/placebo should be delayed until Hgb is < 11g/dL and 
hypertension < SBP 150mm Hg and < DBP 100 mm Hg.  Dosing can commence at ≥7 days after the originally 
planned sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dose that was delayed.  Subsequent sotatercept 
(ACE-011) or sotatercept (ACE-011)/placebo doses will then begin 42 days following this revised treatment dose 
date.  
A delayed sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dose is defined as a dose administered > 4 
days from the planned dosing date (due to Hgb ≥11.0 g/dL, hypertension > SBP 150 mmHg andor > DBP 100 
mmHg and/or sotatercept (ACE-011) related toxicity).  
4Sotatercept (ACE-011)or sotatercept (ACE-011)/placebo should be delayed as above in foot note (3), a reduced 
dose as above in foot note (2) of sotatercept (ACE-011) will be administered based on the evaluation of the Hgb 
and blood pressure at that time.  
5Sotatercept (ACE-011)or sotatercept (ACE-011)/placebo should be held until hypertension resolves to < SBP 
150mmHg and < DBP 100 mmHg and may then be resumed beginning seven days after the previous planned 
scheduled treatment visit as above in foot note (3).  
_  _  _  _  _  _  _  _  _  _  _
Blood pressure (confirmed by two measurements obtained at least five minutes apart) and Hgb 
values must be evaluated prior to dosing at each dosing day for consideration in administration 
of sotatercept (ACE-011) and sotatercept (ACE-011)/placebo.  
_  _  _  _  _  _  _  _  _  _  _
Rationale:
Modified to:

Clarify timing interval between two blood pressure measurements required to assess 
sotatercept (ACE-011) dosing.
Page 500 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
22
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011

Correct typographical error in hypertension criteria determining sotatercept (ACE-011) 
dose delay:
o
Hypertension ≥ SBP 150 mmHg and ≥DBP 100 mmHg
Dose Delay
To be modified with:
o
Hypertension ≥ SBP 150 mmHg or ≥DBP 100 mmHg
Dose Delay

Correct hemoglobin collection day 21 post first dose of sotatercept (ACE-011).
Page 501 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
23
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
2.7.
Section 4.2:  Study Design Rationale (page 46)
Revised Text:
The A011-01, A011-02 and A011-04 studies have shown that dosing with sotatercept (ACE-011) 
resulted in a rapid, sustained and dose-dependent increases in hematopoietic parameters, (Hgb, 
HCT and RBC counts) which occurred earlier than would be expected from a stimulation of 
erythropoiesis by an ESA.  This observation, coupled with nonclinical data demonstrating some 
level of erythrocyte stimulatory effect in the presence of anti-erthyropoietin (EPO) antibodies, 
suggests that the hematopoietic effect of sotatercept is different from that of ESAs. Treatment of 
subjects with metastatic lung cancer with myelosuppressive platinum-based chemotherapy is 
frequently associated with anemia.  Chemotherapy induced anemia is a significant problem for 
subjects with cancer, causing fatigue and reduced quality of life (Groopman, 1999).  Subjects 
with CIA are currently treated with blood transfusion and/or ESAs (NCCN Guidelines, 2009).  
However, with these treatment options CIA is still an area of major medical morbidity.  
Erythropoiesis-stimulating agents can successfully mitigate transfusion need in a proportion of 
these subjects, but concerns have emerged regarding apparent negative effects on survival and/or 
tumor progression in certain patient populations.  
Rationale:
Modified to:

Correct typographical error.
Page 502 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
24
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
2.8.
Section 4.3:  Study Duration (page 49)
Revised Text:
To evaluate sequence and study timelines, please see the Table of Events (see Section 5).  
Approximately 60-90 subjects with selectedadvanced or metastatic solid tumor types in Part 1
and 750 subjects with metastatic NSCLC in Part 2 will be randomized prior to receiving the fifth 
cycle (q3w regimen) OR prior to starting the fourth month (depending upon regimen) of 
platinum-based chemotherapy OR during maintenance therapy following treatment with 
platinum-based chemotherapy.  Each subject will be on the study for approximately 12 – 15 
months (including the Screening Period, the Treatment Period, and the Post Treatment Follow-
Up Period).  The Treatment Period is approximately 6 to 9 months (four to six doses of 
sotatercept [ACE-011] every 42 days) with a Post Treatment Follow-Up Period of six months 
from the subjects’ last dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.  
Subjects who discontinue treatment early will still continue to the Post Treatment Follow-Up 
Period for six months from their last dose of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo.  
All subjects will continue to be followed for TTP and PFS up to 12 months from their first dose 
of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo or until progression of their 
advanced or metastatic disease, whichever occurs first.  All subjects will continue to be followed 
for survival up to 24 months from their first dose of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo.
Rationale:
Modified to:

Expand study population in Part 1 of the study to include advanced and metastatic solid 
tumor types treated with ≥ first-line platinum-based chemotherapy, excluding those solid 
tumors treated with curative intent.

Clarify that subjects must have received at least one cycle of platinum based 
chemotherapy and up to 4 cycles of a regimen administered every 3 weeks OR up to 3 
months of a regimen administered at other intervals. 
Page 503 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
25
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
2.9.
Section 5:  Table Of Events (pages 54-55)
Revised Text:
Table 7:
Sotatercept (ACE-011) Schedule of Assessments
Treatment Period
Screening 
Period
Sotatercept (ACE-011)
Dose 1 Schedule
(± 3 days)
Sotatercept (ACE-011)
Subsequent
Doses 2  through 6 Schedule
(± 3 days)
Post Treatment Follow-Up Period
(± 1 week)
Survival
(±1wk)
Assessments
Day -28
to
Day -1
D1
D8
D15 D22 D29
D43/
D1
D8
D15 D29
D43 
Post Last 
Dose/End 
of Study 
Txt
1
Month
2
Month
3
Month
4
Month
5
Month
6
Month/
Study
DCu
Survival
_  _  _  _  _  _  _  _  _  _  _
Cancer History and Prior Therapiesa
X
Prior ESA and RBC transfusion historya
X
X
_  _  _  _  _  _  _  _  _  _  _
Vital Signs / Blood Pressureb
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
_  _  _  _  _  _  _  _  _  _  _
Administer 
Sotatercept (ACE-011)/Perform Drug 
Accountabilityq
X
X
_  _  _  _  _  _  _  _  _  _  _
Targeted/Maintenance Therapys
Dosing of allowed regimen(s) per standard practice
Overall Survivalv
X
Page 504 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
26
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
aInclude cancer history, date of original diagnosis, clinical stage at Screening and date of metastases and advanced or metastatic site involvement.  Record prior 
ESA history, starting at selected solid tumor diagnosis.  Record RBC transfusion history, starting from diagnosis of advanced or metastatic disease, at a 
minimum of two months prior to randomization.  
bVital signs (including heart rate, seated blood pressure, and temperature) will be measured at Screening and all subsequent clinical visits, on Day 29 post 
sotatercept (ACE-011) or sotatercept (ACE-011)/ placebo dose, at Treatment Discontinuation, and at Study Discontinuation.  Blood pressure should be 
confirmed by two measurements obtained at least five minutes apart Investigators are to report any clinically significant abnormal findings as adverse events.  
_  _  _  _  _  _  _  _  _  _  _
Note:  Footnotes e, f, g :  Hematology, absolute reticulocyte count, serum chemistry and creatinine clearance are to be assessed ≤14 days prior to 
randomization.
_  _  _  _  _  _  _  _  _  _  _
qSotatercept (ACE-011) or sotatercept (ACE-011)/placebo dosing repeats every 42 days and will start after the subject begins an every 3 weeka platinum-based 
chemotherapy regimen.  The first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo may be given at any time following the first dose of 
first-line platinum-based chemotherapy.  Subsequent doses of Sotatercept (ACE-011) or sotatercept (ACE-011)/placebo can be administered at any time 
point during a the chemotherapy cycle or maintenance therapy. 
Administration of subsequent cycles of chemotherapy, including dose reductions and dose delays, should not affect the sotatercept (ACE-011) or sotatercept 
(ACE-011)/placebo dosing schedule, unless determined to be necessary by the Investigator.  If there is a chemotherapy dose delay, sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo administration does not need to be delayed until start of next chemotherapy cycle. 
_  _  _  _  _  _  _  _  _  _  _
sPemetrexed or erlotinib s Targeted/maintenance therapy (e.g. pemetrexed, erlotinib, etc.) is to be administered based on guidelines for administration according 
to manufacturer’s recommendations and standard clinical practice.  
_  _  _  _  _  _  _  _  _  _  _
vSurvival data will be collected monthly, (can be via telephone contact,), following the Study Discontinuation visit for an additional 12 months (up to 24 months 
after first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo).  
Rationale:
Modified to revise footnote text:

Footnote ‘a’ - modified to expand eligible tumor types to include advanced solid tumors and clarify data collection of prior use 
of erythropoietic stimulating agents and red blood cell transfusion.

Footnote ‘b’ – clarify timing interval between two blood pressure measurements required to assess sotatercept (ACE-011) 
dosing.
Page 505 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
27
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011

Footnote ‘e’, ‘f’, ‘g’ – added to clarify screening period for hematology, absolute reticulocyte, serum chemistry and creatinine 
clearance assessments. 

Footnote ‘q’ – clarify that subjects must have received at least one cycle of platinum based chemotherapy.

Footnote ‘s’ – revise description of allowable concomitant and maintenance therapy with chemotherapeutic and/or targeted 
agents (e.g., pemetrexed, anti-EGFR agents, anti-VEGF agents). 

Footnote ‘v’ – clarify that monthly survival data can be collected via telephone contact.
Page 506 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
28
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
2.10.
Section 6:  Procedures (pages 58-61)
Revised Text:
Screening Period (Day -28 to Day -1)
_  _  _  _  _  _  _  _  _  _  _
The assessments and procedures that will be performed during the Screening Period are outlined 
in the Table of Events (see Section 5) and include:
_  _  _  _  _  _  _  _  _  _  _
Cancer history, including date of original diagnosis, histopathology, clinical stage at 
screening, date of advanced or metastatic stage and site involvement
Prior ESA treatment history starting from the initial solid tumor diagnosis of one of 
the selected solid tumors
RBC transfusion history starting from diagnosis of advanced or metastatic disease at a 
minimum of up two months prior to randomization

Serum chemistry, hematology, absolute reticulocyte count to be assessed within ≤14 
days prior to of randomization

Creatinine clearance (per Cockroft-Gault formula) to be assessed ≤within 14 days 
prior to study treatment administration randomization
_  _  _  _  _  _  _  _  _  _  _
Treatment Period (Day 1/Dose 1 of study treatment to Day 43 post last study treatment 
dose)
_  _  _  _  _  _  _  _  _  _  _
The assessments and procedures that will be performed during the Treatment Period are outlined 
in the Table of Events (see Section 5).  
_  _  _  _  _  _  _  _  _  _  _
Serum iron, total iron binding capacity (TIBC), transferrin and serum ferritin at last 
dose and 4342 days after last dose of study treatment
Vitamin B12 and RBC folate levels at last dose and 4342 days after last dose of study 
treatment
_  _  _ _  _  _  _  _  _  _  _
Documentation of concomitant platinum-based chemotherapy and/or 
targeted/maintenance therapy
Rationale:
Modified to:

Expand reference to study population to include advanced disease.
Page 507 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
29
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011

Clarify data collection of prior use of erythropoietic stimulating agents and red blood cell 
transfusion.

Clarify screening period for hematology, absolute reticulocyte, serum chemistry and 
creatinine clearance assessments. 

Correct typographical error of ’43 days’ to ’42 days”.

Add allowed targeted therapy.
Page 508 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
30
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
2.11.
Section 7:  Study Population (page 67)
Revised Text:
Subjects must be receiving their first regimen of first-line platinum-containing chemotherapy, 
given, every three weeks, for the treatment of a selected metastatic solid tumor at At the time of 
randomization: metastatic NSCLC, metastatic small cell lung cancer, metastatic bladder cancer, 
metastatic head in Part 1 and neck cancer, and metastatic endometrial/cervical cancer, where the 
standard of care is first-line platinum-based chemotherapy.  Subjects may Part 2, subjects must 
have already received:
at least one cycle and up to 4 cycles (q3w schedule) of this current platinum-
based regimenchemotherapy and must be randomized prior to receiving Cycle 5.  
OR 
at least one cycle and up to 3 months (depending upon regimen) of platinum-
based chemotherapy 
OR

currently be receiving maintenance therapy following treatment with platinum-
based chemotherapy 
It is expected that subjects be eligible to continue to receive ≥ 2 additional platinum-based 
chemotherapy cycles while on study treatment.  
SubjectsIn Part 1, subjects must have an advanced or metastatic solid tumor treated with ≥ first–
line platinum–based chemotherapy, excluding those solid tumors treated with curative intent. 
In Part 2, subjects must have metastatic NSCLC and must not have received any other regimens 
of platinum containing chemotherapy for the first-line treatment of metastatic solid tumors prior 
to the regimen they are receiving at the time of randomization.  
Rationale:
Modified to:

Clarify that subjects must have received at least one cycle of platinum based 
chemotherapy and up to 4 cycles of a regimen administered every 3 weeks OR up to 3 
months of a regimen administered at other intervals OR be receiving maintenance therapy 
following treatment with platinum-based chemotherapy.

Expand study population in Part 1 of the study to include advanced and metastatic solid 
tumor types treated with ≥ first-line platinum-based chemotherapy, excluding those solid 
tumors treated with curative intent.

Confirm only metastatic NSCLC subjects are eligible for Part 2 of the study.
Page 509 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
31
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
2.12.
Section 7.1:  Number of Subjects (page 67)
Revised Text:
This platinum-based CIA study will enroll approximately 840 subjects, approximately 90 
subjects with selectedadvanced or metastatic solid tumor types in Part 1 and 750 subjects with 
metastatic NSCLC in Part 2.  
Rationale:
Modified to:

Expand study population in Part 1 of the study to include advanced and metastatic solid 
tumor types treated with ≥ first-line platinum-based chemotherapy, excluding those solid 
tumors treated with curative intent.
Page 510 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
32
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
2.13.
Section 7.2:  Inclusion Criteria (page 68)
Revised Text:
Subjects must satisfy the following criteria to be enrolled in the study:
1. Men and women > 18 years of age at the time of signing the informed consent document.
2. Part 1 -– Histologically confirmed (cytology or biopsy) solid tumor malignancy, 
including metastatic non-small cell lung cancer (NSCLC), metastatic small cell lung 
cancer, metastatic bladder cancer, metastatic head and neck cancer, and metastatic  
endometrial/cervical cancer, where the standard of care is first-line platinum-based 
chemotherapyexcluding those solid tumors treated with curative intent.
Part 2 - Histologically confirmed (cytology or biopsy) non-small cell lung cancer.
3. Documented advanced or metastatic disease.
4. Measurable or non-measurable disease evaluable by RECIST criteria (Version 1.1) 
(Appendix A).
5. All of the following laboratory values:
Hemoglobin ≥ 6.5 to < 11.0 g/dL (≥ 65 to < 110 g/L)), due to chemotherapy-induced 
anemia
Absolute neutrophil count ≥ 500/mm3
Platelet count ≥ 75,000/mm3 (> 72 hours since prior platelet transfusion) 
Adequate renal function (creatinine clearance ≥ 40mL/min or ≥ 50 mL/min if 
cisplatin concomitantly administered): 
o
creatinine clearance ≥40mL/min or ≥ 50 mL/min if cisplatin is concomitantly 
administered 
and
o
urine protein / creatinine ratio ≤ 1.0; or ≤ 2.0 if bevacizumab (Avastin®) is 
concomitantly administered
Hepatic function (bilirubin < 1.5 x ULN; AST and ALT < 3.0 x ULN and ≤ 5.0 ULN 
for subjects with liver metastases)
Corrected calcium within normal limits (WNL), previous) or ≤ Grade 1.  Previous
hypercalcemia treatment is allowed
Page 511 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
33
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
6. Subjects maymust have received:
at least one cycle and up to 4 cycles (q3w schedule) of their first regimen of first 
line platinum-based chemotherapy treatment.and be randomized prior to 
receiving Cycle 5

OR 
at least one cycle and up to 3 months (depending upon regimen) of platinum-
based chemotherapy 
OR 

currently be receiving maintenance therapy following treatment with platinum-
based chemotherapy 
Rationale:
Modified to:

Expand study population in Part 1 of the study to include advanced or metastatic solid 
tumor types treated with ≥ first-line platinum-based chemotherapy, excluding those solid 
tumors treated with curative intent.

Clarify that hemoglobin levels ≥ 6.5 to < 11.0 g/dL (≥ 65 to < 110 g/L) must be 
attributed to chemotherapy-induced anemia.

Consolidate definition of adequate renal function in Inclusion Criteria.

Expand allowable corrected calcium levels.

Clarify that subjects must have received at least one cycle of platinum-based 
chemotherapy and up to 4 cycles of a regimen administered every 3 weeks OR up to 3 
months of a regimen administered at other intervals. 
Page 512 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
34
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
2.14.
Section 7.3:  Exclusion Criteria (pages 70-71)
Revised Text:
The presence of any of the following will exclude a subject from enrollment:
_  _  _  _  _  _  _  _  _  _  _
3. HistoryPart 2 only, history of prior regimen(s) of platinum-based chemotherapy for 
metastatic diseaseNSCLC and/or history of adjuvant platinum-based chemotherapy with 
last dose received less than six months prior to the start of current first-line platinum-
based chemotherapy for metastatic diseaseNSCLC.  
_  _  _  _  _  _  _  _  _  _  _
9.   History of second malignancy within 3 years (except excised and cured basal cell 
carcinoma, squamous cell carcinoma of the skin or cervical carcinoma in situ).
_  _  _  _  _  _  _  _  _  _  _
1110. Uncontrolled hypertension.  IfControlled hypertension is considered clinically stable,
and systolic blood pressure (SBP) must be < 150 mmHg orand diastolic blood pressure 
(DBP) must be < 100 mmHg.  
_  _  _  _  _  _  _  _  _  _  _
17. Urine protein / creatinine ratio > 1.0. 
1816. Received treatment with another investigational drug or device within 28 days prior 
to Day 1, or if the half life of the previous product is known, within 5 times the half life 
prior to dosing, whichever may be longer.  
1917. Any prior use of sotatercept (ACE-011).  
2018. Pregnant or lactating females or females planning to become pregnant.  
2119. History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant 
proteins or excipients in the investigational product (Refer to the Investigator’s Brochure 
for further information).  
2220. Major surgery within 30 days prior to Day 1 (subjects must have completely 
recovered from any previous surgery prior to Day 1).  
Rationale:
Modified to:

Clarify allowed prior type and setting of platinum-based chemotherapy in Part 2 only.

Delete exclusion of subjects with second malignancy within the prior 3 years.

Correct typographical error in blood pressure measurement exclusion.

Delete of urine protein / creatinine ratio exclusion criterion and move to define adequate 
renal function in Inclusion Criteria.

Renumbering of remaining Exclusion Criteria.
Page 513 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
35
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
2.15.
Section 8.1:  Description of Investigational Product(s) (pages 72)
Revised Text:
Sotatercept (ACE-011) clinical drug product will be provided as a frozen liquid formulation, 
Process IIa, or as a lyophilized powder, Process III.  
Note:  Subjects receiving Process IIa clinical drug product will begin to receive Process III 
clinical drug product as soon as it becomes available at the study site. 
Process IIa Clinical Drug Product – Frozen Liquid Formulation:
The clinical drug product consists of sotatercept (ACE-011) in phosphate buffered saline (PBS), 
pH 7.5.  It is supplied as a 1 mL solution of 50 mg/mL sotatercept (ACE-011) in labeled, rubber 
stoppered, 2 mL vials providing 50 mg per vial.  The recommended storage temperature for 
sotatercept (ACE-011) Process IIa frozen liquid drug product is -65˚C (colder than -65˚C) until 
thawed for administration.  Vials of sotatercept (ACE-011) frozen liquid must be completely 
thawed (approximately 30 minutes at room temperature) prior to preparation for dosing and must 
be used within six (6) hours of being thawed.  
2.16.
Section 8.2:  Treatment Administration and Schedule (pages 72-73)
Revised Text:
Sotatercept (ACE-011) or placebo will be administered as a SC injection to subjects by the study 
staff at the clinical site and will be documented in the study source record.  Subcutaneous 
injections will be given in the upper arm, abdomen, or thigh.  
At the time of randomization allin Part 1 and Part 2, subjects must be receiving their first-line 
regimenhave already received:
at least one cycle and up to 4 cycles (q3w schedule) of platinum-containing 
chemotherapy, given every three weeks, for the treatment of a metastatic solid 
tumor.  Subjects willbased chemotherapy and be randomized prior to this study 
during the time period in which they are receiving Cycle 1 through Cycle 4 of this 
regimen.  Subjects must not have received any prior regimens of first line 5 
OR 
at least one cycle and up to 3 months (depending upon regimen) of platinum-
based chemotherapy for a
OR 

currently be receiving maintenance therapy following treatment with platinum-
based chemotherapy 
It is expected that subjects be eligible to continue to receive ≥ 2 additional platinum-based 
chemotherapy cycles while on study treatment.  
Page 514 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
36
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
In Part 1, subjects must have an advanced or metastatic solid tumor treated with ≥ first–line 
platinum–based chemotherapy, excluding those solid tumors treated with curative intent. 
In Part 2, subjects must have metastatic solid tumorNSCLC and must not have received any 
other regimens of platinum containing chemotherapy for first-line treatment prior to the regimen 
they are receiving at the time of randomization.  
_  _  _  _  _  _  _  _  _  _  _
Subjects may receive 4-6 cycles of theConcomitant or maintenance therapy with
chemotherapeutic and/or targeted agents (e.g., pemetrexed, anti-EGFR agents, anti-VEGF 
agents) which are approved for a given tumor type, are allowed platinum-based regimen selected 
by the Investigator.  Upin addition to 2 additional cycles (8 total cycles) of platinum-based 
chemotherapy may be given as determined by cancer response.  . 
Platinum-based tumor therapy may be revised at the discretion of the Investigator for toxicity 
reasons only. 
While on study treatment subjects will be allowed to receive maintenance therapy with a 
pemetrexed or erlotinib-containing regimen when indicated.
Page 515 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
37
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
Rationale:
Modified to:

Clarify that subjects must have received at least one cycle of platinum-based 
chemotherapy and up to 4 cycles of a regimen administered every 3 weeks OR up to 3 
months of a regimen administered at other intervals OR be randomized while receiving 
maintenance therapy following treatment with platinum-based chemotherapy.

Expand study population in Part 1 of the study to include advanced and metastatic solid 
tumor types treated with ≥ first-line platinum-based chemotherapy, excluding those solid 
tumors treated with curative intent.

Clarify allowed prior type and setting of platinum-based chemotherapy in Part 2 only.

Remove reference to ACE-011 Process IIa Clinical Drug Product - Frozen Liquid 
Formulation.  In Part 1 of the study, subjects will receive only ACE-011 Process III 
Clinical Drug Product – Lyophilized Powder Formulation.  In Part 2 of the study, 
subjects will receive ACE-011 Process III Clinical Drug Product – Lyophilized Powder 
Formulation or placebo.

Expand allowable concomitant and maintenance therapy with chemotherapeutic and/or 
targeted agents (e.g., pemetrexed, anti-EGFR agents, anti-VEGF agents) which are 
approved for a given tumor type, in addition to platinum-based chemotherapy. 
Page 516 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
38
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
2.17.
Section 8.2.2:  Selection and Timing of Dosing for Each Subject
(pages 74-75)
Revised Text:
_  _  _  _  _  _  _  _  _  _  _
The first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo can be administered 
at any time after the first cycle and prior to the fifth cycle (q3w regimen) or prior to 
starting the fourth month (depending upon regimen) of first-line platinum-based 
chemotherapy OR during maintenance therapy following treatment with platinum-based 
chemotherapy.  Subsequent doses of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo 
can be administered at any time point during the chemotherapy cycle. 
_  _  _  _  _  _  _ _  _  _  _
Following completion of the Treatment Period, subjects who enter the Post Treatment Follow-
Up Period will be followed for 6 months from their last dose of sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo.  Visits will occur every month.  All subjects will continue to be 
followed for PFS up to 12 months from their first dose of sotatercept (ACE-011) or sotatercept 
(ACE-011)/placebo, or until progression of their advanced or metastatic disease, whichever 
occurs first.  
Subjects will be discontinued from the study treatment for reasons listed in Section 8.2.3 of the 
protocol, for unacceptable toxicity, or for progression of advanced or metastatic disease that 
requires the initiation of another treatment.  
Rationale:
Modified to:

Clarify that subjects must have received at least one cycle of platinum-based 
chemotherapy and up to 4 cycles of a regimen administered every 3 weeks OR up to 3 
months of a regimen administered at other intervals

Allow subjects to be randomized while receiving maintenance therapy following 
treatment with platinum-based chemotherapy.

Expand reference to study population to include advanced disease.
Page 517 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
39
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
2.18.
Section 8.2.3:  Discontinuation (pages 75-76)
Revised Text:
Treatment Discontinuation
Subjects will be discontinued from Study Treatment due to the following:
Adverse events(s)
Hypertension ≥Grade 3 – defined as Stage 2 hypertension (SBP ≥160 mmHg or 
DBP ≥100mmHg) confirmed by two measurements obtained at least five minutes 
apart; medical intervention indicated; more than one drug or more intensive 
therapy than previously used indicated or medically significant hypertension 
which cannot be adequately controlled with antihypertensive therapy.
_  _  _  _  _  _  _  _  _  _  _
Urine protein / creatinine ratio > 1.0; or > 2.0 (if bevacizumab [(Avastin®]®) is 
concomitantly administered)
_  _  _  _  _  _  _  _  _  _  _
Concomitant use of ESAs – In Part 1 if administered at any time and in Part 2 if 
administered < 4 months fromafter first dose of study treatment.  
_  _  _  _  _  _  _  _  _  _  _
Protocol violation – as determined by the Sponsor
_  _  _  _  _  _  _  _  _  _  _
Study Discontinuation:  
The following events are considered sufficient reasons for discontinuing a subject from the 
study:
Completed study, per protocol (subject has completed six- to nine- month Treatment 
Period plus up to six-month Post Treatment Follow-Up Period including one year 
tumor assessment to determine TTP and PFS).  Note:  Survival data will continue to 
be collected for up to 24 months fromafter first dose of study treatment.  
Withdrawal of consent
Death
Lost to follow-up
The following events may be considered sufficient reasons for discontinuing a subject from the 
study, as determined by the Sponsor:
Adverse events(s)
Disease progression 
Protocol violation
Page 518 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
40
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
Rationale:
Modified to:

Clarify that subjects must have received at least one cycle of platinum based 
chemotherapy and up to 4 cycles of a regimen administered every 3 weeks OR up to 3 
months of a regimen administered at other intervals OR while receiving maintenance 
therapy following treatment with platinum-based chemotherapy.

.Expand reference to study population to include advanced disease.

Clarify timing interval between two blood pressure measurements required to assess 
sotatercept (ACE-011) dosing.

Clarify that subject discontinuation from treatment and study due to protocol violation 
will be determined by the Sponsor.

Correct grammatical and editorial errors.
Page 519 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
41
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
2.19.
Section 9:  Concomitant Medications and Procedures (page 78)
Revised Text:
9.1.
Permitted Concomitant Medications and Procedures
General concomitant medication usage
_  _  _  _  _  _  _  _  _  _  _
Concomitant therapies considered as supportive care are acceptable while participating in this 
study, including growth colony stimulating factors (G-CSF), anti-emetics to limit chemotherapy-
related nausea and vomiting and, palliative radiation, and bisphosphonates and denosumab 
(Refer to Inclusion Criterion, Section 7.2)therapy for bone metastases.  Additionally, the study 
site should use its standard of care regarding hydration and the minimization of nephrotoxicity 
prior to/following the administration of platinum-based regimens.  
Rationale:
Modified to:

Delete reference to Section 7.2, not applicable following Amendment 2.
Page 520 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
42
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
2.20.
Section 9.2:  Prohibited Concomitant Medications and Procedures
(page 79)
Revised Text:
No concurrent treatments with any other investigational agent are allowed.  Bisphosphonate 
therapy (see Section 7.2),, other than for the treatment of hypercalcemia, mustand denosumab 
therapy for bone metastases can be started prior to randomization but should not be started on 
study.
Rationale:
Modified to:

Delete reference to Section 7.2, not applicable following Amendment 2.

Further clarify when bisphosphonate and denosumab therapy for metastatic bone disease 
is allowed to begin. 
Page 521 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
43
ACE-011-NSCL-001 3.0 FINAL:  01NOV2011
2.21.
Section 10:  Statistical Analyses (page 80)
Revised Text:
10.1. Overview
This is an open-label randomized, phase 2a, dose-ranging study of sotatercept (ACE-011) 
therapy for chemotherapy-induced anemia (CIA) in subjects with selectedadvanced or metastatic 
solid tumor types treated with platinum-based chemotherapeutic agents followed by a phase 
2b/3, double-blind, randomized, placebo-controlled study of sotatercept (ACE-011) therapy for 
chemotherapy-induced anemia (CIA) in subjects with metastatic non-small cell lung cancer 
(NSCLC) treated with platinum-based chemotherapeutic regimens. An IVRS will be utilized to 
ensure an equal weight central randomization based on a permuted-block randomization method 
according to stratification factors defined in Section 4.1 Study Design.  In Part 1, subjects will 
be randomized to one of three doses of sotatercept (ACE-011) plus platinum-based 
chemotherapy.  In Part 2, subjects will be randomized to placebo or the selected sotatercept 
(ACE-011) dose determined from Part 1 plus platinum-based chemotherapy.  Data from Part 1
will not be combined with data from Part 2 in all safety and efficacy analyses. 
A DMC will be used to monitor the study conduct.  
Rationale:
Modified to:

Expand reference to study population to include advanced disease.
Page 522 of 791
088VGY

088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
2
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
MEDICAL MONITOR / EMERGENCY CONTACT INFORMATION
Contact Information:
Note:  The back-up 24 hour global emergency contact call center should only be used if you 
are not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls  
Back-up 24 Hour Global Emergency Contact Call Center: 
Page 524 of 791
PPD
PPD
088VGY

088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
4
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
SITE PRINCIPAL INVESTIGATOR SIGNATURE PAGE
Signature of Site Principal Investigator
dd mmm yyyy
Printed Name of Site Principal Investigator 
Institution Name:_______________________________________
By my signature, I agree to personally supervise the conduct of this study at my study 
site and to ensure its conduct is in compliance with the protocol, informed consent, 
Institutional Review Board (IRB)/Ethics Committee (EC) procedures, instructions from
Celgene representatives, the Declaration of Helsinki, ICH Good Clinical Practices 
Guidelines, and local regulations governing the conduct of clinical studies.
Page 526 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
5
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
COORDINATING PRINCIPAL INVESTIGATOR SIGNATURE PAGE
Signature of Coordinating Principal Investigator
dd mmm yyyy
Printed Name of Coordinating Principal Investigator 
Institution Name:_______________________________________
By my signature, I agree the protocol has been written to comply with ICH Good 
Clinical Practices guidelines and agree to offer guidance throughout the study as 
needed.
Page 527 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
6
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
PROTOCOL SUMMARY
Study Title
An open-label randomized, phase 2a, dose-ranging study (Part 1) of sotatercept (ACE-011) for 
chemotherapy-induced anemia in subjects with advanced or metastatic solid tumors treated with 
platinum-based chemotherapeutic regimens followed by a phase 2b/3, double-blind, randomized, 
placebo-controlled study (Part 2) of sotatercept (ACE-011) for chemotherapy-induced anemia in 
subjects with metastatic non-small cell lung cancer treated with first-line platinum-based 
chemotherapeutic regimens.
Indication
Chemotherapy Induced Anemia (CIA) in Subjects with Advanced or Metastatic Solid Tumors
Part 1 – Advanced or metastatic solid tumors treated with ≥ first–line platinum–based 
chemotherapy, excluding those solid tumors treated with curative intent.
Part 2 - Metastatic NSCLC
Objectives
The primary objectives are:

Part 1:  To determine a dose of sotatercept (ACE-011) that results in a hematopoietic 
response for the treatment of CIA in subjects with advanced or metastatic solid 
tumors treated with platinum-based chemotherapeutic regimens, excluding those solid 
tumors treated with curative intent.  

Part 2:  To assess transfusion rate following initiation of sotatercept (ACE-011) 
treatment versus placebo in subjects with CIA who have metastatic NSCLC treated 
with first-line platinum-based chemotherapeutic regimens.  
The secondary objectives are:
Part 1 and Part 2:

To estimate the effect of sotatercept (ACE-011) treatment on objective response rate 
(ORR), time to progression (TTP), progression free survival (PFS) and overall 
survival (OS).

To evaluate the safety and tolerability of sotatercept (ACE-011).

To determine the pharmacokinetics (PK) of sotatercept (ACE-011) in subjects 
receiving platinum-based chemotherapy.  

To evaluate the hematopoietic response and its duration associated with sotatercept 
(ACE-011) treatment.  

To evaluate the effect of sotatercept (ACE-011) treatment on the quality of life 
(QoL).
Page 528 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
7
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
The exploratory objectives are:
Part 1 and Part 2:

To estimate the effect of sotatercept (ACE-011) treatment on bone metabolism

To explore the relationship between sotatercept (ACE-011) exposure and response 
(hematology, biomarkers, and other clinical outcomes as appropriate).  

To evaluate the expression of Activin A and other proteins/biomarkers (including 
myostatin and follistatin) related to sotatercept (ACE-011) mechanism of action in 
blood.

To evaluate the expression of Activin A and other proteins/biomarkers in archival 
tumor tissue (Part 2 only). 

To assess renal function biomarkers
Study Design
This is an open-label, randomized, phase 2a, dose-ranging study (Part 1) of sotatercept (ACE-
011) therapy for CIA in subjects with advanced or metastatic solid tumors treated with platinum-
based chemotherapeutic regimens followed by a phase 2b/3, double-blind, randomized, placebo-
controlled study (Part 2) of sotatercept (ACE-011) therapy for CIA in subjects with metastatic 
non-small cell lung cancer treated with first-line platinum-based chemotherapeutic regimens.  
The study will consist of two parts:
Part 1 is a dose-finding segment in which up to approximately 90 subjects will be randomized to 
one of three sotatercept (ACE-011) dose treatment arms.  The primary objective is to determine a 
dose of sotatercept (ACE-011) that results in a hematopoietic response in the treatment of CIA in 
subjects with advanced or metastatic solid tumors treated with platinum-based chemotherapy, 
excluding those solid tumors treated with curative intent.  The sample size is for the purpose of 
hypothesis generation; however, it would allow approximately 80% power to detect an effect 
size of 0.33 using a 2 degrees of freedom Chi-Square Test with a significance level (alpha) of 
0.05.  
Part 2 is the phase 2b/3 double-blind, randomized, placebo-controlled segment of the study and 
will be performed in two stages. Its primary objective is to determine the transfusion rate 
following initiation of sotatercept (ACE-011) treatment versus placebo in subjects with CIA who 
have metastatic NSCLC treated with first-line platinum-based chemotherapeutic regimens.
In the first stage, approximately 180 subjects will be randomized to receive sotatercept (ACE-
011), at the dose determined from Part 1, or placebo at a ratio of 1:1.  An interim futility 
assessment based on transfusion rate at 4 months will be performed as described in Section 10.8.
It is expected that accrual will continue during the interim assessment period, with up to an 
additional 570 subjects randomized to achieve full study accrual.  
During Part 2 (first and second stage) overall survival will be assessed.  The total sample size of 
750 subjects will allow observation of at least 536 deaths and thus, at least 80% power to exclude 
more than 15% hazard increase in the sotatercept (ACE-011) arm compared with the placebo 
arm at one-sided significance level of 0.025, i.e., rejecting hazard ratio (Placebo:sotatercept 
Page 529 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
8
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
[ACE-011]) of 0.87, assuming the sotatercept (ACE-011) arm actually reduces at least 10% 
hazard, i.e., true hazard ratio (Placebo:sotatercept [ACE-011]) of 1.11.  
A Data Monitoring Committee (DMC) will monitor the conduct of the study.  
Study Population
At the time of randomization in Part 1 and Part 2, subjects must:

have already received at least one cycle and up to 4 cycles (q3w schedule) of 
platinum-based chemotherapy and be randomized prior to receiving Cycle 5 
OR 

have already received at least one cycle and up to 3 months (depending upon 
regimen) of platinum-based chemotherapy 
OR

currently be receiving maintenance therapy following treatment with platinum-
based chemotherapy 
In Part 1, subjects must have an advanced or metastatic solid tumor treated with ≥ first–line 
platinum–based chemotherapy, excluding those solid tumors treated with curative intent.
In Part 2, subjects must have metastatic NSCLC and must not have received any other regimens 
of platinum containing chemotherapy for first-line treatment prior to the regimen they are 
receiving at the time of randomization.  
Concomitant or maintenance therapy with chemotherapeutic and/or targeted agents (e.g., 
pemetrexed, anti-EGFR agents, anti-VEGF agents), which are approved for a given tumor type, 
are allowed in addition to platinum-based chemotherapy. 
Length of Study and Study Treatments
This study will consist of the following consecutive periods:  Screening, Treatment Period, Post 
Treatment Follow-Up Period, and Survival Follow-Up Period.  Study treatment is defined as 
sotatercept (ACE-011) in Part 1 and sotatercept (ACE-011)/placebo in Part 2.  
Screening Period (28 days):
Potential study subjects will sign an informed consent form prior to undergoing any study-related 
procedures.  Subjects will undergo screening for protocol eligibility within 28 days prior to
randomization, as outlined in the Table of Events, Section 5.  Note:  Screening period tumor 
assessments should be performed within six weeks or as per standard care at the study site prior 
to randomization.  Also, historical tumor assessment data, from prior to the initiation of 
platinum-based chemotherapy through the Screening Period, will be collected and used for 
assessment of tumor response.  
Prior erythropoietic stimulating agent (ESA) treatment history starting from the initial solid 
tumor diagnosis and red blood cell (RBC) transfusion history starting from diagnosis of 
advanced or metastatic disease, at a minimum of up to two months prior to randomization will be 
collected.  
Page 530 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
9
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
All females of childbearing potential (FCBP) participating in the study are to use highly effective 
methods of birth control during the Screening Period, for at least 28 days before starting the 
study.  Some highly effective methods of birth control include:

Oral contraceptives, intrauterine device, tubal ligation or a partner with a vasectomy
OR

Two forms of barrier method birth control, e.g., a latex condom PLUS a diaphragm 
with spermicide OR a latex condom PLUS a contraceptive sponge with spermicide.  
If a non-latex condom is used, it cannot be made out of natural (animal) membrane.  
Treatment Period (up to 6-9 months):  
The Treatment Period is approximately six months (four doses of study treatment given on Day
1, every 42 days), two additional sotatercept (ACE-011)/placebo doses may be given only in 
Part 2, at the discretion of the Investigator.  
In Part 1 (the dose-ranging portion of the study), subjects with advanced or metastatic solid 
tumor types who meet all eligibility criteria will be randomized to receive one of the following 
sotatercept (ACE-011) dose levels, with 10-30 subjects per arm:

Sotatercept (ACE-011) 15 mg SC

Sotatercept (ACE-011) 30 mg SC
Analysis of safety data will be performed following the treatment of at least 10 subjects at the 15 
mg dose level and 10 subjects at the 30 mg dose level, with each subject having received a 
minimum of one dose of sotatercept (ACE-011) and completed a 12-week follow-up period from 
the first dose.  
Following this analysis, the addition of a third dose level:

Sotatercept (ACE-011) 45 mg SC
to the randomization schema will be determined.
Each dose level will be administered every 42 days for up to four doses.  
The effective dose of sotatercept (ACE-011) is defined as follows:
An increase in hemoglobin (Hgb) of ≥ 1.0 g/dL above the study baseline value for 4 
consecutive weeks during the first two doses of sotatercept (ACE-011) (Dose 1/Day 1 
through and including Dose 2/Day 43 [prior to Dose 3]), in approximately 70% of subjects, 
in at least one or more treatment arms (in the absence of RBC transfusions and/or ESAs).  
Evaluation of hemoglobin response decision status will be completed after dosing arms have 
separately enrolled up to 30 subjects, as needed, to determine the sotatercept (ACE-011) dose for
Part 2.  
In addition to the hematopoietic response, the safety profile, dose modifications and extent of 
exposure in each dosing level will be taken into account to determine the study dose to be used in 
Part 2.  
Page 531 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
10
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
In Part 2, a total of 750 subjects with metastatic NSCLC will be randomized to receive either 
sotatercept (ACE-011) or placebo, at a ratio of 1:1:

375 subjects will receive sotatercept (ACE-011) (at the dose determined in Part 1)

375 subjects will receive placebo
Each dose of sotatercept (ACE-011) or placebo will be administered every 42 days for four 
doses.  Up to two additional doses (in Part 2 only) may be given at the discretion of the 
Investigator.  
Part 2 will be performed in two stages. In the first stage, approximately 180 subjects will be 
randomized to receive sotatercept (ACE-011) (at the dose determined from Part 1) or placebo at 
a ratio of 1:1.  An interim futility assessment based on transfusion rate at 4 months will be 
performed as described in Section 10.8. It is expected that accrual will continue during the 
interim assessment period, with up to an additional 570 subjects randomized to achieve full study 
accrual.  
During the Treatment Period, subjects will be assessed for hematopoietic response, transfusion 
need, safety and tumor response.  The severity of AEs will be graded according to the currently 
active minor version of the National Cancer Institute Common Terminology Criteria for Adverse 
Events (NCI CTCAE) version 4.0.  
Concurrent treatment for CIA with blood transfusions is recommended when Hgb value is 
< 8 g/dL or at the discretion of the Investigator if the Hgb value is ≥8 g/dL and associated with 
anemia symptoms such as hemodynamic or pulmonary compromise requiring treatment.  If an 
RBC transfusion is given to a subject during the Treatment Period, sotatercept (ACE-011) should 
be administered > 7 days from the date of the RBC transfusion.
In Part 1, blood samples will be collected to evaluate the full PK profile of sotatercept (ACE-
011) from approximately 30 subjects at select centers, in approximately 10 subjects for each 
sotatercept (ACE-011) dose group investigated.  In subjects participating in the full PK 
assessment, RBC, Hgb, and reticulocyte counts will be collected at each PK time point 
(excluding the 4-hour time point on Day 1) from Day 1 to Day 43 after the first dose.  Subjects 
not participating in the optional full PK assessment may participate in the sparse PK assessment.  
In Part 2, blood samples will be collected for the sparse PK assessment that will be performed in 
approximately 300 (40%) of 750 subjects (approximately 150 subjects in each arm).  
For subjects who do not participate in either Part 1 full or sparse PK assessments or Part 2 
sparse PK assessments, the ACE-011 (sotatercept) concentration may be determined in their anti-
sotatercept antibody samples to assist in the evaluation of immunogenicity, as well as PK.
Subjects will be discontinued from Study Treatment due to the following:

Adverse events(s)

Hypertension ≥Grade 3 – defined as Stage 2 hypertension (systolic blood 
pressure [SBP] ≥160 mmHg or diastolic blood pressure [DBP] ≥100mmHg), 
confirmed by two measurements obtained at least five minutes apart; medical 
intervention indicated; more than one drug or more intensive therapy than 
previously used indicated or medically significant hypertension which cannot be 
adequately controlled with antihypertensive therapy. 
Page 532 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
11
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011

Any AE > Grade 2 assessed to be related to sotatercept (ACE-011) therapy

Any persistent AE > Grade 1 considered to be related to sotatercept (ACE-011)
treatment and causing a subject to miss three months of sotatercept (ACE-011)
therapy

Any thromboembolic event > Grade 2 

Elevated Hgb > 15.0 g/dL (sustained for a 7 day period, confirmed by laboratory 
assessment)

Urine protein / creatinine ratio > 1.0; or > 2.0 if bevacizumab (Avastin®) is 
concomitantly administered

Persistent hematuria ≥Grade 2 - defined as symptomatic; urinary catheter or 
bladder irrigation indicated; limiting instrumental activities of daily living, and 
persisting for one week. 

In Part 1, lack of sotatercept (ACE-011) therapeutic effect, defined as < 1.0 g/dL 
increase in Hgb from baseline following three dose escalations.  In Part 2, lack of 
sotatercept (ACE-011) therapeutic effect, defined as < 1.0 g/dL increase in Hgb from 
baseline following two doses of sotatercept (ACE-011)/placebo (Dose 1/ Day 1 
through and including Dose 2/Day 43, prior to Dose 3).  

Concomitant use of ESAs – In Part 1 if administered at any time and in Part 2 if 
administered < 4 months after first dose of study treatment. 

Sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dose modifications

In Part 1 and Part 2:  A second Hgb increase of ≥3.0 g/dL following a two-level 
dose reduction due to a Hgb increase ≥3.0 g/dL 

In Part 2:  > 3 dose reductions and/or delays

Disease progression 

Withdrawal of consent

Death

Lost to follow-up

Protocol violation - as determined by the Sponsor
The reason for treatment discontinuation should be recorded in the eCRF and in the source 
documents.  
Post Treatment Follow-Up Period (monthly visits for up to 6 months)
Subjects who enter the Post Treatment Follow-Up Period will be followed monthly for up to 6 
months from their last dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.  All 
subjects will continue to be followed for TTP and PFS up to one year from their first dose of 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo or until progression of their advanced 
or metastatic disease, whichever occurs first.  
Page 533 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
12
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
The following events are considered sufficient reasons for discontinuing a subject from the 
study:

Completed study, per protocol (subject has completed six- to nine- month Treatment 
Period plus up to six-month Post Treatment Follow-Up Period including one year 
tumor assessment to determine TTP and PFS).  Note: Survival data will continue to 
be collected for up to 24 months after first dose of study treatment.  

Withdrawal of consent

Death

Lost to follow-up
The following events may be considered sufficient reasons for discontinuing a subject from the 
study, as determined by the Sponsor:

Adverse event(s)

Disease progression 

Protocol violation
Survival Follow-up Period (monthly for up to 24 months after first dose of sotatercept 
(ACE-011) or sotatercept (ACE-011)/placebo)
In both Part 1 and Part 2, survival data will be collected monthly (can be via telephone     
contact) for up to 24 months following the subject’s first dose of sotatercept (ACE-011) (Part 1) 
or sotatercept (ACE-011)/placebo (Part 2).  Collection of survival data will begin following 
Study Discontinuation Visit.  Data to be collected will include:

Overall survival

Post-Treatment Anti-Neoplastic Therapy, if any
Overview of Efficacy Assessments

Serum hematology, absolute reticulocyte counts

Serum iron, total iron binding capacity (TIBC), transferrin and serum ferritin

Serum erythropoietin

Tumor assessments

Documentation of concomitant RBC transfusions
Overview of Safety Assessments

Informed consent

Assessment of inclusion / exclusion criteria

Complete medical history including history of cardiac and thromboembolic events

Vital signs including height, weight, heart rate, seated systolic and diastolic blood 
pressure, and temperature.  
Page 534 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
13
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011

AE(s)

12-lead electrocardiogram (ECG)  

Medically supervised pregnancy testing

Clinical laboratory evaluations (serum chemistry, hematology, absolute reticulocyte 
count, creatinine clearance, serum iron, total iron binding capacity, transferrin and 
serum ferritin, serum erythropoietin, Vitamin B12, serum RBC folate levels, 
urinalysis, FSH, LH, dihyroepiandosterone, estrogen, estradiol, testosterone and
serum thyroid-stimulating hormone).  

QoL Assessment (FACIT Fatigue Scale [Version 4]) – all subjects

Lung Cancer Symptom Scale (LCSS) questionnaire – subjects with NSCLC 

Documentation of concomitant medications / procedures.  
Overview of Exploratory Assessments

Bone or other potential mechanistic or disease-related proteins/biomarkers 

DXA scan

Renal function biomarkers 
Page 535 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
14
TABLE OF CONTENTS
TITLE PAGE..............................................................................................................................1
PROTOCOL SUMMARY ..........................................................................................................6
1.
INTRODUCTION..................................................................................................19
2.
STUDY OBJECTIVES...........................................................................................36
2.1.
Primary Objective...................................................................................................36
2.2.
Secondary Objectives .............................................................................................36
2.3.
Exploratory Objectives ...........................................................................................36
3.
STUDY ENDPOINTS............................................................................................37
3.1.
Primary Endpoint(s) ...............................................................................................37
3.2.
Secondary Endpoint(s)............................................................................................37
3.3.
Exploratory Endpoint(s)..........................................................................................38
4.
OVERALL STUDY DESIGN ................................................................................39
4.1.
Study Design ..........................................................................................................39
4.1.1.
Sotatercept (ACE-011) Dose Modification, Reduction and Escalation Rules...........43
4.2.
Study Design Rationale ..........................................................................................46
4.2.1.
Fixed Dose .............................................................................................................46
4.2.2.
Dosing Schedule.....................................................................................................47
4.2.3.
Starting Dose Levels in Part 1.................................................................................47
4.2.4.
Evaluation of Dosing Schema via Modeling/Simulation .........................................48
4.3.
Study Duration .......................................................................................................49
5.
TABLE OF EVENTS.............................................................................................50
6.
PROCEDURES......................................................................................................58
7.
STUDY POPULATION.........................................................................................67
7.1.
Number of Subjects ................................................................................................67
7.2.
Inclusion Criteria....................................................................................................68
7.3.
Exclusion Criteria...................................................................................................70
8.
DESCRIPTION OF STUDY TREATMENTS........................................................72
8.1.
Description of Investigational Product(s)................................................................72
8.2.
Treatment Administration and Schedule .................................................................72
8.2.1.
Selection of Dose for the Study...............................................................................73
8.2.2.
Selection and Timing of Dosing for Each Subject ...................................................74
Page 536 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
15
8.2.3.
Discontinuation ......................................................................................................75
8.3.
Method of Treatment Assignment...........................................................................76
8.4.
Packaging and Labeling..........................................................................................76
8.5.
Investigational Product Accountability And Disposal .............................................77
8.6.
Investigational Product Compliance........................................................................77
9.
CONCOMITANT MEDICATIONS AND PROCEDURES....................................78
9.1.
Permitted Concomitant Medications and Procedures...............................................78
9.2.
Prohibited Concomitant Medications and Procedures..............................................79
9.3.
Required Concomitant Medications and Procedures................................................79
10.
STATISTICAL ANALYSES..................................................................................80
10.1.
Overview................................................................................................................80
10.2.
Study Population Definitions ..................................................................................80
10.3.
Sample Size and Power Considerations...................................................................80
10.4.
Background and Demographic Characteristics........................................................81
10.5.
Subject Disposition.................................................................................................81
10.6.
Efficacy Analysis....................................................................................................81
10.7.
Safety Analysis.......................................................................................................82
10.8.
Interim Analysis .....................................................................................................83
10.9.
Other Topics...........................................................................................................83
10.10.
Data Monitoring Committee (DMC).......................................................................84
11.
ADVERSE EVENTS..............................................................................................85
11.1.
Monitoring, Recording and Reporting of Adverse Events .......................................85
11.2.
Evaluation of Adverse Events.................................................................................85
11.2.1.
Seriousness.............................................................................................................85
11.2.2.
Severity / Intensity..................................................................................................86
11.2.3.
Causality ................................................................................................................87
11.2.4.
Duration .................................................................................................................87
11.2.5.
Action Taken..........................................................................................................88
11.2.6.
Outcome.................................................................................................................88
11.3.
Abnormal Laboratory Values..................................................................................88
11.4.
Pregnancy...............................................................................................................88
11.4.1.
Females of Childbearing Potential ..........................................................................88
11.4.2.
Male Subjects.........................................................................................................89
Page 537 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
16
11.5.
Immediate Reporting of Serious Adverse Events ....................................................89
11.6.
Safety Queries ........................................................................................................89
11.7.
Expedited Reporting of Adverse Events..................................................................89
12.
DISCONTINUATIONS .........................................................................................91
13.
EMERGENCY PROCEDURES.............................................................................92
13.1.
Emergency Contact.................................................................................................92
13.2.
Emergency Identification of Investigational Products .............................................92
14.
REGULATORY CONSIDERATIONS...................................................................93
14.1.
Good Clinical Practice............................................................................................93
14.2.
Investigator Responsibilities ...................................................................................93
14.3.
Subject Information and Informed Consent.............................................................93
14.4.
Confidentiality........................................................................................................94
14.5.
Protocol Amendments.............................................................................................94
14.6.
Institutional Review Board/Independent Ethics Committee Review and 
Approval ................................................................................................................94
14.7.
Ongoing Information for Institutional Review Board / Ethics Committee................95
14.8.
Closure of the Study ...............................................................................................95
15.
DATA HANDLING AND RECORDKEEPING.....................................................96
15.1.
Data/Documents .....................................................................................................96
15.2.
Data Management...................................................................................................96
15.3.
Record Retention....................................................................................................96
16.
QUALITY CONTROL AND QUALITY ASSURANCE........................................98
16.1.
Study Monitoring and Source Data Verification......................................................98
16.2.
Audits and Inspections............................................................................................98
17.
PUBLICATIONS ...................................................................................................99
18.
REFERENCES.....................................................................................................100
19.
APPENDICES......................................................................................................103
Appendix A:  Response Evaluation Criteria in Solid Tumors...................................................103
Appendix B:  ECOG Performance Status Scale .......................................................................105
Appendix C:  National Cancer Institute (NCI) Common Terminology Criteria for 
Adverse Events (CTCAE) Version 4.0..................................................................106
Appendix D:  New York Heart Association - Classification of Heart Failure...........................107
Page 538 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
17
LIST OF TABLES
Table 1:
A011-02:  A Phase 1b Study in Healthy Postmenopausal Women, 
Hemoglobin Evaluation ..........................................................................................28
Table 2:
Summary of Adverse Events Reported in Greater Than or Equal To 5 
Percent of Patients Overall......................................................................................31
Table 3:
Summary of SAEs Reported...................................................................................32
Table 4:
Number of Subjects with an Increase in Hgb from Baseline at Any Time and 
Sustained for Greater Than or Equal To 28 Days ....................................................32
Table 5:
Sotatercept (ACE-011) and Sotatercept (ACE-011)/Placebo Dose Reduction 
Levels.....................................................................................................................45
Table 6:
Sotatercept (ACE-011) Dose Escalation Levels (Part 1 Only) .................................46
Table 7:
Sotatercept (ACE-011) Schedule of Assessments....................................................50
Table 8:
Schedule of Pharmacokinetic Assessments (Part 1).................................................56
Table 9:
Schedule of Pharmacokinetic Assessments (Part 2).................................................57
Table 10:
ECOG Performance Status Scale ..........................................................................105
Table 11:
Classification of Heart Failure ..............................................................................107
Page 539 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
18
LIST OF FIGURES
Figure 1:
Study Design ..........................................................................................................42
Figure 2:
Simulated Hemoglobin Response in the Hypothetical Anemic Population .............48
Page 540 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
19
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
1.
INTRODUCTION
This is an open-label, randomized, phase 2a, dose-ranging study of sotatercept (ACE-011)
therapy for chemotherapy-induced anemia (CIA) in subjects with advanced or metastatic solid 
tumors treated with platinum-based chemotherapeutic agents followed by a phase 2b/3, double-
blind, randomized, placebo-controlled study of sotatercept (ACE-011) therapy for 
chemotherapy-induced anemia (CIA) in subjects with metastatic non-small cell lung cancer 
(NSCLC) treated with platinum-based chemotherapeutic regimens.  The study will consist of two 
parts.  Part 1 is a dose finding segment in which up to 90 subjects with advanced or metastatic
solid tumor types treated with platinum-based chemotherapy will be randomized to one of three 
sotatercept (ACE-011) dose treatment arms.  Continuous monitoring of safety data will be 
conducted, including the review of Part 1 data to determine the sotatercept (ACE-011) dose to 
be used in Part 2, the phase 2b/3, double-blind, randomized placebo-controlled segment of the 
study.  
Part 2 will include only subjects with metastatic NSCLC and will be performed in two stages.  
Its primary objective is to determine the transfusion rate following initiation of sotatercept 
(ACE-011) treatment versus placebo in subjects with CIA who have metastatic NSCLC treated 
with first-line platinum-based chemotherapeutic regimens.
In the first stage of Part 2 approximately 180 subjects will be randomized to receive sotatercept 
(ACE-011), at the dose determined from Part 1, or placebo at a ratio of 1:1.  An interim futility 
assessment based on transfusion rate at 4 months will be performed as described in Section 10.8.  
It is expected that accrual will continue during the interim assessment period.  Based on the 
results of the futility analysis and upon recommendation to continue the study, up to an 
additional 570 subjects will be randomized in the second stage of Part 2, to achieve full study 
accrual.
A Data Monitoring Committee (DMC) will monitor the conduct of the study. 
Sotatercept (ACE-011) (ActRIIA-IgG1Fc) is a recombinant human fusion protein consisting of 
the extracellular domain (ECD) of activin receptor IIA (ActRIIA) linked to the human IgG1 Fc 
domain, which includes the heavy chain hinge and constant domains, CH2 and CH3.  
The chemical structure of sotatercept (ACE-011) is composed of a disulfide-linked, glycosylated, 
dimeric protein.  Sotatercept (ACE-011) competes with the activin receptor IIA and binds a 
number of TGF-β superfamily ligands including activin, GDF-11, BMP-10, GDF-3 and 
myostatin (growth differentiation factor [GDF]-8).  
In both a single and a multiple dose phase 1 study of sotatercept (ACE-011) in healthy volunteer, 
postmenopausal women, a dose and time dependent increase in hemoglobin (Hgb) and 
hematocrit (HCT), and red blood cell (RBC) levels were observed following sotatercept (ACE-
011) treatment and remained elevated over the course of study.  
Although the mechanism(s) underlying the stimulation effect of sotatercept (ACE-011) on 
erythropoiesis are not yet fully understood, the result of clinical experience showed a rapid and 
sustainable increase in mature erythrocytes released into circulation.  The sotatercept (ACE-011) 
proposed mechanism of action may be different than that of known erythropoiesis-stimulating 
agents (ESAs) and may provide a different clinical profile in the treatment of CIA.  
Page 541 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
20
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
This study will provide information on the pharmacodynamic properties regarding the ability of 
sotatercept (ACE-011) to increase Hgb in subjects with CIA.  
Chemotherapy-Induced Anemia
Chemotherapy-induced anemia (CIA) is an area of unmet medical need.  It is a significant 
problem for patients with cancer, causing fatigue and reducing quality of life (QoL).  
Patients with cancer receiving multi-cycle chemotherapy are frequently anemic.  The etiology of 
CIA is multifactorial, resulting from the myelosuppressive effects of chemotherapy and the 
decrease in the production of the bone-marrow-stimulating hormone erythropoietin due to 
repeated cycles of chemotherapy (Vansteenkiste, 2002).  The incidence and severity of 
chemotherapy-induced anemia (CIA) is further dependent on a variety of factors, such as the 
type, schedule, and intensity of chemotherapy administered, and whether the patient has received 
prior myelosuppressive chemotherapy and/or radiation therapy (Groopman, 1999).  Platinum-
based treatments (eg, cisplatin and carboplatin), commonly used in lung, ovarian, and head and 
neck cancers, are well known to induce anemia due to combined bone marrow and kidney 
toxicity.  Antimicrotubular agents (eg, taxanes and vinorelbine) and camptothecins (eg, 
irinotecan and topotecan) are also considered particularly myelosuppressive (Groopman, 1999).  
Dose intensity, the increasingly widespread practice of administering higher doses of 
chemotherapy over a shorter period of time, is also associated with an increased risk of 
myelosuppression
The association between uncorrected anemia before or during chemotherapy and poorer patients’ 
outcomes has been reported in several studies (Grogan, 1999; Laurie, 2006; MacRae, 2002; 
Obermair, 2003).  Anemia can lead to a multitude of symptoms (eg, fatigue, tachycardia, 
cognitive impairment, shortness of breath, depression, and dizziness) and may also have an 
adverse impact on co-morbid conditions, such as cardiac and pulmonary disease.  The most 
common patient complaints are dyspnea on exertion and chronic fatigue, which may interfere 
with a patient’s ability to perform normal daily activities (Groopman, 1999).  A key 
differentiating characteristic of cancer-related fatigue versus fatigue in healthy individuals is its 
likelihood of persistence at rest (National Comprehensive Cancer Network, 2008)  In various 
published surveys, fatigue has been represented as a symptom that has affected patients’ 
everyday life the most and has been linked to changes in employment status among patients and 
even caregivers (Schwartz, 2007).  The association between Hgb levels and fatigue is well 
documented, with one analysis of 5 randomized trials linking an increase in Hgb concentrations 
of at least 2 g/dL with an improvement in fatigue, and consequently, in energy, ability to perform 
usual activities, and overall health (Cella, 2004).
In looking at the impact of CIA on survival, a meta-analysis of 60 clinical studies found a 65% 
increase in the risk of death and a shortened survival time among patients with cancer and 
anemia compared with patients without anemia (Carlos, 2001). The increased relative risk of 
death was particularly evident in patients with head and neck cancer (75%), a finding that also is
supported by other retrospective studies.  Tumor hypoxia, resulting from the reduced oxygen-
carrying capacity of blood in patients with anemia, has been hypothesized to be a major 
contributor to reduced survival.  Several studies have shown that tumor hypoxia also reduces the 
effectiveness of radiotherapy and chemotherapy, and is associated with tumor progression 
(Aapro, 2006).
Page 542 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
21
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
Treatment of Chemotherapy-Induced Anemia
The current treatment options for CIA include blood transfusion and erythropoiesis-stimulating 
agents (ESAs).  However, blood transfusion involves the risk of complications (such as potential 
transmission of infectious disease, alloimmunization, allergic reactions, hemolytic reactions, iron 
and circulatory overload, and possible immunosuppression) for the patient, and donor blood is a 
limited resource.  The practice of offering blood transfusions to cancer patients receiving
chemotherapy has therefore been rather restricted, generally reserved for emergencies, and 
severely anemic patients with serious symptoms.  
Erythropoiesis-stimulating agents have been approved for treating CIA.  However, the past five 
years has seen a major change in the use of ESAs for cancer related and chemotherapy induced 
anemia.  Clinical studies have demonstrated that ESAs can successfully mitigate transfusion 
need in a proportion of these patients; however, new concerns have emerged regarding apparent 
negative effects on survival and/or tumor progression in certain patient populations.  
Retrospective statistical analysis in one study in head and neck cancer patients, and two studies 
with adjuvant breast cancer revealed substantial safety concerns of increased thromboembolic 
events, and decreased PFS and overall survival.  
Sotatercept (ACE-011) Treatment of Chemotherapy-Induced Anemia
Treatment with sotatercept (ACE-011) resulted in increased HCT, Hgb and absolute red cell 
number in both nonclinical and clinical studies.  The rapid and sustained increases in Hgb and 
HCT levels were observed in two phase 1 studies in healthy volunteers, as well as in a phase 2a 
study in multiple myeloma (MM) subjects.  The ability for sotatercept (ACE-011) to rapidly 
increase and sustain Hgb levels in anemic subjects supports the clinical development of ACE-
011 for the treatment of CIA.  
In a phase 1 single-dose and multiple-dose studies of sotatercept in postmenopausal women 
(Studies A011-01 and A011-02, respectively), and in a phase 2 study in subjects with osteolytic 
lesions associated with MM that examined concurrent administration of sotatercept with 
melphalan, prednisolone, and thalidomide (MPT) anti-myeloma therapy, increases in Hgb, RBC 
count and HCT were observed following sotatercept treatment, and these increases remained 
detectable throughout the course of study.  The observed Hgb, RBC count, and HCT effects of 
sotatercept were dose-dependent and time-dependent.  These phase 1 and phase 2 clinical data 
are consistent with the increased hematologic parameters observed in nonclinical studies, The 
results from the three completed clinical studies A011-01, A011-02, and A011-04 are 
summarized in Summary of Clinical Experience
The mechanism of action of sotatercept with regards to increased RBC counts is not known; 
however, the mechanism of action for the hematopoietic effect of sotatercept may be different 
than that of ESAs, as some level of erythrocyte stimulatory effect was observed in the presence 
of anti-EPO antibodies in one nonclinical study.  As such, sotatercept may provide a unique 
clinical profile with a favorable benefit-risk profile in the chemotherapy-induced anemia patient 
population, thereby addressing some of the unmet medical needs in chemotherapy-induced 
anemia treatment.
Page 543 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
22
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
Non-Small Cell Lung Cancer Current Therapy Status
Lung cancer is the leading cause of cancer death in the world, accounting for 32% of cancer 
deaths in males and 25% in females, affecting approximately 171,000 people annually in the US 
(Parker, 1997; Sandler, 2006) and more than 200,000 people in Europe (Rossi, 2006).  Of these 
patients, approximately 85% have NSCLC, including squamous carcinoma, adenocarcinoma and 
large cell carcinoma (Rossi, 2006; Sandler, 2006).  These histologies are typically classified 
together because the approaches to diagnosis, staging and prognosis, and treatment are similar.  
Patients are often diagnosed with an advanced stage of disease.  Studies of advanced NSCLC 
patients treated with platinum-based chemotherapy report a one year survival rate that ranges 
from 30% to 43% and a median survival that ranges from seven to ten months (Dang, 2008).  
The 5-year survival rate of patients with NSCLC varies by stage, from 60% to 70% for patients 
with stage I disease to < 1% for patients with stage IV disease (Hong, 2008).  Patients having 
stage IIIb/IV NSCLC are not considered to be candidates for curative resection surgery or 
radiation, and radiation therapy is primarily used as palliative treatment in advanced stages of 
NSCLC.  
The role of chemotherapy is now well established as the recommended treatment of advanced 
NSCLC (Non-small Cell Lung Cancer Collaborative Group, 1995).  The current globally 
accepted standard of treatment for NSCLC is platinum-based combination therapy.  In advanced-
stage (stage IIB or IV) NSCLC, doublet combinations of platinum compounds (cisplatin or 
carboplatin) with gemcitabine (Gemzar®), vinorelbine, taxanes (paclitaxel or docetaxel) or 
pemetrexed are reference regimens.  When compared head-to-head in phase 3 studies, these 
doublets have shown comparable efficacy, in regards to overall survival (Schiller, 2002) with 
differences in toxicity profiles (Schiller, 2002).  When administered in a 3-week schedule, 
cisplatin plus gemcitabine, or cisplatin plus pemetrexed are effective and are widely used 
regimens for first-line treatment of NSCLC.  A recent phase 3 study in NSCLC compared 
cisplatin plus gemcitabine with cisplatin plus pemetrexed (Scagliotti, 2008).  Both had similar 
efficacy, with cisplatin plus pemetrexed having better tolerability and more convenient 
administration than cisplatin/gemcitabine.  This study was also the first prospective phase 3
study in NSCLC to show a survival difference based on histologic type (non-squamous benefited 
from pemetrexed plus cisplatin).  Drug-related grade (G) 3 or 4 anemia was at the rate of 6% for 
cisplatin/pemetrexed versus 10% for cisplatin/gemcitabine.  The incidence of RBC transfusion 
was 16.1% versus 27.3% and administration of erythropoietic agents 10.4% versus 18.1% 
respectively.  There was no significant difference between treatment arms in the incidence of or 
reason for deaths (7%).  
In the pivotal Aranesp (darbepoetin alfa) study for CIA in NSCLC, 27 % of patients were 
transfused with packed red blood cells (PRBC’s) at 4 months versus 52% in the placebo arm.  
Activin Biology
The activins (A-E) are a group of proteins that form dimers and heterodimers.  All are part of the 
TGF-β protein superfamily.  The first described activin, Activin A was initially identified as a 
gonadal differentiation factor involved in modulating follicle stimulating hormone (FSH) 
secretion from the pituitary (Ying, 1988).  Subsequently, the pleiotropic nature of Activin A has 
become more apparent (Woodruff, 1998).  There is a growing body of data suggesting a role for 
activins in bone remodeling, specifically as a negative regulator of bone growth (Perrien, 2007).  
Page 544 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
23
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
Before the two molecules were shown to be identical (Rivier, 1985), Activin A was also initially 
described as erythroid differentiation factor (EDF), effecting the maturation and differentiation 
of RBCs (Murata, 1988).  The mechanism(s) by which Activin A influences erythropoiesis 
remains under investigation and, in fact, there are data from in vitro and in vivo studies that 
support erythropoiesis-stimulatory (Shiozaki, 1992; Shiozaki, 1989) and erythropoiesis-
inhibitory effects (Nakao, 1991).  
At the cellular level, the activins bind initially to the high-affinity Type II receptor (ActRIIA).  
The ligand-bound ActRIIA then recruits the low-affinity Type I receptor (ActRIA or ALK-4).  
The receptor heterocomplex, through its cytoplasmic protein kinase activity, then activates the 
Smad signal cascade to eventually influence nuclear transcriptional factors (Chen, 2002; 
Mathews, 1994).  The competitive binding of activins in the blood by the sotatercept (ACE-011)
soluble fusion protein can result in inhibition of the ActRIIA receptor signaling pathway by 
impeding biological processes attributed to these pleiotropic proteins.  
The activin signaling pathway has been shown to induce terminal erythroid differentiation in 
some preclinical models.  Inhibition of activin may indirectly lead to increases in proliferation or 
differentiation of the erythroid lineage.  Based on its pharmacologic effects, sotatercept (ACE-
011) is being developed for the treatment of anemia associated with a variety of disorders, such 
as in chronic renal failure and CIA.  
In a retrospective study (Seder, 2009) activin immunoreactivity was found in 78% of lung 
adenocarcinomas surveyed (n=164).  Expression ranged from moderate in the majority of 
individuals to high in approximately 19.7% of samples evaluated.  Gene expression analysis was 
also used to measure activin mRNA in 86 lung adenocarcinomas and 10 normal lung samples.  
An average of three-fold more activin transcript was detected in diseased tissue relative to 
normal samples and particularly high levels of overexpression were associated with worse 
overall survival in stage I patients with NSCLC.  
Additionally, in the NIH “directors challenge” study for NSCLC adenocarcinoma (Shedden, 
2008), 3 of the 12 molecular subgroups, including the subgroup with the worst survival 
prognosis, demonstrated overexpression of Activin A.  Thus, overexpression of activin may play 
a role in NSCLC tumor progression.  
Sotatercept (ACE-011)
Sotatercept (ACE-011) (ActRIIA-IgG1Fc) is a recombinant human fusion protein consisting of 
the extracellular domain (ECD) of activin receptor IIA (ActRIIA) linked to the human IgG1 Fc 
domain, which includes the heavy chain hinge and constant domains, CH2 and CH3.  The ECD
sequence of ActRIIA is completely conserved among numerous species including mouse, rat, 
cynomolgus monkey and humans, thus mouse, rat and cynomolgus monkeys have been 
considered relevant species for nonclinical evaluation of sotatercept (ACE-011).  However, in 
order to reduce the potential immunogenicity of the human molecule, sotatercept (ACE-011), 
and to maximize the opportunity to maintain exposures in chronic models, a murine surrogate 
molecule was constructed by exchanging the human immunoglobulin Fc sequence portion of 
sotatercept (ACE-011) with its murine IgG2a homolog.  The resultant construct is referred to as 
RAP-011 (ActRIIA-mIgG2aFc), and is described in the pharmacology studies below.  Both 
ACE-011 and RAP-011 bind with high affinity to activin A/B, GDF-11 and, with slightly lower 
affinity, to BMP-10.
Page 545 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
24
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
Pharmacology Studies
RAP-011 was evaluated in a broad range of animal pharmacology studies to assess the effects of 
inhibition of Activin A on the biological processes attributed to that regulatory protein.  RAP-
011 has been shown to have significant effects on the red cell compartment.  RAP-011 treatment 
of mice at 10, 30 and 50 mg/kg by intraperitoneal injection (IP) twice per week for 3 months 
resulted in a 16-26% increase in RBC counts compared to control animals.  Rats treated with 
sotatercept (ACE-011) at 0.3, 3 and 30 mg/kg once per week for 3 months showed RBC count 
increases of 6-15% over control animals.  Finally, in cynomolgus monkeys treated with 10, 30 or 
50 mg/kg of sotatercept (ACE-011) twice per month for 3 months, there was a 21-24% increase 
in RBC counts compared to control animals.  In this study, the RBC count increase was apparent 
as early as 2 weeks following the initial dose of sotatercept (ACE-011).  
RAP-011 administered at 10 mg/kg to mice three days prior to administration of paclitaxel at 30 
mg/kg was sufficient to prevent decreases in RBC parameters typically seen three days later.  
Mice receiving paclitaxel alone had decreased HCT levels from 43% to 38% three days 
following treatment.  RAP-011 administered three days prior to paclitaxel injection was 
sufficient to keep the HCT levels above 42% at three days and up to two weeks following 
paclitaxel administration.  Therefore, prophylactic treatment with RAP-011 was able to prevent 
paclitaxel-induced anemia in mice.  
RAP-011 has also been shown to significantly increase bone mineral density (BMD) and 
strength in normal animals and in a variety of animal models of bone loss (Chantry, 2010; 
Lotinun, 2008; Pearsall, 2008).  In a murine ovariectomy (OVX)-induced model of osteopenia, 
RAP-011 (10 mg/kg intravenous [IV], twice per week x 12 weeks) increased trabecular BMD > 
25% in 6-12 weeks compared to the phosphate buffered saline (PBS)-treated controls (p<0.002).  
RAP-011 treatment was able to reverse the accelerated bone loss associated with ovariectomy.  
As expected, sham-operated (SHAM) mice (i.e., intact ovaries) started the study with a greater 
trabecular BMD than OVX mice.  PBS-treated SHAM mice showed a 10% decrease in 
trabecular BMD after 12 weeks of treatment compared to baseline, while SHAM-RAP-011 mice 
had a 32% increase in trabecular BMD over the same period.  These data demonstrate that RAP-
011 is able to increase trabecular BMD in both the normal state and in a model of established 
bone loss.  The femurs of both the RAP-011 treated OVX and SHAM mice showed statistically 
significant increases in all measured parameters of bone strength (i.e., maximum load, stiffness, 
energy, ultimate strength, and elastic modulus).  In summary, treatment with RAP-011 produced 
bone of superior quality consistent with an anabolic agent.  
RAP-011 was evaluated in a mouse model of skeletal metastasis using luciferase-tagged, human 
MDA-MB-231 breast cancer cells (estrogen receptor negative).  Mice were pretreated for 2 
weeks with RAP-011 (10 mg/kg, biweekly, subcutaneous [SC]) prior to intracardiac injection of 
tumor cells.  Treatment with RAP-011 was continued for an additional 5 weeks following tumor 
implantation.  A parallel study was conducted to examine the effect of RAP-011 treatment, as 
described above, on survival of MDA-MB-231 bearing mice.  
The data suggest that RAP-011 treatment may decrease the incidence of MDA-MB-231 
metastasis to bone and may also play a role in inhibiting tumor growth in the bone marrow 
environment.  Furthermore, in the presence of tumor cells, RAP-011 is able to prevent lytic 
disease through an anabolic mechanism of bone formation.  Lastly, treatment with RAP-011 
resulted in an approximately 25% survival benefit in this model.  
Page 546 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
25
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
RAP-011 was also evaluated in osteolytic bone disease of multiple myeloma.  Multiple myeloma 
is associated with the development of bone disease characterised by increased osteoclast activity 
and a suppression of osteoblastic bone formation.  
Results obtained in the 5T2MM murine model demonstrated that RAP-011 could prevent the 
development of osteolytic bone disease in a preventative setting.  
5T2MM cells promoted the development of osteolytic bone lesions (p<0.001), a reduction in 
trabecular volume (p<0.001) and cortical volume (p<0.005).  RAP-011 completely prevented 
5T2MM-induced decreases in trabecular volume and number in both tibia (p<0.001 and p<0.01), 
femur (p<0.001 and p<0.001) and vertebrae (p<0.01 and p<0.01) when compared to vehicle 
treated mice.  Bone volume was 19% higher in the tibia, 35% higher in the femur and 12% 
higher in vertebrae of RAP-011 treated mice than naïve non-tumour bearing mice.  
This study showed that, in the preclinical murine model for myeloma, RAP-011 stimulates bone 
formation by increasing osteoblast perimeter and number, mineralisation and bone formation rate 
but had no effect on osteoclast activity.  RAP-011 also appeared to inhibit tumor growth as 
demonstrated by decreased serum M protein, indicative of decreased tumor burden.  
The efficacy of RAP-011 was also examined in two orthotopic metastatic models of breast 
cancer using luciferase-tagged human MCF-7 and MDA-MB-231 breast cancer cells (estrogen 
receptor positive and negative, respectively).  Mice were pretreated for 2 weeks with RAP-011 
(10 mg/kg, biweekly, SC) prior to the intra-cardiac implantation of tumor cells into female nude 
mice.  Treatment with RAP-011 was continued for an additional 7 weeks following tumor 
implantation at which time mice were sacrificed and assessed for tumor burden.  RAP-011 either 
modestly decreased the tumor burden (in the case of mice bearing MCF-7 tumors) or delayed 
tumor growth by approximately 3 weeks (MDA-MB-231 model) as measured by bio-
luminescence.  
The ability of RAP-011 to repair osteolytic lesions caused by metastatic disease was investigated 
in mice.  In this model, MDA-MB-231-Luc cells were intratibially implanted in athymic nude 
mice to mimic bone metastasis.  Mice were treated with a chemotherapy regimen of paclitaxel 
(20 mg/kg, IP, every three days) starting seven days after tumor injection and continuing for the 
duration of the study.  On study day 42, mice with detectable but minimal tumor burden, as 
measured by bioluminescent imaging, were divided into two groups and treated with either 
RAP-011 (10 mg/kg, SC, biweekly) or vehicle.  Prior to dosing, μCT scans of the tumor bearing 
tibia were conducted to identify osteolytic lesions.  RAP-011 treatment continued for four weeks 
(to study day 70) and a final μCT scan of the tibia was performed.  On study day 70 there was a 
trend toward decreased number and size of osteolytic lesions in RAP-011-treated mice compared 
to control animals.  While osteolytic disease (most likely related to tumor burden) did progress in 
some of the treated mice, the majority of mice treated receiving RAP-011 developed less severe 
or no bone lesions compared to the untreated group.  Finally, treated animals also demonstrated 
an increased HCT, confirming the ability of RAP-011 to prevent CIA.  To summarize, treatment 
with RAP-011 has the ability to inhibit osteolytic lesions caused by tumors and to build new 
bone after cytotoxic chemotherapy with paclitaxel.  
Toxicology
Sotatercept (ACE-011) has been evaluated for toxicological effects in two species, Sprague-
Dawley rats and cynomolgus monkeys.  The dose levels ranged from 0.3 to 30 mg/kg in rats and 
Page 547 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
26
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
from 1 to 50 mg/kg in monkeys.  These dose ranges were designed to support phase 1a single-
dose levels of 0.01 to 3.0 mg/kg IV and phase 1b multiple doses of 0.1 to 2 mg/kg (monthly, 
SC).  Weekly (rat and IV monkey studies) or every 2 week (SC monkey studies) dosing in 
animals was designed to provide continuous, but fluctuating serum concentrations of sotatercept 
(ACE-011), which would be mimicked by a one-month dosing interval in humans.  
Test article related hematological (increase in RBC parameters) and reproductive (epididymal 
granulomas, testicular degeneration, decreased sperm counts and motility, and change in 
ovarian/uterine weights) findings were expected pharmacodynamic effects of ActRIIA signal 
inhibition, likely mediated via modulation of erythropoiesis and FSH secretion, respectively.  
Unique to rats were adrenocortical and pancreatic findings.  Neither finding was associated with
any clinical signs of adrenocortical (anorexia, weakness, gastrointestinal disturbances, serum 
electrolyte disturbances) or pancreatic (abnormal stool, weight loss) insufficiency.  Kidney 
findings include membranoproliferative glomerulonephritis and/or tubulointerstitial nephritis in 
rats and monkeys.  The glomerulonephritis was presumed to be due to anti-sotatercept (ACE-
011) antibody deposition in the kidneys.  This presumption is supported by a robust anti-drug 
antibody response observed in rats as well as demonstration, by immunohistochemistry, of 
immunoglobulin and complement at the site of injury in monkeys, consistent with immune 
complex deposition.  However, high plasma concentrations of sotatercept (ACE-011) in 
monkeys likely interfered with the immunogenicity assay, so the true incidence of anti-drug 
antibodies is unknown in this species.  
The no-observed-adverse effects levels (NOAELs) in rats and monkeys were 3 (3-month study) 
and 1 mg/kg (9-month study), respectively. 
Summary of Clinical Experience
A011-01:  A Phase 1a Study in Healthy Postmenopausal Women (Single Dose)
Sotatercept (ACE-011) was first studied in a randomized, phase 1a, single dose, dose escalation 
study in healthy, postmenopausal females (Ruckle, 2009).  Sotatercept (ACE-011) was diluted in 
normal saline administered as an IV infusion (over approximately 1 hour) or as a SC injection on 
Day 1.  Dose levels were 0.01, 0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg IV and 0.03 and 0.1 mg/kg SC.  
A total of 48 subjects were enrolled; 5 active and 1 placebo at each of the IV and SC dose levels.  
All subjects were followed for 4 months following a single dose administration.  
The pharmacokinetics (PK) of sotatercept (ACE-011) was linear.  The overall mean exposure 
(AUC) was proportional to doses (0.01-3 mg/kg IV, 0.03-0.1 mg/kg SC).  Across IV doses 
ranging from 0.1 through 3.0 mg/kg, the mean clearance (CL) ranged from 0.092 to 0.128 
mL/h/kg, the volume of distribution ranged from 73.7 to 110 mL/kg, and the mean terminal half 
life in serum (t1/2, z) ranged from 23.7 to 31.8 days, with no apparent dependence on dose.  After 
SC administration of 0.03 and 0.1 mg/kg, sotatercept (ACE-011) was completely absorbed, and 
the mean t1/2, z was approximately 30 days, with no apparent dependence on dose.  
The most commonly occurring treatment-emergent adverse events (AEs; i.e., those occurring in 
more than 1 subject in any treatment group) were headache, infusion site reaction, injection site 
hemorrhage, and toothache.  The majority of the injection site reactions and injection site 
hemorrhages were in the first IV cohort and were related to infiltration of the IV site.  The 
majorities of treatment-emergent AEs was mild in severity and were judged to be unrelated to 
sotatercept (ACE-011).  No deaths, serious AEs (SAEs), or AEs leading to discontinuation were 
Page 548 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
27
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
reported.  Changes in RBCs, Hgb, reticulocytes, liver function tests, glucose, uric acid, amylase 
and lipase occurred in some subjects.  Mild, transient elevations in pancreas enzymes, liver 
enzymes, or glucose were reported as AEs in five subjects.  
There were no clinically significant changes from baseline in vital signs, physical examination, 
endocrine function, or electrocardiogram (ECG) data.  Preservation of adrenal cortical function 
was monitored through evaluation of serum electrolytes (sodium and potassium levels) and 
through cortisol response to adrenocorticotropic hormone (ACTH) stimulation.  
No clinically significant findings were observed at doses up to 3.0 mg/kg IV, and sotatercept 
(ACE-011) was well tolerated in healthy, postmenopausal female volunteers in single dose levels 
up to 0.1 mg/kg SC and 3.0 mg/kg IV, the highest dose levels tested in this study.  
A011-02:  A Phase 1b Study in Healthy Postmenopausal Women (Multiple Dose)
Sotatercept (ACE-011) was studied in a phase 1b, single-center, randomized, double-blind, 
placebo-controlled, multi-dose, dose-escalating study to evaluate the safety, tolerability and 
pharmacodynamics of sotatercept (ACE-011) in healthy postmenopausal women.  Four cohorts 
of 10 subjects each were planned at the following dose levels:  0.1, 0.3, 1.0, and 2.0 mg/kg 
administered SC.  Within each cohort, subjects were to be randomized to either active or placebo 
treatment in an 8:2 ratio.  Subjects were to receive one SC injection of sotatercept (ACE-011) or 
placebo every 28 days for a total of 4 doses.  All subjects were to be followed for 12 weeks after 
the last dose.  
The treatment phase of the study was terminated early after a dose-limiting pharmacodynamic 
effect was observed.  While on study, one subject in the 1.0 mg/kg cohort experienced an SAE of 
progressive and persistent hypertension that was attributed to a rapid and significant rise in Hgb
levels, up to 20 g/dL and HCT levels, up to 57.3%.  Due to symptoms of headaches, nausea, eye 
pain, dizziness and vomiting approximately one week following the second dose, the subject was 
hospitalized for monitoring and evaluation of her hypertension.  The head MRI, fundoscopy, and 
ECG performed were reported as normal and headache symptoms resolved following corrective 
treatment by phlebotomy.  The SAE resolved and the subject was discharged from the hospital 
the following day.  The hypertension was monitored closely and managed initially with 
antihypertensive medication.  The hypertension resolved by the end of the study without need of 
any antihypertensive medication.  The subject received aspirin prophylactically until the end of 
the study and continued taking ibuprofen as needed for headaches.  Further details can be found 
in the Investigator’s Brochure.  
Based on the magnitude of the hematopoietic response, the Sponsor suspended dose escalation to 
the 2.0 mg/kg dose level and further dosing in all cohorts as a result of this dose-limiting 
pharmacodynamic effect at the 1.0 mg/kg dose level.  In total, 31 subjects were enrolled and 
treated.  Dose levels of sotatercept (ACE-011) administered included 0.1, 0.3, and 1.0 mg/kg 
(Cohorts 1, 2, and 3 respectively).  All subjects randomized to active treatment in Cohort 1 
received all 4 planned doses of sotatercept (ACE-011).  Due to early discontinuation of study 
drug, subjects randomized to active treatment in Cohort 2 received 3 doses of sotatercept (ACE-
011), and subjects randomized to active treatment in Cohort 3 received 2 doses of sotatercept 
(ACE-011).  Subjects randomized to placebo treatment received between 1 and 4 doses of study 
treatment.  
Page 549 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
28
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
In the analysis of the data, after the administration of the first dose, a dose and time dependent 
increase in Hgb, HCT, and RBC values were observed (see Table 1 below for changes in Hgb 
levels):
Table 1:
A011-02:  A Phase 1b Study in Healthy Postmenopausal Women, 
Hemoglobin Evaluation
Evaluation Time Point
Mean Change from Baseline (g/dL)
Placebo
N=7a
Sotatercept 
(ACE-011)
0.1 mg/kg
N=8
Sotatercept 
(ACE-011)
0.3 mg/kg
N=8
Sotatercept 
(ACE-011)
1.0 mg/kg
N=8
Baseline Mean, pre-Dose 1
13.20
13.11
13.30
12.71
Day 8
0.17
0.68
0.85
1.21
Day 15
-0.27
0.43
0.44
1.75
Day 29
0.27
0.61
1.21
2.68b
Day 36
0.56
0.64
1.89
2.96
Day 43
-0.02
0.89
1.21
2.85
Day 57
0.27
1.28
1.64b
2.09
Day 64
0.53
1.11
2.49
2.21
Day 71
-0.10
1.34
2.09
1.66
Day 85
0.38
1.18b
2.55
1.86
Day 92
0.00c
1.04
1.60c
3.80c
Day 99
-0.20
1.21
3.20c
1.28c
Day 113
-0.02
1.30
1.29
1.04
Day 141
0.30
0.95
0.34
2.30
Day 169
0.20c
0.06
-
2.00c
aThe number of placebo subjects with data decreases over time as a result of the early discontinuation of the study 
(i.e., there were placebo subjects in each dosing cohort).  There were seven placebo subjects with data at baseline, 
Days 8, 15, and 36; six subjects with data at Days 29, 43, 57, and 85; five subjects with data on Days 71 and 113; 
four subjects with data on Day 64; three subjects with data on Day 141; two subjects with data on Day 99; and one 
subject with data on Days 92 and 169.  
bNumber of doses administered per treatment group:  0.1 mg/kg 4 doses; 0.3 mg/kg 3 doses; 1.0 mg/kg 2 doses.  
Data beyond this study day are considered follow-up results.  
cn=1
Other than the serious case of Hgb increase, no life-threatening events were reported.  The most 
notable AEs were those related to increases in hematologic laboratory measures in the 1.0 mg/kg 
dose group:  HCT, Hgb, and RBC count.  The AEs of increased Hgb and/or HCT were reported 
for seven of the eight subjects in this dose group.  These events were reported as mild or 
moderate elevations; all were considered probably related to study drug treatment.  Three of the 
Page 550 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
29
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
subjects in the 1.0 mg/kg group with elevated Hgb levels underwent phlebotomies and all Hgb 
elevations were resolved by the end of the follow-up period.  No erythroid lineage AEs were 
reported in the 0.1 or 0.3 mg/kg treatment groups.  
Paresthesia and dizziness were reported more frequently in the sotatercept (ACE-011) groups, 
though the events were < G 2 and generally not considered drug related.  Other frequently 
reported events (e.g. fatigue, upper respiratory infection) did not appear to increase with dose 
and were generally mild.  
Hemoglobin levels for all subjects with elevations had returned to within normal limits by the 
end of the study.  
Adrenal cortical function was monitored through evaluation of serum electrolytes (sodium and 
potassium levels) and through cortisol response to adrenocorticotropic hormone (ACTH) 
stimulation.  All ACTH simulation test results were normal.  
The PK of sotatercept (ACE-011) were linear after SC administration.  Both AUC28d and Cmax 
were proportional to dose from 0.1 to 1 mg/kg following the first SC administration.  The t1/2, z 
of sotatercept (ACE-011) following the last dose in all three dose groups was identical, with 
mean t1/2, z being approximately 23 days.  Based on the one-compartmental modeling, the mean 
CL/F ranged from 3.05 to 3.90 mL/d/kg, the mean Vz/F ((apparent) volume of distribution) 
ranged from 97.47 to 103.03 mL/kg, with no apparent dependence on dose.  
Bone mineral density was assessed by dual-energy X-ray absorptiometry (DXA).  A dose-
dependent increase in the BMD of the total hip from baseline to end of study was observed, with 
a significant and rapid increase of 2.4% in the 1.0 mg/kg dose group, compared to a 0.7% 
decrease in the placebo group.  BMD results for lumbar spine showed slight increases of 0.4% to 
1.0% from baseline to study end in all active treatment groups, compared with a 0.5% decrease 
in the placebo group.  
A011-04:  A Phase 2a Study in Patients with Osteolytic Lesions of Multiple Myeloma / 
Preliminary Results
Study A011-04 is a phase 2a, multi-center, randomized, multiple-dose study to evaluate the 
safety, tolerability and efficacy of sotatercept (ACE-011) in subjects with osteolytic lesions of 
multiple myeloma (MM).  
In this study, subjects were randomized in a 4:1 ratio to one of three dose levels of sotatercept 
(ACE-011) (0.1, 0.3 and 0.5 mg/kg) or placebo, administered to subjects every 28 days by SC 
injection, for up to four doses over a 3-month period. Sotatercept (ACE-011) was evaluated in 
combination with the anti-myeloma therapy of melphalan (4 mg/m2 on days 1-7), prednisolone 
(40 mg/m2 on days 1-7) and thalidomide (100 mg per day) (MPT). The sites, Sponsor and 
Sponsor representatives were blinded to treatment assignment.  
Thirty subjects were randomized and received at least one dose of study medication:  6 subjects
received placebo, 8 subjects received 0.1 mg/kg sotatercept (ACE-011), 8 subjects received 0.3 
mg/kg sotatercept (ACE-011), and 8 subjects received 0.5 mg/kg sotatercept (ACE-011).  
Twenty six (86.7%) subjects completed the study.  One subject in the 0.1 mg/kg dose group and 
one subject in the 0.5 mg/kg dose group discontinued due to AEs.  One subject in the 0.1 mg/kg 
dose group withdrew consent and was discontinued, and one subject in the 0.3 mg/kg dose group 
was discontinued at the request of the investigator.  
Page 551 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
30
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
In this study, 50.0% of subjects were female and the mean (range) age was 60.9 (41 to 79) years.  
The mean time since diagnosis of MM was 3.3 years, the majority of subjects had stage III 
disease at screening (83.3%) and had received prior chemotherapy (93.3%).  Approximately
43.3% of subjects were receiving bisphosphonates at screening, which continued during the 
study.  
Fourteen out of 24 subjects (58%) who received study treatment (sotatercept [ACE-011]) did 
receive 3 doses or more (4 out of 8 subjects in the 0.5 mg/kg dose level, 5 out of 8 subjects in the 
0.3 mg/kg dose level and 5 out of 8 subjects in the 0.1 mg/kg dose level).  
Safety:  Overall, 22 (91.7%) subjects receiving sotatercept (ACE-011) and 4 (66.7%) subjects
receiving placebo reported at least one AE.  Among subjects receiving sotatercept (ACE-011), 
AEs were reported in 87.5%, 87.5%, and 100% of subjects in the 0.1 mg/kg, 0.3 mg/kg, and 0.5 
mg/kg dosing cohorts, respectively.  Treatment-related AEs (i.e., those assessed by the 
Investigator as possibly, probably, or definitely related to treatment) were reported by 21 
(87.5%) subjects receiving sotatercept (ACE-011) and 4 (66.7%) receiving placebo.  Most 
subjects had AEs that were assessed as related to MPT:  21 (87.5%) subjects receiving 
sotatercept (ACE-011) and 4 (66.7%) subjects receiving placebo.  No AEs were assessed by the 
Investigator as related to the study medication alone (sotatercept (ACE-011) or placebo).  Two 
subjects had AEs assessed as possibly or probably related to study drug and possibly or probably 
related to MPT, one subject in the 0.1 mg/kg sotatercept (ACE-011) dose group (increased blood 
pressure; sudden death) and one subject in the 0.5 mg/kg sotatercept (ACE-011) dose group 
(hypertension).  Four subjects had SAEs, 1 (12.5%) subject in the 0.1 mg/kg sotatercept (ACE-
011) group and 3 (37.5%) subjects in the 0.5 mg/kg sotatercept (ACE-011) group.  Three 
subjects had SAEs that were assessed as treatment-related.  Of the 3 treatment-related SAEs, 2 
SAEs were assessed as possibly related to MPT and unrelated to sotatercept (ACE-011), and 1 
SAE (sudden death) was assessed as probably related to MPT and possibly related to sotatercept 
(ACE-011).  One subject in the 0.5 mg/kg sotatercept (ACE-011) dose group discontinued study 
drug due to episodes of atrial fibrillation assessed as possibly related to MPT and unrelated to 
sotatercept (ACE-011).  
Table 2 summarizes the most frequent AEs ≥5% in all treatment groups and Table 3 is a 
summary of SAEs reported.  
Page 552 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
31
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
Table 2:
Summary of Adverse Events Reported in Greater Than or Equal To 5
Percent of Patients Overall
Sotatercept (ACE-011) Treatment Group
Preferred 
Terma
Placebo
(N=6)
0.1 mg/kg
(N=8)
0.3 mg/kg
(N=8)
0.5 mg/kg
(N=8)
All Sotatercept
(ACE-011)
(N=24)
Any 
Grade
Grade ≥3
Any 
Grade
Grade ≥3
Any 
Grade
Grade ≥3
Any 
Grade
Grade ≥3 Any Grade Grade ≥3
Neutropenia
4 (66.7%) 1 (16.7%) 4 (50.0%) 2 (25.0%) 6 (75.0%) 2 (25.0%) 6 (75.0%) 3 (37.5%) 16 (66.7%) 7 (29.2%)
Leukopenia
0
0
3 (37.5%) 1 (12.5%) 1 (12.5%) 0
1 (12.5%) 1 (12.5%) 5 (20.8%)
2 (8.3%)
Granulo-
cytopenia
0
0
2 (25.0%) 1 (12.5%) 1 (12.5%) 1 (12.5%) 1 (12.5%) 1 (12.5%) 4 (16.7%)
3 (12.5%)
Anaemia
0
0
1 (12.5%) 1 (12.5%) 1 (12.5%) 1 (12.5%) 2 (25.0%) 1 (12.5%) 4 (16.7%)
3 (12.5%)
Respiratory 
tract 
infection
0
0
1 (12.5%) 1 (12.5%) 1 (12.5%) 0
1 (12.5%) 0
3 (12.5%)
1 (4.2%)
Thrombo-
cytopenia
0
0
1 (12.5%) 0
0
0
2 (25.0%) 1 (12.5%) 3 (12.5%)
1 (4.2%)
Pyrexia
0
0
1 (12.5%) 0
1 (12.5%) 0
1 (12.5%) 0
3 (12.5%)
0
Blood 
pressure 
increased
0
0
1 (12.5%)*1 (12.5%)*0
0
1 (12.5%) 0
2 (8.3%)
1 (4.2%)
Bronchitis
1 (16.7%) 0
0
0
1 (12.5%) 0
1 (12.5%) 0
2 (8.3%)
0
Compression 
fracture
0
0
0
0
1 (12.5%) 0
1 (12.5%) 0
2 (8.3%)
0
Pathological 
fracture
0
0
1 (12.5%) 0
0
0
1 (12.5%) 1 (12.5%) 2 (8.3%)
1 (4.2%)
aAdverse events were those that were treatment-emergent, defined as newly acquired or worsened during or after 
administration of first dose of study medication. A patient with multiple occurrences of an AE counted only once 
under each preferred term.  
*Indicates the adverse event was assessed by the investigator as related (possibly, probably, or definitely) to study 
drug (sotatercept (ACE-011) or placebo).  
Page 553 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
32
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
Table 3:
Summary of SAEs Reported
Study Treatment
Age (y) / 
Sex / Race
Preferred Term
(Verbatim Term)
[Severity / Gradea]
Study Dayb
at Onset
Outcome
(duration)
Relationship to Study 
Treatment
0.1 mg/kg 
Sotatercept 
(ACE-011) and 
MPT
Sudden death
(sudden death)
103
Death
Sotatercept (ACE-011):  
possibly
MPT:  probably
0.5 mg/kg 
Sotatercept 
(ACE-011) and 
MPT
Pain in extremity
(pain in leg)
[severe / G 3]
128
Ongoing at 
end of study
Sotatercept (ACE-011):  not 
related
MPT:  not related
Pathological fracture
(pathological fracture of 
femur)
[severe / G 3]
130
Ongoing at 
end of study
Sotatercept (ACE-011):  not 
related
MPT:  not related
0.5 mg/kg 
Sotatercept 
(ACE-011) and 
MPT
Pneumonia
(pneumonia)
[moderate / G 2]
9
Resolved
(12 days)
Sotatercept (ACE-011):  not 
related
MPT:  possibly
0.5 mg/kg 
Sotatercept 
(ACE-011) and 
MPT
Atrial fibrillation
(atrial fibrillation)
[life-threatening / G 4]
6
Resolved
(1 day)
Sotatercept (ACE-011):  not 
related
MPT:  possibly
F= female; M = male; MPT = melphalan, prednisolone, and thalidomide; NCI CTCAE, v3.0 = National Cancer 
Institute Common Terminology Criteria for Adverse Events, version 3.0; y = years
abased on NCI CTCAE, v3.0.  
bRelative to first dose of study drug.  
Following analysis of the central laboratory data, increases in Hgb values were observed within 
28 days after administration of the first dose of sotatercept (ACE-011)/placebo and sustained for 
≥ 28 days from baseline at any time as presented in Table 4.  
Table 4:
Number of Subjects with an Increase in Hgb from Baseline at Any Time and 
Sustained for Greater Than or Equal To 28 Days
Increase in Hgb
Dose Sotatercept (ACE-011)/Placebo
0.1 mg/kg
N=8
0.3 mg/kg
N=8
0.5 mg/kg
N=8
Placebo
N=6
Overall
N=30
≥ 1.0 g/dL
4
3
7
2
16
≥ 1.5 g/dL
2
3
3
1
9
≥ 2.0 g/dL
1
3
2
0
6
Taken together, these data, suggest a beneficial pharmacodynamic effect of sotatercept (ACE-
011) on erythropoiesis in a patient population with cancer CIA.  
Potential Risks for Human Use
Nonclinical studies to determine the safety of sotatercept (ACE-011) have been conducted in 
cynomolgus monkeys and Sprague-Dawley rats.  Many of the observed effects in these studies 
Page 554 of 791
PPD
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
33
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
were as a result of the expected biologic activity of sotatercept and can be summarized as a 
dose-dependent decrease in sperm count and motility secondary to FSH suppression as well as 
reversible increases in RBC parameters due to the effects on erythropoiesis.  
The most significant toxicity findings are listed below:  

Hematological findings (increase in RBC parameters – RBCs, Hgb, HCT) were 
observed across all studies.  Associated with the increase in RBC parameters were 
increases in reticulocytes and decreases in mean corpuscular hemoglobin (MCH) and 
mean corpuscular hemoglobin concentration (MCHC).  The increase in RBC 
parameters is an anticipated effect of sotatercept (ACE-011) treatment and is being 
targeted as a therapeutic intervention for conditions associated with anemia.  

In the 6- and 9-month monkey studies, glomerulonephritis and/or tubulointerstitial 
nephritis were observed in monkeys administered ≥ 10 mg/kg administered 
subcutaneously (SC) every 2 or 4 weeks. At 2.6 mg/kg administered SC every 4 
weeks for 9 months, kidney findings were limited to a single incidence of 
tubulointerstitial nephritis. The NOAEL in the 9-month study was considered to be 1 
mg/kg every 4 weeks. Serum exposure in monkeys at the 1 mg/kg dose is estimated 
to be ~1.4-fold greater than the projected serum exposure in humans at the maximum 
proposed human dose of 61 mg every 6 weeks in a 50 kg subject.  Because 
sotatercept is a fully human molecule, immunogenicity and, by extension, kidney 
injury is not expected in humans. In the single- and multiple-dose studies in healthy 
postmenopausal women, there have been no changes in serum chemistry or urinalysis 
profiles suggestive of kidney injury. Subjects administered sotatercept (ACE-011)
should continue to be closely monitored.  

In the 9-month monkey study, treatment-related findings in the choroid plexus 
included:  perivascular accumulations of foamy macrophages and intimal thickening 
of small arteries and arterioles primarily at 10 mg/kg administered every 2 weeks as 
well as an increased incidence of small, focal aggregates of mononuclear 
inflammatory cells at all dosages. These changes were also considered related to the 
formation of anti-drug antibodies.  Findings at 1 mg/kg were limited to mononuclear 
cell infiltrates and were not considered adverse. 

Adrenal gland congestion or necrosis was observed in rats but not in monkeys.  The 
finding was more pronounced in female rats and appeared following either one month 
of IV dosing or 3 months of SC dosing.  Although the current data suggest adrenal 
toxicity may be specific to rats, the relevance of the adrenal findings to humans is 
uncertain.  

Elevations in liver enzymes (alanine aminotransferase [ALT], aspartate 
aminotransferase [AST], and/or alkaline phosphatase), as well as triglycerides, were 
observed sporadically in rats and monkeys treated with sotatercept (ACE-011).  There 
were no histological correlates in the liver, and often a dose-response relationship was 
not observed.  The relevance of these findings to sotatercept (ACE-011) treatment is 
uncertain; however, liver enzymes will continue to be monitored in this study. 
Page 555 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
34
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011

Pregnancy and Lactation

Due to the potential for effects on hormones in the pituitary, including FSH, in 
addition to possible direct effects on fetus, there may be potential effects on the 
fetus. Delays in fetal development (decreased fetal weights and delays in 
ossification) were observed in rats at doses ≥15 mg/kg (2.8-fold greater exposure
than the projected exposure at the maximum proposed human dose of 61 mg 
every 6 weeks in a 50 kg subject). In addition, at 50 mg/kg (4.7-fold the exposure 
at the maximum proposed human dose), there was an increase in late fetal death 
coupled with an overall increase in post implantation loss and a reduction in live 
litter size, as well as an increase in the incidence of developmental variations of 
supernumerary ribs with corresponding increases and decreases in thoracic and 
lumbar vertebrae, respectively. No fetal malformations were observed in this 
study at dosages up to 50 mg/kg. The NOAEL for embryofetal development 
effects was 5 mg/kg (1.5-fold greater exposure than the exposure at the maximum 
proposed human dose of 61 mg every 6 weeks in a 50 kg subject) based on 
reduced fetal weights and associated delays in ossification. 

In an embryo-fetal development study in rabbits, post implantation loss was 
increased and average litter size and live fetuses were reduced at 15 and 50 
mg/kg.  In addition, fetal body weights were reduced in all sotatercept dosage 
groups.  Abortions occurred in one rabbit in the 5 mg/kg dosage group and two 
rabbits in the 50 mg/kg dosage group.  Based on these findings, an NOAEL was 
not identified in this study and was therefore less than 5 mg/kg (<1.2-fold greater 
exposure than the exposure at the maximum proposed human dose of 61 mg every 
6 weeks in a 50 kg subject) 

Precautions should be taken to protect females of childbearing potential.
Nonclinical studies on breast milk have not been done.  

If sotatercept (ACE-011) is taken during pregnancy, a teratogenic effect in 
humans cannot be ruled out.  Therefore, all sotatercept (ACE-011) protocols 
describe pregnancy prevention requiring females of child-bearing potential to use 
highly effective methods of birth control.  In addition, since it is unknown if 
sotatercept (ACE-011) is found in breast milk, breast feeding is prohibited in all 
protocols.  

Fertility

In male rats, sperm granulomas and testicular degeneration were observed 
histologically.  In addition, sperm analysis revealed a reduction in sperm counts 
and motility as well as sperm fragmentation in isolated animals (2/10 males) at 
doses of 30 mg/kg IV.  Sperm fragmentation was also noted in 2/5 males 
administered 10 mg/kg IV at the end of the recovery period.  Overall, there was 
some evidence of recovery (motility similar to controls) at the end of the 4-week 
recovery period.  There was no evidence of a treatment-related impact on 
reproductive organs (testes, ovary, uterus) of monkeys in the toxicity studies; 
however, the monkeys on these studies, were too immature to fully assess the 
potential impact on reproductive organs.  The NOAEL for reproductive effects 
Page 556 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
35
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
(testicular or ovarian) was 1 mg/kg IV.  Serum exposure (AUC28d) in rats at the 
NOAEL was estimated to be ~ 8,000 µg·hr/mL based on the single-dose IV 
pharmacokinetic study in rats (Report TR148), ~ 2-fold greater than the serum 
exposure observed in humans at the maximum proposed dose of 61 mg every 6 
weeks (estimated AUC28d ~ 4248 μg·hr/mL in a 50 kg subject). 

In summary, in view of the potential risks sotatercept (ACE-011) treatment has on 
fertility, sotatercept (ACE-011) is targeted toward patient groups for whom the 
potential benefits outweigh the perceived risks.  
Because of the potential risks sotatercept (ACE-011) treatment has on fertility, sotatercept (ACE-
011) was first studied in healthy postmenopausal in two completed phase 1 clinical trials.  In 
addition, due to the potential for effects on hormones in the pituitary, levels of growth hormone, 
ACTH, and thyroid stimulating hormone (TSH) were monitored closely in the phase 1 studies.  
Completed studies in humans carried out in postmenopausal females showed a dose-dependent 
decrease in circulating levels of FSH, with mean levels in the multi-dose study in the two higher 
dose groups remaining below baseline at study end.  FSH will continue to be evaluated in 
ongoing studies.  No abnormal effects of sotatercept (ACE-011) on growth hormone, ACTH, and 
TSH and kidney toxicities were observed.  
Based on the safety data from the two completed phase 1 studies, single doses of sotatercept 
(ACE-011) up to 3.0 mg/kg IV and multiple doses of sotatercept (ACE-011) up to 0.3 mg/kg SC 
were generally well-tolerated in healthy postmenopausal women.  Consistent with observations 
from nonclinical safety studies, many of the observed pharmacodynamic effects in the phase 1 
clinical studies could be attributed to the expected biologic activity of activin inhibition, i.e., 
dose-dependent decrease in circulating levels of FSH, and transient, reversible effects on RBC 
parameters.  In Study A011-02 one subject experienced persistent, progressive hypertension and 
headaches approximately 1 week following her second dose of 1.0 mg/kg sotatercept (ACE-011)
SC that were attributed to a rapid and significant rise in Hgb levels.  The hypertension was 
reported as an SAE.  
In regards to the above safety concerns, appropriate vitals, hematologic, clinical chemistry and 
endocrine testing will be closely monitored in this clinical study.  There may be an effect of 
delayed wound healing, thus subjects with major surgeries within 30 days prior to study 
initiation will be excluded.  As with all biologics there is the potential for anti-drug antibodies 
that can be associated with increased drug clearance and hypersensitivity reactions.  Although no 
current evidence of neutralizing anti-drug antibodies formation was seen in two completed phase 
1 clinical trials, anti-drug antibody formation will be monitored in this clinical study.  
Please refer to the Investigator Brochure for further detailed information on the available 
pharmacology, toxicology, drug metabolism, clinical studies and AE profile of sotatercept 
(ACE-011).  
Page 557 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
36
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
2.
STUDY OBJECTIVES
2.1.
Primary Objective

Part 1:  To determine a dose of sotatercept (ACE-011) that results in a hematopoietic 
response for the treatment of CIA in subjects with advanced or metastatic solid 
tumors treated with platinum-based chemotherapeutic regimens, excluding those solid 
tumors treated with curative intent,.

Part 2:  To assess transfusion rate following initiation of sotatercept (ACE-011)
treatment versus placebo in subjects with CIA who have metastatic NSCLC treated 
with first-line platinum-based chemotherapeutic regimens.
2.2.
Secondary Objectives
Part 1 and Part 2:

To estimate the effect of sotatercept (ACE-011) treatment on objective response rate 
(ORR), time to progression (TTP), progression free survival (PFS) and overall 
survival (OS).  To evaluate the safety and tolerability of sotatercept (ACE-011).

To determine the PK of sotatercept (ACE-011) in subjects receiving platinum-based 
chemotherapy.  

To evaluate the hematopoietic response and its duration associated with sotatercept 
(ACE-011) treatment.  

To evaluate the effect of sotatercept (ACE-011) treatment on the quality of life 
(QoL).
2.3.
Exploratory Objectives
Part 1 and Part 2:

To estimate the effect of sotatercept (ACE-011) treatment on bone metabolism.

To explore the relationship between sotatercept (ACE-011) exposure and response 
(hematology, biomarkers, and other clinical outcomes as appropriate).  

To evaluate the expression of Activin A and other proteins/biomarkers (including 
myostatin and follistatin) related to sotatercept (ACE-011) mechanism of action in 
blood.

To evaluate the expression of Activin A and other proteins/biomarkers in archival 
tumor tissue (Part 2 only).

To assess renal function biomarkers.
Data from exploratory objectives may not be included in the Clinical Study Report.  
Page 558 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
37
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
3.
STUDY ENDPOINTS
3.1.
Primary Endpoint(s)
Part 1: Dose Finding
The following are decision rules for dose determination in Part 1 in order to move forward to 
Part 2:

After completion of two doses of sotatercept (ACE-011), a hematopoietic response in 
approximately 70% of subjects, in at least one or more treatment arms.  

Hematopoietic response is defined as an increase in Hgb of ≥1.0 g/dL above the 
study baseline value for 28 consecutive days, in the absence of RBC transfusions 
and/or ESAs.  In order to determine the dose of sotatercept (ACE-011) to be used in 
Part 2, evaluation of hematopoietic response will be determined from sotatercept 
(ACE-011) Dose 1/ Day 1 through and including Dose 2/Day 43 (prior to Dose 3).  

In addition to the hematopoietic response, the safety profile, dose modifications and 
extent of exposure in each dosing level will be taken into account to determine the 
study dose to be used in Part 2.  
Hematopoietic response will be determined by laboratory analysis of hemoglobin levels.  
Part 2:  Phase 2b/3 Double-Blind

Rate of RBC transfusion within four months following the date of randomization to 
sotatercept (ACE-011)/placebo treatment
3.2.
Secondary Endpoint(s)

Safety (type, frequency, and severity [National Cancer Institute (NCI) Common 
Terminology for Adverse Events (CTCAE) current active minor version 4.0] of 
adverse events

TTP 

PFS (including at 6 and 12 months)

OS (at 12 months and up to 24 months)

ORR

Duration of hematopoietic response

Sotatercept (ACE-011) concentration in serum 

Non-compartmental PK parameters for sotatercept (ACE-011) (Part 1 only)

QoL assessment (FACIT Fatigue Scale [Version 4]) and LCSS questionnaire (Hollen,
1993; Hollen, 1994a; Hollen, 1994b; Hollen, 1995, Hollen, 1999)
Page 559 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
38
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
3.3.
Exploratory Endpoint(s)

Change in serum and urine bone biomarkers, including osteocalcin (OC), serum bone 
specific alkaline phosphatase (BSAP), procollagen type 1 N-terminal propeptide 
(P1NP), C-terminal type 1 collagen telopeptide (CTX) and tartrate-resistant acid 
phosphatase isoform-5b (TRACP-5b), the urine bone biomarker (urine N-telopeptide 
[uNTX]) related to activin or sotatercept (ACE-011) mechanism of action  

Change in BMD (DXA scans of lumbar spine and hip)

Time to first symptomatic skeletal related event (SRE) defined as pathologic fracture, 
clinical need for radiation therapy, surgery to bone or spinal cord compression

A population PK model for sotatercept (ACE-011)  

A population pharmacodynamic model describing Hgb response as a function of time, 
sotatercept (ACE-011) exposure, and subject characteristics 

Expression of Activin A and other protein/biomarkers related to sotatercept (ACE-
011) mechanism of action in blood (including myostatin and follistatin) and in 
archival tumor tissue (Part 2 only). 

Change in renal function biomarkers via urinalysis measuring urine albumin / 
creatinine ratio, urine protein / creatinine ratio and other biomarkers of glomerular 
and/or tubular injury - urine kidney injury molecule-1 (KIM-1), urine trefoil factor 3 
(TTF3), urine cystatin C and + or – urine β2-microglobulin
Page 560 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
39
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
4.
OVERALL STUDY DESIGN
4.1.
Study Design 
This is an open-label randomized, phase 2a, dose-ranging study (Part 1) of sotatercept (ACE-
011) therapy in subjects with advanced or metastatic solid tumor types treated with platinum-
based chemotherapeutic regimens followed by a phase 2b/3, double-blind, randomized, placebo-
controlled study of sotatercept (ACE-011) therapy for CIA in subjects with metastatic NSCLC
treated with platinum-based chemotherapeutic regimens.  
The study will consist of two parts.  Part 1 is a dose finding segment in which subjects with
advanced or metastatic solid tumor types will be randomized to one of three sotatercept (ACE-
011) dose treatment arms.  Continuous monitoring of safety data will be conducted, including the 
review of Part 1 data to determine the sotatercept (ACE-011) dose to be used in Part 2, the 
phase 2b/3, double-blind, randomized placebo-controlled segment of the study in subjects with 
metastatic NSCLC.  
A DMC will monitor the conduct of the study.
Part 1 is planned to be conducted at selected sites and will be extended to additional global sites 
for the conduct of Part 2.  
Study treatment is defined as sotatercept (ACE-011) in Part 1 and sotatercept (ACE-
011)/placebo in Part 2.  
Three starting sotatercept (ACE-011) dose levels, 15, 30, and 45 mg, were selected for Part 1 of 
the study. Up to approximately 90 subjects with advanced or metastatic solid tumor types will 
be randomized to one of the following sotatercept (ACE-011) dose levels, with 10-30 subjects 
per arm:

Sotatercept (ACE-011) 15 mg SC

Sotatercept (ACE-011) 30 mg SC
Analysis of safety data will be performed following the treatment of at least 10 subjects at the 15
mg dose level and 10 subjects at the 30 mg dose level, with each subject having received a 
minimum of one dose of sotatercept (ACE-011) and completed a 12-week follow-up period from 
the first dose.  
Following this analysis, the addition of a third dose level:

Sotatercept (ACE-011) 45 mg SC
to the randomization schema will be determined.
Each dose level will be administered every 42 days for a total of four doses.  
In Part 2, a total of 750 subjects with metastatic NSCLC will be randomized to receive either 
sotatercept (ACE-011) (at the dose determined in Part 1) or placebo, at a ratio of 1:1:

375 subjects will receive sotatercept (ACE-011) (at the dose determined in Part 1)

375 subjects will receive placebo
Page 561 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
40
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
Each dose of sotatercept (ACE-011) or placebo will be administered every 42 days for four
doses; two additional doses may be given at the discretion of the Investigator.  
Part 2 will be performed in two stages. In the first stage, approximately 180 subjects will be 
randomized to receive sotatercept (ACE-011), at the dose determined from Part 1, or placebo at 
a ratio of 1:1.  An interim futility assessment based on transfusion rate at 4 months will be 
performed as described in Section 10.8.  It is expected that accrual will continue during the 
interim assessment period, with up to an additional 570 subjects randomized to achieve full study 
accrual. 
The Treatment Period for Part 1 is approximately six months, which includes up to 4 doses of 
sotatercept (ACE-011) and for Part 2 approximately nine months, which includes up to 6 doses 
of sotatercept (ACE-011/placebo).  Subjects who enter the Post Treatment Follow-Up Period
will be followed for up to 6 months from their last dose of sotatercept (ACE-011) or sotatercept 
(ACE-011)/placebo.  All subjects will continue to be followed for TTP and PFS up to 12 months
from their first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo or until 
progression of their advanced or metastatic disease, whichever occurs first.  
Survival data will be collected monthly for up to 24 months following the subject’s first dose of 
sotatercept (ACE-011) in Part 1 or sotatercept (ACE-011)/placebo in Part 2.  
At the time of randomization in Part 1 and Part 2, subjects must:

have already received at least one cycle and up to 4 cycles (q3w schedule) of 
platinum-based chemotherapy and be randomized prior to receiving Cycle 5 
OR 

have already received at least one cycle and up to 3 months (depending upon 
regimen) of platinum-based chemotherapy 
OR

currently be receiving maintenance therapy following treatment with platinum-
based chemotherapy 
In Part 1, subjects must have an advanced or metastatic solid tumor treated with ≥ first–line 
platinum–based chemotherapy, excluding those solid tumors treated with curative intent.
In Part 2, subjects must have metastatic NSCLC and must not have received any other regimens 
of platinum containing chemotherapy for first-line treatment prior to the regimen they are 
receiving at the time of randomization.  
Stratification and randomization will be performed utilizing a validated interactive voice 
response system (IVRS).  

In Part 1, subjects will be randomized to one of three sotatercept (ACE-011) dose levels 
and will be stratified by:
1. Baseline Hgb level 

6.5 to < 9.0 g/dL

9.0 to < 11.0 g/dL
Page 562 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
41
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
2. Type of platinum-based chemotherapy (cisplatin versus carboplatin)

In Part 2 subjects will be randomized to receive either sotatercept (ACE-011) or placebo 
and will be stratified by:
1. Baseline Hgb level 

6.5 to < 9.0 g/dL

9.0 to < 11.0 g/dL
2. Type of platinum-based chemotherapy (cisplatin versus carboplatin)
3. NSCLC histology (Squamous NSCLC vs. Non-Squamous NSCLC)
4. ECOG Performance Status 0-1 vs. 2
Page 563 of 791
088VGY

088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
43
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
4.1.1.
Sotatercept (ACE-011) Dose Modification, Reduction and Escalation Rules
Subjects should have Hgb and blood pressure measured (confirmed by two measurements 
obtained at least five minutes apart) prior to each dose of study drug.  The Investigator must 
adhere to the following Hgb and blood pressure-based dose modification rules for sotatercept 
(ACE-011) or sotatercept (ACE-011)/placebo for the subject’s second dose of study treatment 
and beyond.  
Sotatercept (ACE-011) Dose Modification Rules:
Hemoglobin < 11g/dL
(per local* lab value) 
Hemoglobin ≥11g/dL
(per local* lab value) 
Hypertension ≥SBP 150 mmHg or ≥DBP 100 mmHg
*Note:  Local laboratory assessments are allowed in cases when timely results are needed (e.g., randomization, 
study treatment and chemotherapy dosing decisions, hematology assessments between clinic visits).  Whenever 
< 2.0 g/dL increase within a 
dosing period or a ≥ 2.0 g/dL 
increase not sustained for a 28 
day period since last dosing day 
≥ 2.0 g/dL increase sustained for a 
28 day period since last dosing day2
Note: ≥ 3.0 g/dL increase sustained 
for a 28 day period since last dosing 
day requires a two level dose 
reduction.  
< 2.0 g/dL increase within a 
dosing period or a   ≥ 2.0g/dL 
increase not sustained for a 28 
day period since last dosing day
≥ 2.0g/dL increase sustained for a 28 day 
period since last dosing day2
Note: ≥ 3.0g/dL increase sustained for a 28 
day period since last dosing day requires a 
two level dose reduction.  If Hgb is > 15.0 
g/dL, sustained for 7 days, subject is to be 
discontinued from treatment2. 
Dose Delay5
Continue 
Dosing1
(Part 1 only-
Dose Escalation 
Table 6)
Continue Dosing 
with Dose 
Reduction 
Table 5: Sotatercept 
(ACE-011) and 
Sotatercept (ACE-
011)/Placebo Dose 
Reduction Levels
Dose Delay3
Dose Delay 
then, Dose 
Reduction4
Page 565 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
44
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
possible a “split” sample should also be forwarded to the central laboratory for analysis.  Local laboratory data 
should be collected in the eCRF.  
1If Hgb increase ≥ 1.0 but < 2.0 g/dL, dose remains the same.
For Part 1 only:  if the RBC transfusion was given > 7 days following the previous dose of sotatercept (ACE-011), 
the subsequent dose of sotatercept (ACE-011) will be increased one dose level (Refer to sotatercept (ACE-011)
Dose Escalation Levels- Table 6).  Hemoglobin level must be < 11 g/dL AND hypertension < SBP 150 mmHg and 
< DBP 100 mmHg on the day of dosing.  Sotatercept (ACE-011) should not be administered ≤7 days post RBC 
transfusion.  
For Part 2:  Subjects who have received an RBC transfusion in the past 42 days should continue at the same
sotatercept (ACE-011)/placebo dose if the transfusion was given greater than 7 days from the previous dose of 
sotatercept (ACE-011)/placebo AND the Hgb level is < 11 g/dL AND hypertension is < SBP 150 mmHg and < 
DBP 100 mmHg on the day of dosing.  Sotatercept (ACE-011)/placebo should not be administered ≤7 days post 
RBC transfusion.  
2Hemoglobin increases of > 2 g/dL sustained for a 28 day period since last dosing day should be confirmed on the 
dosing day, 7, 14 , 21 (after first dose of study treatment) and 28 days after dosing, and reviewed in comparison to 
Hgb level on previous dosing day.  Any Hgb increase of ≥3.0 g/dL sustained for 28 days will require a subsequent 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dose reduction of two dose levels (Refer to sotatercept 
(ACE-011) and sotatercept (ACE-011)/Placebo Dose Reduction Levels (Table 5).  A second Hgb increase of ≥3.0 
g/dL sustained for 28 days, following a two level dose reduction, will require the subject discontinue from study 
treatment.  If Hgb is > 15.0 g/dL (sustained for a 7 day period, confirmed by laboratory assessment) subject is to 
be discontinued from treatment. (See Section 8.2.3 Discontinuation)  
3Sotatercept (ACE-011) or sotatercept (ACE-011)/placebo should be delayed until Hgb is < 11g/dL and 
hypertension < SBP 150mm Hg and < DBP 100 mm Hg.  Dosing can commence at ≥7 days after the originally 
planned sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dose that was delayed.  Subsequent sotatercept 
(ACE-011) or sotatercept (ACE-011)/placebo doses will then begin 42 days following this revised treatment dose
date.  
A delayed sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dose is defined as a dose administered > 4 
days from the planned dosing date (due to Hgb ≥11.0 g/dL, hypertension > SBP 150 mmHg or > DBP 100 mmHg 
and/or sotatercept (ACE-011) related toxicity).  
4Sotatercept (ACE-011)or sotatercept (ACE-011)/placebo should be delayed as above in foot note (3), a reduced 
dose as above in foot note (2) of sotatercept (ACE-011) will be administered based on the evaluation of the Hgb
and blood pressure at that time.  
5Sotatercept (ACE-011)or sotatercept (ACE-011)/placebo should be held until hypertension resolves to < SBP 
150mmHg and < DBP 100 mmHg and may then be resumed beginning seven days after the previous planned
scheduled treatment visit as above in foot note (3).  
Page 566 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
45
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
Table 5:
Sotatercept (ACE-011) and Sotatercept (ACE-011)/Placebo Dose Reduction 
Levels
When required, per dose modification rules above, sotatercept (ACE-011) dose(s) in Part 1 and 
sotatercept (ACE-011)/placebo dose(s) in Part 2 should be reduced as follows:  
Dose Schedule
Sotatercept (ACE-011) or
Sotatercept (ACE-011)/placebo
Dose Reduction*
#1
Dose Reduction*
#2
Dose Reduction*
#3
Every 42 days-
45 mg
38 mg
33 mg
28 mg
Every 42 days-
30 mg
26 mg
22 mg
18 mg
Every 42 days-
15 mg
13 mg
11 mg
9 mg
*Note:  Any Hgb increase of ≥3.0 g/dL sustained for a 28 day period since last doing day will require a subsequent 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dose reduction of two dose levels.  A second Hgb
increase of ≥3.0 g/dL, sustained for 28 days, following a two-level dose reduction will require the subject 
discontinue from study treatment.  
Dosing visits are on Day 1 and repeated every 42 days, for four doses.  An additional two doses 
(total of 6 doses) may be given only during Part 2 at the discretion of the Investigator.  
Blood pressure (confirmed by two measurements obtained at least five minutes apart) and Hgb
values must be evaluated prior to dosing at each dosing day for consideration in administration 
of sotatercept (ACE-011) and sotatercept (ACE-011)/placebo.  
The dose level for the initial dose reduction will be maintained unless subsequent dose 
reductions need to be administered upon evaluation of the dose modification rules listed above.  
A dose level may not be increased following a dose reduction.  
In Part 2, dose reduction steps and the subsequent administration of the reduced dose(s) of 
sotatercept (ACE-011)/placebo will be conducted in a manner that will preserve the blinded 
status of the original treatment group of each subject.  Subjects in the placebo group who are 
designated to undergo dose reduction will continue to receive placebo.  
Placebo will be administered at the same volume as the corresponding sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo dose reduction.  
Sotatercept (ACE-011) Dose Escalation Levels:
The following dose escalation rules apply for sotatercept (ACE-011) dose(s) in Part 1 only.  
Dose escalations are not allowed in Part 2:

Less than 1.0 g/dL increase in Hgb in response to prior sotatercept (ACE-011) dose

Hgb level must be < 11.0 g/dL and hypertension < SBP 150mmHg and
< DBP 100 mmHg

Dose escalation to begin at next treatment visit 
Page 567 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
46
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011

Sotatercept (ACE-011) should not be administered ≤7 days from the date of RBC 
transfusion.  
Subjects who have received an RBC transfusion should receive a one level dose increase of 
Sotatercept (ACE-011) at the subsequent visit per the escalation table below.  
Table 6:
Sotatercept (ACE-011) Dose Escalation Levels (Part 1 Only) 
Dose Schedule
Sotatercept (ACE-
011)
Dose Increase  #1
Dose Increase  #2
Dose Increase #3
Every 42 days-
45 mg
50 mg
55 mg
61 mg
Every 42 days-
30 mg
33 mg
36 mg
40 mg
Every 42 days-
15 mg
17 mg
20 mg
23 mg
Blood pressure (confirmed by two measurements obtained at least five minutes apart) and Hgb 
values must be evaluated prior to dosing at each dosing day for consideration in administration 
of sotatercept (ACE-011) and sotatercept (ACE-011)/placebo.  
4.2.
Study Design Rationale
The A011-01, A011-02 and A011-04 studies have shown that dosing with sotatercept (ACE-011)
resulted in a rapid, sustained and dose-dependent increases in hematopoietic parameters, (Hgb, 
HCT and RBC counts) which occurred earlier than would be expected from a stimulation of 
erythropoiesis by an ESA.  This observation, coupled with nonclinical data demonstrating some 
level of erythrocyte stimulatory effect in the presence of anti-erthyropoietin (EPO) antibodies, 
suggests that the hematopoietic effect of sotatercept is different from that of ESAs.  Treatment of 
subjects with metastatic lung cancer with myelosuppressive platinum-based chemotherapy is 
frequently associated with anemia.  Chemotherapy induced anemia is a significant problem for 
subjects with cancer, causing fatigue and reduced quality of life (Groopman, 1999).  Subjects
with CIA are currently treated with blood transfusion and/or ESAs (NCCN Guidelines, 2009).  
However, with these treatment options CIA is still an area of major medical morbidity.  
Erythropoiesis-stimulating agents can successfully mitigate transfusion need in a proportion of 
these subjects, but concerns have emerged regarding apparent negative effects on survival and/or 
tumor progression in certain patient populations.  
4.2.1.
Fixed Dose
Sotatercept (ACE-011) dose will be fixed at the indicated levels regardless of the subject’s body 
weight.  The fixed dosing approach is supported by an exploratory analysis of the relationship 
between body weight and sotatercept (ACE-011) PK in the previous studies (A011-01, A011-02, 
and A011-04).  In healthy postmenopausal women (Studies A011-01 and A011-02), body weight 
was estimated to explain less than 2.5% of intersubject variability for the two PK parameters 
dictating sotatercept (ACE-011) exposure, clearance and central volume of distribution, 
Page 568 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
47
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
compared to an overall intersubject variability of 17.4% -25.5% for the two parameters.  In MM 
subjects (Study A011-04), body weight had no apparent effect on sotatercept (ACE-011)
exposure.  Because the Hgb response is dependent on sotatercept (ACE-011) exposure and 
because body weight is not a major source for the intersubject variability of sotatercept (ACE-
011) exposure, a fixed dosing approach is considered to be appropriate for the current study.  
4.2.2.
Dosing Schedule
The dosing schedule of once every 42 days (6 weeks) is proposed for the current study.  This 
dosing schedule was chosen by taking into consideration the rapid and prolonged Hgb response 
to sotatercept (ACE-011) as well as the dosing schedule for the platinum-based chemotherapies.  
The Hgb-increasing effect of sotatercept (ACE-011) was usually evident approximately 1 week 
after a SC dose and remained detectable through 6-8 weeks.  In addition, as platinum-based 
chemotherapy is often administered once every 3 weeks, a once every 6 weeks dosing schedule 
allows administration of sotatercept (ACE-011) at the same visit for the chemotherapy, which is 
convenient to both subjects and study sites.  
4.2.3.
Starting Dose Levels in Part 1
Three starting dose levels, 15, 30, and 45 mg, were chosen for Part 1 of the study.  Selection of 
these doses is primarily based on the safety and exposure-response data observed in MM subjects 
under the standard MPT chemotherapy, who received up to four doses of sotatercept (ACE-011)
at 0.1, 0.3, or 0.5 mg/kg (Study A011-04).  In these subjects, sotatercept (ACE-011) had an 
acceptable safety profile and caused exposure-dependent Hgb response.  Further, there was no 
relationship observed between an increase in blood pressure and the maximal sotatercept (ACE-
011) concentration or the maximal Hgb rise within 28 days of the first dose (Report A011-04-
CP).  The three starting dose levels approximate the average doses received by a 70 kg subject 
over a 6-week interval (10.5 mg, 31.5 mg, and 52.5 mg, respectively) in the A011-04 study.  
In Study A011-04, four MM subjects received at least three sotatercept (ACE-011) doses at 0.5 
mg/kg every 4 weeks without a dose interruption, and none of them was reported to have an AE 
related to sotatercept (ACE-011).  In this study, the starting dose level of 45 mg (during the dose 
finding Part 1) will be implemented only after at least 10 subjects at each lower dose level (10 
subjects at the 15 mg dose level and 10 subjects at the 30 mg dose level) have been evaluated as 
well as following DMC review of safety data and assessment of dose effects on Hgb levels.  
In addition, in this study, during the first 6-week treatment period for a 70 kg subject receiving 
the starting dose at 45 mg, the sotatercept (ACE-011) exposure (Cmax, day 1-43 and AUC1-43) is 
projected to be approximately 10% lower than the exposure for the dose regimen of 0.5 mg/kg 
once every 4 weeks.  Afterwards, safety measures (Hgb and blood pressure) will be used to guide 
the adjustment of the second dose and beyond.  Thus, the use of the 45 mg starting dose in the 
current study is not anticipated to significantly compromise subject safety.  
In this study, the 45 mg group will have the highest starting dose, and it may be titrated up to 
61.0 mg for the last dose (Dose 4).  Assuming a 70 kg subject who receives the maximal amount 
of dose during the entire study (i.e., starting at 45 mg followed by dose escalation every 6 weeks 
to 50.0, 55.0, and 61.0 mg for Doses 2, 3, and 4, respectively), the projected cumulative AUC 
during the treatment period (168 days) would be approximately 60% of the steady state AUC 
cumulated during the same period at the NOAEL level of 1 mg/kg (given every 4 weeks for a 
Page 569 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
48
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
total of 6 doses) as reported in the 9-month, repeat-dose toxicity study in monkeys.  The 
projected highest Cmax for the current study would be less than 50% of the steady state Cmax in 
the monkey study.  
4.2.4.
Evaluation of Dosing Schema via Modeling/Simulation
The performance of the proposed dosing schema (three fixed starting dose levels, 6-week dosing 
interval, and dose adjustment rules [see Section 4.1.1 for details]) for this study was evaluated 
via PK/pharmacodynamic modeling/simulation.  A tentative mechanistic PK/pharmacodynamic
model for Hgb was developed using PK and Hgb data from healthy postmenopausal women and 
the model was extended to include MM subjects as a sub-population.  The model was required to 
appropriately reproduce the observed PK and Hgb profiles in MM subjects.  Monte Carlo 
simulations of the Hgb response to sotatercept (ACE-011) in a hypothetical anemic population 
(6.5 ≤ baseline Hgb < 11 g/dL; body weight 47 – 108 kg) were performed using the model 
parameterized with preliminary PK and pharmacodynamic parameters from MM subjects.  In 
this simulation analysis, efficacy refers to an Hgb increase > 1 g/dL from the baseline for 28 
consecutive days while safety refers to both the absolute Hgb levels and the rate of Hgb increase.  
The simulation predicts that the desired efficacy would be achieved 6 weeks after the second 
dose in approximately 70% subjects of the 45 mg group and 6 weeks after the last dose in >70% 
subjects of the 30 mg group.  Further, the simulation predicts the Hgb level would be maintained 
under 12 g/dL in 90% subjects and under 13 g/dL in 95% of subjects during the course of the 
study (Figure 2).  No subjects are predicted to have a Hgb level above the upper limit of the 
normal range for Hgb (16 g/dL).  Approximately 6% subjects are predicted to have an Hgb rise 
> 2 g/dL within 28 days of the first dose, mostly from the 45 mg group (4%); however, the 
fraction of subjects with an Hgb rise > 3 g/dL per 28 days is predicted to be similar between the 
three dose groups (approximately 2.5% for each group).  
Figure 2:
Simulated Hemoglobin Response in the Hypothetical Anemic Population
Time (days)
0
50
100
150
200
250
300
Hb (g/dL)
6
8
10
12
14
Time (days)
0
50
100
150
200
250
300
6
8
10
12
14
Time (days)
0
50
100
150
200
250
300
6
8
10
12
14
Starting dose = 15 mg
Starting dose = 30 mg
Starting dose = 45 mg
The middle solid lines represent the median Hgb level.  The top and bottom solid lines represent the Hgb level at 5% 
and 95% percentile, respectively.  The area between 5% and 95% percentiles represents 90% prediction interval.  
The straight dot lines represent the Hgb level of 12 g/dL.  The arrows indicate the dosing time of sotatercept (ACE-
011).  The two level dose reductions upon ≥ 3 g/dL increase sustained for 28 days of a dose (Table 5) was not 
included in the simulation.  
Page 570 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
49
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
4.3.
Study Duration
To evaluate sequence and study timelines, please see the Table of Events (see Section 5).  
Approximately 60-90 subjects with advanced or metastatic solid tumor types in Part 1 and 750
subjects with metastatic NSCLC in Part 2 will be randomized prior to receiving the fifth cycle 
(q3w regimen) OR prior to starting the fourth month (depending upon regimen) of platinum-
based chemotherapy OR during maintenance therapy following treatment with platinum-based 
chemotherapy.  Each subject will be on the study for approximately 12 – 15 months (including 
the Screening Period, the Treatment Period, and the Post Treatment Follow-Up Period).  The 
Treatment Period is approximately 6 to 9 months (four to six doses of sotatercept [ACE-011]
every 42 days) with a Post Treatment Follow-Up Period of six months from the subjects’ last 
dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.  Subjects who discontinue 
treatment early will still continue to the Post Treatment Follow-Up Period for six months from
their last dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.  
All subjects will continue to be followed for TTP and PFS up to 12 months from their first dose 
of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo or until progression of their
advanced or metastatic disease, whichever occurs first.  All subjects will continue to be followed 
for survival up to 24 months from their first dose of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo.
Page 571 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
50
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
5.
TABLE OF EVENTS
Table 7:
Sotatercept (ACE-011) Schedule of Assessments
Treatment Period
Screening 
Period
Sotatercept (ACE-011)
Dose 1 Schedule
(± 3 days)
Sotatercept (ACE-011)
Subsequent
Doses 2  through 6 Schedule
(± 3 days)
Post Treatment Follow-Up Period
(± 1 week)
Survival
(±1wk)
Assessments
Day -28
to
Day -1
D1
D8
D15 D22 D29
D43/
D1
D8
D15 D29
D43 
Post Last 
Dose/End 
of Study
Txt
1
Month
2
Month
3
Month
4
Month
5
Month
6
Month/
Study
DCu
Survival
Informed Consent
X
Inclusion/Exclusion Criteria
X
Complete Medical History
X
Cancer History and Prior Therapiesa
X
Prior ESA and RBC transfusion historya
X
X
Clinical visits (*study treatment visit)
X
X*
X
X
X*
X
X
X
X
X
X
X
X
ECOG Performance Status
X
X
X
X
X
X
X
X
X
X
X
X
Vital Signs / Blood Pressureb
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Height (at randomization only)/Weight
X
X
X
X
X
X
X
X
X
X
X
X
X
12-Lead Electrocardiogram (ECG) –
Part 1c
X
X
X
X
X
12-Lead Electrocardiogram (ECG) –
Part 2c
X
X
X
Pregnancy Testingd
X
X
X
X
X
X
X
Xd
Page 572 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
51
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
Table 7:
Sotatercept (ACE-011) Schedule of Assessments (Continued)
Treatment Period
Screening 
Period
Sotatercept (ACE-011)
Dose 1 Schedule
(± 3 days)
Sotatercept (ACE-011)
Subsequent
Doses 2  through 6 Schedule
(± 3 days)
Post Treatment Follow-Up Period
(± 1 week)
Survival
(±1wk)
Assessments
Day -28
to
Day -1
D1
D8
D15 D22 D29
D43/
D1
D8
D15 D29
D43 
Post Last 
Dose/End 
of Study
Txt
1
Month
2
Month
3
Month
4
Month
5
Month
6
Month/
Study
DCu
Survival
Hematologye
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Absolute Reticulocyte Counte
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Serum Chemistryf
X
X
X
X
X
X
X
X
X
X
X
X
X
Serum Creatinine and Creatinine 
Clearanceg
X
X
X
X
X
X
X
X
X
X
X
X
X
Serum Iron, TIBC, Transferrin and Serum 
Ferritin, Vitamin B12 and RBC Folate 
Levelsh
X
Xh
X
Serum Erythropoietin (**Full PK subjects 
post first dose only)i
X
X
X**
X
X** X**
X
Xi
X
X
Urinalysis and Renal Biomarkersj
X
X
X
X
X
X
X
X
X
X
X
X
FSH and LH – Males and Females
X
X
X
X
X
X
X
X
Dihyroepiandosterone and Testosterone 
(Free & Total) - Males Only 
X
X
X
X
X
X
X
X
Estrogen and Estradiol & Menstrual 
Status - Females Only
X
X
X
X
X
X
X
X
TSHk
X
X
Xk
X
Page 573 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
52
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
Table 7:
Sotatercept (ACE-011) Schedule of Assessments (Continued)
Treatment Period
Screening 
Period
Sotatercept (ACE-011)
Dose 1 Schedule
(± 3 days)
Sotatercept (ACE-011)
Subsequent
Doses 2  through 6 Schedule
(± 3 days)
Post Treatment Follow-Up Period
(± 1 week)
Survival
(±1wk)
Assessments
Day -28
to
Day -1
D1
D8
D15 D22 D29
D43/
D1
D8
D15 D29
D43 
Post Last 
Dose/End 
of Study
Txt
1
Month
2
Month
3
Month
4
Month
5
Month
6
Month/
Study
DCu
Survival
Sotatercept (ACE-011) drug antibody test
(pre-dose)
X
X
X
X
X
X
Bone Biomarkers (BSAP, OC, P1NP, 
CTX, TRACP-5b and uNTX)l
(**Full PK subjects post first dose only)
X
X** X**
X** X**
X
X
X
Bone Imaging (DXA)m (Optional in 
Selected Centers)
X
X
Activin A and other proteins/biomarkers 
in blood (serum) (pre-dose study 
treatment in a subset of subjects)
X
X
X
X
Activin and other proteins/biomarkers in 
archival tumor tissue (Part 2 only -
optional)
X
Pharmacokinetics–
(Part 1 and Part 2)n
Refer to Table 8 and Table 9 – Schedule of Pharmacokinetic Assessments
Tumor Assessmentso
Xo
< Every 9 weeks or as per standard of care at study site
QoL Assessment
(LCSS and FACIT Fatigue Scale)p
X
X
X
X
X
X
X
X
X
X
X
X
X
Adverse Events
X
All AEs regardless of causality up to 6 weeks (42 days) post last dose of study treatment, after day 43 of last dose 
only AEs assessed as related to study treatment are to be reported
Concomitant Medications
(including ESAs and transfusions)
X
X
X
X
X
X
X
X
X
Page 574 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
53
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
Table 7:
Sotatercept (ACE-011) Schedule of Assessments (Continued)
Treatment Period
Screening 
Period
Sotatercept (ACE-011)
Dose 1 Schedule
(± 3 days)
Sotatercept (ACE-011)
Subsequent
Doses 2  through 6 Schedule
(± 3 days)
Post Treatment Follow-Up Period
(± 1 week)
Survival
(±1wk)
Assessments
Day -28
to
Day -1
D1
D8
D15 D22 D29
D43/
D1
D8
D15 D29
D43 
Post Last 
Dose/End 
of Study
Txt
1
Month
2
Month
3
Month
4
Month
5
Month
6
Month/
Study
DCu
Survival
Concomitant Procedures
X
X
X
X
X
X
X
X
X
Hospitalizations (Record)
X
X
X
X
X
X
X
X
X
Randomization
X
Administer 
Sotatercept (ACE-011)/Perform Drug 
Accountabilityq
X
X
Platinum-based Chemotherapyr
X
Dosing of allowed regimen(s) per standard practice
Targeted/Maintenance Therapys
Dosing of allowed regimen(s) per standard practice
Overall Survivalv
X
Post Treatment Anti-Neoplastic Therapy
X
X
X
X
X
X
X
X
aInclude cancer history, date of original diagnosis, clinical stage at Screening and date of metastases and advanced or metastatic site involvement.  Record prior 
ESA history, starting at solid tumor diagnosis.  Record RBC transfusion history, starting from diagnosis of advanced or metastatic disease, at a minimum of 
two months prior to randomization.  
bVital signs (including heart rate, seated blood pressure, and temperature) will be measured at Screening and all subsequent clinical visits, on Day 29 post 
sotatercept (ACE-011) or sotatercept (ACE-011)/ placebo dose, at Treatment Discontinuation, and at Study Discontinuation.  Blood pressure should be 
confirmed by two measurements obtained at least five minutes apart Investigators are to report any clinically significant abnormal findings as adverse events.  
Page 575 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
54
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
cECG to be performed as follows:  For Part 1:  At Screening,   Day 1 Dose 1 pre and post sotatercept (ACE-011) dose,  Day 8 post dose 1, every sotatercept 
(ACE-011) dosing Visit (post-dose) and at end of study treatment (day 43 post last dose).  
For Part 2:  At Screening, Day 1 Dose 1 pre and post sotatercept (ACE-011)/placebo dose and at end of study treatment (day 43 post last dose).  
dFemales of childbearing potential (FCBP) only:  A female of childbearing potential is a sexually mature woman who has not undergone a hysterectomy or who 
has not been postmenopausal for at least 24 consecutive months (i.e. who has had menses at some time in the preceding 24 months).  A medically supervised 
pregnancy test with a minimum sensitivity of 25mIU/ml must be performed within 3 days prior to the start of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo administration (Day 1) once the subject has been on effective contraception for at least 28 days and be performed within 3 days prior to dose 
administration of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo during the Treatment Period.  Subjects must agree to use highly effective birth 
control measures (e.g., oral contraceptives or two forms of barrier method birth control) during study participation and for at least 112 days following the last 
dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.  Pregnancy test will be performed at Study Discontinuation if date is ≤112 days following 
the last dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.  
eHematology laboratory evaluations (RBC count, Hgb, HCT, WBC count and differential, ANC, MCV, platelet count and reticulocyte count).  Hemoglobin 
should be tested prior to dosing with sotatercept (ACE-011) or sotatercept (ACE-011)/placebo to ensure levels are within normal limits and that sotatercept 
(ACE-011) dose modification rules are followed as outlined in Section 4.1.1.  Any laboratory evaluations may be repeated more frequently if clinically 
indicated.  In addition, RBC, Hgb, and reticulocyte counts will be included at each timepoint within the full PK assessment (Part 1).  
fSerum chemistry laboratory evaluations (sodium, potassium, chloride, CO2 (bicarbonate), calcium, magnesium, phosphorus, BUN, creatinine, glucose, amylase, 
lipase, albumin, total protein, alkaline phosphatase, bilirubin [total and direct], AST/SGOT, ALT/SGPT, LDH and uric acid) if clinically significant any or all 
laboratory evaluations may be reported as AE and repeated more frequently.  
gCreatinine clearance (per Cockcroft-Gault formula) every 2 weeks during the Treatment Period, every month (except month 1) during the Post Treatment 
Follow-Up Period and at study discontinuation .  
Note:  Footnotes e, f, g : Hematology, absolute reticulocyte count, serum chemistry and creatinine clearance are to be assessed ≤14 days prior to 
randomization.
hSerum Iron, TIBC, Transferrin, Serum Ferritin, Vitamin B12 and RBC Folate to be performed at Screening, pre-last dose of sotatercept (ACE-011) or
sotatercept (ACE-011)/placebo and end of study treatment (day 43 post last dose).  
iErythropoietin – collected at day 15 following first 2 doses of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.  For full PK assessment, weekly after 
first dose of sotatercept (ACE-011).  
jUrine collection for:  Urine albumin, urine albumin creatinine ratio, urine protein creatinine ratio and other renal biomarkers of glomerular and/or tubular injury.  
kTSH – collected at screening, on Day 1 of only the first and second dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo and at 2 month post-
treatment follow-up visit. 
lBone Biomarkers- Collected for full PK subjects prior to dose 1, weekly following dose 1, prior to dose 2 , post last dose day 43 and month 3 post treatment 
follow-up visit.  For all other subjects collected prior to dose 1,  prior to dose 2 ,  post last dose day 43 and month 3 post treatment follow-up visit.  Biomarker 
serum samples should be consistently collected early morning. The urine sample should not be from the first morning void.  
mDual Energy X-ray Absorptiometry (DXA) scan of lumbar spine and hip to evaluate overall health on approximately 200 subjects at selected US site(s).  
Performed at Screening, and Month 3 during the Post Treatment Follow-Up Period.  
Page 576 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
55
ACE-011-NSCL-001 3.0 FINAL: 01NOV2011
nPharmacokinetics (Part 1):  Blood samples will be collected to evaluate the blood or serum concentrations of sotatercept (ACE-011).  Approximately 10 
subjects at each sotatercept (ACE-011) dose level, 15, 30 and 45 mg, will have full PK sampling.  In addition, RBC, Hgb, and reticulocyte counts will be 
collected at each time point (excluding the 4-hour time point on Day 1) from Day 1 to Day 43 after the first dose within the full PK assessment.  Subjects not 
participating in the optional full PK assessment may participate in the sparse PK assessment. 
Pharmacokinetics (Part 2):  Sparse PK blood samples will be collected to evaluate the blood or serum concentrations of sotatercept (ACE-011) in 
approximately 300 (40%) of 750 subjects.  Sotatercept (ACE-011) doses 5 and 6 will have pre-dose Day 1 PK (if applicable).  
REFER TO Table 8 and Table 9, SCHEDULE OF PHARMACOKINETIC ASSESSMENTS.  
oTumor assessments:  Screening Period tumor assessments may be performed within six weeks or as per study site standard of care prior to randomization.  Also, 
historical tumor assessment data, from prior to the initiation of platinum-based chemotherapy through the Screening Period, will be collected.  Following 
randomization, tumor assessments will be performed ≤every 9 weeks or per standard of care at the study site, starting from the date of the previous (screening
period) tumor assessment and following the chemotherapy schedule.  
pQoL assessments, FACIT Fatigue Scale (Version 4) – all subjects and LCSS questionnaire – only subjects with NSCLC, to be completed by the subject upon 
arrival at clinic and prior to any study procedures or testing at all visits, as indicated in the schedule, and at Study Discontinuation/One-Year Follow-Up Visit.  
qSotatercept (ACE-011) or sotatercept (ACE-011)/placebo dosing repeats every 42 days and will start after the subject begins a platinum-based chemotherapy 
regimen.  The first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo may be given at any time following the first dose of platinum-based 
chemotherapy.  Subsequent doses of Sotatercept (ACE-011) or sotatercept (ACE-011)/placebo can be administered at any time point during a chemotherapy 
cycle or maintenance therapy. 
Administration of subsequent cycles of chemotherapy, including dose reductions and dose delays, should not affect the sotatercept (ACE-011) or sotatercept 
(ACE-011)/placebo dosing schedule, unless determined to be necessary by the Investigator.  If there is a chemotherapy dose delay, sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo administration does not need to be delayed until start of next chemotherapy cycle. 
rPlatinum-based chemotherapy is to be administered based on guidelines for administration according to manufacturer’s recommendations and standard clinical 
practice.  Type of chemotherapy and dosing will be recorded.  
s Targeted/maintenance therapy (e.g. pemetrexed, erlotinib, etc.) is to be administered based on guidelines for administration according to manufacturer’s 
recommendations and standard clinical practice.  
tDay 43 (6 weeks) post last dose corresponds to the end of Treatment Period.  Subjects who discontinue the sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo Treatment Period early will continue to the Post Treatment Follow-Up Period and be followed for up to 6 months after their last dose of 
sotatercept (ACE-011)/placebo.  
uStudy Discontinuation visit should occur 12 months after starting treatment with sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.
vSurvival data will be collected monthly, (can be via telephone contact), following the Study Discontinuation visit for an additional 12 months (up to 24 months 
after first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo).  
Page 577 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
56
ACE-011-NSCL-001 30 FINAL: 01NOV2011
Table 8:
Schedule of Pharmacokinetic Assessments (Part 1)
Scheduled Time
Time relative to 
Sotatercept (ACE-011)
Part 1a,b
Collection 
Windowe
Full PKc
Sparse PKd
Dose 1, D1
pre-Dose 1
X
X
-2  to  0 hour
Dose 1, D1
4 hours after Dose 1
X
X
±1 hour
Dose 1, D5
4 days after Dose 1
X
-
± 1 day
Dose 1, D8
7 days after Dose 1
X
X
± 1 day
Dose 1, D11
10 days after Dose 1
X
-
± 1 day
Dose 1, D15
14 days after Dose 1
X
X
± 1 day
Dose 1, D22
21 days after Dose 1
X
-
± 1 day
Dose 1, D29
28 days after Dose 1
X
X
± 1 day
Dose 1, D36
35 days after Dose 1
X
-
± 1 day
Dose 1, D43 (Dose 2, D1)
pre-Dose 2
X
X
± 2 days
Dose 2, D8
7 days after Dose 2
X
-
± 2 days
Dose 2, D15
14 days after Dose 2
X
-
± 2 days
Dose 2, D43 (Dose 3, D1)
pre-Dose 3
X
X
± 2 days
Dose 3, D8
7 days after Dose 3
X
-
± 2 days
Dose 3, D15
14 days after Dose 3
X
-
± 2 days
Dose 3, D43 (Dose 4, D1)
pre-Dose 4
X
X
± 2 days
Dose 4, D8
7 days after Dose 4
X
-
± 2 days
Dose 4, D15
14 days after Dose 4
X
-
± 2 days
Dose 4, D29
28 days after Dose 4
X
-
± 3 days
Last Dose, D43 
42 days after final dose 
X
X
± 3 days
PTf Follow up, 1 month
72 days after final dose
X
-
± 1 week
PT Follow up, 2 month
102 days after final dose
X
-
± 1 week
PT Follow up, 3 month
132 days after final dose
X
X
± 1 week
PT Follow up, 4 month
162 days after final dose
X
-
± 1 week
PT Follow up, 5 month
192 days after final dose
X
X
± 1 week
a Notes about PK sampling times:

For subjects participating in full PK sampling, RBC, Hgb and reticulocyte counts will be collected at each 
time point (excluding the 4-hour time point on Day 1) from Day 1 to Day 43 post first sotatercept (ACE-
011) dose.  Erythropoietin and bone biomarkers will be collected at D1, D8, D15, D22, D29, and D43 post 
first sotatercept (ACE-011) dose.  If the time points for RBC, Hgb, reticulocyte, erythropoietin and bone 
biomarkers overlap with the time points defined in Table 7, only one sample is required.  

For subjects who discontinue the treatment early, PK blood sample collection will be continued during the 
follow-up period.  
bAt each time point, collect approximately 2 mL of blood.  After collection, allow the blood to clot at room 
temperature for approximately 1 hour and then centrifuge the blood sample at room temperature for 10 min (1100-
1300 g) to obtain serum.  
cTo be collected for approximately 30 subjects (approximately 10 subjects in each dose group).  
dTo be collected in subjects participating in sparse PK sampling and not participating in full PK sampling.  
eFor subjects who participate in full PK sampling only.  The collection window for sparse PK samples will be the 
same as the visit window defined in Table 7.  
fPT = Post Treatment
Page 578 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
57
ACE-011-NSCL-001 30 FINAL: 01NOV2011
Table 9:
Schedule of Pharmacokinetic Assessments (Part 2)
Scheduled Time
Time relative to 
Sotatercept (ACE-
011)/placebo dose
Sparse PKa,b,c
Collection Windowd
Dose 1, D1
pre-Dose 1
X
-2  to  0 hour
Dose 1, D1
4 hours after Dose 1
X
±1 hour
Dose 1, D8
7 days after Dose 1
X
± 3 day
Dose 1, D15
14 days after Dose 1
X
± 3 day
Dose 1, D29
28 days after Dose 1
X
± 3 day
Dose 1, D43 (Dose 2, D1)
pre-Dose 2
X
± 3 days
Dose 2, D43 (Dose 3, D1)
pre-Dose 3
X
± 3 days
Dose 3, D43 (Dose 4, D1)
pre-Dose 4
X
± 3 days
Dose 4, D43 (Dose 5, D1)
pre-Dose 5 
X
± 3 days
Dose 5, D43 (Dose 6, D1)
pre-Dose 6 
X
± 3 days
PTe Follow up, 3 month
132 days after final dose
X
± 1 week
PT Follow up, 5 month
192 days after final dose
X
± 1 week
a For subjects who discontinue the treatment early, PK blood sample collection will be continued during the follow-
up period.  
bAt each time point, collect approximately 2 mL of blood.  After collection, allow the blood to clot at room 
temperature for approximately 1 hour and then centrifuge the blood sample at room temperature for 10 min (1100-
1300 g) to obtain serum.  
cTo be collected for approximately 300 (40%) of 750 subjects (approximately 150 subjects in each arm).
dExcept for Day 1 (Dose 1, D1), the collection window will be the same as the visit window defined in Table 7.  
ePT = Post Treatment
Page 579 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
58
ACE-011-NSCL-001 30 FINAL: 01NOV2011
6.
PROCEDURES
Screening Period (Day -28 to Day -1)
Prior to screening, subjects must sign an informed consent.  Potentially protocol-eligible subjects 
will be evaluated for the inclusion and exclusion criteria for the Treatment Period of this study.  
All screening assessments must be completed ≤ 28 days prior to randomization.  Screening 
period tumor assessments and tumor evaluation documentation, as per RECIST criteria (Version 
1.1) (Appendix A), must be performed within 6 weeks prior to randomization or as per study site 
standard of care.  Historical tumor assessment data, from prior to the initiation of platinum-based 
chemotherapy through the screening period, will be collected.  Hematology and chemistry 
laboratory assessments should be performed ≤14 days of randomization.  
The assessments and procedures that will be performed during the Screening Period are outlined 
in the Table of Events (see Section 5) and include:

Informed consent

Assessment of inclusion / exclusion criteria

Complete medical history including history of cardiac, renal and thromboembolic 
events

Cancer history, including date of original diagnosis, histopathology, clinical stage at 
screening, date of advanced or metastatic stage and site involvement

Prior ESA treatment history starting from the initial solid tumor diagnosis 

RBC transfusion history starting from diagnosis of advanced or metastatic disease at a 
minimum of up two months prior to randomization

ECOG performance status

Vital signs including height, weight, heart rate, seated systolic and diastolic blood 
pressure, and temperature.  

12-lead electrocardiogram (ECG)  

Medically supervised pregnancy test, with a minimum sensitivity of 25 mIU/ml, for 
females of childbearing potential (FCBP) to be assessed within 3 days prior to 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo administration

Serum chemistry, hematology, absolute reticulocyte count to be assessed ≤14 days 
prior to randomization

Creatinine clearance (per Cockroft-Gault formula) to be assessed ≤ 14 days prior to 
randomization

Serum iron, total iron binding capacity (TIBC), transferrin and serum ferritin

Vitamin B12 and RBC folate levels

Serum erythropoietin
Page 580 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
59
ACE-011-NSCL-001 30 FINAL: 01NOV2011

Urinalysis

FSH (include current menstrual cycle status for pre-menopausal female subjects) and 
LH – both males and females 

Dihyroepiandosterone and Testosterone (free and total) – males only

Estrogen and estradiol – females only

TSH

Bone imaging – DXA scan (optional at selected sites)

Tumor Assessment - Screening period tumor assessments and tumor evaluation 
documentation, as per RECIST criteria (Version 1.1), must be performed within 6
weeks or as per study site standard of care prior to randomization.  Also, historical 
tumor assessment data, from prior to the initiation of platinum based chemotherapy 
through the screening period, will be collected.  

QoL Assessment (FACIT Fatigue Scale [Version 4]) – all subjects

LCSS questionnaire – only subjects with NSCLC  

Documentation of concomitant medications / procedures / hospitalizations

Documentation of concomitant platinum-based chemotherapy
Treatment Period (Day 1/Dose 1 of study treatment to Day 43 post last study treatment 
dose)
Results from screening evaluations must be reviewed prior to randomization to confirm subject 
eligibility.  
In Part 1 (the dose-ranging portion of the study), subjects who meet all eligibility criteria will be 
randomized utilizing IVRS to receive one of the following sotatercept (ACE-011) dose levels, 
with 10-30 subjects per arm:

Sotatercept (ACE-011) 15 mg SC

Sotatercept (ACE-011) 30 mg SC
Analysis of safety data will be performed following the treatment of at least 10 subjects at the 15 
mg dose level and 10 subjects at the 30 mg dose level, with each subject having received a 
minimum of one dose of sotatercept (ACE-011) and completed a 12-week follow-up period from 
the first dose. 
Following this analysis, the addition of a third dose level:

Sotatercept (ACE-011) 45 mg SC
to the randomization schema will be determined.
Each dose level will be administered every 42 days for up to four doses.  

In Part 2, subjects meeting all inclusion and exclusion criteria will enter into the 
Treatment Period and be randomized by a double-blind procedure utilizing IVRS to 
receive sotatercept (ACE-011) or placebo (1:1 ratio).  
Page 581 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
60
ACE-011-NSCL-001 30 FINAL: 01NOV2011

A subject will be considered randomized once a unique multi-digit subject 
identification number has been assigned by IVRS.  
Following randomization, subjects will receive SC doses of sotatercept (ACE-011) or sotatercept 
(ACE-011)/placebo every 42 days during the Treatment Period, as specified in the Table of 
Events (see Section 5).  
In Part 1, the Treatment Period will last approximately 6 months, where subjects randomized to 
sotatercept (ACE-011) will receive treatment on Day 1 every 42 days for a planned 4 doses.  
In Part 2, the Treatment Period will last approximately 6 to 9 months, where subjects 
randomized to sotatercept (ACE-011)/Placebo will receive treatment on Day 1 every 42 days for 
a planned 4 doses with an additional 2 doses of sotatercept (ACE-011)/placebo allowable, at the 
discretion of the Investigator, for a total of up to 6 doses.  
The assessments and procedures that will be performed during the Treatment Period are outlined 
in the Table of Events (see Section 5).  

Updated prior ESA and RBC transfusion history which may have occurred between 
the screening visit and randomization

ECOG performance status

Vital signs including weight, heart rate, seated systolic and diastolic blood pressure, 
and temperature

ECG 

Medically supervised pregnancy test, with a minimum sensitivity of 25 mIU/ml, for 
FCBP within 3 days prior to sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo administration.  

Serum chemistry, hematology, absolute reticulocyte count.  

Hematology laboratory evaluations (RBC count, Hgb, HCT, WBC count and 
differential, mean corpuscular volume [MCV], absolute neutrophil count [ANC], 
platelet count and reticulocyte count) will be collected weekly after the first dose 
of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo and at subsequent 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo doses collected at 7, 14
days and 28 days post-dose.

Within full PK assessment, RBC, Hgb and reticulocyte counts are collected at 
each time point; erythropoietin and bone biomarkers at weekly intervals post first 
dose of study treatment.  

Creatinine clearance will be assessed every 14 days.  

Serum iron, total iron binding capacity (TIBC), transferrin and serum ferritin at last 
dose and 42 days after last dose of study treatment

Vitamin B12 and RBC folate levels at last dose and 42 days after last dose of study 
treatment

Serum erythropoietin
Page 582 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
61
ACE-011-NSCL-001 30 FINAL: 01NOV2011

Urinalysis

FSH (include current menstrual cycle status for premenopausal female subjects) and 
LH – both males and females 

Dihyroepiandosterone and Testosterone (free and total)– males only 

Estrogen and estradiol – females only 

TSH  

Serum for sotatercept (ACE-011) drug antibody test (pre-dose on the day of 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo administration)

Bone or other potential mechanistic or disease-related proteins/biomarkers 

Activin A and other sotatercept (ACE-011)-related proteins/biomarkers

in blood, including myostatin and follistatin:
o
pre- dose on Day 1 and Day 8 after first dose of sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo
o
pre-dose on Day 1 subsequent dosing visits

in archival tumor tissue (Part 2 only)

Tumor Assessment and Response Evaluation, as per RECIST criteria (Version 1.1), 
(performed ≤every 9 weeks or per standard of care at the study site, starting from the 
previous [screening] tumor assessment) and following the chemotherapy schedule

Pharmacokinetics

QoL Assessment (FACIT Fatigue Scale [Version 4]) – all subjects

LCSS questionnaire – only subjects with NSCLC  

Evaluation and all AE/SAE reporting (regardless of causality)

Documentation of concomitant medications / procedures (including use of ESAs and 
all transfusions) / hospitalizations

Documentation of concomitant platinum-based chemotherapy and/or
targeted/maintenance therapy

Administration of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo at:  Day 1 
every 42 days 
Subjects who discontinue from the Treatment Period early will enter the Post Treatment Follow-
Up Period and be followed for 6 months after their last dose of sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo.  Upon completion of the Post Treatment Follow-Up Period, 
subjects will have a discontinuation visit and be followed for survival for up to 24 months from 
their first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.  
Page 583 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
62
ACE-011-NSCL-001 30 FINAL: 01NOV2011
Post Treatment Follow-Up Period (Day 43 post last dose of study treatment to six months 
post last dose of study treatment)
Following completion or early discontinuation from the Treatment Period, subjects will enter the 
Post Treatment Follow-Up Period and continue to be followed for 6 months after their last dose 
of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo. Visits will occur every month.  The 
assessments and procedures that will be performed during this period are outlined in the Table of 
Events (see Section 5) and include:

ECOG performance status

Vital signs including weight, heart rate, seated systolic and diastolic blood pressure, 
and temperature.  

ECG – end of study treatment (day 43 post last dose)

Medically supervised pregnancy test, with a minimum sensitivity of 25mIU/ml, for 
FCBP

Serum chemistry, hematology, absolute reticulocyte count

Creatinine clearance 

Serum iron, total iron binding capacity (TIBC), transferrin and serum ferritin – end of 
study treatment (at day 43 post last dose)

Vitamin B12 and RBC folate levels – end of study treatment (at day 43 post last dose)

Serum erythropoietin

Urinalysis

FSH (include current menstrual cycle status for pre-menopausal female subjects) and 
LH – both males and females 

Dihyroepiandosterone and testosterone (free and total)– males only 

Estrogen and estradiol – females only

TSH (at 2 month end of treatment follow-up visit)

Serum for sotatercept (ACE-011) drug antibody test (pre-sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo dose)

Bone or other potential mechanistic or disease-related proteins/biomarkers 

Bone imaging – DXA scan (optional at selected sites-performed at 3 month end of 
treatment follow-up visit)

Activin A and other sotatercept (ACE-011) related proteins/biomarkers, including 
myostatin and follistatin, in blood at 1 month end of treatment follow-up visit)

Pharmacokinetics

Tumor Assessment and Response Evaluation, as per RECIST criteria (Version 1.1), 
(performed ≤every 9 weeks or as per standard of care at the study site, and following 
the chemotherapy schedule
Page 584 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
63
ACE-011-NSCL-001 30 FINAL: 01NOV2011

QoL Assessment (FACIT Fatigue Scale (Version 4)) – all subjects

LCSS questionnaire – only subjects with NSCLC  

Evaluation and reporting of all AEs regardless of causality (up to 6 weeks after last 
dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo).  After 6 weeks 
post last dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo, only AEs 
assessed as related to sotatercept (ACE-011) or sotatercept (ACE-011)/placebo or 
study related procedures are to be reported.  

Documentation of concomitant medications / procedures (including use of ESAs and 
all transfusions) / hospitalizations

Post-Treatment Anti-Neoplastic Therapy
Study Discontinuation 
Study Discontinuation is the final scheduled visit for this study and should be performed for all 
enrolled subjects.  
Subjects who discontinue from treatment early will enter the Post Treatment Follow-Up Period 
and be followed for 6 months from their last dose of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo.  Follow-up for twelve months for TTP and PFS will be performed from the 
subject’s first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/Placebo.  Following the 
Study Discontinuation Visit, subjects will be contacted monthly and survival data collected for 
an additional 12 months (up to 24 months following the subject’s first dose of sotatercept (ACE-
011) or sotatercept (ACE-011)/placebo).  
The assessments and procedures that will be performed during the Study Discontinuation Visit 
are outlined in the Table of Events (see Section 5) and include:

ECOG performance status

Vital signs including weight, heart rate, seated systolic and diastolic blood pressure, 
and temperature

Medically supervised pregnancy test, with a minimum sensitivity of 25 mIU/ml, for 
females of childbearing potential (FCBP) – if Study Discontinuation date is ≤ 112 
days following the last dose of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo.  

Serum chemistry, hematology, absolute reticulocyte count

Creatinine clearance 

Urinalysis 

FSH (include current menstrual cycle status for pre-menopausal female subjects) and 
LH – both males and females 

Estrogen and estradiol – females only

Dihyroepiandosterone and testosterone (free and total) – males only
Page 585 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
64
ACE-011-NSCL-001 30 FINAL: 01NOV2011

Tumor Assessment and Response Evaluation, as per RECIST criteria (Version 1.1)
(PFS at 12 months)

QoL Assessment (FACIT Fatigue Scale (Version 4)) – all subjects

LCSS questionnaire – only subjects with NSCLC  

Evaluation and reporting of all AEs regardless of causality (up to 6 weeks after last 
dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo).  After 6 weeks 
post last dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo, only AEs 
assessed as related to sotatercept (ACE-011) or sotatercept (ACE-011)/placebo or 
study related procedures are to be reported.

Documentation of concomitant medications / procedures (including use of ESAs and 
all transfusions) / hospitalizations

Post-Treatment Anti-Neoplastic Therapy
Survival Follow-Up Period:
Monthly collection of survival data will begin following the Study Discontinuation Visit and 
continue for an additional 12 months (up to 24 months after first dose of sotatercept (ACE-011)
or sotatercept (ACE-011)/placebo).  

Overall survival

Post-Treatment Anti-Neoplastic Therapy
Additional Procedure Descriptions:
Central ECG
Part 1 – ECGs will be performed and read per Central ECG vendor.  
Part 2 – ECGs will be performed locally and read per Central ECG vendor.  
Please refer to vendor manual for procedures.  
Clinical Laboratory Evaluations
Clinical laboratory evaluations (serum chemistry, hematology, absolute reticulocyte count, 
creatinine clearance, serum iron, total iron binding capacity, transferrin and serum ferritin, serum 
erythropoietin, vitamin B12, serum RBC folate levels, urinalysis, FSH, LH, 
dihyroepiandosterone, estrogen, estradiol, testosterone and serum thyroid-stimulating hormone)
will be performed by a central laboratory.  
Please refer to vendor manual for procedures.  
Note:  Local laboratory assessments are allowed in cases when timely results are needed (e.g.,
randomization, study treatment and chemotherapy dosing decisions, hematology assessments 
between clinic visits).  Whenever possible a “split” sample should also be forwarded to the 
central laboratory for analysis. Local laboratory data should be collected in the eCRF.  
Page 586 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
65
ACE-011-NSCL-001 30 FINAL: 01NOV2011
Exploratory Biomarkers
Analyses will be undertaken to evaluate the expression of Activin A and other 
proteins/biomarkers related to sotatercept (ACE-011) mechanism of action in blood (including 
myostatin and follistatin) and in archival tumor tissue in a subset of subjects (Part 2 only).  
Renal function biomarkers via urinalysis measuring urine albumin / creatinine ratio, urine protein 
/ creatinine ratio and other biomarkers of glomerular and/or tubular injury - urine kidney injury 
molecule-1 (KIM-1), urine trefoil factor 3 (TTF3), urine cystatin C and + or – urine β2-
microglobulin will be evaluated in all subjects.  
Pharmacokinetics

Part 1 -Blood samples will be collected to evaluate the full PK profile of sotatercept 
(ACE-011) from approximately 30 subjects at select centers (approximately 10 
subjects for each sotatercept [ACE-011] dose group).  For full PK sampling, subjects 
who miss more than two PK sampling time points from Days 1 through 43 will be 
replaced.  Subjects not participating in the optional full PK assessment may
participate in the sparse PK assessment. 

Part 2- Sparse PK blood samples will be collected from approximately 300 (40%) of 
750 subjects (approximately 150 subjects in each arm).  
For subjects who do not participate in either Part 1 full or sparse PK assessments or in Part 2
sparse PK assessments, the ACE-011 (sotatercept) concentration may be determined in their anti-
sotatercept antibody samples to assist in the evaluation of immunogenicity, as well as PK.
Detailed PK sampling schedule is presented in Table 8 and Table 9: Schedule of 
Pharmacokinetic Assessments.  

PK samples must be collected predose on the day of sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo administration.  PK samples may be collected at any 
time on non-dosing days.  After collection, allow the blood to clot at room 
temperature for approximately one hour and then centrifuge the blood sample at room 
temperature for 10 minutes (1100-1300g) to obtain serum.  At each time point, 
approximately 2 mL or less blood will be collected.  
Bone Biomarkers
Bone biomarkers will be evaluated in all subjects.  The serum and urine bone biomarkers will 
include BSAP, OC, P1NP, CTX, TRACP-5b and uNTX.  Both serum and urine samples will be 
collected.  
Biomarker serum samples should be consistently collected early morning.  The urine sample 
should not be from the first morning void.  
Page 587 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
66
ACE-011-NSCL-001 30 FINAL: 01NOV2011
Bone Imaging - optional
DXA scan to evaluate overall bone health will be performed on approximately 200 subjects at 
select site(s).
Quality of Life Assessments
QoL Assessment (FACIT Fatigue Scale [Version 4]) will be completed by all subjects and LCSS 
questionnaire will be completed for subjects with NSCLC.  Each assessment will be completed 
by the subject upon arrival at clinic and prior to any study procedures or testing.  The LCSS 
consists of two scales:  one for the patient (Patient Scale) and a counterpart for health 
professionals acting as observers (Observer Scale). 
Independent External Radiology Review (Part 2 Only)
At least 3 independent external radiologists (2 reviewers and 1 adjudicator) will perform a 
blinded, independent assessment of response, including the development of progressive disease 
(PD).  
Independent Review Committee (IRC) (Part 2 Only)
The IRC will review the tumor response data (to include results from the central radiologist and 
relevant clinical laboratory and physical examination findings) and the dates of disease 
progression for each subject.  These data reviewed by the IRC will be used in the primary 
analyses ORR, TTP and PFS for the Clinical Study Report.  
Page 588 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
67
ACE-011-NSCL-001 30 FINAL: 01NOV2011
7.
STUDY POPULATION
At the time of randomization in Part 1 and Part 2, subjects must:

have already received at least one cycle and up to 4 cycles (q3w schedule) of 
platinum-based chemotherapy and be randomized prior to receiving Cycle 5 
OR 

have already received at least one cycle and up to 3 months (depending upon 
regimen) of platinum-based chemotherapy 
OR

currently be receiving maintenance therapy following treatment with platinum-
based chemotherapy 
In Part 1, subjects must have an advanced or metastatic solid tumor treated with ≥ first–line 
platinum–based chemotherapy, excluding those solid tumors treated with curative intent.
In Part 2, subjects must have metastatic NSCLC and must not have received any other regimens 
of platinum containing chemotherapy for first-line treatment prior to the regimen they are 
receiving at the time of randomization.  
7.1.
Number of Subjects
This platinum-based CIA study will enroll approximately 840 subjects, approximately 90 
subjects with advanced or metastatic solid tumor types in Part 1 and 750 subjects with 
metastatic NSCLC in Part 2.  
In Part 1, up to 90 subjects will be randomized to receive one of the following sotatercept (ACE-
011) dose levels, with 10-30 subjects per arm:

Sotatercept (ACE-011) 15 mg SC

Sotatercept (ACE-011) 30 mg SC

Sotatercept (ACE-011) 45 mg SC
and will be stratified by:
1. Baseline Hgb level 

6.5 to < 9.0 g/dL

9.0 to < 11.0 g/dL
2. Type of platinum-based chemotherapy (cisplatin versus carboplatin)
In Part 2, an additional 750 subjects will be randomized to receive either sotatercept (ACE-011), 
at the dose determined in Part 1, or placebo at a ratio of 1:1.  Subjects will be stratified by:
1. Baseline Hgb level 

6.5 to < 9.0 g/dL

9.0 to < 11.0 g/dL
Page 589 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
68
ACE-011-NSCL-001 30 FINAL: 01NOV2011
2. Type of platinum-based chemotherapy (cisplatin versus carboplatin)
3. NSCLC histology (Squamous NSCLC vs. Non-Squamous NSCLC)
4. ECOG Performance Status 0-1 vs. 2
7.2.
Inclusion Criteria
Subjects must satisfy the following criteria to be enrolled in the study:
1. Men and women > 18 years of age at the time of signing the informed consent document.
2. Part 1 – Histologically confirmed (cytology or biopsy) solid tumor malignancy, 
excluding those solid tumors treated with curative intent.
Part 2 - Histologically confirmed (cytology or biopsy) non-small cell lung cancer.
3. Documented advanced or metastatic disease.
4. Measurable or non-measurable disease evaluable by RECIST criteria (Version 1.1)
(Appendix A).
5. All of the following laboratory values:

Hemoglobin ≥ 6.5 to < 11.0 g/dL (≥ 65 to < 110 g/L), due to chemotherapy-induced 
anemia

Absolute neutrophil count ≥ 500/mm3

Platelet count ≥ 75,000/mm3 (> 72 hours since prior platelet transfusion) 

Adequate renal function:
o
creatinine clearance ≥ 40mL/min or ≥ 50 mL/min if cisplatin is concomitantly 
administered
and
o
urine protein / creatinine ratio ≤1.0; or ≤2.0 if bevacizumab (Avastin®) is
concomitantly administered

Hepatic function (bilirubin < 1.5 x ULN; AST and ALT < 3.0 x ULN and ≤5.0 ULN 
for subjects with liver metastases)

Corrected calcium within normal limits (WNL) or ≤Grade 1.  Previous 
hypercalcemia treatment is allowed
6. Subjects must:

have already received at least one cycle and up to 4 cycles (q3w schedule) of 
platinum-based chemotherapy and be randomized prior to receiving Cycle 5 
OR 

have already received at least one cycle and up to 3 months (depending upon 
regimen) of platinum-based chemotherapy 
OR
Page 590 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
69
ACE-011-NSCL-001 30 FINAL: 01NOV2011

currently be receiving maintenance therapy following treatment with platinum-based 
chemotherapy 

For Part 1- any platinum-based regimen approved for the specific indication

For Part 2 -allowed regimens for the treatment of metastatic NSCLC are:
o
gemcitabine plus cisplatin or carboplatin ± bevacizumab
o
pemetrexed plus cisplatin or carboplatin ± bevacizumab
o
taxanes plus cisplatin or carboplatin ± bevacizumab
7. ≥ 28 days must have elapsed since previous treatment with ESA
8. ≥ 14 days must have elapsed (prior to Day 1) since the last RBC transfusion and receipt 
of ≤ 2 units of blood in the past 30 days (prior to Day 1)
9. ECOG Performance status of 0 – 2 (Appendix B)  
10. Females of childbearing potential participating in the study are to use highly effective 
methods of birth control for at least 28 days before starting the study, during study 
participation and for at least 112 days following the last dose of sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo.  
Some highly effective methods of birth control include:

Oral contraceptives, intrauterine device, tubal ligation or a partner with a vasectomy
OR

Two forms of barrier method birth control, e.g., a latex condom PLUS a diaphragm 
with spermicide OR a latex condom PLUS a contraceptive sponge with spermicide.  
If a non-latex condom is used, it cannot be made out of natural (animal) membrane  
Females of childbearing potential must have a negative pregnancy test, with a minimum 
sensitivity of 25 mIU/ml, within 3 days prior to sotatercept (ACE-011) or sotatercept 
(ACE-011)/placebo administration (Day 1).  In addition, subjects must be educated 
concerning measures to be used to prevent pregnancy and potential toxicities.  (A female 
of childbearing potential is a sexually mature woman who has not undergone a 
hysterectomy or bilateral oophorectomy; or who has not been postmenopausal for at least 
24 consecutive months i.e. who has had menses at some time in the preceding 24 
months).  
11. Males must agree to use a latex condom or non-latex condom NOT made of natural 
(animal) membrane during any sexual contact with females of childbearing potential or a 
pregnant female while participating in the study and for at least 112 days following the 
last dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo, even if he has 
undergone a successful vasectomy.  
12. Life expectancy of ≥ 3 months.
13. Is willing to adhere to the study visit schedule, understand and comply with all protocol 
requirements.
Page 591 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
70
ACE-011-NSCL-001 30 FINAL: 01NOV2011
14. Understand and voluntarily sign a written informed consent document prior to any study 
related assessments/procedures are conducted.
7.3.
Exclusion Criteria
The presence of any of the following will exclude a subject from enrollment:
1. Subjects who have any Grade > 3 toxicity (according to the currently active minor 
version of the NCI National Cancer Institute Common Terminology for Adverse Events 
[CTCAE] version 4.0 [Appendix C]) at the time of screening, including Grade ≥ 3 
residual adverse events related to either chemotherapy or underlying disease.  Exception:  
Grade ≥ 3 hematotoxicity (e.g., asymptomatic anemia, neutropenia and 
thrombocytopenia) occurring during the chemotherapy nadir period and resolving or non-
hematological events (e.g., nausea, vomiting, fatigue, or muscle or bone/joint pain), 
occurring during the chemotherapy period and resolving.
2. Prior radiation therapy to > 20% of the whole skeleton.  Use of palliative radiation, if the 
area being treated is < 15% of body surface area with no pelvic radiation or no more than 
10% of the bone marrow reserve is radiated, is permitted during subject participation in 
the study, at the discretion of the Investigator.  
3. Part 2 only, history of prior regimen(s) of platinum-based chemotherapy for metastatic
NSCLC and/or history of adjuvant platinum-based chemotherapy with last dose received 
less than six months prior to the start of current first-line platinum-based chemotherapy 
for metastatic NSCLC.  
4. CNS metastases (exception:  subjects with CNS metastases treated with whole brain 
radiotherapy, gamma knife radiosurgery and/or surgery and stable for at least 2 
weeks prior to randomization).  
5. Clinically significant pulmonary, endocrine, neurologic, gastrointestinal, hepatic or 
genitourinary disease unrelated to underlying malignancy.  
6. Subjects with classification of 3 or higher heart failure as classified by the New York 
Heart Association (NYHA) (Appendix D).  
7. History of thrombosis, deep vein thrombosis (DVT), pulmonary emboli (PE), or embolic 
stroke if not stable on anticoagulants and/or one of these events occurring within the past 
6 months.  Local central line thrombosis is allowed.  
8. Diagnosis of a myeloid malignancy or known history of myelodysplasia.  
9. Subjects with a recent history (within 14 days of Day 1) of administration of IV 
antibiotics or oral antibiotics (due to post septic episode).  Subjects should be free of 
infection at least 14 days after the last dose of systemic antibiotic treatment (prior to Day 
1).  
10. Uncontrolled hypertension.  Controlled hypertension is considered clinically stable and 
systolic blood pressure (SBP) must be < 150 mmHg and diastolic blood pressure (DBP)
must be < 100 mmHg.  
11. Known infection with human immunodeficiency virus (HIV).  
Page 592 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
71
ACE-011-NSCL-001 30 FINAL: 01NOV2011
12. Known active hepatitis B or C antibody defined by positive serology.  
13. Deficiency in iron (transferrin saturation < 20%), vitamin B12, or RBC folate.  Subjects 
may be re-screened following treatment with supplements and normalization of levels.  
14. History of anemia as a result of inherited hemoglobinopathy such as sickle cell anemia or 
thalassemia.  
15. History of anemia due to autoimmune or hereditary hemolysis; or gastrointestinal 
bleeding occurring within the past 6 months.  
16. Received treatment with another investigational drug or device within 28 days prior to 
Day 1, or if the half life of the previous product is known, within 5 times the half life 
prior to dosing, whichever may be longer.  
17. Any prior use of sotatercept (ACE-011).  
18. Pregnant or lactating females or females planning to become pregnant.  
19. History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant 
proteins or excipients in the investigational product (Refer to the Investigator’s Brochure 
for further information).  
20. Major surgery within 30 days prior to Day 1 (subjects must have completely recovered 
from any previous surgery prior to Day 1).  
Page 593 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
72
ACE-011-NSCL-001 30 FINAL: 01NOV2011
8.
DESCRIPTION OF STUDY TREATMENTS
8.1.
Description of Investigational Product(s)
Sotatercept (ACE-011) clinical drug product will be provided as a lyophilized powder, Process 
III.  
Process III Clinical Drug Product- Lyophilized Powder:
The clinical drug product consists of sotatercept (ACE-011) in 10 mM citrate buffer, pH 5.8, 8% 
sucrose, and 0.02% polysorbate 80.  It is supplied as a lyophilized powder in labeled, rubber 
stoppered, 3-mL glass vials.  The recommended storage temperature for sotatercept (ACE-011)
lyophilized drug product is 2°C to 8°C. Prior to administration, the lyophilized drug product is 
reconstituted with 1 mL water for injection (WFI).  The reconstituted drug product consists of a 
50 mg/mL solution of sotatercept (ACE-011).  The reconstituted sotatercept (ACE-011), in its 
original container closure system, may be held for up to 6 hours at 2°C to 8°C.
Placebo (Part 2 Only):
In Part 2, the sotatercept (ACE-011) placebo to be used in the study will be sterile normal saline 
(0.9% sodium chloride for injection) administered as a SC injection.  Sterile, normal saline will 
be supplied by the investigational site’s pharmacy.  The manufacturer’s directions for placebo 
storage and handling are to be followed, as are standard clinical practices for ensuring sterility of 
the placebo.  
8.2.
Treatment Administration and Schedule
Sotatercept (ACE-011) or placebo will be administered as a SC injection to subjects by the study 
staff at the clinical site and will be documented in the study source record.  Subcutaneous 
injections will be given in the upper arm, abdomen, or thigh.  
At the time of randomization in Part 1 and Part 2, subjects must:

have already received at least one cycle and up to 4 cycles (q3w schedule) of 
platinum-based chemotherapy and be randomized prior to receiving Cycle 5 
OR 

have already received at least one cycle and up to 3 months (depending upon 
regimen) of platinum-based chemotherapy 
OR

currently be receiving maintenance therapy following treatment with platinum-
based chemotherapy 
In Part 1, subjects must have an advanced or metastatic solid tumor treated with ≥ first–line 
platinum–based chemotherapy, excluding those solid tumors treated with curative intent.
In Part 2, subjects must have metastatic NSCLC and must not have received any other regimens 
of platinum containing chemotherapy for first-line treatment prior to the regimen they are 
receiving at the time of randomization.  
Page 594 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
73
ACE-011-NSCL-001 30 FINAL: 01NOV2011
Allowed concomitant platinum-based chemotherapy regimens are:

For Part 1- any platinum-based regimen approved for the specific indication

For Part 2 -allowed regimens for the treatment of metastatic NSCLC are:
o
gemcitabine plus cisplatin or carboplatin ± bevacizumab
o
pemetrexed plus cisplatin or carboplatin ± bevacizumab
o
taxanes plus cisplatin or carboplatin ± bevacizumab
Investigative sites will utilize commercial supply of these medications.  
Concomitant or maintenance therapy with chemotherapeutic and/or targeted agents (e.g., 
pemetrexed, anti-EGFR agents, anti-VEGF agents), which are approved for a given tumor type, 
are allowed in addition to platinum-based chemotherapy. 
Platinum-based tumor therapy may be revised at the discretion of the Investigator for toxicity 
reasons only.  
In Part 1 and Part 2, sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dosing may 
occur on different weeks of the chemotherapy cycle due to the subjects’ Hgb.  Dose delays of 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo and/or dose delays of chemotherapy 
may occur.  
8.2.1.
Selection of Dose for the Study
In Part 1, subjects will be randomized to one of the following sotatercept (ACE-011) dose 
levels, with 10-30 subjects per arm:

Sotatercept (ACE-011) 15 mg SC

Sotatercept (ACE-011) 30 mg SC
Analysis of safety data will be performed following the treatment of at least 10 subjects at the 15 
mg dose level and 10 subjects at the 30 mg dose level, with each subject having received a 
minimum of one dose of sotatercept (ACE-011) and completed a 12-week follow-up period from 
the first dose.  
Following this analysis, the addition of a third dose level:

Sotatercept (ACE-011) 45 mg SC
to the randomization schema will be determined.
Each dose level will be administered every 42 days for up to four doses.  
The following are decision rules for dose determination in Part 1 in order to move forward to 
Part 2:

After completion of two doses of sotatercept (ACE-011), a hematopoietic response in 
approximately 70% of subjects, in at least one or more treatment arms.  

Hematopoietic response is defined as an increase in Hgb of ≥ 1.0 g/dL above the 
study baseline value for 4 consecutive weeks, in the absence of RBC transfusions 
and/or ESAs.  In order to determine the dose of sotatercept (ACE-011) to be used in 
Page 595 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
74
ACE-011-NSCL-001 30 FINAL: 01NOV2011
Part 2, evaluation of hematopoietic response will be determined from sotatercept 
(ACE-011) dose 1/day 1 through and including dose 2/day 43 (prior to dose 3).  

In addition to the hematopoietic response, safety profile, dose modifications and 
extent of exposure will be taken into account for dose level selection for Part 2.  
Hematopoietic response will be determined by laboratory analysis of hemoglobin levels.  
In Part 2, subjects will be randomized to receive either sotatercept (ACE-011) (at the dose 
determined in Part 1) or placebo.  
8.2.2.
Selection and Timing of Dosing for Each Subject
Subjects will be randomized to receive sotatercept (ACE-011) or sotatercept (ACE-011)/placebo 
starting on Day 1 (one SC dose every 42 days) and continuing during the six-month (Part 1) or 
nine-month (Part 2) Treatment Period, as outlined in the Table of Events (see Section 5).  
In Part 1, subjects will be randomized to receive one of three dose levels of sotatercept (ACE-
011), with 10-30 subjects per arm.  In Part 2, 750 subjects will be randomized to receive 
sotatercept (ACE-011) or placebo at a ratio of 1:1.  
Each subject will return to the site on each scheduled clinic visit.  During the Treatment Period,
subjects will receive sotatercept (ACE-011) or sotatercept (ACE-011)/placebo every 42 days as 
determined by Hgb levels and randomization schedule.  Hemoglobin levels and reticulocyte 
counts will be repeated weekly after the first dose of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo then at 7, 14 and 28 days after each subsequent dose of sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo.  
The first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo can be administered
at any time after the first cycle and prior to the fifth cycle (q3w regimen) OR prior to 
starting the fourth month (depending upon regimen) of platinum-based chemotherapy OR 
during maintenance therapy following treatment with platinum-based chemotherapy.
Subsequent doses of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo can be 
administered at any time point during a chemotherapy cycle or maintenance therapy. 
Administration of subsequent cycles of chemotherapy, including dose reductions and dose 
delays, should not affect the sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dosing 
schedule, unless determined to be necessary by the Investigator.  If there is a chemotherapy dose 
delay, sotatercept (ACE-011) or sotatercept (ACE-011)/placebo administration does not need to 
be delayed until start of next chemotherapy cycle.  
Following completion of the Treatment Period, subjects who enter the Post Treatment Follow-
Up Period will be followed for 6 months from their last dose of sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo.  Visits will occur every month.  All subjects will continue to be 
followed for PFS up to 12 months from their first dose of sotatercept (ACE-011) or sotatercept 
(ACE-011)/placebo, or until progression of their advanced or metastatic disease, whichever 
occurs first.  
Subjects will be discontinued from the study treatment for reasons listed in Section 8.2.3 of the 
protocol, for unacceptable toxicity, or for progression of advanced or metastatic disease that 
requires the initiation of another treatment.  
Page 596 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
75
ACE-011-NSCL-001 30 FINAL: 01NOV2011
Following the Study Discontinuation Visit, subjects will be contacted monthly and survival data 
collected for an additional 12 months (up to 24 months following the subject’s first dose of 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo).  
8.2.3.
Discontinuation
Treatment Discontinuation
Subjects will be discontinued from Study Treatment due to the following:

Adverse events(s)

Hypertension ≥Grade 3 – defined as Stage 2 hypertension (SBP ≥160 mmHg or
DBP ≥100mmHg) confirmed by two measurements obtained at least five minutes 
apart; medical intervention indicated; more than one drug or more intensive 
therapy than previously used indicated or medically significant hypertension 
which cannot be adequately controlled with antihypertensive therapy 

Any AE > Grade 2 assessed to be related to sotatercept (ACE-011) therapy.

Any persistent AE > Grade 1 considered to be related to sotatercept (ACE-011)
treatment and causing a subject to miss three months sotatercept (ACE-011)
therapy 

Any thromboembolic event > Grade 2 

Elevated Hgb > 15.0 g/dL (sustained for a 7 day period, confirmed by laboratory 
assessment)

Urine protein / creatinine ratio > 1.0; or > 2.0 if bevacizumab (Avastin®) is 
concomitantly administered

Persistent hematuria ≥Grade 2 - defined as symptomatic; urinary catheter or 
bladder irrigation indicated; limiting instrumental activities of daily living, and 
persisting for one week

In Part 1, lack of sotatercept (ACE-011) therapeutic effect, defined as < 1.0 g/dL 
increase in Hgb from baseline following three dose escalations.  In Part 2, lack of 
sotatercept (ACE-011) therapeutic effect, defined as < 1.0 g/dL increase in Hgb from 
baseline following two doses of sotatercept (ACE-011)/placebo (Dose 1/ Day 1 
through and including Dose 2/Day 43, prior to Dose 3).  

Concomitant use of ESAs – In Part 1 if administered at any time and in Part 2 if 
administered < 4 months after first dose of study treatment.  

Sotatercept (ACE-011) or Sotatercept (ACE-011)/placebo Dose Modifications

In Part 1 and Part 2:  A second Hgb increase of ≥3.0 g/dL following a two level 
dose reduction due to a Hgb increase ≥3.0 g/dL 

In Part 2:  > 3 dose reductions and/or delays

Disease Progression 

Withdrawal of consent
Page 597 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
76
ACE-011-NSCL-001 30 FINAL: 01NOV2011

Death

Lost to follow-up

Protocol violation – as determined by the Sponsor
The reason for treatment discontinuation should be recorded in the eCRF and in the source 
documents.  
Study Discontinuation:  
The following events are considered sufficient reasons for discontinuing a subject from the 
study:

Completed study, per protocol (subject has completed six- to nine- month Treatment 
Period plus up to six-month Post Treatment Follow-Up Period including one year 
tumor assessment to determine TTP and PFS).  Note:  Survival data will continue to 
be collected for up to 24 months after first dose of study treatment.  

Withdrawal of consent

Death

Lost to follow-up
The following events may be considered sufficient reasons for discontinuing a subject from the 
study, as determined by the Sponsor:

Adverse events(s)

Disease progression 

Protocol violation
The reason for study discontinuation should be recorded in the eCRF and in the source 
documents.  The Investigator must notify the Medical Monitor immediately when a subject has 
been discontinued/ withdrawn due to an AE (any unacceptable toxicity).  All subjects who are 
withdrawn from the study should complete the tests and evaluations scheduled for Study 
Discontinuation at the time of withdrawal.  
8.3.
Method of Treatment Assignment
All subjects who qualify for the study will be randomly enrolled into the study and receive up to 
4 doses of sotatercept (ACE-011) in Part 1.  In Part 2, subjects will be randomized at a ratio of 
1:1 and receive up to 4 doses of study treatment and may receive 2 additional doses of 
sotatercept (ACE-011)/placebo, if clinically indicated, at the discretion of the Investigator.  A 
unique multi-digit subject identification number will be assigned by IVRS to each subject 
entering the Treatment Period.  
8.4.
Packaging and Labeling
The label(s) for investigational product (IP) will include Sponsor name, address and telephone 
number, the protocol number, IP name, dosage form and strength (where applicable), amount of 
IP per container, lot number, expiry date (where applicable), medication identification/kit 
Page 598 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
77
ACE-011-NSCL-001 30 FINAL: 01NOV2011
number (if applicable), dosing instructions, storage conditions, and required caution statements 
and/or regulatory statements as applicable.  Additional information may be included on the label 
as applicable per local regulations.  
8.5.
Investigational Product Accountability And Disposal
Accountability for sotatercept (ACE-011) is the responsibility of the Investigator.  
Investigational clinical supplies must be received by a designated person at the clinical site and 
kept in a secured location.  The investigational site must maintain accurate records demonstrating 
dates and amounts of sotatercept (ACE-011) received, to whom it was administered (subject-by-
subject accounting), and accounts of any sotatercept (ACE-011) accidentally or deliberately 
destroyed or returned.  Unless otherwise notified, all vials of sotatercept (ACE-011), both used 
and unused, must be saved for drug accountability.  The used vials may be discarded, per the 
institution’s standard practice, after drug accountability has been completed by the monitor.  The 
Investigator must return all unused vials of sotatercept (ACE-011) to the Sponsor at the end of 
the study, or the sotatercept (ACE-011) may be destroyed at the clinical site with the permission 
of the Sponsor.  For either scenario, the outcome must be documented on the drug accountability 
log.  The Sponsor will provide direction for the outcome of all unused vials.  
Celgene will instruct the Investigator on the return, disposal and/or destruction of investigational 
medicinal product.  
8.6.
Investigational Product Compliance
Accurate recording of all IP administration will be made in the appropriate section of the 
subject’s eCRF and source documents.  
The Investigator or designee is responsible for accounting for all IP that is administered during 
the course of the study.  
Page 599 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
78
ACE-011-NSCL-001 30 FINAL: 01NOV2011
9.
CONCOMITANT MEDICATIONS AND PROCEDURES
9.1.
Permitted Concomitant Medications and Procedures
General concomitant medication usage
During screening, and during the study, subjects may take only stable doses of medications for 
chronic conditions that are not specifically excluded by the protocol (see Sections 7.2 and 7.3
Inclusion Criteria and Exclusion Criteria).  The Medical Monitor should be consulted by the 
Investigator if there are any concerns about what constitutes a stable dose or what is a chronic 
condition.  Concomitant medications will be recorded on the subject’s eCRF throughout the 
course of the study.  
Concomitant therapies considered as supportive care are acceptable while participating in this 
study, including growth colony stimulating factors (G-CSF); anti-emetics to limit chemotherapy-
related nausea and vomiting; palliative radiation; bisphosphonates and denosumab therapy for 
bone metastases.  Additionally, the study site should use its standard of care regarding hydration 
and the minimization of nephrotoxicity prior to/following the administration of platinum-based
regimens.  
Concomitant medication for anemia
Concurrent therapy with a new prescription medication related to treatment of anemia during the 
course of the study must first be discussed with the Medical Monitor prior to administration, 
unless appropriate medical care necessitates that medication should begin before the Medical 
Monitor can be consulted.  
Iron supplementation
Iron supplementation within 7 days of Day 1 (besides an oral general multivitamin with iron) 
will not be allowed.  If a subject becomes iron deficient during study treatment (ferritin < 100 
ng/mL [< 224.7 pmol/L] or transferrin saturation < 20%), treatment with iron supplementation is 
at the discretion of the Investigator.  
Erythropoiesis-stimulating agents (ESAs)
The use of an ESA is not allowed in Part 1 of the study; however, ESAs are allowed in 
Part 2 only after a subject has received at least 4 months of study treatment.  The use of 
ESAs will need to result in immediate notification to the study Sponsor and Medical Monitor, as
well as to the clinical site pharmacist, so that no further dosing with sotatercept (ACE-011) in 
that study subject will occur If treatment with ESAs is required in the opinion of the 
Investigator, the ESA label instructions are to be strictly followed.  
In Part 1, all subjects who receive an ESA will be discontinued from the study Treatment Period 
and continue to the Post Treatment Follow-Up Period. In Part 2, subjects who receive an ESA 
at < 4 months from their first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo 
will be discontinued from the study Treatment Period and continue to the Post Treatment 
Follow-Up Period.  Subjects who receive an ESA at ≥ 4 months from their first dose of 
sotatercept (ACE-011)/placebo will continue in the Treatment Period as follows:  The
unblinded pharmacist will ensure that subjects randomized to receive treatment with 
Page 600 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
79
ACE-011-NSCL-001 30 FINAL: 01NOV2011
sotatercept (ACE-011) are changed over to receive treatment with placebo.  Subjects 
randomized to treatment with placebo will continue to receive placebo.  The investigator, 
site personnel and subject will remain blinded. 
RBC transfusions
Concurrent treatment for CIA with blood transfusions is recommended when Hgb value is 
< 8 g/dL or at the discretion of the Investigator if the Hgb value is ≥8 g/dL and associated with 
anemia symptoms such as hemodynamic or pulmonary compromise requiring treatment.  If an 
RBC transfusion is given to a subject during the Treatment Period, sotatercept (ACE-011) should 
be administered >7 days from the date of the RBC transfusion.
9.2.
Prohibited Concomitant Medications and Procedures
No concurrent treatments with any other investigational agent are allowed.  Bisphosphonate , 
other than for the treatment of hypercalcemia, and denosumab therapy for bone metastases can 
be started prior to randomization but should not be started on study.
9.3.
Required Concomitant Medications and Procedures
Not applicable.  
Page 601 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
80
ACE-011-NSCL-001 30 FINAL: 01NOV2011
10.
STATISTICAL ANALYSES
10.1.
Overview
This is an open-label randomized, phase 2a, dose-ranging study of sotatercept (ACE-011) 
therapy for chemotherapy-induced anemia (CIA) in subjects with advanced or metastatic solid 
tumor types treated with platinum-based chemotherapeutic agents followed by a phase 2b/3, 
double-blind, randomized, placebo-controlled study of sotatercept (ACE-011) therapy for 
chemotherapy-induced anemia (CIA) in subjects with metastatic non-small cell lung cancer 
(NSCLC) treated with platinum-based chemotherapeutic regimens.  An IVRS will be utilized to 
ensure an equal weight central randomization based on a permuted-block randomization method 
according to stratification factors defined in Section 4.1 Study Design.  In Part 1, subjects will 
be randomized to one of three doses of sotatercept (ACE-011) plus platinum-based 
chemotherapy.  In Part 2, subjects will be randomized to placebo or the selected sotatercept 
(ACE-011) dose determined from Part 1 plus platinum-based chemotherapy.  Data from Part 1
will not be combined with data from Part 2 in all safety and efficacy analyses. 
A DMC will be used to monitor the study conduct.  
10.2.
Study Population Definitions

Three study populations will be used for analyses.  

The Intent-to-Treat (ITT) Population – All randomized subjects.  

Safety Population – All subjects who take at least one dose of study medication.  

Efficacy Evaluable (EE) Population – All ITT subjects who take at least one dose of 
study medication and have baseline and at least one post-baseline efficacy assessment 
without major protocol deviation.  
10.3.
Sample Size and Power Considerations
In Part 1, up to 90 subjects will be randomized among three dosing groups.  This sample size is 
for the purpose of hypothesis generation.  However, it would allow approximately 80% power to 
detect an effect size of 0.33 using a 2 degrees of freedom Chi-Square Test with a two-sided 
significance level (alpha) of 0.05.  
In Part 2, subjects will be enrolled in two stages.  In the first stage, approximately 180 subjects 
will be randomized in a 1:1 ratio to the selected sotatercept (ACE-011) dose group or placebo 
group.  An interim analysis of transfusion rate will be performed after these 180 subjects have 
received at least two doses of sotatercept (ACE-011)/placebo, and have been followed for at least 
4 months from randomization.  A Data Monitoring Committee will review the results and 
provide recommendations on continuing or stopping the study. Based on the results of the 
futility analysis, further enrollment in the second stage of Part 2 of the study could be continued.  
Upon recommendation to continue the study, an additional 570 subjects will be subsequently 
randomized in the second stage.  The total sample size of 750 subjects in Part 2 (first plus 
second stage) would allow observation of at least 536 deaths and thus at least 80% power to 
Page 602 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
81
ACE-011-NSCL-001 30 FINAL: 01NOV2011
exclude more than 15% hazard increase in the sotatercept (ACE-011) arm compared with the 
placebo arm at one-sided significance level of 0.025, i.e., rejecting hazard ratio 
(Placebo:sotatercept [ACE-011]) of 0.87,  assuming the sotatercept (ACE-011) arm actually 
reduces at least 10% hazard, i.e., true hazard ratio (Placebo:sotatercept [ACE-011]) of 1.11.  
10.4.
Background and Demographic Characteristics
Subjects’ age, height, weight, and baseline characteristics will be summarized using descriptive 
statistics by treatment arm, while gender, race and other categorical variables will be provided 
using frequency tabulations.  Medical history data will be summarized using frequency 
tabulations by system organ class and preferred term.  
10.5.
Subject Disposition
Subject disposition (analysis population allocation, entered, discontinued, along with primary 
reason for discontinuation) will be summarized using frequency and percent by treatment arm.  
A summary of subjects enrolled by site will be provided.  Protocol deviations will be 
summarized using frequency tabulations.  
10.6.
Efficacy Analysis
In Part 1, the primary endpoint will be the hematopoietic response defined as an increase in Hgb 
of ≥ 1.0 g/dL above the study baseline value for 28 consecutive days, in the absence of RBC 
transfusions and/or ESAs.  The analysis will be based on the EE population.  The proportion of 
subjects with hematopoietic response will be estimated and a Chi-square test will be performed 
to compare response rates across treatment groups.  
In Part 2, the primary endpoint will be rate of RBC transfusion within 4 months following the 
date of randomization.  It will be estimated based on Kaplan-Meier method for time to the first 
RBC transfusion.  The analysis will be based on ITT population and will be conducted according 
to the approximate timeline as described in Section 10.8.  Subjects who have documented RBC 
transfusion(s) from randomization until the last dose of concomitant platinum-based 
chemotherapy plus 30 days or from the initiation date of non-platinum-based chemotherapy, 
whichever is earlier, will be considered as having the event on the date of first RBC transfusion.  
Subjects who are discontinued from study treatment due to reasons other than disease 
progression or death will be considered as having the event on the date of study treatment 
discontinuation, or the last dose date of platinum-based chemotherapy plus 30 days or the 
initiation date of non-platinum-based chemotherapy, whichever is earliest.  Subjects who 
discontinue from study treatment due to disease progression or death will be censored on the date 
of study treatment discontinuation, or the last dose date of platinum-based chemotherapy plus 30 
days or the initiation date of non-platinum-based chemotherapy, whichever is earliest.  Otherwise 
subjects will be censored on the date of last contact, or on the date of last dose of concomitant 
platinum-based chemotherapy plus 30 days or on the initiation date of non-platinum-based 
chemotherapy, whichever is earliest.  The comparison on the distribution difference between the 
treatment groups will be based on the stratified log-rank test, and the associated hazard ratio and 
95% confidence interval will be provided using Cox proportional hazard model.  The proportion 
of subjects receiving a transfusion based on Kaplan-Meier estimates at specific time points will 
also be provided by treatment arms. 
Page 603 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
82
ACE-011-NSCL-001 30 FINAL: 01NOV2011
As secondary endpoints for Part 2 of the study, time to progression, progression free survival 
and overall survival will be analyzed based on the ITT population.  
Time to progression (TTP) is defined as the time between the randomization date and date of 
disease progression. Disease progression is based on the IRC reviewed progression date.  If 
a subject dies due to reasons other than disease progression, the subject will be censored at the 
death date.  If a subject does not have disease progression, then the subject will be censored at 
the last tumor assessment (prior to or on the first day of the first subsequent antitumor therapy).  
Progression free survival (PFS) is defined as the time between the randomization and disease 
progression or death.  Disease progression is based on the IRC reviewed progression date.  
Subjects who progressed or died will be considered to have had an event, except if this event 
occurs after the start of subsequent antitumor therapy, in which case the subject is censored at the 
time of last tumor assessment prior to or on the first day of the first subsequent antitumor 
therapy.  The date of progression is taken as the earliest date of:  Date of PD as evaluation of 
response, date of new lesion on tumor measurements page, death date, if death is caused by PD,
treatment termination date if reason is PD, progression date as documented on treatment 
termination page, progression date as documented on the follow-up visit page.  Subjects who did 
not progress nor died (lost to follow-up or still being treated without documented disease 
progression or started subsequent antitumor therapy) will be censored at the date of the last 
tumor assessment prior to or on the first day of the first subsequent antitumor therapy.  PFS 
based on investigators’ assessment will also be analyzed.  
Overall survival (OS) is defined as the time between the randomization and death.  A subject
who dies, regardless of the cause of death, will be considered to have had an event.  All subjects 
who are lost to the follow-up prior to the end of the trial or who are withdrawn from the trial will 
be censored at the time of last contact.  Subjects who are still being treated will be censored at 
the last available date where the subject is known to be alive.  
For TTP, PFS and OS, Kaplan-Meier method will be used to estimate the distribution function, 
six-month and one-year survival rates, as well as the medians and 95% confidence intervals will 
be provided.  The stratified log rank test will be used to compare the distributions of TTP, PFS 
and OS respectively.  The stratification factors are described in Section 4.1 .  The associated 
hazard ratios and confidence intervals will be provided using stratified Cox proportional hazard 
model respectively for each endpoint.  
Sensitivity analyses will be performed on TTP, PFS, and efficacy analyses will also be 
performed using EE population.  Data listings will be provided for all relevant data collected 
during the studies.  Further details will be included in the Statistical Analysis Plan.  
10.7.
Safety Analysis
All safety subjects will be used for safety analyses.  Sotatercept (ACE-011) exposure will be 
summarized.  Adverse events, vital sign measurements, clinical laboratory information, ECG 
interpretations, and concomitant medications will be tabulated and summarized by study part and 
treatment arm.  The incidence of AEs will be summarized by severity grade based on the NCI 
CTCAE version 4.0 (current active minor version).  Serious adverse events (SAE), deaths and 
AEs leading to dose modifications and study treatment discontinuation will be summarized.  
Page 604 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
83
ACE-011-NSCL-001 30 FINAL: 01NOV2011
Safety information obtained during the Post Treatment Follow-Up Period during each segment 
will be incorporated into these analyses.  
10.8.
Interim Analysis
There are two interim analyses planned for this study.  At the first interim analysis, the 
transfusion rate result will be used for go/no go decision, and overall survival will also be 
analyzed.  At the second interim analysis, only the overall survival will be analyzed.  
The first interim analysis on transfusion rate will be conducted after the first 180 eligible subjects 
randomized in Part 2 of the study (stage 1) who have received at least two doses of sotatercept 
(ACE-011)/placebo, have been followed for at least 4 months from randomization.  This sample 
size would allow at least 90% power to detect a 15% difference between two arms (sotatercept 
[ACE-011] arm 15% vs. placebo 30%) in 4 month transfusion rates at two-sided 5% significance 
level based on the stratified log rank test and the assumption of exponential distribution for time 
to RBC transfusion.  If the p-value at the interim analysis does exceed significance level of 0.05, 
the result will be considered as lack of efficacy.  If the p-value is less than or equal to 0.05, 
additional subjects will be enrolled and the study will move on to the Part 2; however, the 
futility analysis result based on RBC transfusion rate may be up to DMC evaluation.  For 
superiority, Type I error 0.0001 will be spent at this interim for transfusion rate, and the 
remaining 0.0499 will be spent at the final analysis after 750 subjects being enrolled.  
Overall survival will also be analyzed at this interim, Type I error spending will be based on 
O’Brien and Fleming Boundary.  
The second interim analysis will be performed when approximately 265 deaths are observed in 
Part 2.  Type I error spending will be based on O’Brien and Fleming boundary.  
The final analysis will be performed when approximately 536 deaths are observed in Part 2.  
10.9.
Other Topics
Pharmacokinetic Analysis
Approximately 10 subjects will be enrolled for full PK sampling in each treatment cohort of Part 
1.  For this portion of the study, subjects who miss more than two PK sampling time points from 
Days 1 through 43 will be replaced.  
Noncompartmental PK parameters for sotatercept (ACE-011), such as tmax, Cmax, AUC42, and 
t1/2,z, will be estimated for subjects providing full PK samples.  Dose proportionality will be 
assessed by regression analysis using the exposure data after the first dose.  Descriptive statistics 
will be provided for plasma concentrations and PK parameters.  
In exploratory population PK analysis, covariates to be tested may include type of chemotherapy, 
the presence of anti-sotatercept (ACE-011) antibodies, demographics (age, race, gender, and 
body weight), markers for hepatic and renal function, and other factors as deemed appropriate.  
Both full and sparse PK data will be included for population PK analyses.  
The relationship between sotatercept (ACE-011) exposure and response (hematology, 
biomarkers, and other clinical outcomes as appropriate) will be explored.  
Page 605 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
84
ACE-011-NSCL-001 30 FINAL: 01NOV2011
10.10.
Data Monitoring Committee (DMC)
A DMC will review safety and efficacy data to ensure the protection of study subjects.  The 
DMC will receive periodic updates of all serious treatment-related toxicities and SAEs leading to 
deaths from all causes. The first planned review by the DMC will be conducted following the 
randomization and treatment of twenty subjects.  The DMC will continue to monitor safety on an 
ongoing basis including recommendation of sotatercept (ACE-011) dose selection for Part 2.  
The first interim analysis will be conducted after the first 180 eligible subjects in Part 2 of the 
study (stage 1) have been followed for at least 4 months for RBC transfusion rate.  The second 
interim analysis will be performed when approximately 265 deaths are observed in Part 2.  The 
final analysis will be performed when approximately 536 deaths are observed in Part 2.  
Ad hoc meetings will be scheduled as needed.  
The DMC will have a consultative role with respect to the Sponsor. The Sponsor will make the 
final decision regarding the recommendation proposed by the committee. A separate DMC 
charter will detail the activities of this committee.  
Page 606 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
85
ACE-011-NSCL-001 30 FINAL: 01NOV2011
11.
ADVERSE EVENTS
11.1.
Monitoring, Recording and Reporting of Adverse Events
An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen 
in a subject during the course of a study.  It may be a new intercurrent illness, a worsening 
concomitant illness, an injury, or any concomitant impairment of the subject’s health, including 
laboratory test values (as specified by the criteria below), regardless of etiology.  Any worsening 
(i.e., any clinically significant adverse change in the frequency or intensity of a pre-existing 
condition) should be considered an AE.  A diagnosis or syndrome should be recorded on the AE 
page of the eCRF rather than the individual signs or symptoms of the diagnosis or syndrome.  
An overdose, accidental or intentional, whether or not it is associated with an AE, or abuse, 
withdrawal, sensitivity or toxicity to an investigational product should be reported as an AE.  If 
an overdose is associated with an AE, the overdose and AE should be reported as separate terms.  
All subjects will be monitored for AEs during the study.  Assessments may include monitoring 
of any or all of the following parameters:  the subject’s clinical symptoms, laboratory, 
pathological, radiological or surgical findings, physical examination findings, or other 
appropriate tests and procedures.  
All AEs will be recorded by the Investigator from the time the subject signs informed consent to 
at least 42 days after the last dose of IP.  The AEs and SAEs will be recorded on the AE page of 
the eCRF and in the subject’s source documents.  All SAEs must be reported to Celgene Drug 
Safety immediately within 24 hours of the Investigator’s knowledge of the event by facsimile, or 
other appropriate method, using the SAE Report Form, or approved equivalent form.  After 42
days post last dose, only AEs assessed as related to study treatment are to be reported.  
11.2.
Evaluation of Adverse Events
A qualified Investigator will evaluate all AEs as to:  
11.2.1.
Seriousness 
An SAE is any AE occurring at any dose that:

Results in death;

Is life-threatening (i.e., in the opinion of the Investigator, the subject is at immediate 
risk of death from the AE);

Requires inpatient hospitalization or prolongation of existing hospitalization 
(hospitalization is defined as an inpatient admission, regardless of length of stay);

Results in persistent or significant disability/incapacity (a substantial disruption of the 
subject’s ability to conduct normal life functions);

Is a congenital anomaly/birth defect;

Constitutes an important medical event.  
Page 607 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
86
ACE-011-NSCL-001 30 FINAL: 01NOV2011
Important medical events are defined as those occurrences that may not be immediately life 
threatening or result in death, hospitalization, or disability, but may jeopardize the subject or 
require medical or surgical intervention to prevent one of the other outcomes listed above.  
Medical and scientific judgment should be exercised in deciding whether such an AE should be 
considered serious.  
Events not considered to be SAEs are hospitalizations for:

A standard procedure for protocol therapy administration.  However, hospitalization 
or prolonged hospitalization for a complication of therapy administration will be 
reported as an SAE.  

Routine treatment or monitoring of the studied indication not associated with any 
deterioration in condition.  

The administration of blood or platelet transfusion as routine treatment of studied 
indication.  However, hospitalization or prolonged hospitalization for a complication 
of such transfusion remains a reportable SAE.  

A procedure for protocol/disease-related investigations (e.g., surgery, scans, 
endoscopy, sampling for laboratory tests, bone marrow sampling).  However, 
hospitalization or prolonged hospitalization for a complication of such procedures 
remains a reportable SAE.  

Hospitalization or prolongation of hospitalization for technical, practical, or social 
reasons, in absence of an AE.  

A procedure that is planned (i.e., planned prior to starting of treatment on study); 
must be documented in the source document and the eCRF.  Hospitalization or 
prolonged hospitalization for a complication remains a reportable SAE.  

An elective treatment of a pre-existing condition unrelated to the studied indication.  

Emergency outpatient treatment or observation that does not result in admission, 
unless fulfilling other seriousness criteria above.  
If an AE is considered serious, both the AE page/screen of the eCRF and the SAE Report Form 
must be completed.  
For each SAE, the Investigator will provide information on severity, start and stop dates, 
relationship to IP, action taken regarding IP, and outcome.  
11.2.2.
Severity / Intensity
For both AEs and SAEs, the Investigator must assess the severity /intensity of the event.  
The severity of AEs will be graded based upon the subject’s symptoms according to the current 
active minor version of National Cancer Institute (NCI) Common Terminology Criteria for 
Adverse Events (CTCAE, Version 4.0); 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
Page 608 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
87
ACE-011-NSCL-001 30 FINAL: 01NOV2011
AEs that are not defined in the NCI CTCAE should be evaluated for severity according to the 
following scale:
Grade 1 = Mild – transient or mild discomfort; no limitation in activity; no medical 
intervention/therapy required
Grade 2 = Moderate – mild to moderate limitation in activity, some assistance may be needed; no 
or minimal medical intervention/therapy required
Grade 3 = Severe – marked limitation in activity, some assistance usually required; medical 
intervention/therapy required, hospitalization is possible
Grade 4 = Life threatening – extreme limitation in activity, significant assistance required; 
significant medical intervention/therapy required, hospitalization or hospice care probable
Grade 5 = Death – the event results in death
The term “severe” is often used to describe the intensity of a specific event (as in mild, moderate 
or severe myocardial infarction); the event itself, however, may be of relatively minor medical 
significance (such as severe headache).  This criterion is not the same as “serious” which is 
based on subject/event outcome or action criteria associated with events that pose a threat to a 
subject’s life or functioning.  
Seriousness, not severity, serves as a guide for defining regulatory obligations.  
11.2.3.
Causality 
The Investigator must determine the relationship between the administration of IP and the 
occurrence of an AE/SAE as Not Suspected or Suspected as defined below:
Not Suspected:
The temporal relationship of the adverse event to IP 
administration makes a causal relationship unlikely or 
remote, or other medications, therapeutic interventions, or 
underlying conditions provide a sufficient explanation for the 
observed event.
Suspected:
The temporal relationship of the adverse event to IP 
administration makes a causal relationship possible, and other 
medications, therapeutic interventions, or underlying conditions 
do not provide a sufficient explanation for the observed event.
If an event is assessed as suspected of being related to a comparator, ancillary or additional IP 
that has not been manufactured or provided by Celgene, please provide the name of the 
manufacturer when reporting the event.  
11.2.4.
Duration
For both AEs and SAEs, the Investigator will provide a record of the start and stop dates of the 
event.
Page 609 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
88
ACE-011-NSCL-001 30 FINAL: 01NOV2011
11.2.5.
Action Taken
The Investigator will report the action taken with IP as a result of an AE or SAE, as applicable 
(e.g., discontinuation or reduction of IP, as appropriate) and report if concomitant and/or 
additional treatments were given for the event. 
11.2.6.
Outcome
All SAEs that have not resolved upon discontinuation of the subject’s participation in the study 
must be followed until recovered, recovered with sequelae, not recovered (death due to another 
cause) or death (due to the SAE).  
11.3.
Abnormal Laboratory Values
An abnormal laboratory value is considered to be an AE if the abnormality:

Results in discontinuation from the study;

Requires treatment, modification/ interruption (delay) of IP dose, or any other 
therapeutic intervention; or

Is judged to be of significant clinical importance.  
Regardless of severity grade, only laboratory abnormalities that fulfill a seriousness criterion 
need to be documented as an SAE.  
If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis 
or syndrome should be recorded on the AE page/screen of the eCRF.  If the abnormality was not 
a part of a diagnosis or syndrome, then the laboratory abnormality should be recorded as the AE.  
11.4.
Pregnancy
11.4.1.
Females of Childbearing Potential
Pregnancies and suspected pregnancies (including a positive pregnancy test regardless of age or 
disease state) of a female subject occurring while the subject is on IP, or within 112 days of the 
subject’s last dose of IP, are considered immediately reportable events.  IP is to be discontinued 
immediately.  The pregnancy, suspected pregnancy, or positive pregnancy test must be reported 
to Celgene Drug Safety immediately by facsimile, or other appropriate method, using the 
Pregnancy Initial Report Form, or approved equivalent form.  
The female subject should be referred to an obstetrician-gynecologist or another appropriate 
healthcare professional for further evaluation.  
The Investigator will follow the female subject until completion of the pregnancy, and must 
notify Celgene Drug Safety immediately about the outcome of the pregnancy (either normal or 
abnormal outcome) using the Pregnancy Follow-up Report Form, or approved equivalent form.  
If the outcome of the pregnancy was abnormal (e.g., spontaneous or therapeutic abortion), the 
Investigator should report the abnormal outcome as an AE.  If the abnormal outcome meets any 
of the serious criteria, it must be reported as an SAE to Celgene Drug Safety immediately by 
facsimile, or other appropriate method, within 24 hours of the Investigator’s knowledge of the 
event) using the SAE Report Form, or approved equivalent form.  
Page 610 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
89
ACE-011-NSCL-001 30 FINAL: 01NOV2011
All neonatal deaths that occur within 28 days of birth should be reported, without regard to 
causality, as SAEs.  In addition, any infant death after 28 days that the Investigator suspects is 
related to the in utero exposure to the IP should also be reported to Celgene Drug Safety 
immediately by facsimile, or other appropriate method, within 24 hours of the Investigator’s 
knowledge of the event using the SAE Report Form, or approved equivalent form.  
11.4.2.
Male Subjects
If a female partner of a male subject taking investigational product becomes pregnant, the male 
subject taking IP should notify the Investigator, and the pregnant female partner should be 
advised to call their healthcare provider immediately.  
11.5.
Immediate Reporting of Serious Adverse Events
Any AE that meets any criterion for an SAE requires the completion of an SAE Report Form in 
addition to being recorded on the AE page/screen of the eCRF.  All SAEs must be reported to 
Celgene Drug Safety immediately within 24 hours of the Investigator’s knowledge of the event 
by facsimile, or other appropriate method, using the SAE Report Form, or approved equivalent 
form.  This instruction pertains to initial SAE reports as well as any follow-up reports.  
The Investigator is required to ensure that the data on these forms is accurate and consistent.  
This requirement applies to all SAEs (regardless of relationship to IP) that occur during the study 
from the time the subject signs informed consent up to 42 days after the last dose of IP, and those 
made known to the Investigator at anytime thereafter that are suspected of being related to IP.  
SAEs occurring prior to treatment will be captured.  
The SAE report should provide a detailed description of the SAE and include summaries of 
hospital records and other relevant documents.  If a subject died and an autopsy has been 
performed, copies of the autopsy report and death certificate are to be sent to Celgene Drug 
Safety as soon as these become available.  Any follow-up data will be detailed in a subsequent 
SAE Report Form, or approved equivalent form, and sent to Celgene Drug Safety.  
Where required by local legislation, the Investigator is responsible for informing the Institutional 
Review Board (IRB)/Ethics Committee (EC) of the SAE and providing them with all relevant 
initial and follow-up information about the event.  The Investigator must keep copies of all SAE 
information on file including correspondence with Celgene and the IRB/EC.  
11.6.
Safety Queries
Queries pertaining to SAEs will be communicated from Celgene Drug Safety to the site via 
facsimile or electronic mail.  The response time is expected to be no more than five (5) business 
days.  Urgent queries (e.g., missing causality assessment) may be handled by phone.  
11.7.
Expedited Reporting of Adverse Events
For the purpose of regulatory reporting, Celgene Drug Safety will determine the expectedness of 
events suspected of being related to sotatercept (ACE-011) based on the Investigator Brochure.  
For countries within the European Economic Area (EEA), Celgene or its authorized 
representative will report in an expedited manner to Regulatory Authorities and Ethics 
Page 611 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
90
ACE-011-NSCL-001 30 FINAL: 01NOV2011
Committees concerned, suspected unexpected serious adverse reactions (SUSARs) in accordance 
with Directive 2001/20/EC and the Detailed Guidance on collection, verification and 
presentation of adverse reaction reports arising from clinical trials on investigational products for 
human use (ENTR/CT3) and also in accordance with country-specific requirements.  
Celgene or its authorized representative shall notify the Investigator of the following 
information:

Any AE suspected of being related to the use of IP in this study or in other studies 
that is both serious and unexpected (i.e., SUSAR);

Any finding from tests in laboratory animals that suggests a significant risk for 
human subjects including reports of mutagenicity, teratogenicity, or carcinogenicity.  
Where required by local legislation, the Investigator shall notify his/her IRB/EC promptly of 
these new serious and unexpected AE(s) or significant risks to subjects.  
The Investigator must keep copies of all pertinent safety information on file including 
correspondence with Celgene and the IRB/EC.  (See Section 15.3 for record retention 
information).  
Celgene Drug Safety Contact Information:
For Local Drug Safety Affiliate Office contact information, please refer to the Serious Adverse 
Event Report Form / Completion Guidelines or to the Pregnancy Report Form / Completion 
Guidelines.  
Page 612 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
91
ACE-011-NSCL-001 30 FINAL: 01NOV2011
12.
DISCONTINUATIONS
Please refer to Section 8.2.3.  
Stopping Rules
In addition to Celgene routine pharmacovigilance surveillance, a DMC will review unblinded 
data on a regular basis (mainly grade 3 or 4 toxicities, SAEs and subject deaths).  Any relevant 
imbalance in toxic deaths, related SAEs or detrimental survival would be considered for study 
discontinuation.  
Page 613 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
92
ACE-011-NSCL-001 30 FINAL: 01NOV2011
13.
EMERGENCY PROCEDURES
13.1.
Emergency Contact
In emergency situations, the Investigator should contact the responsible Clinical Research 
Physician/Medical Monitor or designee by telephone at the number(s) listed on the Emergency 
Contact Information page of the protocol (after title page).  
In the unlikely event that the Clinical Research Physician/Medical Monitor or designee cannot be 
reached, please contact the global Emergency Call Center by telephone at the number listed on 
the Emergency Contact Information page of the protocol (after title page).This global Emergency 
Call Center is available 24 hours a day and 7 days a week.  The representatives are responsible 
for obtaining your call-back information and contacting the on call Celgene/CRO Medical 
Monitor, who will then contact you promptly.  
Note:  The back-up 24 hour global emergency contact call center should only be used if you are 
not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls.  
13.2.
Emergency Identification of Investigational Products
In both Part 1 and Part 2 the blind must not be broken during the course of the study unless in 
the opinion of the Investigator, it is absolutely necessary to safely treat the subject.  If it is 
medically imperative to know what IP the subject is receiving, the Investigator or authorized 
person should call IVRS for unblinded dose information, etc.  However, every effort should be 
made to contact the Clinical Research Physician/Medical Monitor prior to breaking the blind.  
Contact or attempted contact with the Clinical Research Physician/Medical Monitor as well as 
the reason for breaking the blind must be documented in the source documents.  
Page 614 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
93
ACE-011-NSCL-001 30 FINAL: 01NOV2011
14.
REGULATORY CONSIDERATIONS
14.1.
Good Clinical Practice
The procedures set out in this study protocol pertaining to the conduct, evaluation, and 
documentation of this study are designed to ensure that Celgene, its authorized representative, 
and Investigator abide by Good Clinical Practice (GCP), as described in International 
Conference on Harmonization (ICH) Guideline E6 and in accordance with the general ethical 
principles outlined in the Declaration of Helsinki.  The study will receive approval from an 
IRB/EC prior to commencement.  The Investigator will conduct all aspects of this study in 
accordance with applicable national, state, and local laws of the pertinent regulatory authorities.  
14.2.
Investigator Responsibilities
Investigator responsibilities are set out in the ICH Guideline for Good Clinical Practice and in 
the local regulations.  Celgene staff or an authorized representative will evaluate and approve all 
Investigators who in turn will select their staff.  
The Investigator should ensure that all persons assisting with the study are adequately informed 
about the protocol, amendments, study treatments, as well as study-related duties and functions.  
The Investigator should maintain a list of Sub-investigators and other appropriately qualified 
persons to whom he or she has delegated significant study-related duties.  
The Investigator is responsible for keeping a record of all subjects who sign an informed consent 
document and are screened for entry into the study.  Subjects who fail screening must have the 
reason(s) recorded in the subject’s source documents.  
The Investigator, or a designated member of the Investigator’s staff, must be available during 
monitoring visits to review data, resolve queries and allow direct access to subject records (e.g., 
medical records, office charts, hospital charts, and study-related charts) for source data 
verification.  The Investigator must ensure timely and accurate completion of eCRFs and queries.  
14.3.
Subject Information and Informed Consent
The Investigator must obtain informed consent of a legal representative prior to any study related 
procedures.  
Documentation that informed consent occurred prior to the study subject’s entry into the study 
and of the informed consent process should be recorded in the study subject’s source documents 
including the date.  The original informed consent document signed and dated by the study 
subject and by the person consenting the study subject prior to the study subject’s entry into the 
study, must be maintained in the Investigator’s study files and a copy given to the study subject.  
In addition, if a protocol is amended and it impacts on the content of the informed consent, the 
informed consent document must be revised.  Study subjects participating in the study when the 
amended protocol is implemented must be re-consented with the revised version of the informed 
consent document.  The revised informed consent document signed and dated by the study 
subject and by the person consenting the study subject must be maintained in the Investigator’s 
study files and a copy given to the study subject.  
Page 615 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
94
ACE-011-NSCL-001 30 FINAL: 01NOV2011
14.4.
Confidentiality
Celgene affirms the subject's right to protection against invasion of privacy and to be in 
compliance with ICH and other local regulations (whichever is most stringent).  Celgene requires 
the Investigator to permit Celgene's representatives and, when necessary, representatives from 
regulatory authorities, to review and/or copy any medical records relevant to the study in 
accordance with local laws.  
Should direct access to medical records require a waiver or authorization separate from the 
subject’s signed informed consent document, it is the responsibility of the Investigator to obtain 
such permission in writing from the appropriate individual.  
14.5.
Protocol Amendments
Any amendment to this protocol must be approved by the Celgene Clinical Research 
Physician/Medical Monitor.  Amendments will be submitted to the IRB/EC for written approval.  
Written approval must be obtained before implementation of the amended version occurs.  The 
written signed approval from the IRB/EC should specifically reference the Investigator name, 
protocol number, study title and amendment number(s) that is applicable.  Amendments that are 
administrative in nature do not require IRB/IEC approval but will be submitted to the IRB/IEC 
for information purposes.  
14.6.
Institutional Review Board/Independent Ethics Committee Review 
and Approval
Before the start of the study, the study protocol, informed consent document, and any other 
appropriate documents will be submitted to the IRB/EC with a cover letter or a form listing the 
documents submitted, their dates of issue, and the site (or region or area of jurisdiction, as 
applicable) for which approval is sought.  If applicable, the documents will also be submitted to 
the authorities in accordance with local legal requirements.  
Investigational Product can only be supplied to an Investigator by Celgene or its authorized 
representative after documentation on all ethical and legal requirements for starting the study has 
been received by Celgene or its authorized representative.  This documentation must also include 
a list of the members of the IRB/EC and their occupation and qualifications.  If the IRB/EC will 
not disclose the names, occupations and qualifications of the committee members, it should be 
asked to issue a statement confirming that the composition of the committee is in accordance 
with GCP.  For example, the IRB General Assurance Number may be accepted as a substitute for 
this list.  Formal approval by the IRB/EC should mention the protocol title, number, amendment 
number (if applicable), study site (or region or area of jurisdiction, as applicable), and any other 
documents reviewed.  It must mention the date on which the decision was made and must be 
officially signed by a committee member.  Before the first subject is enrolled in the study, all 
ethical and legal requirements must be met.  
The IRB/EC and, if applicable, the authorities, must be informed of all subsequent protocol 
amendments in accordance with local legal requirements.  Amendments must be evaluated to 
determine whether formal approval must be sought and whether the informed consent document 
should also be revised.  
Page 616 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
95
ACE-011-NSCL-001 30 FINAL: 01NOV2011
The Investigator must keep a record of all communication with the IRB/EC and, if applicable, 
between a Coordinating Investigator and the IRB/EC.  This statement also applies to any 
communication between the Investigator (or Coordinating Investigator, if applicable) and 
regulatory authorities.  
Any advertisements used to recruit subjects for the study must be reviewed by Celgene and the 
IRB/EC prior to use.  
14.7.
Ongoing Information for Institutional Review Board / Ethics 
Committee
If required by legislation or the IRB/EC, the Investigator must submit to the IRB/EC:

Information on serious or unexpected adverse events as soon as possible; 

Periodic reports on the progress of the study;

Deviations from the protocol or anything that may involve added risk to subjects.  
14.8.
Closure of the Study
Celgene reserves the right to terminate this study at any time for reasonable medical or 
administrative reasons.  Any premature discontinuation will be appropriately documented 
according to local requirements (e.g., IRB/EC, regulatory authorities, etc...).  
In addition, the Investigator or Celgene has the right to discontinue a single site at any time 
during the study for medical or administrative reasons such as:

Unsatisfactory enrollment;

GCP noncompliance;

Inaccurate or incomplete data collection;

Falsification of records;

Failure to adhere to the study protocol.  
Page 617 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
96
ACE-011-NSCL-001 30 FINAL: 01NOV2011
15.
DATA HANDLING AND RECORDKEEPING 
15.1.
Data/Documents
The Investigator must ensure that the records and documents pertaining to the conduct of the 
study and the distribution of the investigational product are complete, accurate, filed and 
retained.  Examples of source documents include:  hospital records; clinic and office charts; 
laboratory notes; memoranda; subject’s diaries or evaluation checklists; dispensing records; 
recorded data from automated instruments; copies or transcriptions certified after verification as 
being accurate copies; microfiche; x-ray film and reports; and records kept at the pharmacy, and 
the laboratories, as well as copies of eCRFs or CD-ROM.  
15.2.
Data Management
Data will be collected via an electronic data capture (EDC) system rather than paper. Data will 
be entered into the clinical database as per Celgene SOPs.  These data will be electronically 
verified through use of on-line checks during data entry, and through programmed edit checks 
specified by the clinical team. The Clinical team and investigational site personnel will be 
alerted of discrepant data by the functionality of the system. Resolutions to these issues will be 
reflected in the database. An audit trail within the system will track all changes made to the data.  
15.3.
Record Retention
Essential documents must be retained by the Investigator for a minimum of 2 years after the last 
approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region, or at least 2 years have elapsed since the 
formal discontinuation of clinical development of the IP.  The Investigator must retain these 
documents for the time period described above or according to local laws or requirements, 
whichever is longer.  Essential documents include, but are not limited to, the following:

Signed informed consent documents for all subjects;

Subject identification code list, screening log (if applicable), and enrollment log;

Record of all communications between the Investigator and the IRB/EC;

Composition of the IRB/EC;

Record of all communications between the Investigator, Celgene, and their authorized 
representative(s);

List of Sub-investigators and other appropriately qualified persons to whom the 
Investigator has delegated significant study-related duties, together with their roles in 
the study, curriculum vitae, and their signatures;

Copies of CRFs (if paper) and of documentation of corrections for all subjects;

IP accountability records;

Record of any body fluids or tissue samples retained;
Page 618 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
97
ACE-011-NSCL-001 30 FINAL: 01NOV2011

All other source documents (subject records, hospital records, laboratory records, 
etc.); 

All other documents as listed in Section 8 of the ICH consolidated guideline on GCP 
(Essential Documents for the Conduct of a Clinical Trial).  
The Investigator must notify Celgene if he/she wishes to assign the essential documents to 
someone else, remove them to another location or is unable to retain them for a specified period.  
The Investigator must obtain approval in writing from Celgene prior to destruction of any 
records.  If the Investigator is unable to meet this obligation, the Investigator must ask Celgene 
for permission to make alternative arrangements.  Details of these arrangements should be 
documented.  
All study documents should be made available if required by relevant health authorities.  
Investigator/Institution should take measures to prevent accidental or premature destruction of 
these documents.  
Page 619 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
98
ACE-011-NSCL-001 30 FINAL: 01NOV2011
16.
QUALITY CONTROL AND QUALITY ASSURANCE
All aspects of the study will be carefully monitored by Celgene or its authorized representative 
for compliance with applicable government regulations with respect to current GCP and standard 
operating procedures.  
16.1.
Study Monitoring and Source Data Verification
Celgene ensures that appropriate monitoring procedures are performed before, during and after 
the study.  Before the study is initiated at a site visit or at an investigator meeting, all aspects of 
the study are reviewed with the Investigator and the staff.  Prior to enrolling subjects into the 
study, a Celgene representative will review the protocol, eCRFs, procedures for obtaining 
informed consent, record keeping, and reporting of AEs/SAEs with the Investigator.  Monitoring 
will include on-site visits with the Investigator and his/her staff as well as any appropriate 
communications by mail, email, fax, or telephone.  At each monitoring visit, the facilities, 
investigational product storage area, eCRFs, subject’s source documents, and all other study 
documentation will be inspected/reviewed by the Celgene representative for accuracy, adherence 
to the protocol and Good Clinical Practice.  
Accuracy will be checked by performing source data verification that is a direct comparison of 
the entries made onto the eCRFs against the appropriate source documentation.  Any resulting 
discrepancies will be reviewed with the Investigator and/or his/her staff.  Any necessary 
corrections will be made directly to the eCRFs or via queries by the Investigator and/or his/her 
staff.  Monitoring procedures require that informed consents, adherence to inclusion/exclusion 
criteria and documentation of SAEs and their proper recording be verified.  Additional 
monitoring activities may be outlined in a study-specific monitoring plan.  
16.2.
Audits and Inspections
In addition to the routine monitoring procedures, a Good Clinical Practice Quality Assurance 
unit exists within Celgene.  Representatives of this unit will conduct audits of clinical research 
activities in accordance with Celgene SOPs to evaluate compliance with Good Clinical Practice 
guidelines and regulations.  
The Investigator is required to permit direct access to the facilities where the study took place, 
source documents, eCRFs and applicable supporting records of study subject participation for 
audits and inspections by IRB/IECs, regulatory authorities (e.g., FDA, EMEA, Health Canada) 
and company authorized representatives.  The Investigator should make every effort to be 
available for the audits and/or inspections.  If the Investigator is contacted by any regulatory 
authority regarding an inspection, he/she should contact Celgene immediately.  
Page 620 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
99
ACE-011-NSCL-001 30 FINAL: 01NOV2011
17.
PUBLICATIONS
The results of this study may be published in a medical publication, journal, or may be used for 
teaching purposes.  Additionally, this study and its results may be submitted for inclusion in all 
appropriate health authority study registries, as well as publication on health authority study 
registry websites, as required by local health authority regulations.  Selection of first authorship 
will be based on several considerations, including, but not limited to study participation, 
contribution to the protocol development, and analysis and input into the manuscript, related 
abstracts, and presentations in a study.
Page 621 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
100
ACE-011-NSCL-001 30 FINAL: 01NOV2011
18.
REFERENCES
Aapro M, Vaupel P.  Erythropoietin:  effects on life expectancy in patients with cancer-related 
anemia.  Curr Med Res Opin. 2006; 22(suppl 4):5-13.
Carlos JJ, Salas M, Ward A, et al.  Anemia as an independent prognostic factor for survival in 
patients with cancer:  a systemic, quantitative review.  Cancer.  2001; 91:2214-2221.
Cella D, Kallich J, McDermott A, et al.  The longitudinal relationship of hemoglobin, fatigue, 
and quality of life in anemic cancer patients:  results from five randomized clinical trials.  Ann 
Oncol. 2004; 15:979-986.
Chantry A, Heath D, Mulivor A, Coulton L, Evans H, Abdul N, Werner ED, Bouxsein ML, 
Pearsall RS, Seehra J, Vanderkerken K, and Croucher PI.  Inhibiting activin-A signalling 
stimulates bone formation, prevents tumor-induced osteolytic bone destruction and blocks bone 
metastasis. J Bone Miner Res 2010; 25 (12), 2633-46, Erroatum in J Bone Miner Res 2011; 26 
(2), 439
Chen Y-G, Lui HM, Lin S-L, Lee JM, and Ying S-Y.  Regulation of cell proliferation, apoptosis, 
and carcinogenesis by activin.  Exp Biol Med 2002; 227: 75-87.  
Dang TP, Carbone DP:  Cancer of the Lung, in DeVita, VT, Hellman S, Rosenberg SA (eds): 
Cancer: Principles & Practice of Oncology, 8th edition, Philadelphia, PA. Lippincott Williams & 
Wilkens, 2008, 887-971.  
Functional Assessment of Chronic Illness Therapy-Fatigue, FACIT-F Version 4. 
http://www.facit.org/qview/qlist.aspx, last accessed 21Jul2010.
Grogan M, Thomas GM, Melamed I, et al.  The importance of hemoglobin levels during 
radiotherapy for carcinoma of the cervix.  Cancer.  1999; 86:1528-1536.
Groopman JE, Itri LM.  Chemotherapy-Induced Anemia in Adults:  Incidence and Treatment.  
Journal of the National Cancer Institute 1999, 91, 1616-1634.  
Hollen, PJ, Gralla, RJ, Kris, MG, and Potanovich, LM. Quality of life assessment in individuals 
with lung cancer:  Testing the Lung Cancer Symptom Scale (LCSS).  European Journal of 
Cancer, 1993; 29A, S51-S58.
Hollen, PJ, Gralla, RJ, Kris, MG, & Cox, C. Quality of life during clinical trials:  Conceptual 
model for the Lung Cancer Symptom Scale (LCSS).  Supportive Care in Cancer, 1994a; 2, 213-
222.
Hollen, PJ, Gralla, RJ, Kris, MG, Cox, C, Belani, CP, Grunberg, SM, Crawford, J, and Neidhart, 
JA. Measurement of quality of life in patients with lung cancer in multicenter trials of new 
therapies:  Psychometric assessment of the Lung Cancer Symptom Scale.  Cancer, 1994b; 73, 
2087-98.
Hollen PJ, Gralla RJ, Kris MG ‘Lung Cancer Symptom Scale (LCSS)’, Administration, Scoring 
and Procedures Manual, (1995) Ver.1.1.  
Page 622 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
101
ACE-011-NSCL-001 30 FINAL: 01NOV2011
Hollen, PJ, Gralla, RJ, Kris, MG, Eberly, SW, and Cox, C.  Normative data and trends in quality 
of life from the Lung Cancer Symptom Scale (LCSS).  Supportive Care in Cancer, 1999; 7, 140-
148.
Hong WK, Tsao AS, in Lung Carcinoma: Tumors of the Lungs: Merck Manuals Online Medical 
Library for Healthcare Professionals, 2008. 
http://www.merck.com/mmpe/print/sec05/ch062/ch062b.html
Laurie SA, Jeyabalan N, Nicholas G, Dahrouge S.  Association between anemia arising during 
therapy and outcomes of chemoradiation for limited small-cell lung cancer.  J Thorac Oncol.  
2006;146-151.
Lotinun S, Fajardo RJ, Pearsall RS, Bouxsein ML, and Baron R.  A soluble activin receptor type 
IIA fusion protein, ACE-011, increases bone mass by stimulating bone formation and inhibiting 
bone resorption in cynomolgus monkeys.  ASBMR 30th annual meeting, 2008.  
MacRae R, Shyr Y, Jonson D, Choy H.  Declining hemoglobin Turing chemoradiotherapy for 
locally advanced non-small cell lung cancer is significant.  Radiother Oncol. 2002;64:37-40.
Mathews LS.  Activin receptors and cellular signaling by the receptor serine kinase family.  
Endocr Rev 1994; 15: 310-25.  
Murata M, Onomichi K, Eto Y, Shibai H, and Muramatsu M.  Expression of erythroid 
differentiation factor (EDF) in Chinese hamster ovary cells.  Biochem Biophys Res Commun
1988; 151: 230-5.  
Nakao K, Kosaka M and Saito S.  Effects of erythroid differentiation factor (EDF) on 
proliferation and differentiation of human hematopoietic progenitors.  Exp Hematol 1991; 19: 
1090-5.  
National Heart, Lung, and Blood Institute, National Institutes of Health.  New York Heart 
Association Classification. 2008.  
NCCN Clinical Practice Guidelines in Oncology:  Cancer and Chemotherapy Induced Anemia, 
V.2. 2010 http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf; 2009.  
Non-small Cell Lung cancer Collaborative Group ‘Chemotherapy in non-small cell lung cancer:  
a meta-analysis using updated data on individual patients from 52 randomized clinical trials’, 
British Medical Journal 1995 vol. 311, no.7010, 899-909.  
Obermair A, Cheuk R, Horwood K, et al.  Anemia before and during concurrent 
chemoradiotherapy in patients with cervical carcinoma:  effect on progression-free survival.  Int 
J Gynecol Cancer. 2003; 13:633-639.
Oken, MM., Creech, R.H., Tormey, D.C., et. al.  Toxicity And Response Criteria Of The Eastern 
Cooperative Oncology Group.  Am J Clin Onco 1982; 5:649-655.  
Parker SL, Tong T, Bolden S, et. al.  Cancer statistics, 1997.  CA Cancer J Clin, 1997, 47, no. 1, 
5-27.  
Pearsall RS, Canalis E, Cornwall-Brady M, Underwood KW, Haigis B, Ucran J, Kumar R, Pobre 
E, Grinberg A, Werner ED, Glatt V, Stadmeyer L, Smith D, Seehra J, and Bouxsein ML.  A 
soluble activin type IIA receptor induces bone formation and improves skeletal integrity.  Proc 
Natl Acad Sci USA 2008, 105: 7082-7.  
Page 623 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
102
ACE-011-NSCL-001 30 FINAL: 01NOV2011
Perrien DS, Akel NS, Edwards PK, et. al.  Inhibin A is an endocrine stimulator of bone mass and 
strength.  Endocrinology 2007; 148: 1654-65.  
Rivier J, Spiess J, McClintock R, Vaughan J and Vale W.  Purification and partial 
characterization of inhibin from porcine follicular fluid.  Biochem Biophys Res Commun 1985; 
133: 120-7.  
Rossi A, Maione P, Gridelli C Cetuximab in advanced non-small cell lung cancer.  Critical 
Reviews in Oncology/Hematology, 2006 59, 139-149.  
Ruckle J, Jacobs M, Kramer W, et. al.  A single-dose, randomized, double-blind, placebo-
controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women.  J Bone Miner Res
2009; 24 (4): 744-52.  
Sandler A, Gray R, Perry M, et al Paclitaxel-Carboplatin alone or with Bevacizumab for Non 
Small Cell Lung Cancer, NEJM, 2006 vol.355, no.24, 2542-50.  
Scagliotti G, Parikh P, von Pawel J, et al Phase III Study Comparing Cisplatin Plus Gemcitabine 
With Cisplatin Plus Pemetrexed in Chemotherapy-Naïve patients With Advanced-Stage Non-
Small-Cell Lung Cancer, JCO, 2008, 26 (21): 3543-51.  
Schiller J, Harrington D, Belani C, et al Comparison of Four Chemotherapy Regimens for 
Advanced Non-Small-Cell Lung Cancer.  N Engl J Med 2002; 346:92-98.
Schwartz RN.  Anemia in patients with cancer:  incidence, causes, impact, management, and use 
of treatment guidelines and protocols.  Am J Health Syst Pharm.  2007; 64 (suppl 2):S5-S13.  
Seder C, Hartojo W, Lin L, et al Upregulated INHBA Expression May Promote Cell 
Proliferation and Is Associated with Poor Survival in Lung Adenocarcinoma, Neoplasia, 2009, 
11: 388-396.  
Shedden K, Taylor J, Enkemann S, et al Gene Expression-Based Survival prediction in Lung 
Adenocarcinoma: A Multi-Site, Blinded Validation Study: Director’s Challenge Consortium for 
the Molecular Classification of Lung Adenocarcinoma, Nat Med, 2008, 14 (8): 822-827.  
Shiozaki M, Sakai R, Tabuchi M, et. al.  Evidence for the participation of endogenous activin 
A/erythroid differentiation factor in the regulation of erythropoiesis.  Proc Natl Acad Sci USA
1992; 89: 1553-6.  
Shiozaki M, Sakai R, Tabuchi M, et. al.  In vivo treatment with erythroid differentiation factor 
(EDF/activin A) increases erythroid precursors (CFU-E and BFU-E) in mice.  Biochem Biophys 
Res Commun 1989; 165: 1155-61.  
Vansteenkiste J, Pirker R, Massuti B, et. al.  Double-Blind, Placebo-Controlled, Randomized 
Phase III Trial of Darbepoetin Alfa in Lung Cancer Patients Receiving Chemotherapy.  Journal 
of the National Cancer Institute, 2002, 94: 16: 1211-1220.  
Woodruff TK.  Regulation of cellular and system function by activin.  Biochem Pharmacol 1998; 
55: 953-63.  
Ying S-Y.  Inhibins, activins, and follistatins:  gonadal proteins modulating the secretion of 
follicle-stimulating hormone.  Endocrine Rev 1988; 9: 267-93.  
Page 624 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
103
ACE-011-NSCL-001 30 FINAL: 01NOV2011
19.
APPENDICES
Appendix A:  Response Evaluation Criteria in Solid Tumors
Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Terms
Definition
Measurable disease
The presence of at least one measurable lesion by CT or MRI.  If the measurable 
disease is restricted to a solitary lesion, its neoplastic nature should be confirmed by 
cytology/histology.  
All measurements should be taken and recorded in metric notation, using a ruler or 
calipers.  All baseline evaluations should be performed as closely as possible to the 
beginning of treatment and never more than 4 weeks before the beginning of the 
treatment. 
Measurable lesions
Lesions that can be accurately measured in least one dimension by CT scan with 
longest diameter > 10 mm (CT scan thickness no greater than 5 mm).  
The same method of assessment and the same technique should be used to characterize 
each identified and reported lesion at baseline and during follow-up. 
Non-measurable lesion
All other lesions, including small lesions (longest diameter <10mm or pathological 
lymph nodes with P10 to <15mm short axis) as well as truly non-measurable lesions.  
Lesions considered truly non-measurable include:  leptomeningeal disease, ascites, 
pleural or pericardial effusion, inflammatory breast disease, lymphangitic involvement 
of skin or lung, abdominal masses/abdominal organomegaly identified by physical 
exam that is not measurable by reproducible imaging techniques.
RECIST Criteria-Response Evaluation
Evaluation of target lesions
Complete Response (CR)
Disappearance of all target lesions.  
Any pathological lymph nodes (whether target or non-target) must have 
reduction in short axis to <10 mm.
Partial Response (PR):
At least a 30% decrease in the sum of diameters of target lesions, taking as 
reference the baseline sum diameters.
Stable Disease (SD):
Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify 
for PD, taking as reference the smallest sum diameters while on study.
Progressive Disease (PD):
At least a 20% increase in the sum of diameters of target lesions, taking as 
reference the smallest sum on study (this includes the baseline sum if that is the 
smallest on study).  In addition to the relative increase of 20%, the sum must 
also demonstrate an absolute increase of at least 5 mm.  
(Note:  the appearance of one or more new lesions is also considered 
progression).
Page 625 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
104
ACE-011-NSCL-001 30 FINAL: 01NOV2011
RECIST Criteria-Response Evaluation (continued)
Evaluation of non-target 
lesions
Complete Response (CR):
Disappearance of all non-target lesions and normalisation of tumour marker 
level.  All lymph nodes must be non-pathological in size (<10mm short 
axis).
Non-CR/Non-PD
Persistence of one or more non-target lesion(s) and/or maintenance of 
tumour marker level above the normal limits.
Progressive Disease (PD): 
Unequivocal progression (see comments below) of existing non-target 
lesions.  
(Note:  the appearance of one or more new lesions is also considered 
progression).
Evaluation of best overall response
The best overall response is the best response recorded from the start of the 
treatment until disease progression/recurrence (taking as reference for PD 
the smallest measurements recorded since the treatment started).  In general, 
the patient's best response assignment will depend on the achievement of 
both measurement and confirmation criteria.  
Patients with a global deterioration of health status requiring discontinuation 
of treatment without objective evidence of disease progression at that time 
should be classified as having “symptomatic deterioration”.  Every effort 
should be made to document the objective progression even after 
discontinuation of treatment.  
In some circumstances it may be difficult to distinguish residual disease 
from normal tissue.  When the evaluation of complete response depends on 
this determination, it is recommended that the residual lesion be investigated 
(fine needle aspirate/biopsy) to confirm the complete response status.  
Source:  Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R,  Dancey J, Arbuck S, Gwyther S, 
Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R,  Lacombe D, Verweij J.  New response evaluation 
criteria in solid tumours:  Revised RECIST guideline (version 1.1)  (2009).  European Journal of Cancer 45, 228-
247.  
Page 626 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
105
ACE-011-NSCL-001 30 FINAL: 01NOV2011
Appendix B:  ECOG Performance Status Scale 
The ECOG scale (Oken,1982) is used to assess a patient’s quality of life in an evaluation by a 
health professional of the daily activities and how the activities are affected by the disease of the 
patient.  
Table 10:
ECOG Performance Status Scale
Score
Description
0
Fully active, able to carry on all pre-disease performance without restriction
1
Restricted in physically strenuous activity but ambulatory and able to carry out work of 
a light or sedentary nature, e.g., light housework, office work.
2
Ambulatory and capable of all self-care but unable to carry out any work activities.  Up 
and about more than 50% of waking hours.
3
Capable of only limited self-care, confined to bed or chair more than 50% of waking 
hours.
4
Completely disabled.  Cannot carry on any self-care.  Totally confined to bed or chair
5
Dead
Page 627 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
106
ACE-011-NSCL-001 30 FINAL: 01NOV2011
Appendix C:  National Cancer Institute (NCI) Common Terminology Criteria 
for Adverse Events (CTCAE) Version 4.0
Currently active minor version of NCI CTCAE, Version 4.0:
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
Page 628 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
107
ACE-011-NSCL-001 30 FINAL: 01NOV2011
Appendix D:  New York Heart Association - Classification of Heart Failure
Table 11:
Classification of Heart Failure
Class
Symptoms
Class 1
No limitation of activities.  No symptoms from ordinary activities
Class 2
Mild limitation of activity.  Comfortable with rest or mild exertion
Class 3
Marked limitation of activity and be comfortable only at rest
Class 4
Complete rest, confined to bed or chair; any physical activity brings on discomfort and 
symptoms occur at rest
Page 629 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
1
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
TITLE PAGE
– SUMMARY OF CHANGES –
AMENDMENT NO. 4
AN OPEN-LABEL RANDOMIZED, PHASE 2A, DOSE-RANGING 
STUDY OF SOTATERCEPT (ACE-011) FOR 
CHEMOTHERAPY-INDUCED ANEMIA IN SUBJECTS WITH 
ADVANCED OR METASTATIC SOLID TUMORS TREATED 
WITH PLATINUM-BASED CHEMOTHERAPEUTIC 
REGIMENS
INVESTIGATIONAL PRODUCT (IP):
SOTATERCEPT (ACE-011)
PROTOCOL NUMBER:
ACE-011-NSCL-001
ORIGINAL DATE:
17 SEPTEMBER 2010
AMENDMENT No. 4 DATE:
02 MAY 2012
EudraCT NUMBER:
2010-022561-10
IND NUMBER: 
103362
Contact Information:
CONFIDENTIAL
This protocol is provided to you as an Investigator, potential Investigator, or consultant for review by 
you, your staff, and ethics committee/institutional review board.  The information contained in this 
document is regarded as confidential and, except to the extent necessary to obtain informed consent, 
may not be disclosed to another party unless such disclosure is required by law or regulations.  
Persons to whom the information is disclosed must be informed that the information is confidential 
and may not be further disclosed by them.
Page 630 of 791
PPD
088VGY

088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
3
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
1.
JUSTIFICATION FOR AMENDMENT
Significant changes included in this amendment are summarized below:
On February 15, 2012 a letter was sent to all ACE-011-NSCL-001 study sites notifying them that 
Celgene and Acceleron had decided to discontinue further enrollment of subjects into the study.  
This action was taken in response to slow enrollment into the study.  Despite significant efforts 
made by study sites and sponsor support, recent substantial changes in the standard of care for 
cancer patients with anemia have resulted in challenges to timely accrual and completion of the 
study.  The discontinuation of enrollment and thereby early termination of Study ACE-011-
NSCL-001 is not related to subject safety.  This protocol amendment is provided to include 
revisions to the current protocol based on this decision. Research and development of ACE-011 
remains ongoing in several other indications.
Completion of study enrollment is targeted for the end of 1Q2012.
Significant changes included in this amendment are summarized below.  These changes were 
based on feedback obtained from investigators/sites, key opinion leaders and internal 
discussions:

Modified to remove all procedures, reviews and assessments specific to Phase 2B/3 (Part 
2) of the study.

Modified to remove all reference to the Phase 2B/3 (Part 2) of the study.

Modified to remove reference to study treatment as “sotatercept (ACE-011)/placebo” due 
to removal of Phase 2B/3 portion of the study.

Modified to remove the term “Part 1” of the study and all references to “Part 1”.

Modified to remove the sotatercept (ACE-011) 45 mg dose level. 

Modified to revise sample size from approximately 90 subjects to approximately 30 
subjects in Part 1 of the study.

Modified to revise the number of subjects planned for the remaining sotatercept (ACE-
011) dose levels of 15 mg and 30 mg from approximately 30 to approximately 10-15.

Modified to remove reference to safety data analysis of 15mg and 30mg sotatercept 
(ACE-011) dose levels prior to addition of the 45mg sotatercept (ACE-011) dose level.

Modified to:
a.
Abbreviate Post-Treatment Follow-Up Period from six months to 42 days (six 
weeks).
b. Revise term “Post-Treatment Follow-Up Period” to “Post-Treatment Follow-
Up Visit”.
c.
Clarify that the Post-Treatment Follow-Up Visit will also serve as the End of 
Treatment/End of Study Visit.
Page 632 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
4
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
d. Add sotatercept (ACE-011) drug antibody repeat assessments following the Post 
Treatment Follow-Up / End of Treatment / End of Study Visit for subjects with a 
positive sotatercept (ACE-011) titer.  

Revision of Study Objectives:
a.
Modified to change all study objectives to exploratory. 
b. Modified to delete objective to estimate effect of sotatercept (ACE-011) on 
objective response rate (ORR), time to progression (TTP), progression free 
survival (PFS) and overall survival (OS) due to smaller sample size and 
abbreviated follow-up period.
c.
Modified to delete objective to explore the relationship between sotatercept 
(ACE-011) exposure and response (hematology, biomarkers, and other clinical 
outcomes as appropriate) due to smaller sample size and abbreviated follow-up
period.  
d. Modified to delete objective to evaluate the expression of Activin A and other 
proteins/biomarkers in archival tumor tissue (Part 2 only) due to removal of 
Phase 2B/3 portion of the study. 

Revision of Study Endpoints:
a.
Modified to change all study endpoints to exploratory.
b. Modified to revise definition of hematopoietic response to remove criterion 
needed to move from Part 1 to Part 2 of the study and clarify that sotatercept 
(ACE-011) doses and hemoglobin levels will be reviewed.
c.
Modified to delete endpoints of effect of sotatercept (ACE-011) on objective
response rate (ORR), time to progression (TTP), progression free survival (PFS) 
and overall survival (OS) due to smaller sample size and abbreviated follow-up 
period.
d. Modified to delete population PK model for sotatercept (ACE-011) due to smaller 
sample size.
e.
Modified to delete population pharmacodynamic model describing Hgb response 
as a function of time, sotatercept (ACE-011) exposure, and subject characteristics
due to smaller sample size and abbreviated follow-up period.
f.
Modified to delete endpoint of the expression of Activin A and other 
proteins/biomarkers in archival tumor tissue (Part 2 only) due to removal of 
Phase 2B/3 portion of the study. 

Modified to remove references to the Data Monitoring Committee (DMC).  An 
organization Data Monitoring Committee meeting was held to discuss the objectives of 
the committee and the charter but there were no additional meetings held and no study 
data was reviewed by the committee.  Safety data will continue to be monitored by the 
sponsor.
Page 633 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
5
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012

Modified to clarify that subjects will receive “up to four doses” of sotatercept (ACE-011) 
versus “four doses” as subjects may receive from one to four doses of sotatercept (ACE-
011).

Modified to remove Survival Follow-Up Period including collection of overall survival 
and post treatment anti-neoplastic therapy data past the 42 day (six week) Post-Treatment 
Follow-Up Visit.

Modified to clarify that the study will only be conducted at sites in the United States.

Modified to revise stratification to include other non-cisplatin platinum-based 
chemotherapy in addition to carboplatin due to addition of other allowed tumor types in 
Amendment 3.

Modified to revise Pharmacokinetics Assessments to reflect decrease in sample size and 
abbreviated follow-up period.

Modified to delete Section 4.2.4 :  Evaluation of Dosing Schema via 
Modeling/Simulation as simulation performed does not seem to be supported by the 
observed clinical data in subjects with chemotherapy-induced anemia.

Revision of Table 7:  Sotatercept (ACE-011) Schedule of Assessments:
a.
Modified to delete Post-Treatment Follow-Up Period and Survival Follow-Up 
Period.  
b. Modified to replace “D43 Post Last Dose/End of Study Treatment” with “D43 
Post Treatment Follow-Up/End of Treatment/ End of Study Visit”.
c.
Addition of the following assessments to the “D43 Post Treatment Follow-
Up/End of Treatment/ End of Study Visit”:
i. TSH
ii. Bone Imaging (DXA)- optional
iii. Activin A and other proteins/biomarkers in blood (serum)
d. Addition of sotatercept (ACE-011) drug antibody repeat assessments following 
the Post Treatment Follow-Up / End of Treatment / End of Study Visit for 
subjects with a positive sotatercept (ACE-011) titer.  

Modified to better clarify that the LCSS questionnaire consists of two scales, a Patient 
Scale and an Observer Scale.

Modified to provide additional instructions on the storage of reconstituted sotatercept 
(ACE-011) drug product. 

Modified to revise Statistical Section to reflect changes in analyses due to decrease in the
sample size, abbreviated follow-up period, and removal of the Phase 2B/3 portion of the 
study. 

Modified to revise Section 13 Emergency Procedures from those applicable to a blinded 
study to procedures applicable to an open label study. 
Page 634 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
6
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Other administrative changes (e.g., correction of typographical errors, editorial changes, etc.) 
were also incorporated and are outlined in Section 2 Itemized Changes.
Page 635 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
7
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
2.
ITEMIZED CHANGES
Text Modification Key:
Deleted Text
Added Text
Unchanged Text
Page 636 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
8
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
2.1.
Section:  Title Page (Page 1)
Revised Text:
AN OPEN-LABEL RANDOMIZED, PHASE 2A, DOSE-RANGING 
STUDY (PART 1) OF SOTATERCEPT (ACE-011) FOR 
CHEMOTHERAPY-INDUCED ANEMIA IN SUBJECTS WITH 
ADVANCED OR METASTATIC SOLID TUMORS TREATED 
WITH PLATINUM-BASED CHEMOTHERAPEUTIC 
REGIMENS FOLLOWED BY A PHASE 2B/3, DOUBLE-BLIND, 
RANDOMIZED, PLACEBO-CONTROLLED STUDY (PART 2) 
OF SOTATERCEPT (ACE-011) FOR CHEMOTHERAPY-
INDUCED ANEMIA IN SUBJECTS WITH METASTATIC NON-
SMALL CELL LUNG CANCER TREATED WITH FIRST-LINE 
PLATINUM-BASED CHEMOTHERAPEUTIC REGIMENS
Rationale:
Modified to:

Remove the Phase 2B/3 portion and reference to Part 1 and Part 2 in the study title.
Page 637 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
9
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
2.2.
Section:  Protocol Summary (Pages 6-10)
Revised Text:
Study Title
An open-label randomized, phase 2a, dose-ranging study (Part 1) of sotatercept (ACE-011) for 
chemotherapy-induced anemia in subjects with advanced or metastatic solid tumors treated with 
platinum-based chemotherapeutic regimens followed by a phase 2b/3, double-blind, randomized, 
placebo-controlled study (Part 2) of sotatercept (ACE-011) for chemotherapy-induced anemia in 
subjects with metastatic non-small cell lung cancer treated with first-line platinum-based 
chemotherapeutic regimens..
Indication
Chemotherapy Induced Anemia (CIA) in Ssubjects with Advanced or Metastatic Solid Tumors
Part 1 – Advancedadvanced or metastatic solid tumors treated with ≥ first–line platinum–based 
chemotherapy, excluding those solid tumors treated with curative intent.
Part 2 - Metastatic NSCLC
Objectives
The primaryexploratory objectives are:
Part 1:  To explore determine a doses of sotatercept (ACE-011) that results in a 
hematopoietic response for the treatment of CIA in subjects with advanced or 
metastatic solid tumors treated with platinum-based chemotherapeutic regimens, 
excluding those solid tumors treated with curative intent.  
Part 2:  To assess transfusion rate following initiation of sotatercept (ACE-011) 
treatment versus placebo in subjects with CIA who have metastatic NSCLC treated 
with first-line platinum-based chemotherapeutic regimens.  
The secondary objectives are:
Part 1 and Part 2:
To estimate the effect of sotatercept (ACE-011) treatment on objective response rate 
(ORR), time to progression (TTP), progression free survival (PFS) and overall 
survival (OS).
To evaluate the safety and tolerability of sotatercept (ACE-011). 
To determine the pharmacokinetics (PK) of sotatercept (ACE-011) in subjects 
receiving platinum-based chemotherapy.  
To evaluate the hematopoietic response and its duration associated with sotatercept 
(ACE-011) treatment.  
To evaluate the effect of sotatercept (ACE-011) treatment on the quality of life 
(QoL). 
Page 638 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
10
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
The exploratory objectives are:
Part 1 and Part 2:
To estimate the effect of sotatercept (ACE-011) treatment on bone metabolism.
To explore the relationship between sotatercept (ACE-011) exposure and response 
(hematology, biomarkers, and other clinical outcomes as appropriate).  
To evaluate the expression of Activin A and other proteins/biomarkers (including 
myostatin and follistatin) related to sotatercept (ACE-011) mechanism of action in 
blood.
To evaluate the expression of Activin A and other proteins/biomarkers in archival 
tumor tissue (Part 2 only). 
To assess renal function biomarkers.
Study Design
This is an open-label, randomized, phase 2a, dose-ranging study (Part 1) of sotatercept (ACE-
011) therapy for CIA in subjects with advanced or metastatic solid tumors treated with platinum-
based chemotherapeutic regimens followed by a phase 2b/3, double-blind, randomized, placebo-
controlled study (Part 2) of sotatercept (ACE-011) therapy for CIA in subjects with metastatic 
non-small cell lung cancer treated with first-line platinum-based chemotherapeutic regimens.  .  
The study will consist of two parts:
Part 1 is a dose-finding segment in which up to approximately 9030 subjects will be randomized 
to one of threetwo sotatercept (ACE-011) dose treatment arms.  The main exploratory primary
objective is to determine a dose of sotatercept (ACE-011) that results in a hematopoietic 
response in the treatment of CIA in subjects with advanced or metastatic solid tumors treated 
with platinum-based chemotherapy, excluding those solid tumors treated with curative intent.  
The sample size is for the purpose of hypothesis generation; however, it would allow 
approximately 80% power to detect an effect size of 0.33 using a 2 degrees of freedom Chi-
Square Test with a significance level (alpha) of 0.05.  
Part 2 is the phase 2b/3 double-blind, randomized, placebo-controlled segment of the study and 
will be performed in two stages. Its primary objective is to determine the transfusion rate 
following initiation of sotatercept (ACE-011) treatment versus placebo in subjects with CIA who 
have metastatic NSCLC treated with first-line platinum-based chemotherapeutic regimens.
In the first stage, approximately 180 subjects will be randomized to receive sotatercept (ACE-
011), at the dose determined from Part 1, or placebo at a ratio of 1:1.  An interim futility 
assessment based on transfusion rate at 4 months will be performed as described in Section 10.8.  
It is expected that accrual will continue during the interim assessment period, with up to an 
additional 570 subjects randomized to achieve full study accrual.  
During Part 2 (first and second stage) overall survival will be assessed.  The total sample size of 
750 subjects will allow observation of at least 536 deaths and thus, at least 80% power to exclude 
more than 15% hazard increase in the sotatercept (ACE-011) arm compared with the placebo 
arm at one-sided significance level of 0.025, i.e., rejecting hazard ratio (Placebo:sotatercept 
Page 639 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
11
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
[ACE-011]) of 0.87, assuming the sotatercept (ACE-011) arm actually reduces at least 10% 
hazard, i.e., true hazard ratio (Placebo:sotatercept [ACE-011]) of 1.11.  
A Data Monitoring Committee (DMC) will monitor the conduct of the study.  
Study Population
At the time of randomization in Part 1 and Part 2, subjects must have an advanced or metastatic 
solid tumor treated with ≥ first–line platinum–based chemotherapy, excluding those solid tumors 
treated with curative intent.  Subjects must also:
have already received at least one cycle and up to 4 cycles (q3w schedule) of 
platinum-based chemotherapy and be randomized prior to receiving Cycle 5 
OR 
have already received at least one cycle and up to 3 months (depending upon 
regimen) of platinum-based chemotherapy 
OR
currently be receiving maintenance therapy following treatment with platinum-
based chemotherapy 
In Part 1, subjects must have an advanced or metastatic solid tumor treated with ≥ first–line 
platinum–based chemotherapy, excluding those solid tumors treated with curative intent. 
In Part 2, subjects must have metastatic NSCLC and must not have received any other regimens 
of platinum containing chemotherapy for first-line treatment prior to the regimen they are 
receiving at the time of randomization.  
Concomitant or maintenance therapy with chemotherapeutic and/or targeted agents (e.g., 
pemetrexed, anti-EGFR agents, anti-VEGF agents), which are approved for a given tumor type, 
are allowed in addition to platinum-based chemotherapy. 
Length of Study and Study Treatments
This study will consist of the following consecutive periods:  Screening, and Treatment Period, 
including a Post Treatment Follow-Up Period, and Survival Follow-Up Period.Visit.  Study 
treatment is defined as sotatercept (ACE-011) in Part 1 and sotatercept (ACE-011)/placebo in 
Part 2. ).
Screening Period (28 days):
Potential study subjects will sign an informed consent form prior to undergoing any study-related 
procedures.  Subjects will undergo screening for protocol eligibility within 28 days prior to 
randomization, as outlined in the Table of Events, Section 5.  Note:  Screening period tumor 
assessments should be performed within six weeks or as per standard care at the study site prior 
to randomization.  Also, historical tumor assessment data, from prior to the initiation of 
platinum-based chemotherapy through the Screening Period, will be collected and used for 
assessment of tumor response.  
Prior erythropoietic stimulating agent (ESA) treatment history starting from the initial solid 
tumor diagnosis and red blood cell (RBC) transfusion history starting from diagnosis of 
Page 640 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
12
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
advanced or metastatic disease, at a minimum of up to two months prior to randomization will be 
collected.  
All females of childbearing potential (FCBP) participating in the study are to use highly effective 
methods of birth control during the Screening Period, for at least 28 days before starting the 
study.  Some highly effective methods of birth control include:
Oral contraceptives, intrauterine device, tubal ligation or a partner with a vasectomy
OR
Two forms of barrier method birth control, e.g., a latex condom PLUS a diaphragm 
with spermicide OR a latex condom PLUS a contraceptive sponge with spermicide.  
If a non-latex condom is used, it cannot be made out of natural (animal) membrane.  
Treatment Period (up to and Post-Treatment Follow-Up / End of Treatment / End of Study 
Visit (approximately 6-9 months):  
The Treatment Period is approximately six months (and includes up to four doses of study 
treatmentsotatercept (ACE-011) given on Day 1, every 42 days), two additional sotatercept 
(ACE-011)/placebo doses may be given only in Part 2, at, followed by a Post-Treatment Follow-
Up / End of Treatment / End of Study Visit.  
The Post-Treatment Follow-Up Visit will occur approximately 42 days (6 weeks) after the 
discretion of the Investigator. subjects’ last dose of sotatercept (ACE-011).  The Post-Treatment 
Follow-Up Visit will also serve as the End of Treatment / End of Study Visit.
In Part 1 (the dose-ranging portion of the study), subjectsSubjects with advanced or metastatic 
solid tumor types who meet all eligibility criteria will be randomized to receive one of the 
following sotatercept (ACE-011) dose levels, with 10-3015 subjects per arm:
Sotatercept (ACE-011) 15 mg SC
Sotatercept (ACE-011) 30 mg SC
Analysis of safety data will be performed following the treatment of at least 10 subjects at the 15 
mg dose level and 10 subjects at the 30 mg dose level, with each subject having received a 
minimum of one dose of sotatercept (ACE-011) and completed a 12-week follow-up period from 
the first dose.  
Following this analysis, the addition of a third dose level:
Sotatercept (ACE-011) 45 mg SC
to the randomization schema will be determined.
Each dose level will be administered every 42 days for up to four doses.  
The effective dose of sotatercept (ACE-011) is defined as follows:
An increase in hemoglobin (Hgb) of ≥ 1.0 g/dL above the study baseline value for 4 
consecutive weeks during the first two doses of sotatercept (ACE-011) (Dose 1/Day 1 
through and including Dose 2/Day 43 [prior to Dose 3]), in approximately 70% of subjects, 
in at least one or more treatment arms (in the absence of RBC transfusions and/or ESAs).  
Page 641 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
13
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Evaluation of hemoglobin response decision status will be completed after dosing arms have 
separately enrolled up to 30 subjects, as needed, to determine the sotatercept (ACE-011) dose for
Part 2.  
In addition to the hematopoietic response, the safety profile, dose modifications and extent of 
exposure in each dosing level will be taken into account to determine the study dose to be used in 
Part 2.  
In Part 2, a total of 750 subjects with metastatic NSCLC will be randomized to receive either 
sotatercept (ACE-011) or placebo, at a ratio of 1:1:
375 subjects will receive sotatercept (ACE-011) (at the dose determined in Part 1)
375 subjects will receive placebo
Each dose of sotatercept (ACE-011) or placebo will be administered every 42 days for four 
doses.  Up to two additional doses (in Part 2 only) may be given at the discretion of the 
Investigator.  
Part 2 will be performed in two stages. In the first stage, approximately 180 subjects will be 
randomized to receive sotatercept (ACE-011) (at the dose determined from Part 1) or 
placebo at a ratio of 1:1.  An interim futility assessment based on transfusion rate at 4 months 
will be performed as described in Section 10.8.  It is expected that accrual will continue 
during the interim assessment period, with up to an additional 570 subjects randomized to 
achieve full study accrual.).  
During the Treatment Period, subjects will be assessed for hematopoietic response, transfusion 
need, safety and tumor response.  The severity of AEs will be graded according to the currently 
active minor version of the National Cancer Institute Common Terminology Criteria for Adverse 
Events (NCI CTCAE) version 4.0.  
Concurrent treatment for CIA with blood transfusions is recommended when Hgb value is 
< 8 g/dL or at the discretion of the Investigator if the Hgb value is ≥ 8 g/dL and associated with 
anemia symptoms such as hemodynamic or pulmonary compromise requiring treatment.  If an 
RBC transfusion is given to a subject during the Treatment Period, sotatercept (ACE-011) should 
be administered > 7 days from the date of the RBC transfusion.
In Part 1, bloodBlood samples will be collected to evaluate the full PK profile of sotatercept 
(ACE-011) from approximately 30 subjects at select centers, in approximately 5 - 10 subjects for 
each sotatercept (ACE-011) dose group investigated.  In subjects participating in the full PK 
assessment, RBC, Hgb, and reticulocyte counts will be collected at each PK time point 
(excluding the 4-hour time point on Day 1) from Day 1 to Day 43 after the first dose.  Subjects 
not participating in the optional full PK assessment may participate in the sparse PK assessment.  
In Part 2, blood samples will be collected for the sparse PK assessment that will be performed in 
approximately 300 (40%) of 750 subjects (approximately 150 subjects in each arm).  
For subjects who do not participate in either Part 1 full or sparse PK assessments or Part 2 
sparse PK assessments, the ACE-011 (sotatercept) concentration may be determined in their anti-
sotatercept antibody samples to assist in the evaluation of immunogenicity, as well as PK., in 
subjects who do not participate in the full or sparse PK assessments. 
Page 642 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
14
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Subjects will be discontinued from Study Treatment due to the following:
Adverse events(s)
Hypertension ≥Grade 3 – defined as Stage 2 hypertension (systolic blood 
pressure [SBP] ≥160 mmHg or diastolic blood pressure [DBP] ≥100mmHg), 
confirmed by two measurements obtained at least five minutes apart; medical 
intervention indicated; more than one drug or more intensive therapy than 
previously used indicated or medically significant hypertension which cannot be 
adequately controlled with antihypertensive therapy. 
Any AE > Grade 2 assessed to be related to sotatercept (ACE-011) therapy.
Any persistent AE > Grade 1 considered to be related to sotatercept (ACE-011) 
treatment and causing a subject to miss three months of sotatercept (ACE-011) 
therapy.
Any thromboembolic event > Grade 2.
Elevated Hgb > 15.0 g/dL (sustained for a 7 day period, confirmed by laboratory 
assessment).
Urine protein / creatinine ratio > 1.0; or > 2.0 if bevacizumab (Avastin®) is 
concomitantly administered.
Persistent hematuria ≥Grade 2 - defined as symptomatic; urinary catheter or 
bladder irrigation indicated; limiting instrumental activities of daily living, and 
persisting for one week. 
In Part 1, lackLack of sotatercept (ACE-011) therapeutic effect, defined as < 1.0 
g/dL increase in Hgb from baseline following three dose escalations.  In Part 2, lack 
of sotatercept (ACE-011) therapeutic effect, defined as < 1.0 g/dL increase in Hgb 
from baseline following two doses of sotatercept (ACE-011)/placebo (Dose 1/ Day 1 
through and including Dose 2/Day 43, prior to Dose 3).  
Concomitant use of ESAs – In Part 1 if administered at any time and in Part 2 if 
administered < 4 months after first dose of study treatment. .
Sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dose modifications
In Part 1 and Part 2:  A second Hgb increase of ≥ 3.0 g/dL following a two-
level dose reduction due to a Hgb increase ≥ 3.0 g/dL 
In Part 2:  > 3 dose reductions and/or delays
Disease progression 
Withdrawal of consent
Death
Lost to follow-up
Protocol violation - as determined by the Sponsor
Page 643 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
15
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
The reason for treatment discontinuation should be recorded in the eCRF and in the source 
documents.  
Post Treatment Follow-Up Period (monthly visits for up to 6 months)Visit
Subjects who enter the The Post-Treatment Follow-Up PeriodVisit will be followed monthly for 
up to 6 months from theiroccur approximately 42 days (6 weeks) after the subjects’ last dose of 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.  All subjects).  The Post-Treatment 
Follow-Up Visit will continue to be followed for TTP and PFS up to one year from their first 
dosealso serve as the End of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo or until 
progressionTreatment / End of their advanced or metastatic disease, whichever occurs first. 
Study Visit.
The following events are considered sufficient reasons for discontinuing a subject from the 
study:

Completed study, per protocol (subject has completed approximately six- to nine-
month Treatment Period including a 42 day [6 week]up to six-month Post Treatment
Follow-Up/End of Treatment/End of Study Visit) Period including one year tumor 
assessment to determine TTP and PFS).  Note:  Survival data will continue to be 
collected for up to 24 months after first dose of study treatment.  
Withdrawal of consent
Death
Lost to follow-up
The following events may be considered sufficient reasons for discontinuing a subject from the 
study, as determined by the Sponsor:
Adverse event(s)
Disease progression 
Protocol violation
Survival Follow-up Period (monthly for up to 24 months after first dose of sotatercept 
(ACE-011) or sotatercept (ACE-011)/placebo)
In both Part 1 and Part 2, survival data will be collected monthly (can be via telephone     
contact) for up to 24 months following the subject’s first dose of sotatercept (ACE-011) (Part 1) 
or sotatercept (ACE-011)/placebo (Part 2).  Collection of survival data will begin following 
Study Discontinuation Visit.  Data to be collected will include:
Overall survival
Post-Treatment Anti-Neoplastic Therapy, if any
Rationale:
Modified to:

Remove the Phase 2B/3 portion and reference to Part 1 and Part 2 in the study title and 
Protocol Summary.
Page 644 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
16
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012

Revise primary, secondary and exploratory objectives to exploratory due to smaller 
sample size and abbreviated follow-up period.

Delete all objectives related to the Phase 2B/3 portion of the study.

Delete objectives due to smaller sample size and abbreviated follow-up period:
e.
To estimate effect of sotatercept (ACE-011) on objective response rate (ORR), 
time to progression (TTP), progression free survival (PFS) and overall survival 
(OS)
f.
To explore the relationship between sotatercept (ACE-011) exposure on response 

Revise the design of Phase 2a portion of the study to :
a.
include approximately 30 versus 90 subjects
b. delete the 45mg sotatercept (ACE-011) dose level
c.
delete the safety analysis to determine addition of the sotatercept (ACE-011) 
45mg dose level following treatment of 10 subjects at 15mg and 10 subjects at 
30mg 
d. change the number of subjects from approximately 30 to approximately 10-15 per 
dose level

Delete description of statistical analysis of the Phase 2a portion of the study due to the 
smaller sample size. 

Delete reference to the Data Monitoring Committee (DMC).

Revise Post-Treatment Follow-Up Period of six months to the Post-Treatment Follow-
Up/End of Treatment/End of Study Visit occuring 42 days (6 weeks) following the last 
dose of sotatercept (ACE-011).

Revise the defined effective dose of sotatercept (ACE-011) due to smaller sample size.

Delete all references to the Phase 2B/3 study treatment of sotatercept (ACE-011) / 
placebo.

Delete the Survival Follow-Up Period.  Collection of Overall Survival and Post-
Treatment Anti-Neoplastic Therapy will discontinue at the Post-Treatment Follow-
Up/End of Treatment/End of Study Visit.
Page 645 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
17
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
2.3.
Section 1:  Introduction (Pages 17-28)
Revised Text:
This is an open-label, randomized, phase 2a, dose-ranging study of sotatercept (ACE-011) 
therapy for chemotherapy-induced anemia (CIA) in subjects with advanced or metastatic solid 
tumors treated with platinum-based chemotherapeutic agents followed by a phase 2b/3, double-
blind, randomized, placebo-controlled study of sotatercept (ACE-011) therapy for 
chemotherapy-induced anemia (CIA) in subjects with metastatic non-small cell lung cancer 
(NSCLC) treated with platinum-based chemotherapeutic regimens.  The study will consist of two 
parts.  Part 1 is a dose finding segment in which up to 90 subjects with advanced or metastatic 
solid tumor types treated with platinum-based chemotherapy will be randomized to one of three 
sotatercept (ACE-011) dose treatment arms.  Continuous monitoring of safety data will be 
conducted, including the review of Part 1 data to determine the sotatercept (ACE-011) dose to 
be used in Part 2, the phase 2b/3, double-blind, randomized placebo-controlled segment of the 
studyregimens.  
_  _  _  _  _  _  _  _  _  _  _
The chemical structure of sotatercept (ACE-011) is composed of a disulfide-linked, glycosylated, 
homodimeric protein.  Sotatercept (ACE-011) competes with the activin receptor IIA and binds a 
number of TGF-β superfamily ligands including activin, GDF-11, BMP-10, GDF-3 and 
myostatin (growth differentiation factor [GDF]-8).  
_  _  _  _  _  _  _  _  _  _  _
Part 2 will include only subjects with metastatic NSCLC and will be performed in two stages.  
Its primary objective is to determine the transfusion rate following initiation of sotatercept 
(ACE-011) treatment versus placebo in subjects with CIA who have metastatic NSCLC treated 
with first-line platinum-based chemotherapeutic regimens.
In the first stage of Part 2 approximately 180 subjects will be randomized to receive sotatercept 
(ACE-011), at the dose determined from Part 1, or placebo at a ratio of 1:1.  An interim futility 
assessment based on transfusion rate at 4 months will be performed as described in Section 10.8.  
It is expected that accrual will continue during the interim assessment period.  Based on the 
results of the futility analysis and upon recommendation to continue the study, up to an 
additional 570 subjects will be randomized in the second stage of Part 2, to achieve full study 
accrual.
A Data Monitoring Committee (DMC) will monitor the conduct of the study.Safety data will be 
continuously monitored by the sponsor.  
_  _  _  _  _  _  _  _  _  _  _
A011-02:  A Phase 1b Study in Healthy Postmenopausal Women (Multiple Dose)
_  _  _  _  _  _  _  _  _  _  _
Page 646 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
18
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
The PK of sotatercept (ACE-011) were linear after SC administration.  Both AUC28d and Cmax 
were proportional to dose from 0.1 to 1 mg/kg following the first SC administration.  The t1/2, z 
of sotatercept (ACE-011) following the last dose in all three dose groups was identical, with 
mean t1/2, z being approximately 23 days.  Based on the one-compartmental modeling, the mean 
CL/F ranged from 3.05 to 3.90 mL/d/kg, the mean Vz/F ((([apparent)] volume of distribution) 
ranged from 97.47 to 103.03 mL/kg, with no apparent dependence on dose.  
_  _  _ _  _  _  _  _  _  _  _
A011-04:  A Phase 2a Study in Patients with Osteolytic Lesions of Multiple Myeloma / 
Preliminary Results
_  _  _  _  _  _  _  _  _  _  _
Safety:  Overall, 22 (91.7%) subjects receiving sotatercept (ACE-011) and 4 (66.7%) subjects 
receiving placebo reported at least one AE.  Among subjects receiving sotatercept (ACE-011), 
AEs were reported in 87.5%, 87.5%, and 100% of subjects in the 0.1 mg/kg, 0.3 mg/kg, and 0.5 
mg/kg dosing cohorts, respectively.  Treatment-related AEs (i.e., those assessed by the 
Investigator as possibly, probably, or definitely related to treatment) were reported by 21 
(87.5%) subjects receiving sotatercept (ACE-011) and 4 (66.7%) receiving placebo.  Most 
subjects had AEs that were assessed as related to MPT:  21 (87.5%) subjects receiving 
sotatercept (ACE-011) and 4 (66.7%) subjects receiving placebo.  No AEs were assessed by the 
Investigator as related to the study medication alone (sotatercept ([ACE-011)] or placebo).  Two 
subjects had AEs assessed as possibly or probably related to study drug and possibly or probably 
related to MPT, one subject in the 0.1 mg/kg sotatercept (ACE-011) dose group (increased blood 
pressure; sudden death) and one subject in the 0.5 mg/kg sotatercept (ACE-011) dose group 
(hypertension).  Four subjects had SAEs, 1 (12.5%) subject in the 0.1 mg/kg sotatercept (ACE-
011) group and 3 (37.5%) subjects in the 0.5 mg/kg sotatercept (ACE-011) group.  Three 
subjects had SAEs that were assessed as treatment-related.  Of the 3 treatment-related SAEs, 2 
SAEs were assessed as possibly related to MPT and unrelated to sotatercept (ACE-011), and 1 
SAE (sudden death) was assessed as probably related to MPT and possibly related to sotatercept 
(ACE-011).  One subject in the 0.5 mg/kg sotatercept (ACE-011) dose group discontinued study 
drug due to episodes of atrial fibrillation assessed as possibly related to MPT and unrelated to 
sotatercept (ACE-011).  
Rationale:
Modified to:

Remove the Phase 2B/3 portion and reference to Part 1 and Part 2 in the study title.

Delete reference to the Data Monitoring Committee (DMC).

Clarify chemical structure of sotatercept (ACE-011).

Correct typographical errors. 
Page 647 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
19
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
2.4.
Section 2:  Study Objectives (Page 34)
Revised Text:
2.1.
Primary ObjectiveExploratory Objectives
Part 1:  To explore determine a doses of sotatercept (ACE-011) that results in a 
hematopoietic response for the treatment of CIA in subjects with advanced or 
metastatic solid tumors treated with platinum-based chemotherapeutic regimens, 
excluding those solid tumors treated with curative intent,..

Part 2:  To assess transfusion rate following initiation of sotatercept (ACE-011) 
treatment versus placebo in subjects with CIA who have metastatic NSCLC treated 
with first-line platinum-based chemotherapeutic regimens. 
2.2.
Secondary Objectives
Part 1 and Part 2:
To estimate the effect of sotatercept (ACE-011) treatment on objective response rate 
(ORR), time to progression (TTP), progression free survival (PFS) and overall 
survival (OS).  To evaluate the safety and tolerability of sotatercept (ACE-011). 
To determine the PK of sotatercept (ACE-011) in subjects receiving platinum-based 
chemotherapy.  
To evaluate the hematopoietic response and its duration associated with sotatercept 
(ACE-011) treatment.  

To evaluate the effect of sotatercept (ACE-011) treatment on the quality of life 
(QoL). 
2.3.
Exploratory Objectives
Part 1 and Part 2:
To estimate the effect of sotatercept (ACE-011) treatment on bone metabolism.
To explore the relationship between sotatercept (ACE-011) exposure and response 
(hematology, biomarkers, and other clinical outcomes as appropriate).  
To evaluate the expression of Activin A and other proteins/biomarkers (including 
myostatin and follistatin) related to sotatercept (ACE-011) mechanism of action in 
blood.
To evaluate the expression of Activin A and other proteins/biomarkers in archival 
tumor tissue (Part 2 only). 
To assess renal function biomarkers.
Data from exploratory objectives may not be included in the Clinical Study Report.  
Page 648 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
20
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Rationale:
Modified to:

Revise primary, secondary and exploratory objectives to exploratory due to smaller 
sample size and abbreviated follow-up period.

Delete all objectives related to the Phase 2B/3 portion of the study.

Delete objectives due to smaller sample size and abbreviated follow-up period:
a.
To estimate effect of sotatercept (ACE-011) on objective response rate (ORR), 
time to progression (TTP), progression free survival (PFS) and overall survival 
(OS)
b. To explore the relationship between sotatercept (ACE-011) exposure on response 
Page 649 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
21
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
2.5.
Section 3:  Study Endpoints (Page 35)
Revised Text:
3.1.
PrimaryExploratory Endpoint(s)
Part 1:  Dose Finding
The following are decision rules for dose determination in Part 1 in order to move forward to 
Part 2:
After completion of two doses of sotatercept (ACE-011), a hematopoietic response in 
approximately 70% of subjects, in at least one or more treatment arms.  
Hematopoietic response is defined as an increase in Hgb of ≥ 1.0 g/dL above the study 
baseline value for 28 consecutive days, in the absence of RBC transfusions and/or ESAs.  In 
orderaddition to determine the dose of sotatercept (ACE-011) to be used in Part 2, evaluation of 
hematopoietic response, the safety profile, dose modifications and extent of exposure in each 
dosing level will be determined from sotatercept (ACE-011) Dose 1/ Day 1 through and 
including Dose 2/Day 43 (prior to Dose 3).reviewed.  
In addition to the hematopoietic response, the safety profile, dose modifications and 
extent of exposure in each dosing level will be taken into account to determine the 
study dose to be used in Part 2.  
Hematopoietic response will be determined by laboratory analysis of hemoglobin levels.  
Part 2:  Phase 2b/3 Double-Blind
Rate of RBC transfusion within four months following the date of randomization to 
sotatercept (ACE-011)/placebo treatment
3.2.
Secondary Endpoint(s)
Safety (type, frequency, and severity [National Cancer Institute (NCI) Common 
Terminology for Adverse Events (CTCAE) current active minor version 4.0] of 
adverse events
TTP 
PFS (including at 6 and 12 months)
OS (at 12 months and up to 24 months)
ORR
Duration of hematopoietic response
Sotatercept (ACE-011) concentration in serum 
Non-compartmental PK parameters for sotatercept (ACE-011) (Part 1 only)
QoL assessment (FACIT Fatigue Scale [Version 4]) and LCSS questionnaire (Hollen, 
1993; Hollen, 1994a; Hollen, 1994b; Hollen, 1995, Hollen, 1999)
Page 650 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
22
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
3.3.
Exploratory Endpoint(s)
Change in serum and urine bone biomarkers, including osteocalcin (OC), serum bone 
specific alkaline phosphatase (BSAP), procollagen type 1 N-terminal propeptide 
(P1NP), C-terminal type 1 collagen telopeptide (CTX) and tartrate-resistant acid 
phosphatase isoform-5b (TRACP-5b), the urine bone biomarker (urine N-telopeptide 
[uNTX]) related to activin or sotatercept (ACE-011) mechanism of action  
Change in BMD (DXA scans of lumbar spine and hip)
Time to first symptomatic skeletal related event (SRE) defined as pathologic fracture, 
clinical need for radiation therapy, surgery to bone or spinal cord compression
A population PK model for sotatercept (ACE-011)  
A population pharmacodynamic model describing Hgb response as a function of time, 
sotatercept (ACE-011) exposure, and subject characteristics 
Expression of Activin A and other protein/biomarkers related to sotatercept (ACE-
011) mechanism of action in blood (including myostatin and follistatin) and in 
archival tumor tissue (Part 2 only).
Change in renal function biomarkers via urinalysis measuring urine albumin / 
creatinine ratio, urine protein / creatinine ratio and other biomarkers of glomerular 
and/or tubular injury - urine kidney injury molecule-1 (KIM-1), urine trefoil factor 3 
(TTF3), urine cystatin C and + or – urine β2-microglobulin  
Rationale:
Modified to:

Revise all study endpoints to exploratory.

Revise definition of hematopoietic response to remove criterion needed to move from 
Part 1 to Part 2 of the study and clarify that sotatercept (ACE-011) doses and hemoglobin 
levels will be reviewed

Delete endpoints of effect of sotatercept (ACE-011) on objective response rate (ORR), 
time to progression (TTP), progression free survival (PFS) and overall survival (OS) due 
to smaller sample size and abbreviated follow-up period.

Delete population PK model for sotatercept (ACE-011) due to smaller sample size.

Delete population pharmacodynamic model describing Hgb response as a function of 
time, sotatercept (ACE-011) exposure, and subject characteristics due to smaller sample 
size and abbreviated follow-up period.

Delete endpoint of the expression of Activin A and other proteins/biomarkers in archival 
tumor tissue (Part 2 only) due to removal of Phase 2B/3 portion of the study. 
Page 651 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
23
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
2.6.
Section 4:  Overall Study Design (Pages 36-43)
Revised Text:
4.1.
Study Design 
This is an open-label randomized, phase 2a, dose-ranging study (Part 1) of sotatercept (ACE-
011) therapy in subjects with advanced or metastatic solid tumor types treated with platinum-
based chemotherapeutic regimens followed by a phase 2b/3, double-blind,.  Subjects with 
advanced or metastatic solid tumor types will be randomized, placebo-controlled study to one of 
two sotatercept (ACE-011) therapy for CIA in subjects with metastatic NSCLC treated with 
platinum-based chemotherapeutic regimens. dose treatment arms.  Continuous monitoring of 
safety data will be conducted.
The study will consist of two parts.  Part 1 is a dose finding segment in which subjects with 
advanced or metastatic solid tumor types will be randomized to one of three sotatercept (ACE-
011) dose treatment arms.  Continuous monitoring of safety data will be conducted, including the 
review of Part 1 data to determine the sotatercept (ACE-011) dose to be used in Part 2, the 
phase 2b/3, double-blind, randomized placebo-controlled segment of the study in subjects with 
metastatic NSCLC.  
A DMC will monitor the conduct of the study. 
Part 1 is planned to be conducted at selected sites and will be extended to additional global sites 
for the conduct of Part 2. in the United States.
Study treatment is defined as sotatercept (ACE-011) in Part 1 and sotatercept (ACE-
011)/placebo in Part 2.).  
ThreeTwo starting sotatercept (ACE-011) dose levels, 15, and 30, and 45 mg, were selected for 
Part 1 of the study. Up to approximately 9030 subjects with advanced or metastatic solid tumor 
types will be randomized to one of the following sotatercept (ACE-011) dose levels, with 10-
3015 subjects per arm:
Sotatercept (ACE-011) 15 mg SC
Sotatercept (ACE-011) 30 mg SC
Analysis of safety data will be performed following the treatment of at least 10 subjects at the 15 
mg dose level and 10 subjects at the 30 mg dose level, with each subject having received a 
minimum of one dose of sotatercept (ACE-011) and completed a 12-week follow-up period from 
the first dose.  
Following this analysis, the addition of a third dose level:
Sotatercept (ACE-011) 45 mg SC
to the randomization schema will be determined.
Each dose level will be administered every 42 days for a total of up to four doses.  
Page 652 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
24
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
In Part 2, a total of 750 subjects with metastatic NSCLC will be randomized to receive either 
sotatercept (ACE-011) (at the dose determined in Part 1) or placebo, at a ratio of 1:1:
375 subjects will receive sotatercept (ACE-011) (at the dose determined in Part 1)
375 subjects will receive placebo
Each dose of sotatercept (ACE-011) or placebo will be administered every 42 days for four 
doses; two additional doses may be given at the discretion of the Investigator.  
Part 2 will be performed in two stages. In the first stage, approximately 180 subjects will be 
randomized to receive sotatercept (ACE-011), at the dose determined from Part 1, or placebo at 
a ratio of 1:1.  An interim futility assessment based on transfusion rate at 4 months will be 
performed as described in Section 10.8.  It is expected that accrual will continue during the 
interim assessment period, with up to an additional 570 subjects randomized to achieve full study 
accrual.  
The Treatment Period for Part 1 is approximately six months, which includes up to 4four doses 
of sotatercept (ACE-011) and for Part 2 approximately nine months, which includes up to 6 
doses of sotatercept (ACE-011/placebo).  Subjects who enter thea Post Treatment Follow-Up 
Period will be followed for up to 6 months from their Visit.  The Post Treatment Follow-Up Visit 
will occur approximately 42 days after the last dose of sotatercept (ACE-011) or sotatercept 
(ACE-011)/placebo.  All subjects will continue to be followed for TTP and PFS up to 12 months
from their first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo or until 
progression of their advanced or metastatic disease, whichever occurs first.  
Survival data will be collected monthly for up to 24 months following the subject’s first dose of 
sotatercept (ACE-011) in Part 1 or sotatercept (ACE-011)/placebo in Part 2. study treatment.  
The Post Treatment Follow-Up Visit will also serve as the End of Treatment / End of Study 
Visit.
At the time of randomization in Part 1 and Part 2, subjects must:
have already received at least one cycle and up to 4 cycles (q3w schedule) of 
platinum-based chemotherapy and be randomized prior to receiving Cycle 5 
OR 
have already received at least one cycle and up to 3 months (depending upon 
regimen) of platinum-based chemotherapy 
OR
currently be receiving maintenance therapy following treatment with platinum-
based chemotherapy 
In Part 1, subjectsSubjects must have an advanced or metastatic solid tumor treated with ≥ first–
line platinum–based chemotherapy, excluding those solid tumors treated with curative intent. 
In Part 2, subjects must have metastatic NSCLC and must not have received any other regimens
of platinum containing chemotherapy for first-line treatment prior to the regimen they are 
receiving at the time of randomization.  
Page 653 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
25
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
.Stratification and randomization will be performed utilizing a validated interactive voice 
response system (IVRS).  
In Part 1, subjectsSubjects will be randomized to one of threetwo sotatercept (ACE-011) 
dose levels and will be stratified by:
1. Baseline Hgb level 
6.5 to < 9.0 g/dL
9.0 to < 11.0 g/dL
2. Type of platinum-based chemotherapy (cisplatin versus carboplatinother non-
cisplatin chemotherapy)
In Part 2 subjects will be randomized to receive either sotatercept (ACE-011) or placebo 
and will be stratified by:
1. Baseline Hgb level 
6.5 to < 9.0 g/dL
9.0 to < 11.0 g/dL
2. Type of platinum-based chemotherapy (cisplatin versus carboplatin)
3. NSCLC histology (Squamous NSCLC vs. Non-Squamous NSCLC)
4. ECOG Performance Status 0-1 vs. 2
Page 654 of 791
088VGY

088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
27
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Note:  The following insertions in Figure 1 are shaded:
Figure 1:
Study Design
SCREENING PERIOD
TREATMENT PERIOD
POST TREATMENT FOLLOW-UP/ 
END OF TREATMENT/END OF STUDY VISIT
R
A
N
D
O
M
I
Z
E
Subjects 
who 
meet 
eligibility 
criteria 
and 
provide 
signed 
informed 
consent
Sotatercept (ACE-011)
(Dose Finding)
15 mg or 30 mg
(Day 1 Every 42 Days)  
Up to four doses
Post Treatment Follow-Up/
End of Treatment/End of Study Visit: 
Day 43 (42 days after last dose of sotatercept [ACE-011])
Page 656 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
28
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
4.1.1.
Sotatercept (ACE-011) Dose Modification, Reduction and Escalation Rules
Subjects should have Hgb and blood pressure measured (confirmed by two measurements 
obtained at least five minutes apart) prior to each dose of study drug.  The Investigator must 
adhere to the following Hgb and blood pressure-based dose modification rules for sotatercept 
(ACE-011) or sotatercept (ACE-011)/placebo for the subject’s second dose of study treatment 
and beyond.  
Sotatercept (ACE-011) Dose Modification Rules:
Hemoglobin < 11g/dL
(per local* lab value) 
Hemoglobin ≥11g/dL
(per local* lab value) 
Hypertension ≥SBP 150 mmHg or ≥DBP 100 mmHg
< 2.0 g/dL increase within a 
dosing period or a ≥ 2.0 g/dL 
increase not sustained for a 28 
day period since last dosing day 
≥ 2.0 g/dL increase sustained for a 
28 day period since last dosing day2
Note: ≥ 3.0 g/dL increase sustained 
for a 28 day period since last dosing 
day requires a two level dose 
reduction.  
< 2.0 g/dL increase within a 
dosing period or a ≥ 2.0g/dL 
increase not sustained for a 28 
day period since last dosing day
≥ 2.0g/dL increase sustained for a 28 day 
period since last dosing day2
Note: ≥ 3.0g/dL increase sustained for a 28 
day period since last dosing day requires a 
two level dose reduction.  If Hgb is > 15.0 
g/dL, sustained for 7 days, subject is to be 
discontinued from treatment2. 
Dose Delay5
Continue 
Dosing1
(Part 1 only-
Dose Escalation 
Table 6)
Continue Dosing 
with Dose 
Reduction 
Table 5: Sotatercept 
(ACE-011) and 
Sotatercept (ACE-
011)/Placebo Dose 
Reduction Levels
Dose Delay3
Dose Delay 
then, Dose 
Reduction4
Page 657 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
29
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
*Note:  Local laboratory assessments are allowed in cases when timely results are needed (e.g., randomization, 
study treatment and chemotherapy dosing decisions, hematology assessments between clinic visits).  Whenever 
possible a “split” sample should also be forwarded to the central laboratory for analysis.  Local laboratory data 
should be collected in the eCRF.  
1If Hgb increase ≥ 1.0 but < 2.0 g/dL, dose remains the same.
For Part 1 only:  ifIf the RBC transfusion was given > 7 days following the previous dose of sotatercept 
(ACE-011), the subsequent dose of sotatercept (ACE-011) will be increased one dose level (Refer to sotatercept 
(ACE-011) Dose Escalation Levels- Table 6).  Hemoglobin level must be < 11 g/dL AND hypertension < SBP 150 
mmHg and < DBP 100 mmHg on the day of dosing.  Sotatercept (ACE-011) should not be administered ≤7 days 
post RBC transfusion.  
For Part 2:  Subjects who have received an RBC transfusion in the past 42 days should continue at the same
sotatercept (ACE-011)/placebo dose if the transfusion was given greater than 7 days from the previous dose of 
sotatercept (ACE-011)/placebo AND the Hgb level is < 11 g/dL AND hypertension is < SBP 150 mmHg and < 
DBP 100 mmHg on the day of dosing.  Sotatercept (ACE-011)/placebo should not be administered ≤7 days post 
RBC transfusion.  
2Hemoglobin increases of > 2 g/dL sustained for a 28 day period since last dosing day should be confirmed on the 
dosing day, 7, 14 , 21 (after first dose of study treatment) and 28 days after dosing, and reviewed in comparison to 
Hgb level on previous dosing day.  Any Hgb increase of ≥3.0 g/dL sustained for 28 days will require a subsequent 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dose reduction of two dose levels (Refer to sotatercept 
[ACE-011] and sotatercept (ACE-011)/Placebo Dose Reduction Levels [Table 5]).  A second Hgb increase of ≥ 
3.0 g/dL sustained for 28 days, following a two level dose reduction, will require the subject discontinue from 
study treatment.  If Hgb is > 15.0 g/dL (sustained for a 7 day period, confirmed by laboratory assessment) subject 
is to be discontinued from treatment.  (See Section 8.2.3 Discontinuation)  
3Sotatercept (ACE-011) or sotatercept (ACE-011)/placebo should be delayed until Hgb is < 11g/dL and 
hypertension < SBP 150mm Hg and < DBP 100 mm Hg.  Dosing can commence at ≥7 days after the originally 
planned sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dose that was delayed.  Subsequent sotatercept 
(ACE-011) or sotatercept (ACE-011)/placebo doses will then begin 42 days following this revised treatment dose 
date.  
A delayed sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dose is defined as a dose administered > 4 
days from the planned dosing date (due to Hgb ≥11.0 g/dL, hypertension > SBP 150 mmHg or > DBP 100 mmHg 
and/or sotatercept [ACE-011] related toxicity).  
4Sotatercept (ACE-011)or sotatercept (ACE-011)/placebo should be delayed as above in foot note (3), a reduced 
dose as above in foot note (2) of sotatercept (ACE-011) will be administered based on the evaluation of the Hgb 
and blood pressure at that time.  
5Sotatercept (ACE-011)or sotatercept (ACE-011)/placebo should be held until hypertension resolves to < SBP 
150mmHg and < DBP 100 mmHg and may then be resumed beginning seven days after the previous planned 
scheduled treatment visit as above in foot note (3).  
Page 658 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
30
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Table 5:
Sotatercept (ACE-011) and Sotatercept (ACE-011)/Placebo Dose Reduction 
Levels
When required, per dose modification rules above, sotatercept (ACE-011) dose(s) in Part 1 and 
sotatercept (ACE-011)/placebo dose(s) in Part 2 should be reduced as follows:  
Dose Schedule
Sotatercept (ACE-011) or
Sotatercept (ACE-011)/placebo
Dose Reduction*
#1
Dose Reduction*
#2
Dose Reduction*
#3
Every 42 days-
45 mg
38 mg
33 mg
28 mg
Every 42 days-
30 mg
26 mg
22 mg
18 mg
Every 42 days-
15 mg
13 mg
11 mg
9 mg
*Note:  Any Hgb increase of ≥3.0 g/dL sustained for a 28 day period since last doing day will require a subsequent 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dose reduction of two dose levels.  A second Hgb 
increase of ≥3.0 g/dL, sustained for 28 days, following a two-level dose reduction will require the subject 
discontinue from study treatment.  
Dosing visits are on Day 1 and repeated every 42 days, for four doses.  An additional two doses 
(total of 6 doses) may be given only during Part 2 at the discretion of the Investigator.up to four 
doses.  
Blood pressure (confirmed by two measurements obtained at least five minutes apart) and Hgb 
values must be evaluated prior to dosing at each dosing day for consideration in administration 
of sotatercept (ACE-011) and sotatercept (ACE-011)/placebo.).  
The dose level for the initial dose reduction will be maintained unless subsequent dose 
reductions need to be administered upon evaluation of the dose modification rules listed above.  
A dose level may not be increased following a dose reduction.  
In Part 2, dose reduction steps and the subsequent administration of the reduced dose(s) of 
sotatercept (ACE-011)/placebo will be conducted in a manner that will preserve the blinded 
status of the original treatment group of each subject.  Subjects in the placebo group who are 
designated to undergo dose reduction will continue to receive placebo.  
Placebo will be administered at the same volume as the corresponding sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo dose reduction.  
Sotatercept (ACE-011) Dose Escalation Levels:
The following dose escalation rules apply for sotatercept (ACE-011) dose(s) in Part 1 only.  
Dose escalations are not allowed in Part 2:):
Less than 1.0 g/dL increase in Hgb in response to prior sotatercept (ACE-011) dose 
Hgb level must be < 11.0 g/dL and hypertension < SBP 150mmHg and
< DBP 100 mmHg
Dose escalation to begin at next treatment visit 
Page 659 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
31
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Sotatercept (ACE-011) should not be administered ≤ 7 days from the date of RBC 
transfusion.  
Subjects who have received an RBC transfusion should receive a one level dose increase of 
Sotatercept (ACE-011) at the subsequent visit per the escalation table below.  
Table 6:
Sotatercept (ACE-011) Dose Escalation Levels (Part 1 Only) 
Dose Schedule
Sotatercept 
(ACE-011)
Dose Increase  #1
Dose Increase  #2
Dose Increase #3
Every 42 days-
45 mg
50 mg
55 mg
61 mg
Every 42 days-
30 mg
33 mg
36 mg
40 mg
Every 42 days-
15 mg
17 mg
20 mg
23 mg
Blood pressure (confirmed by two measurements obtained at least five minutes apart) and Hgb 
values must be evaluated prior to dosing at each dosing day for consideration in administration 
of sotatercept (ACE-011) and sotatercept (ACE-011)/placebo.).  
_  _  _  _  _  _  _  _  _  _  _
4.2.3.
Starting Dose Levels in Part 1
ThreeTwo starting dose levels, 15, 30, and 4530 mg, were chosen for Part 1 of the study.  
Selection of these doses is primarily based on the safety and exposure-response data observed in 
MM subjects under the standard MPT chemotherapy, who received up to four doses of 
sotatercept (ACE-011) at 0.1, 0.3, or 0.5 mg/kg (Study A011-04). In these subjects, sotatercept 
(ACE-011) had an acceptable safety profile and caused exposure-dependent Hgb response.  
Further, there was no relationship observed between an increase in blood pressure and the 
maximal sotatercept (ACE-011) concentration or the maximal Hgb rise within 28 days of the 
first dose (Report A011-04-CP).  The threetwo starting dose levels approximate the average 
doses received by a 70 kg subject over a 6-week interval (10.5 mg, and 31.5 mg, and 52.5 mg,
respectively) in the A011-04 study.  
In Study A011-04, four MM subjects received at least three sotatercept (ACE-011) doses at 0.5 
mg/kg every 4 weeks without a dose interruption, and none of them was reported to have an AE 
related to sotatercept (ACE-011).  In this study, the starting dose level of 45 mg (during the dose 
finding Part 1) will be implemented only after at least 10 subjects at each lower dose level (10 
subjects at the 15 mg dose level and 10 subjects at the 30 mg dose level) have been evaluated as 
well as following DMC review of safety data and assessment of dose effects on Hgb levels.  
In addition, in this study, during the first 6-week treatment period for a 70 kg subject receiving 
the starting dose at 45 mg, the sotatercept (ACE-011) exposure (Cmax, day 1-43 and AUC1-43) is 
projected to be approximately 10% lower than the exposure for the dose regimen of 0.5 mg/kg 
once every 4 weeks.  Afterwards, safety measures (Hgb and blood pressure) will be used to guide 
Page 660 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
32
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
the adjustment of the second dose and beyond.  Thus, the use of the 45 mg starting dose in the 
current study is not anticipated to significantly compromise subject safety.  
In this study, the 45 mg group will have the highest starting dose, and it may be titrated up to 
61.0 mg for the last dose (Dose 4).  Assuming a 70 kg subject who receives the maximal amount 
of dose during the entire study (i.e., starting at 45 mg followed by dose escalation every 6 weeks 
to 50.0, 55.0, and 61.0 mg for Doses 2, 3, and 4, respectively), the projected cumulative AUC 
during the treatment period (168 days) would be approximately 60% of the steady state AUC 
cumulated during the same period at the NOAEL level of 1 mg/kg (given every 4 weeks for a 
total of 6 doses) as reported in the 9-month, repeat-dose toxicity study in monkeys.  The
projected highest Cmax for the current study would be less than 50% of the steady state Cmax in 
the monkey study.  
4.2.4.
Evaluation of Dosing Schema via Modeling/Simulation
The performance of the proposed dosing schema (three fixed starting dose levels, 6-week dosing 
interval, and dose adjustment rules [see Section 4.1.1 for details]) for this study was evaluated 
via PK/pharmacodynamic modeling/simulation.  A tentative mechanistic PK/pharmacodynamic 
model for Hgb was developed using PK and Hgb data from healthy postmenopausal women and 
the model was extended to include MM subjects as a sub-population.  The model was required to 
appropriately reproduce the observed PK and Hgb profiles in MM subjects.  Monte Carlo 
simulations of the Hgb response to sotatercept (ACE-011) in a hypothetical anemic population 
(6.5 ≤ baseline Hgb < 11 g/dL; body weight 47 – 108 kg) were performed using the model 
parameterized with preliminary PK and pharmacodynamic parameters from MM subjects.  In 
this simulation analysis, efficacy refers to an Hgb increase > 1 g/dL from the baseline for 28 
consecutive days while safety refers to both the absolute Hgb levels and the rate of Hgb increase.  
The simulation predicts that the desired efficacy would be achieved 6 weeks after the second
dose in approximately 70% subjects of the 45 mg group and 6 weeks after the last dose in >70% 
subjects of the 30 mg group.  Further, the simulation predicts the Hgb level would be maintained 
under 12 g/dL in 90% subjects and under 13 g/dL in 95% of subjects during the course of the 
study (Figure 2).  No subjects are predicted to have a Hgb level above the upper limit of the 
normal range for Hgb (16 g/dL).  Approximately 6% subjects are predicted to have an Hgb rise 
> 2 g/dL within 28 days of the first dose, mostly from the 45 mg group (4%); however, the 
fraction of subjects with an Hgb rise > 3 g/dL per 28 days is predicted to be similar between the 
three dose groups (approximately 2.5% for each group).  
Page 661 of 791
088VGY

S otaterce pt ( A C E -0 1 1 )
S u m mar y  of C ha n ges A C E -0 1 1 -N S C L -0 0 1
Cel ge ne C or p orati o n
C o nfi de nt ial a n d Pr o priet ar y
3 3
A C E -0 1 1 -N S C L -0 0 1 4 . 0 FI N A L : 0 2 M A Y 2 0 1 2
Fi g ure 2 :
Si m ul ate d He m o gl o bi n Res p o nse i n t he H y p o t hetic al A ne mic P o p ul ati o n
T he mi d dle s o li d li nes re prese nt t he me dia n H g b le vel.  T he t o p a n d b ott o m s oli d li nes re prese nt 
t he H g b le vel at 5 % a n d 9 5 % perce ntile, res pect i vel y.  T he area bet wee n 5 % a n d 9 5 % perce ntiles 
re prese nts 9 0 % pre dicti on i nter val.  T he strai g ht d ot li nes re prese nt t he H g b le vel of 1 2 g/ d L.  
T he arr o ws i n dicate t he d osi n g t i me of s otaterce pt ( A C E-0 1 1).  T he t w o le vel d ose re d ucti o ns 
u p o n ≥ 3 g/ d L i ncrease s ustai ne d f or 2 8 da ys of a d ose ( Ta ble 5 ) was n ot i ncl u de d i n t he 
si mulat i on.  
4. 3.
St u d y D ur ati o n
T o e val uate se q ue nce a n d st u d y  ti meli nes, please see t he Ta ble of E ve nts (see Secti o n 5).  
A p pr o xi matel y  6 0 -9 0 3 0 s u bjects wit h a d va nce d or metastatic s oli d t u m or t y pes i n P art 1 a n d 
7 5 0 s u bjects wit h metastatic N S C L C i n P art 2 will be ra n d o mize d pri or t o recei vi n g t he fift h 
c ycle ( q 3 w re gi me n) O R prior t o starti n g t he f o urt h m o nt h ( de pe n di n g u p o n re gi me n) of 
pl at i n u m-base d c he m ot hera p y  O R d uri n g mai nte na nce t hera p y fol l owi n g treat m e nt wit h 
pl at i n u m-base d c he m ot hera p y .  Eac h s ubject will be o n t he st u d y  for a p pr o xi matel y 1 2 – 1 5 6
m o nt hs (i ncl u di n g t he Scree ni n g Peri o d, t he Treat me nt Peri o d, a n d t he P ost Treat me nt F oll o w -
U p Peri o d Visi t).  T he Treat me nt Peri o d is a p pr o xi matel y 6 t o 9 m o nt hs ( u p t o f our t o si x d oses 
of  s otaterce pt [ A C E-0 1 1] e ver y  4 2 da ys) wit h a P ost Treat me nt F oll o w- U p P eri o d of  si x m ont hs 
fr om Visi t o c c urrin g at 4 2 da ys after t he s u bjects’ last d ose of s otaterce pt ( A C E -0 1 1 ) or 
s otaterce pt ( A C E-0 1 1)/ place b o. ).  S u bjects w h o disc o nti n ue treat me nt earl y will st ill c o ntin ue t o 
t he P ost Treat me nt Visit.  T he P ost -Treat me nt F oll o w -U p Peri o d f or si x m o nt hs fr om t heir last 
d ose Vi sit will als o ser ve as t he E n d of Treat me nt / E n d of  s otaterce pt ( A C E-0 1 1) or s otaterce pt 
( A C E-0 1 1)/ pl ace b o St u d y  Visit.  
All s u bjects will c o nti n ue t o be f oll o we d f or T T P a n d P F S u p t o 1 2 m o nt hs fr o m t heir first d ose 
of  s otaterce pt ( A C E-0 1 1) or s otaterce pt ( A C E -0 1 1)/ place b o or u ntil pr o gressi o n of t heir 
a d va nce d or metastatic disease, w hic he ver occ urs first.  All s u bjects will c o nt i n ue t o be f oll owe d 
f or s ur vi val u p t o 2 4 m o nt hs fr om t heir first d ose of s otaterce pt ( A C E -0 1 1) or s otaterce pt ( A C E -
0 1 1)/ place b o.
R ati o n ale:
M o difie d t o:

Re m o ve t he P hase 2 B/ 3 p orti o n a n d refere nce t o Part 1 a n d Part 2 i n t he st u d y  desi g n.
Pa ge 6 6 2 of 7 9 1
0 8 8 V G Y

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
34
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012

Delete reference to Data Monitoring Committee (DMC) and confirm that continuous 
monitoring of the safety data will be conducted by the sponsor.

Confirm that the study will be conducted only in the United States.

Delete all references to the Phase 2B/3 study treatment of sotatercept (ACE-011) / 
placebo.

Revise the design of Phase 2a portion of the study to :
a.
Include approximately 30 versus 90 subjects
b. Delete the 45mg sotatercept (ACE-011) dose level
c.
Delete the safety analysis to determine addition of the sotatercept (ACE-011) 
45mg dose level following treatment of 10 subjects at 15mg and 10 subjects at 
30mg 
d. Change the number of subjects from approximately 30 to approximately 10-15 
per dose level
e.
Confirm that subjects will receive up to four doses of sotatercept (ACE-011)

Revise Post-Treatment Follow-Up Period of six months to the Post-Treatment Follow-
Up/End of Treatment/End of Study Visit occuring 42 days (6 weeks) following the last 
dose of sotatercept (ACE-011).

Revise stratification to include other non-cisplatin platinum-based chemotherapy in 
addition to carboplatin versus cisplatin due to addition of other allowed tumor types in 
Amendment 3.

Revise Figure 1:  Study Design to incorporate study design changes

Revise Sotatercept (ACE-011) Dose Modifications:
a.
Delete reference to sotatercept (ACE-011) / placebo
b.
Delete reference to 2B/3 portion and Part 1 and Part 2 in the study design.
c.
Delete the 45mg sotatercept (ACE-011) dose level.
d. Confirm that subjects will receive up to four doses of sotatercept (ACE-011).
NOTE:  Dose modification rules were not changed for the sotatercept (ACE-011) 15 mg and 30 
mg dose levels. 

Delete section 4.2.4 :  Evaluation of Dosing Schema via Modeling/Simulation as 
simulation performed dose not seem to be supported by the observed clinical data in 
subjects with chemotherapy-induced anemia.
Page 663 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
35
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
2.7.
Section 5:  Table Of Events (Pages 44-50)
Revised Text:
Table 7:
Sotatercept (ACE-011) Schedule of Assessments
Assessments
Screening 
Period
Treatment Period
Post Treatment Follow-Up Period
(± 1 week)
Survival
(±1wk)
Sotatercept (ACE-011)
Dose 1 Schedule
(± 3 days)
Sotatercept (ACE-011)
Subsequent
Doses 2 through 64 Schedule
(± 3 days)
Day -28
to
Day -1
D1
D8
D15
D22
D29
D43/
D1
D8
D15
D29
D43 
Post Last Dose 
Treatment 
Follow-Up/
End of 
Treatment / 
End of Study 
TxtVisitt
1 
Month
2
Month
3 
Month
4 
Month
5
Month
6 
Month/
Study
DCu
Survival
Informed Consent
X
Inclusion/Exclusion Criteria
X
Complete Medical History
X
Cancer History and Prior Therapiesa
X
Prior ESA and RBC transfusion historya
X
X
Clinical visits (*study treatment visit)
X
X*
X
X
X*
X
X
X
X
X
X
X
X
ECOG Performance Status
X
X
X
X
X
X
X
X
X
X
X
X
Vital Signs / Blood Pressureb
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Height (at randomization only)/Weight
X
X
X
X
X
X
X
X
X
X
X
X
X
12-Lead Electrocardiogram (ECG) – Part 1cc
X
X
X
X
X
12-Lead Electrocardiogram (ECG) – Part 2c
X
X
X
Pregnancy Testingd
X
X
X
X
X
X
X
Xd
Hematologye
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Absolute Reticulocyte Counte
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Serum Chemistryf
X
X
X
X
X
X
X
X
X
X
X
X
X
Serum Creatinine and Creatinine Clearanceg
X
X
X
X
X
X
X
X
X
X
X
X
X
Serum Iron, TIBC, Transferrin and Serum Ferritin, Vitamin B12 
and RBC Folate Levelsh
X
Xh
X
Serum Erythropoietin (**Full PK subjects post first dose only)i
X
X
X**
X
X**
X**
X
Xi
X
X
Page 664 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
36
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Table 7:
Sotatercept (ACE-011) Schedule of Assessments (Continued)
Assessments
Screening 
Period
Treatment Period
Post Treatment Follow-Up Period
(± 1 week)
Survival
(±1wk)
Sotatercept (ACE-011)
Dose 1 Schedule
(± 3 days)
Sotatercept (ACE-011)
Subsequent
Doses 2 through 64 Schedule
(± 3 days)
Day -28
to
Day -1
D1
D8
D15
D22
D29
D43/
D1
D8
D15
D29
D43 
Post Last Dose 
Treatment 
Follow-Up/
End of 
Treatment / 
End of Study 
TxtVisitt
1 
Month
2
Month
3 
Month
4 
Month
5
Month
6 
Month/
Study
DCu
Survival
Urinalysis and Renal Biomarkersj
X
X
X
X
X
X
X
X
X
X
X
X
FSH and LH – Males and Females
X
X
X
X
X
X
X
X
Dihyroepiandosterone and Testosterone 
(Free & Total) - Males Only 
X
X
X
X
X
X
X
X
Estrogen and Estradiol & Menstrual Status - Females Only
X
X
X
X
X
X
X
X
TSHk
X
X
Xk
X
X
Sotatercept (ACE-011) drug antibody test (pre-dose)t
X
X
X
Xt
X
X
Bone Biomarkers (BSAP, OC, P1NP, CTX, TRACP-5b and uNTX)l
(**Full PK subjects post first dose only)
X
X**
X**
X**
X**
X
X
X
Bone Imaging (DXA)m (Optional in Selected Centers)
X
X
X
Activin A and other proteins/biomarkers in blood (serum)
(pre-dose study treatment in a subset of subjects)
X
X
X
X
X
Activin and other proteins/biomarkers in archival tumor tissue 
(Part 2 only -optional)
X
Pharmacokinetics–(Part 1 and Part 2)n
Refer to Table 8 and Table 9 – Schedule of Pharmacokinetic Assessments
Tumor Assessmentso
Xo
< Every 9 weeks or as per standard of care at study site
QoL Assessment
(LCSS and FACIT Fatigue Scale)p
X
X
X
X
X
X
X
X
X
X
X
X
X
Adverse Events
X
All AEs regardless of causality up to 6 weeks (42 days) post last dose of study 
treatment, after day 43 of last dose – Post Treatment Follow-Up /End of 
Treatment / End of Study Visit-  only SAEs assessed as related to study 
treatment are to be reported
Concomitant Medications
(including ESAs and transfusions)
X
X
X
X
X
X
X
X
X
Concomitant Procedures
X
X
X
X
X
X
X
X
X
Hospitalizations (Record)
X
X
X
X
X
X
X
X
X
Randomization
X
Page 665 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
37
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Table 7:
Sotatercept (ACE-011) Schedule of Assessments (Continued)
Administer 
Sotatercept (ACE-011)/Perform Drug Accountabilityq
X
X
Platinum-based Chemotherapyr
X
Dosing of allowed regimen(s) per standard practice
Targeted/Maintenance Therapys
Dosing of allowed regimen(s) per standard practice
Overall Survivalvt
X
X
Post Treatment Anti-Neoplastic Therapyt
X
X
X
X
X
X
X
X
aInclude cancer history, date of original diagnosis, clinical stage at Screening and date of metastases and advanced or metastatic site involvement.  Record prior ESA history, 
starting at solid tumor diagnosis.  Record RBC transfusion history, starting from diagnosis of advanced or metastatic disease, at a minimum of two months prior to 
randomization.  
bVital signs (including heart rate, seated blood pressure, and temperature) will be measured at Screening and all subsequent clinical visits, on Day 29 post sotatercept (ACE-011) or 
sotatercept (ACE-011)/ placebo dose, at), and at the Post Treatment Discontinuation, and at Follow-Up / End of Treatment / End of Study DiscontinuationVisit.  Blood pressure 
should be confirmed by two measurements obtained at least five minutes apart Investigators are to report any clinically significant abnormal findings as adverse events.  
cECG to be performed as follows:  For Part 1:  At Screening,  Day 1 Dose 1  pre and post sotatercept (ACE-011) dose,  Day 8 post dose 1, every sotatercept (ACE-011) dosing 
Visit (post-dose) and at endPost Treatment Follow-Up / End of study treatmentTreatment / End of Study Visit (day 43 post last dose).  
For Part 2:  At Screening, Day 1 Dose 1 pre and post sotatercept (ACE-011)/placebo dose and at end of study treatment (day 43 post last dose).  
dFemales of childbearing potential (FCBP) only:  A female of childbearing potential is a sexually mature woman who has not undergone a hysterectomy or who has not been 
postmenopausal for at least 24 consecutive months (i.e. who has had menses at some time in the preceding 24 months).  A medically supervised pregnancy test with a minimum 
sensitivity of 25mIU/ml must be performed within 3 days prior to the start of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo administration (Day 1) once the subject 
has been on effective contraception for at least 28 days and be performed within 3 days prior to dose administration of sotatercept (ACE--011) or sotatercept (ACE-011)/placebo 
during the Treatment Period.  Subjects must agree to use highly effective birth control measures (e.g., oral contraceptives or two forms of barrier method birth control) during 
study participation and for at least 112 days following the last dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.  Pregnancy test will be performed at Study 
Discontinuation if date is ≤112 days following the last dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.).  
eHematology laboratory evaluations (RBC count, Hgb, HCT, WBC count and differential, ANC, MCV, platelet count and reticulocyte count).  Hemoglobin should be tested prior 
to dosing with sotatercept (ACE-011) or sotatercept (ACE-011)/placebo to ensure levels are within normal limits and that sotatercept (ACE-011) dose modification rules are 
followed as outlined in Section 4.1.1.  Any laboratory evaluations may be repeated more frequently if clinically indicated.  In addition, RBC, Hgb, and reticulocyte counts will be 
included at each timepoint within the full PK assessment (Part 1).  
fSerum chemistry laboratory evaluations (sodium, potassium, chloride, CO2 ([bicarbonate]), calcium, magnesium, phosphorus, BUN, creatinine, glucose, amylase, lipase, albumin, 
total protein, alkaline phosphatase, bilirubin [total and direct], AST/SGOT, ALT/SGPT, LDH and uric acid) if clinically significant any or all laboratory evaluations may be 
reported as AE and repeated more frequently.  
gCreatinine clearance (per Cockcroft-Gault formula) every 2 weeks during the Treatment Period, every month (except month 1) during and at the Post Treatment Follow-Up 
Period and at study discontinuation ./ End of Treatment / End of Study Visit (day 43 post last dose).  
Note:  Footnotes e, f, g : Hematology, absolute reticulocyte count, serum chemistry and creatinine clearance are to be assessed ≤14 days prior to randomization.
hSerum Iron, TIBC, Transferrin, Serum Ferritin, Vitamin B12 and RBC Folate to be performed at Screening, pre-last dose of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo and endat the Post Treatment Follow-Up / End of study treatmentTreatment / End of Study Visit (day 43 post last dose).  
Page 666 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
38
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
iErythropoietin – collected at day 15 following first 2 doses of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.).  For full PK assessment, weekly after first dose of 
sotatercept (ACE--011).  
jUrine collection for:  Urine albumin, urine albumin creatinine ratio, urine protein creatinine ratio and other renal biomarkers of glomerular and/or tubular injury.  
kTSH – collected at screening, on Day 1 of only the first and second dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo and at 2 month post-treatment follow-up 
visit.and at the Post Treatment Follow-Up / End of Treatment / End of Study Visit (day 43 post last dose).  
lBone Biomarkers- Collected for full PK subjects prior to dose 1, weekly following dose 1, prior to dose 2 , post last dose day 43 and month 3 post treatment follow-up visit.at the 
Post Treatment Follow-Up / End of Treatment / End of Study Visit.  For all other subjects collected prior to dose 1,  prior to dose 2 , post last dose day 43 and month 3 post 
treatment follow-up visit.and at the Post Treatment Follow-Up / End of Treatment / End of Study Visit (day 43 post last dose).  Biomarker serum samples should be consistently 
collected early morning.  The urine sample should not be from the first morning void.  
mDual Energy X-ray Absorptiometry (DXA) scan of lumbar spine and hip to evaluate overall health on approximately 200 subjects at selected US site(s).  Performed at Screening, 
and Month 3 duringat the Post Treatment Follow-Up Period./ End of Treatment / End of Study Visit (day 43 post last dose).  
nPharmacokinetics(Part 1)::  Blood samples will be collected to evaluate the blood or serum concentrations of sotatercept (ACE-011).  Approximately 10 subjects at each 
sotatercept (ACE-011) dose level, 15, 30 and 4530 mg, will have full PK sampling.  In addition, RBC, Hgb, and reticulocyte counts will be collected at each time point 
(excluding the 4-hour time point on Day 1) from Day 1 to Day 43 after the first dose within the full PK assessment.  Subjects not participating in the optional full PK assessment 
may participate in the sparse PK assessment.  
Pharmacokinetics (Part 2):  Sparse PK blood samples will be collected to evaluate the blood or serum concentrations of sotatercept (ACE-011) in approximately 300 (40%) of 
750 subjects.  Sotatercept (ACE-011) doses 5 and 6 will have pre-dose Day 1 PK (if applicable).  
REFER TO Table 8 and Table 9REFER TO Table 8, SCHEDULE OF PHARMACOKINETIC ASSESSMENTS.  
oTumor assessments:  Screening Period tumor assessments may be performed within six weeks or as per study site standard of care prior to randomization.  Also, historical tumor 
assessment data, from prior to the initiation of platinum-based chemotherapy through the Screening Period, will be collected.  Following randomization, tumor assessments will 
be performed ≤every 9 weeks or per standard of care at the study site, starting from the date of the previous (screening period) tumor assessment and following the chemotherapy 
schedule.  
pQoL assessments,- FACIT Fatigue Scale (Version 4) – to be completed by all subjects and LCSS questionnaire – to completed by only subjects with NSCLC, to.  NOTE:  The 
LCSS consists of two scales:  one scale for the subject (Patient Scale) and a counterpart scale for health professionals acting as observers (Observer Scale).  All QoL assessments 
should be completed by the subject upon arrival at clinic and prior to any study procedures or testing at all visits, as indicated in the schedule, and at Study Discontinuation/One-
Year Follow-Up Visit.Schedule of Assessments.  
qSotatercept (ACE-011) or sotatercept (ACE-011)/placebo dosing repeats every 42 days and will start after the subject begins a platinum-based chemotherapy regimen.  The first 
dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo may be given at any time following the first dose of platinum-based chemotherapy.  Subsequent doses of 
Sotatercept (ACE-011) or sotatercept (ACE-011)/placebo can be administered at any time point during a chemotherapy cycle or maintenance therapy. 
Administration of subsequent cycles of chemotherapy, including dose reductions and dose delays, should not affect the sotatercept (ACE-011) or sotatercept (ACE-011)/placebo 
dosing schedule, unless determined to be necessary by the Investigator.  If there is a chemotherapy dose delay, sotatercept (ACE-011) or sotatercept (ACE-011)/placebo 
administration does not need to be delayed until start of next chemotherapy cycle. 
rPlatinum-based chemotherapy is to be administered based on guidelines for administration according to manufacturer’s recommendations and standard clinical practice.  Type of 
chemotherapy and dosing will be recorded.  
s Targeted/maintenance therapy (e.g. pemetrexed, erlotinib, etc.) is to be administered based on guidelines for administration according to manufacturer’s recommendations and 
standard clinical practice.  
Page 667 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
39
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
tDay 43 (6 weeks) post last dose sotatercept (ACE-011) corresponds to the endPost Treatment Follow-Up / End of Treatment Period./ End of Study Visit.  Subjects who 
discontinue the sotatercept (ACE-011) or sotatercept (ACE-011)/placebo Treatment Period early will continue to the Post Treatment Follow-Up Period and be followed for up to 
6 months after their last dose of sotatercept (ACE-011)/placebo./ End of Treatment / End of Study Visit.  Survival Data and Post Treatment Anti-Neoplastic Therapy should be 
captured at this Visit. For subjects with a positive sotatercept (ACE-011) drug antibody assessment at the Post Treatment Follow-Up / End of Treatment / End of Study Visit, 
sotatercept (ACE-011) drug antibody assessments will be repeated every two months or as appropriate for up to one year or until the results are negative, whichever occurs first.
uStudy Discontinuation visit should occur 12 months after starting treatment with sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.  
vSurvival data will be collected monthly, (can be via telephone contact), following the Study Discontinuation visit for an additional 12 months (up to 24 months after first dose of 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo).
Page 668 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
40
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Table 8:
Schedule of Pharmacokinetic Assessments (Part 1)
Scheduled Time
Time relative to 
Sotatercept (ACE-011)
Part 1aPK Samplinga,b
Collection 
Windowe
Full PKc
Sparse PKd
Dose 1, D1
pre-Dose 1
X
X
-2  to  0 hour
Dose 1, D1
4 hours after Dose 1
X
X
±1 hour
Dose 1, D5
4 days after Dose 1
X
-
± 1 day
Dose 1, D8
7 days after Dose 1
X
X
± 1 day
Dose 1, D11
10 days after Dose 1
X
-
± 1 day
Dose 1, D15
14 days after Dose 1
X
X
± 1 day
Dose 1, D22
21 days after Dose 1
X
-
± 1 day
Dose 1, D29
28 days after Dose 1
X
X
± 1 day
Dose 1, D36
35 days after Dose 1
X
-
± 1 day
Dose 1, D43 (Dose 2, D1)
pre-Dose 2
X
X
± 2 days
Dose 2, D8
7 days after Dose 2
X
-
± 2 days
Dose 2, D15
14 days after Dose 2
X
-
± 2 days
Dose 2, D43 (Dose 3, D1)
pre-Dose 3
X
X
± 2 days
Dose 3, D8
7 days after Dose 3
X
-
± 2 days
Dose 3, D15
14 days after Dose 3
X
-
± 2 days
Dose 3, D43 (Dose 4, D1)
pre-Dose 4
X
X
± 2 days
Dose 4, D8
7 days after Dose 4
X
-
± 2 days
Dose 4, D15
14 days after Dose 4
X
-
± 2 days
Dose 4, D29
28 days after Dose 4
X
-
± 3 days
Last Dose, D43 
42 days after final dose 
X
X
± 3 days
PTf Follow up, 1 month
72 days after final dose
X
-
± 1 week
PT Follow up, 2 month
102 days after final dose
X
-
± 1 week
PT Follow up, 3 month
132 days after final dose
X
X
± 1 week
PT Follow up, 4 month
162 days after final dose
X
-
± 1 week
PT Follow up, 5 month
192 days after final dose
X
X
± 1 week
a Notes about PK sampling times:

For subjects participating in full PK sampling, RBC, Hgb and reticulocyte counts will be collected at each 
time point (excluding the 4-hour time point on Day 1) from Day 1 to Day 43 post first sotatercept 
(ACE-011) dose.  Erythropoietin and bone biomarkers will be collected at D1, D8, D15, D22, D29, and 
D43 post first sotatercept (ACE-011) dose.  If the time points for RBC, Hgb, reticulocyte, erythropoietin,
and bone biomarkers overlap with the time points defined in Table 7, only one sample is required.  

For subjects who discontinue the treatment early, PK blood sample collection will be continued during the 
follow-up period.  
bAt each time point, collect approximately 2 mL of blood.  After collection, allow the blood to clot at room 
temperature for approximately 1 hour and then centrifuge the blood sample at room temperature for 10 min (1100-
1300 g) to obtain serum.  
cTo be collected for approximately 3020 subjects (approximately 10 subjects in each dose group).  
dTo be collected in subjects participating in sparse PK sampling and not participating in full PK sampling.  
eFor subjects who participate in full PK sampling only.  The collection window for sparse PK samples will be the 
same as the visit window defined in Table 7.  
fPT = Post Treatment
Page 669 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
41
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Table 9:
Schedule of Pharmacokinetic Assessments (Part 2)
Scheduled Time
Time relative to 
Sotatercept (ACE-
011)/placebo dose
Sparse PKa,b,c
Collection Windowd
Dose 1, D1
pre-Dose 1
X
-2  to  0 hour
Dose 1, D1
4 hours after Dose 1
X
±1 hour
Dose 1, D8
7 days after Dose 1
X
± 3 day
Dose 1, D15
14 days after Dose 1
X
± 3 day
Dose 1, D29
28 days after Dose 1
X
± 3 day
Dose 1, D43 (Dose 2, D1)
pre-Dose 2
X
± 3 days
Dose 2, D43 (Dose 3, D1)
pre-Dose 3
X
± 3 days
Dose 3, D43 (Dose 4, D1)
pre-Dose 4
X
± 3 days
Dose 4, D43 (Dose 5, D1)
pre-Dose 5 
X
± 3 days
Dose 5, D43 (Dose 6, D1)
pre-Dose 6 
X
± 3 days
PTe Follow up, 3 month
132 days after final dose
X
± 1 week
PT Follow up, 5 month
192 days after final dose
X
± 1 week
a For subjects who discontinue the treatment early, PK blood sample collection will be continued during the follow-
up period.  
bAt each time point, collect approximately 2 mL of blood.  After collection, allow the blood to clot at room 
temperature for approximately 1 hour and then centrifuge the blood sample at room temperature for 10 min (1100-
1300 g) to obtain serum.  
cTo be collected for approximately 300 (40%) of 750 subjects (approximately 150 subjects in each arm).
dExcept for Day 1 (Dose 1, D1), the collection window will be the same as the visit window defined in Table 7.  
ePT = Post Treatment
Rationale:

Table 7:  Sotatercept (ACE-011) Schedule of Assessments was modified to:
a.
Delete all Assessments referenced in the Phase 2B/3 portion of the study.
b. Delete all references to Part 1 and/or Part 2 of the study. 
c.
Delete the Post-Treatment Follow-Up Period and Survival Follow-Up Period.  
d. Replace the “D43 Post Last Dose/End of Study Treatment Visit” with the “D43 
Post Treatment Follow-Up/End of Treatment/ End of Study Visit”.
e.
Add the following assessments to the “D43 Post Treatment Follow-Up/End of 
Treatment/ End of Study Visit”:
i.
TSH
ii.
Bone Imaging (DXA)- optional
iii.
Activin A and other proteins/biomarkers in blood (serum)
f.
Add sotatercept (ACE-011) drug antibody repeat assessments following the Post 
Treatment Follow-Up / End of Treatment / End of Study Visit for subjects with a 
positive sotatercept (ACE-011) titer. 
g. Clarify that the LCSS questionnaire consists of two scales, a Patient Scale and an 
Observer Scale.
Page 670 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
42
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012

Table 8:  Schedule of Pharmacokinetic Assessments (Part 1) was modified to:
a.
Delete all references to Part 1 of the study 
b.
Delete Post-Treatment Follow Up PK assessments. 
c.
Revise the number of subjects anticipated to participate in the Full PK assessment

Table 9:  Schedule of Pharmacokinetic Assessments (Part 2) was deleted.
Page 671 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
43
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
2.8.
Section 6:  Procedures (Pages 51-56)
Revised Text:
Screening Period (Day -28 to Day -1)
_  _  _  _  _  _  _  _  _  _  _
The assessments and procedures that will be performed during the Screening Period are outlined 
in the Table of Events (see Section 5) and include:
_  _  _  _  _  _  _  _  _  _  _
Medically supervised pregnancy test, with a minimum sensitivity of 25 mIU/ml, for 
females of childbearing potential (FCBP) to be assessed within 3 days prior to 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo administration
_  _  _  _  _  _  _  _  _  _  _
LCSS questionnaire (consisting of Patient Scale and Observer Scale) – only subjects 
with NSCLC  
Documentation of concomitant medications / procedures / hospitalizations
Documentation of concomitant platinum-based chemotherapy
Treatment Period (Day 1/Dose 1 of study treatment to Day 43 post last study treatment 
dose)
Results from screening evaluations must be reviewed prior to randomization to confirm subject 
eligibility.  
In Part 1 (the dose-ranging portion of the study), subjectsSubjects who meet all eligibility 
criteria will be randomized utilizing IVRS to receive one of the following sotatercept (ACE-011) 
dose levels, with approximately 10-3015 subjects per arm:
Sotatercept (ACE-011) 15 mg SC
Sotatercept (ACE-011) 30 mg SC
Analysis of safety data will be performed following the treatment of at least 10 subjects at the 15 
mg dose level and 10 subjects at the 30 mg dose level, with each subject having received a 
minimum of one dose of sotatercept (ACE-011) and completed a 12-week follow-up period from 
the first dose. 
Following this analysis, the addition of a third dose level:
Sotatercept (ACE-011) 45 mg SC
to the randomization schema will be determined.
Each dose level will be administered every 42 days for up to four doses.  
In Part 2, subjects meeting all inclusion and exclusion criteria will enter into the Treatment 
Period and be randomized by a double-blind procedure utilizing IVRS to receive sotatercept 
(ACE-011) or placebo (1:1 ratio).  
Page 672 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
44
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
A subject will be considered randomized once a unique multi-digit subject 
identification number has been assigned by IVRS.  
Following randomization, subjects will receive SC doses of sotatercept (ACE-011) or sotatercept 
(ACE-011)/placeboon Day 1 and every 42 days for up to four doses during the Treatment Period, 
as specified in the Table of Events (see Section 5).  
In Part 1, the Treatment Period will last approximately 6 months, where subjects randomized to 
sotatercept (ACE-011) will receive treatment on Day 1 every 42 days for a planned 4 doses.  
In Part 2, the Treatment Period will last approximately 6 to 9 months, where subjects 
randomized to sotatercept (ACE-011)/Placebo will receive treatment on Day 1 every 42 days for 
a planned 4 doses with an additional 2 doses of sotatercept (ACE-011)/placebo allowable, at the 
discretion of the Investigator, for a total of up to 6 doses.  
The assessments and procedures that will be performed during the Treatment Period are outlined 
in the Table of Events (see Section 5).  
Updated prior ESA and RBC transfusion history which may have occurred between 
the screening visit and randomization
ECOG performance status
Vital signs including weight, heart rate, seated systolic and diastolic blood pressure, 
and temperature
ECG 
Medically supervised pregnancy test, with a minimum sensitivity of 25 mIU/ml, for 
FCBP within 3 days prior to sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo administration.  
Serum chemistry, hematology, absolute reticulocyte count.  
Hematology laboratory evaluations (RBC count, Hgb, HCT, WBC count and 
differential, mean corpuscular volume [MCV], absolute neutrophil count [ANC], 
platelet count and reticulocyte count) will be collected weekly after the first dose 
of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo and at subsequent 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo doses collected at 7, 14 
days and 28 days post-dose.  
Within full PK assessment, RBC, Hgb and reticulocyte counts are collected at 
each time point; erythropoietin and bone biomarkers at weekly intervals post first 
dose of study treatment.  
Creatinine clearance will be assessed every 14 days.  
Serum iron, total iron binding capacity (TIBC), transferrin and serum ferritin at last 
dose and 42 days after last dose of study treatment
Vitamin B12 and RBC folate levels at last dose and 42 days after last dose of study 
treatment
Serum erythropoietin
Page 673 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
45
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Urinalysis
FSH (include current menstrual cycle status for premenopausal female subjects) and 
LH – both males and females 
Dihyroepiandosterone and Testosterone (free and total)– males only 
Estrogen and estradiol – females only 
TSH  
Serum for sotatercept (ACE-011) drug antibody test (pre-dose on the day of 
sotatercept ([ACE-011]) or sotatercept (ACE-011)/placebo administration)
Bone or other potential mechanistic or disease-related proteins/biomarkers 
Activin A and other sotatercept (ACE-011)-related proteins/biomarkers
in blood, including myostatin and follistatin:
o
pre-dose on Day 1 and Day 8 after first dose of sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo
o
pre-dose on Day 1 subsequent dosing visits
in archival tumor tissue (Part 2 only)
Tumor Assessment and Response Evaluation, as per RECIST criteria (Version 1.1), 
(performed ≤ every 9 weeks or per standard of care at the study site, starting from 
the previous [screening] tumor assessment) and following the chemotherapy schedule
Pharmacokinetics
QoL Assessment (FACIT Fatigue Scale [Version 4]) – all subjects
LCSS questionnaire (consisting of Patient Scale and Observer Scale) – only subjects 
with NSCLC  
Evaluation and all AE/SAE reporting (regardless of causality)
Documentation of concomitant medications / procedures (including use of ESAs and 
all transfusions) / hospitalizations
Documentation of concomitant platinum-based chemotherapy and/or 
targeted/maintenance therapy
Administration of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo aton:  
Day 1 every 42 days 
Subjects who discontinue from the Treatment Period early will entercontinue to the Post 
Treatment Follow-Up Period and be followed for / End of Treatment / End of Study Visit 42 
days (6 monthsweeks) after their last dose of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo.  Upon completion of the Post Treatment Follow-Up Period, subjects will have a 
discontinuation visit and be followed for survival for up to 24 months from their first dose of 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.).  
Page 674 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
46
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Post Treatment Follow-Up Period/ End of Treatment / End of Study Visit (Day 43 post last 
dose of study treatment to six months post last dose of study treatment)
Following completion or early discontinuation from the Treatment Period, subjects will enter 
thehave a Post Treatment Follow-Up Period and continue to be followed for 6 months after their 
last dose/ End of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo.  Visits will occur 
every monthTreatment / End of Study Visit.  The assessments and procedures that will be 
performed during this period are outlined in the Table of Events (see Section 5) and include:
ECOG performance status
Vital signs including weight, heart rate, seated systolic and diastolic blood pressure, 
and temperature.  
ECG – end of study treatment (day 43 post last dose)
Medically supervised pregnancy test, with a minimum sensitivity of 25mIU/ml, for 
FCBP
Serum chemistry, hematology, absolute reticulocyte count
Creatinine clearance 
Serum iron, total iron binding capacity (TIBC), transferrin and serum ferritin – end of 
study treatment (at day 43 post last dose)
Vitamin B12 and RBC folate levels – end of study treatment (at day 43 post last dose)
Serum erythropoietin
Urinalysis 
FSH (include current menstrual cycle status for pre-menopausal female subjects) and 
LH – both males and females 
Dihyroepiandosterone and testosterone (free and total)– males only 
Estrogen and estradiol – females only
TSH (at 2 month end of treatment follow-up visit)

Serum for sotatercept (ACE-011) drug antibody test (pre-sotatercept ([ACE-011]) or 
sotatercept (ACE-011)/placebo dose).  For subjects with a positive sotatercept (ACE-
011) drug antibody assessment at the Post Treatment Follow-Up / End of Treatment / 
End of Study Visit, sotatercept (ACE-011) drug antibody assessments will be 
repeated every two months or as appropriate for up to one year or until the results are 
negative, whichever occurs first.
Bone or other potential mechanistic or disease-related proteins/biomarkers 
Bone imaging – DXA scan (optional at selected sites-performed at 3 month end of 
treatment follow-up visit)
Activin A and other sotatercept (ACE-011) related proteins/biomarkers, including 
myostatin and follistatin, in blood at 1 month end of treatment follow-up visit)
Page 675 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
47
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Pharmacokinetics
Tumor Assessment and Response Evaluation, as per RECIST criteria (Version 1.1), 
(performed ≤ every 9 weeks or as per standard of care at the study site, and 
following the chemotherapy schedule)
QoL Assessment (FACIT Fatigue Scale (Version 4)) – all subjects
LCSS questionnaire (consisting of Patient Scale and Observer Scale) – only subjects 
with NSCLC  
Evaluation and reporting of all AEs regardless of causality (up to 6 weeks after last 
dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo).  After 6 weeks 
post last dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo, only AEs 
assessed as related to sotatercept (ACE-011) or sotatercept (ACE-011)/placebo or 
study related procedures are to be reported.) after last dose of sotatercept (ACE-011).  
Documentation of concomitant medications / procedures (including use of ESAs and 
all transfusions) / hospitalizations
Post-Treatment Anti-Neoplastic Therapy
Study Discontinuation 
Study Discontinuation is the final scheduled visit for this study and should be performed for all 
enrolled subjects.  
Subjects who discontinue from treatment early will enter the Post Treatment Follow-Up Period 
and be followed for 6 months from their last dose of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo.  Follow-up for twelve months for TTP and PFS will be performed from the 
subject’s first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/Placebo.  Following the 
Study Discontinuation Visit, subjects will be contacted monthly and survival data collected for 
an additional 12 months (up to 24 months following the subject’s first dose of sotatercept (ACE-
011) or sotatercept (ACE-011)/placebo).  
The assessments and procedures that will be performed during the Study Discontinuation Visit 
are outlined in the Table of Events (see Section 5) and include:
ECOG performance status
Vital signs including weight, heart rate, seated systolic and diastolic blood pressure, 
and temperature
Medically supervised pregnancy test, with a minimum sensitivity of 25 mIU/ml, for 
females of childbearing potential (FCBP) – if Study Discontinuation date is ≤ 112 
days following the last dose of sotatercept (ACE-011) or sotatercept (ACE-
011)/placebo.  
Serum chemistry, hematology, absolute reticulocyte count
Creatinine clearance 
Urinalysis 
Page 676 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
48
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
FSH (include current menstrual cycle status for pre-menopausal female subjects) and 
LH – both males and females 
Estrogen and estradiol – females only
Dihyroepiandosterone and testosterone (free and total) – males only
Tumor Assessment and Response Evaluation, as per RECIST criteria (Version 1.1) 
(PFS at 12 months)
QoL Assessment (FACIT Fatigue Scale (Version 4)) – all subjects 

LCSS questionnaire – only subjects with NSCLC  
Evaluation and reporting of all AEs regardless of causality (up to 6 weeks after last 
dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo).  After 6 weeks 
post last dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo, only AEs 
assessed as related to sotatercept (ACE-011) or sotatercept (ACE-011)/placebo or 
study related procedures are to be reported.
Documentation of concomitant medications / procedures (including use of ESAs and 
all transfusions) / hospitalizations
Post-Treatment Anti-Neoplastic Therapy
Survival Follow-Up Period:
Monthly collection of survival data will begin following the Study Discontinuation Visit and 
continue for an additional 12 months (up to 24 months after first dose of sotatercept (ACE-011) 
or sotatercept (ACE-011)/placebo).  
Overall survival
Post-Treatment Anti-Neoplastic Therapy
Additional Procedure Descriptions:
Central ECG
Part 1 – ECGs will be performed and read per Central ECG vendor.  
Part 2 – ECGs will be performed locally and read per Central ECG vendor.  
Please refer to vendor manual for procedures.  
_  _  _  _  _  _  _  _  _  _  _
Exploratory Biomarkers 
Analyses will be undertaken to evaluate the expression of Activin A and other 
proteins/biomarkers related to sotatercept (ACE-011) mechanism of action in blood (including 
myostatin and follistatin) and in archival tumor tissue in a subset of subjects (Part 2 only). ).
_  _  _  _  _  _  _  _  _  _  _
Page 677 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
49
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Pharmacokinetics
Part 1 -Blood samples will be collected to evaluate the full PK profile of sotatercept 
(ACE-011) from approximately 3020 subjects at select centers (approximately 10 
subjects for each sotatercept [ACE-011] dose group).  For full PK sampling, subjects 
who miss more than two PK sampling time points from Days 1 through 43 will be 
replaced.  Subjects not participating in the optional full PK assessment may 
participate in the sparse PK assessment.  
Part 2- Sparse PK blood samples will be collected from approximately 300 (40%) of 
750 subjects (approximately 150 subjects in each arm).  
For subjects who do not participate in either Part 1 full or sparse PK assessments or in Part 2
sparse PK assessments, the ACE-011 (sotatercept) concentration may be determined in their anti-
sotatercept antibody samples to assist in the evaluation of immunogenicity, as well as PK.
Detailed PK sampling schedule is presented in Table 8 and Table 9:  Schedule of 
Pharmacokinetic Assessments.  
PK samples must be collected predose on the day of sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo administration.  PK samples may be collected at any 
time on non-dosing days.  After collection, allow the blood to clot at room 
temperature for approximately one hour and then centrifuge the blood sample at room 
temperature for 10 minutes (1100-1300g) to obtain serum.  At each time point, 
approximately 2 mL or less blood will be collected.  
_  _  _  _  _  _  _  _  _  _  _
Quality of Life Assessments
The QoL Assessment (FACIT Fatigue Scale [Version 4]) will be completed by all subjects and 
LCSS questionnaire will be completed for subjects with NSCLC.  Each assessment will be 
completed by the subject upon arrival at clinic and prior to any study procedures or testing.  The 
LCSS consists of two scales:  one for the patient (Patient Scale) and a counterpart for health 
professionals acting as observers (Observer Scale). 
Independent External Radiology Review (Part 2 Only)
At least 3 independent external radiologists (2 reviewers and 1 adjudicator) will perform a 
blinded, independent assessment of response, including the development of progressive disease 
(PD).  
Independent Review Committee (IRC) (Part 2 Only)
NOTE: The IRC will review the tumor response data (to include results from the central 
radiologist and relevant clinical laboratory and physical examination findings) and the dates of 
disease progressionLCSS consists of two scales:  one scale for each subject.  These data 
reviewed by the IRC will be used in the primary analyses ORR, TTP and PFSthe patient (Patient 
Scale) and a counterpart scale for the Clinical Study Report. health professionals acting as 
observers (Observer Scale).
Page 678 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
50
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Rationale:
Modified to:

Clarify that the LCSS questionnaire consists of two scales, a Patient Scale and an 
Observer Scale.

Change the number of subjects from approximately 30 to approximately 10-15 per dose 
level

Confirm that subjects will receive up to four doses of sotatercept (ACE-011)

Remove the Phase 2B/3 portion of the study and all references to Part 1 and Part 2 in the 
study design.

Delete all references to the Phase 2B/3 study treatment of sotatercept (ACE-011) / 
placebo.

Revise Post-Treatment Follow-Up Period of six months to the Post-Treatment Follow-
Up/End of Treatment/End of Study Visit occuring 42 days (6 weeks) following the last 
dose of sotatercept (ACE-011).

Delete the Post-Treatment Follow-Up Period. assessments and procedures.

Add sotatercept (ACE-011) drug antibody repeat assessments following the Post 
Treatment Follow-Up / End of Treatment / End of Study Visit for subjects with a positive 
sotatercept (ACE-011) titer.  

Delete the Study Discontinuation Visit assessments and procedures.

Delete the Survival Follow-Up Period

Include TSH, DXA scan, Activian A and other sotatercept (ACE-011) related 
proteins/biomarkers, including myostatin and follistatin and Overall Survival Data 
Collection in the Post-Treatment Follow-Up/End of Treatment/End of Study Visit.

Remove ECGs and archival tissue collection in Part 2 of the study.

Revise the number of subjects anticipated to participate in the Full PK assessment

Delete requirement to replace subjects in the Full PK assessment

Remove the Independent External Radiology Review and the Independent Review 
Committee, required in Part 2 of the study. 
Page 679 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
51
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
2.9.
Section 7:  Study Population (Pages 57-61)
Revised Text:
At the time of randomization in Part 1 and Part 2, subjects must:
have already received at least one cycle and up to 4 cycles (q3w schedule) of 
platinum-based chemotherapy and be randomized prior to receiving Cycle 5 
OR 
have already received at least one cycle and up to 3 months (depending upon 
regimen) of platinum-based chemotherapy 
OR
currently be receiving maintenance therapy following treatment with platinum-
based chemotherapy 
In Part 1, subjectsSubjects must have an advanced or metastatic solid tumor treated with ≥ first–
line platinum–based chemotherapy, excluding those solid tumors treated with curative intent. 
In Part 2, subjects must have metastatic NSCLC and must not have received any other regimens 
of platinum containing chemotherapy for first-line treatment prior to the regimen they are 
receiving at the time of randomization.  
7.1.
Number of Subjects
This platinum-based CIA study will enroll approximately 840 subjects, approximately 9030
subjects with advanced or metastatic solid tumor types in Part 1 and 750 subjects with 
metastatic NSCLC in Part 2.  
In Part 1, upUp to 90approximately 30 subjects will be randomized to receive one of the 
following sotatercept (ACE-011) dose levels, with 10-3015 subjects per arm:
Sotatercept (ACE-011) 15 mg SC
Sotatercept (ACE-011) 30 mg SC
Sotatercept (ACE-011) 45 mg SC
and will be stratified by:
1. Baseline Hgb level 
6.5 to < 9.0 g/dL
9.0 to < 11.0 g/dL
2. Type of platinum-based chemotherapy (cisplatin versus carboplatinother non-
cisplatin chemotherapy)
Page 680 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
52
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
In Part 2, an additional 750 subjects will be randomized to receive either sotatercept (ACE-011), 
at the dose determined in Part 1, or placebo at a ratio of 1:1.  Subjects will be stratified by:
1. Baseline Hgb level 
6.5 to < 9.0 g/dL
9.0 to < 11.0 g/dL
2. Type of platinum-based chemotherapy (cisplatin versus carboplatin)
3. NSCLC histology (Squamous NSCLC vs. Non-Squamous NSCLC)
4. ECOG Performance Status 0-1 vs. 2
7.2.
Inclusion Criteria
Subjects must satisfy the following criteria to be enrolled in the study:
1. Men and women > 18 years of age at the time of signing the informed consent document.
2. Part 1 – Histologically confirmed (cytology or biopsy) solid tumor malignancy, 
excluding those solid tumors treated with curative intent.
Part 2 - Histologically confirmed (cytology or biopsy) non-small cell lung cancer.
3. Documented advanced or metastatic disease. 
4. Measurable or non-measurable disease evaluable by RECIST criteria (Version 1.1) 
(Appendix A).
5. All of the following laboratory values:
Hemoglobin ≥ 6.5 to < 11.0 g/dL (≥ 65 to < 110 g/L), due to chemotherapy-induced 
anemia
Absolute neutrophil count ≥ 500/mm3
Platelet count ≥ 75,000/mm3 (> 72 hours since prior platelet transfusion) 
Adequate renal function:
o
creatinine clearance ≥ 40mL/min or ≥ 50 mL/min if cisplatin is concomitantly 
administered 
and
o
urine protein / creatinine ratio ≤ 1.0; or ≤ 2.0 if bevacizumab (Avastin®) is 
concomitantly administered
Hepatic function (bilirubin < 1.5 x ULN; AST and ALT < 3.0 x ULN and ≤ 5.0 ULN 
for subjects with liver metastases)
Corrected calcium within normal limits (WNL) or ≤ Grade 1.  Previous 
hypercalcemia treatment is allowed
Page 681 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
53
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
6. Subjects must:
have already received at least one cycle and up to 4 cycles (q3w schedule) of 
platinum-based chemotherapy and be randomized prior to receiving Cycle 5 
OR 
have already received at least one cycle and up to 3 months (depending upon 
regimen) of platinum-based chemotherapy 
OR
currently be receiving maintenance therapy following treatment with platinum-based 
chemotherapy 
For Part 1- anyAny platinum-based regimen approved for the specific indication
For Part 2 -allowed regimens for the treatment of metastatic NSCLC are:
o
gemcitabine plus cisplatin or carboplatin ± bevacizumab
o
pemetrexed plus cisplatin or carboplatin ± bevacizumab
o
taxanes plus cisplatin or carboplatin ± bevacizumab
7. ≥ 28 days must have elapsed since previous treatment with ESA
8. ≥ 14 days must have elapsed (prior to Day 1) since the last RBC transfusion and receipt 
of ≤ 2 units of blood in the past 30 days (prior to Day 1)
9. ECOG Performance status of 0 – 2 (Appendix B)  
10. Females of childbearing potential participating in the study are to use highly effective 
methods of birth control for at least 28 days before starting the study, during study 
participation and for at least 112 days following the last dose of sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo.).  
Some highly effective methods of birth control include:
Oral contraceptives, intrauterine device, tubal ligation or a partner with a vasectomy
OR
Two forms of barrier method birth control, e.g., a latex condom PLUS a diaphragm 
with spermicide OR a latex condom PLUS a contraceptive sponge with spermicide.  
If a non-latex condom is used, it cannot be made out of natural (animal) membrane  
Females of childbearing potential must have a negative pregnancy test, with a minimum 
sensitivity of 25 mIU/ml, within 3 days prior to sotatercept (ACE-011) or sotatercept 
(ACE-011)/placebo administration (Day 1).  In addition, subjects must be educated 
concerning measures to be used to prevent pregnancy and potential toxicities.  (A female 
of childbearing potential is a sexually mature woman who has not undergone a 
hysterectomy or bilateral oophorectomy; or who has not been postmenopausal for at least 
24 consecutive months i.e. who has had menses at some time in the preceding 24 
months).  
Page 682 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
54
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
11. Males must agree to use a latex condom or non-latex condom NOT made of natural 
(animal) membrane during any sexual contact with females of childbearing potential or a 
pregnant female while participating in the study and for at least 112 days following the 
last dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo,), even if he has 
undergone a successful vasectomy.  
12. Life expectancy of ≥ 3 months.
13. Is willing to adhere to the study visit schedule, understand and comply with all protocol 
requirements.
14. Understand and voluntarily sign a written informed consent document prior to any study 
related assessments/procedures are conducted.
7.3.
Exclusion Criteria
The presence of any of the following will exclude a subject from enrollment:
1. Subjects who have any Grade > 3 toxicity (according to the currently active minor 
version of the NCI National Cancer Institute Common Terminology for Adverse Events 
[CTCAE] version 4.0 [Appendix C]) at the time of screening, including Grade ≥ 3 
residual adverse events related to either chemotherapy or underlying disease.  Exception:  
Grade ≥ 3 hematotoxicity (e.g., asymptomatic anemia, neutropenia and 
thrombocytopenia) occurring during the chemotherapy nadir period and resolving or non-
hematological events (e.g., nausea, vomiting, fatigue, or muscle or bone/joint pain), 
occurring during the chemotherapy period and resolving.
2. Prior radiation therapy to > 20% of the whole skeleton.  Use of palliative radiation, if the 
area being treated is < 15% of body surface area with no pelvic radiation or no more than 
10% of the bone marrow reserve is radiated, is permitted during subject participation in 
the study, at the discretion of the Investigator.  
3. Part 2 only, history of prior regimen(s) of platinum-based chemotherapy for metastatic 
NSCLC and/or history of adjuvant platinum-based chemotherapy with last dose received 
less than six months prior to the start of current first-line platinum-based chemotherapy 
for metastatic NSCLC.  
43. CNS metastases (exception:  subjects with CNS metastases treated with whole brain 
radiotherapy, gamma knife radiosurgery and/or surgery and stable for at least 2 
weeks prior to randomization).  
54. Clinically significant pulmonary, endocrine, neurologic, gastrointestinal, hepatic or 
genitourinary disease unrelated to underlying malignancy.  
65. Subjects with classification of 3 or higher heart failure as classified by the New York 
Heart Association (NYHA) (Appendix D).  
76. History of thrombosis, deep vein thrombosis (DVT), pulmonary emboli (PE), or embolic 
stroke if not stable on anticoagulants and/or one of these events occurring within the past 
6 months.  Local central line thrombosis is allowed.  
87. Diagnosis of a myeloid malignancy or known history of myelodysplasia.  
Page 683 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
55
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
98. Subjects with a recent history (within 14 days of Day 1) of administration of IV 
antibiotics or oral antibiotics (due to post septic episode).  Subjects should be free of 
infection at least 14 days after the last dose of systemic antibiotic treatment (prior to Day 
1).  
109.
Uncontrolled hypertension.  Controlled hypertension is considered clinically stable 
and systolic blood pressure (SBP) must be < 150 mmHg and diastolic blood pressure 
(DBP) must be < 100 mmHg.  
1110. Known infection with human immunodeficiency virus (HIV).  
1211. Known active hepatitis B or C antibody defined by positive serology.  
1312. Deficiency in iron (transferrin saturation < 20%), vitamin B12, or RBC folate.  
Subjects may be re-screened following treatment with supplements and normalization of 
levels.  
1413. History of anemia as a result of inherited hemoglobinopathy such as sickle cell 
anemia or thalassemia.  
1514. History of anemia due to autoimmune or hereditary hemolysis; or gastrointestinal 
bleeding occurring within the past 6 months.  
1615. Received treatment with another investigational drug or device within 28 days prior 
to Day 1, or if the half life of the previous product is known, within 5 times the half life 
prior to dosing, whichever may be longer.  
1716. Any prior use of sotatercept (ACE-011).  
1817. Pregnant or lactating females or females planning to become pregnant.  
1918. History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant 
proteins or excipients in the investigational product (Refer to the Investigator’s Brochure 
for further information).  
2019. Major surgery within 30 days prior to Day 1 (subjects must have completely 
recovered from any previous surgery prior to Day 1).  
Rationale:
Modified to:

Remove the Phase 2B/3 portion of the study and all references to Part 1 and Part 2 in the 
study design.

Change the number of subjects from approximately 30 to approximately 10-15 per dose 
level.

Delete the 45mg sotatercept (ACE-011) dose level.

Revise stratification to include other non-cisplatin platinum-based chemotherapy in 
addition to carboplatin due to addition of other allowed tumor types in Amendment 3

Delete all references to the Phase 2B/3 study treatment of sotatercept (ACE-011) / 
placebo.
Page 684 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
56
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Section 8:  Description Of Study Treatments (Pages 62-65)
Revised Text:
8.1.
Description of Investigational Product(s)
Sotatercept (ACE-011) clinical drug product will be provided as a lyophilized powder, Process 
III.  
Process III Clinical Drug Product- Lyophilized Powder:
The clinical drug product consists of sotatercept (ACE-011) in 10 mM citrate buffer, pH 5.8, 8% 
sucrose, and 0.02% polysorbate 80.  It is supplied as a lyophilized powder in labeled, rubber 
stoppered, 3-mL glass vials.  The recommended storage temperature for sotatercept (ACE-011) 
lyophilized drug product is 2°C to 8°C.  Prior to administration, the lyophilized drug product is 
reconstituted with 1 mL water for injection (WFI).  The reconstituted drug product consists of a 
50 mg/mL solution of sotatercept (ACE-011).  The reconstituted sotatercept (ACE-011), in its 
original container closure system, may be held for up to 6 hours at 2°C to 8°C.
Placebo (Part 2 Only):
In Part 2, the sotatercept (ACE-011) placebo to be used in the study will be sterile normal saline 
(0.9% sodium chloride for injection) administered as a SC injection.  Sterile, normal saline will 
be supplied by the investigational site’s pharmacy.  The manufacturer’s directions for placebo 
storage and handling are to be followed, as are standard clinical practices for ensuring sterility of 
the placebo.  
Prior to administration, the lyophilized drug product is reconstituted with 1 mL sterile water for 
injection (WFI) in the closed product vial using sterile needles and syringes following 
institutional standards for reconstitution of sterile products.  The reconstituted drug product 
consists of a 50 mg/mL solution of sotatercept (ACE-011).  The solution must be refrigerated at 
2°C to 8°C upon reconstitution.
The reconstituted sotatercept should be used immediately after reconstitution, and if not used 
immediately, the reconstituted sotatercept, in its original package, may be held for up to 6 hours 
at 2°C to 8°C.
8.2.
Treatment Administration and Schedule
Sotatercept (ACE-011) or placebo will be administered as a SC injection to subjects by the study 
staff at the clinical site and will be documented in the study source record.  Subcutaneous 
injections will be given in the upper arm, abdomen, or thigh.  
At the time of randomization in Part 1 and Part 2, subjects must:
have already received at least one cycle and up to 4 cycles (q3w schedule) of 
platinum-based chemotherapy and be randomized prior to receiving Cycle 5 
OR 
have already received at least one cycle and up to 3 months (depending upon 
regimen) of platinum-based chemotherapy 
OR
Page 685 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
57
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
currently be receiving maintenance therapy following treatment with platinum-
based chemotherapy 
In Part 1, subjectsSubjects must have an advanced or metastatic solid tumor treated with ≥ first–
line platinum–based chemotherapy, excluding those solid tumors treated with curative intent. 
In Part 2, subjects must have metastatic NSCLC and must not have received any other regimens 
of platinum containing chemotherapy for first-line treatment prior to the regimen they are 
receiving at the time of randomization.  
Allowed concomitant platinum-based chemotherapy regimens are:
For Part 1- any platinum-based regimen approved for the specific indication
For Part 2 -allowed regimens for the treatment of metastatic NSCLC are:
o
gemcitabine plus cisplatin or carboplatin ± bevacizumab
o
pemetrexed plus cisplatin or carboplatin ± bevacizumab
o
taxanes plus cisplatin or carboplatin ± bevacizumab
Investigative sites will utilize commercial supply of these medications.  
Concomitant or maintenance therapy with chemotherapeutic and/or targeted agents (e.g., 
pemetrexed, anti-EGFR agents, anti-VEGF agents), which are approved for a given tumor type, 
are allowed in addition to platinum-based chemotherapy. 
Platinum-based tumor therapy may be revised at the discretion of the Investigator for toxicity 
reasons only.  
In Part 1 and Part 2, sotaterceptSotatercept (ACE-011) or sotatercept (ACE-011)/placebo 
dosing may occur on different weeks of the chemotherapy cycle due to the subjects’ Hgb levels.  
Dose delays of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo and/or dose delays of 
chemotherapy may occur.  
8.2.1.
Selection of Dose for the Study
In Part 1, subjectsSubjects will be randomized to one of the following sotatercept (ACE-011) 
dose levels, with 10-3015 subjects per arm:
Sotatercept (ACE-011) 15 mg SC
Sotatercept (ACE-011) 30 mg SC
Analysis of safety data will be performed following the treatment of at least 10 subjects at the 15 
mg dose level and 10 subjects at the 30 mg dose level, with each subject having received a 
minimum of one dose of sotatercept (ACE-011) and completed a 12-week follow-up period from 
the first dose.  
Following this analysis, the addition of a third dose level:
Sotatercept (ACE-011) 45 mg SC
to the randomization schema will be determined.
Each dose level will be administered every 42 days for up to four doses.  
Page 686 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
58
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
The following are decision rules for dose determination in Part 1 in order to move forward to 
Part 2:
After completion of two doses of sotatercept (ACE-011), a hematopoietic response in 
approximately 70% of subjects, in at least one or more treatment arms.  
Hematopoietic response is defined as an increase in Hgb of ≥ 1.0 g/dL above the study 
baseline value for 4 consecutive weeks, in the absence of RBC transfusions and/or ESAs. In 
order to determine the dose of sotatercept (ACE-011) to be used in Part 2, evaluation of 
hematopoietic response will be determined from sotatercept (ACE-011) dose 1/day 1 through 
and including dose 2/day 43 (prior to dose 3). 
In addition to the hematopoietic response, safety profile, dose modifications and 
extent of exposure will be taken into account for dose level selection for Part 2.  
The effective dose of sotatercept (ACE-011) is defined as follows:
An increase in hemoglobin (Hgb) of ≥ 1.0 g/dL above the study baseline value for 4 
consecutive weeks.  
Hematopoietic response will be determined by laboratory analysis of hemoglobin levels.  
In Part 2, subjects will be randomized to receive either sotatercept (ACE-011) (at the dose 
determined in Part 1) or placebo.  
8.2.2.
Selection and Timing of Dosing for Each Subject
Subjects will be randomized to receive sotatercept (ACE-011) or sotatercept (ACE-011)/placebo 
starting on Day 1 (one SC dose every 42 days) and continuing during the six-month (Part 1) or 
nine-month (Part 2) Treatment Period, as outlined in the Table of Events (see Section 5).  
In Part 1, subjectsSubjects will be randomized to receive one of threetwo dose levels of 
sotatercept (ACE-011), with 10-3015 subjects per arm.  In Part 2, 750 subjects will be 
randomized to receive sotatercept (ACE-011) or placebo at a ratio of 1:1.  
Each subject will return to the site on each scheduled clinic visit.  During the Treatment Period, 
subjects will receive sotatercept (ACE-011) or sotatercept (ACE-011)/placebo every 42 days as 
determined by Hgb levels and randomization schedule.  Hemoglobin levels and reticulocyte 
counts will be repeated weekly after the first dose of sotatercept (ACE-011) or sotatercept (ACE-
011)/placeboand then at 7, 14 and 28 days after each subsequent dose of sotatercept (ACE-011) 
or sotatercept (ACE-011)/placebo.).  
The first dose of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo can be administered 
at any time after the first cycle and prior to the fifth cycle (q3w regimen) OR prior to 
starting the fourth month (depending upon regimen) of platinum-based chemotherapy OR 
during maintenance therapy following treatment with platinum-based chemotherapy.
Subsequent doses of sotatercept (ACE-011) or sotatercept (ACE-011)/placebo can be 
administered at any time point during a chemotherapy cycle or maintenance therapy. 
Administration of subsequent cycles of chemotherapy, including dose reductions and dose 
delays, should not affect the sotatercept (ACE-011) or sotatercept (ACE-011)/placebo dosing 
schedule, unless determined to be necessary by the Investigator.  If there is a chemotherapy dose 
Page 687 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
59
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
delay, sotatercept (ACE-011) or sotatercept (ACE-011)/placebo administration does not need to 
be delayed until start of next chemotherapy cycle.  
Following completion of the Treatment Period, subjects who enter will continue to the Post 
Treatment Follow-Up Period will be followed for / End of Treatment / End of Study Visit to 
occur 42 days (6 months from theirweeks)  after the subjects’ last dose of sotatercept (ACE-011) 
or sotatercept (ACE-011)/placebo.  Visits will occur every month.  All subjects will continue to 
be followed for PFS up to 12 months from their first dose of sotatercept (ACE-011) or 
sotatercept (ACE-011)/placebo, or until progression of their advanced or metastatic disease, 
whichever occurs first.).  
Subjects will be discontinued from the study treatment for reasons listed in Section 8.2.3 of the 
protocol, for unacceptable toxicity, or for progression of advanced or metastatic disease that 
requires the initiation of another treatment.  
Following the Study Discontinuation Visit, subjects will be contacted monthly and survival data 
collected for an additional 12 months (up to 24 months following the subject’s first dose of 
sotatercept (ACE-011) or sotatercept (ACE-011)/placebo).  
8.2.3.
Discontinuation
Treatment Discontinuation
Subjects will be discontinued from Study Treatment due to the following:
_  _  _  _  _  _  _  _  _  _  _
In Part 1, lackLack of sotatercept (ACE-011) therapeutic effect, defined as < 1.0 
g/dL increase in Hgb from baseline following three dose escalations.  In Part 2, lack 
of sotatercept (ACE-011) therapeutic effect, defined as < 1.0 g/dL increase in Hgb 
from baseline following two doses of sotatercept (ACE-011)/placebo (Dose 1/ Day 1 
through and including Dose 2/Day 43, prior to Dose 3).  
Concomitant use of ESAs – In Part 1 if administered at any time and in Part 2 if 
administered < 4 months after first dose of study treatment.  
Sotatercept (ACE-011) or Sotatercept (ACE-011)/placebo Dose Modifications:
In Part 1 and Part 2:  A second Hgb increase of ≥3.0 g/dL following a two 
level dose reduction due to a Hgb increase ≥3.0 g/dL 
In Part 2:  > 3 dose reductions and/or delays
_  _  _  _  _  _  _  _  _  _  _
Study Discontinuation:  
The following events are considered sufficient reasons for discontinuing a subject from the 
study:

Completed study, per protocol (subject has completed approximately six- to nine-
month Treatment Period including a 42 day [6 week]up to six-month Post Treatment
Follow-Up/End of Treatment/End of Study Visit) Period including one year tumor 
Page 688 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
60
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
assessment to determine TTP and PFS).  Note:  Survival data will continue to be 
collected for up to 24 months after first dose of study treatment.  
_  _  _  _  _  _  _  _  _  _  _
8.3.
Method of Treatment Assignment
All subjects who qualify for the study will be randomly enrolled into the study and receive up to 
4 doses of sotatercept (ACE-011) in Part 1.  In Part 2, subjects will be randomized at a ratio of 
1:1 and receive up to 4 doses of study treatment and may receive 2 additional doses of 
sotatercept (ACE-011)/placebo, if clinically indicated, at the discretion of the Investigator.four 
doses of sotatercept (ACE-011).  A unique multi-digit subject identification number will be 
assigned by IVRS to each subject entering the Treatment Period.  
_  _  _  _  _  _  _  _  _  _  _
Rationale:
Modified to:

Clarify reconstitution instructions for the ACE-011 Process III lyophilized product 
reconstitution.

Remove the Phase 2B/3 portion and all references to Part 1 and Part 2 of the study.

Revise the defined effective dose of sotatercept (ACE-011) due to smaller sample size.

Delete the 45mg sotatercept (ACE-011) dose level

Delete all references to the Phase 2B/3 study treatment of sotatercept (ACE-011) / 
placebo.

Revise Post-Treatment Follow-Up Period of six months to the Post-Treatment Follow-
Up/End of Treatment/End of Study Visit occuring 42 days (6 weeks) following the last 
dose of sotatercept (ACE-011).

Page 689 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
61
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
2.10.
Section 9:  Concomitant Medications And Procedures (Pages 67-68)
Revised Text:
9.1.
Permitted Concomitant Medications and Procedures
_  _  _  _  _  _  _  _  _  _  _
Erythropoiesis-stimulating agents (ESAs)
The use of an ESA is not allowed in Part 1 of the study; however, ESAs are allowed in 
Part 2 only after a subject has received at least 4 months of study treatment.the study.  The 
use of ESAs will need to result in immediate notification to the study Sponsor and Medical 
Monitor, as well as to the clinical site pharmacist, so that no further dosing with sotatercept 
(ACE-011) in that study subject will occur If treatment with ESAs is required in the opinion of 
the Investigator, the ESA label instructions are to be strictly followed.  
In Part 1, all subjectsAny subject who receive an ESA will be discontinued from the study 
Treatment Period and continue to the Post Treatment Follow-Up Period.  In Part 2, subjects who 
receive an ESA at < 4 months from their first dose of sotatercept (ACE-011) or sotatercept 
(ACE-011)/placebo will be discontinued from the study Treatment Period and continue to the 
Post Treatment Follow-Up Period.  Subjects who receive an ESA at ≥ 4 months from their first 
dose of sotatercept (ACE-011)/placebo will continue in the Treatment Period as follows:  The 
unblinded pharmacist will ensure that subjects randomized to receive treatment with 
sotatercept (ACE-011) are changed over to receive treatment with placebo.  Subjects 
randomized to treatment with placebo will continue to receive placebo.  The investigator, 
site personnel and subject will remain blinded./ End of Treatment / End of Study Visit. 
_  _  _  _  _  _  _  _  _  _  _
9.2.
Prohibited Concomitant Medications and Procedures
No concurrent treatments with any other investigational agent are allowed.  Bisphosphonate , 
therapy (other than for the treatment of hypercalcemia,), and denosumab therapy for bone 
metastases can be started prior to randomization but should not be started on study.
Rationale:
Modified to:

Remove the Phase 2B/3 portion and all references to Part 1 and Part 2 of the study.

Revise term “Post-Treatment Follow-Up Period” to “Post-Treatment Follow-Up Visit”.

Correct typographical error.
Page 690 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
62
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
2.11.
Section 10:  Statistical Analyses (Pages 69-70)
Revised Text:
10.1.
Overview
This is an open-label randomized, phase 2a, dose-ranging study of sotatercept (ACE-011) 
therapy for chemotherapy-induced anemia (CIA) in subjects with advanced or metastatic solid 
tumor types treated with platinum-based chemotherapeutic agents followed by a phase 2b/3, 
double-blind, randomized, placebo-controlled study of sotatercept (ACE-011) therapy for 
chemotherapy-induced anemia (CIA) in subjects with metastatic non-small cell lung cancer 
(NSCLC) treated with platinum-based chemotherapeutic regimens.regimens.  An IVRS will be 
utilized to ensure an equal weight central randomization based on a permuted-block 
randomization method according to stratification factors defined in Section 4.1 Study Design.  In 
Part 1, subjectsSubjects will be randomized to one of threetwo doses of sotatercept (ACE-011) 
plus platinum-based chemotherapy.  In Part 2, subjects will be randomized to placebo or the 
selected sotatercept (ACE-011) dose determined from Part 1 plus platinum-based chemotherapy.  
Data from Part 1 will not be combined with data from Part 2 in all safety and efficacy 
analyses.). 
A DMCAnalyses will be used to monitor the study conduct. exploratory.
_  _  _  _  _  _  _  _  _  _  _
10.3.
Sample Size and Power Considerations
In Part 1, upUp to 9030 subjects will be randomized among threetwo dosing groups.  This 
sample size is for the purpose of hypothesis generation.  However, it would allow approximately 
80% powerEnrollment was limited and there were no power considerations due to detect an 
effect size of 0.33 using a 2 degrees of freedom Chi-Square Test with a two-sided significance 
level (alpha) of 0.05.  
In Part 2, subjects will be enrolled in two stages.  In the first stage, approximately 180 subjects 
will be randomized in a 1:1 ratio to the selected sotatercept (ACE-011) dose group or placebo 
group.  An interim analysis of transfusion rate will be performed after these 180 subjects have 
received at least two doses of sotatercept (ACE-011)/placebo, and have been followed for at least 
4 months from randomization.  A Data Monitoring Committee will review the results and 
provide recommendations on continuing or stopping the study.  Based on the results of the 
futility analysis, further enrollment in the second stage of Part 2 of the study could be continued.  
Upon recommendation to continue the study, an additional 570 subjects will be subsequently 
randomized in the second stage.  The total sample size of 750 subjects in Part 2 (first plus 
second stage) would allow observation of at least 536 deaths and thus at least 80% power to 
exclude more than 15% hazard increase in the sotatercept (ACE-011) arm compared with the 
placebo arm at one-sided significance level of 0.025, i.e., rejecting hazard ratio 
(Placebo:sotatercept [ACE-011]) of 0.87,  assuming the sotatercept (ACE-011) arm actually 
reduces at least 10% hazard, i.e., true hazard ratio (Placebo:sotatercept [ACE-011]) of 1.11
closure.  
_  _  _  _  _  _  _  _  _  _  _
Page 691 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
63
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
10.6.
Efficacy Analysis
In Part 1, theThe primary endpoint will be the hematopoietic response is defined as an increase 
in Hgb of ≥ 1.0 g/dL above the study baseline value for 28 consecutive days, in the absence of 
RBC transfusions and/or ESAs.  The analysis will be based on the EE population.  The 
proportion of subjects with hematopoietic response will be estimated and a Chi-square test will 
be performed to compare response rates across treatment groups.  
In Part 2, the primary endpoint will be rate of RBC transfusion within 4 months following the 
date of randomization.  It will be estimated based on Kaplan-Meier method for time to the first 
RBC transfusion.  The analysis will be based on ITT population and will be conducted according 
to the approximate timeline as described in Section 10.8.  Subjects who have documented RBC 
transfusion(s) from randomization until the last dose of concomitant platinum-based 
chemotherapy plus 30 days or from the initiation date of non-platinum-based chemotherapy, 
whichever is earlier, will be considered as having the event on the date of first RBC transfusion.  
Subjects who are discontinued from study treatment due to reasons other than disease 
progression or death will be considered as having the event on the date of study treatment 
discontinuation, or the last dose date of platinum-based chemotherapy plus 30 days or the 
initiation date of non-platinum-based chemotherapy, whichever is earliest.  Subjects who 
discontinue from study treatment due to disease progression or death will be censored on the date 
of study treatment discontinuation, or the last dose date of platinum-based chemotherapy plus 30 
days or the initiation date of non-platinum-based chemotherapy, whichever is earliest.  Otherwise 
subjects will be censored on the date of last contact, or on the date of last dose of concomitant 
platinum-based chemotherapy plus 30 days or on the initiation date of non-platinum-based 
chemotherapy, whichever is earliest.  The comparison on the distribution difference between the 
treatment groups will be based on the stratified log-rank test, and the associated hazard ratio and 
95% confidence interval will be provided using Cox proportional hazard model.  The proportion 
of subjects receiving a transfusion based on Kaplan-Meier estimates at specific time points will 
also be provided by treatment arms. 
As secondary endpoints for Part 2 of the study, time to progression, progression free survival 
and overall survival will be analyzed based on the ITT population.  
Time to progression (TTP) is defined as the time between the randomization date and date of 
disease progression.  Disease progression is based on the IRC reviewed progression date.  If 
a subject dies due to reasons other than disease progression, the subject will be censored at the
death date.  If a subject does not have disease progression, then the subject will be censored at 
the last tumor assessment (prior to or on the first day of the first subsequent antitumor therapy).  
Progression free survival (PFS) is defined as the time between the randomization and disease 
progression or death.  Disease progression is based on the IRC reviewed progression date.  
Subjects who progressed or died will be considered to have had an event, except if this event 
occurs after the start of subsequent antitumor therapy, in which case the subject is censored at the 
time of last tumor assessment prior to or on the first day of the first subsequent antitumor 
therapy.  The date of progression is taken as the earliest date of:  Date of PD as evaluation of 
response, date of new lesion on tumor measurements page, death date, if death is caused by PD, 
treatment termination date if reason is PD, progression date as documented on treatment 
termination page, progression date as documented on the follow-up visit page.  Subjects who did 
not progress nor died (lost to follow-up or still being treated without documented disease 
Page 692 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
64
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
progression or started subsequent antitumor therapy) will be censored at the date of the last 
tumor assessment prior to or on the first day of the first subsequent antitumor therapy.  PFS 
based on investigators’ assessment will also be analyzed.  
Overall survival (OS) is defined as the time between the randomization and death.  A subject 
who dies, regardless of the cause of death, will be considered to have had an event.  All subjects 
who are lost to the follow-up prior to the end of the trial or who are withdrawn from the trial will 
be censored at the time of last contact.  Subjects who are still being treated will be censored at 
the last available date where the subject is known to be alive.  
For TTP, PFS and OS, Kaplan-Meier method will be used to estimate the distribution function, 
six-month and one-year survival rates, as well as the medians and 95% confidence intervals will 
be provided. The stratified log rank test will be used to compare the distributions of TTP, PFS 
and OS respectively.  The stratification factors are described in Section 4.1 .  The associated 
hazard ratios and confidence intervals will be provided using stratified Cox proportional hazard 
model respectively for each endpoint.  
Sensitivity analyses will be performed on TTP, PFS, and efficacy analyses will also be 
performed using EE population.  Data listings will be provided for all relevant data collected 
during the studies.  Further details will be included in the Statistical Analysis Plan.  
10.7.
Safety Analysis
All safety subjects will be used for safety analyses.  Sotatercept (ACE-011) exposure will be 
summarized.  Adverse events, vital sign measurements, clinical laboratory information, ECG 
interpretations, and concomitant medications will be tabulated and summarized by study part and 
treatment arm.  The incidence of AEs will be summarized by severity grade based on the NCI 
CTCAE version 4.0 (current active minor version).  Serious adverse events (SAE), deaths and 
AEs leading to dose modifications and study treatment discontinuation will be summarized.  
Safety information obtained during through the Post Treatment Follow-Up / End of Treatment / 
End of Study Visit Period during each segment will be incorporated into these analyses.  
10.8.
Interim Analysis
There are two interim analyses planned for this study.  At the first interim analysis, the 
transfusion rate result will be used for go/no go decision, and overall survival will also be 
analyzed.  At the second interim analysis, only the overall survival will be analyzed.  
The first interim analysis on transfusion rate will be conducted after the first 180 eligible subjects 
randomized in Part 2 of the study (stage 1) who have received at least two doses of sotatercept 
(ACE-011)/placebo, have been followed for at least 4 months from randomization.  This sample 
size would allow at least 90% power to detect a 15% difference between two arms (sotatercept 
[ACE-011] arm 15% vs. placebo 30%) in 4 month transfusion rates at two-sided 5% significance 
level based on the stratified log rank test and the assumption of exponential distribution for time 
to RBC transfusion.  If the p-value at the interim analysis does exceed significance level of 0.05, 
the result will be considered as lack of efficacy.  If the p-value is less than or equal to 0.05, 
additional subjects will be enrolled and the study will move on to the Part 2; however, the 
futility analysis result based on RBC transfusion rate may be up to DMC evaluation.  For 
superiority, Type I error 0.0001 will be spent at this interim for transfusion rate, and the 
remaining 0.0499 will be spent at the final analysis after 750 subjects being enrolled.  
Page 693 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
65
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Overall survival will also be analyzed at this interim, Type I error spending will be based on 
O’Brien and Fleming Boundary.  
The second interim analysis will be performed when approximately 265 deaths are observed in 
Part 2.  Type I error spending will be based on O’Brien and Fleming boundary.  
The final analysis will be performed when approximately 536 deaths are observed in Part 2.  
There will be no interim analysis. 
10.9.
Other Topics
Pharmacokinetic Analysis
Approximately 5 - 10 subjects will be enrolled for full PK sampling in each treatment cohort of 
Part 1.  For this portion of the study, subjects who miss more than two PK sampling time points 
from Days 1 through 43 will be replaced.  
Noncompartmental PK parameters for sotatercept (ACE-011), such as tmax, Cmax, AUC42, and 
t1/2,z, maywill be estimated for subjects providing full PK samples.  Dose proportionality will be 
assessed by regression analysis using the exposure data after the first dose.  Descriptive statistics 
maywill be provided for plasma concentrations and PK parameters.  
In exploratory population PK analysis, covariates to be tested may include type of chemotherapy, 
the presence of anti-sotatercept (ACE-011) antibodies, demographics (age, race, gender, and 
body weight), markers for hepatic and renal function, and other factors as deemed appropriate.  
Both full and sparse PK data will be included for population PK analyses.  
The relationship between sotatercept (ACE-011) exposure and response (hematology, 
biomarkers, and other clinical outcomes as appropriate) willmay be explored.  
10.10.
Data Monitoring Committee (DMC)

A DMC will review safety and efficacy data to ensure the protection of study 
subjects.  The DMC will receive periodic updates of all serious treatment-related 
toxicities and SAEs leading to deaths from all causes. The first planned review by the 
DMC will be conducted following the randomization and treatment of twenty 
subjects.  The DMC will continue to monitor safety on an ongoing basis including 
recommendation of sotatercept (ACE-011) dose selection for Part 2.  The first 
interim analysis will be conducted after the first 180 eligible subjects in Part 2 of the 
study (stage 1) have been followed for at least 4 months for RBC transfusion rate.  
The second interim analysis will be performed when approximately 265 deaths if 
data are observed in Part 2.  The final analysis will be performed when 
approximately 536 deaths are observed in Part 2.  
Ad hoc meetings will be scheduled as needed.  
The DMC will have a consultative role with respect to the Sponsor. The Sponsor will make the 
final decision regarding the recommendation proposed by the committee. A separate DMC 
charter will detail the activities of this committeesufficient.  
Page 694 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
66
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Rationale:
Modified to:

Revise Statistical Section to reflect changes in analyses due to decrease in the sample 
size, abbreviated follow-up period, and removal of the Phase 2B/3 portion of the study. .

Delete requirement to replace subjects in the Full PK assessment

Delete population PK model for sotatercept (ACE-011) due to smaller sample size.

Delete reference to the Data Monitoring Committee (DMC).
Page 695 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
67
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
2.12.
Section 12:  Discontinuations (Page 77)
Revised Text:
Stopping Rules
In addition to Celgene routine pharmacovigilance surveillance, a DMC will review unblinded
data on a regular basis (mainly grade 3 or 4 toxicities, SAEs and subject deaths).  Any relevant 
imbalance in toxic deaths, related SAEs or detrimental survival would be considered for study 
discontinuation.  
Rationale:
Modified to:

Delete reference to the Data Monitoring Committee (DMC).
Page 696 of 791
088VGY

Sotatercept (ACE-011)
Summary of Changes ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
68
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
2.13.
Section 13:  Emergency Procedures (Page 78)
Revised Text:
13.2.
Emergency Identification of Investigational Products
In both Part 1 and Part 2 the blind must not be broken during the course of the study unless in 
the opinion of the Investigator, it is absolutely necessary to safely treat the subject.  If it is 
medically imperative to know what IP the subject is receiving, the Investigator or authorized 
person should call IVRS for unblinded dose information, etc.  However, every effort should be 
made to contact the Clinical Research Physician/Medical Monitor prior to breaking the blind.  
Contact or attempted contact with the Clinical Research Physician/Medical Monitor as well as 
the reason for breaking the blind must be documented in the source documents.  
This is an open – label study; therefore, IP will be identified on the package labeling. 
Rationale:
Modified to:

Delete Emergency Identification of IP for blinded study.  This study is open – label. 
Page 697 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
1
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
TITLE PAGE
AN OPEN-LABEL RANDOMIZED, PHASE 2A, DOSE-RANGING 
STUDY OF SOTATERCEPT (ACE-011) FOR 
CHEMOTHERAPY-INDUCED ANEMIA IN SUBJECTS WITH 
ADVANCED OR METASTATIC SOLID TUMORS TREATED 
WITH PLATINUM-BASED CHEMOTHERAPEUTIC 
REGIMENS 
INVESTIGATIONAL PRODUCT (IP):
SOTATERCEPT (ACE-011)
PROTOCOL NUMBER:
ACE-011-NSCL-001
DATE FINAL:
17 SEPTEMBER 2010 
AMENDMENT 1.0 FINAL:
22 MARCH 2011
AMENDMENT 2.0 FINAL:
27 JUNE 2011
AMENDMENT 3.0 FINAL:
01 NOVEMBER 2011
AMENDMENT 4.0 FINAL:
02 MAY 2012
EudraCT NUMBER:
2010-022561-10
IND NUMBER:
103362
CONFIDENTIAL
This protocol is provided to you as an Investigator, potential Investigator, or consultant for review by 
you, your staff, and ethics committee/institutional review board.  The information contained in this 
document is regarded as confidential and, except to the extent necessary to obtain informed consent, 
may not be disclosed to another party unless such disclosure is required by law or regulations.  
Persons to whom the information is disclosed must be informed that the information is confidential 
and may not be further disclosed by them.
Page 698 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
2
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
MEDICAL MONITOR / EMERGENCY CONTACT INFORMATION
Contact Information:
Note:  The back-up 24 hour global emergency contact call center should only be used if you 
are not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls  
Back-up 24 Hour Global Emergency Contact Call Center: 
Page 699 of 791
PPD
PPD
088VGY

Page 700 of 791
PPD
PPD
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
4
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
SITE PRINCIPAL INVESTIGATOR SIGNATURE PAGE
Signature of Site Principal Investigator
dd mmm yyyy
Printed Name of Site Principal Investigator 
Institution Name:_______________________________________
By my signature, I agree to personally supervise the conduct of this study at my study 
site and to ensure its conduct is in compliance with the protocol, informed consent, 
Institutional Review Board (IRB)/Ethics Committee (EC) procedures, instructions from 
Celgene representatives, the Declaration of Helsinki, ICH Good Clinical Practices 
Guidelines, and local regulations governing the conduct of clinical studies.
Page 701 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
5
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
COORDINATING PRINCIPAL INVESTIGATOR SIGNATURE PAGE
Signature of Coordinating Principal Investigator
dd mmm yyyy
Printed Name of Coordinating Principal Investigator 
Institution Name:_______________________________________
By my signature, I agree the protocol has been written to comply with ICH Good 
Clinical Practices guidelines and agree to offer guidance throughout the study as 
needed.
Page 702 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
6
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
PROTOCOL SUMMARY
Study Title
An open-label randomized, phase 2a, dose-ranging study of sotatercept (ACE-011) for 
chemotherapy-induced anemia in subjects with advanced or metastatic solid tumors treated with 
platinum-based chemotherapeutic regimens.
Indication
Chemotherapy Induced Anemia (CIA) in subjects with advanced or metastatic solid tumors
treated with ≥ first–line platinum–based chemotherapy, excluding those solid tumors treated with 
curative intent.
Objectives
The exploratory objectives are:

To explore doses of sotatercept (ACE-011) that result in a hematopoietic response for
the treatment of CIA in subjects with advanced or metastatic solid tumors treated with 
platinum-based chemotherapeutic regimens, excluding those solid tumors treated with 
curative intent.  

To evaluate the safety and tolerability of sotatercept (ACE-011).

To determine the pharmacokinetics (PK) of sotatercept (ACE-011) in subjects 
receiving platinum-based chemotherapy.  

To evaluate the hematopoietic response and its duration associated with sotatercept 
(ACE-011) treatment.  

To evaluate the effect of sotatercept (ACE-011) treatment on the quality of life 
(QoL).

To estimate the effect of sotatercept (ACE-011) treatment on bone metabolism.

To evaluate the expression of Activin A and other proteins/biomarkers (including 
myostatin and follistatin) related to sotatercept (ACE-011) mechanism of action in 
blood.

To assess renal function biomarkers.
Study Design
This is an open-label, randomized, phase 2a, dose-ranging study of sotatercept (ACE-011)
therapy for CIA in subjects with advanced or metastatic solid tumors treated with platinum-based 
chemotherapeutic regimens.  
Page 703 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
7
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
The study is dose-finding in which up to approximately 30 subjects will be randomized to one of 
two sotatercept (ACE-011) dose treatment arms.  The main exploratory objective is to determine 
a dose of sotatercept (ACE-011) that results in a hematopoietic response in the treatment of CIA 
in subjects with advanced or metastatic solid tumors treated with platinum-based chemotherapy, 
excluding those solid tumors treated with curative intent.  
Study Population
At the time of randomization subjects must have an advanced or metastatic solid tumor treated 
with ≥ first–line platinum–based chemotherapy, excluding those solid tumors treated with 
curative intent.  Subjects must also:

have already received at least one cycle and up to 4 cycles (q3w schedule) of 
platinum-based chemotherapy and be randomized prior to receiving Cycle 5 
OR 

have already received at least one cycle and up to 3 months (depending upon 
regimen) of platinum-based chemotherapy 
OR

currently be receiving maintenance therapy following treatment with platinum-
based chemotherapy 
Concomitant or maintenance therapy with chemotherapeutic and/or targeted agents (e.g., 
pemetrexed, anti-EGFR agents, anti-VEGF agents), which are approved for a given tumor type, 
are allowed in addition to platinum-based chemotherapy. 
Length of Study and Study Treatments
This study will consist of the following consecutive periods:  Screening and Treatment Period, 
including a Post Treatment Follow-Up Visit.  Study treatment is defined as sotatercept (ACE-
011).
Screening Period (28 days):
Potential study subjects will sign an informed consent form prior to undergoing any study-related 
procedures.  Subjects will undergo screening for protocol eligibility within 28 days prior to
randomization, as outlined in the Table of Events, Section 5.  Note:  Screening period tumor 
assessments should be performed within six weeks or as per standard care at the study site prior 
to randomization.  Also, historical tumor assessment data, from prior to the initiation of 
platinum-based chemotherapy through the Screening Period, will be collected and used for 
assessment of tumor response.  
Prior erythropoietic stimulating agent (ESA) treatment history starting from the initial solid 
tumor diagnosis and red blood cell (RBC) transfusion history starting from diagnosis of 
advanced or metastatic disease, at a minimum of up to two months prior to randomization will be 
collected.  
Page 704 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
8
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
All females of childbearing potential (FCBP) participating in the study are to use highly effective 
methods of birth control during the Screening Period, for at least 28 days before starting the 
study.  Some highly effective methods of birth control include:

Oral contraceptives, intrauterine device, tubal ligation or a partner with a vasectomy
OR

Two forms of barrier method birth control, e.g., a latex condom PLUS a diaphragm 
with spermicide OR a latex condom PLUS a contraceptive sponge with spermicide.  
If a non-latex condom is used, it cannot be made out of natural (animal) membrane.  
Treatment Period and Post-Treatment Follow-Up / End of Treatment / End of Study Visit
(approximately 6 months):  
The Treatment Period is approximately six months and includes up to four doses of sotatercept 
(ACE-011) given on Day 1, every 42 days, followed by a Post-Treatment Follow-Up / End of 
Treatment / End of Study Visit.  
The Post-Treatment Follow-Up Visit will occur approximately 42 days (6 weeks) after the 
subjects’ last dose of sotatercept (ACE-011).  The Post-Treatment Follow-Up Visit will also 
serve as the End of Treatment / End of Study Visit. 
Subjects with advanced or metastatic solid tumor types who meet all eligibility criteria will be 
randomized to receive one of the following sotatercept (ACE-011) dose levels, with 10-15
subjects per arm:

Sotatercept (ACE-011) 15 mg SC

Sotatercept (ACE-011) 30 mg SC
Each dose level will be administered every 42 days for up to four doses.  
The effective dose of sotatercept (ACE-011) is defined as follows:
An increase in hemoglobin (Hgb) of ≥ 1.0 g/dL above the study baseline value for 4 
consecutive weeks).  
During the Treatment Period, subjects will be assessed for hematopoietic response, transfusion 
need, safety and tumor response.  The severity of AEs will be graded according to the currently 
active minor version of the National Cancer Institute Common Terminology Criteria for Adverse 
Events (NCI CTCAE) version 4.0.  
Concurrent treatment for CIA with blood transfusions is recommended when Hgb value is 
< 8 g/dL or at the discretion of the Investigator if the Hgb value is ≥8 g/dL and associated with 
anemia symptoms such as hemodynamic or pulmonary compromise requiring treatment.  If an 
RBC transfusion is given to a subject during the Treatment Period, sotatercept (ACE-011) should 
be administered > 7 days from the date of the RBC transfusion.
Blood samples will be collected to evaluate the full PK profile of sotatercept (ACE-011) from 
subjects at select centers, in approximately 5 - 10 subjects for each sotatercept (ACE-011) dose 
group investigated.  In subjects participating in the full PK assessment, RBC, Hgb, and 
reticulocyte counts will be collected at each PK time point (excluding the 4-hour time point on 
Page 705 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
9
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Day 1) from Day 1 to Day 43 after the first dose.  Subjects not participating in the optional full 
PK assessment may participate in the sparse PK assessment.  
ACE-011 (sotatercept) concentration may be determined in anti-sotatercept antibody samples to 
assist in the evaluation of immunogenicity, as well as PK, in subjects who do not participate in 
the full or sparse PK assessments. 
Subjects will be discontinued from Study Treatment due to the following:

Adverse events(s)

Hypertension ≥Grade 3 – defined as Stage 2 hypertension (systolic blood 
pressure [SBP] ≥160 mmHg or diastolic blood pressure [DBP] ≥100mmHg), 
confirmed by two measurements obtained at least five minutes apart; medical 
intervention indicated; more than one drug or more intensive therapy than 
previously used indicated or medically significant hypertension which cannot be 
adequately controlled with antihypertensive therapy. 

Any AE > Grade 2 assessed to be related to sotatercept (ACE-011) therapy.

Any persistent AE > Grade 1 considered to be related to sotatercept (ACE-011)
treatment and causing a subject to miss three months of sotatercept (ACE-011)
therapy.

Any thromboembolic event > Grade 2.

Elevated Hgb > 15.0 g/dL (sustained for a 7 day period, confirmed by laboratory 
assessment).

Urine protein / creatinine ratio > 1.0; or > 2.0 if bevacizumab (Avastin®) is 
concomitantly administered.

Persistent hematuria ≥Grade 2 - defined as symptomatic; urinary catheter or 
bladder irrigation indicated; limiting instrumental activities of daily living, and 
persisting for one week. 

Lack of sotatercept (ACE-011) therapeutic effect, defined as < 1.0 g/dL increase in 
Hgb from baseline following three dose escalations.  

Concomitant use of ESAs if administered at any time.

Sotatercept (ACE-011) dose modifications

A second Hgb increase of ≥3.0 g/dL following a two-level dose reduction due to 
a Hgb increase ≥3.0 g/dL 

Disease progression 

Withdrawal of consent

Death

Lost to follow-up

Protocol violation - as determined by the Sponsor
Page 706 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
10
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
The reason for treatment discontinuation should be recorded in the eCRF and in the source 
documents.  
Post Treatment Follow-Up Visit
The Post-Treatment Follow-Up Visit will occur approximately 42 days after the subjects’ last 
dose of sotatercept (ACE-011).  The Post-Treatment Follow-Up Visit will also serve as the End 
of Treatment / End of Study Visit. 
The following events are considered sufficient reasons for discontinuing a subject from the 
study:

Completed study, per protocol (subject has completed approximately six month
Treatment Period including a 42 day [6 week] Post-Treatment Follow-Up/End of 
Treatment/End of Study Visit).

Withdrawal of consent

Death

Lost to follow-up
The following events may be considered sufficient reasons for discontinuing a subject from the 
study, as determined by the Sponsor:

Adverse event(s)

Disease progression 

Protocol violation
Overview of Efficacy Assessments

Serum hematology, absolute reticulocyte counts

Serum iron, total iron binding capacity (TIBC), transferrin and serum ferritin

Serum erythropoietin

Tumor assessments

Documentation of concomitant RBC transfusions
Overview of Safety Assessments

Informed consent

Assessment of inclusion / exclusion criteria

Complete medical history including history of cardiac and thromboembolic events

Vital signs including height, weight, heart rate, seated systolic and diastolic blood 
pressure, and temperature.  

AE(s)

12-lead electrocardiogram (ECG)  

Medically supervised pregnancy testing
Page 707 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
11
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012

Clinical laboratory evaluations (serum chemistry, hematology, absolute reticulocyte 
count, creatinine clearance, serum iron, total iron binding capacity, transferrin and 
serum ferritin, serum erythropoietin, Vitamin B12, serum RBC folate levels, 
urinalysis, FSH, LH, dihyroepiandosterone, estrogen, estradiol, testosterone and
serum thyroid-stimulating hormone).  

QoL Assessment (FACIT Fatigue Scale [Version 4]) – all subjects

Lung Cancer Symptom Scale (LCSS) questionnaire – subjects with NSCLC 

Documentation of concomitant medications / procedures.  
Overview of Exploratory Assessments

Bone or other potential mechanistic or disease-related proteins/biomarkers 

DXA scan

Renal function biomarkers 
Page 708 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
12
TABLE OF CONTENTS
TITLE PAGE..............................................................................................................................1
PROTOCOL SUMMARY ..........................................................................................................6
1.
INTRODUCTION..................................................................................................17
2.
STUDY OBJECTIVES...........................................................................................34
2.1.
Exploratory Objectives ...........................................................................................34
3.
STUDY ENDPOINTS............................................................................................35
3.1.
Exploratory Endpoint(s)..........................................................................................35
4.
OVERALL STUDY DESIGN ................................................................................36
4.1.
Study Design ..........................................................................................................36
4.1.1.
Sotatercept (ACE-011) Dose Modification, Reduction and Escalation Rules...........39
4.2.
Study Design Rationale ..........................................................................................41
4.2.1.
Fixed Dose .............................................................................................................42
4.2.2.
Dosing Schedule.....................................................................................................42
4.2.3.
Dose Levels............................................................................................................42
4.3.
Study Duration .......................................................................................................42
5.
TABLE OF EVENTS.............................................................................................44
6.
PROCEDURES......................................................................................................51
7.
STUDY POPULATION.........................................................................................58
7.1.
Number of Subjects ................................................................................................58
7.2.
Inclusion Criteria....................................................................................................59
7.3.
Exclusion Criteria...................................................................................................60
8.
DESCRIPTION OF STUDY TREATMENTS........................................................63
8.1.
Description of Investigational Product(s)................................................................63
8.2.
Treatment Administration and Schedule .................................................................63
8.2.1.
Selection of Dose for the Study...............................................................................64
8.2.2.
Selection and Timing of Dosing for Each Subject ...................................................64
8.2.3.
Discontinuation ......................................................................................................65
8.3.
Method of Treatment Assignment...........................................................................66
8.4.
Packaging and Labeling..........................................................................................66
8.5.
Investigational Product Accountability And Disposal .............................................67
8.6.
Investigational Product Compliance........................................................................67
Page 709 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
13
9.
CONCOMITANT MEDICATIONS AND PROCEDURES....................................68
9.1.
Permitted Concomitant Medications and Procedures...............................................68
9.2.
Prohibited Concomitant Medications and Procedures..............................................69
9.3.
Required Concomitant Medications and Procedures................................................69
10.
STATISTICAL ANALYSES..................................................................................70
10.1.
Overview................................................................................................................70
10.2.
Study Population Definitions ..................................................................................70
10.3.
Sample Size and Power Considerations...................................................................70
10.4.
Background and Demographic Characteristics........................................................70
10.5.
Subject Disposition.................................................................................................70
10.6.
Efficacy Analysis....................................................................................................70
10.7.
Safety Analysis.......................................................................................................71
10.8.
Interim Analysis .....................................................................................................71
10.9.
Other Topics...........................................................................................................71
11.
ADVERSE EVENTS..............................................................................................72
11.1.
Monitoring, Recording and Reporting of Adverse Events .......................................72
11.2.
Evaluation of Adverse Events.................................................................................72
11.2.1.
Seriousness.............................................................................................................72
11.2.2.
Severity / Intensity..................................................................................................73
11.2.3.
Causality ................................................................................................................74
11.2.4.
Duration .................................................................................................................74
11.2.5.
Action Taken..........................................................................................................75
11.2.6.
Outcome.................................................................................................................75
11.3.
Abnormal Laboratory Values..................................................................................75
11.4.
Pregnancy...............................................................................................................75
11.4.1.
Females of Childbearing Potential ..........................................................................75
11.4.2.
Male Subjects.........................................................................................................76
11.5.
Immediate Reporting of Serious Adverse Events ....................................................76
11.6.
Safety Queries ........................................................................................................76
11.7.
Expedited Reporting of Adverse Events..................................................................76
12.
DISCONTINUATIONS .........................................................................................78
13.
EMERGENCY PROCEDURES.............................................................................79
13.1.
Emergency Contact.................................................................................................79
Page 710 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
14
13.2.
Emergency Identification of Investigational Products .............................................79
14.
REGULATORY CONSIDERATIONS...................................................................80
14.1.
Good Clinical Practice............................................................................................80
14.2.
Investigator Responsibilities ...................................................................................80
14.3.
Subject Information and Informed Consent.............................................................80
14.4.
Confidentiality........................................................................................................81
14.5.
Protocol Amendments.............................................................................................81
14.6.
Institutional Review Board/Independent Ethics Committee Review and 
Approval ................................................................................................................81
14.7.
Ongoing Information for Institutional Review Board / Ethics Committee................82
14.8.
Closure of the Study ...............................................................................................82
15.
DATA HANDLING AND RECORDKEEPING.....................................................83
15.1.
Data/Documents .....................................................................................................83
15.2.
Data Management...................................................................................................83
15.3.
Record Retention....................................................................................................83
16.
QUALITY CONTROL AND QUALITY ASSURANCE........................................85
16.1.
Study Monitoring and Source Data Verification......................................................85
16.2.
Audits and Inspections............................................................................................85
17.
PUBLICATIONS ...................................................................................................86
18.
REFERENCES.......................................................................................................87
19.
APPENDICES........................................................................................................90
Appendix A:  Response Evaluation Criteria in Solid Tumors.....................................................90
Appendix B:  ECOG Performance Status Scale .........................................................................92
Appendix C:  National Cancer Institute (NCI) Common Terminology Criteria for 
Adverse Events (CTCAE) Version 4.0....................................................................93
Appendix D:  New York Heart Association - Classification of Heart Failure.............................94
Page 711 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
15
LIST OF TABLES
Table 1:
A011-02:  A Phase 1b Study in Healthy Postmenopausal Women, 
Hemoglobin Evaluation ..........................................................................................26
Table 2:
Summary of Adverse Events Reported in Greater Than or Equal To 5 
Percent of Patients Overall......................................................................................29
Table 3:
Summary of SAEs Reported...................................................................................30
Table 4:
Number of Subjects with an Increase in Hgb from Baseline at Any Time and 
Sustained for Greater Than or Equal To 28 Days ....................................................30
Table 5:
Sotatercept (ACE-011) Dose Reduction Levels.......................................................40
Table 6:
Sotatercept (ACE-011) Dose Escalation Levels ......................................................41
Table 7:
Sotatercept (ACE-011) Schedule of Assessments....................................................44
Table 8:
Schedule of Pharmacokinetic Assessments .............................................................50
Table 9:
ECOG Performance Status Scale ............................................................................92
Table 10:
Classification of Heart Failure ................................................................................94
Page 712 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
16
LIST OF FIGURES
Figure 1:
Study Design ..........................................................................................................38
Page 713 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
17
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
1.
INTRODUCTION
This is an open-label, randomized, phase 2a, dose-ranging study of sotatercept (ACE-011)
therapy for chemotherapy-induced anemia (CIA) in subjects with advanced or metastatic solid 
tumors treated with platinum-based chemotherapeutic regimens.  
Safety data will be continuously monitored by the sponsor.  
Sotatercept (ACE-011) (ActRIIA-IgG1Fc) is a recombinant human fusion protein consisting of 
the extracellular domain (ECD) of activin receptor IIA (ActRIIA) linked to the human IgG1 Fc 
domain, which includes the heavy chain hinge and constant domains, CH2 and CH3.  
The chemical structure of sotatercept (ACE-011) is composed of a disulfide-linked, glycosylated, 
homodimeric protein.  Sotatercept (ACE-011) competes with the activin receptor IIA and binds a 
number of TGF-β superfamily ligands including activin, GDF-11, BMP-10, GDF-3 and 
myostatin (growth differentiation factor [GDF]-8).  
In both a single and a multiple dose phase 1 study of sotatercept (ACE-011) in healthy volunteer, 
postmenopausal women, a dose and time dependent increase in hemoglobin (Hgb) and 
hematocrit (HCT), and red blood cell (RBC) levels were observed following sotatercept 
(ACE-011) treatment and remained elevated over the course of study.  
Although the mechanism(s) underlying the stimulation effect of sotatercept (ACE-011) on 
erythropoiesis are not yet fully understood, the result of clinical experience showed a rapid and 
sustainable increase in mature erythrocytes released into circulation.  The sotatercept (ACE-011) 
proposed mechanism of action may be different than that of known erythropoiesis-stimulating 
agents (ESAs) and may provide a different clinical profile in the treatment of CIA.  
This study will provide information on the pharmacodynamic properties regarding the ability of 
sotatercept (ACE-011) to increase Hgb in subjects with CIA.  
Chemotherapy-Induced Anemia
Chemotherapy-induced anemia (CIA) is an area of unmet medical need.  It is a significant 
problem for patients with cancer, causing fatigue and reducing quality of life (QoL).  
Patients with cancer receiving multi-cycle chemotherapy are frequently anemic.  The etiology of 
CIA is multifactorial, resulting from the myelosuppressive effects of chemotherapy and the 
decrease in the production of the bone-marrow-stimulating hormone erythropoietin due to 
repeated cycles of chemotherapy (Vansteenkiste, 2002).  The incidence and severity of 
chemotherapy-induced anemia (CIA) is further dependent on a variety of factors, such as the 
type, schedule, and intensity of chemotherapy administered, and whether the patient has received 
prior myelosuppressive chemotherapy and/or radiation therapy (Groopman, 1999).  Platinum-
based treatments (eg, cisplatin and carboplatin), commonly used in lung, ovarian, and head and 
neck cancers, are well known to induce anemia due to combined bone marrow and kidney 
toxicity.  Antimicrotubular agents (eg, taxanes and vinorelbine) and camptothecins (eg, 
irinotecan and topotecan) are also considered particularly myelosuppressive (Groopman, 1999).  
Dose intensity, the increasingly widespread practice of administering higher doses of 
chemotherapy over a shorter period of time, is also associated with an increased risk of 
myelosuppression.
Page 714 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
18
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
The association between uncorrected anemia before or during chemotherapy and poorer patients’ 
outcomes has been reported in several studies (Grogan, 1999; Laurie, 2006; MacRae, 2002; 
Obermair, 2003).  Anemia can lead to a multitude of symptoms (eg, fatigue, tachycardia, 
cognitive impairment, shortness of breath, depression, and dizziness) and may also have an 
adverse impact on co-morbid conditions, such as cardiac and pulmonary disease.  The most 
common patient complaints are dyspnea on exertion and chronic fatigue, which may interfere 
with a patient’s ability to perform normal daily activities (Groopman, 1999).  A key 
differentiating characteristic of cancer-related fatigue versus fatigue in healthy individuals is its 
likelihood of persistence at rest (National Comprehensive Cancer Network, 2008)  In various 
published surveys, fatigue has been represented as a symptom that has affected patients’ 
everyday life the most and has been linked to changes in employment status among patients and 
even caregivers (Schwartz, 2007).  The association between Hgb levels and fatigue is well 
documented, with one analysis of 5 randomized trials linking an increase in Hgb concentrations 
of at least 2 g/dL with an improvement in fatigue, and consequently, in energy, ability to perform 
usual activities, and overall health (Cella, 2004).
In looking at the impact of CIA on survival, a meta-analysis of 60 clinical studies found a 65% 
increase in the risk of death and a shortened survival time among patients with cancer and 
anemia compared with patients without anemia (Carlos, 2001). The increased relative risk of 
death was particularly evident in patients with head and neck cancer (75%), a finding that also is
supported by other retrospective studies.  Tumor hypoxia, resulting from the reduced oxygen-
carrying capacity of blood in patients with anemia, has been hypothesized to be a major 
contributor to reduced survival.  Several studies have shown that tumor hypoxia also reduces the 
effectiveness of radiotherapy and chemotherapy, and is associated with tumor progression 
(Aapro, 2006).
Treatment of Chemotherapy-Induced Anemia
The current treatment options for CIA include blood transfusion and erythropoiesis-stimulating 
agents (ESAs).  However, blood transfusion involves the risk of complications (such as potential 
transmission of infectious disease, alloimmunization, allergic reactions, hemolytic reactions, iron 
and circulatory overload, and possible immunosuppression) for the patient, and donor blood is a 
limited resource.  The practice of offering blood transfusions to cancer patients receiving
chemotherapy has therefore been rather restricted, generally reserved for emergencies, and 
severely anemic patients with serious symptoms.  
Erythropoiesis-stimulating agents have been approved for treating CIA.  However, the past five 
years has seen a major change in the use of ESAs for cancer related and chemotherapy induced 
anemia.  Clinical studies have demonstrated that ESAs can successfully mitigate transfusion 
need in a proportion of these patients; however, new concerns have emerged regarding apparent 
negative effects on survival and/or tumor progression in certain patient populations.  
Retrospective statistical analysis in one study in head and neck cancer patients, and two studies 
with adjuvant breast cancer revealed substantial safety concerns of increased thromboembolic 
events, and decreased PFS and overall survival.  
Sotatercept (ACE-011) Treatment of Chemotherapy-Induced Anemia
Treatment with sotatercept (ACE-011) resulted in increased HCT, Hgb and absolute red cell 
number in both nonclinical and clinical studies.  The rapid and sustained increases in Hgb and 
Page 715 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
19
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
HCT levels were observed in two phase 1 studies in healthy volunteers, as well as in a phase 2a 
study in multiple myeloma (MM) subjects.  The ability for sotatercept (ACE-011) to rapidly 
increase and sustain Hgb levels in anemic subjects supports the clinical development of ACE-
011 for the treatment of CIA.  
In a phase 1 single-dose and multiple-dose studies of sotatercept in postmenopausal women 
(Studies A011-01 and A011-02, respectively), and in a phase 2 study in subjects with osteolytic 
lesions associated with MM that examined concurrent administration of sotatercept with 
melphalan, prednisolone, and thalidomide (MPT) anti-myeloma therapy, increases in Hgb, RBC 
count and HCT were observed following sotatercept treatment, and these increases remained 
detectable throughout the course of study.  The observed Hgb, RBC count, and HCT effects of 
sotatercept were dose-dependent and time-dependent.  These phase 1 and phase 2 clinical data 
are consistent with the increased hematologic parameters observed in nonclinical studies, The 
results from the three completed clinical studies A011-01, A011-02, and A011-04 are 
summarized in Summary of Clinical Experience.  
The mechanism of action of sotatercept with regards to increased RBC counts is not known; 
however, the mechanism of action for the hematopoietic effect of sotatercept may be different 
than that of ESAs, as some level of erythrocyte stimulatory effect was observed in the presence 
of anti-EPO antibodies in one nonclinical study.  As such, sotatercept may provide a unique 
clinical profile with a favorable benefit-risk profile in the chemotherapy-induced anemia patient 
population, thereby addressing some of the unmet medical needs in chemotherapy-induced 
anemia treatment.
Non-Small Cell Lung Cancer Current Therapy Status
Lung cancer is the leading cause of cancer death in the world, accounting for 32% of cancer 
deaths in males and 25% in females, affecting approximately 171,000 people annually in the US 
(Parker, 1997; Sandler, 2006) and more than 200,000 people in Europe (Rossi, 2006).  Of these 
patients, approximately 85% have NSCLC, including squamous carcinoma, adenocarcinoma and 
large cell carcinoma (Rossi, 2006; Sandler, 2006).  These histologies are typically classified 
together because the approaches to diagnosis, staging and prognosis, and treatment are similar.  
Patients are often diagnosed with an advanced stage of disease.  Studies of advanced NSCLC 
patients treated with platinum-based chemotherapy report a one year survival rate that ranges 
from 30% to 43% and a median survival that ranges from seven to ten months (Dang, 2008).  
The 5-year survival rate of patients with NSCLC varies by stage, from 60% to 70% for patients 
with stage I disease to < 1% for patients with stage IV disease (Hong, 2008).  Patients having 
stage IIIb/IV NSCLC are not considered to be candidates for curative resection surgery or 
radiation, and radiation therapy is primarily used as palliative treatment in advanced stages of 
NSCLC.  
The role of chemotherapy is now well established as the recommended treatment of advanced 
NSCLC (Non-small Cell Lung Cancer Collaborative Group, 1995).  The current globally 
accepted standard of treatment for NSCLC is platinum-based combination therapy.  In advanced-
stage (stage IIB or IV) NSCLC, doublet combinations of platinum compounds (cisplatin or 
carboplatin) with gemcitabine (Gemzar®), vinorelbine, taxanes (paclitaxel or docetaxel) or 
pemetrexed are reference regimens.  When compared head-to-head in phase 3 studies, these 
doublets have shown comparable efficacy, in regards to overall survival (Schiller, 2002) with 
Page 716 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
20
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
differences in toxicity profiles (Schiller, 2002).  When administered in a 3-week schedule, 
cisplatin plus gemcitabine, or cisplatin plus pemetrexed are effective and are widely used 
regimens for first-line treatment of NSCLC.  A recent phase 3 study in NSCLC compared 
cisplatin plus gemcitabine with cisplatin plus pemetrexed (Scagliotti, 2008).  Both had similar 
efficacy, with cisplatin plus pemetrexed having better tolerability and more convenient 
administration than cisplatin/gemcitabine.  This study was also the first prospective phase 3
study in NSCLC to show a survival difference based on histologic type (non-squamous benefited 
from pemetrexed plus cisplatin).  Drug-related grade (G) 3 or 4 anemia was at the rate of 6% for 
cisplatin/pemetrexed versus 10% for cisplatin/gemcitabine.  The incidence of RBC transfusion 
was 16.1% versus 27.3% and administration of erythropoietic agents 10.4% versus 18.1% 
respectively.  There was no significant difference between treatment arms in the incidence of or 
reason for deaths (7%).  
In the pivotal Aranesp (darbepoetin alfa) study for CIA in NSCLC, 27 % of patients were 
transfused with packed red blood cells (PRBC’s) at 4 months versus 52% in the placebo arm.  
Activin Biology
The activins (A-E) are a group of proteins that form dimers and heterodimers.  All are part of the 
TGF-β protein superfamily.  The first described activin, Activin A was initially identified as a 
gonadal differentiation factor involved in modulating follicle stimulating hormone (FSH) 
secretion from the pituitary (Ying, 1988).  Subsequently, the pleiotropic nature of Activin A has 
become more apparent (Woodruff, 1998).  There is a growing body of data suggesting a role for 
activins in bone remodeling, specifically as a negative regulator of bone growth (Perrien, 2007).  
Before the two molecules were shown to be identical (Rivier, 1985), Activin A was also initially 
described as erythroid differentiation factor (EDF), effecting the maturation and differentiation 
of RBCs (Murata, 1988).  The mechanism(s) by which Activin A influences erythropoiesis 
remains under investigation and, in fact, there are data from in vitro and in vivo studies that 
support erythropoiesis-stimulatory (Shiozaki, 1992; Shiozaki, 1989) and erythropoiesis-
inhibitory effects (Nakao, 1991).  
At the cellular level, the activins bind initially to the high-affinity Type II receptor (ActRIIA).  
The ligand-bound ActRIIA then recruits the low-affinity Type I receptor (ActRIA or ALK-4).  
The receptor heterocomplex, through its cytoplasmic protein kinase activity, then activates the 
Smad signal cascade to eventually influence nuclear transcriptional factors (Chen, 2002; 
Mathews, 1994).  The competitive binding of activins in the blood by the sotatercept (ACE-011)
soluble fusion protein can result in inhibition of the ActRIIA receptor signaling pathway by 
impeding biological processes attributed to these pleiotropic proteins.  
The activin signaling pathway has been shown to induce terminal erythroid differentiation in 
some preclinical models.  Inhibition of activin may indirectly lead to increases in proliferation or 
differentiation of the erythroid lineage.  Based on its pharmacologic effects, sotatercept (ACE-
011) is being developed for the treatment of anemia associated with a variety of disorders, such 
as in chronic renal failure and CIA.  
In a retrospective study (Seder, 2009) activin immunoreactivity was found in 78% of lung 
adenocarcinomas surveyed (n=164).  Expression ranged from moderate in the majority of 
individuals to high in approximately 19.7% of samples evaluated.  Gene expression analysis was 
also used to measure activin mRNA in 86 lung adenocarcinomas and 10 normal lung samples.  
Page 717 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
21
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
An average of three-fold more activin transcript was detected in diseased tissue relative to 
normal samples and particularly high levels of overexpression were associated with worse 
overall survival in stage I patients with NSCLC.  
Additionally, in the NIH “directors challenge” study for NSCLC adenocarcinoma (Shedden, 
2008), 3 of the 12 molecular subgroups, including the subgroup with the worst survival 
prognosis, demonstrated overexpression of Activin A. Thus, overexpression of activin may play 
a role in NSCLC tumor progression.  
Sotatercept (ACE-011)
Sotatercept (ACE-011) (ActRIIA-IgG1Fc) is a recombinant human fusion protein consisting of 
the extracellular domain (ECD) of activin receptor IIA (ActRIIA) linked to the human IgG1 Fc 
domain, which includes the heavy chain hinge and constant domains, CH2 and CH3.  The ECD
sequence of ActRIIA is completely conserved among numerous species including mouse, rat, 
cynomolgus monkey and humans, thus mouse, rat and cynomolgus monkeys have been 
considered relevant species for nonclinical evaluation of sotatercept (ACE-011).  However, in 
order to reduce the potential immunogenicity of the human molecule, sotatercept (ACE-011), 
and to maximize the opportunity to maintain exposures in chronic models, a murine surrogate 
molecule was constructed by exchanging the human immunoglobulin Fc sequence portion of 
sotatercept (ACE-011) with its murine IgG2a homolog.  The resultant construct is referred to as 
RAP-011 (ActRIIA-mIgG2aFc), and is described in the pharmacology studies below.  Both 
ACE-011 and RAP-011 bind with high affinity to activin A/B, GDF-11 and, with slightly lower 
affinity, to BMP-10.
Pharmacology Studies
RAP-011 was evaluated in a broad range of animal pharmacology studies to assess the effects of 
inhibition of Activin A on the biological processes attributed to that regulatory protein.  RAP-
011 has been shown to have significant effects on the red cell compartment.  RAP-011 treatment 
of mice at 10, 30 and 50 mg/kg by intraperitoneal injection (IP) twice per week for 3 months 
resulted in a 16-26% increase in RBC counts compared to control animals.  Rats treated with 
sotatercept (ACE-011) at 0.3, 3 and 30 mg/kg once per week for 3 months showed RBC count 
increases of 6-15% over control animals.  Finally, in cynomolgus monkeys treated with 10, 30 or 
50 mg/kg of sotatercept (ACE-011) twice per month for 3 months, there was a 21-24% increase 
in RBC counts compared to control animals.  In this study, the RBC count increase was apparent 
as early as 2 weeks following the initial dose of sotatercept (ACE-011).  
RAP-011 administered at 10 mg/kg to mice three days prior to administration of paclitaxel at 30 
mg/kg was sufficient to prevent decreases in RBC parameters typically seen three days later.  
Mice receiving paclitaxel alone had decreased HCT levels from 43% to 38% three days 
following treatment.  RAP-011 administered three days prior to paclitaxel injection was 
sufficient to keep the HCT levels above 42% at three days and up to two weeks following 
paclitaxel administration.  Therefore, prophylactic treatment with RAP-011 was able to prevent 
paclitaxel-induced anemia in mice.  
RAP-011 has also been shown to significantly increase bone mineral density (BMD) and 
strength in normal animals and in a variety of animal models of bone loss (Chantry, 2010; 
Lotinun, 2008; Pearsall, 2008).  In a murine ovariectomy (OVX)-induced model of osteopenia, 
RAP-011 (10 mg/kg intravenous [IV], twice per week x 12 weeks) increased trabecular BMD > 
Page 718 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
22
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
25% in 6-12 weeks compared to the phosphate buffered saline (PBS)-treated controls (p<0.002).  
RAP-011 treatment was able to reverse the accelerated bone loss associated with ovariectomy.  
As expected, sham-operated (SHAM) mice (i.e., intact ovaries) started the study with a greater 
trabecular BMD than OVX mice.  PBS-treated SHAM mice showed a 10% decrease in 
trabecular BMD after 12 weeks of treatment compared to baseline, while SHAM-RAP-011 mice 
had a 32% increase in trabecular BMD over the same period.  These data demonstrate that RAP-
011 is able to increase trabecular BMD in both the normal state and in a model of established 
bone loss.  The femurs of both the RAP-011 treated OVX and SHAM mice showed statistically 
significant increases in all measured parameters of bone strength (i.e., maximum load, stiffness, 
energy, ultimate strength, and elastic modulus).  In summary, treatment with RAP-011 produced 
bone of superior quality consistent with an anabolic agent.  
RAP-011 was evaluated in a mouse model of skeletal metastasis using luciferase-tagged, human 
MDA-MB-231 breast cancer cells (estrogen receptor negative).  Mice were pretreated for 2 
weeks with RAP-011 (10 mg/kg, biweekly, subcutaneous [SC]) prior to intracardiac injection of 
tumor cells.  Treatment with RAP-011 was continued for an additional 5 weeks following tumor 
implantation.  A parallel study was conducted to examine the effect of RAP-011 treatment, as 
described above, on survival of MDA-MB-231 bearing mice.  
The data suggest that RAP-011 treatment may decrease the incidence of MDA-MB-231 
metastasis to bone and may also play a role in inhibiting tumor growth in the bone marrow 
environment.  Furthermore, in the presence of tumor cells, RAP-011 is able to prevent lytic 
disease through an anabolic mechanism of bone formation.  Lastly, treatment with RAP-011 
resulted in an approximately 25% survival benefit in this model.  
RAP-011 was also evaluated in osteolytic bone disease of multiple myeloma.  Multiple myeloma 
is associated with the development of bone disease characterised by increased osteoclast activity 
and a suppression of osteoblastic bone formation.  
Results obtained in the 5T2MM murine model demonstrated that RAP-011 could prevent the 
development of osteolytic bone disease in a preventative setting.  
5T2MM cells promoted the development of osteolytic bone lesions (p<0.001), a reduction in 
trabecular volume (p<0.001) and cortical volume (p<0.005).  RAP-011 completely prevented 
5T2MM-induced decreases in trabecular volume and number in both tibia (p<0.001 and p<0.01), 
femur (p<0.001 and p<0.001) and vertebrae (p<0.01 and p<0.01) when compared to vehicle 
treated mice.  Bone volume was 19% higher in the tibia, 35% higher in the femur and 12% 
higher in vertebrae of RAP-011 treated mice than naïve non-tumour bearing mice.  
This study showed that, in the preclinical murine model for myeloma, RAP-011 stimulates bone 
formation by increasing osteoblast perimeter and number, mineralisation and bone formation rate 
but had no effect on osteoclast activity.  RAP-011 also appeared to inhibit tumor growth as 
demonstrated by decreased serum M protein, indicative of decreased tumor burden.  
The efficacy of RAP-011 was also examined in two orthotopic metastatic models of breast 
cancer using luciferase-tagged human MCF-7 and MDA-MB-231 breast cancer cells (estrogen 
receptor positive and negative, respectively).  Mice were pretreated for 2 weeks with RAP-011 
(10 mg/kg, biweekly, SC) prior to the intra-cardiac implantation of tumor cells into female nude 
mice.  Treatment with RAP-011 was continued for an additional 7 weeks following tumor 
implantation at which time mice were sacrificed and assessed for tumor burden.  RAP-011 either 
Page 719 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
23
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
modestly decreased the tumor burden (in the case of mice bearing MCF-7 tumors) or delayed 
tumor growth by approximately 3 weeks (MDA-MB-231 model) as measured by bio-
luminescence.  
The ability of RAP-011 to repair osteolytic lesions caused by metastatic disease was investigated 
in mice.  In this model, MDA-MB-231-Luc cells were intratibially implanted in athymic nude 
mice to mimic bone metastasis.  Mice were treated with a chemotherapy regimen of paclitaxel 
(20 mg/kg, IP, every three days) starting seven days after tumor injection and continuing for the 
duration of the study.  On study day 42, mice with detectable but minimal tumor burden, as 
measured by bioluminescent imaging, were divided into two groups and treated with either 
RAP-011 (10 mg/kg, SC, biweekly) or vehicle.  Prior to dosing, μCT scans of the tumor bearing 
tibia were conducted to identify osteolytic lesions.  RAP-011 treatment continued for four weeks 
(to study day 70) and a final μCT scan of the tibia was performed.  On study day 70 there was a 
trend toward decreased number and size of osteolytic lesions in RAP-011-treated mice compared 
to control animals.  While osteolytic disease (most likely related to tumor burden) did progress in 
some of the treated mice, the majority of mice treated receiving RAP-011 developed less severe 
or no bone lesions compared to the untreated group.  Finally, treated animals also demonstrated 
an increased HCT, confirming the ability of RAP-011 to prevent CIA.  To summarize, treatment 
with RAP-011 has the ability to inhibit osteolytic lesions caused by tumors and to build new 
bone after cytotoxic chemotherapy with paclitaxel.  
Toxicology
Sotatercept (ACE-011) has been evaluated for toxicological effects in two species, Sprague-
Dawley rats and cynomolgus monkeys.  The dose levels ranged from 0.3 to 30 mg/kg in rats and 
from 1 to 50 mg/kg in monkeys.  These dose ranges were designed to support phase 1a single-
dose levels of 0.01 to 3.0 mg/kg IV and phase 1b multiple doses of 0.1 to 2 mg/kg (monthly, 
SC).  Weekly (rat and IV monkey studies) or every 2 week (SC monkey studies) dosing in 
animals was designed to provide continuous, but fluctuating serum concentrations of sotatercept 
(ACE-011), which would be mimicked by a one-month dosing interval in humans.  
Test article related hematological (increase in RBC parameters) and reproductive (epididymal 
granulomas, testicular degeneration, decreased sperm counts and motility, and change in 
ovarian/uterine weights) findings were expected pharmacodynamic effects of ActRIIA signal 
inhibition, likely mediated via modulation of erythropoiesis and FSH secretion, respectively.  
Unique to rats were adrenocortical and pancreatic findings.  Neither finding was associated with 
any clinical signs of adrenocortical (anorexia, weakness, gastrointestinal disturbances, serum 
electrolyte disturbances) or pancreatic (abnormal stool, weight loss) insufficiency.  Kidney 
findings include membranoproliferative glomerulonephritis and/or tubulointerstitial nephritis in 
rats and monkeys.  The glomerulonephritis was presumed to be due to anti-sotatercept (ACE-
011) antibody deposition in the kidneys.  This presumption is supported by a robust anti-drug
antibody response observed in rats as well as demonstration, by immunohistochemistry, of
immunoglobulin and complement at the site of injury in monkeys, consistent with immune
complex deposition.  However, high plasma concentrations of sotatercept (ACE-011) in
monkeys likely interfered with the immunogenicity assay, so the true incidence of anti-drug
antibodies is unknown in this species.
The no-observed-adverse effects levels (NOAELs) in rats and monkeys were 3 (3-month study) 
and 1 mg/kg (9-month study), respectively. 
Page 720 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
24
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Summary of Clinical Experience
A011-01:  A Phase 1a Study in Healthy Postmenopausal Women (Single Dose)
Sotatercept (ACE-011) was first studied in a randomized, phase 1a, single dose, dose escalation 
study in healthy, postmenopausal females (Ruckle, 2009).  Sotatercept (ACE-011) was diluted in 
normal saline administered as an IV infusion (over approximately 1 hour) or as a SC injection on 
Day 1.  Dose levels were 0.01, 0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg IV and 0.03 and 0.1 mg/kg SC.  
A total of 48 subjects were enrolled; 5 active and 1 placebo at each of the IV and SC dose levels.  
All subjects were followed for 4 months following a single dose administration.  
The pharmacokinetics (PK) of sotatercept (ACE-011) was linear.  The overall mean exposure 
(AUC) was proportional to doses (0.01-3 mg/kg IV, 0.03-0.1 mg/kg SC).  Across IV doses 
ranging from 0.1 through 3.0 mg/kg, the mean clearance (CL) ranged from 0.092 to 0.128 
mL/h/kg, the volume of distribution ranged from 73.7 to 110 mL/kg, and the mean terminal half 
life in serum (t1/2, z) ranged from 23.7 to 31.8 days, with no apparent dependence on dose.  After 
SC administration of 0.03 and 0.1 mg/kg, sotatercept (ACE-011) was completely absorbed, and 
the mean t1/2, z was approximately 30 days, with no apparent dependence on dose.  
The most commonly occurring treatment-emergent adverse events (AEs; i.e., those occurring in 
more than 1 subject in any treatment group) were headache, infusion site reaction, injection site 
hemorrhage, and toothache.  The majority of the injection site reactions and injection site 
hemorrhages were in the first IV cohort and were related to infiltration of the IV site.  The 
majorities of treatment-emergent AEs was mild in severity and were judged to be unrelated to 
sotatercept (ACE-011).  No deaths, serious AEs (SAEs), or AEs leading to discontinuation were 
reported.  Changes in RBCs, Hgb, reticulocytes, liver function tests, glucose, uric acid, amylase 
and lipase occurred in some subjects.  Mild, transient elevations in pancreas enzymes, liver 
enzymes, or glucose were reported as AEs in five subjects.  
There were no clinically significant changes from baseline in vital signs, physical examination, 
endocrine function, or electrocardiogram (ECG) data.  Preservation of adrenal cortical function 
was monitored through evaluation of serum electrolytes (sodium and potassium levels) and 
through cortisol response to adrenocorticotropic hormone (ACTH) stimulation.  
No clinically significant findings were observed at doses up to 3.0 mg/kg IV, and sotatercept 
(ACE-011) was well tolerated in healthy, postmenopausal female volunteers in single dose levels 
up to 0.1 mg/kg SC and 3.0 mg/kg IV, the highest dose levels tested in this study.  
A011-02:  A Phase 1b Study in Healthy Postmenopausal Women (Multiple Dose)
Sotatercept (ACE-011) was studied in a phase 1b, single-center, randomized, double-blind, 
placebo-controlled, multi-dose, dose-escalating study to evaluate the safety, tolerability and 
pharmacodynamics of sotatercept (ACE-011) in healthy postmenopausal women.  Four cohorts 
of 10 subjects each were planned at the following dose levels:  0.1, 0.3, 1.0, and 2.0 mg/kg 
administered SC.  Within each cohort, subjects were to be randomized to either active or placebo 
treatment in an 8:2 ratio.  Subjects were to receive one SC injection of sotatercept (ACE-011) or 
placebo every 28 days for a total of 4 doses.  All subjects were to be followed for 12 weeks after 
the last dose.  
The treatment phase of the study was terminated early after a dose-limiting pharmacodynamic 
effect was observed.  While on study, one subject in the 1.0 mg/kg cohort experienced an SAE of 
Page 721 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
25
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
progressive and persistent hypertension that was attributed to a rapid and significant rise in Hgb
levels, up to 20 g/dL and HCT levels, up to 57.3%.  Due to symptoms of headaches, nausea, eye 
pain, dizziness and vomiting approximately one week following the second dose, the subject was 
hospitalized for monitoring and evaluation of her hypertension.  The head MRI, fundoscopy, and 
ECG performed were reported as normal and headache symptoms resolved following corrective 
treatment by phlebotomy.  The SAE resolved and the subject was discharged from the hospital 
the following day.  The hypertension was monitored closely and managed initially with 
antihypertensive medication.  The hypertension resolved by the end of the study without need of 
any antihypertensive medication.  The subject received aspirin prophylactically until the end of 
the study and continued taking ibuprofen as needed for headaches.  Further details can be found 
in the Investigator’s Brochure.  
Based on the magnitude of the hematopoietic response, the Sponsor suspended dose escalation to 
the 2.0 mg/kg dose level and further dosing in all cohorts as a result of this dose-limiting 
pharmacodynamic effect at the 1.0 mg/kg dose level.  In total, 31 subjects were enrolled and 
treated.  Dose levels of sotatercept (ACE-011) administered included 0.1, 0.3, and 1.0 mg/kg 
(Cohorts 1, 2, and 3 respectively).  All subjects randomized to active treatment in Cohort 1 
received all 4 planned doses of sotatercept (ACE-011).  Due to early discontinuation of study 
drug, subjects randomized to active treatment in Cohort 2 received 3 doses of sotatercept (ACE-
011), and subjects randomized to active treatment in Cohort 3 received 2 doses of sotatercept 
(ACE-011).  Subjects randomized to placebo treatment received between 1 and 4 doses of study 
treatment.  
Page 722 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
26
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
In the analysis of the data, after the administration of the first dose, a dose and time dependent 
increase in Hgb, HCT, and RBC values were observed (see Table 1 below for changes in Hgb 
levels):
Table 1:
A011-02:  A Phase 1b Study in Healthy Postmenopausal Women, 
Hemoglobin Evaluation
Evaluation Time Point
Mean Change from Baseline (g/dL)
Placebo
N=7a
Sotatercept 
(ACE-011)
0.1 mg/kg
N=8
Sotatercept 
(ACE-011)
0.3 mg/kg
N=8
Sotatercept 
(ACE-011)
1.0 mg/kg
N=8
Baseline Mean, pre-Dose 1
13.20
13.11
13.30
12.71
Day 8
0.17
0.68
0.85
1.21
Day 15
-0.27
0.43
0.44
1.75
Day 29
0.27
0.61
1.21
2.68b
Day 36
0.56
0.64
1.89
2.96
Day 43
-0.02
0.89
1.21
2.85
Day 57
0.27
1.28
1.64b
2.09
Day 64
0.53
1.11
2.49
2.21
Day 71
-0.10
1.34
2.09
1.66
Day 85
0.38
1.18b
2.55
1.86
Day 92
0.00c
1.04
1.60c
3.80c
Day 99
-0.20
1.21
3.20c
1.28c
Day 113
-0.02
1.30
1.29
1.04
Day 141
0.30
0.95
0.34
2.30
Day 169
0.20c
0.06
-
2.00c
aThe number of placebo subjects with data decreases over time as a result of the early discontinuation of the study 
(i.e., there were placebo subjects in each dosing cohort).  There were seven placebo subjects with data at baseline, 
Days 8, 15, and 36; six subjects with data at Days 29, 43, 57, and 85; five subjects with data on Days 71 and 113; 
four subjects with data on Day 64; three subjects with data on Day 141; two subjects with data on Day 99; and one 
subject with data on Days 92 and 169.  
bNumber of doses administered per treatment group:  0.1 mg/kg 4 doses; 0.3 mg/kg 3 doses; 1.0 mg/kg 2 doses.  
Data beyond this study day are considered follow-up results.  
cn=1
Other than the serious case of Hgb increase, no life-threatening events were reported.  The most 
notable AEs were those related to increases in hematologic laboratory measures in the 1.0 mg/kg 
dose group:  HCT, Hgb, and RBC count.  The AEs of increased Hgb and/or HCT were reported 
for seven of the eight subjects in this dose group.  These events were reported as mild or 
moderate elevations; all were considered probably related to study drug treatment.  Three of the 
Page 723 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
27
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
subjects in the 1.0 mg/kg group with elevated Hgb levels underwent phlebotomies and all Hgb 
elevations were resolved by the end of the follow-up period.  No erythroid lineage AEs were 
reported in the 0.1 or 0.3 mg/kg treatment groups.  
Paresthesia and dizziness were reported more frequently in the sotatercept (ACE-011) groups, 
though the events were < G 2 and generally not considered drug related.  Other frequently 
reported events (e.g. fatigue, upper respiratory infection) did not appear to increase with dose 
and were generally mild.  
Hemoglobin levels for all subjects with elevations had returned to within normal limits by the 
end of the study.  
Adrenal cortical function was monitored through evaluation of serum electrolytes (sodium and 
potassium levels) and through cortisol response to adrenocorticotropic hormone (ACTH) 
stimulation.  All ACTH simulation test results were normal.  
The PK of sotatercept (ACE-011) were linear after SC administration.  Both AUC28d and Cmax 
were proportional to dose from 0.1 to 1 mg/kg following the first SC administration.  The t1/2, z 
of sotatercept (ACE-011) following the last dose in all three dose groups was identical, with 
mean t1/2, z being approximately 23 days.  Based on the one-compartmental modeling, the mean 
CL/F ranged from 3.05 to 3.90 mL/d/kg, the mean Vz/F ([apparent] volume of distribution) 
ranged from 97.47 to 103.03 mL/kg, with no apparent dependence on dose.  
Bone mineral density was assessed by dual-energy X-ray absorptiometry (DXA).  A dose-
dependent increase in the BMD of the total hip from baseline to end of study was observed, with 
a significant and rapid increase of 2.4% in the 1.0 mg/kg dose group, compared to a 0.7% 
decrease in the placebo group.  BMD results for lumbar spine showed slight increases of 0.4% to 
1.0% from baseline to study end in all active treatment groups, compared with a 0.5% decrease 
in the placebo group.  
A011-04:  A Phase 2a Study in Patients with Osteolytic Lesions of Multiple Myeloma / 
Preliminary Results
Study A011-04 is a phase 2a, multi-center, randomized, multiple-dose study to evaluate the 
safety, tolerability and efficacy of sotatercept (ACE-011) in subjects with osteolytic lesions of 
multiple myeloma (MM).  
In this study, subjects were randomized in a 4:1 ratio to one of three dose levels of sotatercept 
(ACE-011) (0.1, 0.3 and 0.5 mg/kg) or placebo, administered to subjects every 28 days by SC 
injection, for up to four doses over a 3-month period. Sotatercept (ACE-011) was evaluated in 
combination with the anti-myeloma therapy of melphalan (4 mg/m2 on days 1-7), prednisolone 
(40 mg/m2 on days 1-7) and thalidomide (100 mg per day) (MPT). The sites, Sponsor and 
Sponsor representatives were blinded to treatment assignment.  
Thirty subjects were randomized and received at least one dose of study medication:  6 subjects
received placebo, 8 subjects received 0.1 mg/kg sotatercept (ACE-011), 8 subjects received 0.3 
mg/kg sotatercept (ACE-011), and 8 subjects received 0.5 mg/kg sotatercept (ACE-011).  
Twenty six (86.7%) subjects completed the study.  One subject in the 0.1 mg/kg dose group and 
one subject in the 0.5 mg/kg dose group discontinued due to AEs.  One subject in the 0.1 mg/kg 
dose group withdrew consent and was discontinued, and one subject in the 0.3 mg/kg dose group 
was discontinued at the request of the investigator.  
Page 724 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
28
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
In this study, 50.0% of subjects were female and the mean (range) age was 60.9 (41 to 79) years.  
The mean time since diagnosis of MM was 3.3 years, the majority of subjects had stage III 
disease at screening (83.3%) and had received prior chemotherapy (93.3%).  Approximately
43.3% of subjects were receiving bisphosphonates at screening, which continued during the 
study.  
Fourteen out of 24 subjects (58%) who received study treatment (sotatercept [ACE-011]) did 
receive 3 doses or more (4 out of 8 subjects in the 0.5 mg/kg dose level, 5 out of 8 subjects in the 
0.3 mg/kg dose level and 5 out of 8 subjects in the 0.1 mg/kg dose level).  
Safety:  Overall, 22 (91.7%) subjects receiving sotatercept (ACE-011) and 4 (66.7%) subjects
receiving placebo reported at least one AE.  Among subjects receiving sotatercept (ACE-011), 
AEs were reported in 87.5%, 87.5%, and 100% of subjects in the 0.1 mg/kg, 0.3 mg/kg, and 0.5 
mg/kg dosing cohorts, respectively.  Treatment-related AEs (i.e., those assessed by the 
Investigator as possibly, probably, or definitely related to treatment) were reported by 21 
(87.5%) subjects receiving sotatercept (ACE-011) and 4 (66.7%) receiving placebo.  Most 
subjects had AEs that were assessed as related to MPT:  21 (87.5%) subjects receiving 
sotatercept (ACE-011) and 4 (66.7%) subjects receiving placebo.  No AEs were assessed by the 
Investigator as related to the study medication alone (sotatercept [ACE-011] or placebo).  Two 
subjects had AEs assessed as possibly or probably related to study drug and possibly or probably 
related to MPT, one subject in the 0.1 mg/kg sotatercept (ACE-011) dose group (increased blood 
pressure; sudden death) and one subject in the 0.5 mg/kg sotatercept (ACE-011) dose group 
(hypertension).  Four subjects had SAEs, 1 (12.5%) subject in the 0.1 mg/kg sotatercept (ACE-
011) group and 3 (37.5%) subjects in the 0.5 mg/kg sotatercept (ACE-011) group.  Three 
subjects had SAEs that were assessed as treatment-related.  Of the 3 treatment-related SAEs, 2 
SAEs were assessed as possibly related to MPT and unrelated to sotatercept (ACE-011), and 1 
SAE (sudden death) was assessed as probably related to MPT and possibly related to sotatercept 
(ACE-011).  One subject in the 0.5 mg/kg sotatercept (ACE-011) dose group discontinued study 
drug due to episodes of atrial fibrillation assessed as possibly related to MPT and unrelated to 
sotatercept (ACE-011).  
Table 2 summarizes the most frequent AEs ≥5% in all treatment groups and Table 3 is a 
summary of SAEs reported.  
Page 725 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
29
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Table 2:
Summary of Adverse Events Reported in Greater Than or Equal To 5
Percent of Patients Overall
Sotatercept (ACE-011) Treatment Group
Preferred 
Terma
Placebo
(N=6)
0.1 mg/kg
(N=8)
0.3 mg/kg
(N=8)
0.5 mg/kg
(N=8)
All Sotatercept
(ACE-011)
(N=24)
Any 
Grade
Grade ≥3
Any 
Grade
Grade ≥3
Any 
Grade
Grade ≥3
Any 
Grade
Grade ≥3 Any Grade Grade ≥3
Neutropenia
4 (66.7%) 1 (16.7%) 4 (50.0%) 2 (25.0%) 6 (75.0%) 2 (25.0%) 6 (75.0%) 3 (37.5%) 16 (66.7%) 7 (29.2%)
Leukopenia
0
0
3 (37.5%) 1 (12.5%) 1 (12.5%) 0
1 (12.5%) 1 (12.5%) 5 (20.8%)
2 (8.3%)
Granulo-
cytopenia
0
0
2 (25.0%) 1 (12.5%) 1 (12.5%) 1 (12.5%) 1 (12.5%) 1 (12.5%) 4 (16.7%)
3 (12.5%)
Anaemia
0
0
1 (12.5%) 1 (12.5%) 1 (12.5%) 1 (12.5%) 2 (25.0%) 1 (12.5%) 4 (16.7%)
3 (12.5%)
Respiratory 
tract 
infection
0
0
1 (12.5%) 1 (12.5%) 1 (12.5%) 0
1 (12.5%) 0
3 (12.5%)
1 (4.2%)
Thrombo-
cytopenia
0
0
1 (12.5%) 0
0
0
2 (25.0%) 1 (12.5%) 3 (12.5%)
1 (4.2%)
Pyrexia
0
0
1 (12.5%) 0
1 (12.5%) 0
1 (12.5%) 0
3 (12.5%)
0
Blood 
pressure 
increased
0
0
1 (12.5%)*1 (12.5%)*0
0
1 (12.5%) 0
2 (8.3%)
1 (4.2%)
Bronchitis
1 (16.7%) 0
0
0
1 (12.5%) 0
1 (12.5%) 0
2 (8.3%)
0
Compression 
fracture
0
0
0
0
1 (12.5%) 0
1 (12.5%) 0
2 (8.3%)
0
Pathological 
fracture
0
0
1 (12.5%) 0
0
0
1 (12.5%) 1 (12.5%) 2 (8.3%)
1 (4.2%)
aAdverse events were those that were treatment-emergent, defined as newly acquired or worsened during or after 
administration of first dose of study medication. A patient with multiple occurrences of an AE counted only once 
under each preferred term.  
*Indicates the adverse event was assessed by the investigator as related (possibly, probably, or definitely) to study 
drug, (sotatercept (ACE-011) or placebo).  
Page 726 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
30
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Table 3:
Summary of SAEs Reported
Study Treatment
Age (y) / 
Sex / Race
Preferred Term
(Verbatim Term)
[Severity / Gradea]
Study Dayb
at Onset
Outcome
(duration)
Relationship to Study 
Treatment
0.1 mg/kg 
Sotatercept 
(ACE-011) and 
MPT
Sudden death
(sudden death)
103
Death
Sotatercept (ACE-011):  
possibly
MPT:  probably
0.5 mg/kg 
Sotatercept 
(ACE-011) and 
MPT
Pain in extremity
(pain in leg)
[severe / G 3]
128
Ongoing at 
end of study
Sotatercept (ACE-011):  not 
related
MPT:  not related
Pathological fracture
(pathological fracture of 
femur)
[severe / G 3]
130
Ongoing at 
end of study
Sotatercept (ACE-011):  not 
related
MPT:  not related
0.5 mg/kg 
Sotatercept 
(ACE-011) and 
MPT
Pneumonia
(pneumonia)
[moderate / G 2]
9
Resolved
(12 days)
Sotatercept (ACE-011):  not 
related
MPT:  possibly
0.5 mg/kg 
Sotatercept 
(ACE-011) and 
MPT
Atrial fibrillation
(atrial fibrillation)
[life-threatening / G 4]
6
Resolved
(1 day)
Sotatercept (ACE-011):  not 
related
MPT:  possibly
F= female; M = male; MPT = melphalan, prednisolone, and thalidomide; NCI CTCAE, v3.0 = National Cancer 
Institute Common Terminology Criteria for Adverse Events, version 3.0; y = years
abased on NCI CTCAE, v3.0.  
bRelative to first dose of study drug.  
Following analysis of the central laboratory data, increases in Hgb values were observed within 
28 days after administration of the first dose of sotatercept (ACE-011)/placebo and sustained for 
≥ 28 days from baseline at any time as presented in Table 4.  
Table 4:
Number of Subjects with an Increase in Hgb from Baseline at Any Time and 
Sustained for Greater Than or Equal To 28 Days
Increase in Hgb
Dose Sotatercept (ACE-011)/Placebo
0.1 mg/kg
N=8
0.3 mg/kg
N=8
0.5 mg/kg
N=8
Placebo
N=6
Overall
N=30
≥ 1.0 g/dL
4
3
7
2
16
≥ 1.5 g/dL
2
3
3
1
9
≥ 2.0 g/dL
1
3
2
0
6
Taken together, these data, suggest a beneficial pharmacodynamic effect of sotatercept (ACE-
011) on erythropoiesis in a patient population with cancer CIA.  
Potential Risks for Human Use
Nonclinical studies to determine the safety of sotatercept (ACE-011) have been conducted in 
cynomolgus monkeys and Sprague-Dawley rats.  Many of the observed effects in these studies 
Page 727 of 791
PPD
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
31
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
were as a result of the expected biologic activity of sotatercept and can be summarized as a 
dose-dependent decrease in sperm count and motility secondary to FSH suppression as well as 
reversible increases in RBC parameters due to the effects on erythropoiesis.  
The most significant toxicity findings are listed below:  

Hematological findings (increase in RBC parameters – RBCs, Hgb, HCT) were 
observed across all studies.  Associated with the increase in RBC parameters were 
increases in reticulocytes and decreases in mean corpuscular hemoglobin (MCH) and 
mean corpuscular hemoglobin concentration (MCHC).  The increase in RBC 
parameters is an anticipated effect of sotatercept (ACE-011) treatment and is being 
targeted as a therapeutic intervention for conditions associated with anemia.  

In the 6- and 9-month monkey studies, glomerulonephritis and/or tubulointerstitial 
nephritis were observed in monkeys administered ≥ 10 mg/kg administered 
subcutaneously (SC) every 2 or 4 weeks. At 2.6 mg/kg administered SC every 4 
weeks for 9 months, kidney findings were limited to a single incidence of 
tubulointerstitial nephritis. The NOAEL in the 9-month study was considered to be 1 
mg/kg every 4 weeks. Serum exposure in monkeys at the 1 mg/kg dose is estimated 
to be ~1.4-fold greater than the projected serum exposure in humans at the maximum 
proposed human dose of 61 mg every 6 weeks in a 50 kg subject.  Because 
sotatercept is a fully human molecule, immunogenicity and, by extension, kidney 
injury is not expected in humans. In the single- and multiple-dose studies in healthy 
postmenopausal women, there have been no changes in serum chemistry or urinalysis 
profiles suggestive of kidney injury. Subjects administered sotatercept (ACE-011)
should continue to be closely monitored.  

In the 9-month monkey study, treatment-related findings in the choroid plexus 
included:  perivascular accumulations of foamy macrophages and intimal thickening 
of small arteries and arterioles primarily at 10 mg/kg administered every 2 weeks as 
well as an increased incidence of small, focal aggregates of mononuclear 
inflammatory cells at all dosages. These changes were also considered related to the 
formation of anti-drug antibodies.  Findings at 1 mg/kg were limited to mononuclear 
cell infiltrates and were not considered adverse. 

Adrenal gland congestion or necrosis was observed in rats but not in monkeys.  The 
finding was more pronounced in female rats and appeared following either one month 
of IV dosing or 3 months of SC dosing.  Although the current data suggest adrenal 
toxicity may be specific to rats, the relevance of the adrenal findings to humans is 
uncertain.  

Elevations in liver enzymes (alanine aminotransferase [ALT], aspartate 
aminotransferase [AST], and/or alkaline phosphatase), as well as triglycerides, were 
observed sporadically in rats and monkeys treated with sotatercept (ACE-011).  There 
were no histological correlates in the liver, and often a dose-response relationship was 
not observed.  The relevance of these findings to sotatercept (ACE-011) treatment is 
uncertain; however, liver enzymes will continue to be monitored in this study. 
Page 728 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
32
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012

Pregnancy and Lactation

Due to the potential for effects on hormones in the pituitary, including FSH, in 
addition to possible direct effects on fetus, there may be potential effects on the 
fetus. Delays in fetal development (decreased fetal weights and delays in 
ossification) were observed in rats at doses ≥15 mg/kg (2.8-fold greater exposure
than the projected exposure at the maximum proposed human dose of 61 mg 
every 6 weeks in a 50 kg subject). In addition, at 50 mg/kg (4.7-fold the exposure 
at the maximum proposed human dose), there was an increase in late fetal death 
coupled with an overall increase in post implantation loss and a reduction in live 
litter size, as well as an increase in the incidence of developmental variations of 
supernumerary ribs with corresponding increases and decreases in thoracic and 
lumbar vertebrae, respectively. No fetal malformations were observed in this 
study at dosages up to 50 mg/kg. The NOAEL for embryofetal development 
effects was 5 mg/kg (1.5-fold greater exposure than the exposure at the maximum 
proposed human dose of 61 mg every 6 weeks in a 50 kg subject) based on 
reduced fetal weights and associated delays in ossification. 

In an embryo-fetal development study in rabbits, post implantation loss was 
increased and average litter size and live fetuses were reduced at 15 and 50 
mg/kg.  In addition, fetal body weights were reduced in all sotatercept dosage 
groups.  Abortions occurred in one rabbit in the 5 mg/kg dosage group and two 
rabbits in the 50 mg/kg dosage group.  Based on these findings, an NOAEL was 
not identified in this study and was therefore less than 5 mg/kg (<1.2-fold greater 
exposure than the exposure at the maximum proposed human dose of 61 mg every 
6 weeks in a 50 kg subject) 

Precautions should be taken to protect females of childbearing potential.
Nonclinical studies on breast milk have not been done.  

If sotatercept (ACE-011) is taken during pregnancy, a teratogenic effect in 
humans cannot be ruled out.  Therefore, all sotatercept (ACE-011) protocols 
describe pregnancy prevention requiring females of child-bearing potential to use 
highly effective methods of birth control.  In addition, since it is unknown if 
sotatercept (ACE-011) is found in breast milk, breast feeding is prohibited in all 
protocols.  

Fertility

In male rats, sperm granulomas and testicular degeneration were observed 
histologically.  In addition, sperm analysis revealed a reduction in sperm counts 
and motility as well as sperm fragmentation in isolated animals (2/10 males) at 
doses of 30 mg/kg IV.  Sperm fragmentation was also noted in 2/5 males 
administered 10 mg/kg IV at the end of the recovery period.  Overall, there was 
some evidence of recovery (motility similar to controls) at the end of the 4-week 
recovery period.  There was no evidence of a treatment-related impact on 
reproductive organs (testes, ovary, uterus) of monkeys in the toxicity studies; 
however, the monkeys on these studies, were too immature to fully assess the 
potential impact on reproductive organs.  The NOAEL for reproductive effects 
Page 729 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
33
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
(testicular or ovarian) was 1 mg/kg IV.  Serum exposure (AUC28d) in rats at the 
NOAEL was estimated to be ~ 8,000 µg·hr/mL based on the single-dose IV 
pharmacokinetic study in rats (Report TR148), ~ 2-fold greater than the serum 
exposure observed in humans at the maximum proposed dose of 61 mg every 6 
weeks (estimated AUC28d ~ 4248 μg·hr/mL in a 50 kg subject). 

In summary, in view of the potential risks sotatercept (ACE-011) treatment has on 
fertility, sotatercept (ACE-011) is targeted toward patient groups for whom the 
potential benefits outweigh the perceived risks.  
Because of the potential risks sotatercept (ACE-011) treatment has on fertility, sotatercept (ACE-
011) was first studied in healthy postmenopausal in two completed phase 1 clinical trials.  In 
addition, due to the potential for effects on hormones in the pituitary, levels of growth hormone, 
ACTH, and thyroid stimulating hormone (TSH) were monitored closely in the phase 1 studies.  
Completed studies in humans carried out in postmenopausal females showed a dose-dependent 
decrease in circulating levels of FSH, with mean levels in the multi-dose study in the two higher 
dose groups remaining below baseline at study end.  FSH will continue to be evaluated in 
ongoing studies.  No abnormal effects of sotatercept (ACE-011) on growth hormone, ACTH, and 
TSH and kidney toxicities were observed.  
Based on the safety data from the two completed phase 1 studies, single doses of sotatercept 
(ACE-011) up to 3.0 mg/kg IV and multiple doses of sotatercept (ACE-011) up to 0.3 mg/kg SC 
were generally well-tolerated in healthy postmenopausal women.  Consistent with observations 
from nonclinical safety studies, many of the observed pharmacodynamic effects in the phase 1 
clinical studies could be attributed to the expected biologic activity of activin inhibition, i.e., 
dose-dependent decrease in circulating levels of FSH, and transient, reversible effects on RBC 
parameters.  In Study A011-02 one subject experienced persistent, progressive hypertension and 
headaches approximately 1 week following her second dose of 1.0 mg/kg sotatercept (ACE-011)
SC that were attributed to a rapid and significant rise in Hgb levels.  The hypertension was 
reported as an SAE.  
In regards to the above safety concerns, appropriate vitals, hematologic, clinical chemistry and 
endocrine testing will be closely monitored in this clinical study.  There may be an effect of 
delayed wound healing, thus subjects with major surgeries within 30 days prior to study 
initiation will be excluded.  As with all biologics there is the potential for anti-drug antibodies 
that can be associated with increased drug clearance and hypersensitivity reactions.  Although no 
current evidence of neutralizing anti-drug antibodies formation was seen in two completed phase 
1 clinical trials, anti-drug antibody formation will be monitored in this clinical study.  
Please refer to the Investigator Brochure for further detailed information on the available 
pharmacology, toxicology, drug metabolism, clinical studies and AE profile of sotatercept 
(ACE-011).  
Page 730 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
34
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
2.
STUDY OBJECTIVES
2.1.
Exploratory Objectives

To explore doses of sotatercept (ACE-011) that result in a hematopoietic response for
the treatment of CIA in subjects with advanced or metastatic solid tumors treated with 
platinum-based chemotherapeutic regimens, excluding those solid tumors treated with 
curative intent.

To evaluate the safety and tolerability of sotatercept (ACE-011).

To determine the PK of sotatercept (ACE-011) in subjects receiving platinum-based 
chemotherapy.  

To evaluate the hematopoietic response and its duration associated with sotatercept 
(ACE-011) treatment.  

To evaluate the effect of sotatercept (ACE-011) treatment on the quality of life 
(QoL).

To estimate the effect of sotatercept (ACE-011) treatment on bone metabolism.

To evaluate the expression of Activin A and other proteins/biomarkers (including 
myostatin and follistatin) related to sotatercept (ACE-011) mechanism of action in 
blood.

To assess renal function biomarkers.
Data from exploratory objectives may not be included in the Clinical Study Report.  
Page 731 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
35
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
3.
STUDY ENDPOINTS
3.1.
Exploratory Endpoint(s)
Hematopoietic response is defined as an increase in Hgb of ≥ 1.0 g/dL above the study baseline 
value for 28 consecutive days, in the absence of RBC transfusions and/or ESAs.  In addition to 
the hematopoietic response, the safety profile, dose modifications and extent of exposure in each 
dosing level will be reviewed. 
Hematopoietic response will be determined by laboratory analysis of hemoglobin levels.  

Safety (type, frequency, and severity [National Cancer Institute (NCI) Common 
Terminology for Adverse Events (CTCAE) current active minor version 4.0] of 
adverse events

Duration of hematopoietic response

Sotatercept (ACE-011) concentration in serum 

Non-compartmental PK parameters for sotatercept (ACE-011)

QoL assessment (FACIT Fatigue Scale [Version 4]) and LCSS questionnaire (Hollen, 
1993; Hollen, 1994a; Hollen, 1994b; Hollen, 1995, Hollen, 1999)

Change in serum and urine bone biomarkers, including osteocalcin (OC), serum bone 
specific alkaline phosphatase (BSAP), procollagen type 1 N-terminal propeptide 
(P1NP), C-terminal type 1 collagen telopeptide (CTX) and tartrate-resistant acid 
phosphatase isoform-5b (TRACP-5b), the urine bone biomarker (urine N-telopeptide 
[uNTX]) related to activin or sotatercept (ACE-011) mechanism of action  

Change in BMD (DXA scans of lumbar spine and hip)

Time to first symptomatic skeletal related event (SRE) defined as pathologic fracture, 
clinical need for radiation therapy, surgery to bone or spinal cord compression

Expression of Activin A and other protein/biomarkers related to sotatercept (ACE-
011) mechanism of action in blood (including myostatin and follistatin) 

Change in renal function biomarkers via urinalysis measuring urine albumin / 
creatinine ratio, urine protein / creatinine ratio and other biomarkers of glomerular 
and/or tubular injury - urine kidney injury molecule-1 (KIM-1), urine trefoil factor 3 
(TTF3), urine cystatin C and + or – urine β2-microglobulin
Page 732 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
36
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
4.
OVERALL STUDY DESIGN
4.1.
Study Design 
This is an open-label randomized, phase 2a, dose-ranging study of sotatercept (ACE-011)
therapy in subjects with advanced or metastatic solid tumor types treated with platinum-based
chemotherapeutic regimens. Subjects with advanced or metastatic solid tumor types will be 
randomized to one of two sotatercept (ACE-011) dose treatment arms.  Continuous monitoring 
of safety data will be conducted.
The study is planned to be conducted in the United States.
Study treatment is defined as sotatercept (ACE-011).  
Two sotatercept (ACE-011) dose levels, 15 and 30 mg, were selected for the study. Up to 
approximately 30 subjects with advanced or metastatic solid tumor types will be randomized to 
one of the following sotatercept (ACE-011) dose levels, with 10-15 subjects per arm:

Sotatercept (ACE-011) 15 mg SC

Sotatercept (ACE-011) 30 mg SC
Each dose level will be administered every 42 days for a total of up to four doses.  
The Treatment Period is approximately six months, which includes up to four doses of 
sotatercept (ACE-011) and a Post Treatment Follow-Up Visit.  The Post Treatment Follow-Up 
Visit will occur approximately 42 days after the last dose of study treatment.  The Post 
Treatment Follow-Up Visit will also serve as the End of Treatment / End of Study Visit. 
At the time of randomization subjects must:

have already received at least one cycle and up to 4 cycles (q3w schedule) of 
platinum-based chemotherapy and be randomized prior to receiving Cycle 5 
OR 

have already received at least one cycle and up to 3 months (depending upon 
regimen) of platinum-based chemotherapy 
OR

currently be receiving maintenance therapy following treatment with platinum-
based chemotherapy 
Subjects must have an advanced or metastatic solid tumor treated with ≥ first–line platinum–
based chemotherapy, excluding those solid tumors treated with curative intent.
Stratification and randomization will be performed utilizing a validated interactive voice 
response system (IVRS).  
Page 733 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
37
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012

Subjects will be randomized to one of two sotatercept (ACE-011) dose levels and will be 
stratified by:
1. Baseline Hgb level 

6.5 to < 9.0 g/dL

9.0 to < 11.0 g/dL
2. Type of platinum-based chemotherapy (cisplatin versus other non-cisplatin
chemotherapy)
Page 734 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
38
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Figure 1:
Study Design
SCREENING PERIOD
TREATMENT PERIOD
POST TREATMENT FOLLOW-UP/ 
END OF TREATMENT/END OF STUDY VISIT 
R
A
N
D
O
M
I
Z
E
Subjects 
who 
meet 
eligibility 
criteria 
and 
provide 
signed 
informed 
consent
Sotatercept (ACE-011)
(Dose Finding)
15 mg or 30 mg
(Day 1 Every 42 Days)
Up to four doses
Post Treatment Follow-Up/
End of Treatment/End of Study Visit: 
Day 43 (42 days after last dose of sotatercept [ACE-011])
Page 735 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
39
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
4.1.1.
Sotatercept (ACE-011) Dose Modification, Reduction and Escalation Rules
Subjects should have Hgb and blood pressure measured (confirmed by two measurements 
obtained at least five minutes apart) prior to each dose of study drug.  The Investigator must 
adhere to the following Hgb and blood pressure-based dose modification rules for sotatercept 
(ACE-011) for the subject’s second dose of study treatment and beyond.  
Sotatercept (ACE-011) Dose Modification Rules:
Hemoglobin < 11g/dL
(per local* lab value) 
Hemoglobin ≥11g/dL
(per local* lab value) 
Hypertension ≥SBP 150 mmHg or ≥DBP 100 mmHg
*Note:  Local laboratory assessments are allowed in cases when timely results are needed (e.g., randomization, 
study treatment and chemotherapy dosing decisions, hematology assessments between clinic visits).  Whenever 
possible a “split” sample should also be forwarded to the central laboratory for analysis.  Local laboratory data 
should be collected in the eCRF.  
< 2.0 g/dL increase within a 
dosing period or a ≥ 2.0 g/dL 
increase not sustained for a 28 
day period since last dosing day 
≥ 2.0 g/dL increase sustained for a 
28 day period since last dosing day2
Note: ≥ 3.0 g/dL increase sustained 
for a 28 day period since last dosing 
day requires a two level dose 
reduction.  
< 2.0 g/dL increase within a 
dosing period or a ≥ 2.0g/dL 
increase not sustained for a 28 
day period since last dosing day
≥ 2.0g/dL increase sustained for a 28 day 
period since last dosing day2
Note: ≥ 3.0g/dL increase sustained for a 28 
day period since last dosing day requires a 
two level dose reduction.  If Hgb is > 15.0 
g/dL, sustained for 7 days, subject is to be 
discontinued from treatment2. 
Dose Delay5
Continue 
Dosing1
(Dose Escalation 
Table 6)
Continue Dosing 
with Dose 
Reduction 
Table 5: Sotatercept 
(ACE-011) Dose 
Reduction Levels
Dose Delay3
Dose Delay 
then, Dose 
Reduction4
Page 736 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
40
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
1If Hgb increase ≥ 1.0 but < 2.0 g/dL, dose remains the same.
If the RBC transfusion was given > 7 days following the previous dose of sotatercept (ACE-011), the subsequent 
dose of sotatercept (ACE-011) will be increased one dose level (Refer to sotatercept (ACE-011) Dose Escalation 
Levels- Table 6).  Hemoglobin level must be < 11 g/dL AND hypertension < SBP 150 mmHg and < DBP 100 
mmHg on the day of dosing.  Sotatercept (ACE-011) should not be administered ≤7 days post RBC transfusion.  
2Hemoglobin increases of > 2 g/dL sustained for a 28 day period since last dosing day should be confirmed on the 
dosing day, 7, 14 , 21 (after first dose of study treatment) and 28 days after dosing, and reviewed in comparison to 
Hgb level on previous dosing day.  Any Hgb increase of ≥3.0 g/dL sustained for 28 days will require a subsequent 
sotatercept (ACE-011) dose reduction of two dose levels (Refer to sotatercept [ACE-011] Dose Reduction Levels
[Table 5]).  A second Hgb increase of ≥3.0 g/dL sustained for 28 days, following a two level dose reduction, will 
require the subject discontinue from study treatment.  If Hgb is > 15.0 g/dL (sustained for a 7 day period, 
confirmed by laboratory assessment) subject is to be discontinued from treatment.  (See Section 8.2.3
Discontinuation)  
3Sotatercept (ACE-011) should be delayed until Hgb is < 11g/dL and hypertension < SBP 150mm Hg and < DBP 
100 mm Hg.  Dosing can commence at ≥7 days after the originally planned sotatercept (ACE-011) dose that was 
delayed.  Subsequent sotatercept (ACE-011) doses will then begin 42 days following this revised treatment dose
date.  
A delayed sotatercept (ACE-011) dose is defined as a dose administered > 4 days from the planned dosing date 
(due to Hgb ≥11.0 g/dL, hypertension > SBP 150 mmHg or > DBP 100 mmHg and/or sotatercept [ACE-011]
related toxicity).  
4Sotatercept (ACE-011) should be delayed as above in foot note (3), a reduced dose as above in foot note (2) of 
sotatercept (ACE-011) will be administered based on the evaluation of the Hgb and blood pressure at that time.  
5Sotatercept (ACE-011) should be held until hypertension resolves to < SBP 150mmHg and < DBP 100 mmHg and 
may then be resumed beginning seven days after the previous planned scheduled treatment visit as above in foot 
note (3).  
Table 5:
Sotatercept (ACE-011) Dose Reduction Levels
When required, per dose modification rules above, sotatercept (ACE-011) dose(s) should be 
reduced as follows:  
Dose Schedule
Sotatercept (ACE-011)
Dose Reduction*
#1
Dose Reduction*
#2
Dose Reduction*
#3
Every 42 days-
30 mg
26 mg
22 mg
18 mg
Every 42 days-
15 mg
13 mg
11 mg
9 mg
*Note:  Any Hgb increase of ≥3.0 g/dL sustained for a 28 day period since last doing day will require a subsequent 
sotatercept (ACE-011) dose reduction of two dose levels.  A second Hgb increase of ≥3.0 g/dL, sustained for 28 
days, following a two-level dose reduction will require the subject discontinue from study treatment.  
Dosing visits are on Day 1 and repeated every 42 days, for up to four doses.  
Blood pressure (confirmed by two measurements obtained at least five minutes apart) and Hgb
values must be evaluated prior to dosing at each dosing day for consideration in administration 
of sotatercept (ACE-011).  
The dose level for the initial dose reduction will be maintained unless subsequent dose 
reductions need to be administered upon evaluation of the dose modification rules listed above.  
A dose level may not be increased following a dose reduction.  
Page 737 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
41
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Sotatercept (ACE-011) Dose Escalation Levels:
The following dose escalation rules apply for sotatercept (ACE-011) dose(s):

Less than 1.0 g/dL increase in Hgb in response to prior sotatercept (ACE-011) dose

Hgb level must be < 11.0 g/dL and hypertension < SBP 150mmHg and
< DBP 100 mmHg

Dose escalation to begin at next treatment visit 

Sotatercept (ACE-011) should not be administered ≤7 days from the date of RBC 
transfusion.  
Subjects who have received an RBC transfusion should receive a one level dose increase of 
Sotatercept (ACE-011) at the subsequent visit per the escalation table below.  
Table 6:
Sotatercept (ACE-011) Dose Escalation Levels
Dose Schedule
Sotatercept 
(ACE-011)
Dose Increase  #1
Dose Increase  #2
Dose Increase #3
Every 42 days-
30 mg
33 mg
36 mg
40 mg
Every 42 days-
15 mg
17 mg
20 mg
23 mg
Blood pressure (confirmed by two measurements obtained at least five minutes apart) and Hgb 
values must be evaluated prior to dosing at each dosing day for consideration in administration 
of sotatercept (ACE-011).  
4.2.
Study Design Rationale
The A011-01, A011-02 and A011-04 studies have shown that dosing with sotatercept (ACE-011)
resulted in a rapid, sustained and dose-dependent increases in hematopoietic parameters, (Hgb, 
HCT and RBC counts) which occurred earlier than would be expected from a stimulation of 
erythropoiesis by an ESA.  This observation, coupled with nonclinical data demonstrating some 
level of erythrocyte stimulatory effect in the presence of anti-erthyropoietin (EPO) antibodies, 
suggests that the hematopoietic effect of sotatercept is different from that of ESAs.  Treatment of 
subjects with metastatic lung cancer with myelosuppressive platinum-based chemotherapy is 
frequently associated with anemia.  Chemotherapy induced anemia is a significant problem for 
subjects with cancer, causing fatigue and reduced quality of life (Groopman, 1999).  Subjects
with CIA are currently treated with blood transfusion and/or ESAs (NCCN Guidelines, 2009).  
However, with these treatment options CIA is still an area of major medical morbidity.  
Erythropoiesis-stimulating agents can successfully mitigate transfusion need in a proportion of 
these subjects, but concerns have emerged regarding apparent negative effects on survival and/or 
tumor progression in certain patient populations.  
Page 738 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
42
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
4.2.1.
Fixed Dose
Sotatercept (ACE-011) dose will be fixed at the indicated levels regardless of the subject’s body 
weight.  The fixed dosing approach is supported by an exploratory analysis of the relationship 
between body weight and sotatercept (ACE-011) PK in the previous studies (A011-01, A011-02, 
and A011-04).  In healthy postmenopausal women (Studies A011-01 and A011-02), body weight 
was estimated to explain less than 2.5% of intersubject variability for the two PK parameters 
dictating sotatercept (ACE-011) exposure, clearance and central volume of distribution, 
compared to an overall intersubject variability of 17.4% -25.5% for the two parameters.  In MM 
subjects (Study A011-04), body weight had no apparent effect on sotatercept (ACE-011)
exposure.  Because the Hgb response is dependent on sotatercept (ACE-011) exposure and 
because body weight is not a major source for the intersubject variability of sotatercept (ACE-
011) exposure, a fixed dosing approach is considered to be appropriate for the current study.  
4.2.2.
Dosing Schedule
The dosing schedule of once every 42 days (6 weeks) is proposed for the current study.  This 
dosing schedule was chosen by taking into consideration the rapid and prolonged Hgb response 
to sotatercept (ACE-011) as well as the dosing schedule for the platinum-based chemotherapies.  
The Hgb-increasing effect of sotatercept (ACE-011) was usually evident approximately 1 week 
after a SC dose and remained detectable through 6-8 weeks.  In addition, as platinum-based 
chemotherapy is often administered once every 3 weeks, a once every 6 week dosing schedule 
allows administration of sotatercept (ACE-011) at the same visit for the chemotherapy, which is 
convenient to both subjects and study sites.  
4.2.3.
Dose Levels 
Two dose levels, 15 and 30 mg, were chosen for the study.  Selection of these doses is primarily 
based on the safety and exposure-response data observed in MM subjects under the standard 
MPT chemotherapy, who received up to four doses of sotatercept (ACE-011) at 0.1, 0.3, or 0.5 
mg/kg (Study A011-04).  In these subjects, sotatercept (ACE-011) had an acceptable safety 
profile and caused exposure-dependent Hgb response.  Further, there was no relationship 
observed between an increase in blood pressure and the maximal sotatercept (ACE-011) 
concentration or the maximal Hgb rise within 28 days of the first dose (Report A011-04-CP).  
The two dose levels approximate the average doses received by a 70 kg subject over a 6-week 
interval (10.5 mg and 31.5 mg respectively) in the A011-04 study.  
In Study A011-04, four MM subjects received at least three sotatercept (ACE-011) doses at 0.5 
mg/kg every 4 weeks without a dose interruption, and none of them was reported to have an AE 
related to sotatercept (ACE-011).  
4.3.
Study Duration
To evaluate sequence and study timelines, please see the Table of Events (see Section 5).  
Approximately 30 subjects with advanced or metastatic solid tumor types will be randomized 
prior to receiving the fifth cycle (q3w regimen) OR prior to starting the fourth month (depending 
upon regimen) of platinum-based chemotherapy OR during maintenance therapy following 
treatment with platinum-based chemotherapy.  Each subject will be on the study for 
approximately 6 months (including the Screening Period, the Treatment Period, and the Post 
Page 739 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
43
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Treatment Follow-Up Visit).  The Treatment Period is approximately 6 months (up to four doses
of sotatercept [ACE-011] every 42 days) with a Post Treatment Follow-Up Visit occurring at 42 
days after the subjects’ last dose of sotatercept (ACE-011).  Subjects who discontinue treatment 
early will still continue to the Post Treatment Visit.  The Post-Treatment Follow-Up Visit will 
also serve as the End of Treatment / End of Study Visit.  
Page 740 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
44
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
5.
TABLE OF EVENTS
Table 7:
Sotatercept (ACE-011) Schedule of Assessments
Treatment Period
Screening 
Period
Sotatercept (ACE-011)
Dose 1 Schedule
(± 3 days)
Sotatercept (ACE-011)
Subsequent
Doses 2 through 4 Schedule
(± 3 days)
Assessments
Day -28
to
Day -1
D1
D8
D15 D22 D29
D43/
D1
D8
D15 D29
D43 
Post Treatment Follow-Up/End of Treatment / End of Study Visitt
Informed Consent
X
Inclusion/Exclusion Criteria
X
Complete Medical History
X
Cancer History and Prior Therapiesa
X
Prior ESA and RBC transfusion historya
X
X
Clinical visits (*study treatment visit)
X
X*
X
X
X*
X
X
ECOG Performance Status
X
X
X
X
X
X
Vital Signs / Blood Pressureb
X
X
X
X
X
X
X
X
X
Height (at randomization only)/Weight
X
X
X
X
X
X
X
X
12-Lead Electrocardiogram (ECG) c
X
X
X
X
X
Pregnancy Testingd
X
X
X
X
Page 741 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
45
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Table 7:
Sotatercept (ACE-011) Schedule of Assessments (Continued)
Treatment Period
Screening 
Period
Sotatercept (ACE-011)
Dose 1 Schedule
(± 3 days)
Sotatercept (ACE-011)
Subsequent
Doses 2 through 4 Schedule
(± 3 days)
Assessments
Day -28
to
Day -1
D1
D8
D15 D22 D29
D43/
D1
D8
D15 D29
D43 
Post Treatment Follow-Up/End of Treatment / End of Study Visitt
Hematologye
X
X
X
X
X
X
X
X
X
X
X
Absolute Reticulocyte Counte
X
X
X
X
X
X
X
X
X
X
X
Serum Chemistryf
X
X
X
X
X
X
X
X
Serum Creatinine and Creatinine 
Clearanceg
X
X
X
X
X
X
X
X
Serum Iron, TIBC, Transferrin and Serum 
Ferritin, Vitamin B12 and RBC Folate 
Levelsh
X
Xh
X
Serum Erythropoietin (**Full PK subjects 
post first dose only)i
X
X
X**
X
X** X**
X
Xi
X
Urinalysis and Renal Biomarkersj
X
X
X
X
X
X
FSH and LH – Males and Females
X
X
X
X
X
X
Dihyroepiandosterone and Testosterone 
(Free & Total) - Males Only 
X
X
X
X
X
X
Estrogen and Estradiol & Menstrual 
Status - Females Only
X
X
X
X
X
X
TSHk
X
X
Xk
X
Page 742 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
46
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Table 7:
Sotatercept (ACE-011) Schedule of Assessments (Continued)
Treatment Period
Screening 
Period
Sotatercept (ACE-011)
Dose 1 Schedule
(± 3 days)
Sotatercept (ACE-011)
Subsequent
Doses 2 through 4 Schedule
(± 3 days)
Assessments
Day -28
to
Day -1
D1
D8
D15 D22 D29
D43/
D1
D8
D15 D29
D43 
Post Treatment Follow-Up/End of Treatment / End of Study Visitt
Sotatercept (ACE-011) drug antibody test
(pre-dose)t
X
X
X
Xt
Bone Biomarkers (BSAP, OC, P1NP, 
CTX, TRACP-5b and uNTX)l
(**Full PK subjects post first dose only)
X
X** X**
X** X**
X
X
Bone Imaging (DXA)m (Optional in 
Selected Centers)
X
X
Activin A and other proteins/biomarkers 
in blood (serum) (pre-dose study 
treatment in a subset of subjects)
X
X
X
X
Pharmacokinetics–
Refer to Table 8 – Schedule of Pharmacokinetic Assessments
Tumor Assessmentso
Xo
< Every 9 weeks or as per standard of care at study site
QoL Assessment
(LCSS and FACIT Fatigue Scale)p
X
X
X
X
X
X
X
Adverse Events
X
All AEs regardless of causality up to 6 weeks (42 days) post last dose of study treatment, after day 43 of last dose – Post 
Treatment Follow-Up /End of Treatment / End of Study Visit- only SAEs assessed as related to study treatment are to be 
reported
Concomitant Medications
(including ESAs and transfusions)
X
X
X
X
X
X
Page 743 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
47
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Table 7:
Sotatercept (ACE-011) Schedule of Assessments (Continued)
Treatment Period
Screening 
Period
Sotatercept (ACE-011)
Dose 1 Schedule
(± 3 days)
Sotatercept (ACE-011)
Subsequent
Doses 2 through 4 Schedule
(± 3 days)
Assessments
Day -28
to
Day -1
D1
D8
D15 D22 D29
D43/
D1
D8
D15 D29
D43 
Post Treatment Follow-Up/End of Treatment / End of Study Visitt
Concomitant Procedures
X
X
X
X
X
X
Hospitalizations (Record)
X
X
X
X
X
X
Randomization
X
Administer 
Sotatercept (ACE-011)/Perform Drug 
Accountabilityq
X
X
Platinum-based Chemotherapyr
X
Dosing of allowed regimen(s) per standard 
practice
Targeted/Maintenance Therapys
Dosing of allowed regimen(s) per standard 
practice
Overall Survivalt
X
Post Treatment Anti-Neoplastic Therapyt
X
aInclude cancer history, date of original diagnosis, clinical stage at Screening and date of metastases and advanced or metastatic site involvement.  Record prior 
ESA history, starting at solid tumor diagnosis.  Record RBC transfusion history, starting from diagnosis of advanced or metastatic disease, at a minimum of 
two months prior to randomization.  
bVital signs (including heart rate, seated blood pressure, and temperature) will be measured at Screening and all subsequent clinical visits, on Day 29 post 
sotatercept (ACE-011), and at the Post Treatment Follow-Up / End of Treatment / End of Study Visit.  Blood pressure should be confirmed by two 
measurements obtained at least five minutes apart Investigators are to report any clinically significant abnormal findings as adverse events.  
Page 744 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
48
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
cECG to be performed as follows: At Screening, Day 1 Dose 1 pre and post sotatercept (ACE-011) dose,  Day 8 post dose 1, every sotatercept (ACE-011)
dosing Visit (post-dose) and at Post Treatment Follow-Up / End of Treatment / End of Study Visit (day 43 post last dose).  
dFemales of childbearing potential (FCBP) only:  A female of childbearing potential is a sexually mature woman who has not undergone a hysterectomy or who 
has not been postmenopausal for at least 24 consecutive months (i.e. who has had menses at some time in the preceding 24 months).  A medically supervised 
pregnancy test with a minimum sensitivity of 25mIU/ml must be performed within 3 days prior to the start of sotatercept (ACE-011) administration (Day 1) 
once the subject has been on effective contraception for at least 28 days and be performed within 3 days prior to dose administration of sotatercept (ACE-011)
during the Treatment Period.  Subjects must agree to use highly effective birth control measures (e.g., oral contraceptives or two forms of barrier method birth 
control) during study participation and for at least 112 days following the last dose of sotatercept (ACE-011).  
eHematology laboratory evaluations (RBC count, Hgb, HCT, WBC count and differential, ANC, MCV, platelet count and reticulocyte count).  Hemoglobin 
should be tested prior to dosing with sotatercept (ACE-011) to ensure levels are within normal limits and that sotatercept (ACE-011) dose modification rules 
are followed as outlined in Section 4.1.1.  Any laboratory evaluations may be repeated more frequently if clinically indicated.  In addition, RBC, Hgb, and 
reticulocyte counts will be included at each timepoint within the full PK assessment).  
fSerum chemistry laboratory evaluations (sodium, potassium, chloride, CO2 [bicarbonate], calcium, magnesium, phosphorus, BUN, creatinine, glucose, amylase, 
lipase, albumin, total protein, alkaline phosphatase, bilirubin [total and direct], AST/SGOT, ALT/SGPT, LDH and uric acid) if clinically significant any or all 
laboratory evaluations may be reported as AE and repeated more frequently.  
gCreatinine clearance (per Cockcroft-Gault formula) every 2 weeks during the Treatment Period and at the Post Treatment Follow-Up / End of Treatment / End 
of Study Visit (day 43 post last dose).  
Note:  Footnotes e, f, g : Hematology, absolute reticulocyte count, serum chemistry and creatinine clearance are to be assessed ≤14 days prior to 
randomization.
hSerum Iron, TIBC, Transferrin, Serum Ferritin, Vitamin B12 and RBC Folate to be performed at Screening, pre-last dose of sotatercept (ACE-011) and at the 
Post Treatment Follow-Up / End of Treatment / End of Study Visit (day 43 post last dose).  
iErythropoietin – collected at day 15 following first 2 doses of sotatercept (ACE-011).  For full PK assessment, weekly after first dose of sotatercept (ACE-011).  
jUrine collection for:  Urine albumin, urine albumin creatinine ratio, urine protein creatinine ratio and other renal biomarkers of glomerular and/or tubular injury.  
kTSH – collected at screening, on Day 1 of only the first and second dose of sotatercept (ACE-011) and at the Post Treatment Follow-Up / End of Treatment / 
End of Study Visit (day 43 post last dose).
lBone Biomarkers- Collected for full PK subjects prior to dose 1, weekly following dose 1, prior to dose 2 and at the Post Treatment Follow-Up / End of 
Treatment / End of Study Visit.  For all other subjects collected prior to dose 1,  prior to dose 2 , and at the Post Treatment Follow-Up / End of Treatment / End 
of Study Visit (day 43 post last dose).  Biomarker serum samples should be consistently collected early morning. The urine sample should not be from the first 
morning void.  
mDual Energy X-ray Absorptiometry (DXA) scan of lumbar spine and hip to evaluate overall health at selected US site(s).  Performed at Screening, and at the 
Post Treatment Follow-Up / End of Treatment / End of Study Visit (day 43 post last dose).  
Page 745 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
49
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
nPharmacokinetics:  Blood samples will be collected to evaluate the blood or serum concentrations of sotatercept (ACE-011).  Approximately 10 subjects at each 
sotatercept (ACE-011) dose level, 15 and 30 mg, will have full PK sampling.  In addition, RBC, Hgb, and reticulocyte counts will be collected at each time
point (excluding the 4-hour time point on Day 1) from Day 1 to Day 43 after the first dose within the full PK assessment.  Subjects not participating in the 
optional full PK assessment may participate in the sparse PK assessment. 
REFER TO Table 8, SCHEDULE OF PHARMACOKINETIC ASSESSMENTS.  
oTumor assessments:  Screening Period tumor assessments may be performed within six weeks or as per study site standard of care prior to randomization.  Also, 
historical tumor assessment data, from prior to the initiation of platinum-based chemotherapy through the Screening Period, will be collected.  Following 
randomization, tumor assessments will be performed ≤every 9 weeks or per standard of care at the study site, starting from the date of the previous (screening
period) tumor assessment and following the chemotherapy schedule.  
pQoL assessments- FACIT Fatigue Scale (Version 4) – to be completed by all subjects and LCSS questionnaire – to completed by only subjects with NSCLC.  
NOTE:  The LCSS consists of two scales:  one scale for the subject (Patient Scale) and a counterpart scale for health professionals acting as observers 
(Observer Scale).  All QoL assessments should be completed by the subject upon arrival at clinic and prior to any study procedures or testing at all visits, as 
indicated in the Schedule of Assessments.  
qSotatercept (ACE-011) dosing repeats every 42 days and will start after the subject begins a platinum-based chemotherapy regimen.  The first dose of 
sotatercept (ACE-011) may be given at any time following the first dose of platinum-based chemotherapy.  Subsequent doses of Sotatercept (ACE-011) 
can be administered at any time point during a chemotherapy cycle or maintenance therapy. 
Administration of subsequent cycles of chemotherapy, including dose reductions and dose delays, should not affect the sotatercept (ACE-011) dosing schedule, 
unless determined to be necessary by the Investigator.  If there is a chemotherapy dose delay, sotatercept (ACE-011) administration does not need to be delayed 
until start of next chemotherapy cycle. 
rPlatinum-based chemotherapy is to be administered based on guidelines for administration according to manufacturer’s recommendations and standard clinical 
practice.  Type of chemotherapy and dosing will be recorded.  
s Targeted/maintenance therapy (e.g. pemetrexed, erlotinib, etc.) is to be administered based on guidelines for administration according to manufacturer’s 
recommendations and standard clinical practice.  
tDay 43 (6 weeks) post last dose sotatercept (ACE-011) corresponds to the Post Treatment Follow-Up / End of Treatment / End of Study Visit.  Subjects who 
discontinue the sotatercept (ACE-011) Treatment Period early will continue to the Post Treatment Follow-Up / End of Treatment / End of Study Visit.  Survival 
Data and Post Treatment Anti-Neoplastic Therapy should be captured at this Visit. For subjects with a positive sotatercept (ACE-011) drug antibody 
assessment at the Post Treatment Follow-Up / End of Treatment / End of Study Visit, sotatercept (ACE-011) drug antibody assessments will be repeated every 
two months or as appropriate for up to one year or until the results are negative, whichever occurs first.
Page 746 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
50
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Table 8:
Schedule of Pharmacokinetic Assessments
Scheduled Time
Time relative to 
Sotatercept (ACE-011)
PK Samplinga,b
Collection 
Windowe
Full PKc
Sparse PKd
Dose 1, D1
pre-Dose 1
X
X
-2  to  0 hour
Dose 1, D1
4 hours after Dose 1
X
X
±1 hour
Dose 1, D5
4 days after Dose 1
X
-
± 1 day
Dose 1, D8
7 days after Dose 1
X
X
± 1 day
Dose 1, D11
10 days after Dose 1
X
-
± 1 day
Dose 1, D15
14 days after Dose 1
X
X
± 1 day
Dose 1, D22
21 days after Dose 1
X
-
± 1 day
Dose 1, D29
28 days after Dose 1
X
X
± 1 day
Dose 1, D36
35 days after Dose 1
X
-
± 1 day
Dose 1, D43 (Dose 2, D1)
pre-Dose 2
X
X
± 2 days
Dose 2, D8
7 days after Dose 2
X
-
± 2 days
Dose 2, D15
14 days after Dose 2
X
-
± 2 days
Dose 2, D43 (Dose 3, D1)
pre-Dose 3
X
X
± 2 days
Dose 3, D8
7 days after Dose 3
X
-
± 2 days
Dose 3, D15
14 days after Dose 3
X
-
± 2 days
Dose 3, D43 (Dose 4, D1)
pre-Dose 4
X
X
± 2 days
Dose 4, D8
7 days after Dose 4
X
-
± 2 days
Dose 4, D15
14 days after Dose 4
X
-
± 2 days
Dose 4, D29
28 days after Dose 4
X
-
± 3 days
Last Dose, D43 
42 days after final dose 
X
X
± 3 days
a Notes about PK sampling times:

For subjects participating in full PK sampling, RBC, Hgb and reticulocyte counts will be collected at each 
time point (excluding the 4-hour time point on Day 1) from Day 1 to Day 43 post first sotatercept 
(ACE-011) dose.  Erythropoietin and bone biomarkers will be collected at D1, D8, D15, D22, D29, and 
D43 post first sotatercept (ACE-011) dose.  If the time points for RBC, Hgb, reticulocyte, erythropoietin,
and bone biomarkers overlap with the time points defined in Table 7, only one sample is required.  

For subjects who discontinue the treatment early, PK blood sample collection will be continued during the 
follow-up period.  
bAt each time point, collect approximately 2 mL of blood.  After collection, allow the blood to clot at room 
temperature for approximately 1 hour and then centrifuge the blood sample at room temperature for 10 min (1100-
1300 g) to obtain serum.  
cTo be collected for approximately 20 subjects (approximately 10 subjects in each dose group).  
dTo be collected in subjects participating in sparse PK sampling and not participating in full PK sampling.  
eFor subjects who participate in full PK sampling only.  The collection window for sparse PK samples will be the 
same as the visit window defined in Table 7.  
Page 747 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
51
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
6.
PROCEDURES
Screening Period (Day -28 to Day -1)
Prior to screening, subjects must sign an informed consent.  Potentially protocol-eligible subjects 
will be evaluated for the inclusion and exclusion criteria for the Treatment Period of this study.  
All screening assessments must be completed ≤ 28 days prior to randomization.  Screening 
period tumor assessments and tumor evaluation documentation, as per RECIST criteria (Version 
1.1) (Appendix A), must be performed within 6 weeks prior to randomization or as per study site 
standard of care.  Historical tumor assessment data, from prior to the initiation of platinum-based 
chemotherapy through the screening period, will be collected.  Hematology and chemistry 
laboratory assessments should be performed ≤14 days of randomization.  
The assessments and procedures that will be performed during the Screening Period are outlined 
in the Table of Events (see Section 5) and include:

Informed consent

Assessment of inclusion / exclusion criteria

Complete medical history including history of cardiac, renal and thromboembolic 
events

Cancer history, including date of original diagnosis, histopathology, clinical stage at 
screening, date of advanced or metastatic stage and site involvement

Prior ESA treatment history starting from the initial solid tumor diagnosis 

RBC transfusion history starting from diagnosis of advanced or metastatic disease at a 
minimum of up two months prior to randomization

ECOG performance status

Vital signs including height, weight, heart rate, seated systolic and diastolic blood 
pressure, and temperature  

12-lead electrocardiogram (ECG) 

Medically supervised pregnancy test, with a minimum sensitivity of 25 mIU/ml, for 
females of childbearing potential (FCBP) to be assessed within 3 days prior to 
sotatercept (ACE-011) administration

Serum chemistry, hematology, absolute reticulocyte count to be assessed ≤14 days 
prior to randomization

Creatinine clearance (per Cockroft-Gault formula) to be assessed ≤ 14 days prior to 
randomization

Serum iron, total iron binding capacity (TIBC), transferrin and serum ferritin

Vitamin B12 and RBC folate levels

Serum erythropoietin
Page 748 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
52
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012

Urinalysis

FSH (include current menstrual cycle status for pre-menopausal female subjects) and 
LH – both males and females 

Dihyroepiandosterone and Testosterone (free and total) – males only

Estrogen and estradiol – females only

TSH

Bone imaging – DXA scan (optional at selected sites)

Tumor Assessment - Screening period tumor assessments and tumor evaluation 
documentation, as per RECIST criteria (Version 1.1), must be performed within 6
weeks or as per study site standard of care prior to randomization.  Also, historical 
tumor assessment data, from prior to the initiation of platinum based chemotherapy 
through the screening period, will be collected.  

QoL Assessment (FACIT Fatigue Scale [Version 4]) – all subjects

LCSS questionnaire (consisting of Patient Scale and Observer Scale) – only subjects 
with NSCLC  

Documentation of concomitant medications / procedures / hospitalizations

Documentation of concomitant platinum-based chemotherapy
Treatment Period (Day 1/Dose 1 of study treatment to Day 43 post last study treatment 
dose)
Results from screening evaluations must be reviewed prior to randomization to confirm subject 
eligibility.  
Subjects who meet all eligibility criteria will be randomized utilizing IVRS to receive one of the 
following sotatercept (ACE-011) dose levels, with approximately 10-15 subjects per arm:

Sotatercept (ACE-011) 15 mg SC

Sotatercept (ACE-011) 30 mg SC
Each dose level will be administered every 42 days for up to four doses.  

A subject will be considered randomized once a unique multi-digit subject 
identification number has been assigned by IVRS.  
Following randomization, subjects will receive SC doses of sotatercept (ACE-011) on Day 1 and 
every 42 days for up to four doses during the Treatment Period, as specified in the Table of 
Events (see Section 5).  
The assessments and procedures that will be performed during the Treatment Period are outlined 
in the Table of Events (see Section 5).  

Updated prior ESA and RBC transfusion history which may have occurred between 
the screening visit and randomization

ECOG performance status
Page 749 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
53
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012

Vital signs including weight, heart rate, seated systolic and diastolic blood pressure, 
and temperature

ECG 

Medically supervised pregnancy test, with a minimum sensitivity of 25 mIU/ml, for 
FCBP within 3 days prior to sotatercept (ACE-011) administration.  

Serum chemistry, hematology, absolute reticulocyte count.  

Hematology laboratory evaluations (RBC count, Hgb, HCT, WBC count and 
differential, mean corpuscular volume [MCV], absolute neutrophil count [ANC], 
platelet count and reticulocyte count) will be collected weekly after the first dose 
of sotatercept (ACE-011) and at subsequent sotatercept (ACE-011) doses 
collected at 7, 14 days and 28 days post-dose.

Within full PK assessment, RBC, Hgb and reticulocyte counts are collected at 
each time point; erythropoietin and bone biomarkers at weekly intervals post first 
dose of study treatment.  

Creatinine clearance will be assessed every 14 days.  

Serum iron, total iron binding capacity (TIBC), transferrin and serum ferritin at last 
dose and 42 days after last dose of study treatment

Vitamin B12 and RBC folate levels at last dose and 42 days after last dose of study 
treatment

Serum erythropoietin

Urinalysis

FSH (include current menstrual cycle status for premenopausal female subjects) and 
LH – both males and females 

Dihyroepiandosterone and Testosterone (free and total)– males only 

Estrogen and estradiol – females only 

TSH  

Serum for sotatercept (ACE-011) drug antibody test (pre-dose on the day of 
sotatercept [ACE-011] administration)

Bone or other potential mechanistic or disease-related proteins/biomarkers 

Activin A and other sotatercept (ACE-011)-related proteins/biomarkers

in blood, including myostatin and follistatin:
o
pre-dose on Day 1 and Day 8 after first dose of sotatercept (ACE-011)
o
pre-dose on Day 1 subsequent dosing visits

Tumor Assessment and Response Evaluation, as per RECIST criteria (Version 1.1), 
(performed ≤every 9 weeks or per standard of care at the study site, starting from the 
previous [screening] tumor assessment) and following the chemotherapy schedule
Page 750 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
54
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012

Pharmacokinetics

QoL Assessment (FACIT Fatigue Scale [Version 4]) – all subjects

LCSS questionnaire (consisting of Patient Scale and Observer Scale) – only subjects 
with NSCLC  

Evaluation and all AE/SAE reporting (regardless of causality)

Documentation of concomitant medications / procedures (including use of ESAs and 
all transfusions) / hospitalizations

Documentation of concomitant platinum-based chemotherapy and/or
targeted/maintenance therapy

Administration of sotatercept (ACE-011) on:  Day 1 every 42 days 
Subjects who discontinue from the Treatment Period early will continue to the Post Treatment 
Follow-Up / End of Treatment / End of Study Visit 42 days (6 weeks) after their last dose of 
sotatercept (ACE-011).  
Post Treatment Follow-Up / End of Treatment / End of Study Visit (Day 43 post last dose 
of study treatment)
Following completion or early discontinuation from the Treatment Period, subjects will have a 
Post Treatment Follow-Up / End of Treatment / End of Study Visit.  The assessments and 
procedures that will be performed during this period are outlined in the Table of Events (see
Section 5) and include:

ECOG performance status

Vital signs including weight, heart rate, seated systolic and diastolic blood pressure, 
and temperature  

ECG – end of study treatment (day 43 post last dose)

Medically supervised pregnancy test, with a minimum sensitivity of 25mIU/ml, for 
FCBP

Serum chemistry, hematology, absolute reticulocyte count

Creatinine clearance 

Serum iron, total iron binding capacity (TIBC), transferrin and serum ferritin – end of 
study treatment (at day 43 post last dose)

Vitamin B12 and RBC folate levels – end of study treatment (at day 43 post last dose)

Serum erythropoietin

Urinalysis

FSH (include current menstrual cycle status for pre-menopausal female subjects) and 
LH – both males and females 

Dihyroepiandosterone and testosterone (free and total)– males only 
Page 751 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
55
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012

Estrogen and estradiol – females only

TSH

Serum for sotatercept (ACE-011) drug antibody test (pre-sotatercept (ACE-011)
dose).  For subjects with a positive sotatercept (ACE-011) drug antibody assessment 
at the Post Treatment Follow-Up / End of Treatment / End of Study Visit, sotatercept 
(ACE-011) drug antibody assessments will be repeated every two months or as 
appropriate for up to one year or until the results are negative, whichever occurs first.

Bone or other potential mechanistic or disease-related proteins/biomarkers 

Bone imaging – DXA scan (optional at selected sites)

Activin A and other sotatercept (ACE-011) related proteins/biomarkers, including 
myostatin and follistatin, in blood

Pharmacokinetics

Tumor Assessment and Response Evaluation, as per RECIST criteria (Version 1.1), 
(performed ≤every 9 weeks or as per standard of care at the study site, and following 
the chemotherapy schedule)

QoL Assessment (FACIT Fatigue Scale (Version 4)) – all subjects

LCSS questionnaire (consisting of Patient Scale and Observer Scale) – only subjects 
with NSCLC  

Evaluation and reporting of all AEs regardless of causality (up to 6 weeks) after last 
dose of sotatercept (ACE-011).  

Documentation of concomitant medications / procedures (including use of ESAs and 
all transfusions) / hospitalizations

Post-Treatment Anti-Neoplastic Therapy

Overall survival
Additional Procedure Descriptions:
Central ECG
ECGs will be performed and read per Central ECG vendor.  
Please refer to vendor manual for procedures.  
Clinical Laboratory Evaluations
Clinical laboratory evaluations (serum chemistry, hematology, absolute reticulocyte count, 
creatinine clearance, serum iron, total iron binding capacity, transferrin and serum ferritin, serum 
erythropoietin, vitamin B12, serum RBC folate levels, urinalysis, FSH, LH, 
dihyroepiandosterone, estrogen, estradiol, testosterone and serum thyroid-stimulating hormone)
will be performed by a central laboratory.  
Please refer to vendor manual for procedures.  
Page 752 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
56
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Note:  Local laboratory assessments are allowed in cases when timely results are needed (e.g.,
randomization, study treatment and chemotherapy dosing decisions, hematology assessments 
between clinic visits).  Whenever possible a “split” sample should also be forwarded to the 
central laboratory for analysis. Local laboratory data should be collected in the eCRF.  
Exploratory Biomarkers
Analyses will be undertaken to evaluate the expression of Activin A and other 
proteins/biomarkers related to sotatercept (ACE-011) mechanism of action in blood (including 
myostatin and follistatin).
Renal function biomarkers via urinalysis measuring urine albumin / creatinine ratio, urine protein 
/ creatinine ratio and other biomarkers of glomerular and/or tubular injury - urine kidney injury 
molecule-1 (KIM-1), urine trefoil factor 3 (TTF3), urine cystatin C and + or – urine β2-
microglobulin will be evaluated in all subjects. 
Pharmacokinetics

Blood samples will be collected to evaluate the full PK profile of sotatercept 
(ACE-011) from approximately 20 subjects at select centers (approximately 10 
subjects for each sotatercept [ACE-011] dose group).  
For subjects who do not participate in either full or sparse PK assessments, the ACE-011 
(sotatercept) concentration may be determined in their anti-sotatercept antibody samples to assist 
in the evaluation of immunogenicity, as well as PK.
Detailed PK sampling schedule is presented in Table 8: Schedule of Pharmacokinetic 
Assessments.  

PK samples must be collected predose on the day of sotatercept (ACE-011)
administration.  PK samples may be collected at any time on non-dosing days.  After 
collection, allow the blood to clot at room temperature for approximately one hour 
and then centrifuge the blood sample at room temperature for 10 minutes (1100-
1300g) to obtain serum.  At each time point, approximately 2 mL or less blood will be 
collected.  
Bone Biomarkers
Bone biomarkers will be evaluated in all subjects.  The serum and urine bone biomarkers will 
include BSAP, OC, P1NP, CTX, TRACP-5b and uNTX.  Both serum and urine samples will be 
collected.  
Biomarker serum samples should be consistently collected early morning.  The urine sample 
should not be from the first morning void.  
Bone Imaging - optional
DXA scan to evaluate overall bone health will be performed at select site(s).
Quality of Life Assessments
The QoL Assessment (FACIT Fatigue Scale [Version 4]) will be completed by all subjects and 
LCSS questionnaire will be completed for subjects with NSCLC.  Each assessment will be 
completed by the subject upon arrival at clinic and prior to any study procedures or testing.  
Page 753 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
57
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
NOTE:  The LCSS consists of two scales:  one scale for the patient (Patient Scale) and a 
counterpart scale for health professionals acting as observers (Observer Scale).
Page 754 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
58
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
7.
STUDY POPULATION
At the time of randomization, subjects must:

have already received at least one cycle and up to 4 cycles (q3w schedule) of 
platinum-based chemotherapy and be randomized prior to receiving Cycle 5 
OR 

have already received at least one cycle and up to 3 months (depending upon 
regimen) of platinum-based chemotherapy 
OR

currently be receiving maintenance therapy following treatment with platinum-
based chemotherapy 
Subjects must have an advanced or metastatic solid tumor treated with ≥ first–line platinum–
based chemotherapy, excluding those solid tumors treated with curative intent.
7.1.
Number of Subjects
This platinum-based CIA study will enroll approximately 30 subjects with advanced or 
metastatic solid tumor types.  
Up to approximately 30 subjects will be randomized to receive one of the following sotatercept 
(ACE-011) dose levels, with 10-15 subjects per arm:

Sotatercept (ACE-011) 15 mg SC

Sotatercept (ACE-011) 30 mg SC
and will be stratified by:
1. Baseline Hgb level 

6.5 to < 9.0 g/dL

9.0 to < 11.0 g/dL
2. Type of platinum-based chemotherapy (cisplatin versus other non-cisplatin
chemotherapy)
Page 755 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
59
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
7.2.
Inclusion Criteria
Subjects must satisfy the following criteria to be enrolled in the study:
1. Men and women > 18 years of age at the time of signing the informed consent document.
2. Histologically confirmed (cytology or biopsy) solid tumor malignancy, excluding those 
solid tumors treated with curative intent.
3. Documented advanced or metastatic disease.
4. Measurable or non-measurable disease evaluable by RECIST criteria (Version 1.1)
(Appendix A).
5. All of the following laboratory values:

Hemoglobin ≥ 6.5 to < 11.0 g/dL (≥ 65 to < 110 g/L), due to chemotherapy-induced 
anemia

Absolute neutrophil count ≥ 500/mm3

Platelet count ≥ 75,000/mm3 (> 72 hours since prior platelet transfusion) 

Adequate renal function:
o
creatinine clearance ≥ 40mL/min or ≥ 50 mL/min if cisplatin is concomitantly 
administered
and
o
urine protein / creatinine ratio ≤1.0; or ≤2.0 if bevacizumab (Avastin®) is
concomitantly administered

Hepatic function (bilirubin < 1.5 x ULN; AST and ALT < 3.0 x ULN and ≤5.0 ULN 
for subjects with liver metastases)

Corrected calcium within normal limits (WNL) or ≤Grade 1.  Previous 
hypercalcemia treatment is allowed
6. Subjects must:

have already received at least one cycle and up to 4 cycles (q3w schedule) of 
platinum-based chemotherapy and be randomized prior to receiving Cycle 5 
OR 

have already received at least one cycle and up to 3 months (depending upon 
regimen) of platinum-based chemotherapy 
OR

currently be receiving maintenance therapy following treatment with platinum-based 
chemotherapy 
Any platinum-based regimen approved for the specific indication
7. ≥ 28 days must have elapsed since previous treatment with ESA
Page 756 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
60
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
8. ≥ 14 days must have elapsed (prior to Day 1) since the last RBC transfusion and receipt 
of ≤ 2 units of blood in the past 30 days (prior to Day 1)
9. ECOG Performance status of 0 – 2 (Appendix B)  
10. Females of childbearing potential participating in the study are to use highly effective 
methods of birth control for at least 28 days before starting the study, during study 
participation and for at least 112 days following the last dose of sotatercept (ACE-011).  
Some highly effective methods of birth control include:

Oral contraceptives, intrauterine device, tubal ligation or a partner with a vasectomy
OR

Two forms of barrier method birth control, e.g., a latex condom PLUS a diaphragm 
with spermicide OR a latex condom PLUS a contraceptive sponge with spermicide.  
If a non-latex condom is used, it cannot be made out of natural (animal) membrane  
Females of childbearing potential must have a negative pregnancy test, with a minimum 
sensitivity of 25 mIU/ml, within 3 days prior to sotatercept (ACE-011) administration 
(Day 1).  In addition, subjects must be educated concerning measures to be used to 
prevent pregnancy and potential toxicities.  (A female of childbearing potential is a 
sexually mature woman who has not undergone a hysterectomy or bilateral 
oophorectomy; or who has not been postmenopausal for at least 24 consecutive months 
i.e. who has had menses at some time in the preceding 24 months).  
11. Males must agree to use a latex condom or non-latex condom NOT made of natural 
(animal) membrane during any sexual contact with females of childbearing potential or a 
pregnant female while participating in the study and for at least 112 days following the 
last dose of sotatercept (ACE-011), even if he has undergone a successful vasectomy.  
12. Life expectancy of ≥ 3 months.
13. Is willing to adhere to the study visit schedule, understand and comply with all protocol 
requirements.
14. Understand and voluntarily sign a written informed consent document prior to any study 
related assessments/procedures are conducted.
7.3.
Exclusion Criteria
The presence of any of the following will exclude a subject from enrollment:
1. Subjects who have any Grade > 3 toxicity (according to the currently active minor 
version of the NCI National Cancer Institute Common Terminology for Adverse Events 
[CTCAE] version 4.0 [Appendix C]) at the time of screening, including Grade ≥ 3 
residual adverse events related to either chemotherapy or underlying disease.  Exception:  
Grade ≥ 3 hematotoxicity (e.g., asymptomatic anemia, neutropenia and 
thrombocytopenia) occurring during the chemotherapy nadir period and resolving or non-
hematological events (e.g., nausea, vomiting, fatigue, or muscle or bone/joint pain), 
occurring during the chemotherapy period and resolving.
Page 757 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
61
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
2. Prior radiation therapy to > 20% of the whole skeleton.  Use of palliative radiation, if the 
area being treated is < 15% of body surface area with no pelvic radiation or no more than 
10% of the bone marrow reserve is radiated, is permitted during subject participation in 
the study, at the discretion of the Investigator.  
3. CNS metastases (exception:  subjects with CNS metastases treated with whole brain 
radiotherapy, gamma knife radiosurgery and/or surgery and stable for at least 2 
weeks prior to randomization).  
4. Clinically significant pulmonary, endocrine, neurologic, gastrointestinal, hepatic or 
genitourinary disease unrelated to underlying malignancy.  
5. Subjects with classification of 3 or higher heart failure as classified by the New York 
Heart Association (NYHA) (Appendix D).  
6. History of thrombosis, deep vein thrombosis (DVT), pulmonary emboli (PE), or embolic 
stroke if not stable on anticoagulants and/or one of these events occurring within the past 
6 months.  Local central line thrombosis is allowed.  
7. Diagnosis of a myeloid malignancy or known history of myelodysplasia.  
8. Subjects with a recent history (within 14 days of Day 1) of administration of IV 
antibiotics or oral antibiotics (due to post septic episode).  Subjects should be free of 
infection at least 14 days after the last dose of systemic antibiotic treatment (prior to Day 
1).  
9. Uncontrolled hypertension.  Controlled hypertension is considered clinically stable and 
systolic blood pressure (SBP) must be < 150 mmHg and diastolic blood pressure (DBP)
must be < 100 mmHg.  
10. Known infection with human immunodeficiency virus (HIV).  
11. Known active hepatitis B or C antibody defined by positive serology.  
12. Deficiency in iron (transferrin saturation < 20%), vitamin B12, or RBC folate.  Subjects 
may be re-screened following treatment with supplements and normalization of levels.  
13. History of anemia as a result of inherited hemoglobinopathy such as sickle cell anemia or 
thalassemia.  
14. History of anemia due to autoimmune or hereditary hemolysis; or gastrointestinal 
bleeding occurring within the past 6 months.  
15. Received treatment with another investigational drug or device within 28 days prior to 
Day 1, or if the half life of the previous product is known, within 5 times the half life 
prior to dosing, whichever may be longer.  
16. Any prior use of sotatercept (ACE-011).  
17. Pregnant or lactating females or females planning to become pregnant.  
18. History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant 
proteins or excipients in the investigational product (Refer to the Investigator’s Brochure 
for further information).  
Page 758 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
62
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
19. Major surgery within 30 days prior to Day 1 (subjects must have completely recovered 
from any previous surgery prior to Day 1).  
Page 759 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
63
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
8.
DESCRIPTION OF STUDY TREATMENTS
8.1.
Description of Investigational Product(s)
Sotatercept (ACE-011) clinical drug product will be provided as a lyophilized powder,      
Process III.  
Process III Clinical Drug Product- Lyophilized Powder:
The clinical drug product consists of sotatercept (ACE-011) in 10 mM citrate buffer, pH 5.8,   
8% sucrose, and 0.02% polysorbate 80.  It is supplied as a lyophilized powder in labeled, rubber 
stoppered, 3-mL glass vials.  The recommended storage temperature for sotatercept (ACE-011)
lyophilized drug product is 2°C to 8°C. 
Prior to administration, the lyophilized drug product is reconstituted with 1 mL sterile water for 
injection (WFI) in the closed product vial using sterile needles and syringes following
institutional standards for reconstitution of sterile products.  The reconstituted drug product 
consists of a 50 mg/mL solution of sotatercept (ACE-011).  The solution must be refrigerated at 
2°C to 8°C upon reconstitution.
The reconstituted sotatercept (ACE-011) should be used immediately after reconstitution, and if 
not used immediately, the reconstituted sotatercept, in its original package, may be held for up to 
6 hours at 2°C to 8°C.
8.2.
Treatment Administration and Schedule
Sotatercept (ACE-011) will be administered as a SC injection to subjects by the study staff at the 
clinical site and will be documented in the study source record.  Subcutaneous injections will be 
given in the upper arm, abdomen, or thigh.  
At the time of randomization, subjects must:

have already received at least one cycle and up to 4 cycles (q3w schedule) of 
platinum-based chemotherapy and be randomized prior to receiving Cycle 5 
OR 

have already received at least one cycle and up to 3 months (depending upon 
regimen) of platinum-based chemotherapy 
OR

currently be receiving maintenance therapy following treatment with platinum-
based chemotherapy 
Subjects must have an advanced or metastatic solid tumor treated with ≥ first–line platinum–
based chemotherapy, excluding those solid tumors treated with curative intent.
Allowed concomitant platinum-based chemotherapy regimens are:

any platinum-based regimen approved for the specific indication
Investigative sites will utilize commercial supply of these medications.  
Page 760 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
64
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Concomitant or maintenance therapy with chemotherapeutic and/or targeted agents (e.g., 
pemetrexed, anti-EGFR agents, anti-VEGF agents), which are approved for a given tumor type,
are allowed in addition to platinum-based chemotherapy. 
Platinum-based tumor therapy may be revised at the discretion of the Investigator for toxicity 
reasons only.  
Sotatercept (ACE-011) dosing may occur on different weeks of the chemotherapy cycle due to 
the subjects’ Hgb levels.  Dose delays of sotatercept (ACE-011) and/or dose delays of 
chemotherapy may occur.  
8.2.1.
Selection of Dose for the Study
Subjects will be randomized to one of the following sotatercept (ACE-011) dose levels, with 10-
15 subjects per arm:

Sotatercept (ACE-011) 15 mg SC

Sotatercept (ACE-011) 30 mg SC
Each dose level will be administered every 42 days for up to four doses.  
Hematopoietic response is defined as an increase in Hgb of ≥ 1.0 g/dL above the study baseline 
value for 4 consecutive weeks, in the absence of RBC transfusions and/or ESAs. 
The effective dose of sotatercept (ACE-011) is defined as follows:
An increase in hemoglobin (Hgb) of ≥ 1.0 g/dL above the study baseline value for 4 
consecutive weeks.  
Hematopoietic response will be determined by laboratory analysis of hemoglobin levels.  
8.2.2.
Selection and Timing of Dosing for Each Subject
Subjects will be randomized to receive sotatercept (ACE-011) starting on Day 1 (one SC dose 
every 42 days) and continuing during the six-month Treatment Period, as outlined in the Table of 
Events (see Section 5).  
Subjects will be randomized to receive one of two dose levels of sotatercept (ACE-011), with 10-
15 subjects per arm.  
Each subject will return to the site on each scheduled clinic visit.  During the Treatment Period,
subjects will receive sotatercept (ACE-011) every 42 days as determined by Hgb levels and 
randomization schedule.  Hemoglobin levels and reticulocyte counts will be repeated weekly 
after the first dose of sotatercept (ACE-011) and then at 7, 14 and 28 days after each subsequent 
dose of sotatercept (ACE-011).  
The first dose of sotatercept (ACE-011) can be administered at any time after the first cycle
and prior to the fifth cycle (q3w regimen) OR prior to starting the fourth month 
(depending upon regimen) of platinum-based chemotherapy OR during maintenance 
therapy following treatment with platinum-based chemotherapy.
Subsequent doses of sotatercept (ACE-011) can be administered at any time point during a
chemotherapy cycle or maintenance therapy. 
Page 761 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
65
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Administration of subsequent cycles of chemotherapy, including dose reductions and dose 
delays, should not affect the sotatercept (ACE-011) dosing schedule, unless determined to be 
necessary by the Investigator.  If there is a chemotherapy dose delay, sotatercept (ACE-011) 
administration does not need to be delayed until start of next chemotherapy cycle.  
Following completion of the Treatment Period, subjects will continue to the Post Treatment 
Follow-Up / End of Treatment / End of Study Visit to occur 42 days (6 weeks) after the subjects’ 
last dose of sotatercept (ACE-011). 
Subjects will be discontinued from the study treatment for reasons listed in Section 8.2.3 of the 
protocol, for unacceptable toxicity, or for progression of advanced or metastatic disease that 
requires the initiation of another treatment.  
8.2.3.
Discontinuation
Treatment Discontinuation
Subjects will be discontinued from Study Treatment due to the following:

Adverse events(s)

Hypertension ≥Grade 3 – defined as Stage 2 hypertension (SBP ≥160 mmHg or
DBP ≥100mmHg) confirmed by two measurements obtained at least five minutes 
apart; medical intervention indicated; more than one drug or more intensive 
therapy than previously used indicated or medically significant hypertension 
which cannot be adequately controlled with antihypertensive therapy 

Any AE > Grade 2 assessed to be related to sotatercept (ACE-011) therapy.

Any persistent AE > Grade 1 considered to be related to sotatercept (ACE-011)
treatment and causing a subject to miss three months sotatercept (ACE-011)
therapy 

Any thromboembolic event > Grade 2 

Elevated Hgb > 15.0 g/dL (sustained for a 7 day period, confirmed by laboratory 
assessment)

Urine protein / creatinine ratio > 1.0; or > 2.0 if bevacizumab (Avastin®) is 
concomitantly administered

Persistent hematuria ≥Grade 2 - defined as symptomatic; urinary catheter or 
bladder irrigation indicated; limiting instrumental activities of daily living, and 
persisting for one week

Lack of sotatercept (ACE-011) therapeutic effect, defined as < 1.0 g/dL increase in 
Hgb from baseline following three dose escalations.  

Concomitant use of ESAs if administered at any time.  

Sotatercept (ACE-011) Dose Modifications:

A second Hgb increase of ≥3.0 g/dL following a two level dose reduction due to a 
Hgb increase ≥3.0 g/dL 
Page 762 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
66
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012

Disease Progression 

Withdrawal of consent

Death

Lost to follow-up

Protocol violation – as determined by the Sponsor
The reason for treatment discontinuation should be recorded in the eCRF and in the source 
documents.  
Study Discontinuation:  
The following events are considered sufficient reasons for discontinuing a subject from the 
study:

Completed study, per protocol (subject has completed approximately six month 
Treatment Period including a 42 day [6-week] Post-Treatment Follow-Up/End of 
Treatment/End of Study Visit).

Withdrawal of consent

Death

Lost to follow-up
The following events may be considered sufficient reasons for discontinuing a subject from the 
study, as determined by the Sponsor:

Adverse events(s)

Disease progression 

Protocol violation
The reason for study discontinuation should be recorded in the eCRF and in the source 
documents.  The Investigator must notify the Medical Monitor immediately when a subject has 
been discontinued/ withdrawn due to an AE (any unacceptable toxicity).  All subjects who are 
withdrawn from the study should complete the tests and evaluations scheduled for Study 
Discontinuation at the time of withdrawal.  
8.3.
Method of Treatment Assignment
All subjects who qualify for the study will be randomly enrolled into the study and receive up to 
four doses of sotatercept (ACE-011).  A unique multi-digit subject identification number will be 
assigned by IVRS to each subject entering the Treatment Period.  
8.4.
Packaging and Labeling
The label(s) for investigational product (IP) will include Sponsor name, address and telephone 
number, the protocol number, IP name, dosage form and strength (where applicable), amount of 
IP per container, lot number, expiry date (where applicable), medication identification/kit 
number (if applicable), dosing instructions, storage conditions, and required caution statements 
Page 763 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
67
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
and/or regulatory statements as applicable.  Additional information may be included on the label 
as applicable per local regulations.  
8.5.
Investigational Product Accountability And Disposal
Accountability for sotatercept (ACE-011) is the responsibility of the Investigator.  
Investigational clinical supplies must be received by a designated person at the clinical site and 
kept in a secured location.  The investigational site must maintain accurate records demonstrating 
dates and amounts of sotatercept (ACE-011) received, to whom it was administered (subject-by-
subject accounting), and accounts of any sotatercept (ACE-011) accidentally or deliberately 
destroyed or returned.  Unless otherwise notified, all vials of sotatercept (ACE-011), both used 
and unused, must be saved for drug accountability.  The used vials may be discarded, per the 
institution’s standard practice, after drug accountability has been completed by the monitor.  The 
Investigator must return all unused vials of sotatercept (ACE-011) to the Sponsor at the end of 
the study, or the sotatercept (ACE-011) may be destroyed at the clinical site with the permission 
of the Sponsor.  For either scenario, the outcome must be documented on the drug accountability 
log.  The Sponsor will provide direction for the outcome of all unused vials.  
Celgene will instruct the Investigator on the return, disposal and/or destruction of investigational 
medicinal product.  
8.6.
Investigational Product Compliance
Accurate recording of all IP administration will be made in the appropriate section of the 
subject’s eCRF and source documents.  
The Investigator or designee is responsible for accounting for all IP that is administered during 
the course of the study.  
Page 764 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
68
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
9.
CONCOMITANT MEDICATIONS AND PROCEDURES
9.1.
Permitted Concomitant Medications and Procedures
General concomitant medication usage
During screening, and during the study, subjects may take only stable doses of medications for 
chronic conditions that are not specifically excluded by the protocol (see Sections 7.2 and 7.3
Inclusion Criteria and Exclusion Criteria).  The Medical Monitor should be consulted by the 
Investigator if there are any concerns about what constitutes a stable dose or what is a chronic 
condition.  Concomitant medications will be recorded on the subject’s eCRF throughout the 
course of the study.  
Concomitant therapies considered as supportive care are acceptable while participating in this 
study, including growth colony stimulating factors (G-CSF); anti-emetics to limit chemotherapy-
related nausea and vomiting; palliative radiation; bisphosphonates and denosumab therapy for 
bone metastases.  Additionally, the study site should use its standard of care regarding hydration 
and the minimization of nephrotoxicity prior to/following the administration of platinum-based
regimens.  
Concomitant medication for anemia
Concurrent therapy with a new prescription medication related to treatment of anemia during the 
course of the study must first be discussed with the Medical Monitor prior to administration, 
unless appropriate medical care necessitates that medication should begin before the Medical 
Monitor can be consulted.  
Iron supplementation
Iron supplementation within 7 days of Day 1 (besides an oral general multivitamin with iron) 
will not be allowed.  If a subject becomes iron deficient during study treatment (ferritin < 100 
ng/mL [< 224.7 pmol/L] or transferrin saturation < 20%), treatment with iron supplementation is 
at the discretion of the Investigator.  
Erythropoiesis-stimulating agents (ESAs)
The use of an ESA is not allowed in the study.  The use of ESAs will need to result in 
immediate notification to the study Sponsor and Medical Monitor, as well as to the clinical site 
pharmacist, so that no further dosing with sotatercept (ACE-011) in that study subject will 
occur If treatment with ESAs is required in the opinion of the Investigator, the ESA label 
instructions are to be strictly followed.  
Any subject who receive an ESA will be discontinued from the study Treatment Period and 
continue to the Post Treatment Follow-Up / End of Treatment / End of Study Visit.
RBC transfusions
Concurrent treatment for CIA with blood transfusions is recommended when Hgb value is 
< 8 g/dL or at the discretion of the Investigator if the Hgb value is ≥8 g/dL and associated with 
anemia symptoms such as hemodynamic or pulmonary compromise requiring treatment.  If an 
Page 765 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
69
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
RBC transfusion is given to a subject during the Treatment Period, sotatercept (ACE-011) should 
be administered >7 days from the date of the RBC transfusion.
9.2.
Prohibited Concomitant Medications and Procedures
No concurrent treatments with any other investigational agent are allowed.  Bisphosphonate
therapy (other than for the treatment of hypercalcemia), and denosumab therapy for bone 
metastases can be started prior to randomization but should not be started on study.
9.3.
Required Concomitant Medications and Procedures
Not applicable.  
Page 766 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
70
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
10.
STATISTICAL ANALYSES
10.1.
Overview
This is an open-label randomized, phase 2a, dose-ranging study of sotatercept (ACE-011) 
therapy for chemotherapy-induced anemia (CIA) in subjects with advanced or metastatic solid 
tumor types treated with platinum-based chemotherapeutic regimens.  An IVRS will be utilized 
to ensure an equal weight central randomization based on a permuted-block randomization 
method according to stratification factors defined in Section 4.1 Study Design.  Subjects will be 
randomized to one of two doses of sotatercept (ACE-011).  
Analyses will be exploratory. 
10.2.
Study Population Definitions
Three study populations will be used for analyses.  

The Intent-to-Treat (ITT) Population – All randomized subjects.  

Safety Population – All subjects who take at least one dose of study medication.  

Efficacy Evaluable (EE) Population – All ITT subjects who take at least one dose of 
study medication and have baseline and at least one post-baseline efficacy assessment 
without major protocol deviation.  
10.3.
Sample Size and Power Considerations
Up to 30 subjects will be randomized among two dosing groups. Enrollment was limited and 
there are no power considerations due to study closure.  
10.4.
Background and Demographic Characteristics
Subjects’ age, height, weight, and baseline characteristics will be summarized using descriptive 
statistics by treatment arm, while gender, race and other categorical variables will be provided 
using frequency tabulations.  Medical history data will be summarized using frequency 
tabulations by system organ class and preferred term.  
10.5.
Subject Disposition
Subject disposition (analysis population allocation, entered, discontinued, along with primary 
reason for discontinuation) will be summarized using frequency and percent by treatment arm.  
A summary of subjects enrolled by site will be provided.  Protocol deviations will be 
summarized using frequency tabulations.  
10.6.
Efficacy Analysis
The hematopoietic response is defined as an increase in Hgb of ≥ 1.0 g/dL above the study 
baseline value for 28 consecutive days, in the absence of RBC transfusions and/or ESAs.  
Page 767 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
71
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
10.7.
Safety Analysis
All safety subjects will be used for safety analyses.  Sotatercept (ACE-011) exposure will be 
summarized.  Adverse events, vital sign measurements, clinical laboratory information, ECG 
interpretations, and concomitant medications will be tabulated and summarized by treatment 
arm.  The incidence of AEs will be summarized by severity grade based on the NCI CTCAE 
version 4.0 (current active minor version).  Serious adverse events (SAE), deaths and AEs 
leading to dose modifications and study treatment discontinuation will be summarized.  Safety 
information obtained during through the Post Treatment Follow-Up / End of Treatment / End of 
Study Visit segment will be incorporated into these analyses.  
10.8.
Interim Analysis
There will be no interim analysis. 
10.9.
Other Topics
Pharmacokinetic Analysis
Approximately 5 - 10 subjects will be enrolled for full PK sampling in each treatment cohort.  
Noncompartmental PK parameters for sotatercept (ACE-011), such as tmax, Cmax, AUC, and t1/2,z, 
may be estimated for subjects providing full PK samples.  Descriptive statistics may be provided 
for plasma concentrations and PK parameters.  
The relationship between sotatercept (ACE-011) exposure and response (hematology, 
biomarkers, and other clinical outcomes as appropriate) may be explored if data are sufficient.  
Page 768 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
72
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
11.
ADVERSE EVENTS
11.1.
Monitoring, Recording and Reporting of Adverse Events
An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen 
in a subject during the course of a study.  It may be a new intercurrent illness, a worsening 
concomitant illness, an injury, or any concomitant impairment of the subject’s health, including 
laboratory test values (as specified by the criteria below), regardless of etiology.  Any worsening 
(i.e., any clinically significant adverse change in the frequency or intensity of a pre-existing 
condition) should be considered an AE.  A diagnosis or syndrome should be recorded on the AE 
page of the eCRF rather than the individual signs or symptoms of the diagnosis or syndrome.  
An overdose, accidental or intentional, whether or not it is associated with an AE, or abuse, 
withdrawal, sensitivity or toxicity to an investigational product should be reported as an AE.  If 
an overdose is associated with an AE, the overdose and AE should be reported as separate terms.  
All subjects will be monitored for AEs during the study.  Assessments may include monitoring 
of any or all of the following parameters:  the subject’s clinical symptoms, laboratory, 
pathological, radiological or surgical findings, physical examination findings, or other 
appropriate tests and procedures.  
All AEs will be recorded by the Investigator from the time the subject signs informed consent to 
at least 42 days after the last dose of IP.  The AEs and SAEs will be recorded on the AE page of 
the eCRF and in the subject’s source documents.  All SAEs must be reported to Celgene Drug 
Safety immediately within 24 hours of the Investigator’s knowledge of the event by facsimile, or 
other appropriate method, using the SAE Report Form, or approved equivalent form.  After 42
days post last dose, only AEs assessed as related to study treatment are to be reported.  
11.2.
Evaluation of Adverse Events
A qualified Investigator will evaluate all AEs as to:  
11.2.1.
Seriousness 
An SAE is any AE occurring at any dose that:

Results in death;

Is life-threatening (i.e., in the opinion of the Investigator, the subject is at immediate 
risk of death from the AE);

Requires inpatient hospitalization or prolongation of existing hospitalization 
(hospitalization is defined as an inpatient admission, regardless of length of stay);

Results in persistent or significant disability/incapacity (a substantial disruption of the 
subject’s ability to conduct normal life functions);

Is a congenital anomaly/birth defect;

Constitutes an important medical event.  
Page 769 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
73
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Important medical events are defined as those occurrences that may not be immediately life 
threatening or result in death, hospitalization, or disability, but may jeopardize the subject or 
require medical or surgical intervention to prevent one of the other outcomes listed above.  
Medical and scientific judgment should be exercised in deciding whether such an AE should be 
considered serious.  
Events not considered to be SAEs are hospitalizations for:

A standard procedure for protocol therapy administration.  However, hospitalization 
or prolonged hospitalization for a complication of therapy administration will be 
reported as an SAE.  

Routine treatment or monitoring of the studied indication not associated with any 
deterioration in condition.  

The administration of blood or platelet transfusion as routine treatment of studied 
indication.  However, hospitalization or prolonged hospitalization for a complication 
of such transfusion remains a reportable SAE.  

A procedure for protocol/disease-related investigations (e.g., surgery, scans, 
endoscopy, sampling for laboratory tests, bone marrow sampling).  However, 
hospitalization or prolonged hospitalization for a complication of such procedures 
remains a reportable SAE.  

Hospitalization or prolongation of hospitalization for technical, practical, or social 
reasons, in absence of an AE.  

A procedure that is planned (i.e., planned prior to starting of treatment on study); 
must be documented in the source document and the eCRF.  Hospitalization or 
prolonged hospitalization for a complication remains a reportable SAE.  

An elective treatment of a pre-existing condition unrelated to the studied indication.  

Emergency outpatient treatment or observation that does not result in admission, 
unless fulfilling other seriousness criteria above.  
If an AE is considered serious, both the AE page/screen of the eCRF and the SAE Report Form 
must be completed.  
For each SAE, the Investigator will provide information on severity, start and stop dates, 
relationship to IP, action taken regarding IP, and outcome.  
11.2.2.
Severity / Intensity
For both AEs and SAEs, the Investigator must assess the severity /intensity of the event.  
The severity of AEs will be graded based upon the subject’s symptoms according to the current 
active minor version of National Cancer Institute (NCI) Common Terminology Criteria for 
Adverse Events (CTCAE, Version 4.0); 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
Page 770 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
74
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
AEs that are not defined in the NCI CTCAE should be evaluated for severity according to the 
following scale:
Grade 1 = Mild – transient or mild discomfort; no limitation in activity; no medical 
intervention/therapy required
Grade 2 = Moderate – mild to moderate limitation in activity, some assistance may be needed; no 
or minimal medical intervention/therapy required
Grade 3 = Severe – marked limitation in activity, some assistance usually required; medical 
intervention/therapy required, hospitalization is possible
Grade 4 = Life threatening – extreme limitation in activity, significant assistance required; 
significant medical intervention/therapy required, hospitalization or hospice care probable
Grade 5 = Death – the event results in death
The term “severe” is often used to describe the intensity of a specific event (as in mild, moderate 
or severe myocardial infarction); the event itself, however, may be of relatively minor medical 
significance (such as severe headache).  This criterion is not the same as “serious” which is 
based on subject/event outcome or action criteria associated with events that pose a threat to a 
subject’s life or functioning.  
Seriousness, not severity, serves as a guide for defining regulatory obligations.  
11.2.3.
Causality 
The Investigator must determine the relationship between the administration of IP and the 
occurrence of an AE/SAE as Not Suspected or Suspected as defined below:
Not Suspected:
The temporal relationship of the adverse event to IP 
administration makes a causal relationship unlikely or 
remote, or other medications, therapeutic interventions, or 
underlying conditions provide a sufficient explanation for the 
observed event.
Suspected:
The temporal relationship of the adverse event to IP 
administration makes a causal relationship possible, and other 
medications, therapeutic interventions, or underlying conditions 
do not provide a sufficient explanation for the observed event.
If an event is assessed as suspected of being related to a comparator, ancillary or additional IP 
that has not been manufactured or provided by Celgene, please provide the name of the 
manufacturer when reporting the event.  
11.2.4.
Duration
For both AEs and SAEs, the Investigator will provide a record of the start and stop dates of the 
event.
Page 771 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
75
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
11.2.5.
Action Taken
The Investigator will report the action taken with IP as a result of an AE or SAE, as applicable 
(e.g., discontinuation or reduction of IP, as appropriate) and report if concomitant and/or 
additional treatments were given for the event. 
11.2.6.
Outcome
All SAEs that have not resolved upon discontinuation of the subject’s participation in the study 
must be followed until recovered, recovered with sequelae, not recovered (death due to another 
cause) or death (due to the SAE).  
11.3.
Abnormal Laboratory Values
An abnormal laboratory value is considered to be an AE if the abnormality:

Results in discontinuation from the study;

Requires treatment, modification/ interruption (delay) of IP dose, or any other 
therapeutic intervention; or

Is judged to be of significant clinical importance.  
Regardless of severity grade, only laboratory abnormalities that fulfill a seriousness criterion 
need to be documented as an SAE.  
If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis 
or syndrome should be recorded on the AE page/screen of the eCRF.  If the abnormality was not 
a part of a diagnosis or syndrome, then the laboratory abnormality should be recorded as the AE.  
11.4.
Pregnancy
11.4.1.
Females of Childbearing Potential
Pregnancies and suspected pregnancies (including a positive pregnancy test regardless of age or 
disease state) of a female subject occurring while the subject is on IP, or within 112 days of the 
subject’s last dose of IP, are considered immediately reportable events.  IP is to be discontinued 
immediately.  The pregnancy, suspected pregnancy, or positive pregnancy test must be reported 
to Celgene Drug Safety immediately by facsimile, or other appropriate method, using the 
Pregnancy Initial Report Form, or approved equivalent form.  
The female subject should be referred to an obstetrician-gynecologist or another appropriate 
healthcare professional for further evaluation.  
The Investigator will follow the female subject until completion of the pregnancy, and must 
notify Celgene Drug Safety immediately about the outcome of the pregnancy (either normal or 
abnormal outcome) using the Pregnancy Follow-up Report Form, or approved equivalent form.  
If the outcome of the pregnancy was abnormal (e.g., spontaneous or therapeutic abortion), the 
Investigator should report the abnormal outcome as an AE.  If the abnormal outcome meets any 
of the serious criteria, it must be reported as an SAE to Celgene Drug Safety immediately by 
facsimile, or other appropriate method, within 24 hours of the Investigator’s knowledge of the 
event) using the SAE Report Form, or approved equivalent form.  
Page 772 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
76
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
All neonatal deaths that occur within 28 days of birth should be reported, without regard to 
causality, as SAEs.  In addition, any infant death after 28 days that the Investigator suspects is 
related to the in utero exposure to the IP should also be reported to Celgene Drug Safety 
immediately by facsimile, or other appropriate method, within 24 hours of the Investigator’s 
knowledge of the event using the SAE Report Form, or approved equivalent form.  
11.4.2.
Male Subjects
If a female partner of a male subject taking investigational product becomes pregnant, the male 
subject taking IP should notify the Investigator, and the pregnant female partner should be 
advised to call their healthcare provider immediately.  
11.5.
Immediate Reporting of Serious Adverse Events
Any AE that meets any criterion for an SAE requires the completion of an SAE Report Form in 
addition to being recorded on the AE page/screen of the eCRF.  All SAEs must be reported to
Celgene Drug Safety immediately within 24 hours of the Investigator’s knowledge of the event 
by facsimile, or other appropriate method, using the SAE Report Form, or approved equivalent 
form.  This instruction pertains to initial SAE reports as well as any follow-up reports.  
The Investigator is required to ensure that the data on these forms is accurate and consistent.  
This requirement applies to all SAEs (regardless of relationship to IP) that occur during the study 
from the time the subject signs informed consent up to 42 days after the last dose of IP, and those 
made known to the Investigator at anytime thereafter that are suspected of being related to IP.  
SAEs occurring prior to treatment will be captured.  
The SAE report should provide a detailed description of the SAE and include summaries of 
hospital records and other relevant documents.  If a subject died and an autopsy has been 
performed, copies of the autopsy report and death certificate are to be sent to Celgene Drug 
Safety as soon as these become available.  Any follow-up data will be detailed in a subsequent 
SAE Report Form, or approved equivalent form, and sent to Celgene Drug Safety.  
Where required by local legislation, the Investigator is responsible for informing the Institutional 
Review Board (IRB)/Ethics Committee (EC) of the SAE and providing them with all relevant 
initial and follow-up information about the event.  The Investigator must keep copies of all SAE 
information on file including correspondence with Celgene and the IRB/EC.  
11.6.
Safety Queries
Queries pertaining to SAEs will be communicated from Celgene Drug Safety to the site via 
facsimile or electronic mail.  The response time is expected to be no more than five (5) business 
days.  Urgent queries (e.g., missing causality assessment) may be handled by phone.  
11.7.
Expedited Reporting of Adverse Events
For the purpose of regulatory reporting, Celgene Drug Safety will determine the expectedness of 
events suspected of being related to sotatercept (ACE-011) based on the Investigator Brochure.  
For countries within the European Economic Area (EEA), Celgene or its authorized 
representative will report in an expedited manner to Regulatory Authorities and Ethics 
Page 773 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
77
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Committees concerned, suspected unexpected serious adverse reactions (SUSARs) in accordance 
with Directive 2001/20/EC and the Detailed Guidance on collection, verification and 
presentation of adverse reaction reports arising from clinical trials on investigational products for 
human use (ENTR/CT3) and also in accordance with country-specific requirements.  
Celgene or its authorized representative shall notify the Investigator of the following 
information:

Any AE suspected of being related to the use of IP in this study or in other studies 
that is both serious and unexpected (i.e., SUSAR);

Any finding from tests in laboratory animals that suggests a significant risk for 
human subjects including reports of mutagenicity, teratogenicity, or carcinogenicity.  
Where required by local legislation, the Investigator shall notify his/her IRB/EC promptly of 
these new serious and unexpected AE(s) or significant risks to subjects.  
The Investigator must keep copies of all pertinent safety information on file including 
correspondence with Celgene and the IRB/EC.  (See Section 15.3 for record retention 
information).  
Celgene Drug Safety Contact Information:
For Local Drug Safety Affiliate Office contact information, please refer to the Serious Adverse 
Event Report Form / Completion Guidelines or to the Pregnancy Report Form / Completion 
Guidelines.  
Page 774 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
78
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
12.
DISCONTINUATIONS
Please refer to Section 8.2.3.  
Stopping Rules
Celgene routine pharmacovigilance surveillance will review data on a regular basis (mainly 
grade 3 or 4 toxicities, SAEs and subject deaths).  Any relevant imbalance in toxic deaths, 
related SAEs or detrimental survival would be considered for study discontinuation.  
Page 775 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
79
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
13.
EMERGENCY PROCEDURES
13.1.
Emergency Contact
In emergency situations, the Investigator should contact the responsible Clinical Research 
Physician/Medical Monitor or designee by telephone at the number(s) listed on the Emergency 
Contact Information page of the protocol (after title page).  
In the unlikely event that the Clinical Research Physician/Medical Monitor or designee cannot be 
reached, please contact the global Emergency Call Center by telephone at the number listed on 
the Emergency Contact Information page of the protocol (after title page).  This global 
Emergency Call Center is available 24 hours a day and 7 days a week.  The representatives are 
responsible for obtaining your call-back information and contacting the on call Celgene/CRO 
Medical Monitor, who will then contact you promptly.  
Note:  The back-up 24 hour global emergency contact call center should only be used if you are 
not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls.  
13.2.
Emergency Identification of Investigational Products
This is an open – label study; therefore, IP will be identified on the package labeling. 
Page 776 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
80
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
14.
REGULATORY CONSIDERATIONS
14.1.
Good Clinical Practice
The procedures set out in this study protocol pertaining to the conduct, evaluation, and 
documentation of this study are designed to ensure that Celgene, its authorized representative, 
and Investigator abide by Good Clinical Practice (GCP), as described in International 
Conference on Harmonization (ICH) Guideline E6 and in accordance with the general ethical 
principles outlined in the Declaration of Helsinki.  The study will receive approval from an 
IRB/EC prior to commencement.  The Investigator will conduct all aspects of this study in 
accordance with applicable national, state, and local laws of the pertinent regulatory authorities.  
14.2.
Investigator Responsibilities
Investigator responsibilities are set out in the ICH Guideline for Good Clinical Practice and in 
the local regulations.  Celgene staff or an authorized representative will evaluate and approve all 
Investigators who in turn will select their staff.  
The Investigator should ensure that all persons assisting with the study are adequately informed 
about the protocol, amendments, study treatments, as well as study-related duties and functions.  
The Investigator should maintain a list of Sub-investigators and other appropriately qualified 
persons to whom he or she has delegated significant study-related duties.  
The Investigator is responsible for keeping a record of all subjects who sign an informed consent 
document and are screened for entry into the study.  Subjects who fail screening must have the 
reason(s) recorded in the subject’s source documents.  
The Investigator, or a designated member of the Investigator’s staff, must be available during 
monitoring visits to review data, resolve queries and allow direct access to subject records (e.g., 
medical records, office charts, hospital charts, and study-related charts) for source data 
verification.  The Investigator must ensure timely and accurate completion of eCRFs and queries.  
14.3.
Subject Information and Informed Consent
The Investigator must obtain informed consent of a legal representative prior to any study related 
procedures.  
Documentation that informed consent occurred prior to the study subject’s entry into the study 
and of the informed consent process should be recorded in the study subject’s source documents 
including the date.  The original informed consent document signed and dated by the study 
subject and by the person consenting the study subject prior to the study subject’s entry into the 
study, must be maintained in the Investigator’s study files and a copy given to the study subject.  
In addition, if a protocol is amended and it impacts on the content of the informed consent, the 
informed consent document must be revised.  Study subjects participating in the study when the 
amended protocol is implemented must be re-consented with the revised version of the informed 
consent document.  The revised informed consent document signed and dated by the study 
subject and by the person consenting the study subject must be maintained in the Investigator’s 
study files and a copy given to the study subject.  
Page 777 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
81
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
14.4.
Confidentiality
Celgene affirms the subject's right to protection against invasion of privacy and to be in 
compliance with ICH and other local regulations (whichever is most stringent).  Celgene requires 
the Investigator to permit Celgene's representatives and, when necessary, representatives from 
regulatory authorities, to review and/or copy any medical records relevant to the study in 
accordance with local laws.  
Should direct access to medical records require a waiver or authorization separate from the 
subject’s signed informed consent document, it is the responsibility of the Investigator to obtain 
such permission in writing from the appropriate individual.  
14.5.
Protocol Amendments
Any amendment to this protocol must be approved by the Celgene Clinical Research 
Physician/Medical Monitor.  Amendments will be submitted to the IRB/EC for written approval.  
Written approval must be obtained before implementation of the amended version occurs.  The 
written signed approval from the IRB/EC should specifically reference the Investigator name, 
protocol number, study title and amendment number(s) that is applicable.  Amendments that are 
administrative in nature do not require IRB/IEC approval but will be submitted to the IRB/IEC 
for information purposes.  
14.6.
Institutional Review Board/Independent Ethics Committee Review 
and Approval
Before the start of the study, the study protocol, informed consent document, and any other 
appropriate documents will be submitted to the IRB/EC with a cover letter or a form listing the 
documents submitted, their dates of issue, and the site (or region or area of jurisdiction, as 
applicable) for which approval is sought.  If applicable, the documents will also be submitted to 
the authorities in accordance with local legal requirements.  
Investigational Product can only be supplied to an Investigator by Celgene or its authorized 
representative after documentation on all ethical and legal requirements for starting the study has 
been received by Celgene or its authorized representative.  This documentation must also include 
a list of the members of the IRB/EC and their occupation and qualifications.  If the IRB/EC will 
not disclose the names, occupations and qualifications of the committee members, it should be
asked to issue a statement confirming that the composition of the committee is in accordance 
with GCP.  For example, the IRB General Assurance Number may be accepted as a substitute for 
this list.  Formal approval by the IRB/EC should mention the protocol title, number, amendment 
number (if applicable), study site (or region or area of jurisdiction, as applicable), and any other 
documents reviewed.  It must mention the date on which the decision was made and must be 
officially signed by a committee member.  Before the first subject is enrolled in the study, all 
ethical and legal requirements must be met.  
The IRB/EC and, if applicable, the authorities, must be informed of all subsequent protocol 
amendments in accordance with local legal requirements.  Amendments must be evaluated to 
determine whether formal approval must be sought and whether the informed consent document 
should also be revised.  
Page 778 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
82
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
The Investigator must keep a record of all communication with the IRB/EC and, if applicable, 
between a Coordinating Investigator and the IRB/EC.  This statement also applies to any 
communication between the Investigator (or Coordinating Investigator, if applicable) and 
regulatory authorities.  
Any advertisements used to recruit subjects for the study must be reviewed by Celgene and the 
IRB/EC prior to use.  
14.7.
Ongoing Information for Institutional Review Board / Ethics 
Committee
If required by legislation or the IRB/EC, the Investigator must submit to the IRB/EC:

Information on serious or unexpected adverse events as soon as possible; 

Periodic reports on the progress of the study;

Deviations from the protocol or anything that may involve added risk to subjects.  
14.8.
Closure of the Study
Celgene reserves the right to terminate this study at any time for reasonable medical or 
administrative reasons.  Any premature discontinuation will be appropriately documented 
according to local requirements (e.g., IRB/EC, regulatory authorities, etc.).  
In addition, the Investigator or Celgene has the right to discontinue a single site at any time 
during the study for medical or administrative reasons such as:

Unsatisfactory enrollment;

GCP noncompliance;

Inaccurate or incomplete data collection;

Falsification of records;

Failure to adhere to the study protocol.  
Page 779 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
83
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
15.
DATA HANDLING AND RECORDKEEPING 
15.1.
Data/Documents
The Investigator must ensure that the records and documents pertaining to the conduct of the 
study and the distribution of the investigational product are complete, accurate, filed and 
retained.  Examples of source documents include:  hospital records; clinic and office charts; 
laboratory notes; memoranda; subject’s diaries or evaluation checklists; dispensing records; 
recorded data from automated instruments; copies or transcriptions certified after verification as 
being accurate copies; microfiche; x-ray film and reports; and records kept at the pharmacy, and 
the laboratories, as well as copies of eCRFs or CD-ROM.  
15.2.
Data Management
Data will be collected via an electronic data capture (EDC) system rather than paper. Data will 
be entered into the clinical database as per Celgene SOPs.  These data will be electronically 
verified through use of on-line checks during data entry, and through programmed edit checks 
specified by the clinical team. The Clinical team and investigational site personnel will be 
alerted of discrepant data by the functionality of the system. Resolutions to these issues will be 
reflected in the database. An audit trail within the system will track all changes made to the data.  
15.3.
Record Retention
Essential documents must be retained by the Investigator for a minimum of 2 years after the last 
approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region, or at least 2 years have elapsed since the 
formal discontinuation of clinical development of the IP.  The Investigator must retain these 
documents for the time period described above or according to local laws or requirements, 
whichever is longer.  Essential documents include, but are not limited to, the following:

Signed informed consent documents for all subjects;

Subject identification code list, screening log (if applicable), and enrollment log;

Record of all communications between the Investigator and the IRB/EC;

Composition of the IRB/EC;

Record of all communications between the Investigator, Celgene, and their authorized 
representative(s);

List of Sub-investigators and other appropriately qualified persons to whom the 
Investigator has delegated significant study-related duties, together with their roles in 
the study, curriculum vitae, and their signatures;

Copies of CRFs (if paper) and of documentation of corrections for all subjects;

IP accountability records;

Record of any body fluids or tissue samples retained;
Page 780 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
84
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012

All other source documents (subject records, hospital records, laboratory records, 
etc.); 

All other documents as listed in Section 8 of the ICH consolidated guideline on GCP 
(Essential Documents for the Conduct of a Clinical Trial).  
The Investigator must notify Celgene if he/she wishes to assign the essential documents to 
someone else, remove them to another location or is unable to retain them for a specified period.  
The Investigator must obtain approval in writing from Celgene prior to destruction of any 
records.  If the Investigator is unable to meet this obligation, the Investigator must ask Celgene 
for permission to make alternative arrangements.  Details of these arrangements should be 
documented.  
All study documents should be made available if required by relevant health authorities.  
Investigator/Institution should take measures to prevent accidental or premature destruction of 
these documents.  
Page 781 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
85
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
16.
QUALITY CONTROL AND QUALITY ASSURANCE
All aspects of the study will be carefully monitored by Celgene or its authorized representative 
for compliance with applicable government regulations with respect to current GCP and standard 
operating procedures.  
16.1.
Study Monitoring and Source Data Verification
Celgene ensures that appropriate monitoring procedures are performed before, during and after 
the study.  Before the study is initiated at a site visit or at an investigator meeting, all aspects of 
the study are reviewed with the Investigator and the staff.  Prior to enrolling subjects into the 
study, a Celgene representative will review the protocol, eCRFs, procedures for obtaining 
informed consent, record keeping, and reporting of AEs/SAEs with the Investigator.  Monitoring 
will include on-site visits with the Investigator and his/her staff as well as any appropriate 
communications by mail, email, fax, or telephone.  At each monitoring visit, the facilities, 
investigational product storage area, eCRFs, subject’s source documents, and all other study 
documentation will be inspected/reviewed by the Celgene representative for accuracy, adherence 
to the protocol and Good Clinical Practice.  
Accuracy will be checked by performing source data verification that is a direct comparison of 
the entries made onto the eCRFs against the appropriate source documentation.  Any resulting 
discrepancies will be reviewed with the Investigator and/or his/her staff.  Any necessary 
corrections will be made directly to the eCRFs or via queries by the Investigator and/or his/her 
staff.  Monitoring procedures require that informed consents, adherence to inclusion/exclusion 
criteria and documentation of SAEs and their proper recording be verified.  Additional 
monitoring activities may be outlined in a study-specific monitoring plan.  
16.2.
Audits and Inspections
In addition to the routine monitoring procedures, a Good Clinical Practice Quality Assurance 
unit exists within Celgene.  Representatives of this unit will conduct audits of clinical research 
activities in accordance with Celgene SOPs to evaluate compliance with Good Clinical Practice 
guidelines and regulations.  
The Investigator is required to permit direct access to the facilities where the study took place, 
source documents, eCRFs and applicable supporting records of study subject participation for 
audits and inspections by IRB/IECs, regulatory authorities (e.g., FDA, EMEA, Health Canada) 
and company authorized representatives.  The Investigator should make every effort to be 
available for the audits and/or inspections.  If the Investigator is contacted by any regulatory 
authority regarding an inspection, he/she should contact Celgene immediately.  
Page 782 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
86
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
17.
PUBLICATIONS
The results of this study may be published in a medical publication, journal, or may be used for 
teaching purposes.  Additionally, this study and its results may be submitted for inclusion in all 
appropriate health authority study registries, as well as publication on health authority study 
registry websites, as required by local health authority regulations.  Selection of first authorship 
will be based on several considerations, including, but not limited to study participation, 
contribution to the protocol development, and analysis and input into the manuscript, related 
abstracts, and presentations in a study.
Page 783 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
87
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
18.
REFERENCES
Aapro M, Vaupel P.  Erythropoietin:  effects on life expectancy in patients with cancer-related 
anemia.  Curr Med Res Opin. 2006; 22(suppl 4):5-13.
Carlos JJ, Salas M, Ward A, et al.  Anemia as an independent prognostic factor for survival in 
patients with cancer:  a systemic, quantitative review.  Cancer.  2001; 91:2214-2221.
Cella D, Kallich J, McDermott A, et al.  The longitudinal relationship of hemoglobin, fatigue, 
and quality of life in anemic cancer patients:  results from five randomized clinical trials.  Ann 
Oncol. 2004; 15:979-986.
Chantry A, Heath D, Mulivor A, Coulton L, Evans H, Abdul N, Werner ED, Bouxsein ML, 
Pearsall RS, Seehra J, Vanderkerken K, and Croucher PI.  Inhibiting activin-A signalling 
stimulates bone formation, prevents tumor-induced osteolytic bone destruction and blocks bone 
metastasis. J Bone Miner Res 2010; 25 (12), 2633-46, Erroatum in J Bone Miner Res 2011; 26 
(2), 439
Chen Y-G, Lui HM, Lin S-L, Lee JM, and Ying S-Y.  Regulation of cell proliferation, apoptosis, 
and carcinogenesis by activin.  Exp Biol Med 2002; 227: 75-87.  
Dang TP, Carbone DP: Cancer of the Lung, in DeVita, VT, Hellman S, Rosenberg SA (eds): 
Cancer: Principles & Practice of Oncology, 8th edition, Philadelphia, PA. Lippincott Williams & 
Wilkens, 2008, 887-971.  
Functional Assessment of Chronic Illness Therapy-Fatigue, FACIT-F Version 4. 
http://www.facit.org/qview/qlist.aspx, last accessed 21Jul2010.
Grogan M, Thomas GM, Melamed I, et al.  The importance of hemoglobin levels during 
radiotherapy for carcinoma of the cervix.  Cancer.  1999; 86:1528-1536.
Groopman JE, Itri LM.  Chemotherapy-Induced Anemia in Adults:  Incidence and Treatment.  
Journal of the National Cancer Institute 1999, 91, 1616-1634.  
Hollen, PJ, Gralla, RJ, Kris, MG, and Potanovich, LM. Quality of life assessment in individuals 
with lung cancer:  Testing the Lung Cancer Symptom Scale (LCSS).  European Journal of 
Cancer, 1993; 29A, S51-S58.
Hollen, PJ, Gralla, RJ, Kris, MG, & Cox, C. Quality of life during clinical trials:  Conceptual 
model for the Lung Cancer Symptom Scale (LCSS).  Supportive Care in Cancer, 1994a; 2, 213-
222.
Hollen, PJ, Gralla, RJ, Kris, MG, Cox, C, Belani, CP, Grunberg, SM, Crawford, J, and Neidhart, 
JA. Measurement of quality of life in patients with lung cancer in multicenter trials of new 
therapies:  Psychometric assessment of the Lung Cancer Symptom Scale.  Cancer, 1994b; 73, 
2087-98.
Hollen PJ, Gralla RJ, Kris MG ‘Lung Cancer Symptom Scale (LCSS)’, Administration, Scoring 
and Procedures Manual, (1995) Ver.1.1.  
Page 784 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
88
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Hollen, PJ, Gralla, RJ, Kris, MG, Eberly, SW, and Cox, C.  Normative data and trends in quality 
of life from the Lung Cancer Symptom Scale (LCSS).  Supportive Care in Cancer, 1999; 7, 140-
148.
Hong WK, Tsao AS, in Lung Carcinoma: Tumors of the Lungs: Merck Manuals Online Medical 
Library for Healthcare Professionals, 2008. 
http://www.merck.com/mmpe/print/sec05/ch062/ch062b.html
Laurie SA, Jeyabalan N, Nicholas G, Dahrouge S.  Association between anemia arising during 
therapy and outcomes of chemoradiation for limited small-cell lung cancer.  J Thorac Oncol.  
2006;146-151.
Lotinun S, Fajardo RJ, Pearsall RS, Bouxsein ML, and Baron R.  A soluble activin receptor type 
IIA fusion protein, ACE-011, increases bone mass by stimulating bone formation and inhibiting 
bone resorption in cynomolgus monkeys.  ASBMR 30th annual meeting, 2008.  
MacRae R, Shyr Y, Jonson D, Choy H.  Declining hemoglobin Turing chemoradiotherapy for 
locally advanced non-small cell lung cancer is significant.  Radiother Oncol. 2002;64:37-40.
Mathews LS.  Activin receptors and cellular signaling by the receptor serine kinase family.  
Endocr Rev 1994; 15: 310-25.  
Murata M, Onomichi K, Eto Y, Shibai H, and Muramatsu M.  Expression of erythroid 
differentiation factor (EDF) in Chinese hamster ovary cells.  Biochem Biophys Res Commun
1988; 151: 230-5.  
Nakao K, Kosaka M and Saito S.  Effects of erythroid differentiation factor (EDF) on 
proliferation and differentiation of human hematopoietic progenitors.  Exp Hematol 1991; 19: 
1090-5.  
National Heart, Lung, and Blood Institute, National Institutes of Health.  New York Heart 
Association Classification. 2008.  
NCCN Clinical Practice Guidelines in Oncology:  Cancer and Chemotherapy Induced Anemia, 
V.2. 2010 http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf; 2009.  
Non-small Cell Lung cancer Collaborative Group ‘Chemotherapy in non-small cell lung cancer:  
a meta-analysis using updated data on individual patients from 52 randomized clinical trials’, 
British Medical Journal 1995 vol. 311, no.7010, 899-909.  
Obermair A, Cheuk R, Horwood K, et al.  Anemia before and during concurrent 
chemoradiotherapy in patients with cervical carcinoma:  effect on progression-free survival.  Int 
J Gynecol Cancer. 2003; 13:633-639.
Oken, MM., Creech, R.H., Tormey, D.C., et. al.  Toxicity And Response Criteria Of The Eastern 
Cooperative Oncology Group.  Am J Clin Onco 1982; 5:649-655.  
Parker SL, Tong T, Bolden S, et. al.  Cancer statistics, 1997.  CA Cancer J Clin, 1997, 47, no. 1, 
5-27.  
Pearsall RS, Canalis E, Cornwall-Brady M, Underwood KW, Haigis B, Ucran J, Kumar R, Pobre 
E, Grinberg A, Werner ED, Glatt V, Stadmeyer L, Smith D, Seehra J, and Bouxsein ML.  A 
soluble activin type IIA receptor induces bone formation and improves skeletal integrity.  Proc 
Natl Acad Sci USA 2008, 105: 7082-7.  
Page 785 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
89
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Perrien DS, Akel NS, Edwards PK, et. al.  Inhibin A is an endocrine stimulator of bone mass and 
strength.  Endocrinology 2007; 148: 1654-65.  
Rivier J, Spiess J, McClintock R, Vaughan J and Vale W.  Purification and partial 
characterization of inhibin from porcine follicular fluid.  Biochem Biophys Res Commun 1985; 
133: 120-7.  
Rossi A, Maione P, Gridelli C Cetuximab in advanced non-small cell lung cancer.  Critical 
Reviews in Oncology/Hematology, 2006 59, 139-149.  
Ruckle J, Jacobs M, Kramer W, et. al.  A single-dose, randomized, double-blind, placebo-
controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women.  J Bone Miner Res
2009; 24 (4): 744-52.  
Sandler A, Gray R, Perry M, et al Paclitaxel-Carboplatin alone or with Bevacizumab for Non 
Small Cell Lung Cancer, NEJM, 2006 vol.355, no.24, 2542-50.  
Scagliotti G, Parikh P, von Pawel J, et al Phase III Study Comparing Cisplatin Plus Gemcitabine 
With Cisplatin Plus Pemetrexed in Chemotherapy-Naïve patients With Advanced-Stage Non-
Small-Cell Lung Cancer, JCO, 2008, 26 (21): 3543-51.  
Schiller J, Harrington D, Belani C, et al Comparison of Four Chemotherapy Regimens for 
Advanced Non-Small-Cell Lung Cancer.  N Engl J Med 2002; 346:92-98.
Schwartz RN.  Anemia in patients with cancer:  incidence, causes, impact, management, and use 
of treatment guidelines and protocols.  Am J Health Syst Pharm.  2007; 64 (suppl 2):S5-S13.  
Seder C, Hartojo W, Lin L, et al Upregulated INHBA Expression May Promote Cell 
Proliferation and Is Associated with Poor Survival in Lung Adenocarcinoma, Neoplasia, 2009, 
11: 388-396.  
Shedden K, Taylor J, Enkemann S, et al Gene Expression-Based Survival prediction in Lung 
Adenocarcinoma: A Multi-Site, Blinded Validation Study: Director’s Challenge Consortium for 
the Molecular Classification of Lung Adenocarcinoma, Nat Med, 2008, 14 (8): 822-827.  
Shiozaki M, Sakai R, Tabuchi M, et. al.  Evidence for the participation of endogenous activin 
A/erythroid differentiation factor in the regulation of erythropoiesis.  Proc Natl Acad Sci USA
1992; 89: 1553-6.  
Shiozaki M, Sakai R, Tabuchi M, et. al.  In vivo treatment with erythroid differentiation factor 
(EDF/activin A) increases erythroid precursors (CFU-E and BFU-E) in mice.  Biochem Biophys 
Res Commun 1989; 165: 1155-61.  
Vansteenkiste J, Pirker R, Massuti B, et. al.  Double-Blind, Placebo-Controlled, Randomized 
Phase III Trial of Darbepoetin Alfa in Lung Cancer Patients Receiving Chemotherapy.  Journal 
of the National Cancer Institute, 2002, 94: 16: 1211-1220.  
Woodruff TK.  Regulation of cellular and system function by activin.  Biochem Pharmacol 1998; 
55: 953-63.  
Ying S-Y.  Inhibins, activins, and follistatins:  gonadal proteins modulating the secretion of 
follicle-stimulating hormone.  Endocrine Rev 1988; 9: 267-93.  
Page 786 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
90
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
19.
APPENDICES
Appendix A:  Response Evaluation Criteria in Solid Tumors
Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Terms
Definition
Measurable disease
The presence of at least one measurable lesion by CT or MRI.  If the measurable 
disease is restricted to a solitary lesion, its neoplastic nature should be confirmed by 
cytology/histology.  
All measurements should be taken and recorded in metric notation, using a ruler or 
calipers.  All baseline evaluations should be performed as closely as possible to the 
beginning of treatment and never more than 4 weeks before the beginning of the 
treatment. 
Measurable lesions
Lesions that can be accurately measured in least one dimension by CT scan with 
longest diameter > 10 mm (CT scan thickness no greater than 5 mm).  
The same method of assessment and the same technique should be used to characterize 
each identified and reported lesion at baseline and during follow-up. 
Non-measurable lesion
All other lesions, including small lesions (longest diameter <10mm or pathological 
lymph nodes with P10 to <15mm short axis) as well as truly non-measurable lesions.  
Lesions considered truly non-measurable include:  leptomeningeal disease, ascites, 
pleural or pericardial effusion, inflammatory breast disease, lymphangitic involvement 
of skin or lung, abdominal masses/abdominal organomegaly identified by physical 
exam that is not measurable by reproducible imaging techniques.
RECIST Criteria-Response Evaluation
Evaluation of target lesions
Complete Response (CR)
Disappearance of all target lesions.  
Any pathological lymph nodes (whether target or non-target) must have 
reduction in short axis to <10 mm.
Partial Response (PR):
At least a 30% decrease in the sum of diameters of target lesions, taking as 
reference the baseline sum diameters.
Stable Disease (SD):
Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify 
for PD, taking as reference the smallest sum diameters while on study.
Progressive Disease (PD):
At least a 20% increase in the sum of diameters of target lesions, taking as 
reference the smallest sum on study (this includes the baseline sum if that is the 
smallest on study).  In addition to the relative increase of 20%, the sum must 
also demonstrate an absolute increase of at least 5 mm.  
(Note:  the appearance of one or more new lesions is also considered 
progression).
Page 787 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
91
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
RECIST Criteria-Response Evaluation (continued)
Evaluation of non-target 
lesions
Complete Response (CR):
Disappearance of all non-target lesions and normalisation of tumour marker 
level.  All lymph nodes must be non-pathological in size (<10mm short 
axis).
Non-CR/Non-PD
Persistence of one or more non-target lesion(s) and/or maintenance of 
tumour marker level above the normal limits.
Progressive Disease (PD): 
Unequivocal progression (see comments below) of existing non-target 
lesions.  
(Note:  the appearance of one or more new lesions is also considered 
progression).
Evaluation of best overall response
The best overall response is the best response recorded from the start of the 
treatment until disease progression/recurrence (taking as reference for PD 
the smallest measurements recorded since the treatment started).  In general, 
the patient's best response assignment will depend on the achievement of 
both measurement and confirmation criteria.  
Patients with a global deterioration of health status requiring discontinuation 
of treatment without objective evidence of disease progression at that time 
should be classified as having “symptomatic deterioration”.  Every effort 
should be made to document the objective progression even after 
discontinuation of treatment.  
In some circumstances it may be difficult to distinguish residual disease 
from normal tissue.  When the evaluation of complete response depends on 
this determination, it is recommended that the residual lesion be investigated 
(fine needle aspirate/biopsy) to confirm the complete response status.  
Source:  Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R,  Dancey J, Arbuck S, Gwyther S, 
Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R,  Lacombe D, Verweij J.  New response evaluation 
criteria in solid tumours:  Revised RECIST guideline (version 1.1)  (2009).  European Journal of Cancer 45, 228-
247.
Page 788 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
92
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Appendix B:  ECOG Performance Status Scale 
The ECOG scale (Oken,1982) is used to assess a patient’s quality of life in an evaluation by a 
health professional of the daily activities and how the activities are affected by the disease of the 
patient.  
Table 9:
ECOG Performance Status Scale
Score
Description
0
Fully active, able to carry on all pre-disease performance without restriction
1
Restricted in physically strenuous activity but ambulatory and able to carry out work of 
a light or sedentary nature, e.g., light housework, office work.
2
Ambulatory and capable of all self-care but unable to carry out any work activities.  Up 
and about more than 50% of waking hours.
3
Capable of only limited self-care, confined to bed or chair more than 50% of waking 
hours.
4
Completely disabled.  Cannot carry on any self-care.  Totally confined to bed or chair
5
Dead
Page 789 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
93
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Appendix C:  National Cancer Institute (NCI) Common Terminology Criteria 
for Adverse Events (CTCAE) Version 4.0
Currently active minor version of NCI CTCAE, Version 4.0:
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
Page 790 of 791
088VGY

Sotatercept (ACE-011)
Protocol ACE-011-NSCL-001
Celgene Corporation
Confidential and Proprietary
94
ACE-011-NSCL-001 4.0 FINAL: 02MAY2012
Appendix D:  New York Heart Association - Classification of Heart Failure
Table 10:
Classification of Heart Failure
Class
Symptoms
Class 1
No limitation of activities.  No symptoms from ordinary activities
Class 2
Mild limitation of activity.  Comfortable with rest or mild exertion
Class 3
Marked limitation of activity and be comfortable only at rest
Class 4
Complete rest, confined to bed or chair; any physical activity brings on discomfort and 
symptoms occur at rest
Page 791 of 791
088VGY